-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GLC4Iiv2hgX+yMgysn4b58xkziupo141igDm79mjKSEKDn7qsqHcsOq8CszuJctX
 jBMQ9ohcOGYrrn4+gy6oSg==

<SEC-DOCUMENT>0001193125-09-013220.txt : 20090128
<SEC-HEADER>0001193125-09-013220.hdr.sgml : 20090128
<ACCEPTANCE-DATETIME>20090128171714
ACCESSION NUMBER:		0001193125-09-013220
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		23
CONFORMED PERIOD OF REPORT:	20090122
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090128
DATE AS OF CHANGE:		20090128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		09552182

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of earliest event reported: January&nbsp;22, 2009 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 200, Broomfield, CO 80021 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code) </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>201 Industrial Road,
Suite 310, San Carlos, CA 94070-6211 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Entry Into Material Definitive Agreement </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Background
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;27 2009, Nuvelo, Inc. (&#147;Nuvelo&#148;) completed its business combination with ARCA biopharma, Inc.
(&#147;ABI&#148;) in accordance with the terms of that Agreement and Plan of Merger and Reorganization, dated September&nbsp;24, 2008, by and among Nuvelo, Dawn Acquisition Sub, Inc., a wholly-owned subsidiary of Nuvelo (&#147;Merger Sub&#148;), and
ABI, which the parties amended on October&nbsp;28, 2008 (as amended, the &#147;Merger Agreement&#148;). Pursuant to the Merger Agreement, Merger Sub merged with and into ABI, with ABI continuing after the merger as the surviving corporation and a
wholly owned subsidiary of Nuvelo. Immediately following the merger, ABI changed its name to ARCA biopharma Colorado, Inc. and Nuvelo changed its name to ARCA biopharma, Inc. (&#147;ARCA&#148;). Unless the context otherwise requires, all references
herein to &#147;ARCA&#148; refer to ARCA and its wholly owned subsidiaries following the completion of the merger and the name change, all references to &#147;Nuvelo&#148; refer to Nuvelo prior to the completion of the merger and the name change,
and all references to &#147;ABI&#148; refer to ABI prior to the completion of the merger and its name change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As a result of the merger:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">each share of ABI&#146;s series A preferred stock automatically converted into 1 share of ABI&#146;s common stock; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">each share of ABI&#146;s series B-1 preferred stock automatically converted into 1.219875 shares of ABI&#146;s common stock; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">each share of ABI&#146;s series B-2 preferred stock automatically converted into 1.6265 shares of ABI&#146;s common stock; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">each share of ABI&#146;s common stock, including each share issuable upon conversion of ABI series A, series B-1 and series B-2 preferred stock in accordance with
the ratios described above, was converted into the right to receive 0.16698070 shares of ARCA common stock. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each option
and warrant to purchase ABI capital stock outstanding at the effective time of the merger was assumed by ARCA at the effective time of the merger. Each such option or warrant became an option or warrant, as applicable, to acquire that number of
shares of ARCA common stock equal to the product obtained by multiplying the number of shares of ABI capital stock subject to such option or warrant by 0.16698070, rounded down to the nearest whole share of ARCA common stock. Following the merger,
each such option or warrant has a purchase price per share of ARCA common stock equal to the quotient obtained by dividing&nbsp;the per share purchase price of ABI capital stock subject to such option or warrant by&nbsp;0.16698070, rounded up to the
nearest whole cent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As of immediately following the effective time of the merger, former ABI stockholders owned approximately 67% of the
outstanding common stock of ARCA, and Nuvelo stockholders owned approximately 33% of the outstanding common stock of ARCA, after giving effect to the issuance of shares pursuant to ABI&#146;s outstanding options and warrants prior to the merger,
primarily on a treasury method basis, without giving effect to the issuance of stock pursuant to Nuvelo&#146;s outstanding options and warrants. Options exercisable for a total of 4,328,443 shares of ABI common stock (equivalent to a total of
722,686 shares of ARCA common stock), warrants exercisable for a total of 1,075,933 shares of ABI common stock (equivalent to a total of 179,657 shares of ARCA common stock) and warrants exercisable for a total of 56,382 shares of ABI preferred
stock (equivalent to a total of 13,154 shares of ARCA common stock) were assumed by ARCA in connection with the merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Following the
completion of the merger, starting January&nbsp;28, 2009, ARCA&#146;s common stock began trading on the Nasdaq Global Market under the symbol &#147;ABIO&#148;. As of January 27, 2009, immediately following the consummation of the merger, there were
approximately 7.55 million shares of ARCA common stock issued and outstanding. The full text of the Merger Agreement, including the amendment, as well as ARCA&#146;s press releases dated January&nbsp;27, 2009, and January&nbsp;28, 2009 announcing,
respectively, the completion of the merger and the commencement of </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">ARCA&#146;s common stock trading on the Nasdaq Global Market under the symbol &#147;ABIO&#148; are attached hereto as Exhibits 2.1, 2.2, 99.1 and 99.2 to
this Current Report on Form 8-K and are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Material ABI Agreements </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Following the completion of the merger, the following material ABI agreements and arrangements became material agreements and arrangements of ARCA:
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Note and Warrant Purchase Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">On September&nbsp;24, 2008, ABI entered into a Note and Warrant Purchase Agreement, as amended on October&nbsp;10, 2008, with certain holders of ABI&#146;s then outstanding preferred stock pursuant to which ABI sold, for an aggregate
consideration of $8.75 million, its 6% Convertible Promissory Notes due March&nbsp;31, 2009 (the &#147;Notes&#148;) and warrants (the &#147;Warrants&#148;) to purchase a number of shares of ABI&#146;s common stock as determined pursuant to the
Warrants. At the effective time of the merger, the outstanding principal amount and accrued interest on the Notes converted into 5,226,927 shares of ABI common stock, which, as a result of the merger, represent the right to receive an aggregate of
872,792 shares of ARCA common stock. Each Warrant outstanding at the effective time of the merger was assumed by ARCA at the effective time of the merger. Following the merger, the Warrants will have an exercise price equal to $9.7406 per share and
will be exercisable for an aggregate of 179,657 shares of ARCA common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Lease </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;8, 2008, ABI entered into a five-year lease for approximately 15,000 square feet of commercial space at 8001 Arista Place in Broomfield,
Colorado for approximately $20,000 per month for the first three years and $21,000 per month for years four and five. The space is used as ARCA&#146;s headquarters and main corporate office. The lease contains rights of first refusal over
approximately 8,400 square feet of contiguous space on the second floor of the building, rights of first offer to lease 100% of the 8181 Arista Place building with the exception of first floor retail space, and an option to extend the lease for two
additional three year renewal terms at an agreed upon market rate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>License and Sublicense Agreement with CPEC, L.L.C. </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On October&nbsp;28, 2003, ABI entered into a License and Sublicense Agreement, as amended on February&nbsp;22, 2006, under which ABI licensed from CPEC,
L.L.C. (&#147;CPEC&#148;) and Bristol Myers Squibb (&#147;BMS&#148;), the exclusive rights to ABI&#146;s lead investigational compound, Gencaro, for all therapeutic and diagnostic uses in any country until the termination of ARCA&#146;s royalty
obligations in such country. Gencaro, including the trade name, is currently under review by the United States Food and Drug Administration and is not approved. ABI is obligated to use commercially reasonable efforts to develop and commercialize
Gencaro, including obtaining regulatory approvals. CPEC, ARCA and BMS have the right to terminate the license if, among other conditions, the other party materially breaches its obligations under the license agreement and fails to cure any such
breach within the terms of the license. ABI has the obligation to make milestone payments of up to $13.0 million in the aggregate upon regulatory approval in the U.S., Europe and Japan, and to pay royalties based on a percentage of annual sales of
Gencaro in any jurisdiction worldwide. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Diagnostic Collaboration and Option Agreement with CardioDx, Inc. </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On June&nbsp;23, 2006, ABI entered into a Diagnostic Collaboration and Option Agreement, as amended October&nbsp;1, 2007, with CardioDx, Inc.
(&#147;CardioDx&#148;). Under the agreement, CardioDx granted ABI a nonexclusive, royalty bearing license for diagnostic rights to key genetic markers that are relevant for prescribing Gencaro. The term of the agreement extends to the latest
expiring patent underlying the diagnostic rights. The license permits ABI to sublicense its rights under certain conditions, and in February 2007, ABI sublicensed its rights and transferred its royalty and other fee obligations to Laboratory
Corporation of America (&#147;LabCorp&#148;). </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Development, Commercialization and Licensing Agreement with Laboratory Corporation of America Holdings, Inc.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On February&nbsp;1, 2007, ABI entered into a commercialization and marketing agreement with LabCorp, as amended May&nbsp;14, 2007
and June&nbsp;10, 2008, to develop, make, market and sell diagnostic tests (the &#147;Gencaro Test&#148;). The Gencaro Test is currently under review by the United States Food and Drug Administration and is not approved. Under the agreement, LabCorp
is responsible for determining the appropriate regulatory pathway for the Gencaro Test and obtaining market clearance or approval from the FDA. Under the agreement, ABI granted to LabCorp an exclusive license to its diagnostic rights under the
CardioDx agreement and the Company&#146;s diagnostic rights associated with Gencaro. The license agreement has a term of 10 years. The sublicense transferred to LabCorp the royalty and all other fee obligations arising from the CardioDx agreement.
Royalty payments will be made directly to CardioDx by LabCorp. If LabCorp does not fulfill its royalty payment and other fee obligations, ABI is responsible for the payments. In addition, ABI granted to LabCorp 100,000 shares of ABI common stock,
which as a result of the merger, represent the right to acquire 16,698 shares of ARCA common stock. The shares are subject to a restricted stock agreement in which shares vest upon the attainment of certain regulatory approval and drug product sales
milestones. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Manufacturing Agreement with Patheon, Inc. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On September&nbsp;11, 2006, ABI entered into an agreement with Patheon to manufacture Gencaro in tablet form for feasibility and registration manufacturing and validation purposes. The agreement provides that Gencaro
is to be produced by Patheon utilizing standard solid oral dosage processing techniques. Six separate dosage strengths are manufactured. The agreement with Patheon, Inc. will terminate upon completion of the validation process. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Exclusive License Agreement with the Regents of the University of Colorado </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">On October&nbsp;14, 2005, ABI entered into an Exclusive License Agreement with the University of Colorado&#146;s License Equity Holdings, Inc. (&#147;ULEHI&#148;), as amended June&nbsp;23, 2006,&nbsp;July&nbsp;20,
2006,&nbsp;July&nbsp;19, 2007, and August&nbsp;22, 2007, whereby ULEHI licensed to ABI patent applications covering use of Gencaro therapy and various options to license future inventions and targets, among other intellectual property, and ABI
agreed to issue stock to ULEHI (as described below) and to make certain payments beginning in 2006. A portion of the license revenue received by ULEHI is allocated to the research laboratory of Dr. Michael R.&nbsp;Bristow, ARCA&#146;s chief science
officer and chairman of the board of directors. The agreement extends through the expiration for the last to expire of any patents embodying the licensed products and processes. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In connection with the licensing arrangement, ABI issued to ULEHI at total of 302,785&nbsp;shares of ABI common stock, which as a result of the merger,
represent the right to acquire 50,555 shares of ARCA common stock. Pursuant to an anti-dilution provision agreed to as part of the licensing transaction, ABI had issued 69,882&nbsp;shares, 142,903&nbsp;shares, and 0&nbsp;shares in 2007, 2006, 2005,
respectively, and 212,785&nbsp;shares from inception through December&nbsp;31, 2007. This anti-dilution provision was fully satisfied in May&nbsp;2007. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Loan and Security Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ABI entered into a Loan and Security Agreement dated July&nbsp;17, 2007, as amended
January&nbsp;21, 2009, with Silicon Valley Bank (&#147;SVB&#148;) under which SVB provided ABI a growth capital facility of up to $4.0 million dollars, to be used solely for working capital and to fund ABI&#146;s general business requirements. As of
January&nbsp;27, 2009, $3.8 million aggregate principal amount was outstanding under <U></U>the SVB credit facility. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No additional drawings are permitted under the credit facility. The credit facility matures on March 23,
2009 and is not subject to any prepayment penalties. All borrowings under this agreement bear interest at a floating per annum rate equal to SVB&#146;s prime rate. As of January&nbsp;27, 2009, SVB&#146;s prime rate was 4.0%. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In connection with the loan and security agreement, ABI issued to SVB warrants to purchase 31,790 shares of ABI&#146;s series B-1 preferred stock at
$2.43975 per share and 24,592 shares of ABI&#146;s series B-2 preferred stock at $3.253 per share (collectively, the &#147;SVB Warrants&#148;). As a result of the merger, ARCA assumed the SVB Warrants, which following the merger will have an
exercise price equal to $14.61 and $19.48 per share, respectively, and will be exercisable for an aggregate of 13,154 shares of ARCA common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The agreement contains customary affirmative and negative covenants including, without limitation, (i)&nbsp;covenants requiring ABI to comply with applicable laws, provide to SVB copies of ARCA&#146;s financial statements, maintain
appropriate levels of insurance, protect, defend and maintain the validity and enforceability of ABI&#146;s material intellectual property, and (ii)&nbsp;covenants restricting ABI&#146;s ability to dispose of all or substantially all of its assets,
engage in other lines of business, change its senior management, enter into transactions constituting a change of control, assume additional indebtedness, incur liens on its assets, among other covenants. ABI&#146;s obligations under the credit
facilities are secured by all of ABI&#146;s assets. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Completion of Acquisition or Disposition of Assets </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The information set forth in Item&nbsp;1.01 under the section entitled &#147;Background&#148; of this Current Report on Form&nbsp;8-K is incorporated herein by reference. The full text of the Merger Agreement, including the amendment, as
well as ARCA&#146;s press releases dated January&nbsp;27, 2009, and January&nbsp;28, 2009 announcing, respectively, the completion of the merger and the commencement of ARCA&#146;s common stock trading on the Nasdaq Global Market under the symbol
&#147;ABIO&#148; are attached hereto as Exhibits 2.1, 2.2, 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;2.03.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Creation of Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information set forth in Item&nbsp;1.01 above, under the title &#147;Material ABI Agreements &#150; Loan and Security Agreement&#148; with respect to
the SVB loan is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;3.03.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Material Modification to Rights of Security Holders </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Bylaw
Amendment, Reverse Stock Split Amendment and Name Change </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;23, 2009, the board of directors of Nuvelo approved an
amendment to Nuvelo&#146;s amended and restated bylaws to increase the maximum number of directors that may constitute the entire board of directors of Nuvelo from nine to 10 directors (the &#147;Bylaw Amendment&#148;). </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;23, 2009, the stockholders of Nuvelo approved an amendment to Nuvelo&#146;s amended and restated certificate of incorporation to effect a
reverse stock split of the issued and outstanding shares of Nuvelo&#146;s common stock whereby a number of outstanding shares of Nuvelo&#146;s common stock between and including 1 and 50, such number consisting only of whole shares, would be
combined into one share of Nuvelo&#146;s common stock, with this exact number (the &#147;Split Ratio&#148;) within the range to be determined by Nuvelo&#146;s board of directors. That same day, following stockholder approval of the reverse stock
split </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">amendment, Nuvelo&#146;s board of directors acted to set the Split Ratio at 20 for one so that every 20 shares of Nuvelo common stock outstanding immediately
prior to the effective time of the merger represent one share of Nuvelo common stock, and adopted an amendment to Nuvelo&#146;s amended and restated certificate of incorporation to effect the reverse stock split in accordance with the Split Ratio
(the &#147;Reverse Stock Split Amendment&#148;). The Reverse Stock Split Amendment became effective after the close of markets on January&nbsp;27, 2009 and the common stock of Nuvelo (now known as ARCA) began trading on the Nasdaq Global Market on a
post-reverse-split basis on January&nbsp;28, 2009 under the new symbol &#147;ABIO&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;27, 2009, immediately following
the effective time of the merger, the board of directors of ARCA approved a merger with ARCA&#146;s wholly-owned subsidiary, ARCA Merger, Inc., pursuant to which ARCA Merger, Inc. was merged with and into ARCA, and ARCA changed its name from Nuvelo,
Inc. to ARCA biopharma, Inc. (such change in name, the &#147;Name Change&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Bylaw Amendment, the Reverse Stock Split Amendment
and the certificate of ownership and merger that, once filed with the Delaware Secretary of State effectuated the Name Change are attached as Exhibits&nbsp;3.1, 3.2 and 3.3 to this Current Report on Form 8-K and are incorporated herein by reference.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Stock Certificate </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;27,
2009, ARCA&#146;s board of directors adopted a new form of stock certificate representing ARCA&#146;s common stock after the effective time of the reverse stock split and merger. The form of stock certificate is filed as Exhibit 4.1 to this Current
Report on Form 8-K and is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Change in Control of Registrant </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The information
set forth in Item&nbsp;1.01 under the section entitled &#147;Background&#148; of this Current Report on Form&nbsp;8-K is incorporated herein by reference. The full text of the Merger Agreement, including the amendment, as well as ARCA&#146;s press
releases dated January&nbsp;27, 2009, and January&nbsp;28, 2009 announcing, respectively, the completion of the merger and the commencement of ARCA&#146;s common stock trading on the Nasdaq Global Market under the symbol &#147;ABIO&#148; are
attached hereto as Exhibits 2.1, 2.2, 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.02.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pursuant to the terms of the Merger Agreement, effective as of the effective time of the merger, James R. Gavin, III, M.D., Ph.D. resigned from
Nuvelo&#146;s board of directors and compensation committee, Mark L. Perry resigned from Nuvelo&#146;s board of directors, audit committee and compensation committee, and Kimberly Popovits resigned from Nuvelo&#146;s board of directors and
compensation committee, Ted W. Love, M.D. resigned from his position as Nuvelo&#146;s chairman and chief executive officer, and Lee Bendekgey resigned from his position as Nuvelo&#146;s general counsel. These resignations were provided to Nuvelo
beginning January&nbsp;22, 2009. Mr.&nbsp;Bendekgey will remain with ARCA as its chief financial officer and treasurer on a transitional basis. Ted W. Love, M.D., Burton E. Sobel, M.D. and Mary K. Pendergast did not resign from Nuvelo&#146;s board
of directors and will remain members of ARCA&#146;s board of directors following the merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, pursuant to the terms of the
Merger Agreement, effective as of the effective time of the merger, the following individuals were elected to ARCA&#146;s board of directors: John-Francois Formela, M.D., J. William Freytag, Ph.D., John L. Zabriskie, Ph.D., David G. Lowe, Ph.D.,
Linda Grais, M.D., Richard B. Brewer and Michael R. Bristow, M.D., Ph.D. Dr.&nbsp;Love, Dr.&nbsp;Sobel, Dr.&nbsp;Freytag and Dr.&nbsp;Formela have been elected as Class I directors, whose terms expire at the 2009 annual meeting of </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">ARCA&#146;s stockholders, Dr.&nbsp;Zabriskie, Dr.&nbsp;Lowe and Dr.&nbsp;Grais have been elected as Class II directors, whose terms expire at the 2010 annual
meeting of ARCA&#146;s stockholders and Ms.&nbsp;Pendergast, Dr.&nbsp;Bristow and Mr.&nbsp;Brewer have been elected as Class III directors, whose terms expire at the 2011 annual meeting of ARCA&#146;s stockholders. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, effective as of the effective time of the merger, the compensation committee of ARCA&#146;s board of directors will be comprised of
Dr.&nbsp;Freytag, as the chairperson, Dr.&nbsp;Formela and Dr.&nbsp;Grais, the audit committee of ARCA&#146;s board of directors will be comprised of Dr.&nbsp;Zabriskie, as the chairperson, Dr.&nbsp;Sobel and Ms.&nbsp;Pendergast, and the nominating
and corporate governance committee of ARCA&#146;s board of directors will be comprised of Ms.&nbsp;Pendergast, as the chairperson, Dr.&nbsp;Lowe and Dr.&nbsp;Grais. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Finally, pursuant to the terms of the Merger Agreement, effective as of the effective time of the merger, Richard B. Brewer was appointed president and chief executive officer of ARCA, Michael R. Bristow, M.D., Ph.D.
was appointed chairman of the board and chief science and medical officer, Christopher D. Ozeroff was appointed executive vice president of business development, general counsel and secretary and Randall St. Laurent was appointed executive vice
president of commercial operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following is a brief biographical summary for each of Messrs. Brewer, Bristow, Ozeroff, and St.
Laurent: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Richard B. Brewer, 57. </I>Mr.&nbsp;Brewer joined ABI in November 2006. From January 2003 until he joined ABI, Mr.&nbsp;Brewer
was managing partner of Crest Asset Management, where he provided guidance to and invested in biotechnology opportunities. Before that, Mr.&nbsp;Brewer was president and CEO of Scios, Inc., a Johnson&nbsp;&amp; Johnson company. Before Scios,
Mr.&nbsp;Brewer served as chief operating officer of Heartport, a cardiovascular device company developing minimally invasive approaches to major heart surgery. Prior to that, he spent over a decade at Genentech in various management positions,
including senior vice president of sales and marketing and senior vice president of Genentech Europe and Canada. Mr.&nbsp;Brewer holds a B.S. from Virginia Polytechnic Institute and an M.B.A. from Northwestern University. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Michael R. Bristow, M.D., Ph.D., 64.</I> Dr.&nbsp;Bristow joined ABI as one of ABI&#146;s founders in September 2004, and served as chairman and chief
executive officer of ABI until he was appointed to the position of chief science and medical officer in November 2006. Dr.&nbsp;Bristow is a professor of medicine and the former head of cardiology at the University of Colorado Health Sciences
Center, where he has been since October 1991. Dr.&nbsp;Bristow was one of the founders of Myogen, Inc. and served as Myogen&#146;s chief science and medical officer from October 1996 to February 2006 and as a scientific advisor to Myogen from
February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Christopher D. Ozeroff, 49</I>.
Mr.&nbsp;Ozeroff was a co-founder of ABI in September 2004 and has been its executive vice president of business development and general counsel since that date. From August 1999, Mr.&nbsp;Ozeroff was previously a partner with the law firm of
Hogan&nbsp;&amp; Hartson L.L.P., where he practiced in such areas as finance, acquisitions, public offerings and licensing. Mr.&nbsp;Ozeroff completed his undergraduate degree at Stanford University, and his law degree at the University of Chicago
Law School. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Randall St. Laurent, 48. </I>Mr.&nbsp;St. Laurent&nbsp;joined ABI in January 2008. From&nbsp;March 2001&nbsp;until he
joined ABI, Mr.&nbsp;St. Laurent was employed by Scios, Inc., first as the vice president of sales and marketing and later as the vice president of commercial development. From&nbsp;September 1999 until March 2001, Mr.&nbsp;St. Laurent was an
executive sales director at Transkaryotic Therapies in Cambridge, Massachusetts.&nbsp;Mr. St.&nbsp;Laurent received a&nbsp;B.A. with a major in marketing from the Ohio State University. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Employment Agreement with Richard B. Brewer </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Richard B.&nbsp;Brewer is employed as ARCA&#146;s president and chief executive officer under an Employment and Retention Agreement with ABI dated
November&nbsp;2, 2006 that was amended and restated as of July&nbsp;7, 2008 and that was assumed by ARCA in connection with the closing of the merger. Under his employment agreement, Mr.&nbsp;Brewer is entitled to receive an annual base salary of
$300,000, subject to annual increases if approved by ARCA&#146;s board of directors and is eligible to receive an annual bonus as determined by the board of directors in its sole discretion. Mr.&nbsp;Brewer is permitted to serve on a maximum of four
outside corporate boards of directors, so long as such service does not interfere with his duties as president and chief executive officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">If ARCA terminates Mr.&nbsp;Brewer&#146;s employment without &#147;cause,&#148; or if Mr.&nbsp;Brewer terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), ARCA has agreed to pay
Mr.&nbsp;Brewer a severance payment equivalent to (i)&nbsp;12 months of his base salary and (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the
fiscal year in which his employment terminated, to be paid at the same time that the incentive bonus would have been paid had the termination not occurred. ARCA may elect to pay Mr.&nbsp;Brewer additional severance equal to up to 12 months&#146; of
his base salary, which additional payments would extend Mr.&nbsp;Brewer&#146;s obligations under his Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. Severance payments may be made by ARCA on a
monthly basis or, at ARCA&#146;s election, in a lump sum. The severance payment is conditioned on the execution by Mr.&nbsp;Brewer of a legal release in a form acceptable to ARCA. A termination for &#147;cause&#148; includes willful misconduct,
gross negligence, theft, fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure or inability to perform material job duties or habitual absenteeism; or violation of
fiduciary duty, violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other agreement, with ARCA. &#147;Good
reason&#148; includes a decrease in current base salary, with certain exceptions; change in title or reporting relationship; failure of ARCA&#146;s stockholders to elect Mr.&nbsp;Brewer to the board of directors; a move of ARCA&#146;s headquarters
to a location greater than 60&nbsp;miles from Denver, Colorado; resignation within 90&nbsp;days of a corporate transaction; or ARCA&#146;s unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Brewer&#146;s job responsibilities.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Employment Agreement with Dr.&nbsp;Michael&nbsp;R. Bristow </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Dr.&nbsp;Michael&nbsp;R. Bristow, M.D., Ph.D. serves as ARCA&#146;s chief science and medical officer under an Employment and Retention Agreement that was amended and restated as of June&nbsp;4, 2008 and that was
assumed by ARCA in connection with the closing of the merger. Dr.&nbsp;Bristow is permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it does not interfere
with his duties as chairman and chief science and medical officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Under his employment agreement, Dr.&nbsp;Bristow is entitled to receive
an annual base salary of $250,000, subject to further annual increases if approved by ARCA&#146;s board of directors (or ARCA&#146;s compensation committee) and is eligible to receive an annual bonus as determined by the board of directors (or
ARCA&#146;s compensation committee) in its sole discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If ARCA terminates Dr.&nbsp;Bristow&#146;s employment without
&#147;cause,&#148; or if Dr.&nbsp;Bristow terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), ARCA has agreed to pay Dr.&nbsp;Bristow a severance payment equivalent to (i)&nbsp;12 months
of his base salary, (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same
time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 12&nbsp;months, whether he elects or is
eligible to receive COBRA (provided, that even if he does </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the
benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&nbsp;months base salary, which additional payment would extend the covenants and obligations
under Dr.&nbsp;Bristow&#146;s Employee Intellectual Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Dr.&nbsp;Bristow of a legal release in a form acceptable to
ARCA. A termination for &#147;cause&#148; includes willful misconduct, gross negligence, theft, fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure or inability
to perform material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and
Non-Compete Agreement, or any other agreement, with ARCA. &#147;Good reason&#148; includes a relocation of normal work location greater than 30&nbsp;miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#146;s
unilateral decision to significantly and detrimentally reduce Dr.&nbsp;Bristow&#146;s job responsibilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Employment Agreement with Christopher D.
Ozeroff </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Christopher&nbsp;D. Ozeroff is employed as ARCA&#146;s executive vice president of business development and
general counsel pursuant to an employment agreement amended and restated as of June&nbsp;12, 2008, which agreement was assumed by ARCA in connection with the closing of the merger. Under his employment agreement, Mr.&nbsp;Ozeroff is entitled to
receive an annual base salary of $220,000, subject to further annual increases if approved by ARCA&#146;s board of directors (or ARCA&#146;s compensation committee) and is eligible to receive an annual bonus as determined by ARCA&#146;s board of
directors (or ARCA&#146;s compensation committee) in its sole discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If ARCA terminates Mr.&nbsp;Ozeroff&#146;s employment without
&#147;cause,&#148; or if Mr.&nbsp;Ozeroff terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&nbsp;Ozeroff a severance payment equivalent to (i)&nbsp;12 months
of his base salary, (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same
time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover out-of-pocket costs to continue group health insurance benefits under COBRA for 12 months, whether he elects or is eligible
to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out-of-pocket expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so
eligible). In addition ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months base salary, which additional payment would extend the covenants and obligations under Mr.&nbsp;Ozeroff&#146;s Employee Intellectual
Property, Confidentiality and Non-Compete Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&nbsp;Ozeroff of a legal release in a form acceptable to ARCA. A termination for &#147;cause&#148; includes
willful misconduct, gross negligence, theft, fraud or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure or inability to perform material job duties or habitual
absenteeism; or violation of fiduciary duty, violation of any duty of loyalty or material breach of any material term of the employment agreement or the Employee Intellectual Property, Confidentiality and Non-Compete Agreement, or any other
agreement, with ARCA. &#147;Good reason&#148; includes a relocation of normal work location greater than 30&nbsp;miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#146;s unilateral decision to significantly
and detrimentally reduce Mr.&nbsp;Ozeroff&#146;s job responsibilities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>2004 Stock Incentive Plan </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>General </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each option and warrant to purchase ABI capital stock outstanding at the effective time of the merger was
assumed by ARCA at the effective time of the merger. ABI had initially adopted the 2004 Stock Incentive Plan (as amended, the &#147;Plan&#148;) to enhance the ability of ABI and its affiliates to attract and retain highly qualified officers,
directors, key employees and other persons, and to motivate such persons to serve ABI and to expend maximum effort to improve its business results and earnings, by providing to such persons an opportunity to acquire or increase a direct proprietary
interest in the operations and future success of ABI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At the effective time of the merger, each outstanding option awarded under the Plan
became an option to acquire that number of shares of ARCA common stock equal to the product obtained by multiplying&nbsp;the number of shares of ABI capital stock subject to such option by 0.16698070, rounded down to the nearest whole share of ARCA
common stock. Following the merger, each such option has a purchase price per share of ARCA common stock equal to the quotient obtained by dividing&nbsp;the per share purchase price of ABI capital stock subject to such option by&nbsp;0.16698070,
rounded up to the nearest whole cent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Plan authorizes the granting of awards of stock options and restricted stock to ABI&#146;s
employees, officers, consultants and directors and to employees, officers, consultants and directors of its subsidiaries. As of the closing of the merger, no additional option awards or grants of restricted stock will be made under the Plan and all
shares of restricted stock issued under the Plan that were previously unvested were vested as a result of the merger, excluding the unvested shares of restricted stock held by LabCorp, which vest upon the attainment of certain regulatory approval
and drug product sales milestones. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Limitations on Transfer; Beneficiaries </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Except for certain authorized transfers to family members: (i)&nbsp;during the lifetime of a participant, only the participant (or, in the event of legal
incapacity or incompetency, the participant&#146;s guardian or legal representative) may exercise an option and (ii)&nbsp;no option shall be assignable or transferable by the participant to whom it is granted, other than by will or the laws of
descent and distribution. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Assumption of Awards Upon Certain Reorganizations </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If ARCA is the surviving entity in any reorganization, merger or consolidation with one or more entities and in which no change of control occurs, any
outstanding awards under the Plan will pertain to and apply solely to the common stock to which the participant would have been entitled immediately following such reorganization, merger or consolidation with a corresponding adjustment in the price
of any options. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Acceleration Upon Certain Events </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In the event of a &#147;change of control&#148; (as defined in the Plan) of ARCA in which ARCA is not the surviving entity, all outstanding options and restricted stock may be assumed or continued, or substituted for
new common stock options and new common stock restricted stock relating to the stock of a successor entity, or its parent or subsidiary, if provision is made in writing in connection with the change of control. In this event, appropriate adjustments
as to the number of shares and option prices would be made and outstanding options and restricted stock would continue in the manner and under the terms so provided. If the options and restricted stock awards are not to be assumed, continued or
substituted, then (i)&nbsp;all outstanding shares of restricted stock will be deemed to have vested, and with the exception of any rights of first refusal, repurchase rights or other restrictions as formerly discussed, all restrictions and
conditions applicable to shares of restricted stock will be deemed to have lapsed immediately prior to such change of control, and (ii)&nbsp;either of the following two actions shall have been taken: (x)&nbsp;15 days prior to the scheduled
consummation of a change of control, all options outstanding shall become immediately exercisable and shall remain exercisable for a period of 15 days or (y)&nbsp;the compensation committee of the board of directors may elect to cancel any
outstanding grants and pay or deliver, or cause to be paid or delivered, to each participant an amount in cash or securities having an equivalent value (as determined by the compensation committee in good faith). </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Amendment </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">An amendment to the Plan is contingent on approval of ARCA&#146;s shareholders only to the extent required by applicable law, regulations or rules. No grants can be made after termination of the Plan. No amendment,
suspension or termination of the Plan will, without the consent of the participant, alter or impair rights or obligations under any grant theretofore awarded under the Plan. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Plan, including all amendments, and the forms of agreements evidencing awards of stock options made thereunder are attached hereto as Exhibits 10.1,
10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 and 10.10 to this Current Report on Form 8-K and are incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Option and
Restricted Stock Grants under the Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following executive officers and directors of ARCA were granted stock options to
purchase shares of ABI common stock prior to the merger. The number of shares of ARCA common stock issuable pursuant to these option grants and the exercise price, as adjusted for the merger, is set forth opposite such executive officer&#146;s and
director&#146;s name in the following table. The options will remain subject to the terms and conditions of the Plan and the stock option agreements between ABI and each director and executive officer. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="38%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Grant Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>ARCA<BR>Option&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Exercise&nbsp;Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>Vesting</B></FONT></P></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Richard&nbsp;B.&nbsp;Brewer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">11/2/2006</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">165,644</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&nbsp;0.90</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fully&nbsp;exercisable&nbsp;at date of grant, subject to ARCA&#146;s right to repurchase(1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/22/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">25,047</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> 5.57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Equal&nbsp;monthly installments over&nbsp;a&nbsp;four&nbsp;year period from the date of grant</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Michael&nbsp;R.&nbsp;Bristow, M.D. Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/03/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">118,319</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> 0.06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">02/14/08(2)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">09/09/08(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">25% on October 18, 2005; 6.25% at the end of each three month period thereafter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/22/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">25,047</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> 5.57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Equal monthly installments over a four year period from the date of grant</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">John L. Zabriskie, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">8/03/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3,887</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"> 0.60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">971 shares on May 4, 2006; 242 shares at the end of each</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">quarter thereafter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">8/03/2006</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5,694</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&nbsp;0.90</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1,423 shares on August 3, 2007; 355 shares at the end of each quarter thereafter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2/02/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4,174</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&nbsp;1.68</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1,043 shares on February 2, 2008; 260 shares at the end of each quarter thereafter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5/02/2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4,174</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.86</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1,043 shares at the end of each quarter following grant date</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/22/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1,786</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fully exercisable at date of grant</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">J.&nbsp;William&nbsp;Freytag, Ph.D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2/2/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">13,692</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.68</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3,423 shares on February 2, 2008; 855 shares at the end of each quarter thereafter.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5/2/2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4,174</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.86</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1,043 shares at the end of each quarter following grant date</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/22/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1,786</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fully exercisable at date of grant</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/03/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">65,623</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">0.06</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">9/23/08(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">25% on October 18, 2005; 6.25% at the end of each three month period thereafter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Randall&nbsp;St.&nbsp;Laurent</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2/12/2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">30,056.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1.86</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">25% on January 2, 2009; 6.25%</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">at the end of each three month&nbsp;period thereafter</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1/22/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10,018.00</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5.57</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Equal&nbsp;monthly installments over&nbsp;a&nbsp;four&nbsp;year period from the date of grant</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The options were exercisable immediately and if exercised are subject to ARCA&#146;s right of repurchase, which lapses at the rate of 25% upon grant and 6.25% at the end of each
three-month period following the first anniversary of the November&nbsp;2, 2006 grant date. Of these options, as of December&nbsp;31, 2008, 124,233 were subject to a right of repurchase in favor of ARCA. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">96,134 shares exercised. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">14,790 shares exercised. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">61,522 shares exercised. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, Mr. Brewer
received 500,000 shares of ABI restricted common stock under the Plan, pursuant to the terms of his restricted stock agreement with ABI, which was amended in October 2008 to provide that all 500,000 shares of ABI restricted stock subject to the
agreement would vest in full upon the closing of the merger. As a result of the merger, these shares represent the right to acquire 83,490 shares of ARCA common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Transactions with ARCA&#146;s Chief Science and Medical Officer and Chairman </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>University of
Colorado Research Grant </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ABI entered into an unrestricted research grant with a research laboratory of the University of Colorado led by
Dr.&nbsp;Michael&nbsp;R. Bristow, ARCA&#146;s chief science and medical officer and chairman of the board of directors, for the advancement of research in chronic heart failure. Under this agreement, ABI paid the research laboratory $22,500 per
quarter and $7,500 per month to offset salary expenses at the laboratory. This arrangement was in place through June 2007. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Effective
July&nbsp;1, 2007, ABI terminated its prior grant funding arrangement and entered into another unrestricted research grant with Dr.&nbsp;Bristow&#146;s research laboratory for $23,917 per month. Total expenses under these arrangements for the nine
months ended September&nbsp;30, 2008 and 2007 were $226,920, and $112,834, respectively. Total expenses during fiscal years 2007, 2006 and 2005 were $222,502, $154,992 and $123,311, respectively, and $742,638 from inception through
September&nbsp;30, 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><I>University of Colorado Materials Transfer Agreement </I></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ABI also entered into a materials transfer agreement with the University of Colorado, under which ABI has agreed to pay $35,000 per year to maintain the
Heart Tissue Bank associated with Dr.&nbsp;Bristow&#146;s research laboratory at the University of Colorado. Total expenses for the nine months ended September&nbsp;30, 2008 and 2007 were $26,250 and $17,500, respectively. Total expenses during
fiscal years 2007, 2006 and 2005 were $35,000, $35,000 and $35,000, respectively, and $140,000 from inception through September&nbsp;30, 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>Gilead Sciences, Inc. (formerly Myogen Inc.) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On October&nbsp;7, 2005, ABI entered into a strategic alliance agreement with
Myogen, Inc., now known as Gilead Sciences, Inc., in exchange for certain sublicenses and licenses for technology licensed by Myogen. At that time, Dr.&nbsp;Bristow served as a director of Myogen and as its chief science and medical officer and as
ABI&#146;s chief executive officer and chairman of ABI&#146;s board of directors. Dr.&nbsp;Freytag was </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">also president, chief executive officer and chairman of the board of directors of Myogen at that time, and until the acquisition of Myogen by Gilead Sciences
in November 2006, but was not then a director of ABI. On February&nbsp;21, 2006, Dr.&nbsp;Bristow resigned as Myogen&#146;s chief science and medical officer. In connection with the strategic alliance agreement, ABI issued 614,834&nbsp;shares of its
common stock to Myogen, which as a result of the merger, represent the right to acquire 102,665 shares of ARCA common stock. The estimated fair value of the shares granted was $0.12 per share. ABI recorded the estimated fair value of the shares as
research and development expense because the rights granted under the agreement have no alternate use other than ABI&#146;s research and development efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><I>Exclusive License Agreement with the Regents of the University of Colorado </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As described above in
Item&nbsp;1.01 of this Current Report on Form&nbsp;8-K under the section entitled &#147;Material ABI Agreements &#150; Exclusive License Agreement with the Regents of the University of Colorado&#148; which description is incorporated herein by
reference, ABI entered into an exclusive license agreement with ULEHI, whereby ULEHI licensed to ABI patent applications covering use of Gencaro therapy and various options to license future inventions and targets, among other intellectual property,
and ABI agreed to issue stock to ULEHI (as described below) and to make certain payments beginning in 2006. A portion of the license revenue received by ULEHI is allocated to the research laboratory of Dr.&nbsp;Bristow. ABI expensed $18,750 and
$25,000 for the nine months ended September&nbsp;30, 2008 and 2007, respectively. During 2007, 2006 and 2005, ABI paid $25,000, $25,000 and $0, respectively and has paid $68,750 from ABI&#146;s inception through September&nbsp;30, 2008. In addition,
ABI will owe royalties based upon its commercial sales (other than Gencaro) and other milestones, if any. In August&nbsp;2007 ABI executed an amendment to the license agreement to acquire additional patent rights and paid $15,000 for those rights.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As part of its licensing arrangement, ABI has issued to ULEHI at total of 302,785&nbsp;shares of ABI common stock, which as a result of
the merger, represent the right to acquire 50,555 shares of ARCA common stock. Pursuant to an anti-dilution provision in the license agreement, ABI issued 69,882&nbsp;shares of its common stock, 142,903&nbsp;shares of its common stock, and
0&nbsp;shares of its common stock in 2007, 2006, 2005, respectively, and 212,785&nbsp;shares of its common stock from inception through December&nbsp;31, 2007. The estimated fair value of shares granted in 2007 was $0.29 per share. The anti-dilution
provision was fully satisfied in May&nbsp;2007. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Convertible Promissory Notes and Warrants </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As described above in Item&nbsp;1.01 of this Current Report on Form&nbsp;8-K under the section entitled &#147;Material ABI Agreements &#150; Note and
Warrant Purchase Agreement&#148; which description is incorporated herein by reference, ABI entered into a Note and Warrant Purchase Agreement dated September&nbsp;24, 2008, as amended on October&nbsp;10, 2008, with certain holders of ABI preferred
stock. Atlas Venture Fund VII, L.P., of which Dr.&nbsp;Jean-Fran&ccedil;ois Formela is a partner in the life sciences group, purchased $3,674,630 in principal amount of notes and corresponding warrants, Skyline Venture Partners Qualified Purchaser
Fund IV, L.P., of which David G. Lowe is a partner, purchased $1,825,696 in principal amount of notes and corresponding warrants, and InterWest Partners IX, L.P., of which Dr.&nbsp;Linda Grais is a partner, purchased $1,461,872 in principal amount
of notes and corresponding warrants. Each of these investors acquired convertible notes and warrants on the same terms and conditions as the other investors under the Note and Warrant Purchase Agreement. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Investor Rights Agreement and Related Financing Documents </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">In connection with its preferred stock financings, ABI entered into an Amended and Restated Investor Rights Agreement dated May&nbsp;31, 2007 with its investors, including Atlas Venture Fund VII, L.P., and Skyline
Venture Partners Qualified Purchaser Fund IV, L.P. and InterWest Partners, IX, L.P., pursuant to which such investors received registration rights with respect to their shares of preferred stock, an Amended and Restated Right of First Refusal and
Co-Sale Agreement and Amended and </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Restated Voting Agreement. As a condition to completion of the merger, each of these agreements and the rights thereunder was terminated. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Indemnification of Directors and Officers </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">ARCA has entered into indemnification agreements with each of its directors and certain of its executive officers. These agreements provide for the indemnification of the directors and executive officers of ARCA for all reasonable expenses
and liabilities incurred in connection with any action or proceeding brought against them by reason of the fact that they are or were directors or officers of ARCA. ARCA believes that these indemnification agreements are necessary to attract and
retain qualified persons as directors and officers. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;5.03.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Amendments to Articles of Incorporation or Bylaws </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">The information set forth in Item&nbsp;3.03 of this Current Report on Form&nbsp;8-K is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Financial Statements of Businesses Acquired. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">The
consolidated financial statements of ABI, including the report of the independent registered public accounting firm, KPMG LLP, required by this item have not been filed on this initial Current Report on Form 8-K but will be filed by amendment on or
before February&nbsp;2, 2009. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pro Forma Financial Information. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">The pro forma financial
information required by this item has not been filed on this initial Current Report on Form 8-K but will be filed by amendment on or before February&nbsp;2, 2009. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Shell Company Transactions. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">N/A </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Agreement and Plan of Merger and Reorganization, dated as of September&nbsp;24, 2008, among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.(1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 1 to Agreement and Plan of Merger and Reorganization dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to amended and restated bylaws of the registrant.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to amended and restated certificate of incorporation of the registrant.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Ownership and Merger merging ARCA Merger, Inc. with and into Nuvelo, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Common Stock Certificate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.1&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.2&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 1 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.3&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 2 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.4&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 3 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.5&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 4 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.6&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 5 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.7&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 6 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.8&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Executive Incentive Stock Option Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.9&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Non-executive Incentive Stock Option Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.10&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Nonqualified Stock Option Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press release of ARCA biopharma, Inc. dated January 27, 2009.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press release of ARCA biopharma, Inc. dated January 28, 2009.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Compensatory plan or agreement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA&#146;s Form&nbsp;8-K, filed September&nbsp;25, 2008, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form&nbsp;8-K, filed October&nbsp;29, 2008, File No. 000-22873.
</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President of Business Development, General Counsel and Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Dated: January&nbsp;28, 2009 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Agreement and Plan of Merger and Reorganization, dated as of September&nbsp;24, 2008, among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.(1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 1 to Agreement and Plan of Merger and Reorganization dated October 28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc. and ARCA biopharma, Inc.(2)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to amended and restated bylaws of the registrant.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment to amended and restated certificate of incorporation of the registrant.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Certificate of Ownership and Merger merging ARCA Merger, Inc. with and into Nuvelo, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Common Stock Certificate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.1&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.2&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 1 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.3&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 2 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.4&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 3 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.5&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 4 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.6&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 5 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.7&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Amendment No. 6 to ARCA 2004 Stock Incentive Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.8&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Executive Incentive Stock Option Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.9&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Non-executive Incentive Stock Option Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.10&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Form of Nonqualified Stock Option Agreement.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press release of ARCA biopharma, Inc. dated January 27, 2009.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press release of ARCA biopharma, Inc. dated January 28, 2009.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Compensatory plan or agreement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from ARCA&#146;s Form&nbsp;8-K, filed September&nbsp;25, 2008, File No. 000-22873.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Previously filed with the SEC as an Exhibit to and incorporated herein by reference from Nuvelo, Inc.&#146;s Form&nbsp;8-K, filed October&nbsp;29, 2008, File No. 000-22873.
</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>dex31.htm
<DESCRIPTION>AMENDEMENT TO AMENDED AND RESTATED BYLAWS
<TEXT>
<HTML><HEAD>
<TITLE>Amendement to amended and restated bylaws</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 3.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT TO AMENDED AND RESTATED BYLAWS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OF </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC., </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>a Delaware
corporation </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Effective January&nbsp;23, 2009 by resolutions duly adopted by a majority of the Board of Directors of Nuvelo, Inc. (the
&#147;<B><I>Company</I></B>&#148;) on January&nbsp;23, 2009, Article III, Section&nbsp;1, Subsection (a)&nbsp;of the Company&#146;s Bylaws was amended to read in its entirety as follows: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT FACE="Times New Roman" SIZE="2">&#147;(a) The number of directors of the corporation shall consist of not less than two (2)&nbsp;nor more than ten (10)&nbsp;directors, the exact number
of directors to be determined from time to time by resolution adopted by the affirmative vote of a majority of the directors. A director shall hold office until the later of (i)&nbsp;the next annual meeting of the stockholders of the corporation
immediately following, or (ii)&nbsp;coinciding with the expiration of the director&#146;s term or until the director&#146;s successor shall be elected and shall qualify, subject, however, to prior death, resignation, retirement, disqualification or
removal from office. Directors need not be residents of the State of Delaware or stockholders of the corporation.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The remainder of
the Company&#146;s Bylaws remain in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Executed at San Carlos, California, on January&nbsp;23, 2009. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Lee Bendekgey</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey, Secretary</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>dex32.htm
<DESCRIPTION>AMENDEMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
<TEXT>
<HTML><HEAD>
<TITLE>Amendement to amended and restated certificate of incorporation</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 3.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>CERTIFICATE OF AMENDMENT TO THE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>N<SMALL>UVELO</SMALL>, I<SMALL>NC</SMALL>.</B>, a corporation organized and existing under the General Corporation law of the State of Delaware
does hereby certify: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>ONE: </B>The date of filing the original Certificate of Incorporation of this company with the Secretary of State
of the State of Delaware was March&nbsp;16, 2004 as amended and restated on March&nbsp;18, 2004. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>TWO: </B>The Board of Directors of the
Company, acting in accordance with the provisions of Sections&nbsp;141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Article IV shall be amended to add the following provisions in their entirety to the existing provisions of Article IV: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">&#147;Effective at 5:00 p.m. Eastern time, on the date of filing of this Certificate of Amendment to the Amended and Restated Certificate
of Incorporation with the Secretary of State of the State of Delaware (the &#147;Effective Time&#148;), the shares of the Corporation&#146;s Common Stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time and
the shares of Common Stock issued and held in the treasury of the Corporation immediately prior to the Effective Time shall be combined into a smaller number of shares such that each 20 shares of issued Common Stock immediately prior to the
Effective Time are combined into one validly issued, fully paid and nonassessable share of Common Stock, par value $0.001 per share. Notwithstanding the immediately preceding sentence, no fractional shares shall be issued and, in lieu thereof, upon
surrender after the Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time, any person who would otherwise be entitled to a fractional share of
Common Stock as a result of the combination, following the Effective Time (after taking into account all fractional shares of Common Stock otherwise issuable to such holder), shall be entitled to receive a cash payment equal to the fraction to which
such holder would otherwise be entitled multiplied by the then fair value of the Common Stock as determined by the Board of Directors. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Each stock certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall, from and after the Effective
Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Effective Time </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">into which the shares of Common Stock formerly represented by such certificate shall have been combined (as well as the right to receive cash in lieu of
fractional shares of Common Stock after the Effective Time), provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time shall
receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Effective Time into which the shares of Common Stock formerly represented by such certificate shall have
been combined.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THREE: </B>Thereafter, pursuant to a resolution by the Board of Directors of the Corporation, this Certificate of
Amendment was submitted to the stockholders of the corporation for their consideration and was duly adopted and approved in accordance with the provisions of Sections 228 and 242 of the General Corporation Law of the State of Delaware at a special
meeting of the stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, Nuvelo, Inc. has
caused this <B>C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> A<SMALL>MENDMENT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL>
I<SMALL>NCORPORATION</SMALL> </B>to be signed by its Chairman of the Board of Directors and Chief Executive Officer this 27th day of January, 2009. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>N<SMALL>UVELO</SMALL>, I<SMALL>NC</SMALL>.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Ted W. Love, M.D.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Ted. W. Love, M.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board of Directors and Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>4
<FILENAME>dex33.htm
<DESCRIPTION>CERTIFICATE OF OWNERSHIP AND MERGER
<TEXT>
<HTML><HEAD>
<TITLE>Certificate of Ownership and Merger</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 3.3 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>CERTIFICATE OF OWNERSHIP AND MERGER </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>MERGING </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA MERGER, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(a Delaware
corporation) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>WITH AND INTO </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(a Delaware corporation) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(Pursuant to Section&nbsp;253 of the General Corporation Law </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>of the State of Delaware)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo, Inc., a Delaware corporation (the &#147;<U>Corporation</U>&#148;) does hereby certify: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FIRST</B>: That the Corporation is incorporated pursuant to the General Corporation Law of the State of Delaware (the &#147;<U>Delaware Law</U>&#148;).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>SECOND</B>: That the Corporation owns all of the outstanding shares of each class of the outstanding capital stock of ARCA Merger,
Inc., a Delaware corporation (the &#147;<U>Subsidiary</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THIRD</B>: That the Corporation, by the following resolutions of its
Board of Directors (the &#147;<U>Board</U>&#148;) duly adopted by unanimous written consent on January&nbsp;27, 2009, determined to merge Subsidiary with and into the Corporation pursuant to Section&nbsp;253 of the Delaware Law: </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>WHEREAS,</B> the Corporation owns all of the outstanding shares of each class of the outstanding capital stock of the Subsidiary; and
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>WHEREAS,</B> the Board has determined that it is fair to, advisable and in the best interests of, the Corporation and
its stockholders for the Subsidiary to be merged with and into the Corporation pursuant to Section&nbsp;253 of the Delaware Law, with the Corporation surviving the merger and assuming all of the Subsidiary&#146;s liabilities and obligations (the
&#147;<U>Merger</U>&#148;); now, therefore, be it </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>RESOLVED,</B> the Merger be, and it hereby is, authorized, approved
and adopted in all respects; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FURTHER RESOLVED</B>, that, in accordance with Section&nbsp;103(d) of the Delaware Law, the
Merger shall become effective upon the filing of the Certificate of Ownership and Merger with the Secretary of State of the State of Delaware; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2"><B>FURTHER RESOLVED, </B>that pursuant to Section&nbsp;253(b) of the Delaware Law, the Board deems it advisable and in the best interest of the Corporation and its stockholders, and hereby approves, a change in the
Corporation&#146;s corporate name to </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%">
<FONT FACE="Times New Roman" SIZE="2">&#147;ARCA biopharma, Inc.&#148;, such change to become effective upon the effectiveness of the Merger; </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FURTHER RESOLVED, </B>that the assumption by the Corporation of all of the Subsidiary&#146;s liabilities and obligations of the
Subsidiary be, and it hereby is, authorized, approved and adopted in all respects; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FURTHER RESOLVED, </B>that by virtue
of the Merger and without any action on the part of the holder thereof, each then outstanding share of common stock of the Subsidiary shall be canceled and no consideration shall be issued in respect thereof; and </FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FURTHER RESOLVED,</B> that the President or any Vice President of the Corporation be, and is hereby, authorized to make, execute and
acknowledge a Certificate of Ownership and Merger setting forth a copy of the resolution to merge said Subsidiary with and into the Corporation, to effect the name change above and to assume the Subsidiary&#146;s liabilities and obligations and the
date of adoption thereof and to file the same in the office of the Secretary of State of Delaware, and to do all acts and things whatsoever, whether within or without the State of Delaware, which may be in any way necessary or appropriate to effect
said Merger. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>FOURTH</B>: Pursuant to Section&nbsp;253(b) of the Delaware Law, upon the effectiveness of the Merger, the Corporation, as
the surviving corporation in the Merger, will change its corporate name to &#147;ARCA biopharma, Inc.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">[Remainder of page
intentionally left blank] </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF,</B> the Corporation has caused this Certificate of Ownership and Merger to be
signed by an authorized officer this 27 day of January, 2009. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President of Business Development and General Counsel</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>5
<FILENAME>dex41.htm
<DESCRIPTION>FORM OF COMMON STOCK CERTIFICATE
<TEXT>
<HTML><HEAD>
<TITLE>Form of Common Stock Certificate</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 4.1 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="100%"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">

<IMG SRC="g90806img.jpg" ALT="LOGO"></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ARCA BIOPHARMA, INC. </FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">THE
CORPORATION WILL FURNISH TO ANY STOCKHOLDER, UPON REQUEST AND WITHOUT CHARGE, A STATEMENT OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF AND THE
QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND/OR RIGHTS. ANY SUCH REQUEST SHOULD BE ADDRESSED TO THE SECRETARY OF THE CORPORATION AT ITS PRINCIPAL OFFICE. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="14" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="13" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT FACE="Times New Roman" SIZE="1">The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though
they were written out in full according to applicable laws or regulations:</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">TEN&nbsp;COM</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">- as tenants in common</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">UNIF&nbsp;GIFT&nbsp;MIN&nbsp;ACT-</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">Custodian</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(Cust)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(Minor)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">TEN ENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">- as tenants by the entireties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">under Uniform Gifts to Minors Act</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(State)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD ROWSPAN="2" VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT FACE="Times New Roman" SIZE="1">JT TEN</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT FACE="Times New Roman" SIZE="1">- as joint tenants with right of survivorship and not as tenants in common</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">UNIF TRF MIN ACT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">Custodian&nbsp;(until&nbsp;age.<U>&nbsp;&nbsp;&nbsp;&nbsp;</U>)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(Cust)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(Minor)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="1">under&nbsp;Uniform&nbsp;Transfers&nbsp;to&nbsp;Minors&nbsp;Act</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1">(State)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="9" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">Additional abbreviations may also be used though not in the above list.</FONT></P> <P
STYLE="font-size:4px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1">PLEASE&nbsp;INSERT&nbsp;SOCIAL&nbsp;SECURITY&nbsp;OR&nbsp;OTHER&nbsp;IDENTIFYING&nbsp;NUMBER&nbsp;OF&nbsp;ASSIGNEE</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">For value received, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> hereby sell, assign and transfer
unto</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) </FONT></P> <P STYLE="font-size:14px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">Shares of the Common Stock represented by the within Certificate,
and do hereby irrevocably constitute and appoint </FONT></P> <P STYLE="font-size:14px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:1px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="1">Attorney to transfer the said stock on the books of the within-named Corporation with full power of substitution in the premises. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">Dated:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="4" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="1">Signature(s) Guaranteed: Medallion Guarantee Stamp</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT FACE="Times New Roman" SIZE="1">THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks,
Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15.</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">Signature:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="1">Signature:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="1">Notice:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="1">The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change
whatever.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g90806ex4_img1.jpg" ALT="LOGO"></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px">&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g90806ex4_img2.jpg" ALT="LOGO"></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px" align="left">&nbsp;</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>dex101.htm
<DESCRIPTION>ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>ARCA DISCOVERY, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">TABLE OF CONTENTS </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Page</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">PURPOSE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">DEFINITIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">ADMINISTRATION OF THE PLAN</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Board</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">4</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Committee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Grants</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">5</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Deferral Arrangement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">3.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">No Liability</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">STOCK SUBJECT TO THE PLAN</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">GRANT ELIGIBILITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Employees and Other Service Providers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">6</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Successive Grants</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">5.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Limitations on Incentive Stock Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">AWARD AGREEMENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">TERMS AND CONDITIONS OF OPTIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Option Price</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Vesting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">7</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Term</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Exercise of Options on Termination of Service</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Limitations on Exercise of Option</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Exercise Procedure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Right of Holders of Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">7.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Delivery of Stock Certificates</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">TRANSFERABILITY OF OPTIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Transferability of Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Family Transfers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">RESTRICTED STOCK</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Grant of Restricted Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Restrictions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Restricted Stock Certificates</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Rights of Holders of Restricted Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">10</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Termination of Service</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">9.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Purchase and Delivery of Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">FORM OF PAYMENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">General Rule</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Surrender of Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">11</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Cashless Exercise</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Promissory Note</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">WITHHOLDING TAXES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">RESTRICTIONS ON TRANSFER OF SHARES OF STOCK</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Right of First Refusal</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Repurchase&nbsp;and Other Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Installment Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">General Rule</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Exception in the Case of Stock Repurchase Right</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- i - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">12.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Publicly Traded Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">12.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Legend</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">PARACHUTE LIMITATIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">REQUIREMENTS OF LAW</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">14.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">General</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">14.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Rule 16b-3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">14.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Financial Reports</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">EFFECT OF CHANGES IN CAPITALIZATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Changes in Stock</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Reorganization in Which the Company Is the Surviving Entity and in Which No Change of Control Occurs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Reorganization, Sale of Assets or Sale of Stock Which Involves a Change of Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Adjustments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">15.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">No Limitations on Company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">17</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">16.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">DURATION AND AMENDMENTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">16.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Term of the Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">16.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Amendment and Termination of the Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">GENERAL PROVISIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Disclaimer of Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Nonexclusivity of the Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Captions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Other Award Agreement Provisions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Number and Gender</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Severability</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">17.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Governing Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">19</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">18.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT FACE="Times New Roman" SIZE="2">EXECUTION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">20</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- ii - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA DISCOVERY, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">ARCA Discovery, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), sets forth herein the terms of its 2004 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;) as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>PURPOSE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Plan is intended to enhance the
Company&#146;s and its Affiliates&#146; (as defined herein) ability to attract and retain highly qualified officers, directors, key employees, and other persons, and to motivate such officers, directors, key employees, and other persons to serve the
Company and its Affiliates and to expend maximum effort to improve the business results and earnings of the Company, by providing to such officers, directors, key employees and other persons an opportunity to acquire or increase a direct proprietary
interest in the operations and future success of the Company. To this end, the Plan provides for the grant of stock options and restricted stock in accordance with the terms hereof. Stock options granted under the Plan may be nonqualified stock
options or incentive stock options, as provided herein. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>DEFINITIONS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For purposes of interpreting the Plan
and related documents (including Award Agreements), the following definitions shall apply: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.1 &#147;<B><I>Affiliate</I></B>&#148; means,
with respect to the Company, any company or other trade or business that controls, is controlled by or is under common control with the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including, without limitation,
any Subsidiary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.2 &#147;<B><I>Award Agreement</I></B>&#148; means the stock option agreement, restricted stock agreement or other
written agreement between the Company and a Grantee that evidences and sets out the terms and conditions of a Grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.3
&#147;<B><I>Benefit Arrangement</I></B>&#148; shall have the meaning set forth in <B>Section&nbsp;13 </B>hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.4
&#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.5 &#147;<B><I>Cause</I></B>&#148; means, as determined by
the Board and unless otherwise provided in an applicable employment agreement with the Company or an Affiliate, (i)&nbsp;gross negligence or willful misconduct in connection with the performance of duties; (ii)&nbsp;conviction of a criminal offense
(other than minor traffic offenses); or (iii)&nbsp;material breach of any term of any employment, consulting or other services, confidentiality, intellectual property or non-competition agreements, if any, between the Service Provider and the
Company or an Affiliate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.6 <B><I>&#147;Change of Control&#148;</I></B> means (i)&nbsp;the dissolution or liquidation of the Company or a
merger, consolidation, or reorganization of the Company with one or more other entities in </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 1 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">which the Company is not the surviving entity (other than a recapitalization transaction which results in 50% or more of the combined voting power of all
classes of stock of the surviving entity being held by one or more persons that were Affiliates of the Company immediately prior to the transaction), (ii)&nbsp;a sale of substantially all of the assets of the Company to another person or entity, or
(iii)&nbsp;any transaction (including without limitation a merger or reorganization in which the Company is the surviving entity) which results in any person or entity (other than persons who are shareholders or Affiliates immediately prior to the
transaction) owning 50% or more of the combined voting power of all classes of stock of the Company, other than the sale by the Company of stock in transactions the primary purpose of which is to raise capital for the Company&#146;s operations and
activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.7 &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as now in effect or as hereafter amended.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.8 &#147;<B><I>Committee</I></B>&#148; means a committee of, and designated from time to time by resolution of, the Board, which shall
consist of one or more members of the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.9 &#147;<B><I>Company</I></B>&#148; means ARCA Discovery, Inc. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.10 <B><I>&#147;Disability&#148;</I></B> means the Grantee is unable to perform each of the essential duties of such Grantee&#146;s position by reason
of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than 12 months; provided, however, that, with respect to rules regarding
expiration of an Incentive Stock Option following termination of the Grantee&#146;s Service, Disability shall mean the Grantee is unable to engage in any substantial gainful activity by reason of a medically determinable physical or mental
impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">2.11 &#147;<B><I>Effective Date</I></B>&#148; means September&nbsp;30, 2004, the date the Plan is approved by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">2.12 &#147;<B><I>Exchange Act</I></B>&#148; means the Securities Exchange Act of 1934, as now in effect or as hereafter amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">2.13 &#147;<B><I>Fair Market Value</I></B>&#148; means the value of a share of Stock, determined as follows: if on the Grant Date or other determination date the Stock is listed on an established national or regional
stock exchange, is admitted to quotation on The Nasdaq Stock Market, Inc., or is publicly traded on an established securities market, the Fair Market Value of a share of Stock shall be the closing price of the Stock on such exchange or in such
market (if there is more than one such exchange or market the Board shall determine the appropriate exchange or market) on the Grant Date or such other determination date (or if there is no such reported closing price, the Fair Market Value shall be
the mean between the highest bid and lowest asked prices or between the high and low sale prices on such trading day) or, if no sale of Stock is reported for such trading day, on the next preceding day on which any sale shall have been reported. If
the Stock is not listed on such an exchange, quoted on such system or traded on such a market, Fair Market Value shall be the value of the Stock as determined by the Board in good faith. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 2 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.14 &#147;<B><I>Family Member</I></B>&#148; means a person who is a spouse, former spouse, child,
stepchild, grandchild, parent, stepparent, grandparent, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law, or sister-in-law, including adoptive relationships, of the Grantee, any person sharing
the Grantee&#146;s household (other than a tenant or employee), a trust in which any one or more these persons have more than 50% of the beneficial interest, a foundation in which any one or more of these persons (or the Grantee) control the
management of assets, and any other entity in which one or more these persons (or the Grantee) own more than 50% of the voting interests; provided, however, that to the extent required by applicable law, the term Family Member shall be limited to a
person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law, or sister-in-law, including adoptive relationships, of
the Grantee or a trust or foundation for the exclusive benefit of any one or more of these persons. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.15 &#147;<B><I>Grant</I></B>&#148;
means an award of an Option or Restricted Stock under the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.16 &#147;<B><I>Grant Date</I></B>&#148; means, as determined by the
Board, the latest to occur of (i)&nbsp;the date as of which the Board approves a Grant, (ii)&nbsp;the date on which the recipient of a Grant first becomes eligible to receive a Grant under <B>Section&nbsp;5</B> hereof, or (iii)&nbsp;such other date
as may be specified by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.17 &#147;<B><I>Grantee</I></B>&#148; means a person who receives or holds an Option or Restricted
Stock under the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.18 &#147;<B><I>Incentive Stock Option</I></B>&#148; means an &#147;incentive stock option&#148; within the meaning
of Section&nbsp;422 of the Code, or the corresponding provision of any subsequently enacted tax statute, as amended from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">2.19 &#147;<B><I>Nonqualified Stock Option</I></B>&#148; means a stock option that is not an Incentive Stock Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.20
&#147;<B><I>Option</I></B>&#148; means an option to purchase one or more shares of Stock pursuant to the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.21 &#147;<B><I>Option
Price</I></B>&#148; means the purchase price for each share of Stock subject to an Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.22 &#147;<B><I>Other Agreement</I></B>&#148;
shall have the meaning set forth in <B>Section&nbsp;13 </B>hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.23 &#147;<B><I>Plan</I></B>&#148; means this ARCA Discovery, Inc.
2004 Stock Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.24 &#147;<B><I>Purchase Price</I></B>&#148; means the purchase price for each share of Stock pursuant to a
Grant of Restricted Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.25 &#147;<B><I>Reporting Person</I></B>&#148; means a person who is required to file reports under
Section&nbsp;16(a) of the Exchange Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 3 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.26 &#147;<B><I>Restricted Stock</I></B>&#148; means shares of Stock, awarded to a Grantee pursuant to
<B>Section&nbsp;9 </B>hereof, that are subject to restrictions and to a risk of forfeiture. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.27 &#147;<B><I>Securities Act</I></B>&#148;
means the Securities Act of 1933, as now in effect or as hereafter amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.28 &#147;<B><I>Service</I></B>&#148; means service as an
employee, officer, director or other Service Provider of the Company or an Affiliate. Unless otherwise stated in the applicable Award Agreement, a Grantee&#146;s change in position or duties shall not result in interrupted or terminated Service, so
long as such Grantee continues to be an employee, officer, director or other Service Provider of the Company or an Affiliate. Subject to the preceding sentence, whether a termination of Service shall have occurred for purposes of the Plan shall be
determined by the Board, which determination shall be final, binding and conclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2.29 &#147;<B><I>Service Provider</I></B>&#148; means
an employee, officer or director of the Company or an Affiliate, or a consultant or adviser currently providing services to the Company or an Affiliate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">2.30 &#147;<B><I>Stock</I></B>&#148; means the common stock, $0.001 par value per share, of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">2.31 &#147;<B><I>Subsidiary</I></B>&#148; means any &#147;subsidiary corporation&#148; of the Company within the meaning of Section&nbsp;424(f) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">2.32 <B><I>&#147;Ten-Percent Stockholder&#148;</I></B> means an individual who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company, its parent or any of its
Subsidiaries. In determining stock ownership, the attribution rules of Section&nbsp;424(d) of the Code shall be applied. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>ADMINISTRATION OF THE PLAN </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Board. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board shall have such powers and
authorities related to the administration of the Plan as are consistent with the Company&#146;s certificate of incorporation and by-laws and applicable law. The Board shall have full power and authority to take all actions and to make all
determinations required or provided for under the Plan, any Grant or any Award Agreement, and shall have full power and authority to take all such other actions and make all such other determinations not inconsistent with the specific terms and
provisions of the Plan that the Board deems to be necessary or appropriate to the administration of the Plan, any Grant or any Award Agreement. All such actions and determinations shall be by the affirmative vote of a majority of the members of the
Board present at a meeting or by unanimous consent of the Board executed in writing in accordance with the Company&#146;s certificate of incorporation and by-laws and applicable law. The interpretation and construction by the Board of any provision
of the Plan, any Grant or any Award Agreement shall be final, binding and conclusive. To the extent permitted by law, the Board may delegate its authority under the Plan to a member of the Board or an executive officer of the Company who is a member
of the Board. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 4 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Committee. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board from time to time may
delegate to one or more Committees such powers and authorities related to the administration and implementation of the Plan, as set forth in <B>Section&nbsp;3.1 </B>above and in other applicable provisions, as the Board shall determine, consistent
with the certificate of incorporation and by-laws of the Company and applicable law. In the event that the Plan, any Grant or any Award Agreement entered into hereunder provides for any action to be taken by or determination to be made by the Board,
such action may be taken by or such determination may be made by the applicable Committee if the power and authority to do so has been delegated to the Committee by the Board as provided for in <B>Section&nbsp;3.1</B>. Unless otherwise expressly
determined by the Board, any such action or determination by the Committee shall be final, binding and conclusive. To the extent permitted by law, the Committee may delegate its authority under the Plan to a member of the Board or an executive
officer of the Company who is a member of the Board. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Grants. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to the other terms and conditions
of the Plan, the Board shall have full and final authority to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">designate Grantees, </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">determine the type or types of Grants to be made to a Grantee, </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">determine the number of shares of Stock to be subject to a Grant, </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">establish the terms and conditions of each Grant (including, but not limited to, the Option Price of any Option, the nature and duration of any restriction or condition (or
provision for lapse thereof) relating to the vesting, exercise, transfer, or forfeiture of a Grant or the shares of Stock subject thereto, and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options),
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">prescribe the form of each Award Agreement evidencing a Grant, and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(vi)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">amend, modify, or supplement the terms of any outstanding Grant. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Such authority specifically includes the authority, in order to effectuate the purposes of the Plan but without amending the Plan, to modify Grants to eligible individuals who are foreign nationals or are individuals who are employed
outside the United States to recognize differences in local law, tax policy, or custom. As a condition to any Grant, the Board shall have the right, at its discretion, to require Grantees to return to the Company Grants previously awarded under the
Plan. Subject to the terms and conditions of the Plan, any such subsequent Grant shall be upon such terms and conditions as are specified by the Board at the time the new Grant is made. The Board shall have the right, in its discretion, to make
Grants in substitution or exchange for any other grant under another plan of the Company, any Affiliate, or any business entity to be acquired by the Company or an Affiliate. The Company may retain the right in an Award Agreement to cause a
forfeiture of the gain realized by a Grantee on account of actions taken by the Grantee in violation or breach of or in conflict with any non-competition agreement, any </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 5 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">agreement prohibiting solicitation of employees or clients of the Company or any Affiliate thereof or any confidentiality obligation with respect to the
Company or any Affiliate thereof or otherwise in competition with the Company or any Affiliate thereof, to the extent specified in such Award Agreement applicable to the Grantee. Furthermore, the Company may annul a Grant if the Grantee is an
employee of the Company or an Affiliate thereof and is terminated for Cause as defined in the applicable Award Agreement or the Plan, as applicable. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Deferral Arrangement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board may permit or
require the deferral of any award payment into a deferred compensation arrangement, subject to such rules and procedures as it may establish, which may include provisions for the payment or crediting of interest or dividend equivalents, including
converting such credits into deferred Stock equivalents and restricting deferrals to comply with hardship distribution rules affecting 401(k) plans. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>3.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>No Liability. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No member of the Board or of the
Committee shall be liable for any action or determination made in good faith with respect to the Plan or any Grant or Award Agreement. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>STOCK SUBJECT TO THE PLAN </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as
provided in <B>Section&nbsp;15 </B>hereof and the limitation of the next paragraph relating to Restricted Stock, the number of shares of Stock available for issuance under the Plan shall be 700,000. Stock issued or to be issued under the Plan shall
be authorized but unissued shares or, to the extent permitted by applicable law, issued shares that have been reacquired by the Company. If any shares covered by a Grant are not purchased or are forfeited, or if a Grant otherwise terminates without
delivery of any Stock subject thereto, then the number of shares of Stock counted against the aggregate number of shares available under the Plan with respect to such Grant shall, to the extent of any such forfeiture or termination, again be
available for making Grants under the Plan. If the exercise price of any Option granted under the Plan is satisfied by tendering shares of Stock to the Company (by either actual delivery or by attestation), only the number of shares of Stock issued
net of the shares of Stock tendered shall be deemed delivered for purposes of determining the maximum number of shares of Stock available for delivery under the Plan. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>GRANT ELIGIBILITY </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>5.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Employees and Other Service Providers. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Grants
(including Grants of Incentive Stock Options, subject to <B>Section&nbsp;5.3</B>) may be made under the Plan to any employee<B>, </B>officer or director of, or other Service Provider providing services to, the Company or any Affiliate. To the extent
required by applicable state law, Grants within certain states may be limited to employees and officers or employees, officers and directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 6 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>5.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Successive Grants. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">An eligible person may receive
more than one Grant, subject to such restrictions as are provided herein. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>5.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Limitations on Incentive Stock Options. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">An Option
shall constitute an Incentive Stock Option only (i)&nbsp;if the Grantee of such Option is an employee of the Company or any Subsidiary of the Company; (ii)&nbsp;to the extent specifically provided in the related Award Agreement; and (iii)&nbsp;to
the extent that the aggregate Fair Market Value (determined at the time the Option is granted) of the shares of Stock with respect to which all Incentive Stock Options held by such Grantee become exercisable for the first time during any calendar
year (under the Plan and all other plans of the Grantee&#146;s employer and its affiliates) does not exceed $100,000. This limitation shall be applied by taking Options into account in the order in which they were granted. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>AWARD AGREEMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each Grant pursuant to the Plan
shall be evidenced by an Award Agreement, in such form or forms as the Board shall from time to time determine, which specifies the number of shares subject to the Grant and provides for adjustment in accordance with <B>Section&nbsp;15</B>. Award
Agreements granted from time to time or at the same time need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing a Grant of Options shall specify whether such Options are intended to be
Nonqualified Stock Options or Incentive Stock Options, and in the absence of such specification such options shall be deemed Nonqualified Stock Options. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>TERMS AND CONDITIONS OF OPTIONS </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Option Price. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Option Price of each Option
shall be fixed by the Board and stated in the Award Agreement evidencing such Option. In the case of an Incentive Stock Option the Option Price shall not be less than the Fair Market Value on the Grant Date of a share of Stock; provided, however,
that in the event that a Grantee is a Ten-Percent Stockholder, the Option Price of an Incentive Stock Option granted to such Grantee shall be not less than 110% of the Fair Market Value of a share of Stock on the Grant Date. To the extent required
by applicable law, in the case of a Nonqualified Stock Option, the Option Price shall be not less than 85% of the Fair Market Value on the Grant Date of a share of Stock; provided, however, that in the event that a Grantee is a Ten-Percent
Stockholder, the Option Price shall be not less than 110% of the Fair Market Value of a share of Stock on the Grant Date. In no case shall the Option Price of any Option be less than the par value of a share of Stock. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Vesting. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to <B>Sections&nbsp;7.3
</B>and<B> 15.3 </B>hereof, each Option granted under the Plan shall become exercisable at such times and under such conditions as shall be determined by the Board and stated in the Award Agreement. For purposes of this <B>Section&nbsp;7.2</B>,
fractional numbers of shares </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 7 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">of Stock subject to an Option shall be rounded down to the next nearest whole number. To the extent required by applicable law, each Option shall become
exercisable no less rapidly than the rate of 20%&nbsp;per year for each of the first five years from the Grant Date based on continued Service. Subject to the preceding sentence, the Board may provide, for example, in the Award Agreement for
(i)&nbsp;accelerated exercisability of the Option in the event the Grantee&#146;s Service terminates on account of death, Disability or another event, (ii)&nbsp;expiration of the Option prior to its term in the event of the termination of the
Grantee&#146;s Service, (iii)&nbsp;immediate forfeiture of the Option in the event the Grantee&#146;s Service is terminated for Cause or (iv)&nbsp;unvested Options to be exercised subject to the Company&#146;s right of repurchase with respect to
unvested shares of Stock. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Term. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each Option granted under the Plan shall
terminate, and all rights to purchase shares of Stock thereunder shall cease, upon the expiration of ten years from the Grant Date, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the
Board and stated in the Award Agreement relating to such Option; provided, however, that in the event that the Grantee is a Ten-Percent Stockholder, an Option granted to such Grantee that is intended to be an Incentive Stock Option shall not be
exercisable after the expiration of five years from its Grant Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exercise of Options on Termination of Service. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Each Award Agreement shall set forth the extent to which the Grantee shall have the right to exercise the Option following termination of the Grantee&#146;s Service. Such provisions shall be determined in the sole discretion of the Board,
need not be uniform among all Options issued pursuant to the Plan, and may reflect distinctions based on the reasons for termination of Service. Notwithstanding the foregoing, to the extent required by applicable law, each Option shall provide that
the Grantee shall have the right to exercise the vested portion of any Option held at termination for at least 30 days following termination of Service with the Company for any reason (other than for Cause), and that the Grantee shall have the right
to exercise the Option for at least six months if the Grantee&#146;s Service terminates due to death or Disability. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Limitations on Exercise of Option. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Notwithstanding
any other provision of the Plan, in no event may any Option be exercised, in whole or in part, prior to the date the Plan is approved by the shareholders of the Company, or after ten years following the Grant Date, or after the occurrence of an
event referred to in <B>Section&nbsp;15</B> hereof which results in termination of the Option. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.6</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exercise Procedure. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">An Option that is exercisable
may be exercised by the Grantee&#146;s delivery to the Company of written notice of exercise on any business day, at the Company&#146;s principal office<B>, </B>on the form specified by the Company. Such notice shall specify the number of shares of
Stock with respect to which the Option is being exercised and shall be accompanied by payment in full of the Option Price of the shares for which the Option is being exercised. The minimum number of shares of Stock with respect to which an Option
may be exercised, in whole or in part, at any time shall be the lesser of (i)&nbsp;100 shares or such lesser number set forth in the applicable Award </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 8 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Agreement and (ii)&nbsp;the maximum number of shares available for purchase under the Option at the time of exercise. The Option Price shall be payable in a
form described in <B>Section&nbsp;10</B>. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.7</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Right of Holders of Options. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Unless otherwise
stated in the applicable Award Agreement, an individual holding or exercising an Option shall have none of the rights of a shareholder (for example, the right to cash or dividend payments or distributions attributable to the subject shares of Stock
or to direct the voting of shares of Stock) until the shares of Stock covered thereby are fully paid and issued to such individual. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>7.8</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Delivery of Stock Certificates. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Promptly after the
exercise of an Option by a Grantee and the payment in full of the Option Price, such Grantee shall be entitled to the issuance of a stock certificate or certificates evidencing such Grantee&#146;s ownership of the shares of Stock purchased upon such
exercise of the Option. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>TRANSFERABILITY OF OPTIONS </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>8.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Transferability of Options. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Except as provided in
<B>Section&nbsp;8.2</B>, during the lifetime of a Grantee, only the Grantee (or, in the event of legal incapacity or incompetency, the Grantee&#146;s guardian or legal representative) may exercise an Option. Except as provided in
<B>Section&nbsp;8.2</B>, no Option shall be assignable or transferable by the Grantee to whom it is granted, other than by will or the laws of descent and distribution. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>8.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Family Transfers. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If authorized in the applicable
Award Agreement, a Grantee may transfer, not for value, all or part of an Option that is not an Incentive Stock Option to any Family Member. For the purpose of this <B>Section&nbsp;8.2</B>, a &#147;not for value&#148; transfer is a transfer which is
(i)&nbsp;a gift, (ii)&nbsp;a transfer under a domestic relations order in settlement of marital property rights; or (iii)&nbsp;unless applicable law does not permit such transfers, a transfer to an entity in which more than 50% of the voting
interests are owned by Family Members (or the Grantee) in exchange for an interest in that entity. Following a transfer under this <B>Section&nbsp;8.2</B>, any such Option shall continue to be subject to the same terms and conditions as were
applicable immediately prior to transfer, and shares of Stock acquired pursuant to the Option shall be subject to the same restrictions on transfer of shares as would have applied to the Grantee. Subsequent transfers of transferred Options are
prohibited except to Family Members of the original Grantee in accordance with this <B>Section&nbsp;8.2 </B>or by will or the laws of descent and distribution. The events of termination of Service under an Option shall continue to be applied with
respect to the original Grantee, following which the Option shall be exercisable by the transferee only to the extent, and for the periods specified in the applicable Award Agreement, and the shares may be subject to repurchase by the Company or its
assignee. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 9 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>RESTRICTED STOCK </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Grant of Restricted Stock. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board may from time
to time grant Restricted Stock to persons eligible to receive Grants under <B>Section&nbsp;5</B> hereof, subject to such restrictions, conditions and other terms as the Board may determine. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Restrictions. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">At the time a Grant of Restricted
Stock is made, the Board shall establish a restriction period applicable to such Restricted Stock. Each Grant of Restricted Stock may be subject to a different restriction period. The Board may, in its sole discretion, at the time a Grant of
Restricted Stock is made, prescribe conditions that must be satisfied prior to the expiration of the restriction period, including the satisfaction of corporate or individual performance objectives or continued Service, in order that all or any
portion of the Restricted Stock shall vest. To the extent required by applicable law, the vesting restrictions applicable to a Grant of Restricted Stock shall lapse no less rapidly than the rate of 20%&nbsp;per year for each of the first five years
from the Grant Date, based on continued Service. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board also may, in its sole discretion, shorten or terminate the restriction period
or waive any of the conditions applicable to all or a portion of the Restricted Stock. The Restricted Stock may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of during the restriction period or prior to the
satisfaction of any other conditions prescribed by the Board with respect to such Restricted Stock. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Restricted Stock Certificates. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company shall
issue, in the name of each Grantee to whom Restricted Stock has been granted, stock certificates representing the total number of shares of Restricted Stock granted to the Grantee, as soon as reasonably practicable after the Grant Date. The Board
may provide in an Award Agreement that either (i)&nbsp;the Secretary of the Company shall hold such certificates for the Grantee&#146;s benefit until such time as the Restricted Stock is forfeited to the Company<B>,</B> or the restrictions lapse, or
(ii)&nbsp;such certificates shall be delivered to the Grantee, provided, however, that such certificates shall bear a legend or legends that complies with the applicable securities laws and regulations and makes appropriate reference to the
restrictions imposed under the Plan and the Award Agreement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Rights of Holders of Restricted Stock. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Unless the
Board otherwise provides in an Award Agreement, holders of Restricted Stock shall have the right to vote such Stock and the right to receive any dividends declared or paid with respect to such Stock. The Board may provide that any dividends paid on
Restricted Stock must be reinvested in shares of Stock, which may or may not be subject to the same vesting conditions and restrictions applicable to such Restricted Stock. All distributions, if any, received by a Grantee with respect to Restricted
Stock as a result of any stock split, stock dividend, combination of shares, or other similar transaction shall be subject to the restrictions applicable to the original Grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 10 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Termination of Service. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Unless otherwise provided
by the Board in the applicable Award Agreement, upon the termination of a Grantee&#146;s Service with the Company or an Affiliate, any shares of Restricted Stock held by such Grantee that have not vested, or with respect to which all applicable
restrictions and conditions have not lapsed, shall immediately be deemed forfeited. Upon forfeiture of Restricted Stock, the Grantee shall have no further rights with respect to such Grant, including but not limited to any right to vote Restricted
Stock or any right to receive dividends with respect to shares of Restricted Stock. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>9.6</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Purchase and Delivery of Stock. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Grantee shall
be required to purchase the Restricted Stock from the Company at a Purchase Price equal to the greater of (i)&nbsp;the aggregate par value of the shares of Stock represented by such Restricted Stock or (ii)&nbsp;the Purchase Price, if any, specified
in the Award Agreement relating to such Restricted Stock. The Purchase Price shall be payable in a form described in <B>Section&nbsp;10 </B>or, in the discretion of the Board, in consideration for past Services rendered to the Company or an
Affiliate. To the extent required by applicable law, the Purchase Price of a share of Restricted Stock shall be not less than 85% of the Fair Market Value on the Grant Date of a share of Stock; provided, however, that in the event that the Grantee
is a Ten-Percent Stockholder, the Purchase Price shall be not less than 100% of the Fair Market Value on the Grant Date of a share of Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">Upon the expiration or termination of the restriction period and the satisfaction of any other conditions prescribed by the Board, having properly paid the Purchase Price, the restrictions applicable to shares of Restricted Stock shall
lapse, and, unless otherwise provided in the Award Agreement, a stock certificate for such shares shall be delivered, free of all such restrictions, to the Grantee or the Grantee&#146;s beneficiary or estate, as the case may be. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>FORM OF PAYMENT </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>10.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>General Rule. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Payment of the Option Price for the
shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock shall be made in cash or in cash equivalents acceptable to the Company. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>10.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Surrender of Stock. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To the extent the Award
Agreement so provides, payment of the Option Price for shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock may be made all or in part through the tender to the Company of shares of Stock, which shares,
if acquired from the Company, shall have been held for at least six months at the time of tender and which shall be valued, for purposes of determining the extent to which the Option Price or Purchase Price has been paid thereby, at their Fair
Market Value on the date of exercise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 11 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>10.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Cashless Exercise. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">With respect to an Option only
(and not with respect to Restricted Stock), to the extent the Award Agreement so provides and the shares of Stock have become publicly traded, payment of the Option Price for shares purchased pursuant to the exercise of an Option may be made all or
in part by delivery (on a form acceptable to the Board) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell shares of Stock and to deliver all or part of the sales proceeds to the Company in payment of the
Option Price and any withholding taxes described in <B>Section&nbsp;11</B>. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>10.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Promissory Note. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To the extent the Award Agreement
so provides, payment of the Option Price for shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock may be made all or in part with a full recourse promissory note executed by the Grantee. The interest rate
and other terms and conditions of such note shall be determined by the Board. The Board may require that the Grantee pledge the Stock subject to the Grant for the purpose of securing payment of the note. In no event shall stock certificate(s)
representing the Stock be released to the Grantee until such note is paid in full. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>WITHHOLDING TAXES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company or any Affiliate, as
the case may be, shall have the right to deduct from payments of any kind otherwise due to a Grantee any Federal, state, or local taxes of any kind required by law to be withheld with respect to the vesting of or other lapse of restrictions
applicable to Restricted Stock or upon the issuance of any shares of Stock upon the exercise of an Option. At the time of such vesting, lapse, or exercise, the Grantee shall pay to the Company or Affiliate, as the case may be, any amount that the
Company or Affiliate may reasonably determine to be necessary to satisfy such withholding obligation. Subject to the prior approval of the Company or the Affiliate, which may be withheld by the Company or the Affiliate, as the case may be, in its
sole discretion, the Grantee may elect to satisfy such obligations, in whole or in part, (i)&nbsp;by causing the Company or the Affiliate to withhold shares of Stock otherwise issuable to the Grantee or (ii)&nbsp;by delivering to the Company or the
Affiliate shares of Stock already owned by the Grantee. The shares of Stock so delivered or withheld shall have an aggregate Fair Market Value equal to such withholding obligations. The Fair Market Value of the shares of Stock used to satisfy such
withholding obligation shall be determined by the Company or the Affiliate as of the date that the amount of tax to be withheld is to be determined. A Grantee who has made an election pursuant to this<B> Section&nbsp;11</B> may satisfy his or her
withholding obligation only with shares of Stock that are not subject to any repurchase, forfeiture, unfulfilled vesting, or other similar requirements. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>RESTRICTIONS ON TRANSFER OF SHARES OF STOCK </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Right of First Refusal. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to
<B>Section&nbsp;12.4 </B>below, a Grantee (or such other individual who is entitled to exercise an Option or otherwise acquire shares pursuant to a Grant under the terms of this Plan) shall not sell, pledge, assign, gift, transfer, or otherwise
dispose of any shares of Stock acquired </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 12 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">pursuant to a Grant to any person or entity without first offering such shares to the Company for purchase on the same terms and conditions as those offered
the proposed transferee. The Company may assign its right of first refusal under this <B>Section&nbsp;12.1 </B>in whole or in part, to (1)&nbsp;any holder of stock or other securities of the Company (a &#147;<B>Stockholder</B>&#148;), (2)&nbsp;any
Affiliate or (3)&nbsp;any other person or entity that the Board determines has a sufficient relationship with or interest in the Company. The Company shall give reasonable written notice to the Grantee of any such assignment of its rights. The
restrictions of this <B>Section&nbsp;12.1 </B>apply to any person to whom Stock that was originally acquired pursuant to a Grant is sold, pledged, assigned, bequeathed, gifted, transferred or otherwise disposed of, without regard to the number of
such subsequent transferees or the manner in which they acquire the Stock, but the restrictions of this <B>Section&nbsp;12.1</B> do not apply to a transfer of Stock that occurs as a result of the death of the Grantee or of any subsequent transferee
(but shall apply to the executor, the administrator or personal representative, the estate, and the legatees, beneficiaries and assigns thereof). </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Repurchase&nbsp;and Other Rights. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Stock issued
upon exercise of an Option or pursuant to the Grant of Restricted Stock may be subject to such right of repurchase or other transfer restrictions as the Board may determine, consistent with applicable law. Any such additional restriction shall be
set forth in the Award Agreement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Installment Payments. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.3.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>General Rule. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the case of any purchase of Stock
or an Option under this <B>Section&nbsp;12</B>, the Company or its permitted assignee may pay the Grantee, transferee of the Option or other registered owner of the Stock the purchase price in three or fewer annual installments. Interest shall be
credited on the installments at the applicable federal rate (as determined for purposes of Section&nbsp;1274 of the Code) in effect on the date on which the purchase is made. The Company or its permitted assignee shall pay at least one-third of the
total purchase price each year, plus interest on the unpaid balance, with the first payment being made on or before the 60th day after the purchase. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.3.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Exception in the Case of Stock Repurchase Right. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">If an Award Agreement authorizes, upon the Grantee&#146;s termination of Service, the repurchase of shares of Stock acquired by the Grantee pursuant to the exercise of an Option or under a Grant of Restricted Stock, to the extent required
by applicable law, payment shall be made in cash or by cancellation of indebtedness within the later of 90 days from the date of termination of Service or 90 days from the date of exercise or purchase, as the case may be. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Publicly Traded Stock. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If the Stock is listed on
an established national or regional stock exchange or is admitted to quotation on The Nasdaq Stock Market, Inc., or is publicly traded in an established securities market, the foregoing transfer restrictions of <B>Sections&nbsp;12.1</B> and
<B>12.2</B> shall terminate as of the first date that the Stock is so listed, quoted or publicly traded. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 13 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>12.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Legend. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In order to enforce the restrictions
imposed upon shares of Stock under this Plan or as provided in an Award Agreement, the Board may cause a legend or legends to be placed on any certificate representing shares issued pursuant to this Plan that complies with the applicable securities
laws and regulations and makes appropriate reference to the restrictions imposed under it. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>PARACHUTE LIMITATIONS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Notwithstanding any other
provision of this Plan or of any other agreement, contract, or understanding heretofore or hereafter entered into by a Grantee with the Company or any Affiliate, except an agreement, contract, or understanding hereafter entered into that expressly
modifies or excludes application of this paragraph (an &#147;<B>Other Agreement</B>&#148;), and notwithstanding any formal or informal plan or other arrangement for the direct or indirect provision of compensation to the Grantee (including groups or
classes of participants or beneficiaries of which the Grantee is a member), whether or not such compensation is deferred, is in cash, or is in the form of a benefit to or for the Grantee (a &#147;<B>Benefit Arrangement</B>&#148;), if the Grantee is
a &#147;disqualified individual,&#148; as defined in Section&nbsp;280G(c) of the Code, any Options or Restricted Stock held by that Grantee and any right to receive any payment or other benefit under this Plan shall not become exercisable or vested
(i)&nbsp;to the extent that such right to exercise, vesting, payment, or benefit, taking into account all other rights, payments, or benefits to or for the Grantee under this Plan, all Other Agreements, and all Benefit Arrangements, would cause any
payment or benefit to the Grantee under this Plan to be considered a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G(b)(2) of the Code as then in effect (a &#147;<B>Parachute Payment</B>&#148;) and (ii)&nbsp;if, as a result of
receiving a Parachute Payment, the aggregate after-tax amounts received by the Grantee from the Company under this Plan, all Other Agreements, and all Benefit Arrangements would be less than the maximum after-tax amount that could be received by the
Grantee without causing any such payment or benefit to be considered a Parachute Payment. In the event that the receipt of any such right to exercise, vesting, payment, or benefit under this Plan, in conjunction with all other rights, payments, or
benefits to or for the Grantee under any Other Agreement or any Benefit Arrangement would cause the Grantee to be considered to have received a Parachute Payment under this Plan that would have the effect of decreasing the after-tax amount received
by the Grantee as described in clause (ii)&nbsp;of the preceding sentence, then the Grantee shall have the right, in the Grantee&#146;s sole discretion, to designate those rights, payments, or benefits under this Plan, any Other Agreements, and any
Benefit Arrangements that should be reduced or eliminated so as to avoid having the payment or benefit to the Grantee under this Plan be deemed to be a Parachute Payment. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>REQUIREMENTS OF LAW </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>14.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>General. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Company shall not be required to sell
or issue any shares of Stock under any Grant if the sale or issuance of such shares would constitute a violation by the Grantee, any other individual exercising a right emanating from such Grant, or the Company of any provision of any law or
regulation of any governmental authority, including without limitation any federal or state securities laws or regulations. If at any time the Company shall determine, in its discretion, that </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 14 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">the listing, registration or qualification of any shares subject to a Grant upon any securities exchange or under any governmental regulatory body is
necessary or desirable as a condition of, or in connection with, the issuance or purchase of shares hereunder, no shares of Stock may be issued or sold to the Grantee or any other individual exercising an Option pursuant to such Grant unless such
listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way affect the date of termination of the Grant.
Specifically, in connection with the Securities Act, upon the exercise of any right emanating from such Grant or the delivery of any shares of Restricted Stock, unless a registration statement under the Securities Act is in effect with respect to
the shares of Stock covered by such Grant, the Company shall not be required to sell or issue such shares unless the Board has received evidence satisfactory to it that the Grantee or any other individual exercising an Option may acquire such shares
pursuant to an exemption from registration under the Securities Act. Any determination in this connection by the Board shall be final, binding, and conclusive. The Company may, but shall in no event be obligated to, register any securities covered
hereby pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or the issuance of shares of Stock pursuant to the Plan to comply with any law or regulation of any
governmental authority. As to any jurisdiction that expressly imposes the requirement that an Option shall not be exercisable until the shares of Stock covered by such Option are registered or are exempt from registration, the exercise of such
Option (under circumstances in which the laws of such jurisdiction apply) shall be deemed conditioned upon the effectiveness of such registration or the availability of such an exemption. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>14.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Rule 16b-3. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">During any time when the Company has a
class of equity security registered under Section&nbsp;12 of the Exchange Act, it is the intent of the Company that Grants pursuant to the Plan and the exercise of Options granted hereunder will qualify for the exemption provided by Rule 16b-3 under
the Exchange Act. To the extent that any provision of the Plan or action by the Board does not comply with the requirements of Rule 16b-3, it shall be deemed inoperative to the extent permitted by law and deemed advisable by the Board, and shall not
affect the validity of the Plan. In the event that Rule 16b-3 is revised or replaced, the Board may exercise its discretion to modify this Plan in any respect necessary to satisfy the requirements of, or to take advantage of any features of, the
revised exemption or its replacement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>14.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Reports. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To the extent required by
applicable law, not less often than annually, the Company shall furnish to Grantees summary financial information including a balance sheet regarding the Company&#146;s financial condition and results of operations, unless such Grantees have duties
with the Company that assure them access to equivalent information. Such financial statements need not be audited. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 15 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>EFFECT OF CHANGES IN CAPITALIZATION </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Changes in Stock. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The number of shares for which
Grants of Options and Restricted Stock may be made under the Plan shall be proportionately increased or decreased for any increase or decrease in the number of shares of Stock on account of any recapitalization, reclassification, stock split,
reverse split, combination of shares, exchange of shares, stock dividend or other distribution payable in capital stock, or for any other increase or decrease in such shares effected without receipt of consideration by the Company occurring after
the Effective Date (any such event hereafter referred to as a &#147;<B>Corporate Event</B>&#148;). In addition, subject to the exception set forth in the last sentence of <B>Section&nbsp;15.4</B>, the number of shares for which Grants are
outstanding shall be proportionately increased or decreased for any increase or decrease in the number of shares of Stock on account of any Corporate Event. Any such adjustment in outstanding Options shall not change the aggregate Option Price
payable with respect to shares that are subject to the unexercised portion of an Option outstanding but shall include a corresponding proportionate adjustment in the Option Price per share. The conversion of any convertible securities of the Company
shall not be treated as an increase in shares effected without receipt of consideration. In the event of any distribution to the Company&#146;s stockholders of securities of any other entity or other assets (other than dividends payable in cash or
stock of the Company) without receipt of consideration by the Company, the Company may, in such manner as the Company deems appropriate, adjust (i)&nbsp;the number and kind of shares subject to outstanding Awards and/or (ii)&nbsp;the exercise price
of outstanding Options to reflect such distribution. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Reorganization in Which the Company Is the Surviving Entity and in Which No Change of Control Occurs. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to the exception set forth in the last sentence of <B>Section&nbsp;15.4</B>, if the Company shall be the surviving entity in any reorganization,
merger, or consolidation of the Company with one or more other entities and in which no Change of Control occurs, any Grant theretofore made pursuant to the Plan shall pertain to and apply solely to the common stock shares to which a holder of the
number of shares of Stock subject to such Grant would have been entitled immediately following such reorganization, merger, or consolidation, and in the case of Options, with a corresponding proportionate adjustment of the Option Price per share so
that the aggregate Option Price thereafter shall be the same as the aggregate Option Price of the shares remaining subject to the Option immediately prior to such reorganization, merger, or consolidation. Subject to any contrary language in an Award
Agreement evidencing a Grant of Restricted Stock, any restrictions applicable to such Restricted Stock shall apply as well to any replacement shares received by the Grantee as a result of the reorganization, merger or consolidation. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Reorganization, Sale of Assets or Sale of Stock Which Involves a Change of Control. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to the exceptions set forth in the last sentence of this <B>Section&nbsp;15.3</B> and the last sentence of Section&nbsp;<B>15.4 </B>upon the
occurrence of a Change of Control, (i)&nbsp;all outstanding shares of Restricted Stock shall be deemed to have vested, and, with the exception of such restrictions imposed under <B>Section&nbsp;12</B>, all restrictions and conditions applicable to
such shares of Restricted </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 16 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">Stock shall be deemed to have lapsed, immediately prior to the occurrence of such Change of Control, and (ii)&nbsp;either of the following two actions shall
be taken: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(A) 15 days prior to the scheduled consummation of a Change of Control, all Options outstanding hereunder shall
become immediately exercisable and shall remain exercisable for a period of 15 days; or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">(B) the Board may elect, in its
sole discretion, to cancel any outstanding Grants and pay or deliver, or cause to be paid or delivered, to the holder thereof an amount in cash or securities having a value (as determined by the Board acting in good faith), in the case of Restricted
Stock, equal to the formula or fixed price per share paid to holders of shares of Stock and, in the case of Options, equal to the product of the number of shares of Stock subject to the Option (the &#147;<B>Option Shares</B>&#148;) multiplied by the
amount, if any, by which (I)&nbsp;the formula or fixed price per share paid to holders of shares of Stock pursuant to such transaction exceeds (II) the Option Price applicable to such Option Shares. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">With respect to the Company&#146;s establishment of an exercise window, (i)&nbsp;any exercise of an Option during such 15-day period shall be conditioned
upon the consummation of the event and shall be effective only immediately before the consummation of the event, and (ii)&nbsp;upon consummation of any Change of Control the Plan, and all outstanding but unexercised Options shall terminate. The
Board shall send written notice of an event that will result in such a termination to all individuals who hold Options not later than the time at which the Company gives notice thereof to its shareholders. This <B>Section&nbsp;15.3 </B>shall not
apply to any Change of Control to the extent that provision is made in writing in connection with such Change of Control for the assumption or continuation of the Options and Restricted Stock theretofore granted, or for the substitution for such
Options and Restricted Stock for new common stock options and new common stock restricted stock relating to the stock of a successor entity, or a parent or subsidiary thereof, with appropriate adjustments as to the number of shares (disregarding any
consideration that is not common stock) and option prices, in which event the Plan and Options and Restricted Stock theretofore granted shall continue in the manner and under the terms so provided. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Adjustments. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Adjustments under
<B>Section&nbsp;15</B> related to shares of Stock or securities of the Company shall be made by the Board, whose determination in that respect shall be final, binding and conclusive. No fractional shares or other securities shall be issued pursuant
to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward to the nearest whole share. The Board may provide in the Award Agreements at the time of Grant, or any time thereafter
with the consent of the Grantee, for different provisions to apply to a Grant in place of those described in <B>Sections 15.1, 15.2 </B>and <B>15.3</B>. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>15.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>No Limitations on Company. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The making of Grants
pursuant to the Plan shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations, or changes of its </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 17 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">capital or business structure or to merge, consolidate, dissolve, or liquidate, or to sell or transfer all or any part of its business or assets. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>DURATION AND AMENDMENTS </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>16.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Term of the Plan. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Effective Date of this Plan
is the date of its adoption by the Board, subject to the approval of the Plan by the Company&#146;s stockholders. In the event that the stockholders fail to approve the Plan within 12 months after its adoption by the Board, any Grants already made
shall be null and void, and no additional Grants shall be made after such date. The Plan shall terminate automatically ten years after its adoption by the Board and may be terminated on any earlier date as next provided. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>16.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Amendment and Termination of the Plan. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Board
may, at any time and from time to time, amend, suspend, or terminate the Plan as to any shares of Stock as to which Grants have not been made. An amendment to the Plan shall be contingent on approval of the Company&#146;s stockholders only to the
extent required by applicable law, regulations or rules. No Grants shall be made after the termination of the Plan. No amendment, suspension, or termination of the Plan shall, without the consent of the Grantee, alter or impair rights or obligations
under any Grant theretofore awarded under the Plan. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>GENERAL PROVISIONS </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Disclaimer of Rights </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">No provision in the Plan or
in any Grant or Award Agreement shall be construed to confer upon any individual the right to remain in the employ or service of the Company or any Affiliate, or to interfere in any way with any contractual or other right or authority of the Company
either to increase or decrease the compensation or other payments to any individual at any time, or to terminate any employment or other relationship between any individual and the Company or any Affiliate. The obligation of the Company to pay any
benefits pursuant to this Plan shall be interpreted as a contractual obligation to pay only those amounts described herein, in the manner and under the conditions prescribed herein. The Plan shall in no way be interpreted to require the Company to
transfer any amounts to a third party trustee or otherwise hold any amounts in trust or escrow for payment to any participant or beneficiary under the terms of the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Nonexclusivity of the Plan </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Neither the adoption of
the Plan nor the submission of the Plan to the shareholders of the Company for approval shall be construed as creating any limitations upon the right and authority of the Board to adopt such other incentive compensation arrangements (which
arrangements may be applicable either generally to a class or classes of individuals or specifically to a particular individual or particular individuals) as the Board in its discretion determines desirable, including, without limitation, the
granting of stock options otherwise than under the Plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 18 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Captions </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The use of captions in this Plan or any
Award Agreement is for the convenience of reference only and shall not affect the meaning of any provision of the Plan or such Award Agreement. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other Award Agreement Provisions </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Each Grant
awarded under the Plan may contain such other terms and conditions not inconsistent with the Plan as may be determined by the Board, in its sole discretion. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Number and Gender </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">With respect to words used in
this Plan, the singular form shall include the plural form, the masculine gender shall include the feminine gender, etc., as the context requires. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.6</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Severability </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If any provision of the Plan or any
Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall
remain enforceable in any other jurisdiction. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>17.7</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Governing Law </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The validity and construction of
this Plan and the instruments evidencing the Grants awarded hereunder shall be governed by the laws of the State of Delaware other than any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of
this Plan and the instruments evidencing the Grants awarded hereunder to the substantive laws of any other jurisdiction. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 19 - </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>18.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>EXECUTION </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">To record adoption of the Plan by the
Board as of September&nbsp;30, 2004, and approval of the Plan by the stockholders on September&nbsp;30, 2004, the Company has caused its authorized officer to execute the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA D<SMALL>ISCOVERY</SMALL>, I<SMALL>NC</SMALL>.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Michael R. Bristow</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Michael R. Bristow</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer and President</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 20 - </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>7
<FILENAME>dex102.htm
<DESCRIPTION>AMENDMENT NO. 1 TO ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 1 to ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT NO. 1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO THE ARCA DISCOVERY, INC. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The ARCA Discovery, Inc.
2004 Stock Incentive Plan is hereby amended as set forth below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. The first sentence of Section&nbsp;4 is hereby deleted and replaced with the following
sentence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as provided in <B>Section&nbsp;15 </B>hereof, the number of shares of Stock available for issuance under
the Plan shall be 2,954,694. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The remaining sentences of Section&nbsp;4 shall not be amended. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Capitalized terms as used in this Amendment No.&nbsp;1 (this &#147;<U>Amendment</U>&#148;) and not otherwise defined in this Amendment, shall have the meanings
assigned to them in the Plan. The Plan shall otherwise be unchanged by this Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">*&nbsp;*&nbsp;* * * </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Amendment was duly adopted by the board of directors of ARCA Discovery, Inc. by unanimous written consent on
February&nbsp;17, 2006, and approved by the written consent of the stockholders of ARCA Discovery, Inc. on February&nbsp;17, 2006, in accordance with Section&nbsp;16.2 of the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ARCA DISCOVERY, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff, Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 2 - </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>8
<FILENAME>dex103.htm
<DESCRIPTION>AMENDMENT NO. 2 TO ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 2 to ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.3 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT NO. 2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO THE ARCA DISCOVERY, INC. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The ARCA Discovery, Inc.
2004 Stock Incentive Plan (as amended, the &#147;<B>Plan</B>&#148;) is hereby amended as set forth below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. The first sentence of Section&nbsp;4 is hereby
deleted and replaced with the following sentence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as provided in <B>Section&nbsp;15 </B>hereof, the number of shares
of Stock available for issuance under the Plan shall be 3,954,694. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The remaining sentences of Section&nbsp;4 shall not be amended. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Capitalized terms as used in this Amendment No.&nbsp;2 (this &#147;<B>Amendment</B>&#148;) and not otherwise defined in this Amendment, shall have the meanings
assigned to them in the Plan. The Plan shall otherwise be unchanged by this Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">*&nbsp;*&nbsp;* * * </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Amendment was duly adopted by the board of directors of ARCA Discovery, Inc. at a meeting held on November&nbsp;2,
2006, and approved by the written consent of the stockholders of ARCA Discovery, Inc. on November&nbsp;2, 2006, in accordance with Section&nbsp;16.2 of the Plan. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV
ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ARCA DISCOVERY, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff, Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 2 - </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>9
<FILENAME>dex104.htm
<DESCRIPTION>AMENDMENT NO. 3 TO ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 3 to ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.4 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT NO. 3 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO THE ARCA DISCOVERY, INC. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The ARCA Discovery, Inc.
2004 Stock Incentive Plan (as amended, the &#147;<B>Plan</B>&#148;) is hereby amended as set forth below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. The first sentence of Section&nbsp;4 is hereby
deleted and replaced with the following sentence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as provided in <B>Section&nbsp;15 </B>hereof, the number of shares
of Stock available for issuance under the Plan shall be 5,157,846. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The remaining sentences of Section&nbsp;4 shall not be amended. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Capitalized terms as used in this Amendment No.&nbsp;3 (this &#147;<B>Amendment</B>&#148;) and not otherwise defined in this Amendment, shall have the meanings
assigned to them in the Plan. The Plan shall otherwise be unchanged by this Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">*&nbsp;*&nbsp;* * * </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Amendment was duly adopted by the board of directors of ARCA Discovery, Inc. by unanimous written consent on
May&nbsp;31, 2007, and approved by the written consent of the stockholders of ARCA Discovery, Inc. on May&nbsp;31, 2007, in accordance with Section&nbsp;16.2 of the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ARCA DISCOVERY, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff, Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 2 - </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>10
<FILENAME>dex105.htm
<DESCRIPTION>AMENDMENT NO. 4 TO ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 4 to ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.5 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT NO. 4 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO THE ARCA DISCOVERY, INC. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The ARCA Discovery, Inc.
2004 Stock Incentive Plan (as amended, the &#147;<B>Plan</B>&#148;) is hereby amended as set forth below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. The first sentence of Section&nbsp;4 is hereby
deleted and replaced with the following sentence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as provided in <B>Section&nbsp;15 </B>hereof, the number of shares
of Stock available for issuance under the Plan shall be 6,388,339. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The remaining sentences of Section&nbsp;4 shall not be amended. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Capitalized terms as used in this Amendment No.&nbsp;4 (this &#147;<B>Amendment</B>&#148;) and not otherwise defined in this Amendment, shall have the meanings
assigned to them in the Plan. The Plan shall otherwise be unchanged by this Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">*&nbsp;*&nbsp;* * * </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Amendment was duly adopted by the board of directors of ARCA Discovery, Inc. by unanimous written consent on
December&nbsp;20, 2007, and approved by the written consent of the stockholders of ARCA Discovery, Inc. on December&nbsp;20, 2007, in accordance with Section&nbsp;16.2 of the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ARCA DISCOVERY, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff, Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 2 - </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>11
<FILENAME>dex106.htm
<DESCRIPTION>AMENDMENT NO. 5 TO ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 5 to ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.6 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT NO. 5 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO THE ARCA DISCOVERY, INC. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The ARCA Discovery, Inc.
2004 Stock Incentive Plan (as amended, the &#147;<B>Plan</B>&#148;) is hereby amended as set forth below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. The first sentence of Section&nbsp;4 is hereby
deleted and replaced with the following sentence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as provided in <B>Section&nbsp;15 </B>hereof, the number of shares
of Stock available for issuance under the Plan shall be 6,356,550. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The remaining sentences of Section&nbsp;4 shall not be amended. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Capitalized terms as used in this Amendment No.&nbsp;5 (this &#147;<B>Amendment</B>&#148;) and not otherwise defined in this Amendment, shall have the meanings
assigned to them in the Plan. The Plan shall otherwise be unchanged by this Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">*&nbsp;*&nbsp;* * * </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Amendment was duly adopted by the board of directors of ARCA Discovery, Inc. by resolution of the Board of Directors
of the of the Corporation adopted at a meeting held on February&nbsp;1, 2008, and approved by the written consent of the stockholders of ARCA Discovery, Inc. on February&nbsp;27, 2008, in accordance with Section&nbsp;16.2 of the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ARCA DISCOVERY, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff, Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">- 2 - </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>12
<FILENAME>dex107.htm
<DESCRIPTION>AMENDMENT NO. 6 TO ARCA 2004 STOCK INCENTIVE PLAN
<TEXT>
<HTML><HEAD>
<TITLE>Amendment No. 6 to ARCA 2004 Stock Incentive Plan</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.7 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>AMENDMENT NO. 6 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO THE ARCA DISCOVERY, INC. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The ARCA Discovery, Inc.
2004 Stock Incentive Plan (as amended, the &#147;<U>Plan</U>&#148;) is hereby amended as set forth below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">1. The first sentence of Section&nbsp;4 is hereby
deleted and replaced with the following sentence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2">Subject to adjustment as provided in <B>Section&nbsp;15 </B>hereof, the number of shares
of Stock available for issuance under the Plan shall be 6,756,550. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The remaining sentences of Section&nbsp;4 shall not be amended. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">2. Capitalized terms as used in this Amendment No.&nbsp;6 (this &#147;<U>Amendment</U>&#148;) and not otherwise defined in this Amendment, shall have the meanings
assigned to them in the Plan. The Plan shall otherwise be unchanged by this Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">*&nbsp;*&nbsp;* * * </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">This Amendment was duly adopted by the board of directors of ARCA biopharma, Inc. by unanimous written
consent on January&nbsp;22, 2009, and approved by the written consent of the stockholders of ARCA biopharma, Inc. on January&nbsp;22, 2009, in accordance with Section&nbsp;16.2 of the Plan. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">ARCA biopharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Christopher D. Ozeroff, Secretary</FONT></TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>13
<FILENAME>dex108.htm
<DESCRIPTION>FORM OF EXECUTIVE INCENTIVE STOCK OPTION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Executive Incentive Stock Option Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.8 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
FACE="Times New Roman" SIZE="2"><B>Option No.: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA
DISCOVERY, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>INCENTIVE STOCK OPTION AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ARCA Discovery, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;),
hereby grants an option (the &#147;<B>Option</B>&#148;) to purchase shares of its common stock, $0.001 par value, (the &#147;<B>Stock</B>&#148;) to the optionee named below. The terms and conditions of the Option are set forth in this Incentive
Stock Option Agreement, consisting of this cover sheet and the attached terms (the &#147;Option Agreement&#148;) and in the Company&#146;s 2004 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;). Capitalized terms not defined in the Option Agreement
are as defined in the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Grant Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 200<U>&nbsp;&nbsp;</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Name of Optionee:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Optionee&#146;s Social Security
Number: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Number of Shares Covered by Option: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Option Price per Share: $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <B>(At
least 100% of Fair Market Value)</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vesting Start Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>By signing this cover sheet, you agree to all of the terms and conditions
described in the Option Agreement (including the attached terms) and in the Plan, a copy of which is also attached. You acknowledge that you have carefully reviewed the Plan, and agree that the Plan will control in the event any provision of this
Option Agreement should appear to be inconsistent. </I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Optionee:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Signature)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Company:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Signature)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Attachment </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><I>This is not a stock certificate or a negotiable instrument </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA DISCOVERY, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INCENTIVE STOCK OPTION AGREEMENT </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Incentive&nbsp;Stock&nbsp;Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">This Option applies to the number of shares of Stock set forth on the cover sheet of this Option Agreement (the &#147;<B>Option Shares</B>&#148;), and gives you certain rights, as set forth
herein, to purchase the Option Shares, at a price per share equal to the Option price set forth on the cover sheet. This Option is intended to be an incentive stock option under Section 422 of the Internal Revenue Code and will be interpreted
accordingly. If you cease to be an employee of the Company, its parent or a subsidiary (&#147;<B>Employee</B>&#148;) but continue to provide Service, this Option will be deemed a nonstatutory stock option ninety (90) days after you cease to be an
Employee. In addition, to the extent that all or part of this Option exceeds the $100,000 rule of section 422(d) of the Internal Revenue Code, this Option or the lesser excess part will be deemed to be a nonstatutory stock option.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Vesting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Option is only exercisable before it expires and then only with respect to the vested portion of the Option. Subject to the preceding
sentence, you may exercise this Option, in whole or in part, to purchase a whole number of vested shares not less than one hundred (100) shares (unless the total number of vested shares under the Option is less than 100 shares, in which case you may
purchase such total) by following the procedures set forth in the Plan and below in this Option Agreement.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Your right to purchase the Option Shares vests as
follows: twenty-five percent (25%) vests one year after Vesting Start Date and 6.25% vests at the end of each three (3) month period thereafter. The resulting aggregate number of vested shares will be rounded to the nearest whole number, and you
cannot vest in more than the number of Option Shares.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Notwithstanding the foregoing
vesting schedule, if a Change of Control (as defined in the Plan) occurs prior to expiration of this Option and at a time when you remain in Service as an Employee, then fifty percent (50%) of your unvested Option Shares shall become fully and
immediately vested upon the closing date of such Change of Control (to the extent such Option Shares have not yet then vested), and any remaining unvested Option Shares shall continue to vest according to the vesting schedule set forth herein;
provided, however, that on the earlier to occur of (i) the one-year anniversary of the closing date of such Change of Control and (ii) your Involuntary Termination Date (as defined below), any Option Shares that remain unvested on such earlier date
shall become fully and immediately vested (provided further, that, in the case of clause (i), you remain in continuous Service as an Employee during such one-year period).</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">You will experience an &#147;<B>Involuntary Termination Date</B>&#148; on your employment termination
date if your Service is terminated by the Company or its successor without Cause or by you for Good Reason. For purposes of this Option Agreement, &#147;<B>Cause</B>&#148; means that you have committed or engaged in: (i) willful misconduct, gross
negligence, theft, fraud, or other illegal or dishonest conduct,</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">any of which are considered to be materially harmful to the Company; (ii) refusal, unwillingness, failure, or inability to perform material job
duties or habitual absenteeism; or (iii) violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of any contract between you and the Company; and, &#147;<B>Good Reason</B>&#148; means (i) the relocation
of your normal principal place of work greater than thirty (30) miles from your then current normal work location; (ii) a decrease in your then current base salary of more than fifteen percent (15%), other than any such decrease resulting from a
general reduction by the Company in the base salary of all similarly situated employees; or (iii) the Company unilaterally makes significant detrimental reductions in your job responsibilities; provided, that you shall give written notice to the
Chairman of the Company&#146;s Board of Directors setting forth your intent to resign for Good Reason and the facts in support of your claim that Good Reason exists; and the Company shall have twenty (20) days after the applicable party has received
such notice to take such actions, if any, as the Company may deem appropriate to eliminate such claimed Good Reason (without thereby admitting that such Good Reason had occurred). If the Company so acts to eliminate such claimed Good Reason, then
you shall not be deemed to be resigning for Good Reason under such facts.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">No additional
Option Shares will vest after your Service has terminated for any reason. As described below, in certain cases this Option will expire after your Service, and the vesting of this Option has already terminated.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Term</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">This Option will expire in any event at the close of business at Company headquarters on the day before the tenth (10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2">) anniversary of the Grant Date, as shown on the cover sheet. This Option will expire earlier if your Service terminates, as described below.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Regular&nbsp;Termination</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates for any reason, other than death, Disability or Cause, then this Option will expire at the close of business at Company headquarters on the ninetieth
(90</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">) day after your termination date.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Termination for Cause</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If your Service is terminated for Cause, then you shall immediately forfeit all rights to this Option and the Option, including any vested portion, shall immediately expire.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Death</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates because of your death, then this Option will expire at the close of business at Company headquarters on the date twelve
(12) months after the date of death. During that twelve (12) month period, your estate or heirs may exercise the vested portion of this Option.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">In addition,
if you die during the ninety (90) day period described in connection with a regular termination (i.e., a termination of your Service not on account of your death, Disability or Cause), and a vested portion of this Option has not yet been exercised,
then this Option will instead expire on the date twelve (12) months after your termination date. In such a case, during the period following your death up to the date twelve (12) months after your termination date, your estate or heirs may exercise
the vested portion of this Option.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Disability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates because of your Disability, then this Option will</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">expire at the close of business at Company headquarters on the date twelve (12) months after your termination date.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Leaves&nbsp;of&nbsp;Absence</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">For purposes of this Option, your Service does not terminate when you go on a <I>bona fide</I> employee leave of absence that was approved by the
Company in writing, if the terms of the leave provide for continued Service crediting, or when continued Service crediting is required by applicable law. However, your Service will be treated as terminating ninety (90) days after you went on
employee leave, unless your right to return to active work is guaranteed by law or by a contract. Your Service terminates in any event when the approved leave ends unless you immediately return to active employee work.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The Company determines, in its sole discretion, which leaves count for this purpose, and when your
Service terminates for all purposes under the Plan.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Notice of Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you wish to exercise this Option, you must notify the Company by filing the proper &#147;Notice of Exercise&#148; form at the address given
on the form. Your notice must specify how many shares you wish to purchase (in a parcel of at least one hundred (100) shares generally). Your notice must also specify how your shares of Stock should be registered (in your name only or in your and
your spouse&#146;s names as joint tenants with right of survivorship). The notice will be effective when it is received by the Company.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">If someone else wants to exercise this Option after your death, that person must prove to the Company&#146;s satisfaction that he or she is entitled to do
so.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Form of Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you submit your notice of exercise, you must include payment of the option price for the shares you are purchasing. Payment may be made in
one (or a combination) of the following forms:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman"
SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash, your personal check, a cashier&#146;s check, a money order or another cash equivalent acceptable to the Company.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of Stock which have already been owned by you for more than six (6) months and that are owned free of any liens, claims, encumbrances or securities interests and which are surrendered to the Company; <I>provided, that</I> such tender would not
violate the provisions of any law, regulation or agreement restricting the redemption of the Company&#146;s stock. The value of the shares, as determined in good faith by the Company&#146;s Board of Directors as of the effective date of the Option
exercise, will be applied to the option price.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT FACE="Times New Roman"
SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the extent a public market for the Stock exists as determined by the Company, by delivery (on a form prescribed by the Company) of an irrevocable direction to a licensed securities
broker acceptable to the Company to sell Stock and to deliver all or part of the sale proceeds to the Company in payment of the aggregate option price and any withholding taxes.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Withholding&nbsp;Taxes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">You will not be allowed to exercise this Option unless you make acceptable arrangements to pay any withholding or other taxes that may be due as a result</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">of the Option exercise or sale of Stock acquired under this Option. In the event that the Company determines that any federal, state, local or foreign tax or withholding payment is required
relating to the exercise or sale of shares arising from this grant, the Company shall have the right to require such payments from you, or withhold such amounts from other payments due to you from the Company or any Affiliate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Transfer&nbsp;of&nbsp;Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">During your lifetime, only you (or, in the event of your legal incapacity or incompetency, your guardian or legal representative) may exercise
this Option. You cannot transfer or assign this Option. For instance, you may not sell this Option or use it as security for a loan. If you attempt to do any of these things, this Option will immediately become invalid. You may, however, dispose of
this Option in your will or it may be transferred upon your death by the laws of descent and distribution.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
FACE="Times New Roman" SIZE="2">Regardless of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your spouse, nor is the Company obligated to recognize your spouse&#146;s interest in this
Option in any other way.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Market Stand-off Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the
Company&#146;s initial public offering, you agree not to sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or agree to engage in any of the foregoing
transactions with respect to any Option Shares without the prior written consent of the Company or its underwriters, for such period of time after the effective date of such registration statement as may be requested by the Company or the
underwriters (not to exceed 180 days in length (or such longer period, not to exceed eighteen (18) days after the expiration of the one hundred eighty (180) day period, as the underwriters or the Company shall request in order to facilitate
compliance with NASD Rule 2711))<I> provided, however</I>, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company during such period. You further agree to execute and deliver such
other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to your Option Shares until the end of such period.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Investment Representation; Securities Law Compliance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If the sale of Stock under the Plan is not registered under the Securities Act, but an exemption is available which requires an investment or other representation, you shall represent and
agree at the time of exercise that the Stock being acquired upon exercise of this Option is being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or
appropriate by the Company and its counsel. Notwithstanding anything to the contrary contained herein, you may not exercise this Option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act of
1933, as amended, or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">registration requirements of the Securities Act. The exercise of this Option also must comply with other applicable laws and regulations governing this Option, and you may not exercise this
Option if the Company determines that such exercise would not be in material compliance with such laws and regulations.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>The&nbsp;Company&#146;s&nbsp;Right of First Refusal</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In the event that you propose to sell, pledge or otherwise transfer to a third party any Option Shares, or any interest in such Option Shares, the
Company shall have the &#147;<B>Right of First Refusal</B>&#148; with respect to all (and not less than all) of such Option Shares. If you desire to transfer any Option Shares, you must give a written notice (a &#147;<B>Transfer Notice</B>&#148;) to
the Company describing fully the proposed transfer, including the number of shares proposed to be transferred, the proposed transfer price and the name and address of the proposed transferee.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Transfer Notice shall be signed both by you and by the proposed new transferee and must
constitute a binding commitment of both parties to the transfer of the shares. The Company shall have the right to purchase all, and not less than all, of such Option Shares on the terms of the proposal described in the Transfer Notice (subject,
however, to any change in such terms permitted in the next paragraph) by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date when the Transfer Notice was received by the Company.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If the Company fails to exercise its Right of First Refusal within thirty (30) days after the date
when it received the Transfer Notice, you may, not later than ninety (90) days following receipt of the Transfer Notice by the Company, conclude a transfer of the Stock subject to the Transfer Notice on the terms and conditions described in the
Transfer Notice. Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by you, shall again be subject to the Right of First Refusal and shall require
compliance with the procedure described in the paragraph above. If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Stock on the terms set forth in the Transfer Notice within sixty (60) days after the
date when the Company received the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the Stock was to be made in a
form other than lawful money paid at the time of transfer, the Company shall have the option of paying for the Stock with lawful money equal to the present value of the consideration described in the Transfer Notice.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In the case of any purchase of Stock under this Right of First Refusal, at the option of the Company,
the Company may pay you the purchase price in three or fewer annual installments. Interest shall be credited on the installments at the applicable federal rate (as determined for purposes of Section&nbsp;1274 of the Code) in effect on the date on
which the purchase is made. The Company shall pay at least one-third of the total purchase price each year, plus interest on the unpaid balance, with the first payment being made on or before the sixtieth (60</FONT><FONT FACE="Times New Roman"
SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">) day after the purchase.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman"
SIZE="2">The Company&#146;s rights under this subsection shall be freely assignable, in whole or in part, shall inure to the benefit of its successors and assigns and shall be</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">binding upon any transferee of the Option Shares.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s Right of First Refusal shall terminate in the event that the Stock is listed on an established national or regional stock exchange, is admitted for
quotation on The Nasdaq Stock Market, Inc., or is publicly traded in an established securities market.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Retention&nbsp;Rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Neither this Option nor this Option Agreement gives you the right to be retained by the Company (or any Parent, Subsidiaries or Affiliates) in any capacity. The Company (and any Parent,
Subsidiaries or Affiliates) reserve the right to terminate your Service at any time and for any reason.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Stockholder&nbsp;Rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">You, or your estate or heirs, have no rights as a stockholder of the Company until a certificate for your Option&#146;s shares has been issued (or an appropriate book entry has been made). No
adjustments are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued (or an appropriate book entry has been made), except as described in the Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Adjustments</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In the event of a stock split, a stock dividend or a similar change in the Stock, the number of shares covered by this Option and the option price per share shall be adjusted (and rounded
down to the nearest whole number) if required pursuant to the Plan. This Option shall be subject to the terms of the agreement of merger, liquidation or reorganization in the event the Company is subject to such corporate activity.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Legends</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">All certificates representing the Stock issued upon exercise of this Option shall, where applicable, have endorsed thereon the following legends:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS
ON TRANSFER AND OPTIONS TO PURCHASE SUCH SHARES SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE
FURNISHED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.&#148;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&#147;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT
BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION OR QUALIFICATION THEREOF UNDER SUCH ACT AND SUCH APPLICABLE STATE OR OTHER JURISDICTION&#146;S SECURITIES LAWS OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS
COUNSEL, THAT SUCH REGISTRATION AND QUALIFICATION IS NOT REQUIRED.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Applicable Law</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">This Option Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer
construction or interpretation of this Option Agreement to the substantive law of another jurisdiction.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>The Plan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">The text of the Plan is incorporated in this Option Agreement by reference.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Certain capitalized terms used in this Option Agreement are defined in the Plan, and have the meaning set forth in the Plan.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">This Option Agreement and the Plan constitute the entire understanding between you and the Company
regarding this Option. Any prior agreements, commitments or negotiations concerning this Option are superseded.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other&nbsp;Agreements</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">You agree, as a condition of the grant of this Option, that in connection with the exercise of the Option, you will execute such document(s) as necessary to become a party to any stockholder
agreement or voting trust as the Company may require.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Certain&nbsp;Dispositions</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If you sell or otherwise dispose of any Option Shares following termination of the Company&#146;s Right of First Refusal and sooner than the one year anniversary of the date you acquired the
Stock, then you agree to notify the Company in writing of the date of sale or disposition, the number of shares of Stock sold or disposed of and the sale price per share within thirty (30) days of such sale or disposition.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>By signing the cover sheet of this Option Agreement, you agree to all of the terms and
conditions described above and in the Plan. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>14
<FILENAME>dex109.htm
<DESCRIPTION>FORM OF NON-EXECUTIVE INCENTIVE STOCK OPTION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Non-executive Incentive Stock Option Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.9 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
FACE="Times New Roman" SIZE="2"><B>Option No.: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INCENTIVE STOCK OPTION AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ARCA biopharma,
Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby grants an option (the &#147;Option&#148;) to purchase shares of its common stock, $0.001 par value, (the &#147;<B>Stock</B>&#148;) to the optionee named below. The terms and
conditions of the Option are set forth in this Incentive Stock Option Agreement, consisting of this cover sheet and the attached terms (the &#147;Option Agreement&#148;) and in the Company&#146;s 2004 Stock Incentive Plan (the
&#147;<B>Plan</B>&#148;). Capitalized terms not defined in the Option Agreement are as defined in the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Grant Date:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 200<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Name of Optionee:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Optionee&#146;s Social Security Number:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Number of Shares Covered by Option:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Option Price per Share:
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> <B>(At least 100% of Fair Market Value)</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Vesting Start Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>By signing this cover sheet, you agree to all of the terms and conditions described in the Option Agreement (including the attached terms) and in
the Plan, a copy of which is also attached. You acknowledge that you have carefully reviewed the Plan, and agree that the Plan will control in the event any provision of this Option Agreement should appear to be inconsistent. </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Optionee:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Signature)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Company:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Signature)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Attachment </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><I>This is not a stock certificate or a negotiable instrument </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>INCENTIVE STOCK OPTION AGREEMENT </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Incentive Stock Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Option applies to the number of shares of Stock set forth on the cover sheet of this Option Agreement (the &#147;<B>Option Shares</B>&#148;). This Option is intended to be an incentive
stock option under Section 422 of the Internal Revenue Code and will be interpreted accordingly. If you cease to be an employee of the Company, its parent or a subsidiary (&#147;<B>Employee</B>&#148;) but continue to provide Service, this Option
will be deemed a nonstatutory stock option ninety (90) days after you cease to be an Employee. In addition, to the extent that all or part of this Option exceeds the $100,000 rule of section 422(d) of the Internal Revenue Code, this Option or the
lesser excess part will be deemed to be a nonstatutory stock option.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Vesting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This Option is only exercisable before it expires and then only with respect to the vested portion of the Option. Subject to the preceding sentence,
you may exercise this Option, in whole or in part, to purchase a whole number of vested shares not less than one hundred (100) shares (unless the total number of vested shares under the Option is less than 100 shares, in which case you may purchase
such total) by following the procedures set forth in the Plan and below in this Option Agreement.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Your right to purchase the Option Shares vests as follows: twenty-five percent (25%) vests one year after Vesting Start Date and 6.25% vests at the end of each three (3) month period thereafter. The resulting
aggregate number of vested shares will be rounded to the nearest whole number, and you cannot vest in more than the number of Option Shares.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">No additional Option Shares will vest after your Service has terminated for any reason. As described below, in certain cases this Option will expire after your Service,
and the vesting of this Option has already terminated.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Term</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Option will expire in any event at the close of business at Company headquarters on the day before the tenth (10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2">) anniversary of the Grant Date, as shown on the cover sheet. This Option will expire earlier if your Service terminates, as described below.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Regular Termination</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates for any reason, other than death, Disability or Cause, then this Option will expire at the close of business at Company headquarters on the ninetieth (90</FONT><FONT
FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">) day after your termination date.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Termination for Cause</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If your Service is terminated for Cause, then you shall immediately forfeit all rights to this Option and the Option, including any vested portion, shall immediately expire.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Death</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates because of your death, then this Option will expire at the close of business at Company headquarters on the date twelve (12) months after the date of death. During
that twelve (12) month period, your estate or</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">heirs may exercise the vested portion of this Option.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">In addition, if you die during the ninety (90) day period described in connection with a regular termination (i.e., a termination of your Service not on account of your
death, Disability or Cause), and a vested portion of this Option has not yet been exercised, then this Option will instead expire on the date twelve (12) months after your termination date. In such a case, during the period following your death up
to the date twelve (12) months after your termination date, your estate or heirs may exercise the vested portion of this Option.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Disability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates because of your Disability, then this Option will expire at the close of business at Company headquarters on the date twelve (12) months after your termination date.
</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Leaves of Absence</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">For purposes of this Option, your Service does not terminate when you go on a <I>bona fide</I> employee leave of absence that was approved by the
Company in writing, if the terms of the leave provide for continued Service crediting, or when continued Service crediting is required by applicable law. However, your Service will be treated as terminating ninety (90) days after you went on
employee leave, unless your right to return to active work is guaranteed by law or by a contract. Your Service terminates in any event when the approved leave ends unless you immediately return to active employee work.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The Company determines, in its sole discretion, which leaves count for this purpose, and when your
Service terminates for all purposes under the Plan.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Notice of Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you wish to exercise this Option, you must notify the Company by filing the proper &#147;Notice of Exercise&#148; form at the address given on
the form. Your notice must specify how many shares you wish to purchase (in a parcel of at least one hundred (100) shares generally). Your notice must also specify how your shares of Stock should be registered (in your name only or in your and your
spouse&#146;s names as joint tenants with right of survivorship). The notice will be effective when it is received by the Company.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">If someone else wants to exercise this Option after your death, that person must prove to the Company&#146;s satisfaction that he or she is entitled to do
so.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Form of Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you submit your notice of exercise, you must include payment of the option price for the shares you are purchasing. Payment may be made in one
(or a combination) of the following forms:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman"
SIZE="2">&#149;&nbsp;&nbsp;&nbsp;Cash, your personal check, a cashier&#146;s check, a money order or another cash equivalent acceptable to the Company.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;Shares of Stock which have already been owned by you for more than six (6) months and that are owned free
of any liens, claims, encumbrances or securities interests and which are surrendered to the Company; <I>provided, that</I> such tender would not violate the provisions of any law, regulation or agreement restricting the redemption of the
Company&#146;s stock. The value of the shares, as determined in good faith by the Company&#146;s Board of Directors as of the effective date of the Option exercise, will be applied to the option</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">price.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;To the extent a public market for the Stock exists as determined by the Company, by delivery (on a form
prescribed by the Company) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell Stock and to deliver all or part of the sale proceeds to the Company in payment of the aggregate option price and any
withholding taxes.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Withholding Taxes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">You will not be allowed to exercise this Option unless you make acceptable arrangements to pay any withholding or other taxes that may be due as a result of the Option exercise or sale of Stock
acquired under this Option. In the event that the Company determines that any federal, state, local or foreign tax or withholding payment is required relating to the exercise or sale of shares arising from this grant, the Company shall have the
right to require such payments from you, or withhold such amounts from other payments due to you from the Company or any Affiliate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Transfer of Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">During your lifetime, only you (or, in the event of your legal incapacity or incompetency, your guardian or legal representative) may exercise this
Option. You cannot transfer or assign this Option. For instance, you may not sell this Option or use it as security for a loan. If you attempt to do any of these things, this Option will immediately become invalid. You may, however, dispose of this
Option in your will or it may be transferred upon your death by the laws of descent and distribution.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
FACE="Times New Roman" SIZE="2">Regardless of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your spouse, nor is the Company obligated to recognize your spouse&#146;s interest in this
Option in any other way.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Market Stand-off Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the
Company&#146;s initial public offering, you agree not to sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or agree to engage in any of the foregoing
transactions with respect to any Option Shares without the prior written consent of the Company or its underwriters, for such period of time after the effective date of such registration statement as may be requested by the Company or the
underwriters (not to exceed 180 days in length (or such longer period, not to exceed eighteen (18) days after the expiration of the one hundred eighty (180) day period, as the underwriters or the Company shall request in order to facilitate
compliance with NASD Rule 2711))<I> provided, however</I>, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company during such period. You further agree to execute and deliver such
other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to your Option Shares until the end of such period.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Investment Representation; Securities Law Compliance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If the sale of Stock under the Plan is not registered under the Securities Act, but an exemption is available which requires an investment or other representation, you shall represent and agree
at the time of exercise that the Stock being acquired upon exercise of this Option is being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or
appropriate by the Company and its counsel. Notwithstanding anything to the contrary contained herein, you may not exercise this Option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act of
1933, as amended, or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of this Option also
must comply with other applicable laws and regulations governing this Option, and you may not exercise this Option if the Company determines that such exercise would not be in material compliance with such laws and regulations.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>The Company&#146;s Right of First Refusal</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In the event that you propose to sell, pledge or otherwise transfer to a third party any Option Shares, or any interest in such Option Shares, the
Company shall have the &#147;<B>Right of First Refusal</B>&#148; with respect to all (and not less than all) of such Option Shares. If you desire to transfer any Option Shares, you must give a written notice (a &#147;<B>Transfer Notice</B>&#148;) to
the Company describing fully the proposed transfer, including the number of shares proposed to be transferred, the proposed transfer price and the name and address of the proposed transferee.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Transfer Notice shall be signed both by you and by the proposed new transferee and must
constitute a binding commitment of both parties to the transfer of the shares. The Company shall have the right to purchase all, and not less than all, of such Option Shares on the terms of the proposal described in the Transfer Notice (subject,
however, to any change in such terms permitted in the next paragraph) by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date when the Transfer Notice was received by the Company.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">If the Company fails to exercise its Right of First Refusal within thirty (30) days after the date
when it received the Transfer Notice, you may, not later than ninety (90) days following receipt of the Transfer Notice by the Company, conclude a transfer of the Stock subject to the Transfer Notice on the terms and conditions described in the
Transfer Notice. Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by you, shall again be subject to the Right of First Refusal and shall require
compliance with the procedure described in the paragraph above. If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Stock on the terms set forth in the Transfer Notice within sixty (60) days after the
date when the Company received the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the Stock was to be made in a
form other than lawful money paid at the time of transfer, the Company shall have the option of paying for the Stock with lawful money equal to the present value of the consideration described in the Transfer Notice.</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In the case of any purchase of Stock under this Right of First Refusal, at the option of the Company, the Company may pay you the purchase price in
three or fewer annual installments. Interest shall be credited on the installments at the applicable federal rate (as determined for purposes of Section&nbsp;1274 of the Code) in effect on the date on which the purchase is made. The Company shall
pay at least one-third of the total purchase price each year, plus interest on the unpaid balance, with the first payment being made on or before the sixtieth (60</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2">) day after the purchase.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s rights
under this subsection shall be freely assignable, in whole or in part, shall inure to the benefit of its successors and assigns and shall be binding upon any transferee of the Option Shares.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s Right of First Refusal shall terminate in the event that the Stock is listed on an
established national or regional stock exchange, is admitted for quotation on The Nasdaq Stock Market, Inc., or is publicly traded in an established securities market.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Retention Rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Neither this Option nor this Option Agreement gives you the right to be retained by the Company (or any Parent, Subsidiaries or Affiliates) in any capacity. The Company (and any Parent,
Subsidiaries or Affiliates) reserve the right to terminate your Service at any time and for any reason.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Stockholder Rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">You, or your estate or heirs, have no rights as a stockholder of the Company until a certificate for your Option&#146;s shares has been issued (or an appropriate book entry has been made). No
adjustments are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued (or an appropriate book entry has been made), except as described in the Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Adjustments</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In the event of a stock split, a stock dividend or a similar change in the Stock, the number of shares covered by this Option and the option price per share shall be adjusted (and rounded down
to the nearest whole number) if required pursuant to the Plan. This Option shall be subject to the terms of the agreement of merger, liquidation or reorganization in the event the Company is subject to such corporate activity.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Legends</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">All certificates representing the Stock issued upon exercise of this Option shall, where applicable, have endorsed thereon the following legends:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS
ON TRANSFER AND OPTIONS TO PURCHASE SUCH SHARES SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE
FURNISHED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.&#148;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">&#147;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE
SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">EFFECTIVE REGISTRATION OR QUALIFICATION THEREOF UNDER SUCH ACT AND SUCH APPLICABLE STATE OR OTHER JURISDICTION&#146;S SECURITIES LAWS OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND
ITS COUNSEL, THAT SUCH REGISTRATION AND QUALIFICATION IS NOT REQUIRED.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Applicable Law</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Option Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer
construction or interpretation of this Option Agreement to the substantive law of another jurisdiction.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>The Plan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The text of the Plan is incorporated in this Option Agreement by reference. Certain capitalized terms used in this Option Agreement are defined in
the Plan, and have the meaning set forth in the Plan.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">This Option Agreement and the
Plan constitute the entire understanding between you and the Company regarding this Option. Any prior agreements, commitments or negotiations concerning this Option are superseded.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other Agreements</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">You agree, as a condition of the grant of this Option, that in connection with the exercise of the Option, you will execute such document(s) as necessary to become a party to any stockholder
agreement or voting trust as the Company may require.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Certain Dispositions</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If you sell or otherwise dispose of any Option Shares following termination of the Company&#146;s Right of First Refusal and sooner than the one year anniversary of the date you acquired the
Stock, then you agree to notify the Company in writing of the date of sale or disposition, the number of shares of Stock sold or disposed of and the sale price per share within thirty (30) days of such sale or disposition.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>By signing the cover sheet of this Option Agreement, you agree to all of the terms and
conditions described above and in the Plan. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>15
<FILENAME>dex1010.htm
<DESCRIPTION>FORM OF NONQUALIFIED STOCK OPTION AGREEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Form of Nonqualified Stock Option Agreement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 10.10 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="right"><FONT
FACE="Times New Roman" SIZE="2"><B>Option No.: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA DISCOVERY, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NONQUALIFIED STOCK OPTION AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">ARCA Discovery, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby grants an option to purchase shares of its common stock, $0.001 par value, (the &#147;<B>Stock</B>&#148;) to the optionee named below. The terms and
conditions of the option are set forth in this cover sheet, in the attachment and in the Company&#146;s 2004 Stock Incentive Plan (the &#147;<B>Plan</B>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Grant Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 200<U>&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">Name of Optionee:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Optionee&#146;s Social Security Number:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>-<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Number of Shares Covered by Option:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Option Price per Share:
$<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vesting Start
Date: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, 20<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>By signing this cover sheet, you agree to all of the terms and conditions described in the attached Agreement and in the Plan, a copy of which is
also attached. You acknowledge that you have carefully reviewed the Plan, and agree that the Plan will control in the event any provision of this Agreement should appear to be inconsistent. </I></B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0">

<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Optionee:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Signature)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Company:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">(Signature)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>Attachment </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><I>This is not a stock certificate or a negotiable instrument </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA DISCOVERY, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>2004 STOCK INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NONQUALIFIED STOCK OPTION AGREEMENT </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Nonqualified Stock Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">This option is not intended to be an incentive stock option under Section 422 of the Internal Revenue Code and will be interpreted accordingly.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Vesting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This option is only exercisable before it expires and then only with respect to the vested portion of the option. Subject to the preceding
sentence, you may exercise this option, in whole or in part, to purchase a whole number of vested shares not less than one hundred (100) shares, unless the number of shares purchased is the total number available for purchase under the option, by
following the procedures set forth in the Plan and below in this Agreement.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Your right
to purchase shares of Stock under this option vests as to the total number of shares covered by this option, as shown on the cover sheet (the &#147;<B>Option Shares</B>&#148;), on the one-year anniversary of the Vesting Start Date
(&#147;<B>Anniversary Date</B>&#148;), provided you then continue in Service.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">No shares
of Stock will vest after your Service has terminated for any reason.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Term</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Your option will expire in any event at the close of business at Company headquarters on the day before the tenth (10</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2">) anniversary of the Grant Date, as shown on the cover sheet. Your option will expire earlier if your Service terminates, as described below.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Regular Termination</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates for any reason, other than death, Disability or Cause, then your option will expire at the close of business at Company headquarters on the ninetieth
(90</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">)day after your termination date.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Termination for Cause</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If your Service is terminated for Cause, then you shall immediately forfeit all rights to your option and the option shall immediately expire.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Death</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates because of your death, then your option will expire at the close of business at Company headquarters on the date twelve
(12) months after the date of death. During that twelve (12)-month period, your estate or heirs may exercise the vested portion of your option.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">In addition, if you die during the ninety (90)-day period described in connection with a regular termination (i.e., a termination of your Service not on account of your
death, Disability or Cause), and a vested portion of your option has not yet been exercised, then your option will instead expire on the date twelve (12) months after your termination date. In such a case, during the period following your death up
to the date twelve (12) months after your termination date, your estate or heirs may exercise the vested portion of your option.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Disability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If your Service terminates because of your Disability, then your option will expire at the close of business at Company headquarters on the date twelve (12) months after your termination
date.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Leaves of Absence</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">For purposes of this option, your Service does not terminate when you go on <I>a bona fide</I> employee leave of absence that was approved by the
Company in writing, if the terms of the leave provide for continued Service crediting, or when continued Service crediting is required by applicable law. However, your Service will be treated as terminating ninety (90) days after you went on
employee leave, unless your right to return to active work is guaranteed by law or by a contract. Your Service terminates in any event when the approved leave ends unless you immediately return to active employee work.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The Company determines, in its sole discretion, which leaves count for this purpose, and when your
Service terminates for all purposes under the Plan.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Notice of Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you wish to exercise this option, you must notify the Company by filing the proper &#147;Notice of Exercise&#148; form at the address given
on the form. Your notice must specify how many shares you wish to purchase (in a parcel of at least one hundred (100) shares generally). Your notice must also specify how your shares of Stock should be registered (in your name only or in your and
your spouse&#146;s names as joint tenants with right of survivorship). The notice will be effective when it is received by the Company.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">If someone else wants to exercise this option after your death, that person must prove to the Company&#146;s satisfaction that he or she is entitled to do
so.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Form of Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">When you submit your notice of exercise, you must include payment of the option price for the shares you are purchasing. Payment may be made in
one (or a combination) of the following forms:</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman"
SIZE="2">&#149;&nbsp;&nbsp;&nbsp;Cash, your personal check, a cashier&#146;s check, a money order or another cash equivalent acceptable to the Company. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;Shares of Stock which have already been owned by you for more than six (6) months and that are owned free
of any liens, claims, encumbrances or securities interests and which are surrendered to the Company; <I>provided</I>, <I>that</I> such tender would not violate the provisions of any law, regulation or agreement restricting the redemption of the
Company&#146;s stock. The value of the shares, as determined in good faith by the Company&#146;s Board of Directors as of the effective date of the option exercise, will be applied to the option price.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;To the extent a public market for
the Stock exists as determined by the Company, by delivery (on a form prescribed by the Company) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell Stock and to deliver all or part of the sale proceeds to
the Company in payment of the aggregate option price and any withholding taxes.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Withholding Taxes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">You will not be allowed to exercise this option unless you make acceptable arrangements to pay any withholding or other taxes that may be due as a result of the option exercise or sale of
Stock acquired under this option. In the event that the Company determines that any federal, state, local or foreign tax or withholding payment is required relating to the exercise or sale of shares</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">arising from this grant, the Company shall have the right to require such payments from you, or withhold such amounts from other payments due to you from the Company or any
Affiliate.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Transfer of Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">During your lifetime, only you (or, in the event of your legal incapacity or incompetency, your guardian or legal representative) may exercise the
option. You cannot transfer or assign this option. For instance, you may not sell this option or use it as security for a loan. If you attempt to do any of these things, this option will immediately become invalid. You may, however, dispose of this
option in your will or it may be transferred upon your death by the laws of descent and distribution.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
FACE="Times New Roman" SIZE="2">Regardless of any marital property settlement agreement, the Company is not obligated to honor a notice of exercise from your spouse, nor is the Company obligated to recognize your spouse&#146;s interest in your
option in any other way.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Market Stand-off Agreement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">In connection with any underwritten public offering by the Company of its equity securities pursuant to an effective registration statement filed under the Securities Act, including the
Company&#146;s initial public offering, you agree not to sell, make any short sale of, loan, hypothecate, pledge, grant any option for the purchase of, or otherwise dispose or transfer for value or agree to engage in any of the foregoing
transactions with respect to any shares of Stock without the prior written consent of the Company or its underwriters, for such period of time after the effective date of such registration statement as may be requested by the Company or the
underwriters (not to exceed 180 days in length) <I>provided</I>, <I>however</I>, that nothing contained in this section shall prevent the exercise of a repurchase option, if any, in favor of the Company during such period. You further agree to
execute and deliver such other agreements as may be reasonably requested by the Company and/or the underwriter(s) that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing
covenant, the Company may impose stop transfer instructions with respect to your shares of Common Stock until the end of such period.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Investment Representation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">If the sale of Stock under the Plan is not registered under the Securities Act, but an exemption is available which requires an investment or other representation, you shall represent and
agree at the time of exercise that the Stock being acquired upon exercise of this option is being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or
appropriate by the Company and its counsel. Notwithstanding anything to the contrary contained herein, you may not exercise your option unless the shares of Common Stock issuable upon such exercise are then registered under the Securities Act of
1933, as amended, or, if such shares of Common Stock are not then so registered, the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act. The exercise of your option also
must comply with other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>The Company&#146;s Right of First Refusal</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In the event that you propose to sell, pledge or otherwise transfer to a third party any Stock acquired under this Agreement, or any interest in such
Stock, the Company shall have the &#147;<B>Right of First Refusal</B>&#148; with respect to all (and not less than all) of such shares of Stock. If you desire to transfer Stock acquired under this Agreement, you must give a written notice (a
&#147;<B>Transfer Notice</B>&#148;) to the Company describing fully the proposed transfer, including the number of shares proposed to be transferred, the proposed transfer price and the name and address of the proposed transferee.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The Transfer Notice shall be signed both by you and by the proposed new transferee and must
constitute a binding commitment of both parties to the transfer of the shares. The Company shall have the right to purchase all, and not less than all, of the shares of Stock on the terms of the proposal described in the Transfer Notice (subject,
however, to any change in such terms permitted in the next paragraph) by delivery of a notice of exercise of the Right of First Refusal within thirty (30) days after the date when the Transfer Notice was received by the Company.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">If the Company fails to exercise its Right of First Refusal within thirty (30) days after the date
when it received the Transfer Notice, you may, not later than ninety (90) days following receipt of the Transfer Notice by the Company, conclude a transfer of the Stock subject to the Transfer Notice on the terms and conditions described in the
Transfer Notice. Any proposed transfer on terms and conditions different from those described in the Transfer Notice, as well as any subsequent proposed transfer by you, shall again be subject to the Right of First Refusal and shall require
compliance with the procedure described in the paragraph above. If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Stock on the terms set forth in the Transfer Notice within sixty (60) days after the
date when the Company received the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the Stock was to be made in a
form other than lawful money paid at the time of transfer, the Company shall have the option of paying for the Stock with lawful money equal to the present value of the consideration described in the Transfer Notice.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In the case of any purchase of Stock under this Right of First Refusal, at the option of the Company,
the Company may pay you the purchase price in three or fewer annual installments. Interest shall be credited on the installments at the applicable federal rate (as determined for purposes of Section&nbsp;1274 of the Code) in effect on the date on
which the purchase is made. The Company shall pay at least one-third of the total purchase price each year, plus interest on the unpaid balance, with the first payment being made on or before the sixtieth (60</FONT><FONT FACE="Times New Roman"
SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2">) day after the purchase.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">The Company&#146;s rights under this subsection shall be freely assignable, in whole or in part, shall inure to the benefit of its successors and assigns and shall be binding upon any transferee of the shares of Stock.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s Right of First Refusal shall terminate in the event that the</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Stock is listed on an established national or regional stock exchange, is admitted for quotation on The Nasdaq Stock Market, Inc., or is publicly traded in an established securities
market.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Right to Repurchase</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Following termination of your Service for any reason, the Company shall have the right to purchase all of those shares of Stock that you have or will
acquire under this option. If the Company exercises its right to purchase the shares, the Company will notify you of its intention to purchase such shares, and will consummate the purchase within one year (or 90 days to the extent required by
applicable law) of your termination of Service or, in the case of Stock acquired after your termination of Service, within one year (or 90 days to the extent required by applicable law) of the date of exercise.</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The purchase price shall be the Fair Market Value of the shares on the date of your termination of
Service if the Company exercises its right to purchase such shares within 90 days of your termination of Service or exercises its right within 90 days of the date of your exercise of the option following termination of Service; otherwise the
purchase price shall be the Fair Market Value of the shares on the date the Company gives you notice of its intent to exercise its right to purchase the shares; <U>provided</U>, <U>however</U>, that if your Service is terminated for Cause, the
purchase price shall be the exercise price paid by you for such shares of Stock.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">The
Company&#146;s rights of repurchase shall terminate in the event that the Stock is listed on an established national or regional stock exchange, is admitted for quotation on The Nasdaq Stock Market, Inc., or is publicly traded in an established
securities market.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Retention Rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Neither your option nor this Agreement give you the right to be retained by the Company (or any Parent, Subsidiaries or Affiliates) in any capacity. The Company (and any Parent, Subsidiaries or
Affiliates) reserve the right to terminate your Service at any time and for any reason.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Shareholder Rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">You, or your estate or heirs, have no rights as a shareholder of the Company until a certificate for your option&#146;s shares has been issued (or an appropriate book entry has been made). No
adjustments are made for dividends or other rights if the applicable record date occurs before your stock certificate is issued (or an appropriate book entry has been made), except as described in the Plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Adjustments</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">In the event of a stock split, a stock dividend or a similar change in the Stock, the number of shares covered by this option and the option price per share may be adjusted (and rounded down to
the nearest whole number) pursuant to the Plan. Your option shall be subject to the terms of the agreement of merger, liquidation or reorganization in the event the Company is subject to such corporate activity.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Legends</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">All certificates representing the Stock issued upon exercise of this option shall, where applicable, have endorsed thereon the following legends:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">&#147;THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS
ON TRANSFER AND OPTIONS TO PURCHASE</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">SUCH SHARES SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR HIS OR HER PREDECESSOR IN INTEREST. A COPY OF SUCH AGREEMENT
IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY AND WILL BE FURNISHED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY BY THE HOLDER OF RECORD OF THE SHARES REPRESENTED BY THIS CERTIFICATE.&#148;</FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">&#147;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF
1933, AS AMENDED, OR ANY SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION OR QUALIFICATION THEREOF UNDER SUCH ACT AND SUCH APPLICABLE STATE OR OTHER
JURISDICTION&#146;S SECURITIES LAWS OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION AND QUALIFICATION IS NOT REQUIRED.&#148;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Applicable Law</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">This Agreement will be interpreted and enforced under the laws of the State of Delaware, other than any conflicts or choice of law rule or principle that might otherwise refer construction or
interpretation of this Agreement to the substantive law of another jurisdiction.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>The Plan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The text of the Plan is incorporated in this Agreement by reference. Certain capitalized terms used in this Agreement are defined in the Plan, and
have the meaning set forth in the Plan.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="2">This Agreement and the Plan constitute the
entire understanding between you and the Company regarding this option. Any prior agreements, commitments or negotiations concerning this option are superseded.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other Agreements</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">You agree, as a condition of the grant of this option, that in connection with the exercise of the option, you will execute such document(s) as necessary to become a party to any shareholder
agreement or voting trust as the Company may require.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Certain Dispositions</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">If you sell or otherwise dispose of Stock acquired pursuant to the exercise of this option following termination of the Company&#146;s Right of First Refusal and sooner than the one year
anniversary of the date you acquired the Stock, then you agree to notify the Company in writing of the date of sale or disposition, the number of shares of Stock sold or disposed of and the sale price per share within thirty (30) days of such sale
or disposition.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>By signing the cover sheet of this Agreement, you agree to all of the terms and conditions
described above and in the Plan. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>16
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE DATED JANUARY 27, 2009
<TEXT>
<HTML><HEAD>
<TITLE>Press Release dated January 27, 2009</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="top">

<IMG SRC="g90806ex99_1apg001.jpg" ALT="LOGO"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">

<IMG SRC="g90806ex99_1bpg001.jpg" ALT="LOGO"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Contact:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Derek Cole</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Danielle Bertrand</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">ARCA biopharma</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">WeissComm Partners</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">720-940-2163</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">415-946-1056</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">derek.cole@arcabiopharma.com</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><U>dbertrand@wcpglobal.com</U></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA biopharma and Nuvelo Complete Merger </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Creating Late-Stage Cardiovascular Company </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><I>Combined Company to Begin Trading as </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><I>ARCA biopharma, Inc. (Nasdaq: ABIO) on January&nbsp;28, 2009 </I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Broomfield, Colorado and San Carlos, California, January&nbsp;27, 2009</B> &#150; ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted
therapies for heart failure and other cardiovascular diseases, and Nuvelo, Inc. (Nasdaq: NUVO) today announced the completion of their business combination creating a Colorado-headquartered, cardiovascular focused biotechnology company with an
experienced cardiovascular leadership team, a near-term commercial opportunity, Gencaro (bucindolol hydrochloride), and a development pipeline, including the novel, short-acting anticoagulant NU172, which recently completed a successful Phase 1b
study. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">&#147;The merger of ARCA and Nuvelo creates a late-stage company with multiple significant milestones and a near-term commercialization opportunity
in Gencaro, potentially the first genetically-targeted heart failure treatment, followed by a cardiovascular development pipeline,&#148; commented Richard B. Brewer, president and chief executive officer of ARCA. &#147;With our significant
cardiovascular drug development and commercialization expertise, and financial resources expected to fund operations beyond the anticipated FDA response to the Gencaro NDA, we believe we are well-positioned to provide both near- and longer-term
value to our stockholders.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The combined Company is named ARCA biopharma, Inc. ARCA&#146;s common stock will be traded on the Nasdaq Global Market
under the stock ticker symbol ABIO, beginning January&nbsp;28, 2009. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">In connection with the merger, Richard B. Brewer was appointed as president, chief
executive officer and a board member of the combined Company. Michael R. Bristow, M.D., Ph.D., and a founder of the pre-merger ARCA, will assume the chairmanship of the new board and was appointed as chief science and medical officer of the combined
Company. In addition, the following directors were appointed as members of ARCA&#146;s board of directors: Dr.&nbsp;J. William Freytag, Dr.&nbsp;Jean-Fran&ccedil;ois Formela, John Zabriskie, Dr.&nbsp;David Lowe, and Dr.&nbsp;Linda Grais from </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">ARCA&#146;s board prior to the closing of the transaction, with Dr.&nbsp;Ted&nbsp;W. Love, Dr.&nbsp;Burton&nbsp;E. Sobel, and Mary K. Pendergast continuing
from Nuvelo&#146;s board prior to the closing of the transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Under the terms of the merger transaction, Nuvelo issued approximately 4.87&nbsp;million
new shares of common stock to shareholders of pre-merger ARCA. As a result, former ARCA pre-merger equity holders now hold approximately 67 percent, and former Nuvelo stockholders now own approximately 33 percent, of the common stock of the combined
Company after giving effect to the issuance of shares under the pre-merger ARCA options and warrants assumed by the combined Company, primarily on a treasury method basis, and without giving effect to issuance of stock pursuant to Nuvelo&#146;s
outstanding options and warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Effective January&nbsp;27, 2009, prior to completion of the merger, Nuvelo implemented a 20-for-1 reverse stock split so
that every 20 shares of Nuvelo common stock were exchanged for 1 share of Nuvelo common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">The combined company following the merger, ARCA biopharma, Inc., is dedicated to developing and commercializing genetically targeted therapies for heart failure and other
cardiovascular disease. The combined Company&#146;s lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other
indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted heart failure treatment. The New Drug Application for approval
of Gencaro for the indication of chronic heart failure, including the proposed brand name, is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) date of May&nbsp;31, 2009. ARCA is
collaborating with Laboratory Corporation of America to develop the companion genetic test for Gencaro. The combined Company&#146;s second compound in development, NU172, is a direct thrombin inhibitor which has completed Phase 1b development for
use as a potential short-acting anticoagulant during medical or surgical procedures. For more information please visit www.arcabiopharma.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Forward-looking statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This press release contains &#147;forward-looking statements&#148; which include, without limitation, statements
regarding the anticipated benefits of the completion of the business combination transaction between Nuvelo and ARCA and Dawn Acquisition Sub, Inc., the combined Company&#146;s ability to fund future operations, the progress of ARCA&#146;s clinical
stage and research programs, commercialization opportunities for Gencaro, and ARCA&#146;s developmental pipeline, which statements are hereby identified as &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including, without limitation, the risk that Nuvelo&#146;s and ARCA&#146;s business operations will not be integrated successfully; the combined Company&#146;s inability to further identify,
develop and achieve commercial success for products and technologies; the risk </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">that the combined Company&#146;s financial resources will be insufficient to meet its business objectives; uncertainties relating to drug discovery and the
regulatory approval process; clinical development processes; enrollment rates for patients in the companies&#146; clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of
critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without
limitation ARCA&#146;s quarterly report on Form 10-Q for the quarter ended September&nbsp;30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>17
<FILENAME>dex992.htm
<DESCRIPTION>PRESS RELEASE DATED JANUARY 28, 2009
<TEXT>
<HTML><HEAD>
<TITLE>Press Release dated January 28, 2009</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right">

<IMG SRC="g90806ex99_2pg001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Derek Cole
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Vice President, Investor Relations </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">and Corporate
Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">720.940.2163 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><U>derek.cole@arcabiopharma.com
</U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>ARCA biopharma, Inc. Announces Commencement of Trading on the NASDAQ Global </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Market under the Symbol &#147;ABIO&#148; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><I>Experienced Cardiovascular Team Developing the First Genetically-Targeted Treatment for </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><I>Heart Failure </I></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Broomfield, Colorado, January&nbsp;28, 2009</B> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for
heart failure and other cardiovascular diseases, announced that on January&nbsp;28, 2009, its common stock will commence trading on the NASDAQ Global Market under the symbol &#147;ABIO.&#148; This follows the merger on January&nbsp;27, 2009 of a
wholly-owned subsidiary of Nuvelo, Inc. with the company formerly known as ARCA biopharma, Inc. The combined Company is named ARCA biopharma, Inc. (&#147;ARCA&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2">&#147;This is an exciting milestone in the history of ARCA which we believe will provide greater market visibility and increased liquidity for our current and potential future investors,&#148; said Richard B. Brewer,
ARCA&#146;s President and Chief Executive Officer. &#147;We believe the listing of ARCA common shares on Nasdaq will support our business strategy and reinforces our commitment to enhancing shareholder value as we build a company focused on
improving the lives of patients with cardiovascular disease. With known industry leaders that have significant cardiovascular drug development and commercialization expertise, we believe we have the right team to lead the development of potentially
the first personalized heart failure medicine, Gencaro.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Cardiovascular Product Portfolio </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">ARCA is positioned to bring personalized medicine to cardiovascular therapy. The Company&#146;s business strategy combines expertise in cardiovascular pathophysiology,
molecular genetics, clinical development and product commercialization. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>Gencaro(TM), (trade name pending FDA approval):</I> an investigational, genetically-targeted beta-blocker with a unique pharmacologic profile being developed for
the treatment of chronic heart failure. ARCA has identified common genetic variations that interact with Gencaro&#146;s novel pharmacologic properties and which the Company believes predict individual patient responses to Gencaro. The New Drug
Application (NDA) for Gencaro is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of May&nbsp;31, 2009. ARCA is </FONT>
</P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0%">
<FONT FACE="Times New Roman" SIZE="2">collaborating with Laboratory Corporation of America (LabCorp) to develop the companion genetic test for Gencaro. The PMA for this companion diagnostic test
is also under FDA review. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><I>NU172:</I> a short-acting anticoagulant that is being tested as a potential new therapy in indications where heparin and protamine are the current standard of
care, such as coronary artery bypass graft (CABG) surgery, kidney dialysis and a variety of vascular surgical and coronary interventions. NU172 recently completed a successful Phase 1b study. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Experienced Leadership Capable of Driving Value </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Chief Executive Officer: Richard B. Brewer, former president and CEO of Scios and senior vice president of sales and marketing of Genentech;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Chief Science and Medical Officer: Michael R. Bristow, MD, PhD, former CSMO of Myogen and Professor of Medicine and the former Division Head of Cardiology at the
University of Colorado Health Sciences Center; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Executive Vice President of Commercial Operations: Randall St. Laurent, former vice president of commercial development at Scios; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Vice President of Marketing: James Carr, instrumental in the successful commercialization of Coreg, a leading beta-blocker treatment for heart failure; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company&#146;s Board of Directors, which includes: </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Brewer </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Bristow (Chairman) </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Jean-Francois Formela, Partner at Atlas Ventures </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;J. William Freytag, former CEO of Myogen, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Linda Grais, Partner at InterWest and founder of SGX Pharmaceuticals </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Ted&nbsp;W. Love, former CEO of Nuvelo </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;David Lowe, Managing Director of Skyline Ventures and former Director of Cardiovascular Research at Genentech </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Mary K. Pendergast, President, Pendergast Consulting and former deputy commissioner and senior advisor to the Commissioner, FDA </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;Burton&nbsp;E. Sobel, professor of medicine and biochemistry and former chair of the department of medicine at the University of Vermont and Fletcher Allen
Health Care </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Dr.&nbsp;John Zabriskie, co-founder of Puretech Ventures and former President and CEO of Pharmacia and Upjohn </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Resources to Execute Strategy </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Experienced cardiovascular workforce; approximately 50 employees </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Offices in Broomfield, Colorado (headquarters) and San Carlos, California </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">The Company believes its current cash is sufficient to fund operations beyond the anticipated FDA response to the Gencaro NDA. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">For more information about ARCA and its development programs, please visit <U>http://www.arcabiopharma.com</U>. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Forward Looking Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">This press release contains &#147;forward-looking statements&#148; which include, without limitation, statements regarding the anticipated benefits of the completion of the business combination transaction between Nuvelo and ARCA, the
potential for Gencaro to be the first genetically targeted treatment for heart failure, the benefits of listing ARCA common stock on the NASDAQ Global Market and the clinical, regulatory and commercial potential of ARCA&#146;s development compounds,
Gencaro and NU172, which statements are hereby identified as &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on the companies&#146;
managements&#146; current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the
risk that ARCA does not successfully integrate the business operations of Nuvelo; the company&#146;s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the company&#146;s financial
resources will be insufficient to meet the company&#146;s business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in the companies&#146;
clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes.
These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation ARCA&#146;s quarterly report on Form 10-Q for the quarter ended September&nbsp;30, 2008 and subsequent filings. We
disclaim any intent or obligation to update these forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g90806ex4_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90806ex4_img1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-0$D`P$1``(1`0,1`?_$`),``0`"`P$!`0$`````
M```````%!@$$!P,""`H!`0$!`0`````````````````!`@,0``("`0,#`P($
M!`0%!0````(#`00%`!$2(1,&,10502)187$'\($C%I&AT23!\3)")>&",T,7
M$0`"`@$#`P,$`04!`````````1$A,?!!`E%A$I'!(G&!H;'QT>$R0F(#_]H`
M#`,!``(1`Q$`/P#^Z7/_`+A.P.4OTG8H9JTZ3;"K-F\VFW)-5BWY/CC>5%E"
MQ`2GLFKW`V8*9*%R,=4/)OCP?):ZP?-/SO.9'V=;'8&E8R-RI=R4)?DLEC:J
ML=2]B#)EV2P56PRVVQ?$`@5=B(CD3(]-7QY9?L'Q2R:5W]T6U,9X]?C#K%OD
M%[*4859R>Z*#,;DTXTC;9HU+TV%E+9*92!^GV\MXG5\&833<+.NY.>*><6/+
M5Y>*N,2BQC5)['*^PZ=U[GY.N,Q8BD#TU2/'<H(DPSB?4(F-M1HURX^)%E^X
MF6KXFAE[GC0DG+VLAC,:G'9)MUIYE%@ZF-H69/'UA0O*W$-`6QR%?&-]^6LS
M%B.A>\YF&8+!LRC*\6&H*@#$`V>,G<NU:90+N$S(**QOOQW*!^F^K#=;D2EE
M0\I_<57B^2OXY^-=8]KAZF2J61="D7;MFU:2.(DC&83::FH;%3,R+.!#T*(W
MJXOD,<?)D97_`'(S-NJQJ,!CO<*R.(H/I6<S=IW*I9RR-2D-NJ_!A92Q+YV8
M7"4''53#VG:O_P`WU@RFGDU\A^ZSL=D[6/=AZQ^VR[<-Q5D['NN_7"J;K1*;
MC%URI[V)@>#B;.T;A$3.Q<&]]BM^/>>Q.M\XRSLUY!A,-@:U]_C,J9D67,R&
M-%M>PD&5!J<Z;P]R\H9$]PEJ"`B9/[HB,M-1W+Q2:NF>^,\RR=EM1=_$4ZD6
M_)K/C(%5R;;G&Q2JW[-JR7<QU2.W!4H`(C?GRWWB(B)PW'4UXK9[21WDO[BW
M\#6SN3K8!>1Q.!R:L&\_E(K7[&5L13A<(JG3-,4P=?6N2)HG,S,B,Q'7?%/D
MZ,.%6Y&%^[@GDF5ZV'VH5RH!:R.1N/IJ38LJJ39Q;270M5:.4HO>P#&TU"I)
M4Q![SMK3XOJ:XI<K=?L[,!<AWF-NLZR9/O0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0&-^NVT_K]/^>@,Z`K?D7D"\*E*TU+.4RUYL(Q6&I&H+>0?$<S*#<8*K
M4JP1R<]DPM8_B4B,QLJ4WT-?Q+,9',TK3<I5IU;E+)W<6\<>]UJBQE.0AA57
MO4AC!0TR092,1+%'MTU%+')0^T%LUH@T`T!5K_AOCN4M/N7\:%EUH>-F#?:%
M#YFJ=+O,J@\:Q6AJ,E8MX=P1G:"C6//DL)EEQ&QIE^WWB9U54V8MC4)-AKEN
M2RS'C#E`AZ1M'?*R-6PE8BQ//M'$?<,ZBY<YM,LL]:W@?BE2TN[7PU5#D/79
MK=LK`IIN4Y5F"I5N_P"WIP;T@9PH0@R".43KJVW-Y)-1T)7&^/8C$OR%G&U%
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M:VL<CTVB/6-IZZ*L;D7)IRB/_P#SSP\@6#,,MG`FD9':ODRW+F@YH9%LV^YE
M$FQ0S(6):&XQTU&O)R\%\^1/#@L4$I(:2A)&1?EU3$G]F3M"X+%P8YQ'=:%@
MXGIM$%TC2$3R9%9+PCQ?+676\CB$VW6#4VQ#'6H18>A<*1:?4!XU6VTKB!%Q
M!+!B(B)Z1K+;XNI95R:4'P_P3Q6S>MY)N'1[W(.A^0:MEE$7V1"(VO*KV%)M
MKGVX3(,$@DAY3&\S,U?*VK'D\;%M&.,;?K]-OKZ;1K1D^M`8WCTWC0&=`8F8
MCUF(_70&=`8WB.DS$?ST!G0#0#0&-XCUF(]/K^/I_CH#.@&@,3,1ZSM_'_KH
M#.@&@(S-9(,/B,GE6*:]>-H6KS%)V[C`JI-QB$E]HS(AZSTB.OTU&X15;.>T
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ML8F_4MG5:2+]6%2Y06:3[-2R$0T?N69;%N)1!1,1)3P9:@LNJ0:`HN3?GJ^9
M'V#FV:YGA]J;5H53XVWY1=R"N+I.M#"5U5%OO/&2Z^L:S#F3<J(U^R)LY?R!
M>'QMMI-JW"N9D;:$5BECHKW[*Z-=#&4+"IDDP,@+%J]S$QLP9U'/W*DI>O?^
M"R9*WD@/(15@UBOQZ+=<RJ&^5Y"7/`MP5#"::U".ZQ@ICUB"Z1-,\4FU."('
M*9</&SR:!MW+53)3$KFLMK;](FPF)K0NK3[ZP[\%#>RHIA<[Q]91L6%Y=B$3
ME/,R/(IN!=2I5&U2IWJ]"G`-S>'1WVW%@P7&53-')@L27VX[8\)W+5:XI2FI
M$)TS>NW\Y5N92I6N7'G6I)^-DQ3$VWLI),V2`80U,(K#2C>'"(2/_P`<Q&VK
M"2D9B56NY%6\UYO3C**&K:>8UK2J!!3"R2+R;%RT##<JO61<AV,K\8F`!<M)
M<;;SO,K,W_/L$DW#5?Q[GJ&5\W:"E6*EI5JBKW%[=%44-&Q>QQK@877M!:BM
M2M.5P4U3"E,D4Q.C7&*<WL51OB#T^;\H_P#'QD9LX\VG!V@0O:O%2:2CKNBU
M\1DR.PYTL[BNVO@8\8F(V(HHN,01I;:_*+'@<CE+%V5O=9M*FOD3MA9I>V"C
M85DH1CT5WQ6KRX;%.2(HF63$!!;QRZDYP.227H1&6N>:*L7XQ:V$#LBW'T`D
M*;I@`77>%P%O35%:E*!T$37F+#,8B(G5XPZ8A1?0T2ROEC*\9.)?2HNR4H.J
MU8#917,@XB`?#6G5U()9@;60_GO$C`^NJ_&<Z]!<Q%Z[DO@\GG9RM?Y!CIQ-
MQF0KH<V%$+'I]E[,!%6,HN3W>3IYG,BW;H(;1&L3?8-?'_HM/D5FQ4H`VLYM
M<BOXU3["$C8:BHZZE5IH*-3Q^U)%O,@7&)WU6S*4LIV)R^??;6-IUR73G"IH
MI,QD5T7?&^)]O.//VXG7M,`>4_U`$2CAVXDXC69<ZP;:4;1]=^FO4\_(LOY1
M0OW`I)<S'/R^'J(?7HS8=CJATTVLQ:*.!S862S82RF)X.3`3$\H'6X]3*LE_
M''Y6UE;_`'LC?M8=83.-;8HUJL6ES(AR)D4J[SE38.(F./*!@MMIB9F7FBN(
M[FKY'E_(:N0<.+H6K&/KU)K&X:JGC.4M*<Y5B(ED66C2!0#(B!+8;MIG>-M&
MQQ2?WUKZ$%>SN64G,13RV:>---0\`R,`ADY=C!GY"#F*`PY5`YB)(13*HW+9
MG':;Z^@2XTO<EZ#O)<C<D$W7!CTKJ^XLG*"'^I-^+(5^Y@*1V;`BM7$HA0!,
M_<);Z-6A7&95Z[EIHQE9\:!A6&MS#L7WQ9:3768WF5(,5FA24J$0?TD9'?\`
M&=3BZO)GE$U@K'C]_P`FRV4LKR7=Q^-/$#?K#-,46$GE+)E23WG*(9LXNK7(
M6`7+[B&2CKJ_$KJZG?['B_(^85,4]E11Y.W\*-P9N@-=PY&;[4BA2JU"$NF4
MK'<"D-HG>9Z[ZRI-1P;Z*375G<P-JRE=O)7$V\'4FC8?AY4:?)666KN45D%)
M:YFO5X%P8,POKN1;3MIJ%"_R$*9J/J7?$>_C#]ZY9M6;<G;/D]*$M&`<Y:!A
M24(&1[8#/49DM_7;;655OJ9Y1-8.>#FO*C<-7)'?QT*\<KV57Z>*%HY//.@S
MK(@2JV05+E;0Q$<9ARRB"&-N5E9-0LKKU+A@79N#HADW6G$]>8*T#TUUC6;4
MMU%U%"=="1XRHSF)G?G$;QHKN],G*-HV_131\@\L%R*V1BU5`,!%[WR*'`,A
ME6O*:-+D5&^NJUM?F+5\.7=1$1(PR)D]H+'&SK5!K'TZKW+-;75:S6`P>!@Q
MB1,UF&Y0!@<S$QO.TZJP8>35S6$QOD-!F+R]>+>/<2C=6)CE`V4L%@"PD,49
M+DACD._$HWB=XG1I/(3:M%*O^,I\3",]XL#4QB$VG7,"=VZ6-OXF5"=RI1KF
M\Z^/N)[/>00AQELR)=#F8RX3A9-+Y9]3HE9Z[:$V4E!)>M;TG'H2F@+`+_W"
M43K9AD#D?$O&,E89=R/CV&R%M@=MC[6+J6'-&>([-,TD3)V&(B9WD8CI.VHR
MRSET8REY1@/+?(%KI?-W+%N<9-J^[W&#Q^'FJ5.A;]M9KLPY]^@5EB`)?W'$
M,*?NU9;ZEW@\/#<;Y?A*:\EX^NKY!@\V(>0669>S9H9^\;Z]1*\>JJ]CZF.M
MI6!L[\M8NQ,1!<=^Y,?<F:W+Y4_<;">^^'S2[7CF:$HYXW*"!RI!B)U[;LA2
M*UC%5[`F,"1.C9D\9Z[;R7NBQ*E'0=^F_P#/^/IK1DYOE<SY!6RMFC51O6"P
MBN-GV)L7$9I:QQK>41L2\:^K8]Q^1!OM&LJ%DVDFN^OV:U/,>17VP)^]Q`NR
M]8ZO/&5"[V`R`OBOW"*;$"^L5.9,YX%$.CD/2-)4?4-).M,\QS6>L-OIKV2]
MX&>BBJJI=#NIHCEW5N_"VU9)<S26,P;C,9@M]NL:-I.@K5K;N1UGRWRZI7>1
M8X[-F:N,L)BOCFF0G6@&YRK.W)9.M"U:E3N(B<E,=!U4^+^@:7T-X<YY<P*J
MCKN5:I3(Y<"IU@693DZ2P=*N5@^RS%V^8BEG."B9F>FVGQ3ZL1-EE\:RV2NM
M<K,K]G9D%G5JBK==BM/?CWON(&![S"64$GIV8"/7EO*5)&HP>GDN3S./G_Q%
M`+LQB,W<9!'*NW8I!2*CQGLN[I,-AQ"HB)/;UZ=8\D4/.2IT?)[H2Y=C+!8:
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M,N8!!9N:EH\56DK%FC86K'XT04B`F+RB(_3N,VV"8VG4FK-0G46;^>S&?IUT
M>UKR#\CBH<J/;^X''9*FN;V1!\\2@@.ER!<%ZM#:-YG1UDG&'CJ5IOD?E$!%
MBE89?KJLX1-@O;X]ZPC(VV*M@<4ZM>P;%+@=N'1<EN>\:-[+!7Q6?ZHM-^WY
M*N]G'TMCI8F4LK5VA7[=\5T:MRS6Y^W*X+7<V`#1.0`MHXSM,:2B)<7'4W<K
M<S6,PM*TN1M7R;75<%-4B`F9'G65*E=2!-6_8213/_U`4EMO.T<I!)<F^A3U
M>0^8/'*@Y-J@05C''60Q*9!U[#35K96(AQ/)J,C:<TD<ECLI4<"+EK4K8D7]
M_P`$Q=S.8K9+-4QND9TL:1XU!)I=RY8C%0^6RD:W><16YGHLX"(C:8]=1E23
MBM_<B6^0^85&/KMK&XR#(TTR=,'L3D#"J>'LO.D,56U@EA]WB,#,<8WB8G?7
MQG)5Q34S5?W/.GY%YA>HU@.A:J7[+TW5B5.K7(L58Q60L+7(V9M5EO7?I1#.
MY(,B&0/&.DRY>,CQ49N_4L&!SF6LWUAF%C5J,7M4>-8Q'(6R33ERCYC)T8JF
M_9<%O+^1?=L&TYE.]@U3W9T&/3U_+\?KZ[_CK1S,Z`Q/7ZS'Z:`;?R_30#;I
MZS^N^\_RWWT!G0#0'FP1,3`Q@P,9`A+K!"7VD,Q/3:8G;7-^7G*6Q2F_M[8-
MWB]1<B_L4;62QM"P\8&;V,Q]^Q5QUP!B>4+946$1RB"GCO,===';#+M,;Z$.
M=>64/"#M*C,'4Q>;LK-E3*5@E.30*YA<VWOKC.U)<L@3*S_MR$I`MXF8U):W
MW-2VFMC7;.6\4\")%/*4,WFJ:BJ8RY<@*M1C;5R545"E3+!M'')>(K2$FQL+
M$8_ZHTSE6*GL<M_;_%9;RG)9?N9#++QWL[=3R#R!U!5'(>2V<E8!K:B%V:C/
M8%5%!(:VNQBB0I(AQF)UJ5LPY516M>I^COBZOQOQ.S?9^P^-V[S.][7V_MMO
M<<N]W.U_W\N6_7?68)-R2&T;;?Q_$ZI#'`>O3UVW_/;T]?PWU(`XQ^?KOZ_Z
MZ0!QC\_7?IT]?TVU8!G:-YG\?X_XZ`<8B9GZS^?Y1'I^D:D`;1OO_E].G_+2
M`8@8C?Z[[>O7T]/ST@"!B/QW_'UG_&?QT@&.`_G'IOMTWV_']=(!F`B.G7;\
M-YV_PCIUT@&>,=?7K_IMI"!B!VC;>9C\^OK].OTU0("(F=MXW^D3T_E'T]=2
M`9VCZ=/T_G_KJ@QQC\_7?>?7Z?Z:D("`B/3>/\.D?AZ>FD`^M4'S([_6?X_S
MT!F!B/XC\9GT]/KH#'&.FW3;;;^6I`'&)]>L;[[3MI`,<!_SB?I])F8CT](F
M=(0/O5`T`T`T`T`T`T!IY%KD8^\^N$LL)IVFH`8W(W+09J"(Z[R1Q$:/`(;P
MY%:MXKX\JJ<&B<31:#-]Y<=BN%AKIF9F9)SF$4_G,ZBP'DLLQOTU0<0\Y\`R
M[[493QFSEFV[^0OOO)')J2"[%NDJK1>R&]GW&(I0!@=8C/B#>2XB8VFRHAR6
M7VD@F^&7_%F/\HN!C59505<#BFT9=[*UE\NY7CE3R&WCRVJX<1I6`-RT[]ZP
M1$1=`C3):>)UKT.]8C&5\-C,?BJLE-?'4J]-4G.Y&%=0K[A_3N,D>13]9F=1
M&626@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@,3&\3$^D])_2?UT!1!P>?\`'9'^U[*+^+@V;^.YNQ*E5%L:3=L+DZ]1
MCZ@*DY&$O!R^.T"00,1)='C5&YXO.3QK^9W\;<"CYMB$^/%9E7Q^2I6K67PM
MB6-E$IMY'XZFK%6(:2X&'\1/N1L6^\:?HC2_UP;-_P`]Q2&V*N,K9;/WZSHK
MS5PV+N64D[N"DUEE#4O%+A32XL*7;+F)WZQJ7EP%QDJ^1\A^2\C\5P^?HNPT
M?).-V'NOJNBUDXJC8\<NILUV&C)8\+*7C(KVE=L5\QC89F3#C<J52L:G)V"/
M2/TC6C!G0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0&CDO8>RL_*>V^/[)>\][V?9^WV_J>Y]Q_M^UQ]>73;4*IFL
MD%X?_;O]OT?[3V_M_G<^/[7N>QQ][9[_`+;O_=V?=<^.WV[?]/37-^<UB2ON
M2EWX/W&,^2^,]W[D_A_?^V]S[SM3S^,]Q_5]QV=]^U]W'7184Y,_HEX](V]/
&IJ@:`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g90806ex4_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90806ex4_img2.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P`0`P$1``(1`0,1`?_$`&X``0$``P``````````
M``````<(`P8*`0$!`0```````````````````0(0``$%`0$``0,#!0$`````
M``8"`P0%!P$(`!(R%!$3,V&!0E(5%Q$``P`"`@,!``````````````$1(0)!
M$C%A<5'_V@`,`P$``A$#$0`_`.T'4[;VE6;)33<<SW"2_$8('<0KNN.M?)P$
MVOM!M;8?D5%LUVJQ+0H510"5/5SX_P"RB4M=D]:\<<XUR*VE<R5=9[&'*;O9
M[NOMG=GST`SRT8G--T<$`T^YU"%95JHS:WIEA8W.:9D]5RVY:E-I81&E)4CG
M%_N\[WZ.,AS@CG8@[U3%]0617F#086PRG.:D<R>Q.=W-!$4P*0Q_T8&E%-[Y
MOH:QVDW618.6D&=%FN2&IO'F6Z[LBM8_24X*I,B!Y+R0KS$U]`SI^M$VRA9;
M=9VX.&)9ILK0;B<8C0>J@UE^15\E/4&=JD&#'Z]HZ=B!5P^I^AB*QQ/T_"G!
M=MJDI(%_IGS\2TFB:-Z.'/3H!Y[8+@K/Q6Y/#;,HI4>@ZL^N)%U4"^6GLH\&
M44@1IUJJ.R1#?X$U^W[QW\)UF9)0XRA=6G%*Q#\/9\N-0G/H=TVRTO<]22`_
M1&?_``W.;_*\IY75P]VOKB2O%RN\ORF<9F#<I4J[M+%UJ7)ZB-'4RCD1*ED9
MV\S\`#U37^;9_I^DG&.E>R(>P1(N7`=178HH[L,]SN7K-_:#P5+A.I%+@%!"
MXSFQY/9D^-)9M78$3JWU<C-<^*;U[=<3J/OAL*SS&A_0//(5H'H,QL<2NZ46
MO*[T19/6%U55JZMQ`K>@:T5=;4/9J8PH#[]?(@=<8=>COMKXT^RZTER9W;VR
MX3=[2U+,(III^:5OF"9MA/<V?F*ETXC[N%?@SE<<E9A-K_-,<1+>6+AI3EE&
M0SG9C%Y5L5<6O4YQ/Y[LGBXZ!O1.6Q9]_2@O#R@^FE;6`HRDRRW9A(A#IFU-
MGNQV'HDB*)1*+ID`MRYM=R0$%X1PHXY7JC,ULWE>]4I:[],-MF0T]((QN[S5
M\AJVLZKG%WZ`WC#SWS9"WBZ;R7&Z^A%1;+Z@N,M"#CNUT&S(*(])3%VM`A_-
MQTE%(4B,[<VE;`9L'E*1UR5UM/QZ"J2:<R._DL(G9^%7@_SRYFGE`=3?=FCH
M-G9</E<B[;EPHW)Q&:+%A(=I*\F6ZPB.I#4RZZIEE'?R^IXE'!E_:51S^5?V
4?:C[?O\`\OY/Z?Z_W^4AD^`?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g90806ex99_1apg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90806ex99_1apg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*P![`P$1``(1`0,1`?_$`*X```("`@,!````````
M``````<(!@D`!`,%"@(!`0`"`04!```````````````'"`8#!`4)"@$0```&
M`0(#!`8&!P@#``````$"`P0%!@<1"``2$R$4-@DT%346%S<Q05$B(V,R,U,D
M9F<889%"@E1D)55EU3@1``$#`P,"!`(%#`,```````$``@,1!`4A$@8Q!U%A
M(A-!"#)"4A0)\'&AL=%B<L(C,],69-05_]H`#`,!``(1`Q$`/P#U8W'(5LR9
M<)%8LC)-(EJ_<,X>*9.E$$FS=)44BEY4#)]5VL">JAQU$3#H'9H''G=Y?SGN
MY\V?>&_R,V2R./X-9WTL%G:6\TD38HHWE@`$3FA\T@;NEE=N)<=K:-``M;B,
M#A^)82)GM1/O7QATDCFAQ<2*_&M&BM`/#4ZU4FCJ;8G#$SI-[,'(#51R`A(/
MCF,*+M!FJB8.J(E5(=<!$OV"'V\6OXQ\M-RW#[S<9)Y$)?5UU<N<2U[6.:29
M:[@7`D>%/%<!=<BL63^V60@[Z?0935I<#TZ:=?V*&66.LD"X4.A,3;=PS6Y0
M.61>\I'2`@8Q"'%<2BHD;ZP^L.*]]Y>PW,^*.?F>)9C,6F4M9-S=MY<[#(RA
MHVLGI<TCJ*ZZTU608C)XS(,$<\$#HWM^+&?1/CIT*>#;[D"2R!1>\3:@KS,+
M(+0[YV)2E%Z5)--5LZ4Y0`O>#(J<JF@!J8O-_BX[*?D7[V<I[T]F/O7.G&7F
M>&R$MA<S%H:;@1M8^*9X``]TL?LE(`W.9O.KR!!_<;CMIQ[/^WCQML9XA(UO
MV:DAS1Y5%1Y&GP1TXN<L!5>4-O20D]^,SMHZC8M,0J:\'%2`H$(9WE2%+Z\G
M6R;\Q=5D6\6J+$R(&$"NT!#0!'M(K#>"*IS=IN0W3;;LDXPI\/:,3VR-S3.N
M(*JJ2="F(I]6G8S,3'(A+':VUTWED$R327XA"HF,)#:E#LX(BUG_`"/NQVT8
MX<9B?V'%.7:S5CQAKQ56M&FZ+*$CW[U!@O)P<RG;+&F*;1=R0!36;B($-SB8
M0*)1(FSQ#F"JYCQ)4\QP*AX^L6FOC/"$HHBBI$%;"NE+-I!;F!`@Q3MHLFHI
MJ!!!/G["CP1)Y3MT65]U=[M%>VO,J_5<1T>1&(L6>;M%.I[UY+%#F/'4*I$<
MQK=V;IB!P7=K"0J0D4.0.<J9B(BY)HV\:JU64L&*<[0N0;/&M%'J=,OF,:O'
ML)T6Y3*J,8N4K:D6YCWKDH""15A4(8P%*)R:B;@B.N`;_)Y2PMC3($VB@VGK
M14HJ0L#1L@HU096$$>[3S)-LJHLJW*SET%DN0QC"7DT$1X(@WOCW&/=M."9>
MY5SNRU[EG[.`I+-R@#Q,\BJ)GTG(+LM#&691$&S<KJFTY""!1-H7@B/>'\C1
M67<6T+)D*<IH^ZUB*G4RE$![NX=MB=_9&T$P`JP?E51.&NH'3$!^C@B)'!%4
MKC)1D[L+A)VJR%-25=E%-T>0(8XF>*@4$31[=PX(MS=I=`[1^D-.SCI6^53$
MXCWY&3>PT/OIZA^\$N=.\DM=&USMU>GF*$%6MY<9X[)KH@^HB;0M#?LCKN(%
M$QT'?6ZEXL$/+R;F*804BI'(,TS@@KJU2;D%T[#I-S.'CD$BG.=0@";0HB`#
MQ=WAG<>URW,,MB\I<OMK?'7TENV$'86^S1N^04:722;6O+G#7TZ*-,A@I(\-
M;W=K&)9IX@\N.H]1)VMU-&MJ0`#XZK0RDYB7]?9S"*C1/O(O$&RSGOI`72;.
M#I**L$6[06!C+F`3*'.H903ZCV<;;O"W#97C`R8,0:]LC6N?[@!#'$%T88SV
MZN-2YQ<7%W@M?C#+NWR#K5P<=NTD#;H2`0'$NW:=```**8;/UB+5"W"02B!;
M68-"_0`]P;#_`'CQC'R"VMO:<8Y9';`!AY&7$#Q-M%7]2V?=\.&6LMW7[I_.
MY%#<9F2'V_X0R5E^:,04*36'TBQ:F,4#2<\L!6-=B$@,.AE96==-T`#MTZFO
MT`/%_%$2\ZVZ'(>*L;XAV@YHQAE>LV[/N'+>C9LH)1"KP96<EKY)'O=N>.U%
MFI`4:LK6JX9&`QS'!LZ*0!Y4P`"+TRX_NT'DFC5#(-:<E=U^ZUN&L\.N4Y#\
MS";CT)!N4XD$Q062(OR*%UU*<H@/:'!%23YO]D-6\X[$G9&CZ143R&_=)Q<8
M5-21DSM+30%"L(]%51%)5\\-HFD4QR%,H8`$P!V\$4XW/[MTMTL\\\OG'-2M
M>),L90!BUL4UGJ.;4=I!5EDLUL3TL#%M7LTZM4S.1K(P,DT3D37("G*IS@'!
M$2MXM8_H\\L&U8XH<G(NB5RK0%&<V(X@B_=$M-D:(VF64*0YBMB2AI!R3I@)
M@327Y`$=.;@B./EDP,-!['L".(=%-/WFK#FW2JQ2D!1Y,3\O(.GB[@Q1'J*(
ME`B!1'M!)$A>SETX(GRX(M=JT:L4"MF39NT;$$YB-VJ*;=`AE5#*JB5)(I$R
MBHJ<QC:!VF$1'M'@BJ,RYF_;WE#=-F"AYCR16JU1L-XFEL0PS*95<G3D<EY=
MCCFO\VU12;+)'<U"L-V4>!A$IT5G*O*.AQX(H/Y,.<$IVB9:VWR<TE*S&$[D
M^?5UP543DD:18'[E`KICS%3$6;><9JJ=A0Y2O2:Z<P<$5V?!%0?&W21HUSG&
M#TSN,>1\]*-7J!#BV>H&2?+%6;@?0#HJ`'8(_8.O;QYQ>U7<S*=L>=Y+C&;]
MZSO[;*7,;VFK)&GWW[V5(])&HT_2%>_(8.WSF&@N;?9+#);L<T]6FK10^83'
M!D;&%D*$Y/P;96<;QH+&58OWL>#KH/8]DPC'QFRX#("G'`JHJNH(KJ&,&IM"
M@'%[O]R[.\JN/]LS-FT<C%L'2.@GE@$VQ\<<,4XC<!*YL6YSI7?U75`+R&@"
M,/\`P>48X?<+*8BQ=)0!S&OVU:YSGMJ/15]`&CTBF@UJH#D[-K.13&-B%"M8
MML`M6C9J;HM%8\FHL2K,@-TDGK=,P$,<H:J"&IOO:B,8=\/F%PT>'DQ>(>(\
M?&PLCC8=K'1#^V',K02-!VN<-74JZKJDY!Q;A-Q%(+B[&ZY=ZG%VK@_ZU'=2
MTG4`].@TT#C;%"/5\7V"7<HG3;2EQ>F8JF`0[PDU9LT%E$P'Z4R+:DY@[!,4
M?L'BPGX:[,M>=I,WR7(1N;;9'D4SH7'Z[8H8HW$?NAU6U&A<UP&K2HK[Z&"/
MD]M9Q&LD5FW</`N<X@'S(UIX$>*1W=?O"VXYHWC[5=HR>:L;GH=;NKO-V:YU
M2UP0TMU-8\9K.\98K=V4[WU`K,RUKT=.V1EC"";=-$P=13E+V+J$U8!O/J&'
M+EM;R_5<CV2@46LW.BS,;&6VT2\#6X=I8#QJ\I5WB$R_6:H"LG*,DEB%24%1
M0A#<FNO!%5+Y'._G%UOV_16V?).2*S6\K8SL+Z`HT19YIG#.+O3)AX+V!2JR
MDHNW3FI"+D7:[(6:!CN`1*B8""!A$"(%>=+N4PR&YS8LC"90IM@'&&2G4SDY
M.LSS"Q'I$<WNM#45-9"PJS[U:[31B71A;*\K@"HB(D`!#4B;SS2L+PVYO!=>
MWI[1+I7KAEG;<N-KB+7C&=BK$-CJ,&JVGYF)2D8-P\3<3U.$"RC5L<W4`@KH
MB35<"B12O!6[W;MYL&S"6PM:<C4ZFYNR+2%J=;:"]F8Z.L;2^QZ";R-MM/A'
MB[=Y8X%:68(R21695!(ESH*<HE$1(A%Y<.Z=]L]!UY?6^<4\,7FASDL&%<A6
MY88W%^3:C+R"TD2,K]\D2M815VWD7BRK(%52=5NL"`\BZ`I"16X9IW>;:]OM
M(D+_`)3S)0H"#9LE7C-LG98B1G[$H1(RB$=5J^Q>+2MADWH@!446R9Q,(@)A
M*4!,!$CU)\S.J06R.Q[P<ZSM=I;B[OLL6K!&*9-=A%7F;IL)/2-:QU6&T$*Y
M9:Q2\B]B0.\>)(F23!T)A$J1"CP1%'ROR4"?VE4BSL;A2<EW_(+B4RUF67@Y
M2'GW;/)64'[FT347-)MSK.XAW%%7(R(U<%3.DFTY2EY2AP15#;@=R^&=DWG*
M53+5?R+47V*,T4EK!YX0I4RQGVM(DW9UZN_<6=E7EG16#ME*P49*JMS@"Y2`
MJL)!$>TB]"?]7.UCNO?OZC<(]R]T??WOGQ/IO=?<WUQ[N^\G>/7'2]5>\'[C
MU==.^?@_K/N\$75Y;VEXES!-&LLTUEX.QK$(1[+5E\G'J28)E`B9Y)LLV=M'
M*Z:8<H*@0BH@``8P@`!Q4_O+\F79;O7GSRW/6]W8<J>`)+FQE;"Z?:*-,['1
MR1O>!I[@:V0@`.<X`!27Q/NORSB-F,;9OBGQP/ICF:7AE>H806N`)UVU+?`"
MJ$Y/+YQ.F7E);<B`4/J"7C/_`%/$8P?AX=JK:,119ODP8/\`D0?]=9.[OWRA
MQW.M,?7^!_\`D7.S\OK#*3Q%R_F[]*()&`QV3B;9H(N---"*J-8Q)P"8_7R'
M(8?M#C0A_#>['27[+S,W_(KZ%KJF*2ZC:U_DXL@:\#QV.:?!P7R3O[S$PF*W
M@L(GD:.$;B1Y@.>17\X(\DZ=>KT)5(6.KM<C6L1"1+8C2.CF28)MVR!!$>4A
M>T3&.<PF,8PB8YA$QA$1$>+T<9XS@.&X&UXOQ>TAL<!91".&")NUD;!\`.I)
M)+G.)+G.)<XEQ)4-9#(7N5O9,AD9'37LKMSWN-2X_EH`-`*`:)<"P.VUUE5U
M@I#!5%=3K.GIWN7/\+*<6KL(1[)"S8F6=JQQ2.'LC*%4`J::1Q`R9S&$--1Y
MU;-%/()<=.5J-1+Q0V]QCK/-BTK\>[HB5NK$+)0D<L^;/Y;KQ[V*K:3=L0R;
M9RJ"8`<>0@@(\$6T3"V'$W3)ZGB;&:;V,>(2,<[)1*L1U'R#4X*-GS)P6*!5
MH\;J`!DU4Q*<A@U`0'@BU`PW@\CU=`N*\4DD7QW,NZ1"CU$KUXHNN'?)1=,(
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MTVGU:I%EEDG,H%9K\3`A).$$Q207D`BFC4'BR*1A*0ZG,8I1T`=."*,EPEA@
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MWCC('Q5R#E&A(JE&J8HPQ&A)U'%E7DXM,AR1M[E[2W0=J++G!\N=-T70$2`4
M"(76"W6V_P"X:WY%QQD.;?7M+<I0MO&*H."E6B3,,74.1:6'<$ZLE=9D62>4
M]L=9PD9\[+H99NB)%.HJF7@B(>Y6X#:=REA5^(JM#KVW?$,_#Q`P<DQ9W:ZY
MLRA`*S+.G8^!P1TX4L+>JQS,'`M$57947PHE`G5$X$1$N^Y:3P!C/"^/,OW8
MD)DQSA9;(66;8\[M(61E$TV(8!/L*O&&1Z%BOECG5QCVY^F=%L":[Q4@E(4!
M(AZ&3<EPOE]NLE-LCVZ1RYER>2"EJKO"R$VWL61;2W@J5CVN2CAJFW(WB6*S
M<BSYJDHGJDZ72'0>8I$=+<G>=L>VK(=VN>:+Y?<CR-5J<<S/)C#2*:61%FS6
MML8'&T.2/:=V=6R;?IH@9P9X(+`5T8AN50IB*MRRY*W(52-EH^9W%W99_6XJ
MF[>YB3:2K,C&P;E[V[2GWT#75D6#AR#;#5:3.,X_0ZKZ0<)F;$Y1.!2D5A6X
MK=5!8';0F.IN\.64G`X;4R?>+2J@D2[S\#%"G78N)J,.Z;*$"XWRQ(+"X<J)
M"E#M45ECE`PIB0B.>T4UE=[?Z#/7&US%QM-L9N[9-RTR[7>G0=SKYP\+#1[A
M9!L5:*@FQDVB"B1>@X!$5DA$BA1X(F3X(LX(LX(LX(LX(@IA;T.V_)3Q0]^2
MWH?Z1O%O\4?M_P"W7@BD-$]N9%^6OBLW@3VYZ(G\Q?XK^W\K3@BC^.->\9*T
M^$VOKQSI\(.7U]KTW6GOMS_<][=?T=>SFYM>")2_+U[E\-X'U?\`!+NG=;UR
M>[/K_P",?/\`$:<Z_P`0/>?_`)GOG>.?OW4_#[WR]'\'I\$336'QI6OD-\Q#
M>(?&GL)KX:_F)]O^QY."+ZRCXB8_(GP7;?FCXB]$4]!_@O\`[;\G7@BF"?AG
M'_RX]-K/ZOPSZ&;Y?_[W_K/R=>"+O+;Z)$^%?$<'XM]$]-)[)_B/_0_GZ<$0
MSDOUD!\B?FZ[]I?K/H<^P/YN_M?\_!%I93\1NO\`Y\^7LK\T_$?IP^E?R]_U
A?Y_!$=(KV7&^S_9[/V5[+]'3]F_^/_8_EZ<$6_P1?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g90806ex99_1bpg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90806ex99_1bpg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*0"4`P$1``(1`0,1`?_$`*8``0`#`0`"`P$`````
M```````("0H'`@8#!`4+`0$``@("`P$``````````````0<("04&`@0*`Q``
M``8"`@$#`@0$`PD``````0(#!`4&!P@`"1$2$Q0A"C$5%A=!46$C@2(8D;%"
M,R1TM3<9$0`"`0,#`P($`P8$!P`````!`@,`!`41!@<A$@@B$S%!8111<16!
M,E)B%@F10B,SP;)SLR0U-__:``P#`0`"$0,1`#\`W\<4J,.']N,.9MS3L+@2
ME31E\A:W6*$@+O'.#-BD?DF(=H\4E8$4UU%7K"%G#N8A_P"2E.U?M1*<`*JB
M8_6<1NS#YK,Y#!63ZY#&R*L@.G7N4'N7KU"MK&W\+KH?B-;PY$\?.1^,>-=H
M<K[FM@FT-Z6<T]E(O<2AAF9!%/JH"230".[@T)$L$H923'(%S9]@G>-M6SRY
M<-6-><3/=?+/"6Q;'LE8[RWCK#EB0EG3PD?'K5R+(#RH5EK,)NDEF;@HS!UT
M%DEVZZ8&*/,<M_<V[I3+3;7V_:''W22^T7E`><L3H"B]8T#:@J?]34$,K#I6
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M1)5=HBX=HQIWWM@N9),ZA4O4)2F'P`_E/[WL/]MV_<=A[>[7M[M/3W::G373
M70$Z?"O?Q8QIR=L,T9AA_?C]\PA3,(>\>Z8@Y5#($[NP,RJ6T#$#4UDWUSZL
M>U/4G;V)VO@IG"N4IB2MTW)Y4C8C)TI&+9%K%UE3OK[#OOU94(5ND[E3+&=-
M%#G4*VD46ZP@;V_`XJ;=XNY1VGNY-U0/974S3,9PLS`RI(VLJGOC4:MKW*>N
MCA6^5;^^9/._P.\@?'>XX"REMN;!8Z#'01XN27&Q2+C[FRB"6,J?:W<S%(@H
MBE4!3);O+&"._47=;2];F)MF=C]9-HG2#*MY$P=?ZS8+<(L$UD\ETVKJK3D%
M6IWXY_;/+5VTMVJC1V85`^$9PV/ZRF0,C=6Z..<5N7<6,W.X6/(6-PCR=-?>
MC3U*C:?YD<*5;KZ>Y3J.WMUB<$^9^_\`A+AG>_!D#RWNS]TXBYM[3UD'&WER
M!!/<P=PU$5Q:M*LL0[3[PAF7M82B6G#M@TIV9[$^Q2OT##=4,QQ_B+#E%K-P
MRO;"/(G'M7D[%-V*XR2028MU#V&<)"V!B<(^-3<NA`"BH"2?]PM/\J[+W+R%
MR%'88>+MQ]I9Q)).^JQ(SL\A]6GK;M=?0@+?CH.M;'?`3R9X2\._#N\W;R/?
MB7=VX=QWUS9XJU*2Y"YBMX+>SC/M=P%O`9K>8?<7+1Q:Z]A=_29^:':)=?\`
MHAF6O8;9W:M97WED*._NCF8M0-G-JA8%D""$D[IE70^=&8W:.V\IY1(HN>:?
MLBK*>^JW34!/ONQ=C;!V+F(\.DT=UO=H#(6?0NJC0,8T&JP@ANFI,C+J>XJ#
MIB7Y6>5/EOY5\<7G(]SC+W`>+D.4CLUAM>Y;6:=^YHTO+ENR7(NC1>LJBV<$
MQC7VHYG0O=ORZ:UCUD)[RNYG=?K/[-M7ZIA>'-E/5Y'6I+..QV"V5)@I.6L%
M189+R!6[Y;V-W+$.+94'59JD2U<-W)'9(IJX;%4>)*-S+E,J16GO6#9G#.XF
M",;[(:_W!G=\592K[:P5N8;>E-VV$XF0DX">CP446A;16Y-)5C),51]UF]04
M2-]2^14(TJIC4+=79#*G>/VB:;WJ]MI;7C7#%&O]FP]1TZK5HYQ6)B\4^ARU
ME>+6>/B6UGG/S%]..C^A\[<)I`<"IE(!0XJ*O8:OF3\AE6+MJ\3(H*1U&KA)
MP0BI0`3)F.B<Y2J%`P>0'ZAYXI7Q*2D8D=TFK(L$U&*957I%'C<AVB1_'H4=
M%,H!FZ9O4'@3^`'SQ2OM(KHN4DUVZR2Z"I0.DLBH15)0@_@=-0@F(<H_P$!$
M.*5X$=M%'*K,CIN=V@0BB[4BR9G**:GU3450`PJID.`_01``'^'%*Y3;-@\"
M4*TM*->LWXAI=U?@V%C3[9DJF5RTO0>>/B"TK\Q-,Y9P#KU![?H1'U^?\OGB
MIT-13[7L[Y-UEZWMQ]@<*V%&K94Q1@ZTW*AV16)B)]&(GXXK863\T1.LI*&D
M2I@H/A-P@JD;S]2CQ45]CJHSEDW9CKCTUS]F:?2M65,LX(I=TOEB1B8F"2F;
M'+M#JOWQ(>"91T-'`L<`'VFR"21?^$H<4J4".Q&O[B^#BQOG/#J^3@>&CAQR
MCDVE*WP)`GU.Q&H$FS6`'A`#ZI?']8?RXI77SJ)I`!E%")E$?`"<Q2`(^!'P
M`F$`\^`$?\.*5Y>0_F'^W^GG_=Q2LA_8IG;LZTLWT'&^NV9\IW6C9]<M[W@[
M'DC"QF6"JJSCQ9O9<>0\;982P2*:5;LJ;@&[9LHG\:)7:"(E`/(8E<AYWDO9
MF^_T[;UY=36-^1+;1%5G_>.CQ*'5SZ'UT`([8RE?0QX=<5>#_DMXH_UGS%MO
M!8S=.TD:QS>0CFEQ1`A0-;9":2VFMXR;FV,?N22*WN74=P-"3H=&^EX;D+X?
MCY;=I_BX,JS`MWJ-:QE`/(PM4BSMP$(VV2QI^6AYRT**F]3@8Q!LQ;"'MIG<
M?\WF1.S?ZP;$++O1K7]5?0]D*D=BZ?!V[F5G_'L`4?`%OC6FOR4/CC%R+-8>
M,D6=_H*W#(;G)3I(;J4-_N6L0@BF@M@.D?W+R3R#UNL/[E2ZYVRL>ZJ5[0]C
MMZL5496EZ3:RY!OMDL$68TOF^$BHBVLJ*V<`JFJUJ=%8O9"Q3-N*0OJ!T\CP
MCV8"`E3='$01JCD[<6^,78FSV7C;B>YD7U7*JL@B!^4<0)=I/YF3L7Y!C\-@
M/@SPUXL;]W2NY?)O>^(Q.%LY](L+-++:/?,NA#75\Z1V\-IJ=/:AN/N)B"&>
M!!_J8FJ+EG935+:ZD;(Y#A<G1F6ZID)O<K"ID^.LT/9+B"ZYT+;$SCNS-D9)
MT2TP;ETQ<'/ZA]I<?'X!XPNL<MN3:NZH-QY!+E<M%<"1_>#J\FITD5BX!/>I
M93]#7TV;JX_X5Y\X"RG"^S[K!S\?7^(:SMQC)+::VL^U0UI+`ELS1J;6=8IH
MP-!W(-?B:_I+8RR+5,O8[I&4J+))3%.R%5H2WUN12,00<Q$_'H2+,52D,<$7
M223@"+)"/J25*8AO!BB'-C6-R%KEL?!E+%@]G<1+(A_%7`(_;UZCY'I7Q=;V
MV=G^/=X938NZ8&M]QXB_GM+F,Z^F:"1HWTU`U4E=48=&4AAJ"#6:_:R"A+3]
MTKH;6++$1M@K=DZR\^0-@@9EDWDH><@Y=[GQA*Q$M&O$UFDA&23%P=%=!4AT
MU4CF*8!`1#GO5U?X5"=ZAD/[73>1279(6:X](.[V1$R2;9,9.><Z8YHF"JB4
M[9`AG;D8I"/:^2&]/O3];:BD/OR<*F9TJ?C4U="+#`V[[D#N+MU4FHJR5:U:
MDZ566LV.!?M96$L%?G,08EDX>;AY1BJNRD8R4CW*:R"Z1SIJIG`Q1$!XJ*Y[
M]GRLLMH/M09=99<P;]9=*!EU5%C`4,=XC\%`RAC"!?Z?S^O%*]0UIP]3-C?N
M"?N!\`9.:+2^.LO:GX=QU:HSWC>K\DN&-<40K]>/$XF(SD6J;L5FRQ``R+@A
M5"^#!YXI7O7V^.TKO4C7C?GKPW`MQ8FY=0V0\GS$G8YE<Y`D]7GZECO4;<HT
MKYRHLXAV3Z/DGC<`4]"47,1:1?'J*'%3UJ*50V&SCJ+TU]D7>C.M'4)N!V6Y
M$CK;B`\LW3=OL.X5M%W:87UDBF2;SW6ZB-&I,X[L<>/@[=ZB,=[R:@$$!4U/
M[:X%J)"]!;#4RLPFX.K^W&U^S>8Z9&W/9#9'(NF.W]WR/9\I7:);S%I?4?)Q
M*LK+0<-"R+XS:+>Q#E`[UNW3=+*+*K'.90G4ZU\^N&7\RR717WK:M70^>[/@
M75J"NL?IKE#8C']YH5_M>N-^<696HUU^VO49&22QJDA4B+_'])AC2RP-2@DV
M2;)$4^M=)V>V]S5KI]M-U.85UUMLGC[+>\,)@765G?X)ZYC+%4:98H63?7!Y
M79-DJB^C):9,BRB3.4#%7192#@R)TUO:4(IT^=719)^W,ZRY/2J9UQI.NE#K
M&58G'+E*E;3,HHK78=KF*+AODPN59C*J1QM\H]=7)LG(/8Y5T>+43.=N1NFC
MZ"D4UZUP3HARC/\`;'U%4.K[@NS9#O\`K=L>VQI-W*T,F5FFK<[P%8J1D2F2
MU@7G$7J<E+OZA/)5R5>F$SI^U*X55.99RJ8RFOS^=25_^#6*/V'_`&'_`-5>
MTOY;^\O[O?J_]61'ZN]G]AO]./[>?/\`ROT_H;]L_P#I?8\>_P"O^Y[GN?Y^
M*:]=:[EV-=GNM.BDA$A/TT,K;+,H"6''M690R;1S6XVR),?FN9C(K^,<)5:!
MG!8M_DMX\SIZ[*W(!VX$`JA:GY$Y,VWL:1/N(?NMR"-O:0+H4#Z:EIBI[%;0
M:A.YFT&JZ=1L#\-O!WFKRHM+@XC)?H/"LEW%^H73S%UN)+<OV+#CXY5-U/![
MDGMR7`BAB,C]LW<2C5?=1.X.S/85V$7C*N;+@H%*Q+AFW25/QC6RN8K'E.D[
MG8JO7&!(V'!=8TC*FAA?`:0D%73Y0I3`"A2>"%K+B7=^Y>0-_P`^5S4W_A6E
MG(8X4U6*-I'1!HNO5NWN];EF/XZ=*SF_N%>.O"7B#XAXO87&6.']3;@W):1W
M>3N>V7(7D=G;W5PYDF[0(XO>]DB"W6*!202A;5C;MKWV38QV&VKVBTV3>MJ5
MD?$=KL->QM-H.FCLN0H>MQR$9;Y&'0D4G+!2U4FVH/5%&8E52<QI$URD,5)V
M!+:V_P`CXS<&Z<GL\,(<C:2ND+`@^ZJ`+(5!U'?'(&)7J"@#:'1]->G+OA=O
MCA_@;8OD@\3Y/9FX;"WN,C"RNGZ?-<R-):1S-&5<6M[:-"JS:HT=R7B+*9+<
MO0%LCW!]I>DF?[_@+*KK#5VE*1+"G%SUAQ2:,:W2I/?+NLW"/+4K#6TB-;!$
M'35,1,1^,O[B!O[B1P"A-Q\N\H;*S\^!RILYY8']+/!VB2,]4D'MNG1UT.@^
M!U4]0:VU\+_VZ_!/R=XDQ/+6PDW+B['*0:RP6^4$K6=TGHN;.3[NWN26@E#*
M&;3W(^R5?1(IJ^KK#V-S'OSK`]S+L[C7$C")GKG,P%"AJ[69=2-GJ[74D(^8
ML,JRN$W:$%"NK(+IFB5$2%`&*@F]7K+XO;C/<68WYMDYC<MM:+%),RQ*B-HR
M)H&=A(SCJ_<HT_A/XUJA\X>&N.?$WG*/C?A#-;@FO[3&PSWTUQ<PB2"XN"TD
M-O$]I#;,.VV]J9R^I)G4#3M.MEU7JE8I$&QK%,KL'4ZU&`X",K];BF,)"1Q7
M3I9ZY(PBHU!LQ9IKO'*BIBIIE**AS&\>1'EDVMK;64"VUG&D5LNNB(H51J23
MHH``U))Z#XFL*<YGLYN?*2YS<EY=9#-3]ON7%S*\TTA5513)+(S.Y5%5068D
M*H'P%9_<^8-S/-?<KZ+9\B,4Y"E,'4_0;+U,M>7F%2FG6-ZW;I*5S,>/K$Y<
M46AX*,GGI)=H*3198BZ@.4Q*40,'/WKB:NRV0UTP_MI@_(^NV>J>PO6*,J5M
MW6;97WP"0YF[CTJLY2)?$#Y,/88*022>QSY`2N&3U!)9(P'(`\5(.E9<NA_J
MEV,ZN^SW?/'63E;GDG!DUKQC1GKSL%)L)5:O77'C&]NFE<I;V9.F>(A+_1H-
MB5E(022Q?B)H$7;)_`6;',I7#.IC8:_=%\EN3HCN%ICNC9%)_:>[9DU]RKKG
MKS<\W4K-M8M<9!5B/CZV_KPE;!)NVM48N6I?>.)%'ZK5]\-PV$JBFG^%2YZD
MJ-MG9N\'M&VYS_I_F/5JD[`80PFO0&N18M5[&K-H^.QVTB(->\Q;=2E25_)7
M(E-S.1,:]>A"2`N&)UE3-C*G5'Y5R3O%ZC=CMA>QW6_*NIZERK.-]_*M'::=
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M':\CEW)<X#N35K[-`1@&0-F9C*N0<#Q45`_8KJMV:VO^W<Z[,>8TI<[3]V-+
M*GAO-M'Q/>6(T^R2=IIL+*Q5JQM*,+.6.""M"\=)E>LD7PH%5D(]%LJ9(JXJ
M$BO(=.A^-2_MG?/;;7J_+TW'O7WOV'9#8J(]I,?K(^U4RO'0-2S5(Q"D*I8I
MG*$C"-:6&(Z]8%OS'YWS"/%XPA`.@@8YCI34::DZ5,;H<Z\KQUI==F.\#Y:>
M1SK-=MM-LS3F1O$N4)".@KUD`T:G^E6\LV46;S"U5K,'&L'3M(YV[A\@N=`Q
MD#)F%2KE.*BO3+UCC'N4(-:L9*HU0R!7'`&]Z"NE;A[/$J"8``3#'S3-ZU!3
MP`>#`4#`(`(#Y#GIWV.Q^3@-MDH(;BW/^61%=?\`!@179-K;RW=L;*+F]EY3
M(XC,I\)[.XFMI1I\O<A=&T^FNGTJ%T9K=J/UT4W939C#^-(O%Y#8QD+/>F43
M*S)Z^^:XZC;#8(MG$0<G)/(^#7?O7QT?99%026.9(H$\E+SIL6W-I\>6>2W)
MB+9;4?;%Y0K-V$0AW4*K$A222-%T!.@TK)2^YG\@_,?<FRN$^1<W/G&&<CM;
M%Y8H1<(V1DM[>5YIXHTDG5$C5^^8R,BAV[M":R+:-=9_8ELIEZ`V3JJ4SKV0
MMV#);3/F149*OO'$V^E'$VO-T^K*)%L=S!^Y44$1%%*)=IJF36<^V<P#B9LC
MC;D+<F7CW):]^/'O>\+J8%26+%BT:?OR:G7Y"-@="VA-?0GY2>;7AYPKQY=\
M*YTVV\'.,_37P6/:.=%A2)8%AN[H$V]G[:A?@[W<+*'C@[U4C0GW)]:EKW'P
MKCW(6.V4?9]H\1H0=?=.XU@A7TLF5&9>,FMH8?#7?.RQQ(&8<JS<<@HZ7^*@
M9X@4RAURFY?_`##QO=;PPUOD,<JR[GM`J$@!/>C8@.-"3IVL3(@+'M'>H)+5
MJ%_MP>:N!\<>2\OM'>,LUCP7N%IIU21VN#C;N%':VD[U13(9X56RN'6)/=D%
MM*RHL1%6[:\88KFNV#<58/JA"!!XPI$#4VZY"B09)W',DRRTTL4PB/RYV7.N
M]6'^*RYAY;6W\-;[>PEKA+7_`&+:!8P?Q('J8_5FU8_4FM>O,').9YAY1SW*
M&?)_5,YE)[ME)U]M)'/M0K_)!"$A3^1%KLG.8JN*<4IQ2G%*<4IQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2N+[#_\`IN[?]M%?^?B><-N#_P!//^0_YEJR>(?_`*/C
M/^I)_P!B6NT<YFJVIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2O
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g90806ex99_2pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90806ex99_2pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@"?`P$1``(1`0,1`?_$`*D```("`@,!`0``````
M```````(!PD%!@(#"@$$`0$``P`"`P$`````````````!@<(!0D"`PH$$```
M!@$#`@0$`@<)`0`````!`@,$!08'`!$($A,A,10)02(R%5$U86(C-!8V-T)2
M,T149%5F%S@1``$#`@4!!04##0$```````$``@,1!"$2!08',4%1(A,(87&!
M,A1"TA7PD:&QT5)B<X/#TQ8)-/_:``P#`0`"$0,1`#\`]55TRW<<ESSLR<F_
MC(!)T8(Z)9.#MT6R)!$J9ES(=!G#LX>)C&$0\?#8``-?.-R#S;S?ZK]_W/TN
MIWVD\?Q7)%M9P2NA9%&TT:7F(M,UP1B^1[B`31H#:-6L=%VGH6T].9FBCFU$
ML\<C@'%Q/6E:Y6CL`'OQ68A*M8WI%-GTTHLBU%X*9Y%]UK-R=(J*(`"P@J4I
M!ZQ$-PZ`$?AK2>P?3-J7T^>\O=7N+IL7F'S+RY<7M'S.:/-H0!CAAE!/4+B=
M0U^PB<!Y<`879<&,P/97##N]ZV&4HMA9)NCK/I<B#9LR7,OZ]\4#&D$4E6R1
M`[P"8YA5VV\P`HCY!JQMQ>F.9EI,'W&HMACB8[,+JY:296@M:"):UJ?A0D]%
MQEIN6RE>T-CA+G.<*9&?9)!/3V?IHHM>OKC4WR;^,GIUD]:#UD$7[D3D#P'Y
MDUE%"F`Q?,IBB`AYAK%6_N/>7.'M6;NW86X-;MM1M#G#3=3N<T#$T$CG-<".
MK'M(<,#@5,[4Z)K5N;:\M[=\#\/D;0_$`?G!5@^#\AN\D49M,R:9"2S-RO&2
M1TB`1%RX;=.SI(@?*GWR&`3%#P*;<`\-=Q/HXYSUKGSAFVW5NB)D>ZK6XDL[
MMS&Y62RPTI,UHP9YK2'.8,&NJ!A19XWYMR#;.OOLK0DV;V"1@)J6AWV2>VAP
M![0I@UJQ0M+9RPSPAQXPM9+TW1!_:W0$KM`A"(F=+S5TETU4XENDS3`RKM)D
M":CM<A0W%NW/MX[:(H_X(<FC\G<'L+)-NFJM_K#Y6MWM)LDDV(I(I;KQ\NFT
M1*1-NWEX\Q3`!0`O>35`H```&B)T]$59?-O-O)7BK46^48&]8YM-5D+:W@"U
M>:QT\8RK`DH5RLQ$DVQM9T'Q&Q6XD4$S=(QO`0\Q`"+=^/-@Y89RPW5,LO<M
MXNJZEYB0FH6#8XC>S"$:S665(V3D7SF]L57:QTTP,<$R)@7?;J-YZ(HH@N=U
M_P`5\F4.,')FN5<SZ8D86,K&2J"208QD@I90;A7G<E`RCAX=LR?JKE25,DN(
MM%MP,!RE$P$5E]PN%9H%8FKE<IEC7ZS7F"\E,2\BJ"+5FT;D$YSF,.YCG-])
M"%`QU#B!2@)A`-$5=^/.6V<N6UEFV?%ZEU^EXGKS\\=)9KRJT?R9Y!T3YO35
MJFQKI@#EX9$P*=I9R()E$HJG2$P$T1,ZIB;/BC7NARCFTI?HZ]DL68["`[_;
M$.W]M49*27I.Z.^WKNYL&W5HB@W'&2N5M'Y.0F%^0+VCV:A76J6>4H%_J=:7
M@S3<Q7S1RZD8_1]>Y3CI%!BX4.JW$@EVZ3$4,4=$5A6B)'^>/*%YQIQ$9Y41
M1<Y0MJSAA2V)VGW$&36,1"0LMI>,.DX'BZ_%$$3G.44B++)=?R[Z(I?XNYRC
M.1.$*1E%B=`KZ5CP8V=D@)=HRUQ8%:SC,4RB;LD.Y#OI$$1$&ZR>_CHB8'1%
M3-C]ZU5>I`LX;D`RP[]]%PX(8!4,!RF2;)J*_,`>/3L;^[KH0]+UCI,5M#F,
M3"Z1Q.=KG@DNQ^4%U1[*'N-5L;=#)VQ'*UQHWL(!Z=YH/RQ307&WK4QK2HV.
M,>*CIOUSI:02(^;B=1(B2*C1@:32(_8H*I*B94H&V5`0^`#OOO>_(#MBZIH&
MVK=QLM'OX99?/`D8)'M+6.AB=*T/C&5V9[`?&"*8`JJ]'T=NL&]NYP);F`M:
M&$M-`:D.=D.5Q!%`>S'O4D1-YK*K2):,W[F1DGCIN@#518'(K'4#L%.W*L"H
MD<I$,/0<`W(`>&KIT[>6W);*VM[2=T]],]K0PNSEQ/A!:#6C@":.&(49N=&U
M%LLLDK&QV[&DY@*4IC0TI@3U':H&S$2,C'CU!%1LB)#K@9(6LL5VJ('-LHLX
MD4BE5,?S$Q!`H[[^.LR<_:;I%O%<PCRFNJ[`LG#W&O5SY!C7M+:-/7VJ>[.D
MN;AC'N#B"!CF90>X-.'QQ4]<0%R+XZEC$$#%"T/P^7R#]D@.P?#4M_YZVUM:
M\5ZS%:`"'_8[DT'05:Q0_F%KF[BAS=?I&?K*;#6^54RIE<<J,,Y6YHV6RWVP
M2(8AXRL)BA8Y;LJ;<K7#7++,Z52.R!:P7K,!,1RJ%7CDAC6P*FWZS@ND(=0C
MHB0WC%GJE<2/<2L=!KL\^4X]9TERP\$^EH:<K+5@2=6];4G!F%E813M(E;FU
MU(L[@Q!`S81$!W/HB]1FB*G7WN)0(GB1!N1,)`-ENHI[@.WU-9?P\AW\M$6A
M8(YVGXP\"L&W&Z\<\V35,CZ;&1S>_5\*2\ISXR[ETFP>NGA;2:<@V,@KLF11
MW'D*"GRB.XE`2+HXT848^X!F6+Y_9"NM7-5&4M%EI.&*2_=2DA5I"E]HD5$Y
M'FGC6/%&39.D2/'#9N@*;HR@&*H")BE$B_)[ZV2['4</8DJ3!9RTKEON<J\G
MU43]"3Y>N117,1%N@WW42%P[,Y`NVW6W*/F`:(K)."=9KU5XC8&95I)$K&1Q
M]"6%TNEVC'>2MA0"6E'+E5$-EW'K'1DQ,81,!4P*/TZ(FUT1="C5LLJ@NLW0
M57:B<S991),ZK<RA>A0R"ABB=$5"!L82B&X>`Z(ATZ;,6KEZ]<(M&;-NLZ=N
MG*I$6[9LW3,LNX764$J:2**1!,8QA`"E`1'PT14A8VY)\?,^99S[F?,\Q-&I
MDW#3.`\)5X^/\@3\>&*P!1O;[J@XAJS*197M[EQ'H.10KA%NB9(_AMHB63VM
M^0K'!O*K(W$B:GWCRC7^:DCXSE9AC(PIGD[%'75@798Z:91[YBK<:YL4R0HD
M%1X0A?$"@.B+TOZ(O/8YF)W'=IEH&82<1$Q#2"S5XV5ZDEFRJ9C"(%'<!,FH
M0`,0Y1Z3`.X:^8;:VZ=T\*;TN]H[IAFL=4L;N2.1AJ'1OS&N/[IK5KVX.%"T
MT(*[`W6-AN32H;^R<V6TFC#FD8@C]HZ$'IT*8.OYXA'4*ZB+!'QDQ'@B=1*/
MDTRO1?3"A!01D7[I4QG(C'D5.HD5,Y"E,`!X[F$=_:!SULS<^VW:/N^UL]0T
MW('-BG;YADN"*-F=(?&#$"YS,CF4(#>TDUE?[&U"VO6W>G22PW&:A<PY<L8Q
M+&@8>+`.J#7KV!;0.::#50?_`,(0L3$NA91AF<D"0O53+>B2"88KB]4=&!B^
M464*!2[=)BEV$`U+HN7^,-DMF_T^SM;6Y\F(QS$NF.8QM\Z,F9[R(Y"YPHVE
M"!B`N,.T-?U4L_%II98L[\S/E%,QR.&4-\30`:GJ"<"4N%TRV:946!)<Q&YM
MS)M1=**MVPFW$P-^Z<QDD@$?`!$>D/#<=8SYH]0C-89):Z?(XUJ`P/<YK#VY
M:DY6]WLPJ596@;/%F&N>T9^^@!/OIU*L\X50\Q&X;2?2[55I]^G)&5CBKIF2
M57CE>VFW=BF8"[).>@3)C_:)L/QUV2?\ZMM;AT/@/\3W##)`_5M4N+N$/#FN
M="_*UDE'`'+)0N8<<S:'H5G#FN\LKG>1@LWA_P!/`R-]#4!XJ2VO>WH>XX),
M/<H]S/'F!L29+QQA:PN[WR1?FD<?-82E0LW8#XSDW)?1S=@M#^.CUH^*D*^R
M64,U;F6%P=[VQ[8D(?;>JJ%,Q[<SOC]'<8Z%CW`=^AKZVH\'&C?)%B#I"7-?
M+&FK,660LD=((-I*-DY2;.Y."*Y`,DF0$P^4@:(JJ_?R?88L]'IJ]9NT>OR@
MQ#:(T6=%KS23E[J[IMG!LL^!=M%,W`Q[>)=%:2:2RYB%`$C%)N8^PD3A>W9[
MGF)\Y8DQ5C_,=H=X^Y'HM(VD2E9O,%8(%2]33%,&3";K,M),`C9E6=:I$46(
M#@'!70J=28%$HB1)[[YO*3#F0N/S/"F*[D3(>4X+,$&[L56I<3.V!:O-X!O*
M)2H3CZ-C5HV/7067*0$CK=PYMP`O@.B)H?;&Y$\9\M\.<(\4KG88I?)*^.7M
M$M^&;S"R\+-2_HTI-260:,)E@U3EV!XU$ZZ:[90X@0G6`E,7P(JO+B.=O9$Y
MEH25-A+7DSB%FV0,HC",FSZ65?0K94%'L(H+1%5-AD:@).A,S7,4I9%D)>KY
M3J$2(K>LVN^)WNY8(E,.XTRPV;9&CV3?(E-)+0,_!VVB3[)$[-!W8:K.L(N1
M-#N/N!F$@"76';6$4SB<I!T1*#PLY9Y@]N^*)Q-]PS&EVI&/JI(O&>)N2<+7
MIRY8K4AW+PZX0D[8X%E(>CBP77.JR=*D(LB4XHN$4P*!BD5PB?.3ALK7RV<G
M*/`YH<[?U15/_3ZB#X4ND3?DPRH3(*[!_A^G[GPZ=]$5?%G]RV0Y'<F,&\<.
M%D9>9FES-_CY+,/(].A3)*,RIE<1=3<M6:R^GX,&BZ-@(P*S7DSE2`O>`C83
M&-W`(HU]S_W)L9/L9$XY<?KR^L=ERY8VE$R?D:FUNRS]<Q3CAQ))QUW>.Y>-
MC#MGLPZ9F4;"W:'74(V!QU=!^WN16\\7Y;"#["5&AN/-DA+3BZDPS"D0<C!+
M'6;$-`,6J*Z+LRJ2"X2IQ4!9UW"%4,LJ8Q_F$=$7G`][^YXR2S/AS-'':]-[
M#R-QG9?X6O\`6:,RF)B;A25A=6;K4U.N8ABJVC5825;+L#D.L"ZA7A0`HE3$
M0(K7<9^ZQA3*7&2UWZ'DW,/R#I^"K_D&0P?9Z_-P-L?VW'M$E+%),*_'R+!!
MM88V0D8P?3&9K+=22A2FZ3[E`BL&R/@G%.6#)KWJGQ\L_13!)&624=1DPFD7
MZ4OND8NT>'1+\"'.8@?AJF.4/3UP[S(]MQR%H=K>ZBQH:VX!?#<AHZ-\^!T<
MI:.QKG%H[E+-N[YW5M4&/0[R2*W)J8S1\9/?D>'-!]H`*APO!CCJ0=R5J<(/
MZMML`?I_UNJ8M_0+Z;+7_P`^F:@SW:C>#^ZI>[F[D%_S7$!_H1?=7,>#?'D0
M$!KL\(#Y@-NL&WCY_P"=U[I/0=Z<Y6Y)-/U(M[OQ&\_RKQ'-F_P:BX@K_(B^
MZL[6^'''JL2*,JUHI9)VW4(LW"?EY>;:I*)CU$-Z!\]48JB!@W_:)GURFV/0
M]Z:-JZFS5[7;K+N\C<'-^LGN+J-I::@^5+(Z)V./C8Y?CU'F#D#4K<VLE]Y<
M3A0^5''&X@_Q-:'#X$)G$TTT4TT44R)))$*FDDF4I$TTR%`I$TR%`"D(0H``
M`````&M811101-@@:UD+&AK6M`#6M`H``,``,`!@!@%6CG.>XO>27DU).))/
M4D]Z@+..<$<-N,=Q#&FOKM:,IV].GUB#BY".CECR)R)+.)%\+D%G?VF.;',J
MZ7106!`A=S](&*(^Q>*GQ,A2EZ@333.<"F4Z`#83;>.Y@`O7M\!T1:/4;3*6
M24N+.3H5BJ"5<F_M$;*SWVDS6XL@3$X3<&,<^>+_`&WJ+T[."I*;B'R^8`1;
MP)$C#XD3,8@@(;E*(D-Y@/EN4=M$6NR]KJ5=E:_!S4W#Q,Q;WKAA6HQXZ;MG
MT^_:MC/'3>-;'$%7BR#4HJ'`H#TE#<=$6;>*)M6SAYV4U#-&R[@I1.@@(]I(
MZ@D]0X,F@@!]MA.<Q2%WW,(!N.B*$>/>;2\@:2\O[.HOJM7CV29A:T:4?M7S
MFP,8)Q]N>3B9&B146S0\JFN@F`'5Z@1$W5L(!HBG<"$`W4!"@;;IZ@*'5T_A
MOMOMHBXG(DN11)0J:R9@%-5,X%4(8!#8Q%"&`2B`@/B`Z(M)3Q?C-)R5ZECN
MBIO"*BL5VG4H`CDJPB)A5*N6/!4JHF$1ZM]]]$6\%*1,I2$*4A2@`%(4`*4`
M`-@`I0V```-$7$I$B@`%(F4HB.P%*4`$1W$=@`-MQVT1<BD(0!`A2D`1$1`I
M0*`B/F(@`!XCHBXE(B!C])$P,(@93I*7J$1#P$^P;[B'XZ(OHIIB(&%,@F+N
M!1$I=PW\]AVW#?1%ST1&B(T1&B(T14QY'//9MY494G;!5LH2:V&&[S$^#,00
M#"T58+U+2;0PV'(L]?D$(Z*K]`=.7($,]1D&ZRS1(R>ZG2"2I%/E\973B=P3
MC:4>1R!D3)J+%O5XQU32SLO+.;9;)AW(^D/)MFDE-,Z?"`Z40.X#M.?0(`1)
M1-8Y!`BZ7<;EOCOP`2;8O:7J>RPG%L#2,E96KJ2MT3(6RQH-K7<BPCE>7=@C
M76#U5\V9'`RY6Z1.ZF5;N%`BQG'.GVQUR(B9NB.;L&&,;XRDJK?<@V]:QI*\
MA,LV%TT>/YM!M9#)/9=G57#8YT7Y42MR=\S=$PD*`:(EFR%8*QR!SCR7NY8B
MXY0;X]K[O!_':EQJ%CE"3&6I!LJVL]PJCUJBC`P<96Y8J2:KPSE`K0Z*HJGW
M$H"1-CD6,SMB_A!CC";$\W>L^7N&J6&WEB9$EYY"$>V-(4;7:9^9*DX62A*_
M"`X24>+J$$3"02F$=@$BC'`6$F#W)/')QAZ8R0K1L#5ZT-LHY&MR-WJ9+S.K
M,TZ_"4&#JE@+%-#,&#E!P^<&19F;$;*I[JJ+J]0D75R)Y57P7N=$(_&V8)2*
MQ9+LJ%2:/6:A=HV/NMCF2$9*Y%O=PB6*:KJBQ,FY*1C&1:YE'8$%9?Y1)T$4
MPUN"D\#\#9,Q(W+,_?755E)F3:L"3*N2+9D&R'%,I&16YY>8BF;Z04231$PH
M*HL2@=0$3B?8BRG$SA\&.J+C*SY=L%QM68H55Y;#'7O%R2@:E(V9$RSZL,H`
M)LL9(,F)7`D6]:DX[C@HFWV`HZ(E&S$URC<<L96Y`-HK.CRCT5^[P[AO&L>:
MYQDEF+(,^?T"T@Y81S6/+6<-0;]0.IX9-#UB*`]UP(")SD6&PCA+($)R&PSA
MFPR>8+`3![=/)&2[LBYN!:>YN5I(::C,?U-_*/6<`GCZK&5#URH'</7[E04>
MV)!`$R)H>1W)JV0N1LGT=M1,N/*=AZCQUH<1=`JEG"4S-8YECZU"&;7F/9BQ
MKU#KJ"R99(S98)!VY.*)-RD,F<BE7@53)>`PL>WVZ/LS"^90GWUUM25F)+MQ
M:!(]*\-!5]C//74RSK-;CG(,VP.R(KG.FH82F3%,YB)V]$1HB-$1HB-$1HB-
M$1HB-$6*G?R29^G\JD?K^C]T6^K]7\?T:(E#X"__`#G$?TH_G&__`-&_Y1_F
CJ1_>?^S_`/)_[OKT1.CHB-$1HB-$1HB-$1HB-$1HB-$7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g90806img.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90806img.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@![`,J`P$1``(1`0,1`?_$`/,```$#!0$!````````
M```````$!P@!`@,%!@D*`0$!`0`"`P$``````````````0(#!@0%!P@0```&
M`0,#`04%`@<*"`8"(P$"`P0%!@<`$0@A$A,4,4$B%0E183(C%G&!D4)2,],D
M%Z&QP6)RDJ-4)5:"0U,TE-08"O#1HK)C<S55E2;ADS8X@V5F-[>X&3FYLT1V
M)W=Y>O'"TN+#9'2D176V1U<1``$#`P($`P0(`P4%!@8!!0$`$0(A`P0Q$D%1
M$P5A(@9Q@3(4\)&AL4(C)`?!4A71X3,T%O%B<K)D@I)#5"4UHL)SPT0F4W32
MA#87_]H`#`,!``(1`Q$`/P#[^-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB
M-$1HB-$1HB-$1HB-$3;WZ-!_+XL5&NRL]\KR0E)`[C9`&*%8$M(N[,+%,)"B
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M^L<#]R9`,7(8`!_!_N4>^1_UZ,Q81X_YFS'$\?,:3TIC"G+V:/A)&Y6AHPE7
M"7U%<U<*0:O'3:+5<-T1JF+6\[W$*8WS!VHA_,D*<851;!+/]&3W8K^LGE#(
M/+/-O'5[A.@QT'BOF/PWXRQUE:VFPKRLO`<F\>Y-N<_:GK%6/(S;3%5=41%!
MFW3.9%PFX.90Q1*4!)TQM!?@?L7,\H_K8Y6P#COE+=8;!>/;$ZX_P/+R7AF,
MG;+(R;V)3C;SFPYQ.@D915K'*J,B6>MY,<3#L4@.*#YJFBGW)',8*H(`M].#
MI)1?K<Y8MO([(>$7.",>,XFEI_2R.UG4+;9%9%\/U`9?"\;=`<-%(TK9+^SH
MF4'!HOM,/K1:)@OV=YMHZIMAG]OV+M>1OUD,H826Y5)1.$Z%.AQ[1Y\*PHR-
MIL+0;&/#^J<0[%60E`;1ZOH@NB_)%^D_\7?Z4D6@*7>*JG:=(VP6\6^UTP]3
M^O;F*Q72;JZW'O&C9O%<'^"'*U-VE<K2=9:Q<N<K<=,>66HG3/%@0L+366;'
M;EBY`?.Y58(E5*4JAQ+4Z8Y\3]CJ67);ZL>1\%Y0Y'T&(P_29]GA&P<BH:)D
M9*R3K-U/)85^G;4N:D4O(HM6*J312=M=C4@W`)"8$H](JY-UA$FHZD8"0=_H
M[*#]2_[PAFJQLZ@Z7XXXN;&LGTL7GU`ERI7:V'!K=&V5I+'I<<I">*`5*N=D
MQ*Y%Z.SL%3"7Q]H;Z+72#Z\67I)R!^I=?,-\B\G84B\75&;BJ%>*C5&<Z_GY
MEK(2#:Q\&>37+%=XY:-V:C9%=M9,$,X<A2&$IF,@LL(@JF0IJL"#A_IJI"_2
MVYCVCG_P2P1RWN=)@,=V3+C"Y/)*G5B4D9J#AC5C(=LI;<C&2E6[5^Y*Z:UT
MBYQ43+VJ*F*&X``Z*2&V3+T"T64:(C1$:(C1$:(C1%RTY1J59W23VRU"KV%X
M@@#9!U.5^(EG*+8#G5!NDN_9N%DT`44,;L*8"]QA';<1U&XHZX;^R3%G_P#R
M_'W_`+/[?_`-6_YO^5_[%?A_QO[NHP^U:?[D\6M+*-$1HB-$1HB-$1HB-$1H
MB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB;>_1_KI?%BOZ>EYSY9DA.0]5%R/H$
M*SM2+PR_4,TCXE?FD07UOHA;;DW<O45.[\K8>R=@R.AB=UA\Q9L=7MIAMG#>
M;WZG&ETK9<;+GEZF^ODMSBWF<=*]78?S?<>P7/D\C*Z'>Q<WVKG3CC?H<Z'S
M%\,>K9&_H].GYEZW-_(Q<C76UW56F.0G:!C%*)S=A`,8"]YQ`3`4NXAW&$"B
M.P==@T17:(H4YTY+7/&.7(NGU^OU9_4J[&X*G,BK3)Y8UGF8_D#GL,"UYE00
M8N&\>QD*D_;N)5Z9ZF\*_(+=DD1N=87*9:`<>*C1>OJ`YCJ:<O%O,35>%LL!
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M8MT$7380=/$U3',1,R9RR`#JH.8NYZY:S(6J2E9IV,*Q$98C[%"X\86A[:'T
MY6KM2JOB*RS[^V!&+-26R#GPR*];P,:P1C';URUC$S.R_.!,P+1B`M&E]07.
MGRBOVQSAJ/1@'&/;!%+1I8.55D+/RAA39V8A@I5Z%W+-8DFR2F)V*#EO)5^<
M*WD)!:.%Z*J:"[@FT<THK?U"LFS,Y,PA*I2G[?$MIIL;E*=<53)M!6R#!Y#R
M%BFC02V*:5>5&EIJ,S!$R4JL^1FRR`.74>BW0`B;\CIN3:$\U=Y7YDLAJ8B%
M,P]68^Z\.+'R%CKO<;],PU79W:N3N,8N>96-JG#.U:SC6K,,@"[7?*/%WCX4
M#$*5J1,5U2FW[UQ1.6W)$C3$-A/4L=/(2T,LU7BTP:=&R1$7"QX(P:ZFG<AF
MVE,):U$<T]OD:)?55K`5Z99O'OS"QI**N3-RG%,JP6Z5Y6YTJ5"I-\NJ7'><
M)E*J4Z_U6LTB;M*%BK<!9J=<K4\833:3DI`MJ@F(Q4:V;6QK\M:O'"KA,T6A
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MU4P[.UFURSF>GZ+$-<@07*V]/;*^@X>;8R<DG/X_XYLG,/`%EFKYH^G%F[UX
M)H]7O)M%?#^Y=Y.9^Y/PM^Q57AE>+\G"6;'N>+7<E:NRO]I*E,<<IVK0-OB:
M[9T[I$,&2UE7LHE,V>1ZRU8?-5V3@\B=,5A(P;BF\Q;RTY3Y-Q[@"81A<>UB
MW<@[K1*_%GO&`LS4NLU6,GN/N7<X3SA@A,Y3%_DT$E<=MH]N]9.8QLBFX.NJ
MF?O3(4C!SR"VD)]0V0C4&LUD^NU*NU6KNI2'R=.5MU-3[7YA20YO0MPF*"NI
MZ0\O`3UGXHQYX,JZ(+>EF54EQ,J0B@$V<OII_:N=Q[]07)66H?&#*HUW#C"W
MY9M][H3-ZWLTID.CT:R5//&2Z(0)N6K<A#!:R$QYCTJYDF2[,CR:?H^%<K,Y
M#&)M`=]`MAC_`)TY:O[J.EIJ`HF%Z#=L7I3&-;E<:O/7:IS60H7"\)F?(:$C
M::QDB$?L*_583YV9NV=P<>I(LH<[E-\4YR-C%=H'M752?/E3%_&1E?<U$H45
MR(L%"2O%5Q<W&R4FJN$;T\F5L1M;;9+0,PQI9EJ^W;N;,"C]V>).B](@5T9-
M`JY3;5AHE%2Y;YIR%(X_&B,<#6&(R1@NJY-3<-I>Z'C<9*W3'E<F:E;,GW)$
MBL$SB+KDF2>P4%56R)IR59L_F*+T4R/$F91@-74I^+^8)G.&(F%ULT6U@K4S
MMN1Z19X5LPD896/F,>9`LM*.,C799W)2=5E)-G!HOG$2N\?'C3NA;^J<@F"Z
MA208LI":*(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(
MT1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1?$=P2_\`IHO)/_\`&#[Y_P#.:<_=
M#JO(E\/_`&?XA07Y^?\`PCO+3_[U#S_ZO1R[U#JM1^(?3@IA\:__`*9WS`__
M``L'TGO_`)A7(?0+)^`?\)^]-W]2#_Y0WU(__M)^J9_]65XHZJ0U'TX+689_
M^'ZSM_ZG_NVO_P#E'$G62J?A'O\`XIW>?/\`SOZEG_\`"?6U_P#F9?2TU5(:
MCW?Q4+,8_P#RV[A_^!U^BU_\\QP*T"T?XG[BO3GZA'_PQO/S_P"WCGG_`/4'
M,7Z<5F&@^GXEX[8P_P#8G%G_`.+92O\`\\O8-.:V=?\`MKZ`N<?_`,/IR*_^
M_'B__P"HU?40U5Q1^'Z<PIU?]VZ_^DO<+/\`^R98_P#F[9.T6+GQE>X^BPC1
M$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1
M$:(C1$:(C1$V]^CP?2^*U1K\Q.?+<D)R`.HJ0%BWK0A1[PS_`%!.)`DK\RAR
M@\]&+?<G]9>(J=WY>P]D[!D&QB=U@,BS8ZO;3#;.&XWOU.-+I6BXV7/+U-]?
M);G%O,XZ5ZNPQE=Q[!<.'DY70[V+F^U<V1QOT.=#YB^&/4LC?T>G3\V]:F_D
M8N1KK:[JK3$(?M$Q2F$AN\@F*`]AP`2@8NX#VFV,(;AUV'1%=HB;^RXHQI<[
M54KQ;*+5K%;Z&NHYIUCEX9D^EJZLHL@Z\D:[72.HB*+UJDY2#<01=(IKI]JJ
M9#@5<Z+16G`6$KNAZ:W8IH5B;C;W%^41EJS%/"+W)XS0CI"PN2JMA]5(2D:U
M3;.S*=P.VQ`26`Z?PZ(Y5L/Q^P?7Y*RR\)B>@1<G<;%"6VSO&=8BD5IFRUNS
MA=X&9>"5ML+Z*NO=,HF*!>R744>A_65#JF(Y6GNW&K#-ZE;'99&E1$7<[;^E
M26&]P#"/CKC)MJ?9:K:8QFYFS,W"JC=R]I46B[W**CEHQ01.;M;M_$02(3@Y
M`QO0LJUQ:HY(J,#=:TNZ:/CPUACT)!F#UBIY6;U$BQ1,W=MS"(%53$IP*8Q=
M^TQ@$H"1HN&D.-/'V4>V61D,,8V<O;A7(VHV1P>HPP'E*Y#DA2146IV-2E11
MCBUF+!$R0$43^5,>TP>B:^(JY29OQ<XXM7T/)(X.Q<5[`55S2(E8U+@E/2U5
MXTF6#J%%-1F=)PU78V231,*I3G%&3>D[NUVX!4FX\TI8<:L`1848&.'\?H&Q
MI*OYVBJA6X]1Q6YJ4?M):0EF+E5)1P:1>3,>V?'64,HH+YJ@YW\Z"2A".4D;
M<9L)GQG!8ELM#@;]4('&QL1D0OL7%V1Y*8^75@G,C6YE=PQ22?1LP]K$>X=H
M>,B"Z[-(YB;IEV(Y=UV=+Q!B_'1(HE'HE:K(PD9.0D0K&1B"3F.A[-,M+#88
MMH[,4[I&/FIU@@[<H@?QJKHD.8!$A1`A).J:U+A[QRCO&%7Q74J.FI<(BY3"
M-,@8:#0LKB$96)@QK\^DE'J$=TY)"UR';%)@DT3,Z5,F4@JJ=Y-Q75W'C7@#
M(+6.9W7#F.[(WAX6N5R)+)U:*6/&P-/<O'E3B&*X-RKM8^LN9%R=@D0Q2-#.
MEO$!?,KW$<A:]GQ6XWQ\U2K(TPEC=*?QTU9LZ5,#5XU60@&T9(O9B'2:NED5
M%50@IB2<.X\514&/=+J+-A24.8PD<IR&V-L?LGS23:4NL-I%C<)K(3)\A"L$
MW36]6.&DJ[/V]NN1`%$K',P,R[9N7A1!=9LY43,82G,`D<KAI/C3Q]F*_,5:
M1PUCAQ7I]PS>2L4%3B$&SE['66SW.->D!NV2.T>QMLNLQ)-ED3)J-WLFZ63,
M4ZZ@F(Y750V(L65V.JT3`X[ID-%TBNSE1I\?&5R*9,ZU6+/\N&R0,*W;M4TH
M^+L!HEL9ZBF!2.C($,H!A*`Z(Y31-N$_$IG7C5-KQ[Q:A632$)*D@DZNQ+&-
MI*MQTQ$0+QBU`OBCUXF(L+YH@*`)]C9VJD'Y9S%$FX\UTC#C3BR%O-0O5<BE
MZLK1&E.CZK5JR6,A*3#1M%J>::9`1K"NL8Q)!E'I0^>)OO11.F054VIB@4$C
ME5(Y5;#QBPI:Y=_(V&D1$K&2E?E(&0J+EDP_2+E69R*KE>3LAHE-H0Z=M=7Y
MPK)&D"*E6]4J=7^=,)]$<A;$G&WC\E+RL\EAC&B,K-TQ3'DLZ0IT&@#^D+0+
M.JKUEPW29D:FBG%5CFT6HGV!Y(QJ@T,(MT4DR$<IWUXV/=1RT0Y9-5XIPR4C
M5XY5!,[):/60%JJR4;"443-5&QA3%,0[1(.VVVBB893B7QE5F9VP*8*QB:8M
M$"WJ]C>#4HH!G:\SJ\52643+(`@#:09L:C!LHU`JI#>!FT12)VD2(!2NXIW:
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M"A(V#_A/WIO_`*B=`O\`)X,^HLWC*#>I)Q)TSZGI(Q".IME?+R1Y7ZP?%B9B
MB1R+2,64?'E85HJ]:@D!Q<,TCKI]R1#'"I#4?3@M;A['^0$>=^<9!:@7M&/<
M(_\`=S_3R"U,LR3!Q^FK/Q1-9?`]4BRMEOTT5HL,CVF'T`(J"OXP(;:%#\/U
M_P`4[/.ZBWJ0=?4>&/HMVD`DVOUH@C!85&Q/0DQF\;?3"2@PC?31JOK_`)VK
M%.RLO#W^K,U7!+O%%0"D@:CW?Q4-<:XWR0EE>W+*XXR$DB?Z0WT;88BRM&M2
M:1YF$Y(\%74W#$4/$E(:7A&K!PJ\:@/G:)MU3*D(5,XEJI(^T_Q7I7S\IETD
M>0_/!S'4RX2+:0NW.A2/<Q]6GGK>03?_`$,L9P#!1@NUCU4GI'\^D9@@*0G!
M9\0S<G<L`D"+,"&'TXKR'QGC/)J45C`JN,\CI"E_W<R4K2H*4*VIBE9AY(3S
MD*TJ!X<!3L8M3`J#`VSL4A`_C[1WTYKD</\`]I>]G-FIVQ]SIY"2#&J6E]'N
M<O8R6;/V5<FGC%RBE]'SZ@D*JLW>-F*K9=%*:D6S(QB&$I7CE)`1!54A#5<4
M?A^G,*<'_=U(*=K7T<.&T)98*;K4VRALJ%>PMBB)&"F61E<XY+71*\BI9LSD
M&HK(*E4("B9>XABF#<!`1+%SXRO;+181HB-$1HB-$1HB-$1HB-$1HB-$1HB-
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M?=>^]ML]UQ[MF.-?S#C`2W;A,0-QR`#Y6&KZ\%Z7.[YCX-^>/.$S.%O?1JAV
M;VU3.P'U5L;6:280\%AK+TI*2((>E8,4ZD[=+F641`$T$V]B4\JOA6!0`W*7
MM#XA+UV]SD_M5W3$L2R;^9AQLQU),P/K,6UI[5ZZUZKQ+DQ&-JZY]A^P%TG=
M_5MP@TDI>//CW*(H0KEM'O)I-C"/J^E)NG:K1!FXF8:6E631)QZ595)PH8K<
MZ*95!.5-0AA0_:COL[,+LK^+NN1,HQ)D)F(#DB,H@DAQ05>FJW/U5@Q+"%TA
MV=J.ELK]5'&T&14\MA[*[4J3U2-*X)^E'L>ZD$7`LEV4?*Q\\ZCI-R@_**)R
M-E%3`H40V$=@'%C]K.Y9=;67B$L[$SC(!G!,3$$!F-0*%U9>JL2'Q6[@^IOK
M=DA0^K/AYV[2:,\:Y*?+KG7321CE:C)JJ+-C@5PU2)&V!X"KU`BB1CHE,)P!
M4H["4P&'G/[3=ZMP-R]E8L!3XNH&!T-8"A;5<<O5>*&'2NN?&+_4Z42/U6\6
MPZ0A)8DRVA)*L)]\QKZ#*$DK$Y"M%.$PF\BHN4>*U\&"Y014&1%H;RF`I"G'
MN[>&S^UG=\F3V,K$-L&+S,I1AY_A:4H@2?4;7HMGU1CQ%;-XFM/*]/!TK-]5
M#%BU7972,Q5E.3K+Q=ZP-*MAJ!F[249.541C'@HV186;MTW*1PCY_$"Z"@&3
M$^Q@+B/[6]VGF2P+V3BV\F+>4F;D'C'RU`-"VAH53ZIQA#J1M790=BVVA\:^
M_P!B[O!7U%,<YYR:PQG7Z'=H1Z_K\I84Y6:7KQFH-XPJ!A1*WCI1ZY,HY!81
M+N!>T"")@#IOX7J#]O>Z^G>VGN65>LSM"X(-'<X)YN`RYNW>H<?N.2,:W;G$
MF)+DAJ>PJ:1[Y'D,8HLWFY3"40`41]@B'_*?=KHPLSE5=C$25;^OH_\`U)[_
M`*'^DUOH3\%=B/U]'_ZB]_T/])IT)^";"J_KV/\`]1>_Z'^DTZ$_!-A5/U]'
M_P"HO?\`0_TFIT)^";"J_KV/_P!1>_Z'^DU>A/P38J?KZ/\`]2>_Z'^DTZ$_
M!-B/U]'_`.I/?]#_`$FG0GX)L1^OH_\`U)[_`*'^DTZ$_!-B/U]'_P"I/?\`
M0_TFG0GX)L1^OH__`%)[_H?Z33H3\$V(_7T?_J3W_0_TFG0GX)L1^OH__4GO
M^A_I-.A/P38C]?1_^I/?]#_2:="?@FQ'Z^C_`/4GO^A_I-.A/P38C]?1_P#J
M3W_0_P!)IT)^";$?KZ/_`-2>_P"A_I-.A/P38C]?1_\`J3W_`$/])IT)^";$
M?KZ/_P!2>_Z'^DTZ$_!-B/U]'_ZD]_T/])IT)^";$?KZ/_U)[_H?Z33H3\$V
M(_7T?_J3W_0_TFG0GX)L1^OH_P#U)[_H?Z33H3\$V(_7T?\`ZD]_T/\`2:="
M?@FQ'Z^C_P#4GO\`H?Z33H3\$V(_7T?_`*D]_P!#_2:="?@FQ'Z^C_\`4GO^
MA_I-.A/P38C]?1_^I/?]#_2:="?@FQ'Z^C_]2>_Z'^DTZ$_!-B/U]'_ZD]_T
M/])IT)^";$?KZ/\`]2>_Z'^DTZ$_!-B/U]'_`.I/?]#_`$FG0GX)L1^OH_\`
MU)[_`*'^DTZ$_!-B/U]'_P"I/?\`0_TFG0GX)L1^OH__`%)[_H?Z33H3\$V(
M_7T?_J3W_0_TFG0GX)L1^OH__4GO^A_I-.A/P38C]?1_^I/?]#_2:="?@FQ'
MZ^C_`/4GO^A_I-.A/P38C]?1_P#J3W_0_P!)IT)^";$?KZ/_`-2>_P"A_I-.
MA/P38C]?1_\`J3W_`$/])IT)^";$?KZ/_P!2>_Z'^DTZ$_!-B/U]'_ZD]_T/
M])IT)^";$?KZ/_U)[_H?Z33H3\$V(_7T?_J3W_0_TFG0GX)L1^OH_P#U)[_H
M?Z33H3\$V(_7T?\`ZD]_T/\`2:="?@FQ'Z^C_P#4GO\`H?Z33H3\$V(_7T?_
M`*D]_P!#_2:="?@FQ'Z^C_\`4GO^A_I-.A/P38C]?1_^I/?]#_2:="?@FQ'Z
M^C_]2>_Z'^DTZ$_!-B/U]'_ZD]_T/])IT)^";$?KZ/\`]2>_Z'^DTZ$_!-B/
MU]'_`.I/?]#_`$FIT)^";%7]?1_^HO?]#_2:OR\_!-A1^OH__47O^A_I-.A/
MP3853]?1_P#J+W_0_P!)IT)^";$?KZ/_`-1>_P"A_I-.A/P384?KZ/\`]2>_
MZ'^DTZ$_!-BBSR*YSTCCC,4>'LM(M\^>\M)IU'K0;BOI>F&$-%^H262E91B*
MG>E)@<#%'M#QF#?NV`>T>F_1F?ZGCD2Q;MFW#',7,]S'<[?"#R7H^Z]ZL=KG
M"W=A.9F"?*U&('%N:9V,^J9C&1AYZQAB;*R5>K+)R\F9DP5`&3,Y"`+%H=5:
MR-TQ=RZIBIM40,*ZIS="=H&,'NLG]KNZX]^WCG)Q)9-R0$8@W'/BVS0:DZ!>
M!;]4XDHF9MW1;`UH?N6LC?JRX?E_@8XSR@DX%C,S*3>60@(,KZ`A7Z[%Q-Q$
MA*2S>&EVIO""GB0<G==BI#%2,01,'+>_:GO5@;KF5B-NC$[3*32(?;("),3X
MD`!BY5'JC%/PVKFC\!3F*U0^^K%B>,>&CY7%64X=ZDW.X=-YDM7B%F)4U/3F
M]<21G&XM2^L.FD!C[`<ZI`+W&$"ZY+7[4=YR("=G)Q)P)8&)E)^--L2]*_:5
MB?JO&A0V;P]K#[RKF?U7<52)7IXW$V6I%./,;UBS)O6'#9D@4HK>ND'B<X+)
MC'>E$JOJ3J>G%,P'`XIB!QQ<_:SNMB(E=R\,;M`3,$EV8#:Y+T8!WHSJ?ZJQ
MR6%F\WN_M6&2^K7AF%<BTD\:Y2(=K.#7IITR:0<A$0LKZ95PFP6GTY5."D7R
MGI5R`FS<N`$Z7:!A.8I1U:_:?OE^V)V<C%.Z&Z(,I1E*+L^S;N`J-0*%UR#U
M3B$&1MW-HU-&^MUMK+]4K'%3D4H^;Q#E1J=UX5&"_DIAVDDS>-T7,;(1SU.R
M&8/X^426`[==%91$Z8=W>'LUPX?[7]TS[!R,?*Q?*2)#S[HD4(D-E".(-5B?
MJG'MSV2LWM'_``U',5J%T-,^ICB2WI8P,-(R%&K9:S;_`&%5=`$J](>ELWRZ
M!DQD[`JVFBEBX86TZ':8GG5,9N<`)U)W>-F_MIWO#EE0ZUB?R>#\U<(,@\"9
M1:+QK(&.E!75>;8]08MZ,#LG$SN;`[:T\?%>DFOGOM7O4:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$V]^8>ME\5J_(9J:^6Y(3
M?^JB)#T3:N;4>\,_GT^EX5?F4*7UGHQ;[D_K3Q!3N_+[3=D[!D=##[K'KV;/
M4[:8;;D-QO?J<:72M%QLN>7J;Z^2W.+>9QTGU=B?-=Q[!<^4RLKH=[%S=9N;
M(XWZ'.AU\@,>I8\_1Z?E_-O6IOY&+D:ZVN[+YQOJ+&$O+_.'DAV*#<W#.I)%
ML[EK*@N#Y?+]<19Q;9\1U\B`Y5E"B1-9$7!E%0*01*;M']$_MT/_`-2P)"9<
M=\GY''_EI>9OB_@N@]_C_P"IWI'3Y7_YHJ"5%8V*PP=SQI3W3=FM&2!"7^Z.
MFRI8(C!I/5N'@H#U$/&6(S.+6M3\T@^6<H-U%4HQP(]A&IB#WGNEW'Q,C'[M
MG;IVY1>U9CMW.8R,[C2,02(!@`3M,HLYDNNV;<B\01$;WE*K;781H.9?Q6R&
MSVZ6<QV)\&N[`[I-2)&H/G<Y&0L)6K&_AH5:$1NEV8NDH;]+0A"PGE;#+KO)
M85'JJ3<B2YA*7QX8>#8$N^>HMD>XY$B81C*4IVHR.X0MMNW3+^;8!"@,B1KY
M4[ER4/E<8DV8UJ``::RT;P!)(YN59'TBBT@\<A*!9\9/;$WE$HBXXFR&^D<2
M6"-CBL8^6!S$I59]:Z+--)&R3:JD6[%^=J51$Z!RI)).B9GW#N'<+DAC]'+C
M9(W6\BS&&3%W,9"6\0NQ,8VP)1VN`1(.3%<<H68`&1E#>/BC)X'0$,02"*\#
MX<TL>,\"LF)VT=9,LF@7YH*-F:C1'4I7Y&T/V0+*R'D9O:\\CEIU:(<2#28<
M^=-J9RX4(@R,W0323EN7J21,\FU@]:.XQNW6G&$20PI/02$3;`#L`3(&1)L)
M8!&VV;DG'PZ$GDY'&O'W,D/Z>R7AU0\[186-IHUR6CW5N94>WHY"OL=,Q,?*
M1L\.1K"BG$A(-7,*V.UE%X5BI$QJZ"[1R"R9A,;DAD]F[_$8_=KER].]!K9N
M6^C:,208]&'F`(E6'4D)R!$HL:+CN6[V//?9(@0:L=THZN)'PXM3@:+>Q?J)
M`5<V8]%6322K`M<IXUD8Y8RKYM7V=19V9N#JL55O7Y2NVB/:DE6S]NJR4;F,
MZ`Y"N6FZOBWVL1'I[NK6YBZ^/D`T&Z4S;??,RC(2.R42"#Y:[94YX1$_U6.=
MT6\\3J6`!T%015]?J3[?3;<L%>5U>EHV4+\OL5*R8>,0<-V"4N="/<1B)ROR
M,E1;&?((IE,H*!CB!%Q`Y$QW`OJ_W-A<CZ2N6+M;\,BP9%R1Y@2XI0'QY4)7
ME>G?_=8-3=&=.0;C]*KWU5.H954$TQ`!5/L=8>P.AA]B8`*A@_:!=?G`,P?D
MOJ1I3BL!O@V\S@2B/4"D`J>_M_"`]ZIOW#K0'$!16@4@^Q!PIO\`QE#&*4?O
MV65*80'V]"ZOFYA5:BP35?J<#,6FUR=>JU9K\<YEY^QV68805?@XEDF*SR3F
M9J2,WC8R/:I!W*++J$3('M$-3<W%1N2:-]R:XT15*JV2Y3D#@"-QS>9)2%I%
M^?Y@H;*FV^8;J*).8FM65S+I0\U(LE$C%70;K**-Q*(*`35WQ9R:?3Q5;ZUT
MTKFC#,"M96\WE?%\,XI<K3X*XHR&2JO'K52;R)X?[/H>R)/)=N:%E+V#A/Y*
MW<@DI*`<OIBJ[AIN'-&*N8YJP])NX-A&9<QX_?6>WVC'M:9,;[49-U8;_2$U
M5KK1X1LVE7+F5N-.1;J'E8U`#O(XB9A733`!'4>)XA%IZSR/X^W-C(2E-S]A
M&W1<1;X;'\K(5[)]*E6<;>[&]^6URF/WL=.NFS6T6.2_J\>Q/VN'RX"1`BA@
M$-/(?]KHQ782V4\;UZIV.^6&_4F#HU/?2\7;KK)VVOLZE5Y2ORAH.=B[#873
M]"-AI*%FR"R=-W!TUD'@>`Y05^'4(&H(9$WJG+'BNDO46JO)CC^DZO["*E*&
MU5S%CU-S=HV=D5X>%?U)N>P%6L+.6F&JK1NHT*J59TD=$HBH0Q0S3F$8KJ8/
M/."K,[R&PK>;,0S[W$97BF5VL-DJF2:^,DHXSI.17R`FSFEC4]M'JL5R.%9#
MTZ:*B*A#F*8A@"..:,5BK_(#`MLK[&V5;.&'['5I*$N%EC[+!Y+IDI`O*[CP
M&AL@3S>7932S`\/1"R#<9ESY/%%@X2%R9(%";G",4YD5*Q<]%QLY"2+&8A9E
M@SE8>7C'2+Z-E8N1;INX^2CGK8ZC=XP?-%B*HJIF,11,P&*(@(#JJ)?HBKL(
M^P-$1L/V#HJJ:*(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(
MT1&B(T1&B(T1&B(T1&B(T1&B*NP_8.B(T1<7?\CX[Q/5WEWRG?:7C2F1Z[1J
M^MM_M$)3ZTT=/U?`Q:+S=@>Q\<F[>K?"BD*GD5,`@4!V'0D#5771<Y(9YP5$
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MAI8LLS(99N+954%42F4+N0HF#3`5)#(Q=EI"<E>/"]U+C9'D#@PV1#E[R4)#
M*M(=W0R80GZF%4M;3G22QD/TW_M'R`@)/0?UC?Q?'J^1VX^U&*3QW)OCA,8]
MGLMQ/(;#,MBJJR)8>T9+C<J4%:@UV74.V32B9RW)3@PL5)N#NT@106<$66\I
M.PI@,7<\6=X_6C'Q=;TV;,*EAE+&?+>+AKZ<%4+2:>4R;5#1`5O(,HX@J!8/
MF2<RJP&'O,XT590SDIQ1E'B1T&QE%2&*%W1X$(Q=.>*8`.W@:]P#L(&5,!@'
MV#ONAW;_`+=:^M17`@&W_-&_0>@%/^[?<42@`ZQN\2B!(0OM;+%VZ@*)Q$`'
M[@25`_M_Q=6O-55)L8=DG!NX/:FIL<W[RG`JVW[]#HY"BR=RI/QI@H7?\2(_
M$'[43#W?YIC:@`.B+QT^JX5!U/84$)%DU4C*7DJ;<$<)HJ+JQT>YI:JB7@>*
M(HF3*X*4B0F.BF"CH_<H4/9]L_:">RWGQ:1E.Y8@&I4BYQK0:GC31=!]71)R
M;#,XA,_:.'%0=:%1G8RDY,M:DI"XBI"!I6K5?Y,Y?SUU<04C4RNP;%/!NZPK
M)Y`LZ)2.'"[\&+-J#T5$Q;L2)*=WNW+N-?O]IPAUN^9#1G>>(A:$A*DB")CI
MVR"(QB\CM8O(D==B!*$+]QX8\>#$F1?1C3S'CP]RT29\DY@;C+6U&`FL=MB0
M+-FSRO,$KM9%G6TY-&'A:7:85NB]9^.=:'=NY!A%?)8PW>9RF<ZI@'R3;[/V
M&?1PS<AW?SRD<>/4F3-B3<MS)B1M+"$I[Y"D2`LQ.1DW-]\#IZ#?)F`_E('M
MX,^JVK"!P_"J*U>V265*<VJ\JR0MF.;_`&-W<:\E.-FJK"04\U2@8]E.5%O/
MFFEU%V3F.4,5V"Z`JG2(L7@E?[]?A\WA#"R#=@3;OVH"U-B10QG+R7-@@`)"
M0IMDP)"Y)1Q;<VR#<BWQ1),G(Y;8AQQX:\4G=57&ML.SK,4.4,E+0\*O*MX>
MTY(4H6-JA6&+]F,RI?I9U2A/%^C@K'+M2LHI!5P=4Q$&BYQ3221Y!G=UP(_-
M9!Q<*%R8#V[(O7[LR*"S'J5><8$RF1$?$8AR3R6[=B=+,IR:+U+1B/\`></3
MP]QX+&PM-WQ`ZC8>Y-3.,3SA81H>(H24/^A)!G$+N74.K#&F@G&1;)!-HT&R
MT;)E;3*#9=0$URHF[@W/"[9WN$KF!)N]VR9;[VX7@XJ)B&TF$B208&4"0'BX
M6+=Z]8FUYSC2'X?A]H=P_MJWM2*S13G$]`<03J2-<\6SLB<*+:T8B0:?()1N
MSJ+A-V\9V6(A$&!;52Y%`DJP5<JJMG<6]`#>5F<Q]X.3;[SW'YFT!C=UMP_.
MM[H^>+W`1$Q,B=EP>6;!XRCPE3CO1Z=K:9"=J4O*0#P`(U'\M"-''@GGPPD+
M!3A_$G9LK"I$_4/3CWBR3>5,%?43JF-U"RB`QZ[=NEN0$NP)!'L*BL!RE$1[
MM>H[W*-Z7>KVXVQ/TX)!V>7YERA?7_LG@SKS\(B4,8C_`,Z/NBOJ\U^5POIJ
M-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB;>_L?
M62^*U?D<[,?+LD)OO4PS[T;:O[4>\-/GEB2\*OS""+ZOT@H;I_UMVW4[OR^T
MW9.P7^CA]UCU[%GJ=M,6N1W2N_J<:72LEQLN^7J;J_EV[D6\SCI/J_$^9[CV
M"?RN7D]'O8N;K-S9''_0YT.OD#:>I8\_2Z?E_.NV9[O(Q<C76UW9?-W]27L'
MEKG4KF7'P*\*:VW-`)K6!%11-3+M=34D1*P1*P41/YA1.<JZ;@J?<7;L$1U^
MC/VW_P#]3P-D/S/Z[,[R(M_EYT<U\=&]ZZ%Z@D1W&]&FWY8?\\5YY,K)&ST3
M!,)=JZ3K]OM47CW)`D!XZ9^H0C/%2,A(U.+:.&(N7#Z1=N9E5=5LV<_+`,@5
M!PNL"WT#(P[F+DW+T"#D8]B5ZQH[$_G61.1!9@!;#$C?YMP`;KT)QF8VY^42
M9VT)=A(C[_$43P0-=6A\4+TJ'BF!5:7;9)OG.`+,1*=SKEWC9)]2ZLM*02+Q
MVDO7WT3$IC7CHBH"KMXY`53+F4(;TU_N%N_WDYN3.4!?L@XDVETYVC$7)`2+
M-(2D1='*,6H`W)<LRCC2A$QZ<"3,:R$]Q`#<8_REM20GLDLMR%2HM^P)B_$-
M#R7<%#0Z637>43^CQ['7!M&NF4?7:T[9$0E9_)\'77R[F46^;Q[.+3()!5.J
M=1,>O6^R6L_.QO47=\R]B8#R-DV*WC!W-R;N(V92#6_(92<4:J]A;OPQ;$L*
M%L7)76W[@\8D#2(H=X!J79W97U:^\E./UY96R]<>>,4VU<8YB4FTCBM$*]?6
M+5W#OA^0TQ)R\L\0[ORA2KHD=.V!$9E9!-,'X@J'?,GMOI3U/B''[9W+ND+T
M<DC;D'J6B7I.Y\,HVC3X2\`7VTIS1OY';KHNW+-C<8U,8@%N8;\7M%>:XYKZ
M:4N--ON%6T:K5W4(XM-7D;$XCJS&P]7KRC\MC_5*#Y=L2&>UQ!FZ1L3<RB)$
M$/4*B)DNXP^P-SY?M^1V_OQE\Q;N"$XVP9F4Y`;.FVL9$@VC4DL*%>ME8$LB
M-[$'ED\@20&B-07IN`U?@X"CXK$P-5M;>?QJW*E&Y+R;+4_'T\S.X9Q*6.*D
MM%!>+;$V.*2E%$81>;GE&\'\S0;E!NQ6,Z%5NY41'L<;US-Q/E>ZN98>)&[=
MC)I2ZUS<+5N42SW!&(-T1)8R`BQB"L=.-J74LEK4I2`(I0,YKPJWL4HOIT3,
M9*<Q*^K'1ZS!DRQG:H."8*F7<"G"032-8LW\D90%2OIV8V5?O7K@1<K/GSDY
M/&DJ*6NM_N3BWK'HR77F)7I9-N<Y"GFD9':!PA"D8`4$8@%R'7F^G[@GW>$P
M*;)`>P`-_?XKZ"E2^=982;I(^53900_-5^(>J8"&Q$Q_E#U'W![]?FP28#FR
M^H2)!6,4T$1[$TQ.L(;[`/<H(?RE53"(E)[=A$>ON`=7<3KHCE5\)A`3*J@D
M4`Z@D/:`![^Y90.X?V@!=-U:!3<5%GF)@B=Y%8,>8_I3JMH6B,R+AK*D"SOZ
M4@OCJXR&&<JU/)Z-`R"5DW?27Z*O`U88YZJ@U>&;@N5?TZX)BB>2)(8L%8R8
MJ%UHX@<H'UQ9YUC\8\"%\@V;&G)S#]PP<_0N\+AFI0?(*W5"S1^2X^Y-,:RL
MEDS*B"-2!E=7*]=@"VQDLDBBHS]+W+Y\Q8L'6A(:54&;)]#W+YYYLE"9OQO-
MTY.(P*SM*=E1M"$OD:?XLX8P?0,"VN?2:0\LC'.:M<86\R0(`X="D@_BR@H<
MY5?#GIR^GA]"M=0>];MM]%/+KS*<M8)3-6/H*AR%^SYD.`85E6S)V3'UQY10
M^=:9F6^UOU,*P:.+'*TY_C@4DA70*9U'3!3+%*=%1=L+OPK]/N4WCDG6N7TL
M,N<A&%,B<Y1_'?&M8IU!XDX$DZEQWF;JDPO>->/N5RY%LV4G$VM1ZC(5+(#9
MNW23H\,FB^+`KK.C+2QP5+L,#Q;[4W@:.G^KW!?.3?@/:>-V0[3BS-V;);D9
M;,Z25R>V#(N*XBZ+O>0PYAA[&VM=";L[AB3,1F""#YO,,&<LQA[,7O%H_9@8
MAM>;;M.K_P`5-PW/P6QQ-P<R9!1?"TN5K5C.<L?'^^<N;->WD8Q;+64*_P`@
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MRCK/9.H1UH^7MPGF-5D92+C)%U7&TH"A6)W+9NOZ4$_(F4VX:Y7(U`7&]?!=
M%XA'_BW@[_RUR)]??T*H`@&WW:;FY(Y5@HE]ID0`>FXJ/U`'?[![>\.HC]NF
M[E]RCE`)([=2(;]1V%Z8=Q'_`!A+O_<U=QU"K_6J`B7?HB4?;T(^.(_P"!`T
M,OHR.?!7^';VIO">WJ5P14.H_890YA#]VH9>Q'5/@*'_`#DY.O3U*(%W]G3O
M`J(?W1T?P1UF`AP#N\2:Q?Y:*@`(_L*IL4?\[4W!'*J!FXB!3?EG'V$5`4S#
M^SNV*;]PCIN/)-Q6KGIROU>-6E[%)LX>-0$"'=/5?&4RI@$2((D`#+.'"FWP
MIIE,<?<&F[P4,B`YT32AR*Q`8YB)S4HMVCMW)5V8,0WV"41;%'8?O`-3>L]4
M<"LI^0>*$P`QY.8`!#<!_3DL.X;B&_1#[0TWIU/%;&"SCBBQ2"46QLQ&SUPH
M5)NE+L7T0FX6./:1%-R]03:^4YN@%,<HF'H&XZ;T%T$L]4[PHD`=A+L(>T!Z
M#IO6MQ5/$G_)TWIN*N*@4P[%()AV$=@`1'8`W$=@^P--Z;BK?$G_`"=-Z;BK
MB-_(8")IF.<=]BD*)C#L&X[%*`B.P!J[_!-Q63T*N_;Z9;N^SQ'W_@[=]-_@
MFXJBC,Z0;JMU4P'V"HF<@#^\Q0U-Z;BL7B3_`).F]-Q1XD_Y.F]-Q6<6*I2%
M.9LL4A_P',F<I#_Y!A``-^[5W^";BJGCETB>11HX33VW[SHJ%)M]O<)0+MJ;
MTW%)_$G_`"=-Z;BJ@B4P@4I!$1$```ZB(C[``--Z;B@42`(@)=A`=A`>@@(>
MT!#[=-Z;BJ>(G\G5W^";BL9A;E-V"("?_DR;G/\`YA`,8/;[]M-QY*[BJ=AQ
MW$J`)E#^.LH`;??V)]XA^\0TW)N*P_`.X"Y`Q@'82MD?(/[S?G;=/M`-5_!'
M1XM_81Z?IM\2I$?X0`Z8A^X--WL1U:9$OO1`/_6/CE'_`,D3[Z"2.53Q([;=
MB`=.H>M,(_YW8`@/[M7>?=[$?ZU4$2=!!(@CT_`_4$=_NW`H?W0U-_T9'*A]
MROP9DC)<]QOR=BF+Q[:KAQNRG:<A-L7YBFI>&QSD-I<\4W'%CLKNR0M<O+ZL
M6RGDM82<0]&&D$@.FN@8J8K@LGDEV(9P51)J'0J!MT^G9GZ9B,ITUFAQ$CZ_
MRAQ5Q@H>5K9"U.X40_%V4P&^<KRX\5Z$TK-B93%3=)NQD:TT=S5;5B+0*LBL
M*I5_"G@QD3PT^E%=X\:?2J8!C]''.*.99/(37)^*'E62RMG/-54JCAQ:$C0.
M3>0BV:JWDFX"Y&LF!:3GL:+X[9J]B>WJF<Q\0D,B=PZ9!<T^G^Q;W`A<K0_H
MBYMJ3&88/,HXDF"0&)TL38FAEF5HEJI%8^I>6..W(:@X9ND>6%9.'V+Y[+%.
MOK.>*@85B0LVP,D@X.19N2"V>8]_N_O4ZBD#DCZ8V<,X99DN0%DM^&^/F59'
M*%RS53*YA>5M]B@\)Y1@N.M-P[ABWQ<G)4FE#DB6L5BJZRM\!Q%Q;60KKH(\
MA'!RBJ-,)GS>/T^GN4%P"B>K*?!#+MBX6\+,%PY<92V4N,=,K<#+SA\IY*PZ
MJPL+/"4GBN4L.&\E52I7-:-8"]E%$W\38ZE,1MCKRRS-=!LL8BH:()B`&<<O
M[5-PW$\%2Y_3COV1:A.5>SWW&C&<LWTO(CA),Y"J&/FM41',3.U#-R%[94B*
MCH6,C\92<>7T2K%FX:.18**-DT$4Q(!<F#ZFK-]B"?$`ZNN/EN"W)2TY@B.5
M4M7N(]5R?0[;QPD:WQCJ5EO+CC]D&)P)0\]4=Q-WN\*8LCY2'OCL<\G<U==*
MJR2-<;UQ@V5.Y$XJH7;(^9@_V<?[4$AHN=F_IHYNELUX^Y0-+#QRJF3<.TOC
M>XH^$:#"62J<3YO(>.\MYWM.3XNUT%U691R#`F.LTJM:?:$B&DXNV>IFBL&I
MU2IEFV;B7'[.*T).&7N/XBJB8R9&BA1$1V$>XP![=C*$!0!,7V".P;^W7-N;
MFN,G@%3PHEZG:&3V_CH#W@`![1'P]JH`'^3J;^2CJ\J(&`#H+^0H^P%!\R8A
M[P`Y1!0O7[QV^S4W<PCE':BH()KI`50>A-Q[BG$/>BKL4>[V]/A,'V;:NX@4
M5<JHIF1^(.Y9,-]RB(F6)]@D$?YTH>\!^+[!'V:"3^U'X+QK^JS._IZ^<;YP
MC1&44BX2^O6D6_24=P\P@+JHI.HJ1:`NW9.VDNV479K%4,1P5LNKX3I&,)]?
M;/V@QQEXW<L?<8;C:&X%I0+3:42QK$L1P<!P0NA>K9[,JR6!&R;CF'C1>:<E
M&1-N,_C'<=99:+QA5*CD"K.!<FL5B5Q+Y(!A?HU2;E6T5"(66JMY\7"9457(
MG;1SA)1(7JZZRGTZU>N]MB+XE;AD9=ZY9N4$8C(\YLR(#SV3,6JU91(.T`#K
MFSJQD`3TX`$<3L+;@/$??XJ4$A%$E+C79E4:>KC5A5UWU)M$+.-9>C_V3T1H
MXCW3Y19)RH[;0<6UB5@>D5-Y32PN$3)`N4Y-=5CEBW@W+%OK1[K*Z!=M7(F-
MTY%P@@#@220Q`;;M+LN:5B4KXZFV5K:\9`^40C374,U1S==C*98RMG>6PW#X
M'P)@A"IUELG%TVV\A(H7]Z0JZ+:7;PSRS4F/&!CDZY+1**KJ,BCDFG8-BHKJ
M>)17<_AVNS]D]-6LV_ZB[CG?-W:W+6'+;:,BQE&%P[I&<32<GA%W`<"GLXY<
M\V=O'L6+9%L-$S`,M/Q:!N08K65G,]@IU!=8:Y`X9Q+CZ(G+NR<IW+$)QDXI
ME;T'CTE0F,MM'9["*%-D)QXY9M9-E*@2-<D!-9LB0YCZ978L3-S_`.N^F<[,
MRKL+#FWD4D;9`WC'DT?S(Q`)C*/F&A)HN(Y0Z)P<BU"$=U)18>8.V_5XN^A#
M)L96(+5Z1EQM?8^+BZ4=20BSI2<M%)V28RO6U9&8I$!4(M9V"DE;5)%ILEW^
M9$\.]7.J8J1CB;W5O,^8R\&7;Y2N=Q&V>Z,3LA8FT;D[LM8PVZZ'J1#5T\&S
MCSA"Z+S"T200:'?&H$0-:_835,T)?[,SV"G.(-55GBQ"JO9Z&<JOHV/L>8I0
M406A9*(2!2"L];KS%^Z1=%1D#&7>0HG.8C1PJDM[N+]ZZ>?&>VYEW+D83#&4
M,:#^82H8SF0#%X$",^,@".`DX\Y6KAW"(#A@QD1_"KZ:!/C@!85DN'`HV!5H
MX-]0P57@O7<L1>T+.:OC5X]8F3:,C,7AEEE3O/&H9!BD<IQ2`HAVZ]/Z@M[;
MG>^I`2$?3@`8!H@3N@&I<4#4<GBO.[=N%O&BVF:/NC4KZTM?DZ)<+Z>C51&B
M(T1-?FS*#/"F(LCY<D8&:M#''%.G;B[KM<226GIIO!,57RL;$)+J)(J/W1$A
M*F!S%*)A#<=21VAUJ,3.0B-2HB<4><.1N4[FES+;A1G[%F);S$2TO$YDOUDP
ML%;22C4'GID'E6A<C2.2&RTK(,C-$N^&*!51`RG8G\>I&0EHZU*V8:D/[:J?
M$U)EA8>5F#LI.2)%1SV1/'PK%:3F'Q&3=1R9I%1K<!<2$BX!/L103`3JJ"!2
M]1#6EQIGZ+R/Q%E&FV2Z8SL;F^-ZBP1?V*L5^#FS9$B`=L5)*.92..)%A'W:
M/E)ABB95BV<,4EGQ"[H%4#;<JQ&JLJG)/#V0,>V')>.K.MD&`JC5N[L47482
M;D[O#`ZCFDTV:2F/#Q[:[QLLY@WJ3Y%BX8)/'#10JB21RG)W$8@L52'Y*8<M
M&+[#F"E6E2]TNIID4M'Z-A9N>M->_J<=*N6TW16L?^M(N580,JA(K,%V!)`&
M"A5BH&*<G<1B[%6I<FL(OL<&RO!W0+93B6.)IJAJ7`6>XV5&YS;^+C8ZG.:-
M6H64N[.V'=3;3RQJT>F];IKE46333'OT1CHL8\F,3DQW9LH.7ERCJM3+":JV
MM*9QADJ#M%>FRHQ;D6TK29BIL;@T0]%-M''J#,?3"V7(J"G8/=HC%V79XDRY
M1\XT:,R/CEY-2%1F',FUC7T]4+?1WKH\1(.8MXLE!WB"KLZ+`SMH?T[KTWIG
M:7:J@HHD<AS$(8L5T]O=VMA5YYY18.$LMQ;1CI:MP%DL3RI0$O+D3$6;"7LT
M?7;:]@V#A78%'*48^.D7J")_9HHHB<(N5M]Y55K),KD'!ZN$)O'-Y2HKR&"R
M6JT-G$RC!1TE88E:0MF+<4.TI^GRSP\=)(MF;UD1=,!2=J]P@0M2B(Z*;VBR
MC1%`C,_+>?KUSDZ/C2'B7BM?<F83<[-).GB1Y)$0*[9QS)LZ9E*DQ5$4E%E#
MF[E0,!2`!0,;EC"CR7&9EV"Y)IR+Y`N6ZBXMJ<!2,2R`&+7GW:9N*Z;?NW&;
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M.I*@_=$`K<F6X`I&*$.(`T?K]QQ.5?<_B,8"B0PB`#^B?V\A.7HW"+^0=]E3
M_P#QY5?4+H'J(C^H7_\`^D'_`#Q7FPQ8-U:FHDR,H\0E+35QMDVO"&DT<:,(
M&UP3:#EW$`V1.Y>/920EUV[=P+LHMV@K(@=(ZAE#_2K]V<<X3FT=EFX+4=S=
M8RA+=$R-!&(B"S5+&K,NK"L6B_3H#_NAW'O)//P4S:LR4?<V:`F9ZXAB6J#(
MU>MF\(^O/ZZD6C>=D7E;E0;.T'CYO'V:MMXII9$`;H$+&(N#-SD\AR]`O&7_
M`/S^_NB+D+-XF),A;-F)E`;HO^*4)&9MDDG?(/HO?V1_ZM``,\1PW/0N#X.&
M?P!6?Z=Z%8GXNHVFS3<E8,D(HYEL48Z<52PSDQ7+\G9%'KUFR@262*B+8DWD
MY,JQ$2K`XD'"ZB'B(F(^1^YLLW&NW<+%MPL]H/RL3MG$"=O8P,I;2;=(L=0(
M@2JN;M'2-X2E_C;)EM2"&VL'\Q>OMHI)/;AFG+F$;VZYG8]9TV7K@XG7QG'A
M09"%BI!I*QJ9V=_D+'7[8HX_4%A5<J+RM<(U<*0!T@2`O:*@%ZK#$[-V?U!B
MCT1E3R(W.J+QWB1#2:5L1E;`V1'P726N:THO/NY&3?P;O]3AMG&,-GE9R8Z@
MNY)XAJ<EYYJ]ZN">6)6EXGE(-AR[>5*O2#FH/BJ65&>KIY2T4U2<?2#UK3(V
M/E:M'+'75!1>1(T*`%2!97L^FP@/]3=GE<Q[?S9[/U)Q%SX#&;6[K`#J2,92
M``I%R:L%Z&8'R%Z0(V#(`'EU!!)<Z1T!\66WR0S<I/L*@A"%<_+,;3L1(0#`
MCA%Y3H29@H-O=+!'O71ILM5)7(R67'O5*N63(FH]!3Q.Q:CXG99[X]Q,KC&6
M;"49DOU9QE+I0(&W>)F+<-I:.L-R\>\\96H0'DZ1!BU`&&YAP(_OXLGD^FNW
M;LN5;%O&R8O4TJE>T6[WY25HD]:-B1J2+MH`&*1%,[0Z?04TP*14GPE,J'=X
MO[GSG<])2ZD1$]:T3%W8G=3QJ_'AX+S/3H;NPE%_AFS\J+Z"'9Q(HH"8`*AU
M3$2`=Q`!$1W.;[2)$`3#]NVWOU^:(U`?1E]1EJL92IH$,(CT#=150^XF.;;J
M<XAU$?L#]P:KDJ+&1,R@@HN'7H*:(_A2^P3A_'6'WB/0OL#[1$\`BJ)SK&,5
M(>PA1$IU^@F$P=!(D4P"41+[!,.X`/0`$=]E!KJBY&_76LXPIEGO]J.Z)`4^
M%=V";79M3R,@G',@`5U$4.XIE%!$P``=Q"B(^T``1`_$T"K<DP)N:N`092[P
M;9)D6@48%26BDX%1L]9K6'(3K%S5@:0E'+6NK.V%Q;IIO3$>^F:M'C-V946S
MMNHI-P59=F;DEB,L%7K$I89A")MM0KE[K[E[!R#(\E6;--EK[9XF@[:IG*I$
MO5"*R:9RE]`R.1TH/IS%4'0/&C(QT5E3Y!8RO4/#3U;EW:D=.O\`&<4Q5?03
MQF^2E<N+.FM-C7[10D<YBWWKF*[>126[3QCA$Z3@"'*(:"4>#GZU&/%<U3.4
MV'\B+W5&M2-EG4<>UU[9[,[4@3F;-HZ.A8NQ.DV<4+M.RO7WRJ9;F3(FS4*L
MH84TSG4+VZNX<*?3Z<$,66.G\L\-7&!&>BY:;AX4N/7V2UEYJK2!VJ=?BXJ(
MGY-D5=OZILZLD=`6*.?&8M%70G:2+=1(RG>($FX&J;2%>TY688<)R1OF5T:A
M$.`CI1-_2;45LRGT[)5:A-U5TW;QRBS:PU&>O$0G-(=H(QB3\BRJHI%5.2[A
M[_M6R&%%(\0!LH<NS=DH0QBG/')F>I"8INT?(5,H`7K[Q3^_NUHO[?:N-R?:
MJJ";^<7*N(;=':3A-J`E'J(F31'S=I=OL4#]FIX!OO1!3#L)BD;O$QZ`=(KE
MTJ&PA^(H]J2HAUWV$H_<.GM<(LJ9B'W\8%^'H/:R33,0?>!BJJ]Y1#IT,`#H
MS:_>M1KJLP=W:!0*H/V[-6Q@W^T0*;IK)0Z^"M'8/Q^`-Q_X]BHF'[!4`PE#
M?5UY_6HKP)L`'*@'7J!V;@Q>GV@4PIE'I]XZB*\IS"(E37$3;?S+I/M/MU^P
M$E=OOV,&FB*T03*.ZB9FI]]O,B;M3'J(?$<@`4-__2%VTK[460?*4.U0I7*0
M^WX2^78>NXI;>-7_`(.P_8`ZE/84)7GWR-D7T_DTE<(JJ,17HV-!FU!1042.
M9-L1Z]<^,PCV.%04*GU#<I$P#IUU)&M5P3K)N`2VDXP*^].GV`9%^F=%NN(=
M$GY2>1!%Q[?$<RI0(._0Q3]P;AK#J`)Q'V)"HLV[M5J)"-8;SJD.F("=Z=X[
M0:M=O:*AE#D$P>WL*.H[:Z*L6]RC;>:(K#'.51/L=`'<LAMU1`P;@FX]P.#`
M.XD]I/8;8=P"@K)"G3@*PR%DQ;7W<JLHX>L%9"$.Y6,)UG",4Z,@T46.;XCK
M%:"0AC#U-V;CUUM<L"\4\FBVOF;_`.\H\L\N8FP/CG#''IQ/-+NA8JCRDS)9
MZTX7;K8YP_BO)M5KF-7L^Y:*I+M8F]\@9R);@0=RN21*Q#`*0J;<5PD!@N6T
M`2Y7O7Q;S]7>57&[!W)"JF2"&S3C.K7P&R)BF+%3$K'IEM$"<"C\"U=M"#UB
MH4>I3MQ#7("X=<<@Q(7<Y2QC4\R4.>QO>/U+^E[(FT3DC4^[W+'%E)Z!\VDF
MJD7=,?SM:MT*LF\:$$QFCU'RD`4U.],QR&$.@+57Q:.\9Y-:_7\9?3:)S-YT
MGXINI5O835@W*_+WZL+`+<>ULQFI078MC"9&,"P)>D!WOZ_Y>/;Y?-^=KA8[
M]KEES..GN8.O6?ZG/#>V<,^(^3^8?!+E+R^PGECCI&Q5^EZ_8^2^6,W8UR72
M6T]%15GA;12,V6.^Q)Y%HPDQ>MU4R@@KZ<Z"R)RJE.GN4=H>)+A8C+=+;(!B
MI\_2/YQSGU"^#V.N0=SAHJ"R8WG;5C'*;*`;J-*^\O=#<M$7EA@&*BJYXV+M
M,/)LI`&G><&:SA1$AA(0@ZU`[HOQ69QVR;@O/'F9]27DGR,YRL?I0?3!GH2E
MY*C5I`O*#EU)Q+:S,\'PT"BW<WJ/H48Z3<11IFDMGB+5](K$565GG*,6Q!%8
MJKLF92).V&JW&($=\]%/BB_2!X7Q,(D7-$%DKEYD5V@4UIS)RAS%E+(=WLDJ
MH7=[(M(\MQ852EM5UA$R+*(9-DVQ!`O>H)>\;L'&I6=Y>E`H!9]^FO-\'^3G
M$7E[PMRKR(@L"0?*##E0Y,\4G&8,KW['Z5"R9;V6/QO51A9NQS3M2L0DI9$`
MFHA_ZULV;G(]0.BFW63UDQVD$:.J);@8R9VU7T@J$%,YR#[2',0=AWZE$0'J
M'0?9KE7&O&'Z[O(.\8>X#9#QIAQM-26<.3,5<L:5%E6%54K%#XTJU)FLD\B\
M@,E6RB3IHVIF&ZU($.X3,!T5Y%'L'R"0!Q<+1IJ5NV`9.=`G6^C9RS#F'].3
MCGE"6E/FU^JE;-A7*"@J`X?+W[$I&]:7DG0"85#+VBLIQDN8YQ^/UXF$??JV
MR91=)Q:1"]/#%.8!.N?Q)E#<4DS[;%_],N`@(C]Q>T/O'7(&T&JP@G<(=K=,
MJ*7N4.00,;<?:1#X1'?^4<0'[AU/;JJZQB"0CMLH\4#IN<P&2*/O`VX%;D$!
M]Q2B;5K[$5YC')L558B._0J3<G<H(?87N*<YO^"0--45HD[@$?"H</Y;M<Q2
M@`?:F4RFVW["Z.HN>LU@95.N3UG>,GLBQKL4^F7[*M0:LY,JL8Y`SIZ,>P(L
MCZYPDV3,IXP,4QBD';<>@C0/55GHF%0Y?8(.,6T=V>3B)V8>03)"FRM9.WN[
M8;/7:I:X)](U%LJ^FVL5)05VC%4W0IF1$[GQ=WF(=,)NB:JL?<MY#<D<9V2A
MPF0X`ENG8FS69:GUB'C*.O)6VQS[>%=V1PRAH%BZ.+H&U=CW+U<_E*#9-LLD
MOXG21VY:#X(S&J;Z9YM8'@49QQ(O+''M*[;GU(E';RK&BE4;+%1UIE9:./&2
M$RQF(U:-8TR2$Y9!NS754;@DW275.0@W=$<UHQY:I;*<Q,-0#:3?3+?),0WC
M)UO6DI"=J#J.9R<N[1H[MNE#'FGC5$4#L<DP;@57/HDDT9`HJ'(=-8B<WC0T
M]RQM/!=E#\C,:6>5?1,:I:98\"*X7*1<4N61JV/#)(3#A(U\L+8',3!MWB5>
M?"BX`SIJ)6XG.JFFHB=0)-HX58A<"OS1PFC#1]@\.2CUJ5KE.LT=8&5.=1E7
M48WRU.*17V#F0G)"*^5S87%@ZC'K-ZFV.Q=M%R+@3L`3-X=!$NNTNG)C%N/P
MK*%ED9HJUNB:S.148PK3A948VW?J$(8[QZU468BZ$*L^**"2AW"ZB9$FQ'"R
MR*:FB0-7!^OZ?6J0^B19$Y,XUQ/8IFNV^-O\&XA&],7=S32L)IU%<,@R\C`5
M,K:U/Y5"/,I)2T*^1,+GTA43,5A4$@`3O;@-:I$.*:I"CR]P*8[$#W4Q4WHX
MC+ZE[79ED5J&<6KA[0%9)T_;.$XYN=!%,9558$DH0';4SXR!'"9AAE'Q48\$
MA)S:P.9(YB25U/M*4^%;E-62L!=REYAE)^`:(FEGD0@U,M%I"?N>&;$6_P#L
M87``80RXX(Q5COG%@)A'HRKJ<M*<<M8[-5D5UZXU7,K*TY1PC92`R9S`S"9X
MU9L)"M3-PDG9C%!LT7$VIN#U"K%=!-\P./\`!RZ4'*61_P#,CY(L>*#F9P#]
M5!O;ZJ^J49+D]08&SEW%_,KQ'(-W#--R+HZBHI$,1NN=-N'!1B5V$9R$QS*7
M6@4"+>S$E.9+HE>R56=XYNS13IUK)-G@I.2-(/V3[N=!7G?D20;N%VH)@*X$
M*8IM5P=-5&2*G<E,-Y!N2U$J%F=N+DC,*0RD.[@9>,,X<(5N=M1W)5'K5)N[
MB0BZV^)ZU$QTDW:'ISF!0Q"&@D-"JQU*?L.QPE\11[3=#%-T.FH0>H#M^%1,
MP>T/?U#5+@K*HF8P"=)0>Y1,`,!]OYQ(PB!%!_QP$!*;W;AO[]&XJT)7C9]5
M\4RSV#Q4<J)IDAKRH";1N559+QN:7W'4$RJ1"@591/81Z=RP%'<5"E-]P_9L
MG9GD`&MK4^$_[UT#U>'R+//;/[PH58A9IM,JU@"&\->C<=3\!!V/T*IU+_$R
M$]%JSKQDHT:1Y%HZ%GY5V@E7B?F/"@JT`R*BQG)^Y^H[L_Z)?G0Y,LR$YP?_
M``91B1"A)\Q@(R-S0.)%]NT>EPRV3"`<6C`L?YJE_M+-[G7"/3RL5Q+Y)"G/
MRD"G$Y8Q3$2\1&5AY*(XXJ]NOAU[+)15K1D4$7R#AS6(M!2%74%P=1J!BN!!
M542^Q%NU?]:]JE<MQNW)X5^0E*8!O3MVFAO@U&$I;9@:$TH%<8#Y"Z!1KL08
MMH"2_F]H#CBP7J%0Y"[8UQW/VSB?4&F2,WR.:82OOZ_(U>;>P=YAE$E!4:VF
MQ3UF9EQTU!BN9VM*@V%,KI`&Z1Q*<Y@^4]PLXG=.\V\/UC>.+V6.%*0E&40;
M1I_AB,#UB_E$=2"269E[_`F;.)*]VV(N9G5`/E?<'.M?+3CX:IB^6XQ=DPC$
MWG)[Q_5,R6#C=9)#(<VICF>I\\V>^DCVHQ"-*8VM[%,T"NW96IU5S-$UVHB[
M3W\IB']WZ).3C^H)X/:1&]V*'<X1M@W1*)%2)=0P!)8;MH'Q>4\UXG<NG<C"
MYDTS)623Y=M0:#:Y_P"]RJF/FB/7]_X>N;',OWT@\P5C6^VB`>U%^R1JDG.4
MI1W.WA)VH_:O\A31VM>:RWG042;LSM44_"L)#@GV#&VXW;._#$MB%OY^_;A,
M3'G`N@1M$,>G`&1@!Q$B7%%X5[?\SC;BYZ4"1M^&A>0KYBP!^S@4S5]:++3&
M832*9X]JKD%]86]F:IE?$=WM.(@VSJ@+22K!9.Z.8..GE_1RJ2S8O>"R_:D1
M?P#V#M$P,?`-HB5R.+&!MDZ6B9$7@'\FZ40)1()T%6=>MON;]R5P$0-S4<Z/
M'W?W\4]N&E(UNCPG17;B[*?Z@31-H8BRT0:.=DJF.!3<+L@]8,F"9BBF5(3D
M\93E,<YM^X_I^][[MSOL@0&]/5XN.I=#/1N>G@O.[>!*WC'<7&=_"*^L;7Y1
M&B^I(U41HB-$4>.6RLLAQASVM!+-F\TGBJZ&BU7O]J'HP?A"._2D=CA(#9?*
MV55V*H-:`9LI3"+3\X":S+X5NW\84*/IR<N,?V+&6%>-\VM?7.<8RH2B=B5:
MX8YK,\7E=1`R<R[)%9=Y64=G;)-JG&]I4E;!*F?N5_RD]_RR:D3PJM7(_B>/
M#13]Y"JRZ&!<TKP$XPK,VCBN_JQ-BE)U*KQT%()U:4.TEGME</8UO7F\>L`*
MF>J.$$VH%\IU"%*)@VN,:KRRP5/P"G%_EW&84NL/7:)5\;P24`[G#<>,5W&K
M6!:(N1[?)3LMAR:81#".DH=!@G#S=C?I*N9)%Z<7!FA`7,6SJ'U]ZQ8LGH!Y
MP]Y41V+[G7Z_BRM-Z=$01U@X\8GN=>C`9Q);^UEPQ3+0=,BWD]`_U2ON+&\;
M.)%Z)@<*"R.DJ<A^(/JL](G*U*\'.13.HV^"B,.0UYHE=BO2H\=\8VZ)Q_YL
M6)Y&KLQ%8XE:]C)A9;+%.9%I!,YYRW<S`.VR3SN;NDN\GXAS74XZ=1UWX>VZ
M&I5EID?CL_(?'=5IECD(;$--FL<5H9/$8+2\E`X&LU)KM;R1#7)RY=UXJ#YM
M8!37C%C$.NHFD8AU\5J@JLQ+<!<A0,U(U')-I/DF.?QTM2H1]FV5R1DMK'TN
M7E(A5Q$VO+4Z_P`AQ^4D9"OH3CB3(>*1BV[LZK1JW*L4GXE-7@JI<QX]PB%X
MD[M.RK.QVQLTG\@JW]6QR\6,PLX;G5+E!HSO*3&+<.%8]N#XINY)F!T3F0,D
M82S+5.KR3H5FRE@3+>.Z=>1QK:+A1IV"A;N+N3CT8)Z]:&(15Y(P<A$3T9&O
M"`+9TZCW;60;-UCJM5DURIG*4!8NF!X)X*MV#JIDEK87N-X6'MEV83-3Q#AS
M(-_R?B_$\>PJ<)"R+6NVW);.(L:KZYS#):7?M4HZ-CVR[C=)%18[EVY*R+J=
MFBRC1%Y'5JIC-95O"O@D3*FOEJ,1RUBU9=(HC8)#X73,A045;F#H;M$^Y1'X
M#:YB6B/8N(!/PM8%6=BD:74*+"RK&O'6BIIU+KRNSATJO'2,O$PZ:'I7+6);
M2339,SGRK%,90NW;U-G@Y.JUX`.M+EBG,Y2O)6%M&22!9,KIZ]:(QR[MS\V%
MPL1\$G+@BDQ0;M'!3)MD42'V2`#F`ICCI$\%"$\W#=`6V(%D!`Q?%<[*4"&W
MW(`G:&`O4`VVWU+GQ>Y:@&"E;K"TC1$V]^8@\E\5JC"3\O\`+LD)O@<PCWTC
M6`$*/>&GSNR)^)7U\`4'?I11W)_7'3<_=\&P]D[!?-G#[K'KX]GJ=M,6N1W2
MN_J<:73LEQLN^7?NK^7"Y%O,XZ5ZNQ!D]Q[!,XN7D]'O8N;K$]D<?]#G0Z^2
M&/4Q_/TC#R_G7;,G\K%R-=;7=5\ZOU!W*I>9.94G,Z0(O_L:UE$T'\R7,Y0<
M.,O5</F3>%3[45DUP[2BH<W<!T@V*(`(A^A?V_C$^CL([)&?]<D7VT88\Z;N
M?%ET'U``.XWS^(X@_P"8*$+2`,:%J*$4_3C"6&U$NUPG(H#/)&L8MQJ>2,VE
MW$-ZF-F_1VB:BY9O'F;/"*NI.-*V$ABJ`8O<+^7NR\@7!NG:QS;LQ-!._>8&
M(DQB\(R@9.&C&1DX(77[-H&$#<-#,3/'RCBW+5N;*2U&+^5,9[AQ9,;ODR;E
M?D=CAGS]>$HU<K%C1=0&+X-&:CS2;>PNJPRCCSQGQSD%NMX19F$XNU.K=P@2
M8>G<D'^FX<([X$?F7+DX>;(G*)8PWF0M[:N'W,-H]I;N;`<VT6RKI+'\,0)4
M@`>+,Y/#ZTKM.$\Q5U\OGOCE6X?(R7S9O:7..8^?:42QX[NSMR\L5J+4)E4(
MYI:\?SIWCB41;'$[^*D?(")3-0$`SA=^[/E68>GO5%R>+0P%V4#>A>M@"%K?
M&IMW8`"!D!MG$`EBN>YV^Y*Y\]@^;C(182A*A+5&X'7F/<KK-)<\.5DQ`U"S
M<?)FD0L=$1L@2=S-?B(UN,G92%ERJ3+J`:"G+V6L.9$IE&Z;-)5S)MHXJ9P`
M3J"#%M^@O2,+F;C=RM95^5QA#'LG?*`D#M$R=MN;4)):))9Z+FR;?=>Y2C:G
M:N"$1K*3#_B_N8DKIS4AC7(8,)>J7R)4I!A+-[6DJV8P<SEF_74C%*4MRC=K
M#+L8NPQ\A%,UH!-)&0:L21[<@-UC%45-X(S+V9E'OT'QNXPD.D7,K>/9MN1;
M<EY1D#(7)$C=N-0[+@(A;A'#!%W&(J`&-R1U(\8TV^S11EL"`PLM5X)"6:3\
M)@.\6FFW)9NZD4V[["UY;-HR/G[7.2CE>!2L&.*]'2$=/$BV;Q=D!6:B:A#K
M%!/M>+(W[-_+,#:O=PQX7;7ADV228VX1\PA>E*,K>\Q$B9@@L7\+=&W*%EP8
MPE*!/$PE_,><:@^Y/WP-A&4#R_80BI&KF2B*Q?HPZK<PD36:MFD2=K(D6`@I
M&2?1T@W<(B4G:JBX(H4>TP&UZ?UYE3R_1IR!2,[UH^]Y/$C@07!&H(9>1V&W
ML[Q$$N!"7VZ?7P7NTJ&[UR/_`"(]A?L[E3F,<?N'M3+_`.`Z_/?X1[%],E\2
MQG^(R2?N$PJF^\$MA*`_=Y3%']VJ%%54Q@(($'8YQ(D0?>4QQ`O=^TA=S?NT
M&M=%4?`BG_)32(([?80@"/\`#L'\.E2?%1<Y8JY`W2MS53LL2A88*R,C1]@B
MG1E"L'[-4Q%%&+E5(R:AFX"F4HD3'J`=?:("(>AT5T38R/'7!DW9T;U-XSJ+
MNS)6!.Q-Y4(X47#I^V;5YBW1?E14+\X@6Z-0C`;Q#@JD2AZ%$Y&Q3@)A;0*#
M5'*S37'_`!!:8"H5"8H,<]J^.HB<K=2CY%[-+%AX"RPOZ>G*ZV'YH#EQ#/*X
M(,CH.U%4TVI2))E(4@;4B+5U1RN?1XP8,8.YX];IKZ!/8Y-A.RC2HW.[5"NL
M;#%SI[-"V:&@*Q9(>O5FRP\^=1TR=Q;9JY;***]ABD44*>;0U=$<K;UGC]B>
MAJ3*58A):'1L\+\BEJ_%7&ZEAW3`(&'K)G)(D\\JQC90T)`-$3R;9%"0,9+R
M><5CJ'-1S`8)5<9`<2L'TB+5BJ[3P8,WM?E:V[8R=DN,VK-L9TS<;&XDU%K$
M*[R7LQ&;<DI(',9X]2;HIJG,FD0@:B(:-3ZE'.J5Q>"\1UM65(>A*(O+`Q49
MRBTG:;-**S7J)J!GI277!_*KI/)^PS-7C'$I)+`1_)*,&Y73A0$RAK>R.L2\
M4,BGN5G"%,J)P=D<"<WD3:))I#W=3&%>-;G.L43FZ;@<.OO`-!`FH9OIQ4)9
M9$UW0D]0A'G:]YQ*#C=%)!3V#WKH@+AXD8PCM\0E/N'M]FC#0E_I]252OQN3
M;*K@5$Q]MW#<1=H''J`E5*L8#]P&#V&+N'L`=]9<:!5*#(@':HLF0Q0#8CQH
M*1=@`>H*D6;[ICO[2F,)?=[=1^`^I$H*4Q2@<4T'2>X[G(@5!<@A[E"I``%,
M7WB!?O';4XMQ3V:)4D8%"]S94Q1#VIJF\A"_8'XA.!3``[&*82C[M]0TU550
M*0YA#M%NX`.X?&/;W!OMWE$``BZ8CT'N+N'L$`WTK[0BJ(@?M1<$*81$12.`
M;%4,'4>SJ)D5B@&^P#U]H#TV":5&JBKW'1Z*&[T1$"^0VPF3$=P`JP_A.F;H
M`&_SM_;IKIJK[502&0^),HBE[3H!N(D#KN=`!$=MAZB3W^[8>@J'75/!0<R8
M@5?-\^H5PV1[FE<V.N;\HY!A6@AW%\2I#D$!Z[@(:Q(57!/XDZ<M+DK%5B5X
MX6#5U-S+2*=/XI=?L;(%:N7IC>%4H)LWJW@["G3VV*)NT`'8=9&A;55V%-4\
MD/)5IK6$G)'2AI/N2-L985/(([!N(',83*B8?A'V@;J&N-RZT"P4?LM1K-(K
MHC16';@!E04[5UUY)0XB(F%RX71.8B@F]I4Q(&_MWUR#B`LRIHN\XX$!/&*!
M"B`@%CL?4!W`=W:8]!_?K8T6X:)^`[-]U%4T$PW,HNL<J:*"90[E%EE#"!4T
M4B`)C&'H4H"(ZJTOFKQ!DCAMSOI/U1LK9VY+\=*:;G#*6[BOA.!R!FG&=9LU
M&XS\=XR:HN';&I`S]F92L(:Y9B=RUV`%$DS*@JV6#<.PVN+RR<EERG=%@`:)
MK_\`NLG)AW9./.>N%=NEV;VW<8LD/+?4BM)!O(M'6.LCR;YE8DX1ZV67;2$+
M`Y0A7JR:R!SHF2FT3%$2G*(K1IMY*W17=S7U1ZY5PKXF\S9"0Q7_`-ZT4OCJ
MF9*R"A!PL#Y*EB"E/LB9#E"R'#(8WO@*=&K-WTP#`7?J'0)&[DFB2BFQNS8>
M$TNKF%;(4Y>8OU%X'ZK,?D'Z27!JMVRGYUS&V>5[,]QY7U]S@**Q5CNB3D-8
M<DP\719I9_DJ[Y'69QY$QB6T:BJG'>I<`)BD$Z=E+=Y8J1CL\\M%[%\1N*=)
M^F7P83PMBQ\]MJN(*#DO)<];I)FFSDLAY1-`RENL5H<1B*KA*-;24K')-V;(
MJBH-8]N@B)U#$,H;8&V+!8)W2<KYR/\`NF$$WNDKS\Y#V9?YQDRPR^)*U(SC
MT_J)11O=7E_R3;G1W"G<KW6*S-VRJYM_S#M2[[]NN.UQ*Y;W`+[*]<RX%<4Y
MB#W$,8AMA#N*(E'8P"4P;@(#L8HB`_:`Z(J`&_0.HCT``]^B+PIKO(_B]F7Z
MG_*Z]9USE@FJXWX;XN)P7Q13<FY7Q]3W%GR%E<K2Z\O+HPAK3/QSETQ18M82
ME^M*D*1BM'B0&'8Y=8&TS+Z!<C$1#:FO]B\KO^[SY4KG%WGSSR^FPTO]8O&.
M)JQ67(N!+=5+)%6FJV5?%KXS)5>N3T,]?14D:UX:FXUXL""IQ\T$H4WQD,`8
MMGS&`T6[@>(EQ7V0E(90P'5#;J!DD1'X4OL,??H940]ON+[`]XZYS2@7"J=7
M'O$K?<=NT1*9QMT$>X-A*W^S;J?[@]M^'VHJB8PCXD.U,B8]IS@4-DQV_FDB
M[=OD#IOON!?>`CTU/$HJ;%2$4T2@98X=QS&,(B!1'8%%U/QF`=A[2@.YO=L`
M;@UJ=%%&[)_(F#Q;=9&"LJ%9;0%8J,)<K-+V2[(5^Q2+.Q?KDC%IBVCGA7YK
M_(1IZ&L#Y$KMHJ0SM!-'S*B8NIN8^#+0%%'UASD:W@D13'F(I**F;\SCJ0>'
MLECDH>%CLDRT;ELU^Q';'Z-1-9X27KT%C91^U7-'I#-13U1RW32%H8JLW<`-
M56:O),]8LP8_"F14[*<7Z+-2&V-):+H\1E^0<7B0N=@P+2[=1G$2PFJS!*.L
M?L<>P</7EYMRHDT)-M#E%N=(BKHYX\15&\4XQK;Q_8\:)G)U5QY9I.IQ^>00
ME/+DJY0>3(:2C\B#@&;R&_MBCY3(%?G*U18MZ5>),Z(J9BP6BC*B`F4UK<-O
M^U&+KA<0W'C-D*]L,>FPZ[CH.Z&RF_24M]PMT[C"-M2LKDJJ1$$$9.++TV`M
M66<.)2]D*BFHD^;(2":)4U5CD<E`QT(8?6A<!^*[#*F2,3P&;*CB5KBJKY'F
MDK1`6&3L\ID:9<1]4N2*,5#.R6-L$=8Y-U:HF,PQ`J+(R:I07(BFHML*BAU]
M':X`4&YG3"#R!PY=/),W+C>>ODO4]#+WAC(Y:OU8A;!7KPU7F6LY-8Y/!0\M
MD5)F6ZN`9/B1CZMI&?+)-Y%(I5@0C`\$J.*<K'=MQWE"`QZVB^,<="IYQM[)
M"%:XYR98JPG29^`>$SP#F7;L8FHA2F+&/<S\^@K!IN4'<JR.T$A!?E4U8B+`
MT$3]-4)->8737R<HV1)56L3^.JI:)%"2MV$H"&?9\N<)D9W`8M3RHA)-,NQ<
M0P=V!C3+0M"/@2,LM*_,V<JBHZ*!Q3(`F.@%/;_#_:C%/+CR;@<R7NF0.0L(
MP$%-VO%N)<L!+NKH:V4MQ3%R3DIBV`CFTO"5UU8[7$VV?L*#R+5CBMDV3<[H
MRKE)5!`N=V[44^G)&;11RQM=.)\Y-1M5?<=8&H7YK*T*N,H:PVE20L=LA\ZY
M&F<0M5R23X57V3*>VQW4V4LU;N_6-X]B"D:FDQ48K#K(8U"T7YT6D'-'&##E
MIE9"OX"FI*(PF\MD?6+"^MUPDHBOXWQG4)."A<EU*'MXR$87'4]D>NO*[)KQ
MI73=J*3>;='6(90$6Z(X51BVJ[2J6+!LQ1\G6)?#<2NA4X9>TL8`,TVFZ5R!
M0RMF*SX[DFMB<3J#=O@>Q,;+7`GY!>.25"'C0]:U5`[,2@!#,11U&/--S.W;
MC&PBI2T&X\4A1/'+1.`M2-5RY=*\_O$RC/WP$'L17'-<K#W,=6:3&.O5V><L
M"/J"IB8ZH/RQYQ-EP^B5YIPK-ES$.!;>M.T6D)6H^.TJ/C>GOXSDYD&=E7;1
MY46%XB$IFF*J6A@YPU4@O3V/;._+)E:2)RMTVI`<$\=+`TT]J,5VF(K[A$V=
MZ%4E<(0](OS:;O$EC_(;>TR<E".5+5@VHV?)Y8.0E&D6Z._02F(:#?0[])(>
MYPS?-TQ.8Y4A(<%DJVJ>B>Y1JQ%JG*XT@,?IJ#DE_BR"+9\MMJY*,)^"G8^O
MRMMR5`EJ4F[HN.I`S],\7()GD%7YUV"8HI'DD1)3*GL4;BI`8TO*&2\?TG(C
M>-5ATK9%%?A&*NTGX-?*LY:J>FDT4D$):+7<L?*R>$33*\9J)+E(0%>T-1JH
MW#BO,/ZGZ:3FWX.9J);NEX2ZDCTC).51?.7,C1XYJW2*@81\R[Y\FDB':/<J
M;;W[:^R?M3<%K&[A=+",3:))+``"9))Y4==$]5D"[9?6K>)<*"PN7E'G[4\B
M9F#814938S!>.I9^J_>4Z1OLS*MY.YWA>7K"K==LSQ_+,9H%U'[99%.7%FV*
MN5-0AR=ZD!W+$M1OPG*]/)EEWXAHW!:@#&W:VR%>L#;81+F&^1C0OU]XX]R3
M2@XCMB^@,BYE[JESQ92D@Z-6*;'%P>C'O(W&LHQD("YQ<JX;*V&QFFWC*>B\
MGJN21:C0+2@:.C7$+X4MD&[!!-19\0#&-U+*SLW*O?Z@D1<[J)1G:E`2$8"(
MV&PSOL(,A<T.XEA!>SA"U;/R6F)($2J-Q!KN]NACX`!RM#7J]S*XI6N*>X]Q
M9+YTK5K(@U?7S$=D8UV?ML2LM+R46Z>8U67.>)NKV'$BTBV32^7+OF)ET%!2
M.?7G9.3Z)]78LX]QS+7;LVV:6LBV9QA)HB0%\'S6]P.RNX`M(.%R8^/W'M]_
MJ8T#.$A\4360U#Q&A]U>:U<=B'DAR.E)'*7(VHEPW45U44[<$Q:V]XOUVK9F
M[R/1I%:8$!V-3:614BK&3EG223MM&H'19%%7R&UJ[WSTWZ9LQ[3Z7O1SL[:=
MFVV;5NW<<'JSD_YFP5A`%C*LJ+(P\[*R#G9P,+3ZFK_[H!T?^:@`6ZR/%.\D
MPDS89-6-C[;C?U]XQ[9?.G$5W&P1#!C'P-/G44H\R@8VL+R*9-P11!HLC(*@
M81>"H+<?&[7.':KMNU9$YX>7MM9%N0W3O&4B97(%VZUMY2<N-H?R_$N*_(Y(
ME.\(BY;>49!F@U!$CD:`#GS4<)9(+;,9*G6Y$2U?($?$Y;QV5X+YF@QGZLS>
ML+ICR(8SJ\I:9!S%5^/E7H%5,S3&'C4'A4A47`"=IQC+M]G%LS?YS&E/'O-Y
MGA(@VKTS%H`2E*$7\QWR,785\*=L7[LYQ'Y<P)QX5&H#U<!^.@!7<8>.#=7A
MX6%F$(MJ//YD5^4TH9@,PE^CL;@I'MFJJBOS8XBX`#%'VI]Q@'N'8W#WB)G/
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MVJM["SLD##XZL^,+%5%:/3XVC,FU5]#$'09DA``CY!=.3:JG.N50E7T3?VY?
M&]DXN9+G,<9)R)DFW63.5=(AD2RQ9H*\S.<(:=HM1JJ]>1B6^$*I"LF45!1:
M<;(-_ET`@P3!ZY55+ZHZA6KUY+%CR$O2/$.]5W$L>;'6:V=]CX-!M`VUG0(F
MAV]*`H<7CU25L-NLN?:W/T.)Q\:N>)!@:>;3$(+9!)F9R=0H$_%713PPNVR6
MTQW"HY<N5/OMY(M*A)62C1)XB!7;A*O"QK+L%P=&1E(E@5-L]?(MHU!Z[245
M38,BF!LF62STT3+<^T:4XX9<CT<B.95K3SXOG@EU86$@;*_,(`B:.;A7[7(1
M%4F6;R5!!)TVE7K&+6:G4*[<MVXJ+$*Q^(,HB?21Q;6\,5/D-CLE>DJ=DR&R
MI7WF4JB$-A2+JD.^L&/J_8ZVI4G.!5G--E&DC"ROE4,[.69:%\31P4Z"#1TZ
M*S+D<EZ\:+"-$7C[%61&%RM>D7*")UTKY:P[9!=PW9(`%@?B*SHC8Z*ZJ:8=
M1*!P`?9VFW`-<[.![%Q<5+VOS-02DW=S83*D8M)MU9.5;GC6RR3L&KB/B',T
MU:E70^6C(NECG*V'R[%1,;N`QMM<9<4*T"$TN;;_``Z[9:/;)-SDCS.&:@`J
M=*0;+%64,9VDZ0$&LI&R1C>8@J(]Z1CB3X0[3&L0=5"73X\-5#+X=,X$#`5>
MXV91(3!^-,%6J8&#V@(=Q!#]H:ESXEJ&BE=K"TC1$V]_9>KE\5J?)K#+>@R0
MF]]1!O/2M(+:CWAK\YLR?A6]=7B^J]**.Z?]==-C]WP=INR=@O\`1P^ZQZV/
M:ZG;3%KL=TKOZG&ET[)<;;OEW[J_EPN1;S..D^K\7YCN/8)_+9F1T>]B>ZQ/
M9"Q^ASH];)&T]3'\W2,/+^==LRW>5BY&NMKNR^=#Z@@13CFKF5D\;2!'"G"F
MMKNEV\HU;M7D$CEV"]4@K%KQKQ)^4%A%-85C'(=%3P^!0#CK]#>@>O'T5ARM
MRBW]<DPVDD2./(.XD&;4`#4.ZZ%W\R/<[U?+'%'_`#14265ZBCI7>:M]786?
M&U_=0=4C639"*&;J+NHHP<O3X*,<2,S1K#$JKU1.::("G+2"2CY1JMW**I*)
M:[+=[=>A+'LX%Z5KO&-ON$R,MMX7-T;DY-&Y$CJ&V2-L2([G8%UZ>SD"(N7+
ML0;,V%&>+5B!44VN-:I3!VB4P>[-'5^-A\KX>N[ZOF:LF:1D)*6]/".ODJ1(
M]N1&?QS?V]>09I%([(X*Z05`$CR3=`%RYO8]GOT!._<N87?\<3C(EC&-0]:Q
MNVS+<:,15]ADR@-S`I$0O8MVH&ATYUVR'U>T53@7C*S5W"$I\A=&N#,:%<)#
M-4`;Q'RN2<ANGA(EU&3MNCZS%.XNC,(.$>OD6\6Z776`Q#K.&9W!""EZS`[-
M=%^679QY=P[K('9>-LPL6=I(D(&4@;DC+:3(`"K1EM*\F>4.B+(D;.,X>(EN
MG-^;"@;E[PZY*JVN(I-NAI3'')XM8O2B3'Y3.6(IHN%4K\JC'Q[*'>-X6-FD
M"U.1]20[!)X595B@4J+J-9+MNPOF7\*]W+%G;[EV<W.WQ<&,")3$@Y,HDRCY
MP?BVLYK&<XEUQVIQQKHN8^28W>9<1;^4ZEF_O`766#.=A:K0J&.L1,JQ;KV5
MNTBK0WL[+(E3:J6*.<C$-,9ST/XHY3QD-YPD7Y3R,8U\:2Z*"B2BX>-A]AQ+
MD)R[GG3GV_'BYM=,V)D0(<WH2J3PVQ(C(@D$@@*3RIB1^3MB-Z9^)Q(>;^4B
M@UU-1RHFXJR-3QX=G`0$77KIF6\5DD!$K-VU?EZG5"VQ*M.(9@QFY.SQ-:GY
M6(JDTJ\?OV<7)M"24PT!)XLG&'5UYV6<GNWZV[.=CT]CW=S'=&<]@D"6C"4H
MQG.(C&!G&1$#Y09@+%J%G&D;46N9D@1HXB2`6<EB0.+$5UHI*_3_`'Z$KR9Q
MTB9<DI8Z;BVZUEQ-LNY)"8@6#Q12`*\[8V'*\0@V4T=!L`(MVJ/G`@("8B*H
M>C_</'.-Z9R)!XXM_+M3V%R8S/Q,7DVXAY.22SO4A>?Z>D)=QA$!Y0MR#\Q_
M<]%[EG'^MOA_E+%,`?<!3)[_`+Q(.O@#>4#D/O7TMMQ6+?\`/+]Z*H![=]P.
MB(_X-&HABU%8LJ4IT"``J*>8!!,H@&P^)7M$YA$"IE'[^OV`.J!]2FUEB=@`
MH',Y,4Q!.B44R[E2`#KIE$#?A,L(%-[^GW:HUHKMIXK(J=4Z2HI%\)`34$IS
M%#R;`4>WQ(CT('WF_P`W0,]5-J$_&B3M1)YE$R%(90QAV+V%`-CN#;[;;?A+
MN/W::^Q&6-,I"HI"Y.*JAR^7P$+\!C*?F&'Q`(^0`,8=S'$2A]VFNBNWQ5$S
M'!'RN%`;$5'RB0@[J]HAN0G>!1V[$@`.T@"(;=!T:K"JC+$13TZ!W!B^D!<2
MF'IWNE1-\*""91[_`,P>X``![S=PB.VC.6U3:L8F,W`=ORW2I#*++&V6<%1(
M'Q*&,<13;()[;%`P[";W!UU0']B;62%)L:3`WY94X]4I?*NKW&>/A*`%!7RF
M`BY@$`Z#^60`]A3!T#1.W_B^P)L<ZK%Z1.&50*1$I&FXE;/D@`KEHJ/X$3*"
M/;X3>P4C;)'#\/:.X:KF8U\WT^G--C+9E5,`"NF!$UP_+73)W>C>``@)RB0?
MB1<]GQ$`>ON'NZAK#<#HFU9MP1/Y6X`!#BF5RS4-^68JG1-=`P`)0#<0#?J0
MQ1Z[;::T.O-&5VXH*>5L'PG.1-RT4$2@4Q_A34)N)O&?NV+[R&*/W;ZFHJFU
M&P)'!PU'Q_$1-RU4^`O:<P%*80V$R"J9AZ"&Y1+OT'VZ>!5;BA4`W,Y;;HN$
M>JR)R[%52,(>0%DP'XN@"8IR]=P]H]0T'(Z*;4H.850V`!3<I[J)D$P"`B'M
M[#]`424#<#>\`'J`:@#%^";5D'M62#V@54I3E$!V,01V,0P;[;&3-U#[PU&8
MJ[%1,WD2#R`'</<FJ3^*)BB)%`^SM$2_P#H0QHFQ41$Q0,F([BB;L`V_4R8@
M!DC"/O-V&V'[1`=4AZIMJO/[,<BG$YNG1.F!DSLJ\JF10QRICW1#;NW[!*<4
M^X!Z`8/?K$N:\:=)D)X(.8@[9!A6K(*:[1\!%SH-!*P3@$V)1<DDVRB!0[99
M,B9A+N!MBCVG[N\2:P[4X*CD=/N6TA8.MUH$)$9R8GS-F19AC&2AVC=OXD7*
MJ*@*&9I%,X=M2)"J01V)\`B)!VTIJU56B`XJ6=-!E.ZIO?*(K)R#<X&%NZ63
M(E(HA_JSE9'M$ZJ/L^/R%,&QB]!Z5EDU+ZI]>-)SGQ4R5,40\U@L:A1'^,47
MI2[A]H;E$/VAK8"YK4=T'\5#+ZP>?[1AOAK-XXQ2^%OR(YC7&K\.>/C9NL"<
MD2ZYP?$J]AM#(@""OAI%&=R#Y18O1!<6XB("<N^9E@PU-%RQA5SH%*7$7"KC
M%A;%&,\/PF"\+S,5BR@U+'S&:F\44"8F9M.I03&$/-RTK)UUU(2$E,KLSNEU
M5E#J'56,(B.J(@!D:1JZ^6[,1(7Z3O\`WCK&>3HUK&4/C5SEK\7'6!JP;M8.
MH03/*YVV/KBFFS:D;1D='T[-E9BI\Q2E(FV:O1$`*4=<1\EP<BM[=UO:=0OL
MX4(=%0Z2A1(HF<R9RC[2G((E,`_L$-<S+CV>*^-F5W#_`+W=$?;\D8^_KUX/
M/#!^\2]?V:XO_&7)M_*VIZ?^\0\,[_CFR8O^L!Q.4=53-W'>>IX9MDJ^W_K:
M\)!OV[3'>8'S9$`"2)5G"Q:]8RJ`)7=?>MP6W1;*CI<B1YXZI`,-IT7NQ]/G
MFMC/ZC7$NDY^K3-DV4LD>[I.:,=$<`NI0LDLH]-G>Z2Z[MUOE3Y)YZR*6.']
M:B'J"GXN\"\D2)!U@VV.J^83Z7[]S]%OZN.?^"'(EY^D<,<J$XYG@C)\\;Y;
M4+`I$628DL#V+YPY%./2;62$L+^KR1S*`$?8BHH+B0H@;7#'R3VG0KDD-\7X
MA?:^<ITCF34(9-0@B4Y#@)3E,'02F*(`("&N=EQ;/%1+YO\`+S'O!OC3D+D-
MD$[9\>OLOD^.J.:0(PE\KY7G"F94/&=<$2++JR-CFE$P<*I)*^ACR+NCE\:)
MM21$0Z"VYU6NYG\KD.&/"K+_`"GO+%@QLV.,4I2\75471G+:3S18HUI$4NA1
M2SE-!>4!YD640:DW3*JJU244$@=I@`2T7*"VYUHF-^GCP5QWA#AW@ZH9FQ9C
M'(6;Y6JJY+SC=+QCRG6RRV#,^8))UDW)3F0F;!"R,BO\NL-F/'I%,J)4TF8`
M4`#2,0(A]2K($R<:+P&^N71F'TYOJ+_3\^ICA>FPE0J!9J-J63*_2X*.K<"Y
ME<<2"JLVR&)@VC*-2<9!PG;))B8`2`53Q7<.XAKBF-DA,:+</-$P*^Q6'L$%
M;H&O6BJRC:;JMRAHJSUN<8K$<,I>KST<WF(>5:.$A,FJWDXQVB<ABB("537.
M.:XMM66V5.8B8B38#B)4D@]P'.(%+T]G:3??]@:`5JFVJ/@02-M^!(HF]O4^
MW41$?Y9Q_A$=&<IL0D42E#O'\P_YBQOM4-U$/\D@?"'W!H4V+6K,(MXX;23Z
M+CG\BBFX)'+NHYD[>LFCD"E719.'*)U6:#LI"BOV&*50=@-OL`:I"FTJGHVB
MJZSYXT9J*JNO(4@-4CF5=)$%'U:IA3\KU^!!,F54_P`14MRAL41WNE(J[?%8
M5(F*</2R#N+BRJM&9(ENL$<R.]]#Y$W01HNP;BY&/26`IB-$S`@50.[M$0`0
M"@IJC4U5GRF*,Y?N31<<U!X9H:2!)@S!S+N&OG59#)G31[W9F8.U#)%$3&*H
ML<V^XCHS::E&\58\A8:3;GCI"$BE(D'C1X,0>-8K(O91J9%PS>.&XHBB9S'F
M13,F</C3,`;G^'8`H/%&2-]`UJ2.LZE:S6Y+^NDD2HO(2*=IGDD4",T)A^NY
M9JF<2B:"1445C;J$1*!2CVAN%;AS3:DKJ$BIQVU(XA(5\M&G;*$DGD2R7-#J
ML_,9@6%.JD92*49"Y5%'P&(L453CW$`QN[5(A_J4V_6AE5(:K)"G7ZY!,XP7
M(OEVL7#1\<L5Z*?A&0($>V;&%X"(B05B;*>,1*)1`1'4!$C6DD,&]BV+=A%+
M+K.@C8Y1[(>!P:4%@Q1EGYF2!VK51>53;I+OG4>U5,D4%C=Y$3F)T*)BZ&+%
M^/%&2E6.CY$C05XZ/=N8=R@X8`Y9-O5Q#YFBY0:.&)S);MQ1;O52)"7QB5)8
MX%-L<=XS5X*MP*O&.C796KA*/C5'+'L68"Z8-3NXITF1R1,[!T9`SJ/51%VN
M4IB#T*JH`"`*&WA#&JFW@LQ6,8Z23V8,VZIF2C,J)V+02E9.0_K+(B0I"D+%
M83""B:8@0V_Q!UTJ%6<K$RC8AJT<(EA8A@C)'5<20,8YDU;23IVGX7;B0!L@
MD#AR[((E5,N!A4+N!C&#49C31&6!G7X-HW8)(5^`,A%,W\1%II0D2B>+BG1S
MH/8J.*1J1)O&/4P[5FZ7C36+T.4^A`?DC)*RJ=02(_3CZK56B+A(8MVW1K,*
MDU=1H^!T,6\:$8$(I'`Y-W^`0\8*?%V[]=4C1TVI42$KPI$BCUZ"18-31SEI
M'$B(TD:@[9.`<,EV+4C5-NW7:KM$CIB4A#D,F00_"&T(I31-M4J=PL([</3/
M(.%=GFF7HYLSR(CG)YIDU%$&K.8.NU4-*-&N_P"4DX\B:?\`%`-1J)MX+8G`
MI2MTDRD(0JK=--,A0(FFFB'PIID*`$(1--/8H```4`V#5C3ZDVL5Y3_4DETZ
MW=\*6%4KDDBVJ&4654?G5[FD/.R#*M12,X@W21=.VSV)3F%0*Z2(/A]3N9-Q
M\"9?K7[98L\W$SL:)/2-RP9@:R@#*1B[@,6%#JU#$U71O5$I6LJS<C\0A-O;
M2OT]NJ\_D4:M88RD8GO#2"@[[7HL4:)?T(N.5@YEM;%JZXHHVAQ69)D\^3S+
MF3<QKM\I572K$)2/74(F,8H0OT*9S</*O]Y[;.5S!E-K]G<=\=FX7(P$P0\=
MHG&/6&XQF`^\%==B;639AAS_`"[WX".18ASXU!)!9QR768_RK8&(Q6-;OC5:
M\*5F$@"TZ:K,U7HF0B89RDM(U9.:NSQPYH3^IOHD$$&\LHH+>-4`!375*D9(
MO!W'M.-<W]T[7F=`79S-R$XRD\PPF8VP!.-P2<F#>:M`[K5N^8?DY=DSE!A$
MN`6X.?A(Y%);7D:.R98(@;QR`CX^3!C&DQ[3L:V(M@A\7PZC>,DF5(JTY.LJ
MW!2,TVCY(K8LLJYCDRF;@NYD%/$`:X,+M=SM.)+^G]ME*(D3=N7QTYWBY!F8
M1,C&+UV@3-6C&JY;F4,B_NOWQIY8Q+B$>$:L"?%QS)*VF/,ELZZVDJU2<JUW
M*%&E5VK>9Q!.VU+'CJ<GG;F';1ERHDA9J\QK$7-Q+QX_53C7/RLCA,AFSA1?
MQ)G3QW/M%W*,,SN&%=P\^#RCD6[9O1C$`DPO1A(S,2-HWC?M=P`[*8]T61.U
M;NB>.?B@9;7(XP<:_4.;K1VBZVG*3E3%U<J$9C&C1DS7I:94NCDL=*>I:NI`
MT3*VJ8?-GQGIB2Z*)XN#C&2R_E7`[5N\.@*Q?-QL3"[+`=US<B>9GRC*$!;8
MQ&YMT(1>)#Q)$[DI-0O*(DRXI3N91^7LB-K'<$OJ1SD>/@`/K*YQQ:*XWKS2
M&PLP9P\#C>X1=TEL@3$1#1MAF'Z[B"KM0*FDZG[_`&%DA,M6\Z^]`FWCBE:.
MV*)P23;&4UY%O"R[V9._WZ6_+RK,K<+492(C$;I3-(VXDP)MQW&4G,9$.2RD
M[Q&.(8E+<);C(Q8DL!&KFA:18<ZIPJ`YK#F<X?R<8PD6D?._47&2@XIFY31B
MV3YS6J"Z50]$Z;+@HR8IK+G433.5UZI05E5UC&[C^'E_-6[/>;-R<3<M^FQ&
M4B"92&^Y5W%=`^C4`"\S#F)0QKL8@"69]5(AAR7U5:_+H#+Z4C51&B(T11WY
M;OCQG&+/$BG$W.>58XNM[M&&QT>/3ODFLA$.%46=0/*P%IC26%94H`U%>-?)
M@KMW(J!\(YG\)7):_P`0<%Y^?3BL>3)R#Q$ZD?I_6/&5,=U6P"7DWEO(V!W^
M;'!"C*&;H7.FT^B46[I2,V]2*Q$/E[(J;8$U%""3J;,!Q8?Q^Y;NRJ1N/LX?
M>5[%&*!@$I@`Q3`)3%,`"!@$-A`0'H("&N1<"U_RB)^6'A/E<=\F48FC#Q'H
MFWRP\:=`6IX\[#Q>D,Q,V,*8I"3QB0>W;;IHB2QU9K</&DAXBOPD7$)F:'3B
MHZ)8,8U,[!-HDQ.1BV;I-2F9),$"I"!=TRHI@78"%V(E4;#Q$,5X2(BXZ*)(
MR+R7D"QK%LQ*^EI%3S2$H\*U22!U(OE?B67/W*JFZF,(Z(HI<\EX=OQ1RPM/
MU1U=(I-A!'=P+>2I,&@H4MHA3%D9BQ9$K]IJ%9KL(<`>R,DZ8K"Q8H*K)=JI
M"'*5CJH73$#*P7T\OU$\N3:1MT#?R9-AIANRPA$DLED"<,I%UW'$?@.$R_2;
M-/+).@9559TREYM661:.W!4G**/@+?XE.CAO58.I80BV5?QWD'%4<^L5IDDZ
M+DF-A(6<A`/++,D"L(B`08M65=<LV*2K$[EHRE7J)_5R2!)!PZW+$M5W_(NL
MVZZ8)RS4*$W,[N=GHM@@JTV^;5R#16EY1BHS:)OY.WT[(E60BC*+?UPLA`S+
M15KY$U&3DIQ1.04*C?\`3[X_YKXWXUN=!S6E@5&16NI)NN!QDQS6\-X8-#O*
MW"H.CP.*(2KQ,E5)PTPT<?-%I*5L*\HXV<HN6C4Z$4P*R()<*?&BRC1%#',G
M$=K?;2[NU-LB55FI50J\TQ?,5'D4_>@4I#R*!VRR+ADZ<%(`K%[52*'^/X3"
M83<D9L&*P8.7"X5MQ*RDW1.E_:'5C`=L5H/^SYD`!`ATCE(`=X]`,D`[?;UU
M=X\4VE:XW"BZS+]`;%DF&3CORRN1BX=^N^,BF!2`1$'CI%N"GC*!0,83`78-
MRF]FG4`X*;#SHIX4JG0=`J\/4:XW,WB(5MZ=N"I_*X6.<YUG+MVMVE\SMXY4
M.JJ;8`$YAV``V`.,ERY6P&#!=3J*HT1-O?V7JY?%:GR:PROH,D)O?403STK2
M"VH]X:_.;.GX%O75X/5>E%'=/^NNFQ^[X.TW9.P7NEA]UCUL>UU.VF+78[I7
M?U.-+IV2XVWO+OW5_+A<BWF<=)]7XOS'<>P3^6S,CH][$]UB>R%C]#G1ZV4-
MIWX_FZ1@\?SKMF6[RL7(UUM=V7SO?4!^9&YC9E3<RL(QK(\/*OY0DE6QQ:20
MY7K@`]>1D2PE[D]8`0"`!T6XM$U>T%-P$VOT!Z"G"WZ.PY0C<EDCO<F$:./E
MY4$I$6P7YG<1HNB]\AN[I=%`^*-=/BCJU?<R9SBO0Y#(=KGL=QTY57:"L.@<
MZDA#6-]7[@2-F8Y\T=N6$A&5LYXIH[:IKHF!1%\BN=,P%*'>(>P]:=U_I>%:
M[C<MWA<E.C3C&=HF)$@X,JR!((K$A>K[/B3SLJ6)$P%MB[Q)C*KNU*^-"I?(
M?3\RHQAW-*B\WD9XV3=0:D%3748]F2UUI$1CF*<-XB1EI)TE'&EV2Y4EBH-4
MVH@'>=!50J1D^C3_`')[;*[;SKG;=W=([MUP3$#(EB"1`#=M-0[D:`@$OV2?
MI?*Z1L1R(_*EJ;26;D[L_P!JZ1E]/I"NMA:40*'32@LKX'@0SRU32#(ZTJ[2
M8DF[2ZD7OA0=3;OM[>P?&Y4(/<0PEUX4_P!S,S(O&[G=6]1MN_IQX!]D``[1
M%=7`.M5L^E;8AMLSZ9YLY^LN4K#@"X8@LSC5Z5'5^1=S+RQ5EU!+3D7-2\\+
MSYPY64FSNWK$R;60,@V225*9JBH82&*JHHLH/[D9%QIWX7)Y$1$0F)[3`1;:
MVU@68$N"YUHP"7I:#[M\!%Z@Q=_K]M.7!:1O]/NU5F;)9<2W2OXOF#)3;B75
MB8J4G63N9?L%XZ%GF+*7DU/T^XJ:2Z9&22"GIB)I)]I"+IIN"^4?W)M9F-\I
MWJQ<S+?EVO(6R(`N8DQ#S$C\1-2Y<D$A8/I:["0NX]V%JX#P&ZIT;DW#DKX?
M@'=HAE)**Y`AY&XV&,79VJ]2;6:?V:<*LE'1_I?724L_>L8!RPA&R*[;RJG6
M%`"^842@B7%_]R,2]=A^E,<"W)[=F)CTXL27:(B#)Y$@D4]M4AZ7NPC+\Z)O
MS^*9!=S34N0&'!==@+A7;L$9=1RBVN$+84@@)2"4KY63B&-X9,6IC$1DTA>E
M,U3<,D51*9OWG.0!$P"`B;Q_4/[@VO4'9OZ7\M.W+JQENW`CRO\`A:A8D:Z+
MG[=Z;.#F#)ZQE':00PX^.K*="B5O\ZAS0L*F8>XITS3;ON`WD,;80^3`("43
M"`[Z^?&]:&CD^Q=KTT6%5&X&%,Q(R$3[!/W;3;KN,0Q-NTAC0Y@(/<`#OL(A
MMTZ]=09$!P*A$CHCT]K`I2IQ$$7L4*<O^VW8B80'XA,88<3&,8HB`B.X]=7Y
MB/(_4FV3+"Q=N72,I\S;HH/XR058&(W7.[1%5%LU=D,S[D$3?F`N`=2B;I[=
M<P,9,8?"R@+CQ6W.4SA)05!\:1TS;)%-L8Q3%'85E`,':`@/4I1V#WB/LU';
M15E:4YG#<"H;)(J(=%0*&X@=/J"">W;MN(_$;I]@#K1#&NJBL*8"-3^F+W&]
M/NHN<>_<P(^PY^IEE0]FP#L'VA[-3CYN:JM4+LCXT?S5C@D@9=0=RI@H8A#%
MW#8-^T1_+)M]XAJ\7.B4*QJ'("@'`YNU(HJJ.1*!SJ*#N1)!FD'P[AL80V#L
MZ`/40W"J),U:"\,#E8W]5$_E!$AC&!RN0PE3,NJ.WJ$FP`(%]I3&$1#X=A,D
M6IQ5%5O?_P`G[@Z!KC6E8HFFLF=)4A5$E"B10AP`2F*/M`0'_P`-]`2*C5%H
MR%69NO"H`*IG$J:9U`^!VV.;9NBN(AL5RU5'Q@?W@<O=[AUR4(<+#59*R@46
MRJ!Q.*2)E4DE1'9=H/;W)%5'<3;%(H4.X=]@#XMPZZG%QJGL618?(W`RH@18
M40.@Y)\(''8JO8._L,)@#<@B)3;;A]P4+<$U5[K\Q-8JNR2Y4E135(&X'``$
MP]FX#W!N&YDS;_=]NI$UIHKIKJLJ@`H`IK@":O:IXU"#V@<O:/<9$X[["(;[
MD-[OM#KI[-$TU5$_B213<%`#"5(2*A\!3'[`V[3`.Z*V_NW_`&"/LT]B>U6H
M&%)),J@]R>YRIKB&VP`H<"E6*7H41]QOPC[]M"']J`K.G[5@]P+C_"9)$QO_
M`"A'4.@5!JJ!T7/M_&02$0_8HL`#OIP3\2COG'"B^1%F%@KCELSM3)L9DHD\
M.9!G+L6XF7;IG<D*<6KYJ=0P)G,`D.0W:;MV*(1G7%=MF9>/Q*/\9B?-T0"B
M?Z7[RF`J(JISD&(&*94G0N\@`B"AP+U]X?MUG:3HN'IW!J/N71.*%FXY&XDJ
MBG<V;BB&\U![=@G7.<H_[2ZE,580'[0'3:53;F*M]RYEAQ[RQ99!)*9:L:Y&
M'.0SA\]DV;T4T1$#"=!E'KN%G2X%'X2B*9=_:8/;HS(+5R6M`IYU.N1E-@(>
MMQ*0C'0S8B"?G'=1T?O,LY<NA3$FZSUP<QS]NVPFV#8`#6EY48B,1$:!>3F>
M?HTXJY.9:JF<\V<N.=5KR=C.P'LN&YN.RUCVIQN%'Q)Q&P,!QI6JUB*/@X12
M-?LVVSHZ2SYR5JEZE=<2!K!@"7)+K8++U$Q=39O'E)A*E9,G7W,\O$&>^JR)
ME'])?K>Q$=/W#Q`LZ:B5:DUI0T<W6*U2.WCFYSHI%%45%1,H;:B\B^3?T+./
M'-*ZL+]RPY*<SLV3\#'R<+4$Y?(N+:U"TJ`E9$\FY@ZS!5'#,-&,F1G78)SG
M34<N/"GYE5!*`AQFV#4DNJ)-HRF9B?A=9\-X<LV%:OS?YG3,/(1E8A:'<K[;
M,1WK)&&HJMNQ5.QQ];;#AUTN\2G(X",''S].:%NU3+Z06Z@>36A%@SE1U`A;
M_N_'%QQFL.33CD[SX5Y,!94[B7/IL]U@,CDLZ+0L>E+IR1<7%03,E'%!J5N5
M,&I68>F!+P?EZSTH^+JO1J,O7ZI8@088>=X9RG=[CR/AYJ"L]6N5DS4A3GME
MOE7M1'[22@K8E2*I2JP\9$AI`S$IDHY!4Z!0,H<ZNZ@[:C&JGL7E'QO^A/@3
MAW,SUCXL<KN=F#9JRK$^>?I#+N/G=<F6#59=2*BY^DV7$<[4[(C"I+BDV7?M
M7#Q-,1V6W,<38%L1T)5W/JO0_ECPEXQ<X\:-L5<HL71.3X&,%1Q79QPJM!WJ
MG2R[=-NZG:7<X,6,S69)\"8&<D;G!DZV`J[=0A2D#9`D&*CD%PHT8YX#\F,&
MUUG0<)_5&Y)L\9P[=*/J]6SKB+`G(ZP5"';E!)E#0F1[;7H"VN8Z/;E!-N20
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MJHI.99_(O$TEE"@KL<V^96Q*I)5C)G;5/'PPX`P'!EFRIN+N2O*B\8:AH"0B
M*Q@S-%YI5]Q]3C2#YN[(^J+HF.X:Z0`1YT%`09-Y4D64'"@BV$>T2V,=HH2R
MA+E3X4ZG0`?9Y#F_>""NP_NUH:%0H7_FA#V@*B("'^**Q`-_`4=`A5JRAS%6
M*CMWD(IWJB&Y$S=H_"!>GE5Z_A#H'O'W:`<U"51("IE!-$OD5$J?<8X[]H=H
M=IUC@'0-O84/W``==7Q.B49UC;@"::>VZ[@Y!$1-[2@)Q[A-[011*??IU$1^
MT=#]B4]ZHC\`F'^?<F5<[!MVE(7S'*(AT-X4OAVWZF/]_L"E_<I3WJJ.X'4$
M!*LZ,NL)C#OXD"=_8'0-Q3*)2AL4![S[?9U`?L9&28#B5LH=,^RBG=YG9@#X
M3KJ;%30*.Y>XHJAL`!L40VZFU6KX*I*L"IU4F;0GB\?:5+<G>#8XE[CO7`CO
MY':380[0'<"F4#?<VV@8!RHMT@@DV2!%$O:0!$P_RCG,.YU#C_&.<P[B/OU@
MDDN5H!EEU%5IWK+L%5TW$"E-LJY1[3F3%1(NZ;M,A-S%62V$#]FQC$$=MQ#8
M>2,N!62A%8BIDE]SF(J3L%0HAZAJJF`G*;O+_P`X;G)W`4X;@<H`(@/M`:44
M2I/8#*%6$NQ5A,D[2$"@4%@(J`&$O\UW"<>O5,WW>S4/@J%5(=D"IN2@=(IS
ME*J)=BE$BJA2BH```I&V]APZ?LU#K35!K57-Q4203W[ED3%[NX?B7(4XF-\6
MW\^38>H_CV]QO;H:GQ45&P?U=-5L8IB*]RH(F-^68%#F.'C,&_B'8WLV[=_<
M'MTEJQ5'@M6]>KI^A".;HJR$G*&9)%=.#M")`*#I8IUS)(.3*)BFSZ!VF*._
M0=#Y8F1T`_L_M62[4U68&UO_`#/)&5L_D[`,`R\AV[$(`=`&)-_&W'V]-]<'
MS$.`DI$7.+*A&UQ(<1%C7CE`@$3*:9D3&('>(F_,&([C`(`&V^XAM[1U3D0/
M"2VT_!90;7%11+MC:\8Q3&[2%EY$1.8Q!(7;:'$1$.[H&LG(@`^V2-,ZLHE<
MF^)]EY)2V/9I2R0M/"E-9AMNV06L/S5"8<PZBWIU5B1Z#,"FA`*8W:N)QV`=
M@(!==T]*>M;7I:.3;%J5[KF)%=H&UVT=]=%U[NW8Y]VG;F;@@(`@C5W(_L34
M..`,V^@(Z`DKG!/$X%VK)5:1".D6<U59%.0C9:/<04LS?(N62996(;N'*9=@
M543*=,45`\FO9P_<<PR99%G%(%P-<CU'A<BQCYHF!!+2(!X+PCZ6`@+?6#`4
M\A<>PN[.-$@6^GS<K8$4GE_*K;*C6(@THMLB_92\"Z5?L'[UU79J0FF$NYG'
M[JKMG":+4#N>]8$">I472(DBGRQ_<FQ@]278\(8=Z<]QD);XL0TXB$AMCO-2
MPHY8`N^/]+7KNWYK(ZL8AF(8_P#>U+>*Z![P"3D6SJ$<+4!"FR#-PSDJI$5@
M\(V<>H6=N@=$E6*GSE-TT>/EE4#'65`GF43V%!0Z)O&A^Y&3"0NPC<.:)`BY
M*YN+!O*Q&UB``0PT!U#K9]*P):4X]-M-O/B^NOCX:*DCP#^>HOF%E>46PQ*X
MN$XU@[KBS-S76#AK*1P1T+.1JS6;11:Q<PNW2.=90P%644-WK*'4,C^X^79,
M;F*+UJ^&W$3W"9>,GG&3Q),H@FE6`T#(/2T'(G*$[9#`$,PY`BOVK1DX"Y)A
MV<A7*1FPM,H\A/P[]2JQ<=*%7+6(?UQD*2:RMIEA,.(8'#SO$RHG%?8`=E=&
M*50OD3_<;M]^[',S>W=?N`MF/4G.AF?Q]/:8"34IH-&T4CZ7R(0-NUD;;)X`
M5\!N<$CPX^*A5R,Q^?"$A'8@B$H8M?AV$=(M6\?%3:38SARS+7322HL8^6)+
MSK&$K#3UKMP9(3`J0J*14]R:[]Z1[G'O]BYWN\+GS4IR!>49%@TA&-8[8F4Y
M$`#VE=<[UACMUX8H(($`1P#DL215RP9_J2'&#9XS-PO:05GKEFCR<_UBR;Z+
M*+=J+`E=QB)EFB-SA(.=4>R2Z2)Q!@@0_C(!AW[5!+Y_<[D+I[Y/)M7;5S_3
MXVB1!+[[M/RY&+`$CS'7W*X4(PMXL82C(?.C1^4=7`-5]2VOS"OI2-$1HB-$
M4?N5S-Y(\:<Z,(]!%T_>8ON#9DV<5RT6])=VM#.DVZ(UBDSE9M\X914P`5O&
MR+%ZH80!)=(^QPS/X2MV_C'^Q>/GTT\M<RTLF8QPE<&SB*XZP=5M232)_P"P
M;R/P\V;)Q\._>0Y/[;<MYFR*T*I\\5*;L>^J<OA$42*%$0$,0)=N'T\%S71%
MMS'=S=__`)BOH$URKQD:(C1$:(H]\J6S)]@>_1TG*#$Q$FSCHR:7^:WJ#2=P
MLC,1[*6B'<MC.-E;XQ8S4>NHT7/&)IN?"L8`60`15(5&J\ZIBNK.>!N9V\#5
MZG&5IGEA2SP9</TZS/V3RJ1S:FSMGMDVE?,96W)=DG'LNE++3<RZCPGG!O(J
MTDD0!LZ+%O\`%53`^GVUCHKC9!5]E0X/&KNNVR\Q4Y3H'^U`&L?-&LCV3<NW
M1<Q-D+ZG)S:$BD^<%='<IE4<[(KJH@0VJLRU3G<NUIU'B]GS]-1]YDYQ?%5S
M91[3&:<<K?!4D(5TP4<5=&5K=R:+2;%!R=<I`B)1<Y4S`@T<KBFB<H-0HM?2
M]AF%3PW<*14GW*:;Q93[C%PN+;%RC:0T/)2]<1HU6!Y_9K6&-$HLI5,=,YL'
M!&D>Y+()('$WA<(B*T>R+4]7+.I@Y;:VE!S$V"+N%NJ\)&LGZ+U>K1+"P)1\
MFLLT5935CKCB-?O+!7DFZ2J2Z;;L5;=X*!\`G42U%M&7%)^"YO&.2<HV1K#N
M7]>K-RKKF>>0+^[5-Y(0)F98]9RR5E5*M86X*R$>Y<$2.1=F[.'A4,(I%,02
MA2(CP*@,O<O.OE?SMSQQ8^HU6:)6N.?(/E/Q\LW#Z%N^5:[Q]KB%SM6"I^)S
M%?(>$R>WIRSF.5M3>\Q:SF.>Q[-Q\T63A$56J*_IUDS87/&(E'4`NIT<9^>O
M$KEWZYA@K,]<L5SA2B%IQ1/HRE!S12W"28'=-+CA^]L*[D:N*LQW*<[F-(@)
MBB)%#E^(2R8RCKHI?Z+*-$1HB-$3;WYH#J7Q8I\HLDIZ+)";L'$`[%LTA!"C
MWAM\WM*8(J^MK8>I],*0B0/7.6Q^[X.TW9.P7NEB=UCUL:UO[:8M=CNE<_4X
MTNG8+C;>IOW5_*A=#5<=*]78W7[CV"?RV;?Z7>Q/=CSVPL?H<Z/6R@QWXWFZ
M9AY?S[EB3^5BY&NMKNJ^=;Z@L>W-S:RF5LO*C,3/"N#*1..0;*MF[=GEB+,D
M=Z<Z@O3.'*[<4BHIIF(H@J<P_&0"F_0OH"<H^B,64P.A'OI=R7)Z$M.#`5)\
M`N@^H(G^I7GH)8T6/CN#_P`$A^GO(1K/-D34GXG_`%6V9VC^KH(N$XJ+90["
M!&7CBN%/3D>RBKZQ-E-T2+M"-TA`%"J]Q=>'^Z%K(N]E&;:$!@F[;>3O*9D)
M;2!PBT2[L7X,GI8F/<90N2)N")8<!0/[:E>[_@#^3_Y7_O=?`JKZ&Y7-W2'L
M$Q3+E#U&9+6+;+U&SQ-4LQTS+DK=HDH)^RKU@.B4#G4)"S"Z+D0`IA$$N@"/
M30.KN/%>!E1X[<U,2<>T8;C+Q3M7&?-+.+XV4_D?DR(SKCB\Y&Y,R5097PF:
M<A8QK4Q>Y+'R\S(VQ]%R9KI8WL';[#&OW;)5LD#-$!JTX/Q%PG(L6`/J36]S
MCZZ90R+F6RRU-Y.8B<NL;8XM6"Z507^(D^&0UK(%V?U@A54YINXY36>0^=1;
MR=?`6((L>,:J%39K:,4W14>Z#PA^HKC%Z^RW0(9!MG^0QW5(2+E;A-X4DX*E
MRE0^F9`8SAX:GD2CCA68B)Y0O):)8M$C*1)3)HNET3L%'+EP;P5,@?9_>I*3
ME>^J',7#C_%4)GR9JF,$9D[?),YF#*7$RP7]Y0[)D6T0EF0R:VQW&14?'VZJ
MX[=1TE`NXM6PN0)VD,!'K9=5=50&(Y.L'![&GU0L?9*XR53-$ID1I@"C8%QY
M5KY%W>;PW>?63<%B"=ALA-[O8X*VC=7F2'6>DVCZORS%O*(K5`&J3M4BQGX%
M>Q"8M35>XW@#^3_='_QZE5ARCP!_)_NC_P"/2J.4W4>1-&3MBA]A,6S+I@;J
M8P]T7%=J9"^WN4W]@!N;IKSK1\@`Y?Q*D2/M2]!,1`Q7&Q"MCB!$A$.TJ6W>
MBHN8!$%#`F(!M^$HE]XAOKD?DM(0`RH&3'N(@D<Q0`?@463-LJF(]-TD>PVW
MMW-M[@]H_:BQHE\S8R*8^-ND"S<3%'L$Y2]VP)^P4T?'MN;VB`].G4:36NJ+
M'N11JT,)1*U[FH%2(4>]P80^$`*&P@03AT#VG'J;X=0ZGFB3*)F=.C-A_P",
M5[7)B;E(W9MDD3>F2-N`=ZBJH`<??OM[-]J"P=1;T"%*`%+L!2@!2E+T*4I0
M````V#8``-M8HM.R.T/OTHFXH[0^_2B;BD4BV%PT4*F`"LF`J)`/L,(%$#I&
MVV^!5,1#[AV'V@&K$M+P4)29H<51%9,W>=5J@L)1V_K*90425*;<``'#<X=N
M^P;^_H/2GD=$53`F$>0-NYHNBBF`&_X@RG8GL/3<$@$=O_1F^[V7\7BB4."_
M!Z=41.195-%)40W-W&4#X#B'X5"D`>T_OV^WVP:OR5=9G#=<4A06164!P)4&
MZWB/LHHJ/84@B4OP."]VX"'XMNG7IJ.'=UEQ[UE4:NFZ8E<-7!T1*!4E3('`
MJ@B&R2"P=H`"QC;`4?8?[AZ#-T35U7#*XD>]:I$370<"B4@$%91(WY9M@`Q7
M`B`@)!,(@!_W#]HC*)JCCP6)%@]02\GI70ME3'6V].J)D"G,)BF#X=S(@GL(
MAU$@>SI[*91/&J`@+*FW5,997Q*"GW$2(<"&$INPHF-L?82F#O4$.G3IJ/'0
M:INKXK$)=URE'V)I',.X>P5#`4O[Q`AM7@J[H5*`BD0!ZG6)T_Q4]UC;]/9^
M7M^_0<T<E56#M15,&^_88`]GXC!VE#]YA#0:HY(60"```7?\(`7[OA``Z=/9
MTT1T=H??J43<5'K(%QAHS*$"E,3TG&UZBUUU:K*S8JR;E&1DY!0R-<9KP\81
M8[SY<W27?+',02))%()Q`-MU'7%*;3#Z`)V;3:JY7ZNYGYB:4BXAQ'&50DF:
M:KAZ"3MIWI.XULB@NNJNBDJ"I1\9@)L!C[!I1;,P`YT5$GT53*I$'F[#(2#=
MNVC6"4Q+@9S.3SQZ!",2"U:MP</IB1.H`%122%0P^[H(Z43=MB'6TC)Z'EX]
MQ)M7A4VC)R^92)GQ18*1;V,5,C(M)-)T"9F2[)0OY@'V``V$!$H@(J*[G#K@
M:5EF"N$BI&BBXC%7\I8&]067;OA96V'KJI4'<M&R2C-&.46%0%#"W354.1(H
M&$=Q$`468W=Q;ZEHLDS;9'(>-X9>7DV,?&I2URL32/6D%`E&D>*36O11HB-!
M1>6=/ITW<FD5-0PD0/T[0,(%)R\\1RJG;KT]#VN%C[#`N_6Q,HB==HY%)5N8
MQ4U5$5BJH.")K(*HK)&*<IP`2B4=*+8FX<:+6,[M6)&P(5B.?JOY9Q&.Y@@-
M63P[`(QFX3:*//F9D",5$%7:GB2.F=0JBA3``[@.E%!<!+#5:28RQC^">R\=
M(3BGKH-NW<R#=G&2<@<$W"RS?9KZ)FL#X[91NIY_$)P;@0WD$O:.RB&X!3DM
M[8[I5JDG&*V"63CR2[IHT8]R3A4QSOCE3067*BD<63/O.`&66[$R#N`CN`AI
M1#<$=5S1\QXZ1*].I-N2C&S+2#>I&A)HKAL]>F:D:++-S,"K(QC@[Q(".C@5
M$XG`"F$1`-**=6*<%9RTC&:[F0=(LVK(ZA%W"YRII)_GBFF3<>ICJ&.4I"EW
M,<P@!0$1`-4ZK6Y@ZTM;M4':%Y\D*NZ<%@I,D7(J+Q[Q@FG)%:I*.&J7KD&Z
MJJC4HE!;X0\9S=H]=%!-W9=&)?STA#<0.11+IL/Q`(*D#^`I].#*OQ695JX[
M"J%07$J:A#G$$S[`F(BF<=^W;8"G$?W:FZ.CIN5BD>^=I*$0;N02$I@\Q43[
MJF+U`J)M@V)W@`"H'M]A?MU1*(/BAD-"KDVCI=,"M6RWC[=CJ$2$Q4MP`13(
M`!L98`-UWZ%]_7IJ/'5T<>Y6(,W@)E:MVK@56X^)<XHJ'*B<GP]RO3=1PH4H
M"!?:.^X[!MO3*+N2@(6)%JNCYFB2*XK)J&,J<Z1Q["*_FIJK_"&YQ*?8I>@=
M.FQ=#*)J]$<+$FF9%1PV()O*"P**K'`!$H+)E.43=``ZQC=W:7H``'7IMO7!
MJJXX*B!2!ZA%,PD22<*BX6W^(XF[5CE!3;J?XA[S?Q0Z!U]@\U$F$`!"/,8"
MHD+VG03-T(BD@@<ZCQ4O03"F`!VE'[?M$=CAR!JCJ^)0$$3NE!,*CLYE"`)A
M$2-S',<@#OU[U3F$YOM$0#V`&DN7)/%;3M#[]9HKN*.T/OTHFXJO:'VC_P"'
M[M*)N*T"J0,7(%3`")'4(Z;*"`B1!7S)HN43`7V-E"JEZ!MVB;</?K;[AXJ+
M8)`)%7)B$$"E,EZEKMU*<2&$QTA$`*;O(&_;T*<!]QM]0Z!%C2$46)5D]U$#
M("<"$ZF2\V^PI@/4R?<<`$GM*/L^S5U+(LIR&;-P],/>D8A$B)%'?8RG:F51
MO[>G7?L]G0=MAZ"<$UU154)XT?*S,7O.!$B$'HFJ<P^,G<`["FH0?:;H(;=?
M9TCOJB0NR)&D:F!0V.E82(]IP`%$P^42FY3>T=C`7?H/:/MUPWGV>[^*AX>U
M.)X`_D_W?_>Z\.JKH\`?R?[H_P#CTJHY3%\H:%/9+XVY[QU58>5G;+>\1WRH
MPD)!9!_LIG)>0GZ\]C4HZ%R8:)GT:++O`<"1M)+,G+=NN)173%$5-E502Z\%
M*#P>Y^4^HL)#%-5LN")K&3/FE9,)*0$GQ_QW>YJU7C#_`!S98CC<P8SIEKR3
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MI/`'\C^[_P"]TJHY1X`_D_W?_>Z55!(7AS]06:79Y2D822ABQ;:1@X]Q4+>#
M59R$V]1FH^*N4%*_+Y%Z]18QB5@B1:*#&D*FY<J^1<43CXONG[7XYN=NG=M2
M$Q"_^;;<#:#`RMS@2U6C/>-U0`P?7H/J;<<X1D!&V10_S<P?>00HX8_BAA&G
M"TTTT<LW<5]0U@0J"#)LLBL^?US'A&;-R\442,SBF:+5P9!9$JAUE]B]OC'O
MUW7-R!E7.^2LMTY>G-2>`E<<@<2Y`(+<2O5X(,+.*#\4<MCX%H_6OJMU^60O
MIB-5$:(C1%%CG!"15DX>\EZ_./',=#S6%[_&2,BSGJ;5G+!H\KSU!5\C9,B1
MDS0X,[0I_)ZJ8:.(U`"][@ADP,&LS^$KDM/U`R@W]*RVYIK6">/6%(KC9+#Q
MNK]'F$*[RBD.2O&_)7ZE:ININ68/!JN$8B!BWWS>;<&9%/&,V[5`H`<X#L81
MD';@WO\`[%J[M>K[Z<!_`E>Q>MKA1HB-$1HBC+S`8.GF`;DY;E8ND8)U6;/*
M0TW(0455++"5NSQ,S-5F\/[);*1$-J/.QK-5O*F6D2%]&<^Z#PO<R<%8ZJ$M
M.MLW%\08^TJQ.2L&P&1LZ/%AQK2,9QB\G%XW?,'2;VHX;IUL1O\`&EHUJ0KZ
MTT#QZQC4'2#Q\X;LF2*[9+1:-9-JID<,4<6L<%0T/B!M=650AIRQ-"LLAUR'
MJ]O;23N0--/`EHV#A8)@8%R2J:R"P("=1LHF)SF,`[%F3O5;'FA7U+5Q0Y!U
M]*DR>1SRF*[8W_1$/;D*'(V(@1JJJC)M:W2+IK%=J:8J'\J+A)<A#(G16*H*
M1R1U"AE](2DO:K@_(4ROCU_4XZ^Y#86R!N0D@J]6\L0CFB55M'W"GXUK-'QS
M!T:%;(-P8^1")($VJV,_\[@%BB6+4]5Z171'*!9*&?4%Y6%6#=!^29K]E:ND
MDY)<?"JR41G&*AW<4($352`Q6[HH**$$R1B]PET&XKC+\$5JV695A`I7*E3$
M'.S$S*1"B$;Z6>C6"+!!V[:S,I)1CA9M'1TDW;`1,QQ`PN#E()2]P``@<#1`
M3QU2!G9,3FS;:*HS"#)F]CBJC62T*%AS(V)3$\C;<B1M'!W8C,B)OH-M;HFQ
M"@S!RH+-=194R:8.2F4BU5O!?-A]4'EK]'VL<Y&5BYHVC'&48RF<2INOQ;?$
MRLA<,RU',)<SUR1B&-:N&(Y)E;L7WQ&MM7*B+E6:A5$6P'`52D.(&+E@)[6C
MS4?.'7U$OJM94RO#H?3LXC\H.0/"-4RJ))GZEERK=:?MF9729B/<?<D6\+'V
MMS%H1_P@WF'&39$1$!*<HCVC*JRC`#S$;O!?8M#KRCF(BW,W'M8F:<1S%>7B
MF4B:79QDHJV24?Q[26.QBSRC5D[,=--P+9N*Y"@<4D^[L"K@6QT1&B)M[\T]
M5+XK4^4V63]%DA-WYZ^Z],SA=J/>&WS:U$\"WK*T'J?3"ENG_7G+8_=\':;L
MG8+W2Q.ZQZN-:W]M,6NQ>5S]3C'IV"XVWJ;]U?RH70U7'2O5V/U^X]@G\OG7
M^EWL3W8\]L+/Z'.CU<H;3OQO-TS!X_GW+$MWE8N1KK:[JOG?^H_&R3_EW>Q2
MB4$V`</8=)&Q'B&ZJI)H,N1JS1G\[-W`DBU*0J_HW!%6[@X!WD.EY"#^@_VZ
MG9'I#&C*1-P][+P$B/+\N7+<^#AB!H79=!]1U[A<'_2C_G'^Q;7@6[6D\X0M
MH\#,[V]1LJRO#EE7"HK?K*@M546TW*69P19XJ%WKMC;J^C\@&4D8QXY$PIF3
M23]-^XMF%OM`Q:B-B]&5L&1K;O.=NW1[4XR#\(3C'5RN;TQ.,\TW1&(E<A4C
M42B`'?\`W@?K!7N<#0QA'^^(^W7Q$N%WO<57T1ON_P`[4<J[RO)'ZEF=N6F`
M<A8!L''",F[?2(7$'+W*.?\`&4!5VT].WRH8Z@<31L.M2'ZT8[4:90Q\M>W=
MEA(P%DB6((ES'"FL=9/QZ"U$B0KX*,:7U4N0%%Q5'P3_``TRR-FZH8C"VS32
M9A<C1<M<8F)X"XEY&0>2)E"`KB<5%%R5F^T3E8.BS3`A#Q2Z39#U2"R1"TWC
M1_XJ_,7/GG)`L+-7Y2DXMQR\KN8PK3/)='J^7YR%1AL,<[>/."\DREWAYR)L
M+HV-LEXJRP]D1"*WE&$=$O7*#H_>11F?@H&/'Z,LD=]67DV[L5<B1XKU=S&.
M\,Y(R(C-(K7R+;9@3IK/DHXB\FX3:31VM@5Q6_2PA!/%(]U&O94S&XH"+QL<
MK#YH1O%>TF`)K)%XPKC&[9:C:A"Y"N=-A+=8H2BIV)&L09[*S3FX^$8A;%%+
M`JZAXM\@V=JN`2%9XDJ<J2)#%2)"2L&2=_T1ON_SM1RF\H]$;[OX='*;BF@1
M(1&=M[G?8I+*HFJ)Q^!(HQ46)%B@/0H@)A*<W\D?L#7FVO\`#!YA2*7'#O43
M<'+_`%?<J8D,`AWE[ORG"H?R4U!^$ON*;<?L#EX-Q6T'W46*I[&IQ!!4?>N?
M<12$!]G@!01*(_QQ,'N#K/O1`""C@P#L#4Y?(`C^%99OL53[@0(3M'[#B4?<
M'6\/%$F$QP3*?V'3>$2:)F]I4CK$-YU`'J`F;J;_`.*38OM$=.+<&171A0$'
M:P"8Q5'*B:0F$=_&DHJ8QQW]IUE53&,/OZ?8&DSP\%%M-<:JJ`"/LU61*R,'
M)B]YB`BG[E%S%1(/[!4$O=^[?4)'"JFX(\+9,?S'(J&#V@V2$X?:`^14R0?W
M!U1HZ.ZY\#M&RT@@W;*;I%/Z47"^X$<&.LND/:B1+\M=!7QB`B/0@^\=41D6
M)-%`.:7@\4!1`4&J!$OQO$BMB*BD=N'@!0PJ@H/\Z8`4'V&`H&]VFV(U-49*
MA"2.N5H<K@&J8=B)1#Q$(LL0>QJ<P^,`[4-Q((COL8`]P;@P#A*`JAD7RS@&
MCMT!R)%[DS.'I/S%#%^%(XBL(`Y;I&[M^@CN!@Z@.QX\BCCDK%$%3KE8.'K4
MY.WS'.=R)R+%`1\;<XD*8!7*8O?M_&*3<.N^H\14`NCC1E59$Y3$8J/VIRN@
M,1-;RJ&`$BE'S)K&%'?R"3X2C_'[@]X#N>.K*..2O4(LQ+L5\V.B(@DV[7"O
MY2IOA21.8Q2[(F-T*;?X?8/3;1XG@K3DK@1=QR.Y)!(6I=SK%3?`'B.(B95P
M0HJ%'Q&.(F,4`'M]H>_1Q(LU4\O)*VOS@2'7*<ZWG$B@@*Z#D2I=NS<HE%0X
M[^/J(?:(ZLMO$H=JL`\@=8ZBK(IR(]R("HQ+L*@B4RP@8B90^#M`OM]N^LM!
MM4IS2=1P@HHBDHQ1#8WF6\2BZ1A32$>TH@914A1.MV_Q?84=:&GBJQX%*.Z/
M/T[72(^\?R5R?_L#A_=U&GP*55WI&ZAB^)ZW$O3<%"JH&]H;_C*8F^P_RM9<
MCXM5`2U5&6&QY;IT<AH3-:D8>1OMJDT+?:ES,5D`Q^R<$:Q%=J1VCMVX=#*P
M[<I%%3$21;@J<YA,H5,FJX7&*N)4)-?9X+J<E04U.R%"JT771>5E.3&3L3@5
M&[9@W9U\K56$K[Y8YO5HQCZ03257(D10RR;0J8%$1W"K4@2P&B5WF-EE+M0K
M,G$/[%#U9I;'A(F,*B9<UM>LVK6ON5DUUD444!0.X3!R8W8U,;N,(`.^AHK)
M]P+.`ZY1TWF,78;LSEXHB]O-E?RKXZ;4WE;*7>_2!&;&.8&.!?,C'*N4R$.(
M`!_`)^@#HH7A;/\`,?O*6U*BN22^/%5(Y[#U_%=4<Q44C)D(A)35JFVB#29D
MCM2*JF1CV*2:@%4.(&<N%C&*`IE`QB1C4/H!]JQEB[&SO=QNAJA)24[/'6I=
M)=`K'!'5NO0\204)R655>%69,+#-.53&,B11<$DNT2;G[3$8[C)JF@2F9J\M
M5*)0Z)6HF3LD2E+1<7<!C%FC-^\@@(ZD)E45'CELBV:SLN)4W)N_<C54Y>N^
MHJ08Q$14)5C&)MY[)>;+<81*(D)202@XA,JJ1F[.KP)_#!QL"W0$P_*#>55P
MHLH")EE3D[4P`!VJD=SDR^@6YQ[1)=O9;W?K#%#%S%EF%HN';NA:I#%4R%$&
MD6BF)5112/,G2,[6*4=Q`Q.[KN&HXX)%G,CJ?N6KO55DK!<V3Y[#?-*SCZ"6
MM4<P1%JK^N[X8'18*$#O63W90)"F4,*XD1\SGH(AW:`OP20,B"U!7VE<+#X[
MGF,Q1&,G#.9H9"1<Y1RC8%G#5O'2-],N!86"<+@=PZ6BZH5RLLW1(F<%UDTQ
M^`HG.7326=DG#\2Y7;WA[=TKHNZKE)6GV<-2GLM41<ND#PPWY11PBH]D$%'"
M#A]*Q\4@1-@@1,2BHX.83$W\A!TKHK+<_@!]JZK%,%8JM181M*1:K66$SN1G
M%W2*+F1>R<XN60EI*77(15`KU235./C(H<J+<I"B;N`P!GRGBK$`!CJG+<DF
M#D^)0R1R"51(IG*#?M.F("4.WR$V`WX1^XVJ&]RT-K423M<R*9@,_(#0X&(K
MY'WQK=!*HB`%.803(/PG';J8!*'3<='`X51PL22:RO>T!^V(9L)4G"P*JB':
M!0%(J/:F8!442`!$?83]NVCQ%62FC*A4105&/0>LR_"*Y%.];QH(G,(G*.Z0
MF,N"AA$H==P.!AZ!H\=65!'$*@MSM5R-FSQGN[W,8_J#_E*D`0%=P8Y"=QG!
M"B!0'J<Q/LT>)#L5''$*Y1)XS6(5J[3%1QL1=1-Z0W8)A$4W+@?*7O.8VY``
M?:(A[@':C:=0E.*O,$LV6*B@+K90/"[5W!P)!5,8R)SG_,`SAP?O*`^WXM_<
M`".PU)8I0I.=V=-P*:R#<K5,H&.11L0OD6:;E,D)BE(<Q4R&+N`B(G.7;W#I
MM#.'59:ITJDHBDDLU43567616%NN)3)E5%9%FW*"I5BAV>3R".X;]@[]!#5B
M*N"HQX%=,5NQ.4"(.!;@0H%*1RB/:`%````50%7W![1*&^L%^-2K4*TT>Y`!
M.F4JZ8!OY&YRK%V_Q@((G(/^4`:./>JX2+80WW]W0?N$-5D1J(M=+%W8*G_Y
M`?,(=0`R?:9-9,VW40.BH/W[[:W`^9D6+N.(.SI&`ZY?$FEUV%RW523!(!'K
M\?<I[?<<-_XPZUR!31*#B4ID!1W%`1\ZY2AU*1#X2*@4.H&!7;O+[^T?>'6?
M>BJ8!*OY"?$V2`5%2EZ[*JE'95$`V`0*D(B8`]O=N'7VN'BHJ]HBN+A#XR)"
M`'3+U(X4,4NZB8@/;Y44AV`?883"`]>NG"JJ2*"1S/TXQ0[DR6,J8G`=O*8T
M3*B8@^P=D0#]H''[AUBY$].1\/XA9(7`N\;<HEL>6^%9<@*DVR/)YE4M5/O"
MN+X]:*K.&#7*,ETL6OZYYP3EYXE0;NHL9@3%$55RK^/8GB'PBX5W_4RCC=,^
MY9@N9-^H3-PX5J5;JCZ*H..&LU25U[I.?]G2PYK;VJ9HJM6-DA:`4M$$XA26
M5C/H1Z#]HC%#&*J.UGB-0&CJ/[ODQE='!(RJ'(9=6/2N<DJWS[Z'%YUWTJTX
M/,>2+7&`J$JH496-7S6Y5B?3IL0E31*/R@''K`,YU%7K].:>N&Y#Y/><I+W4
M+K<&>,:BPH,DSBH9[)4.2A::[CN-N+\URN5+K0)"O1^0(^K5ZRVV79_J%6R_
M*7*T>6(5CT3[/Q(]'%2F<EN264VG'NM7RO\`(5X]K%@F.0=QQCE29+B%[=KW
M&XQQ`QN6'\:9`91%7)3XM_F*YDD)$D`V8LK06LG91JAV\B5R)2/5EZ/2E"Y%
M/R9_6B\QUN`/?*S"-N/;-QC]F_-@>RIU!5A.R%H4.N4V14'-M5(^314%$4DD
MQ1[NX?)HZSN6_9TK-*=WQ'+/LIP3JC5O'LW"Y@J25+9H2.2\BO&D`2&NL%.%
M.!ZA%Q+Y@^4-'$*<JQ'A2]Q03$%#IO7$-\:\HR8]@H5QR`J2V16>;`MD]=28
MOCTXN8PA^MGLR;$[6O><4F$_^C548D)ON$WE2%?Q[&\0'5W_`%)SZY5,H,,E
MY.GK+?HF>QC8&U,)BZ@M:RWC);'[F*C7B%U7E[.FH9:SEM,FJDNW*8I/1IIB
M3XA'<#J;OK7C[SIG_69OL57EHUDYJN-XJOY;4+.0[.:B9BV.T']5JL"T=I$-
M+5==:9.V>O1[TD9*.CETD1!<OE3^V_M[@B/9OG;);,R[US'#2,3&$6G.X1I+
MR@PC_+*0)I1=#]07Y'/E:E6S;`FW.1#`>SC[BHQ8_0GW3#C#*.&);3)R7U%8
MJ9L<HYBC2JK="0K6/EG,X@L(&;P3M(QTDSN2D3.L``*IE'`F6-W7/CC6[W=[
M,";5J/IO;`;MKD3GY2/Q#6G#@P8+U6'(SLV)2+S.>#[VBOJD#_"/]_7Y@=U]
M-5=$1HB-$4>>6BLTCQDSRK7&5VD9\N++E\EC\;S;FMWU[)C"NBLFM0GV4-8G
M<1/KN!*5LX28/%$E!`2HJ"':.9_"=5NU\8T]Z@]].')/,25QYAFH91P77ZGB
MPE0F%5[QD_E19LE<HB.4EI-U&-;]CZ9X^X\\LNX?G!%8RDB@+5D!#@500`AI
M`EF8MXK=T#<2\7Y!>L^MKA1HB-$1HBC+RU7C$\-S25FH6-,A4I9[##:XG*U?
MF[K5FZ+>:C5X1\:@P%7L\A<)!I8B-54$0]&5LHF#GU!!1`!*QU\5K.,Z..[_
M`(?C%V&+\?UJ%C;?-N&\'6ZI*P]84L#0#LWEHC:_;:K6)>+>2!'JR:@*ME#!
MW'*"ZQ#=XE3JI+0T!!5UNLT@(:+A&CATH]7;1+!K'-UGBJ:2*CI1%HDDF=<Z
M2!"B80W$I"A[`#1932<E:\SMN"LFU>7MM:HM:L-6D(6Y6NVS=AK$+#4F33]%
M;W2MIJMOHDW6'85]=P#>02DVX-5Q(<_>0#$,5&J:_ACB;B?A?&\Y5.(EJB[/
MC\+)ZZPJP^;9[-<>RM@0D4T>#Z^9N=P:UAZ_CF;=PY9,A9(*JG%R9#R+'4.5
MD22\DY>5H>7L3:`GX)K9[57B-#JJQM#O+RFV!$SOP.8^SP3AO(QD18C)MP,0
MS5XL4O:<IT1$>\A]1('M7'+FNZQL>R'JK4MG+-`\2<.4F*MF2B6]G<1!#A\O
M5L:,$Y=Q!9<J8B10R)P!4I"J&*0YS$+"ST5#M5?/+]3[Z7>2/J7_`%+<8P#3
M,63>/.!L=\,&I,UWK'"DNRELD_J_-=S_`$OB.,6!TSK$@J4M<?R+X9$DBE'H
M&1,+,YG29@RN:$Q"&CEU.;B#]#/Z9O"WY9*XVXX5N\7^,$%4\IYN\>5[R#P#
M%.#^.-8VYZO5WA5`[@/#1D:(".JLRN3EJ5ZWD(1,A4TRE(F0I2$(0H%(0A0`
MI2E*4`*4I2AL`!T`-%A7:(C1$:(FXOS0'4OBQ08JS2?HLCINP7KSGT[.&$*1
M>&WS6V$\2OJZR`.?3BEN3^ON&IN[X=A['V"]TL3NL>KC6M_;3%KL7E<_4XQZ
M=@N-MZF_=7\J%T-5QTKU=C#([CV"9Q\Z_P!+O8GNQY;86?T.='JY88[\;S=,
MQ\OY]RQ)_*Q<?77%W5?.9]2--$O,Z^N2O2EDPX3QR#-H=@IV)-%<PQH+N/FQ
M7)&K<ZZ^R0I+)F,("!BCL!M?HC]N03Z,QX[/R_ZZ7DXU^7E^%G/M"Z'ZB'_J
M%R3Z8\?^?1OM6I^F.[D/[>(U`YF[UA/LK`5469TGJ4'(UEBP,S%[()@JB5]/
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MJX?R)$8`E?D.=GF+<CR:*<%=4,/S`F0F1;F*`%356;>I;(K+$5386=:*K?47
MX[V;&^1LDK)9BJ2..4L:OG5%O.'+[6,JW*+S;*_I_`LSCG';V/&P7=EFVR)&
MBZX#1,7"TFBJU<IM5T%2)UBKL+LZH]^H9@)''%6OK&#S58[+;K_<L7,L$UK#
MMMG.1,?D+&S!W,Y-K,]B9JD,U$N:!`LQD)%PH?T9V:[11JLY]>Q!S&JFPNSJ
M^[_44XLTA'&<H:Q7&W5/)>.:;F4]]H..;;:Z1C3#61)8("CY6S)/,6`)8VI5
MCG4W#5)=\0%T18/E5T4F[!XL@8J;"IW>D$/XN_\`P#;#^_?;;4KR49,()`-8
MKHV4*`)%LJAS$'\+D?E,1N3[TTMP[@Z;B(>[V^;;^`#D%J!HE'0YS,3[F*"?
M<HH;VJ-C!L".X=?-V]#^_L^+^,&W(S5"VJ#VG`8\PC_-?$<!'?T>X$)V[!T5
M[@[?M#;N]X:>*JM.47``V`H>1H)%%````I^W?P)@'L!-TD`[^X`Z::5X*+"N
M/G%=5/J5XAZ5J/4!!8H_$I]QC=0^X$=44]R)9%)F<-DO3HF/Y57!B)EW,;XG
M"H@&P;#L!=NGNU)$`UU1P%M_3MT!_K2H=X#U;MA!53</:!UMQ12Z_P"6(?9K
M.NBCDZ*OKCAT:(IMNFW>7\Q?;_UZG4H_Y(%U-L14HPXJA6CISNLJ(E+_`,NY
M4`A!#W]JBIMSA_D[Z;@-!14,K_#'I=%5U%SA[2MR]B>__KENI@_834<FH"M>
M"YU8P&DW";=NB4509'3%3\\WE8!ZH-^\P%V.(E*;<OL'I[=<GX7.BC46P3<O
MS@9\4B_II$")$(D3PI*"4IBMB#V@FF'J@,8!W]O3?66CH-5/*K?1G02.V=+M
MQ7.(&3$[@JAUC+#[=TO,;^JF#J/M*0I1T,@]!15U0J#5)`Z*[L57!#]NZ"!^
MYPN<1,DX3.<R8$,H8HC[!`G:/N#5>1T".>2R))QH-5"NUW0KE-WN3I()$[E!
M_FEFXBJ8X`;8`(';N`AV_MCS?P4>2HW(R4*H1V#KU)M@.4/`4H)`(B@*>V_:
M/\8P@/13?W`&J\M0KYD-_0KG,5P#LY4P,#<1!#9RD81*9R("4`[A+\`A[O;[
M#!J'>!P3S!4`&)E_1F6=^`OQ>4R2:@J%(`&*T.(*D`RA?Q&'?JGM[]]#OU#*
M>956!JU.FBW<[%<G$B/E;F*#903%W[O&=4?!L81+L'0^Q?XP;`":R"M>*7)H
M^F2W1D4BIIEWV!9=)0=C=1V,0G<H<P[^T1$1U"0^BC\PLJ))8`,H/]:,J(&.
M7N;O@(!`$$TNHJCNF01W_P`81'WZOE]B>7V*IUCD_P"=1J'7_P!$JV/^[L.0
MN_\`P=98'X35`!P-5C_V8?\`BNFX_84Q'!`'W]#%2/M^\=:\[<"J750;AOW-
MGR)AV^$IA.V4Z^P-U`*3?_AZRXXBJC\PLIS2:`=SA+SI[`'<X3(Y((`'398>
M\0Z?88-:\I3RG18O,Q6V\S<R0^SN:J&[?V^-45`V#[`,&IM(T1B-%Q5JQ^TN
M#ZNO!LLBS3K4PTGXZ,;DBTFBTNR\H-G4@E(,'?K!2(J8I$_.4A1'N`.[8VCM
MJ*K)#L[T7;#&N@$0],J(AUW[#=FPC^+R[^/M^_?;4$_`+DHK?2MT_P#G+E(G
M^(CNY4W]X?EB"(?O/JU.@"A)X*GE8DZ(M5%C>XSE40(/_P`20[!]OVF'0"7$
M@!2O&B4)GDU"[()^!(=P[D4R-2;;;#NN'8([!]IAU#LUU3RK"9L0INYV^2$1
M]H$.=TI^W=/N3$=OM.&J"X\H1^00`QA`V`CIR;<>IC$;I_<``4%CC_#IY^85
M`)5Q%NX>QK&(&'^*(I*NC[^X1\AC%$0_R=&/$J'Q*RJI2ZA-A$&8E,!TSB9!
MD!%"[]@[`*0B4=Q`W3J41#4\@\5/*DH$,X3$5WZ'Q=Y%4CK++F(<![54S`0A
MP'^'80Z^P='')--`D'C;^4[$71C"D4HJ+IMSB*B`@7QD*=0Z0^7M-VJ=-REV
M'^,&MC1V94.A7T+=4J2!W/8OL)A!)(A6A]P()^WR*%[%@^$GL_,ZCT$=H\S4
MJ^95<@P;%)Z0CPZVPD`AC(CY4@W,=8_P;B*1A[]]_B$1+[3!H-YU9/,JJ%CB
MMRBAZHZYC`HV4,=$06<&#?N5'Q[@D<O0_P#))[/8&KY^(2JKVQ@MC?&]%=00
M*<HIHBIZP-OA`2J%[2I&#<H@&Q4P`?VSS^"E>*QD2:"V43.Y[WIC`FJ11`Y2
MK*G`>Q1-0ACB5OV!W!T#L*40]H:/(5(\JM54C(X)&9$>MSNE#]AU05\)E`,`
M*#(`"WAV`H%Z!["J`!=#(:M11W53EDRD(EVKB6,.1=8HB"Z!SD*;QE[A%1(2
MN$Q,I]XB&^J#'ZT<<%KCNBKNFIU6[<Y'3U"1$2%!!3QB3T:12F((```3M,/P
M[]QA^W4$&J-49=#XV"V_B55;&^Q<OE3^X/(F!3A_F:CF.H1SQ5?2.T@\J/YB
M9/\`CVQQ4*7W_$*>QT^O\H"ZA,>.JT"&JJ>O.IL#M-)R7\/<<!*N4/?VKI['
M$?\`*[M78U1JLLK@;M''_-E.P^X?D.3`01WZ`5-?X4CC_E=G[]*C4!6O%:J3
M0,DV>(K)&(86B^Y#]Q1^)(X`(#O^$1]@AT^P=:B>/BBU"!@[$#`&P-CJ/3A[
MA:./B0*(].A"&[@#W"CK91+"G\)C.`*(E>G`$2!TV4V'TY-Q]A7)=S#]@[_;
MK/WA%<4?1]C8HE,=<3F1/ML4JP_&Y$0VV\90$3E#_@_9IK555V!IXVR(?"ON
M")QZ^%0?B444W_B',81+]J@]OO#9KJHL2;=,ECI*9#;%5LOQ)CU,820TL8ZX
M#UV,8?Q[]!,._MWUBY)H$>'\0I(KE'<QR^3QU<'['%^&5\HM,SGB*17E[Q/)
MU.8P.6Z1;5.X3<P#`7<=?3T-5VZ&.(0Z`/DDTN_M,)@\/59\KZEECRA<\C8I
MEN0N8)[&6/GV*<0<=)&[4*Z,'[M7*UGL-9C[7;KQ0YAHE%N'$140)"QZC,S5
M18[ARJ<PHB<A=S*``L'JZAS(\F,A16'&;17'&(6UQI[W/N2,F5"TX?GZ;#Q\
M=Q\KU8R\^K:&/!O%A;U7)MV2O$:\CYPLU.LVZ:@21D%'"JC)L\5I@^I7:9)Y
M5SM%NO(VRR6.Z#8*O0\:<B8VLMT:Q*+Y'DWG':MXGM$C'7&?(^D`L%'O<OEE
M<B,6TCFYV)6*2GD=J/C%;D$79(B9;O['">.I"L47`WZO0SG.T>?Q.]PW/U6Q
M6[*-;N#-I7JO2\9QURGH[']T"L).YV7M)YVRQM>CXP)$OJF)U56:J-6I+)T&
MF?L]6>[Y<JM#J6,9IZ-?Y)H8'K\V>R0#D]XXV7+'N/'K?)MK+)23)W`9$L60
MTW391C',CQ#1H!#B\,OWIQE-H9W*D6T>Y_/=\1,WU(QXACZ5QY./\VS+>RRB
MMBJ63DFE?/7Z_1HP[4&]AJSMZM))N'BYTU4R(HF`HB<=JRC"M2ZXA"9Y?FQ[
M!/W.+L,IY.7S<6'L4`G>)X]68<?AO#YH-SCI?T`.W>0BX_(W=?+#$*W%^<R7
MD[0[M1BC1?4LG2K*^7W.3<GQMMJ],C,21K6EFQ%98:9D7UQLSMY&/%;XG<(-
M=!-E!HPTJ5!)B**B@N4C&,;MVV$0HPYEUX/?4A<E-GF^Q3-HI'NFU?IEHE[&
MY`21;YHQ45AZW4#N_1=C60/*3;UVD118Z*H@`]J:@%./Z&_:J)':(7KLHSM&
M_.W"`^*)D-T[A#UBT8AP`1XBB^?^I0/GYP'Q,"3PTH/;JF"Q@7U-:X=JO91)
M%PC]1:#%D((K2A%5_P!(T,`8D68K`T;$=MC"H91;N(;M#LV,4._M/=AMS.^;
M([O_`-<+Z!OS;E:AS[!7^'@8`/RU@C_SP^Z"^L77Y2&I7T]&JB-$1HBC_P`K
M6@/^-6<V9H6'L9'.+[@BI`V"I1]]A)9,\.Y!1C)TJ5M-(CK4T7)N!F"TQ&IN
MOYL7"7=W!F?PE;M_&%Y1?3<I/'N*N6,):(^FC9</9G3JUI%YRNA>+^-,*8M<
MG58R*#UO#'K.9\J3$`A8(@_R\B!7;\BZX&`RA`/L7,/9[W_O7)=.H?W,W\%[
MNZY%P(T1&B(T1-'GB=J]7Q%?+->*,YR+3*Y`NYZVU=FPK$JY6K<.4)&:E$HR
MWR43"2`U^.;*/Q1,MYU`;"#<BJXIIG*C5-9PV9\>F^(U''&917^S=W8/2'9*
M1*\($38:C5:KC^2BP8.(>',+AJUJ+;U;@I7!';XRRX+J@IW:*R=ZZJ5^BRFC
MSW9X^EX7R;;);^SX8ZOTV:E'9,K.GS+'2R35H=3T]N7C(.SR?R=R8`3.1K'/
MG*HF`B2"JABD$J*E0C^E?B&BT+CS/6ZHLV\:OE7(5R=2D9#6A.R5FO1E#G)3
M&U1K-457QKB6UQ$9!5FMHD.QL\(C;6#PZS:555<(;@6IERQ4C+9CMIBU5C+4
M)]DFG5LC)1!\G0?47.-82B:J1D)*=Q_,IS17T6X;`<JBL:BFLFKN93H?R$V"
M]"SKA(;1V3BX7L%ZL4)(/;8LSDXI-^LWJ]A-7YFGSM@9)++>9_+527(88M'O
M,5-L8BFZQ""82%#M,>2`!HK%SJO#'ZFGU5\N?3C^H9CVLUC`&6>6M#S-P^:R
M;C#6+I6>-,TNWT7,=P1#)$;!1U8N#,R,_"V8(V46%JW44!BQ`5Q!$J9LKGC`
M2@[M51?>_P#>@\CQKB+:27T>.:$<[G'QHN#:R"LZR<S4H1B]E#QD.W<X>26E
M)$D7&N7(H(`HJ#9NJJ)>Q,YBQ7I>(3)\I/\`O+>?YSCSF"LU/Z8G+/CY9;?1
M)^F0F<;XYMT-6\3R%N8*UU"_+R*&+()1O(5<TEZMB/K6@>M22$52@`Z55C:#
MU(7V25=)1"LUU!5VL_51@HA)1\Y6.X</5$X]N0[M=PH8RBZS@P=YSF$1,81$
M1W'57`M[HB-$3;WYKZF7Q8?Y9:)'T>2$W7FKKGT[*(VI%X;_`#.W$\"WJJN'
MJ/3BGNG_`%]PU-W?#VF[)V"[T\3NL>KBV]_;3%KP>5S]3C'9CU&V_3>]?RH7
M0U7'2O5V/U^X]@ET,^]T^]B>['EMA9_0YT>KEC:=^+YNF8^7]1<QY;O*Q<C7
M6UW5?.3]3$%B<MLDG1AD2]_"B.[K"X2FR@80R]'IFBP6064@UFZ29O*9-9`5
M1.8"E,`'$!_17[9QB?2N*3)__7?@>/\`Y:56U^UET/U`W]4D_P#Y8?\`.%R_
MTL$C,,_Q+^1BE4'ENCK6QC'ZC9R5)9G3F40YF7(/2*F:KNWLA9FY.U4O=VHJ
MF2$/S0U?W@F+G9[=JV08VKT#(!G!N=01#<@($^\/P7C>D(D9DC)WE&3/R!K]
MX7L-]0'E]$\*N,]JS&H2'<VN0F*YC7%[6SJOF%+4RCD.0"!J#_($VR06/7<=
M5QRHI+6!^.QD(=@Y\/>X,BF?\Y\%]'C'<67DM!W7BM5<*<6[U@W.$7RUA^(_
M,RN<GOJ`Y+I3!]:[=.V7.&,,YX\N7)VYUV%CG4LXCZSD6\MYH&C-%V-?JD+X
MVY?31212U;JY!#.**1G'+E[@WF[]4!S<>/T\62KG'CB7F/%MQM;E6';1^5GV
M0<ZXEE:;(XK>LI1^CD_'U<C<92+YU+1IUT(5S/-63X&<@X5:D*$&,*\2FMRA
M:H2'R#R?XD2$FLAR/SA]4GAYG3$E.!@_5L-JPVQE^&UXE\OUXA&Q_74;&-=P
M7:6LQ))F%O%.8(S=<Z:JS8BI4:"7`1/\5$.TQ\CFCB[A?ASBQI(6#DWQJPC]
M2^)SUCF(9.5;91I%QA'-V&82)MK7Q$4BU<[W[(L0YK/E,7]1,5C/FGG0245)
M%=#N.A(3WYDS)C?/>;(7F%A^Q$M7&KCO"_34-FNZ0L;*+0%56@>363;Q<(F=
M*1@"J<MQZJ5MCY^V,^PSBLM76[PB"A%2$J@!`VG6JW5!S3B^@\R'G.VZ6Z-K
MG#O)^>>9-2H6<)<%&F+W$O(<?N"]2A+DTLQDOEPUW)-DXO7:,A),#>DFG3-)
M-HJL9ZU!:(SQV_B8?Q4;JC)HX(XJ<D\3Y>83-7R7S:^FEC&K<5L<3D%*M[1D
M6X7"S<O82'PG5(=1D*R^0:6]SK5EY&%*4'<8UF`<K)IH(N%$BNL@1P-5]5E9
M9N8BMUZ)D77JY&,@XF/?.MS']2]9,&[9TX[Q#<WF73,;<?;OJEV7"F3<&(:=
MO.Q@$Z-H$R>PAWE5/#Q!$]@$?8H8>T0'H8-PUY,/@B>8_B5R"C,KR@!43`K\
M#A(1664+N805$!$5D]_QHG#X2AM^'X1ZZY-?8M*P@&,F914H(NT]W"H;;@F8
M2CVE+[U&YD@`G_ZP:'5D5@"H5N9TFF;U9=_4(]1,*BNP`@;[3)")?&/OVZ=!
M'2G'1$I*S`GHRJ'%)LH15XP/V[F6<HE*4"%((@!4W!E!'N-L7?O#J.VLDOIJ
MLFNB(MVJ#$6K<?$F54QC%3-W+'37`JY`<J@'><2^02[="_#[-"`:R0#FMJFQ
M4.4JRRA4$/;Y%=]S_:5%,-SJFWZ=``/M$-3=P`1^"O,NBAOZ-(!/_P`NL!3J
M_9NDD&Z*/_EC]^FNNBK<UB*F[>F,<QE%!)^)54X@4@?XRJABD('W;ZK@:!1P
M%F!)BD``LL=RK[R-MBI[]=@%=0HB;[^T@AM[]9\QTT6@2N=([\KUVJT(1N*[
MXK8#D(!U$VR;<S990BJG><HK")2`/380W#V:UM(9]&6?:EI6KITDN+A0R#5J
M(F9G=*"DF7R?FIKID5-W'*!Q$J8$*.X`/\H-5P/AJ4<!'C;`W)(N'!@5(4%`
M;HHG.**1A`%6HF4\91<*["`]H&^,``/9OJ/(T&B.5>8S(@%D#H+G,B4Q@357
M(0A6)@`RI3`FF8`6$``XB`B`;=H#MN(SS_#P2IY*IUBJJ)O$XY("(;F20$7"
MHK)&#JJH'D`?(`#W)%V#;]INAN&Y&/-7J"X?@15K&IF12'O[T6BARO"#L)VI
M#?'W('V`1'WG``#IW:`-3<GO6=<SQR0A6<8CYR]BR:I8X1!N4P"`>4`*.Y52
M[E[!]OM]@;Z!N,D]ZL,)_2E*,2(=PB1,`:K>I]403"/:("4#.2J%$3"/3H(C
M\.J!7XD;Q5B6QR*^MBR%6-NDZ(0SI$B0`&Y4DQ,<W:D!1[P,(;B([_L4'XE?
M%UB;&:+G[7)'10;["B)52&%P4=P3>'(HB7H!>@!O^(!-TW*`"9:Q9E*K8^%B
M<VQ':J)O=YD!V`?O,@HH(=/NU#N&M0E4I23D"[^F?D6`/^+*Z]H?^I<"01_S
M=0RB*2#*ACJ%C65<$'^MQJ)NFW>9N*(C[MP40\93#_#J@!J%/85A+\O5'H5T
MV-_B]KE,H_L$$3@`#]XZAW`,69/,E:#1UW;L'/J#;;]B1S(J"'VBDIV".P>W
MVAK)(TT2G$)2HB=(`^:)-0`0`0+X1]:8ONV4;^,A>GO.;02#T=T]BQ%-%[;-
M4?$KN804D"@Z3#J':``EVE((?:)%-'E^+1&/%*O2S@!W@L44!*(@;R$]-XQ'
M<?R-MA+OUV\?MU-T/%'C[TF.:+$-G"8K*@(=QF)?2I^WXA$%=RG'[P2)^W5>
M?#1*K*FF901^4)H=.O8*(@\+U]@J+^0AA`/Y!@_9J:TGJI[4D7:.@,`R#H41
M,'<";A0ZJO:/4!!%/R&*40]GLU7!T%5H$<&28?0)``E(Y=;?RNUNGO\`L`%C
MB'[PUOS'6BA<K.B=RH&[..23(`C\8-SKB'0.IE%Q.4-OMV#63M!8ERGM5YP>
MF`07D"(AM\28NO8'O*"#<5!V#[.W1AR2G`)%XV@=5':JP#[D6QMM]_Y:ITQ'
M_-'6F;X152IX)$Z.U1$%6J#A=53\LZ1SE`51*0PE4*1-/N$S<H;B&_Q%#M]N
MVM`G\2K'BLNZ0-B"W8=YB#Y$7']87.JNH(!N)0.0A_4&-VF+L'0=NFW2:FI4
M;Q5Z!E_$OYXE(JH;J/2BS6.4H&`P%`ICB;=J!0$$Q]X`/\;?0^!2IXH;@^;B
M/J8TO<KVE0468@/:B4!%-L<1)L"Y"!W&'_C!W'VAJ$?[R>]8R@Z25.]-%E%N
MMOV)BQ.4K=,PAW."%*4NQ'(AW*`'L#80Z=VG@9)[ZK'Y2J*B])'MQ#L%)-(@
MK)$<(^PRQ#>;8%3"`^,0Z"0`#V&WT;AN1N15"BR>&%XDBJEV`9%J)%^XA@*?
M9R54%$A,`*J%[0W'<@EW]XZT3(45JA-)F\!1Z@Z%NHD)TDDWJ)BB5)/^<364
M;BL`>8P";?M$-NTP:CR%"HY6,B#PK0'K,QQ5<F\;E-LJ!E@(L(`*)TDS>4JK
M5$>@"&QB[[?B#3<'8BB..*U[UR!#`<Z22R+-5DX;`*8%,"`*F570!5/L.($,
M<IPW$=BA[.FJ`>=4(Y+I139..J2AFIC!N4JOYR!M_9^<F7R%`?;\11_;K(,@
ME0L1T7K,2*`)RA_Q:Z!Q,F;[B+)")1'IU#??5!B:JN]%G!TBON5VW[A'H+A`
M")KE'[3AV@DMU^T`$?MU-LAHJS*Q9D<I!5;'*Y;E'<QTPV53#[5T=Q43#[^I
M/OT$AQU1QHM>[=JECUFZA2K$4*""0+[[)"N<J8F24'XDQ*4PFZ#MT]@ZUM>3
M@LLL$E;-2JE2!`?(#I@19VB(?G-VS7M(BF8-@!0JR2GQ&#V!W;@'34)(/@"C
MD>U82`"B)S+"8"(B*#;H/<.Q@%)R!>@F45*).P/;M^T=:IJ%I7ANHW\RQ!*Y
M6`"E(00$R2Z9A[$4_=N14HB8WL'J(]`#30MP45Q1`R!C+%W67^`Y$]]P6((E
M\*.^W:5`X"(&^[N'VZ*K&Q[_`-0TLZVPN/U/XES%_`!PA)CM*E[-DA*?N#WC
MW;CK,VV2]G\0LR%'6C=\A<AM<=6^[)\7<QNYVLYG/BZ,QVW4JPVFW50EUBZL
M&8X`33!8\U#/$/U)@OE4(Z%DV4#L[MAUX?!88<UUL_D69D+=E_&LG@>[6&G5
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M&4W]MR>BBN12;7B/G;%`I55"R3IE%NRM:UHGZ#+-2Q;F3D=84N-3&`RN+/'8
M1LRPOD>^?9%)DC+)L)8Z+=2-XYS%87/D:W13*2+X`DG$E!))OWI!>LC,48LL
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M%`[G;ES_`%=0"$;I"H*GZ)_:>%K'[-:R[DA&-[*N62Y`J([[='?A(:`5&IT^
M>>HQ*6?<B`6B(R_@3_:F2PV=<].X?G=PS:146^HI#`<P'G':C(I:O05"RI21
M:K-F=\R.F)3&>>9+M,*@`)N[79>_QB>X=[:6P#TX2!0/^9.E7+'P]B]?VX2&
M/9!?_/AO^[%?6@'^$?[^ORBOJ2KHB-$1HBC-S.B(&?XF\B82T-_55V6Q#>&$
MRW%^]BRJQSJ#=HN2GD8VG9"D&2?C,(F50@I=8A=Q(T7-LF;,VVE]%R6G%P-J
MO)OZ5O,-NV=8;X/U6DXHAZ#3ZA;&L),QF3<_6>^F2B$9:U%26BKAPEP+1'`K
M+N%`5.,HQ%-`NZ:2RFQ#Y@1\(^\+=V,B3,_<1]I7O[KD7`C1$:(C1%%OF?##
M/<;\A1I("HV9RH%;78P]]R%&8MIRT@TM<(Z8N;#<YB%L,>QCHYRD5P9N=HH+
M\4@:E,D98JI"U'5:3@X]EG^`HE29N=LR$[2L-B;EN-EDZ_,QLRW2=)@D./)6
MJPD/77^,(_<6D&HT4DTQ:(`!I%\<#N#DEJI?Z+*C[RN8IR7&O.#%2-I4MZG&
MMI31C\C0EYL=&7=C&K"R&SPN,4ELC/8I%X!%#_(B_-TQ*!V@E7*0P%1JF6^G
M.Z9I\7*57S%(6R0CRS.+B9M#W*.CWM@L=ML$^ZFH^1OT'"W&R-K`9Z+TK^9%
MU/.06`\HNJ^,L<Q6?Q*0649NS1$K"!"6Z-HZ"D=)J%EK:SBW=#EI@CF/*QKD
MRJHLPFXR1=MSK*MUV[I,@D34+XUC]I0T&:JXR[K1T/*N0K`>+3E\?1,FP<3J
M]?EK;0K:RFH2&>M#+(.SOHQZDUE2().2)[';F=I>%4%!4``$-#$#B@D2HG<U
MN5?!#Z<]PFN97)S)*%6R9:\00.&ZS3V#A"PY!NU/I=NN%Y;Q&.,>-@3F'+I[
M8K@M\RD554(I,K=H#I=N"0'-E<L1*7E&B\$87ZE?U&>6.4\6?5`E>(]HQ-])
MWA5:;!DMS4A(K)YMR[5[E1[?A:S9LKL29NBOD,,24[(LC-JMHQ)G!H1J#Y-!
M]*.RE,2+DV0`V/YRIA\W?KK?3FY"\3\H\<^,&4WO)3D!RVH,YQTQ!A^HXWR0
MSE7UWSE$.,>P3NQN;93X2(AHJ`=V('KH3+'7,FV,")#F$!"K,;<@7E2(7TC5
MF+6@ZW7X1PX]6O#PD3%KNNO]96CV#=HHXZ@`_G'1$W[]%Q+=Z(C1$V]^:^IE
M\6'^66B0]'DA-UYJXY\#*)VH]X;_`#.WD\"WJJN'J/`*>Z?^T%VIN[X>TW9.
MP7>GB=UCU<6WO[:8M>#RN?J<8[,>HVWZ;GK^5&Z&JXZ5ZNQ^OW'L$NAGWNGW
ML3W8TML+/Z'.CU<L;3NQ?-TS%X_J+F/+=Y6+D:ZVNZKYO_J9-B..8.1B$G`:
MJ*\*HI!5DF%A,]8IJ9@CA-*M5F'IHICY$DQ(!SN//Y"`8$U"$$A_T5^VMPQ]
M(8P%M_\`UUW.UC^GE0O4_4WB%T/U&'S;H_Z<%_9(46L^FU(OUN4'G6C4',(\
M@I6)J-G8.5&3-&KT-NVCX6M$A4G;ABDFW:6K?P^)HNFLV.Y.F8SA0^O&_=2Q
M;M^G[)%PC)C>B;MLL29W=Q-PRU-8-Q#$`$;5Q^F9F7<JQ<=.32\`U!P\>>J^
MBL'@E$>O\(;A_`("&OS]JOH-%7UQ@Z@.P_:7X1_N`&HE%K?1Q/KF,G\IBPDH
MMI(,(R1+'-"OHUC+*LEY5E'NRH`X9,Y->.;G<))F*1<Z"9C@82%$*E/%;#U8
M=Y5!*452D.D542@*I$E#)G42(IV]Y4U#I%$Q0'8PE`1#H&HE%0'12G.H4I"*
M*]GE5(0"*J^,!*EY5"E`ZGB*(@7N$>T/9MHE/%!712%,4A$R$.94YR$3*0AS
MKF,=8YR%*!3G6.81.(@(F$1$=]$IXJT5TA2*W%)(6Y`2*1N9(@MR%0$ID2D0
M$@I%*B8@"0`#8H@&VVVB4\5>9V!C$.8"G.D<5$CF*!CI*&3.D91(QBB9)0R2
MABB8NPB4PA[!T2GBK@>FW#J/]W_Q:,E$R)`!Q9+<)#`FJC9EU^X.N_\`LF((
MDFJ4/Q)''N'8?>7<.H:\JU_AQCR']JU'3WI:L'J#(H_S+DI_(8.ANU-,`.("
M&X>9LJH!0_\`$(=.71:5ZH"X\1`V3=`J4!#J8!2+NHI[-C*MEO'M]H"/N$-9
MW-JCLERA/3'0.8I/F1%0,HR4$!3*DDF=4H.=Q[5#"<0,EMT*/XO>76"02RFO
ML2!0YG3DY]SG26(`JAM^:T=&<#W*@3;X!`Y`$P!N!1#N#X1'5$1&IU318V*B
M40\2*L4BKAZW31.F/:9LW=MS&315,`=%A=%W#M_`10!*.X]-60E/_A"&OL6Z
M,*[M4#&$RZRIBE`"[F,(CT*4I0#H`>X`#8`T<`,KH$I%%LTZJ]JZX?\`$IFV
M13$!V$%E"&[E!`?:4FP=.IO=K+RE19J5A467=F(GN)@`1!)%,G:F01]R:1`[
M0$1^P!$=4>6I5`2:1*G'MCBL<?7'_):-$`*JL=RKL5$#B(@FGV";N$-Q-L'L
M#5B92+CX4KP6K16*BV4(B1-LB#Q,JRZ8"957P"1`C1)80%04BB00,)-A.81#
MVB;4VD%R4;FEPMG!G)7;[9NF=`@MB.3`4YC)*&(4Q4NJRS@Q5]BE(`@0/WCJ
MO$"B4"J@+-NHL=V*RIDU"JH(D$J:20N"`/MV547<"J!PZ`&V^Q?M&$&50E3H
MLC=?\13-&Z*;4XF114)Y3%3.'D14<"L*A#'2*(E*4`[2=N_4>H9(KJHL[=27
M6(=OW+M6J0_!Y%"LQ<(*?$D!>X43$0`-R[_B,`>X/;3&("4U5B0KE.HQ3?HI
ME1V,4X.#K(MT3B/:D4J0*%.JB("4"!T*4`[O<`Y:(JRT"W!!$V[(QD"OO(9?
MN<(E(5P=594?^<%,<Z90Z'$#"<=BE`^WL``T?PHJ[AT$130<^922`HN"#N?L
M<II-E"!W&(F(EW`%DB_$<0`3B3KL&P!2:4":JJGF.H5<DB`-3B1!8BBKM/U1
M!$0066*=(.UNFH;8"CU,4VX@```#*,Q#%0A1FGN9N!(7EU5>#\C?TQY,6S%T
MCF&!I?R=TZC'5)8GD`=-W-G,W&&9VAU'PKN0:Q2IP>+L&9W!"^,-QHE$>6KI
MMH_!1YL7U:^'E5N=^J=H;9RB(;%V:G''K(^95.-V7UN/=)RRVGHJL*5VR9LA
MH%_1H='YY.L4/5+K$;E%XB8YBE.4=-T0=2KMES7092^J!PWP[E:T8GNEBR@5
M;'ERJ>.<OY1J>'LA7;`6$<@W<8TM7I>7LRP5?<4ZE6*1&:9^5!5PJ##U:/JS
M("<`T,P[:H(RUHGPNG,7C[C?E/A[AA8\C?*^0F=ZC8KMCBHC%R@QLC!5HDRJ
MX++V1,AX.$DYA.MR(Q31PJ"LGZ!?P@;LZY>(+'5`*.U$IY1<P,-<0D\4(Y>B
MLH6R>S?<I2@8NJV&L2V_*]NM5LA:R_N$E'L*Y0V;V<=%;5V*<N14!'M$B)^O
MPB.INJP4`)T3<47ZD'%+*1,0MJQ:KW"R6:,\7SC)`4^U8MNE*L]1SEC.CRN1
MKK0LK5FRQ<1/8YDX2FQ!WAE)1+PJ)JI=AS>0NC@:55VD5*XS&/U5.'.3LD4K
M'56M^4PB,IWR2Q;AS,4_A')=<XU9KR3%N'S1>D8JSK8*ZA0+7,O744Z2CQ34
M*A*K('(R4<&VW;P>#>*$'4K#C3ZM?#7*.2ZMB^`-F:LR%_RO<\&8_OEOX_Y0
MJ6)KOF&A2,_#6/&]5R[,01J'*6PLG5WR+9J1V@9TJW,1/X]BZ4T!JJ8$!RS!
M.I5>=G&RYXZXI9@@KI:EJ7S2R@&'<!22]'LC26GK\)+RM\NL,6NF1S4V($QS
M*_UMX8B.Z2?7\TFIO#:*,0XXA=?3>:?'3('*S*O"FKVL9SD;A&H5R]9!JC^(
M?LVS.!LA(11LG%V+PIQ$W+1*-GC3R;-)19>.*_0%4``_2ZEG4VEG4;<9_5JX
M?YCM&-ZU`/L^56)S'DM]AO%&0\C<;LMT?"-]RDPF9RO?H2N9==5C]`.Y^0GJ
MT^9,TCN4_4NFQD2F\@=NH)-1G"NTA:-S]9SZ?L+QYRYR9D,GW%UB7"&=O^S=
MD'NQC:OU*RRNH;="'B:>HT/.S,6X;IK.$Y!J0&QF[9=0#]J1]FX&NBNTNVA*
MDY?^</&?&.<N,_&^Y7/]+Y@Y<1\G+81@E(*3D64XSC6";]$\[-E06:4X\X=3
MTD85Z8@R#Y,[=+=0HAJEHD5=9VEGX!2Q%@\7,EYWQ3D64!$@HJG=%\AC@0`'
MQ`**6YA#VB7V[ZKC0"J.-%Y[8[^I;PMR9D'`.,*YD*=2N7)Z1SI#X39VFI3%
M3C[?.\<[K*4')D">4D4!:QDTC8H5T6,;N#D/+)(B=MW[E`UWGBU53&53P227
M^I[Q1C<?8VR#"CD^^+9DO&7\=XGQCC/"N0,D9NR#8,!VF9I^7W==Q=`,'LXI
M6*+,P*WK)9<&\>5(Z)@4$5TR&;@SN5-AXG12<X]<@,;<I,55S.>$K4C.X]M!
MYB/C';Z)D*I.Q<M7)=U!6JN66K3C&/L59M5<L,>NRD&#Q!-=LLAL("42F-08
MGF5#%J%.\8JWF.I\Q*HF@?=5!,[HX'<J!W'6;AXBD`Z29^I1V`QC"(?$'42`
M:"BHHL2Z;=VHB"<D(^,!5,L"#DP;`;9)NH0_4R:BA1,8H["'9[AZZNFH".R#
ME;N]F:KLI%%^X7"1TW(E].0P"=1(Y";G(H82E`0V,43=0`0U"2`[("LJPN&P
M$0++)=C@X()N2KJH>,HEW."_E32`ABD`0*?\)AVWV'VQX\8U4/L0L289(F3:
MF.N@<2H$;H*INO%W_#WMB`93X2)@)A)M[NGV#N.SWIY4D65,FGW(-VXG4*5L
M!?#X?)N()@(BEXA(X2(`_$(#^'8P?92QXH51P$>X3)Z<%F:XG1:&24#RI`EO
MN*+@H`19/L2(;M,'<(>T-P'88-P2HHJG:JJ+-W#'M.N03J*H)G_-`J2>Q2JI
M@'E*)3+;IJ``E^_;V-X%).Z.-"DR[@!0>B=,JB`+(K#Y4^YPQ72*FH8^X"!P
M2/U`Y1$Q0`1'80,.H`>&J&*4QA".DE&J2A$W;)4R0M5C`0RC81W:';J?S:P&
M0V#KVB.V_OU7,2\M"E1JEA5W#(YD]S)&`=E$5";E,/O*JD<HE-^\-&W5&BM"
ML_8U>&`$^UFY-M\!C#Z58^_L*H8=VXC[@-N3[PT<Q%:A2H\5@V<LUAZJ(+)C
MMTW*8!^S[RF#]H"&K2056LD724B[;M`3*15L!W:Y$Q*1N[6*F8K9N8#;$;J*
M>03F'\'8&X[;]8PCQU4*3)IG;BU[SBF"`F%TM^`55BMPW;E#;<$B"3M$`]NP
M%#?KK3@T56VW(^<*KJ!X7AR(G;-"E[0<*!Y$E3%(7X"/U"=OP]"`7V;#OKC^
M#_A3@W!:X`%NNMYRB9PIV'31)U[/)N51)(#"'4#)`*AQV^T>FVN4%PZ*TOY"
MZIU?C5<$(=(B?4>X-R*)(%'81WV*)C=-_:.P`&B)+V*$LE*6,`&.M8_'L4=R
M("G#RHD*4P^T3E$0,?VB)0#H&L7-"W+^*DEQSSF)AACCRWY2<.[P6HT?,JF!
MK`L3&UW5ED\AI72+H9T&,"G#&EI.OEGYA#_::"1V7IQ,IW_"(:\5UG;5GJNY
M>9^Q^PO^3L9N5[*6U8@QM$98NR2=/LR\6WILW^H!9+0TTC''C;%,`6M.148,
ME%G9/@#L$QA`IRIMH[J-.1)_C;R1?\2I>;E,M,EL_P`#93XJ2@*W9:\A><?+
MQU/RO;L?Y<*_K+U2JU::/1X9TLBX4BGZB[+P(NBI+."*G6@-K^";ET3BS/+<
MI9\&^>)YA\R?T)9LP0(XA2W+)N7T6,[&\:3MBI*(W*Y<C:^T75+,."B$PW:O
M&Y$H=4BRI7P^GO2$K3B=87G&6-"6SK)N)XY)MW.^!!,LVYR3GIG<&T/RB<EA
MVY(AS>.4U9,FBUB6['QSK5RR`S>*4625)6NGTY++6$<%RE:Y7RU:FN6F0HJ[
M9>B)J4:1T37)J2E\L/LC(H4VU8#F6=<9OUCTZXTYBUCPM$B+""@X5@JLW1A#
MMG#DIQ'-D_&(<^X&ID)@K%M$<9!E8;(];@;-!VZ:@W+I%I(Y;F+G+5YSE>>4
M^7_);QEBZP%B\:23,4#2K9=,P-4U&H*'4,2:KM&_,3##K'T%DY%W>!J5CS:'
M'R+6-C:\$ECY(-=WV/BMW,$:&"5:5T;!'J_[542*R].`*=_7MT<J;?%.?6\R
MTVUY+R;B2'5G#7/$3:F.KJD^K<Y'0J"5^C7DM7?DUB>LT8:PG59,3F7*S55%
MN;8I]ATJFWBZ\,/J73/HLZ'<5!GYL@PA(VW/;`91R@A3J]'(MH&'>+(J?)HB
M4+*NK'*`IYWCCN01.S,CVN@*/WW]J\?J=IN_/2;MLYFW&##\VX09$/4O$1C\
M(#$[G\JZ!ZGVPS`8B1N@!SR'`<F+_P`%'O%S5@UA.*9(NPH-81/ZDD8YB2%"
M=1.K&JUJA$:P+8&)'""2!DEO&@D\3:-4FR0))E[@4.?MO=NH,KO'6M$WSZ98
M_"6(N3>1?[6))-3R'@X8@+-@0T.</NC7ZE]8P?X1_O\`3^YK\JN."^F*NB(T
M1&B*.',%M*/>+'(-I"LIN2E7.)+PBQCJW>9K&5@?+J03PI6D-D.N.V%@I4DX
M`1(C)LEDW3,X@HD/>4-9G\)6[8!F`=$Q7TY+Q7D>*6`<=SUB:Q&46-+<$EL:
MVO.[K-^4(9=*2E9!9E/7*VS<G?;<[9L3@H9R^[EDT.TH]I$P`)"3ABVY:NP(
MDX!V4JWA[`O036UQ(T1&B(T1-GE.J6RWUXL75)*B-E1<=\A$Y*H:N0:?/-"E
M[DV<C$-+'5GS=9L[(FLBNFY,!#D^))0!#M*AN*187QHIBFEA5E'-?.*DO)S(
M1U.@Y6K4F`&4.FLI"4RK2]GMZM:KK58ICI,T7GI4U%3BBDB0P)%(2Z=G111=
MYL1,E.\3.0,-#Q]YEI64QE8V,?&8V;$>71^Z<MO$BUB&:A%DG::QS;.TCI."
M*,A6*9!<HBB<K'5,7]+:`NL)Q)JJ]P/;8M*=L5VG:[0;=1HFAJXWBY&W33ES
M6:Q&QD573+X^5EE'#RO>:+C#-X9PW0(V3233W+4VW44GLKY!5K5FJ=36/CM>
M*MK&7!U#W9Z\8N)MRT7CTVT3'N?2NX9IZ\CE0"*/4SHG<$(D/:*A3:U$.'JN
M(EBR=*H(P"$"T2K<(TK<:0[@IH-I&LXDL8^(NHG(-%V#`I6B3I%X0X*"GW$.
M8.XIC%$##"[U6@O(_EC].C`'(7Z@]0YJ\Q*C0YOCYQ?XG,HJMKY+G()KCI7)
MBV5[C;9N=R+%2SY!D[K>,ZHS;.D"RQ/DRKB:,H<%3M=DXMB1$=L=24P&2/\`
MO,_T><;3ZN/&F6KAD.)9)_)%Y;&.&K7/8^3:)D]$=HQD'[&$:342BB'C`T<B
M[:J)!^68Y!#<ZT+4S5/U]..E_1.SC:9[E5].[&?&!YDQJX<&LT_2J(WJV2\=
MOK$10SLB]$L4=&3^,#3)%%4@69QS!N])Y2)**I]X:+,NH/+)V7LWHL(T1&B)
MN;ZV\\OBT_RZU/\`TN1DW/FK2XHL8O:D7=#YC<2@BKZFJAY_`*>Y/]H+M#=W
MP]H]C[#<Z>)W0=3%M[^VD->#RG^IQCLQZAK]-SU_*C=#5<=+]6V>MW'L,NAW
M"]T^]"3XTML+7Z+-CU,P,=V+YMACY?U$\<O1BXVNN+NB^<KZE2I!YD7IJ5EL
M\<\+8E%&0]0MXSMG&98U!6/7;G%***V!8Y55CKG\GB`>T0+W`/Z*_;8F/HW'
MF9'I_P!<+Q85;&E5]?`-Q71/41/S]P4KC#_F%5K?IM_-8W/AH15ZR5C6\5)/
M%&K>2A7Z19I@DWB%GL=\K>.4%&ZJ#M0GJ6NZ)D@(0YMP*`>+^[/R][LEG+`(
MO&]$`[9`[2)%I.!7BTJ@Z+A]*]2/<C;_``=.3AP:N*C[J+Z`?4&^_P#AU^?:
MKZ*P1Z@W_@.E48(]0;_P'2J,$>H-_P"`Z51@CU!O_`=*HP1Z@W_@.E48(]0;
M_P`!TJC!'J#?^`Z51@CU!O\`P'2J,$UD:4J\]>#`<"+IV,G:?H)@(>(C^XIB
M[[J(]X=0'W_8.O*MEH@*16V$@K.TTU/RG!$3BD8AMMQ%1/N.B(A^840('<00
MWV]H>_7*[`G@M+8G3,V69@OLG(&!=5DL78"I`9,G:X3$PF_K"A!'9(_0"]?B
M`0$.)W#A9U]B0G056>,TSG,5V<ZY4%2%,8%U#E*;M+W#\0J=OQ)"/=[P$?;K
M>ZAHM)4?N9/.Q$2DD3M%$G)N[^KKIIG+W(MU``V^Q%-A/^,O4NPE_$K(-P1E
MHSL_.DL5(NQ&*YSF`2#W,$%.UPJ"NP"(,P`PF*<-^PQ`$NX>ROM/M4-/8M\P
M?B=NJU3`$GJ!A1D%?8=P`AN19OT#L9.4C`8.W?NWZCT`-8D:U^%')U2ANR55
M,.Y^Q(@;JJJ&$4TB^X1V#<3#[BA\0^X-7?'AJJZO</48Y!841!%$I1%9XIN"
MYBE#J4!+N*29O<0NYC>P1'V:@&\I[5RI"&?+#(K>5)!LD;PH'`"J"<Q1'QH@
M`[E6.0P"J?W=Q2%$-A$W(3M\H90FJVQ-F@,F[=-)5^FJF)3=H^)F8B2BAQ('
M:=-$PF#J80%40'8H%#V\7,G119/"Y</@$RGJ7?B5%1913QHH$[D`V45.)@03
MW'V?$H?[!Z:HV@.-%H;5D\;-F\*=432+E1L()E*4Z2!134Z@@3?S&3$JG4YQ
M)O[Q`.FCOIHH753G=*.-U?&@D=`!%LW(":)115**8JF*'>X4+YOAWW#?;8!'
MKJ/$#WJ`!4.Q44<I'<N0:IKD42-U%9XMV;JDW*3N\`"'?^(P*>W\.M=2E!5:
M!^I"I&2*B!&@+.!*<[<QS%20;)%5+N4!`HJF.8%DR[E`=^H[B&^LF4CX!0NJ
MJBW;%35*R\BX*D,)C++*KKIB/C53(FGV%`A2'$=B@!2[`(_;H"_&BKD)2X:.
M7!#'4BDP\8%500*1X8A%4C`H0ZAA5`%U-R;?R"@/3<>NH.8)1V2\C?U12]\3
MVH+E+WJ)^M[BHK``B<`\QA$2D-N`?;H#S*R[<5\S-X^F[]1FV9"R+SSC+?C.
M'Y)-><=;Y.XSXQO*U6'LHYQ[A=1Q@S'^*U>5/ZU)'5B"N'&F1E%)&&^6*QP2
MDD<JZWF,)T\$'5ZNN42#`<&5UT^E!R5D3<@\TQ#6<M\[(_5`MO)U#A-=^0LA
M&\7>4O&B:L-#F(:.N-7B;*SHU6S-`/F"LU&/)$#H*/H5LVDDET#(]F3*1^M-
MV@\/J4N*5BSZC'%VW\G\3<=L%8.RQ1.4G,FS<IJCR3R_E:'9U[#\#FJ8I<SE
MBJYDP<W])?K_`&VCC`/F]?4KS]5E($6:G46;>G,0P/H%*$`EPP48>1_TS?J(
M9VRCRGYI5_(&-<>YN9<D,5Y2XJ8,F:I6)Z0DJ3PW4<QW'R''D0G>D&>(F67X
M^RV=U.PZ<<\0*I.'3>'W,;PB2"ZHE``"JF+]4;C)G#DR'!*WXLQ!9<A'P?F^
MU91RYC2H<DV7&6^Q41:L'V:FHQ5,S;&SL4\8R4-;9Q%-9>+>%%VS16(`BBL(
MC9N0"5(EG!Y>U0NPQ],7F"D7CY'W>C,:!C&#^H3R4S^]J$CG*'S#E7"^#<W<
M2[UB!W+7G.CQ%A)9ZR9,96M"L@FJHM*2;)@L@@H\51;E!*``5\5=X&FK+LL?
M</.>ECP+P;^G5D[".*Z!B'AKF_CG=+ES$@,X04]#Y1QMQ0NWZPH*6)\-Q\&W
MR/4\E9+^6L&\L,N+=E$B9XH59QY2%"^8@.*(2*R&K:)Y^#'TH'5%8P.2>5$G
ME^:R#CKEMR:Y#XHP>KG=>P<7Z).7;+V3IS%V4X7'M=(C`&O85"ZB\$[UXY.R
MD7BQSI%5W`*(Q-3JH9AV')12X_\`TA,NX1QC]+.Y$AKO*9_XZ<HG65.2=#E>
M4=CLN(:]1FL;G-1HIC*B3]Q>8BCIY^_L4`B!H%@W73!XZ,<P%%T)L!Z!:,G?
M1B/>MY@/Z:_U%\,Y5XN\WYJ^XSNF=!Y/Y0R]R:P+%UBK0#^,Q_S$?MH/D%72
M<DU[RZCLJML2U:N5I>`BSQ[-#RP*1&9^XA16UMX\5#*)\OA]*+7<;?I2\D<`
M$X!93FT)K+LQAOE!EFU\@.)%\Y#24_A&EPMWR[DJ:QCRDX]PBUB9XV@,PX>@
M9]G(JQ`E<I2@2+L4R(RA/*,J*(9.XX,H>6GZ'G.R5IUVJL=6*0%*O>$^5M\L
M],#(]3.RG.9!;ARGH7%F54D%'H,2,W^#N0R+MT_-LA'NXU))<Q%TR%%3CR*U
MOBZF;R3^EYSQY,7#E%GUMEK&N'<C0+?CW6>'V+Y*I5_),M(Q'#!E%9*Q'/-,
MU-;M')X&-E//DA-'E6Z3&04^7KI^M#Q@!`$$568R`8`4XKW6XZ9@R?DB>R;%
MY'P5(XCDL8S>,8!S)A;6UO@+I.VK%-2R!?R5YU"QS**1;X[M=A7@502=22#@
MS8JY5B^044][MXKJL'VKY^J1]'+D%=F6`*[EMG7\52>'\>_4-FZ1ERK7FO3E
MHPGR2RCSBK?(WB=DBMLX1RX?21F$-#F<20-_RTV:KB.<"4RXAK.TE;W@:5T_
MO7;<7N$/U!>(]=X6<F'V':-G3/V)Z;SAQ#R'X_UK,U,I"CF,Y4<D7V=8#)V(
M,B3*3VB$?-9IJB$C%O3LU1C'Q2$,*S8Z6H"S%D)B21I_<O8WCY/\PT(#%4;R
M3P;BJ.L%LA\L6W+%AP]?B)5#"CUM8V[S$6+D8"3:.)O+%EG:I(G2G;-'*L8Q
M.4CU52M_&Y2UR1))JLDC@5+Q!FZ(DGO$)B80[CF4,\ZJ'$3G'HJ0`^(1_<&M
M$QXD_4L[AS2--NZ'O>(QB('<*&4,0Q'7A73#9-(#@503%,5,@"!PW$!$=]PZ
M:C#1RI18B'0<++^>.*DJF8J2:8+N$%T/&'QJ(F$QP.4RIQ#NV,`[;#]FKIH5
M:C16%]+ZDY7A5DR)HE3*NF":J(F7,8QO.F8J7C'QE*`]>PWW;[:FZ0^'1">"
M#1_8Y(#)RFX322.N5NH/@7()Q\:?IQ6V2,`D[]B]_P"P0]FM[W%5>%543NB.
M41*<HB!EE54'28J)**$*5(/.D<.]-8`6Z&#8W[0#63M;Q4HA8&CQRU*8AXQX
M0%SB)-UDC`4G:&Z8_$HB8RG7M,;;?V`.K$[?$*+$LV6;NFISG!!3Q+>F?-C]
MR"INY#X4UMP,4Q@'JBIL;[AZ#JN#JMZAT&7(X=+I/R%2<K)(@5\D`[+%$JJ7
MC6*;9-4![/PGV4`1^$X^\(F-7=E'Y:+3*-%6IV[Q(1!1'=HL0"_";L.)!*41
MV$[901]FW>B8Q3`';N4;N=P=%'73LI!%^W(97=PEU3\@B!7;0Y1$IDC;[B/C
M'H)#;@.VY1#VZP:%M`HW$(<,SH;*%.55$P"*:Q-P*8/>40'J10H#U*/4/V==
M:$@:%:6!S))HLA(Z3,L8-DV()[BY%RI\"*"8`!A41,H(=Q?X@;B&P^UM8N-%
M#S"Y\&RJ23A58R?>Z.5J9VD`F!85E`1739"4!%8RBQ3`)@_"5,"E]FX4FJ:K
M=CLNJP0<%`BJ22PQR)`3V2*0"))@Z/MV`4!5^%0>B7L#??6`^JC),J@JU?&[
M_P`Q^5N)#$'<A&Y17#8HFV-XDO@WW'<R@ATW]VP7#'1;2S87CHH;"XE_1G[Q
M#X071*H0P"8O4$/$7<=NIU=M_B-N.LUCI\*GW)`H3P.D0'=9VH1<O:`@&R8@
MD?8H#_,H`8H=1Z_M'7(*A^")&\2,C+T]0QP46&RD`H%W*!0&)EMTT$]P$0`=
MMQ'<1_@`.*9>$CX?Q"R:FB0K9\PHVK4U<G&6,<H5"N7<V,[!9E;9"$@8;(99
MIK634J3DA=>D:68)Q\BT%H<P*^10O3M'?7BJM[5T"^4<>-K%;*@YO-1;VJB5
M9G=[O77$]&)3-3ILD#_T5HL;%1<KB*@'18AP)7*P%2[41$1`!*(D;VI!&9LQ
M1)CC%6*R517XYE;.93$`M+)%+?VELV$4%A>.Z04C@1L"+2($'*HMP-V)_BV'
MIHFT>*\](7!&"Z#"<C<AU;D)C>*AXC)\1VST#38V21QME:F\E77)"/@<Q(U^
MT+RV8[RVRM;D85NU3"'DQ@EB,4"B\<'<F56O"JZ:O8HQ#'W7C37(;DG6W\K:
M:M0;HK7DX-F\D,^L\?Y9LO)BD6ND2S6<]!0XV5R3+S+P6JI94\I#(K-F@@HR
M7=%*'0IJ:]B;#-&PSR9>8AY>T+']7GI^NXOG+W5<>.2KU6&990N=[DZE;"5>
MZP=GR5DW(+?*;ZNHVR(<1CU2%!LM'`+I)1T-JKQJZ?-K2\4/LTX!@&^><8-)
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MA^@/VIQX'M$\R9G*Y&_*,17;$F$7(84E+0G5@P7SWU61+/C`4'2!)YZL[\@*
M>U1YQF@G$5[B1&/VK&2>M?J1Q+5L#.0$63=^-0QVH>1:/8;U<)/-V:/<41\O
MA`ZFY=SF*.NV=TN"_E=YN6C*,3Z:)+ZD=6Y0B32'/1UX.$3\OC$,1\Z.(Y1^
MOW+ZOP_PZ_*@H3[5],5=5$:(C1%''F`G%K<6>0*<VV@GD,;$MW"5;6=OCYU7
ME8X()X+P)AOEB5@\9*L"MP,90)]VWB=@_K)RI=VLS^$K=OXQ]/[5Y0_3$Q3A
MR,F,.7ZG?32J%&FG-/L1V?.NC,N%#&LV5%W&2C1P\B&_&S)EK(@TM3<31@A#
MHK,O((^02%[Q#,0'T+_3Q7)<,B-1MI2C_<%[V:Y%P(T1&B(T1&B(T1&B*-W,
M+O'BYG<J=4D[R=3&ME2+4X>NP5M?31E61DP:A7+-"V2"EFA._P`CE-Q&R)`;
M$4,#5P8"HG*QU";7Z>--7Q]Q5IM/=UZ6K#V$MN6VTA&/PKWRA21/E>YKR$I0
M#U:F8\@UL6S3Q4[NL*H0D:56$6;'\0]W><K(N5(/*,Q7(=NQ<7#'\O;ZWX)`
MDE*1L`UM#6"14*B18LQ"$54EW$8[1$3G,BU=)$,B!C@42D,&HN=#58+#4*[#
M3G'SVED>8R27;U9S+2BJ35523.BW?><"/2,22BBJB#!10@*)D2$J(`?<I2B(
ME!)W\VJ19J:+QP^HOQNN/U1.7>/^`,W=[10N%N#\9U?DSS""DR!XFQYDM=\N
M%IK&`\'%E`(H$="()8WGY^25[%0(!&IB$!T5JNAA<L3L&[\7!3LQE]+'Z<.(
M*@VH]'X1<9T()N@#=0]DQ%3;U.R!?'XSJS-JO,78K/-.52B/>J[>+*&$1$1U
M5DSD2[E>8/,CZ3^,^&LT/U-OIEU%#CYR!XTLI#(N3<)T%=S%8<Y/X-@NZ;S#
MBF7HQ5QB*Y8YFELW2L,M&)MVPRS9MWMQ<>%VW+<9[O).H7T*U"U0MZJ57NU;
M=>MKMQKL):H%[V]OJX6PQK:7BW7;N/;ZAB[3/MOTWT7$:471:(C1$W%];>HE
M\6G^76M]Z7(Z;GRUI?PL8S_W2+NA\QN1?"KZBJ!Y_"*>Z?\`M%9H;N^'M-V/
ML-SIXG=!U,2WO[:0UX/*?ZG&.S'J&OTW/7\F-X-5QTOU;9ZW<>PRZ/<+O3[T
M)/C2VPM?HLV/4S!M.[$\VPQ\OZB>.=U&+CZZXNZ+YU/J4KR!.6F2$49Y0K`_
M#&*-^G4IE=%523+EID9%^$$D;QN$3H%\1G8@*C<=NT!#?7Z&_;:,/]*8LNF3
M<'?#Y]H9OEY4W:Z\.*Z)ZBKW&8?_`/%_^9<E]-Q:+3S<P(YDU1MZL38&*U?.
MLT,K$P\&T@@>*RI4C`LD]4?R31-NT,FDJFB0ZJ@!N4!S^[4LB79(;(`8/6@1
M.K2E(3H'X,"2=.`XK@]*"V.YDR/YO3D&;0.*NO?CSC]W\!M?G>B^DLCSC]W\
M!M&",$>H'[OX#:,$8(\X_8'^:;1@C(\X_=_`;2B,CSC]W^:;2B;4><?N_P`T
MVE$8(\X_=_FFTIS1@CSC]W\!M*<T8+B(<A#REI.IN`+658A3E'L.FNG%19TQ
M*8/88Y#F#;J`]NP@(#KRHGRAN2XXZMXKI`*5`4W3](#M4C&1]0`=I!66*!D/
M-L.[<4U4P$QRCV[#[2[[:U4T5#&BQ/CJ=%G6[I(J@'66,'<J")BB0YURE_&5
M,#`8#DZ@!?9[]!31$J<%,R:)*B`/?*!%R"4>]9LS,!TSF+V]%S*HG$Q3`/D(
M!?>([@'FTHFNJ0*D%5-!5(!?MB'*=(R(B9<J1P[3B42#W*^,ANX!*(*`)>H#
MJ@L6T*T%E=&3;"FL@N"K<2=B\JWV,54@CWI&<%#8BC-`PB`CL!1`PF$"B`#H
M*T*R5J19.BK)F:&*@LU(=5H/>!FKEH81459HB8Q/.(FZIH"(*;#^6/MU:-71
M%M5+`@JT*84U$`2*!ACRB!U@4[``RIS&\0&[S?QS]@%_"(`8.W4V,6&BGM6I
M$CA\9-Q(%*B4WQ1\>9,RHE,40'UAFXE!1P9,=MC*%(F40#8H[]-`[?A1TN$`
M,=-M\2"*1@55(F85GKA7?O(510HF[3&./>?MW`O3J7?;67>O%$N3223/Y76[
M1NW*)$6B1]G+E9<"G$RJI0'P$!,"[]G<H83[`(=1U#IS6CI16^59PN8"$*T;
M-T2IE`$P*)!5,*JGC1'X2"(`41.IW'$1W$-&`"@')9$0;I.#=I3+G!`.\/(;
MM[E%>@N7)@,<X@"7X4]Q^\NG!4.:JBRXB[;D$>]4$US)H()["7<R)-D4"B(E
M[A-MWG$3#[S>[48,[*,HF<K,@9YQZZQ7$X6@*]+SETEWC%ZWLL--R\&V62N^
M(X1BVGYJ!<H#58^2@K=,%6=G[@:@F#L2JIM%4SM_\JU%O<F!K_+/.5I++RJ=
M.D*%,-5;&KB?!UIPG;7]OS4>/N^6X8(![8FKQ)I27U0+3(IBZD$-XX!5-)K"
MNQD6`%FXDM)#'FN6M7)/EZ"3Q/%0FS##,\>62ZRF18["JE,,-DB*C%RLSC12
MIVB0:*R#2@RKXB[IM$E4L;MN\-'($7E&*WDP_!@@C%=_'9MY9JMG%OMSJMTS
M#4YE"UTA3)BN/"3+S']9B,B7F&K60(*GMI=S8)2EV"O5B/9N)*ULVGI'<VVD
M"HJ,BK%"LU0A9FXKC:URJY3QDG^J+=C.7DL51$I(U\JL3C%W$*7H[3#DU<*4
MI$12K]_D*K6C,5J1C!C`>(F@(PKT\8\73?`AY),GBJPX+;..0',&)H]EL#])
M6L7K'6),S2-^HSS";9:)>93QU.XTCJM*5N89VNP[5G(%1R*6P)-$GDCX3LU4
M"K'],[(``D.A`]RZBM<ELT2>1ZM!HW>(MJ<D7"R3.J%Q8>4)D=I<\P9&J&6Y
M%KD2MHLH"KDP[CZ$8S1U01!J3L$CHAQ=)"`Z>*FT`+=96Y'\@XZRV+'>):E4
MI7)<-ER<ARL+'1;FK76>+7\]BZ+QG9IV1C%T6I(RRFNKI%63;J*@3P++%0,#
M!T0N22=4`'&@39MN8?).<E[.^:0$M39B/<HH4W`MMPE9ALEFCO[6<VTJXNW]
ML9N0;1JV*ZA1(Z54<H]T7*%3[B`HE*LCA052!HM6ARCY7OJI0['5H^(OH_HI
M_<,G2L?0(F5B*@^0M&'(HS.Q,H`D=.F@8.$N$U(OV,0U=V<C9H91,BWIQ3-1
M(LRC-X*5F;+]R-I>3)QSCF01M5*:U+%\S`4%W0V;9*3F;;FR#QI880V2FRS@
MK1)G6'+B6[Q:G!D!@76`S5,2BE2G%0-H=4UF+N2&=K/R,_064("&QQ6TIR?C
MH^N?(V9G%@39Y*S;6&"3"RR$>`VHJ=>I,&L9Y&`T1,+L5C$\:Y`T!.G!5@VJ
MV]]Y69:955VTQ=3Y/)&8Z[FK*$?;J##TN236A\(XKO-X<*.%FDS)UZ++/9`H
M=>BHR'=H/'(*R,V1\@T=)HG;Z.!3BFT>Y-NIRIY1R$C/-8C'L2SCRQF1VM;N
M\UA_(ZD863PI`SLY:;;-5N%"0FCUS)R=SIJ=>;M6BSHAH^9%--V8HI(SS"BK
M#G]/:G8A\]Y8EL'8[N,I934\LYEJS43(&7WF-D[#&U"CP["Y.H*YQU5@WKFO
MS\+:K##1<$C8A1:Q/=("Y.P;G[4B'^M2FC<%MN+63.2^8[%=9+)]71HE.BHV
M%AJ\<E,80GKYV0Q]0K"6SJU^R/%+FS2D'MA=/BM%SBU8D,6-7$SILL<;45X(
M0`FZDLV<Q:1`R[PD,TS(^2K?(.4&0)2B4`M9-B_.D;C*CN/D3$94EO\`U33P
M7F!CDS(+O>_R-C@W*74>C<%&B_)=!BKD!F*WX-SU>)E[6&>2Z=$RSJLQ3RDR
M"\947B$A:&C,;!4ZG#/KH[9II1R*BR7@?O")HG5`AR=Q#6K<PFA8.RY-KR!Y
M..J?3[_#R,[;4I"EYJ:M*9'85AWBEUR/4LC43'>)D(ZTQ]C)$A5+LYR$#M:1
M1".9/F,.L[12CT/4D1R7U*K1THM-,9_Y6-J?8[J]1:4Z1K./<;(V2ES6'62*
M,/DU;/2N$LJO4)WYQ.)J5YM#0J]KC2$,_;MH^11547<-"%,:N6H@`?FGDO.;
M<EP6.L'V!KD6+K<;<(3(,I;,OLL8+Y+BDK95F#12CT).L55*,9MEKT\>OB%<
M%3(=P:'%FT%-X]04+7#,C"M%H\?YEY2V?$_(S*&2Z:O4)6I52_N<748M;CUB
MEMM4K*LJWBW<6V<FNT^+><:BT-Y1*E)]W]6V';=7DC#@FE:<GLV+7JDP"EOC
M)+%\Q+33='-0XN2IC2]G9L<(.%H%G'V1)[&H.:]*7F>8F58D0-(BR`$A!5D[
M,>CV(WUKJG/+;)\I3<"OL<U9[:9E6$937*-U'X\G%6.*VKP8&FK,$HR2E861
M:S,#:+2K/KM&I)AV>(K#MMZ<HNTW*=UX(U2Z;UERJYGS\8YCX3$2Z5KM<1\P
MQFA_9Q/N$8V7D)UCB19C9OG%AK\<*L%?*O;+JL59]'$=5(L>V`X&7(X5>Y"(
MA:*>YB\LU8VZ7F,Q<[K51.SL;"OM[3C4Z[J`M\!@['EMD*K()Q:Q[">SQ>0I
M:=;E?R#4*M(1\*Z215,[!L5R>7"@5$8\UZ/X/G9&ZX\AK(XLD?999V:32=NF
MR<6U8N#,IN4:)H,30S5K%&,W11(0PHIE*<WM*)MQUH:563XIT!6$':::G<@X
M!!8OB5*`&^!1(1)L;=-9/K[`W$/N'0#EHLFJ'`$.HV!1$0^)4@]HF.GWBEWE
M,F/\^BINE[!WV'V&U>%%:\505W+4Z!R&!TU,<[=5,X)G$Z2Y1*!%0-^0Y)Y"
ME#KVG#W"(Z@B"_-.%5<JD@ILZ8"42$`47D8X.83))+;=JC<ZH"KXBK%`!(H`
M]O=[>T-PNX_#+54Z,4B$2I*&2[04;.P`BS![N004`O8045N[<A3DZ`8HCVF`
M-C%WU:J)$LBX0<G<1YNU<PB*C9<G8H]3`H`!7*8&`KAP@!=@62'O,&PF`V_1
M0BNBFGM6U9V%N#907":@%/NFXCU-@454)T'TIS`0GE(([@8>TQ`_&!0W#4V,
M7"HK3BM,+9XNX*Y5`P*.TC`R;I'$HM&!Q$%%5C#VF:**@42B8Y054W^$I2[A
MK9-&5/@MPS$BZA$1.GZ5H04D7@A_4F*YB^(_HR;_`!IHIAVJC[!,81$=R]NL
MZ>U0`-XJQ),XJN%$Q\:0[)>N5$IC+D3ZG60$=B&2.?\`"<0!,"%#M`0'4-/:
MFI=*6Q?F!%C-]B`4A?&Z-\2KQJW`QCG3[]Q55*<YA!53VIEV`!Z:NGM1RDK0
MPBLHJQ$")D,1--X/Q]RB1A,LJCN.[E051[>\?@W+_&#IH2="CN/!*U`376,X
M9)B<2E\+UPH(F2(_.;N5$RA1`5#"FF`@0-@(81+\.VH[!N"HTJN=E_RI:I]I
MA.H%@(HNL?\`&'=%2I42$VV!,HF`1[2[````CN([ZDC^7(^'\5.(2);%N+EX
M*5JJ^.*.M69RVGOTU7E:Q%J0TO>5)9M/*7*2CC-A:O;0>=9(O1?*%,Y%XD1;
MO\A0,'B46_%;I:HT]Q.6.SKU2NK62XUYK4K;/J0[0TQ9JJR!Z#*N3LB*7JI2
M#9_,G/B:K&.BGZA7M*'D/NHC!:]GCS'<<6A$CZ'4&),6-73'&)&E=CFY<>,G
ML66#>,Z45)N4*RU<PA09J)L_$4S4/$(=GPZ4YHR8SD'Q^97W&+NM8VKT!!RY
MLU4;.DU"Q5BG<1-\E6.MV9A+6AI/Y"H3!U::W-7*+0,FI-MT'#LJZ2/D`R?<
M('"-]R:JM<:,N1=SP:_L-JK%HC*W6^-:^5+>YF)W]6A;^-S7,!V[2K1CB!43
MLT;?7N5$4UI-\_CW;=*.<K+(.%7H`G:!5G^U-2'"_+:V-X^(F7-/D+#09?CE
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MDNBQE*NDZD2HPPR-<4D6KI$"*',N+X6ZA"F%#O\`T%^T_6_I4C8D+F++(E&Y
M#4VO+29`JTQ%CR9QQ7SKU8(_/@%XS%L$'A*M1_V73"8A^<L:GQ,:)R1ZT8?J
M'PS>68OI\6*LDQ)6<=BM$$C3BC\S<F<IE,+84B=NP"7<Q0UVOO70.;W@SCU`
M/3IVD1<1/4N-)^`;BO`P80C8QV%?G@WA2-:_P7U>A^_VC[?VC_<U^5E]-5=$
M1HB-$4;N8E;BKAQ7Y!5:<B@G8>?Q-=8J3A!86R4"79/(1TBXC1CZ)7+?<W7K
M4S"GVQ<5(O?B_*;+'V3-F8>)6[9:8/T^U>3_`-+SD!D>KRF(>&\9C"ATO"5*
MJ5J807R[%W.V`M,<E&M96RM4E[/G'BWB3&12+2+@Y3E</VBRA3@1N1178ALP
M<4X>S^]<ES:1N<;O:/N8+WQUR+@1HB-$1HB-$1HB-$3&\D\<*Y>PCD'&`-8=
MXQO,.%<G$)VTR5,CQKL@Z;ISQS3\77K6J@JE&>0Q$%H]PS>F#TSDH-U5!`J"
MQ=(^,>"<><:<,53">+962F*=2SS)8]W+/81T]!:<FI"PO40;UF*@:W$,T7DH
M<K=E'L&;1L@!"$2#81$A))<IP;M?FE"!F^FH.PN*VJ1P:5LT-'C+LJV*1D03
M5G&#)12:28+$.<PN46RZ2/C'RB0!`=4!_:LDM[$CQ6^I\I67,K1YQ>>@Y2PV
M&2\ZSY%\FR?OY)9U(1C+TP`V:1[1PJ/@13W(5,P"`F[NX4G>NJ!FIHO,:S\H
ML2<6_J]/L.9=M4)1T^=O%C$<EA^R661;Q,/+Y8X\Y`RY7;!C<)!XHDT0FK-4
M\GQ;J+(H<@.G#-5NF(N%D$U8N1B8..!7L%HL+R-^L!]1K!?!_BGF2%G+7#6'
MD3DC%EOJ6$L"P;I.:R-<;3<X.4K<#-N*E&@\F(ZAPS]T9U(RCE%)H"#51%,Y
MW)TD3EN$3*0Y+T-XYT]QCSCW@B@.SF4=4;#6,*>Y4.`E.=Q6:1!PJQS@/4#&
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MH#'^HW->H,8>SX@H3XJO\W2+$A9\5R#.,O\`D]=U7XV?4AWDY/5R[-FS=]:Z
MF[EGO978J&MLU(13>'<&(U.Y)XT5B(F9[K=O[WV>QW.S\IWN,I]LPAO-L2VP
MG;):%T;?.96P)FX`X#$@G>6]#A95_$E&]BR`R)T=G+_RC4,7I_!E(V$Y=\A6
MV+*Q+2V69"5M-X?RDA'37RF(0A8J,KBR]6?5U->+:'C',K^J8Y^O)@J!S,")
MMTDU>I_)U6YZ%])W.\WX6<:,<;&B!*`N2W3,@)[R)EVV2@(D4)<GP]P?4/=8
M6H;KA,KCL2(L`"S#D7!=_!/M-<P$,;8FFY'*67,CKY(G89A8Z;%8XK[.T6NN
MQB)7$(O-6*G"FE`1=(F["Y1!L\EY%L=P8O:V$_:8I^LV/0$.[]Y@.S8EH=MA
M<E&X;]V5NW(_%MA/XI3C%]PA$[>++SH=[OVL8RR[LNO*L-@B2&UW`T$3K5<W
MC+Z@=+=7M&,R3:^4E0B5<?1DXT#(^/H*!JQ73Z.,[+=[)::$,S,5RD.DW#=5
M$ZK06J"2@F7<]I-C^;W7]K,B.$;G:8=LOS&21+H7[DKGE/\`APA=($[@8@@$
M$LPBY7)C]\VWWR+MX1VL!*,6W$:EOP\J'VK73_*3-5!O\?#SN296RP"1V"3H
M(E&,=*3R+DQQ&1AWT.B+=XSEV1_4Q:Z2B:*O:F`@<HF[N7']$^FNY=MG>M8_
M1O,3NG<E$0,=1($AI`TG$NU5ZZ[WSO./E",KN^#:"(+CF/X%-(XY8\J*98[9
M#V'+<C9$8>_,<71!$X*$!X_M2[=E)O22+:OLSR,(I6XJ:8!.`JW,C'*/4S)B
ML9%1!3W,?0GH_/P[-W&Q>G=GC=>9%VXT;8,H@QW%I=0QETZ^81+L""N#^N=[
MM7&E>>._:'B*D\"&X<:T*D'P]Y(9AS)R/A\:VO)3RR4]O19DTT>/;)0?SJZU
M]HR^;RL0]9"BZ95\)E9TDQ;[J'<,$FJZATUC+(CU_P!9>B^R=H],'NN/C='-
ME?AM>9D8VIF6V,@=9[=ID102)`<`%>?VGN^=E]QCCWKQE9VDN`(N0!RX.X]B
M]@EZDR(H84Y&TF*F8Q54OU/-"?M$WPG3_K6YC$V_#_&+[.H!O\38-4`CV+O;
M#Q5!JC$Z93MY:R&`1`P;V>9[5"AN!D^X7(B03>S?VE$.OO#3;'^5&',O[T%J
ML<J50I)6T)J%#M,4]EF141,(#L)TQ=;&`?\`-,'L'1HO\*;?;]:V,3$LX]-6
M/0!T*CYT+A4[MXX>+.71RI)`ND\<F,H)@!$G:41`Q1#V>_7+(DU-&5B66\>*
M>,2LE]E6[8ITA7(0116.8=ESKI@(BF8YN@B.Y!*`=0]FL#1PE$E9(';&%5OV
MNF*`%5.D*@'[B`8`(B!MQ'\TQ@`!+N.WM((@(ZIJ&XJ@T;BD'G*"QSH*%:JJ
M',<S)WW-R@)MQV1`X%(H0`#8.P0$H=!'8-@-13PXJ\CE-B05T>YD[="<$T3"
MFJV,F.X*JI*I*&`!6$W:4!`#@&_;M[S/K4*5=:DSU=%3\AD=L=8P`<JRA"QJ
MACC\6QU`(<O>(^P2>_H.W36FI4JL>"3OTY@4CL"G9,&`J@(I`919LNL7J4Z,
MFL1$K(R>X]G87<I@Z";5&WA4J,?>M>E`O1<BN@J<'!!,J9]Y1,Y[2E^$2.G1
M48YTJ?\`"`ALN.^PB8OPZNX?"48BJ7-Y1TD)V[QN9F!>XJKJ,`\BN?MZB+PP
M@99HL8V_Q'`"=P_#MT#6=H(<?V(ZZ!HLD#8KAH+9L@<Y@*LX42<++*AU4543
M.<3JJ%'J/?W`)QZ^\-0BM4U*N(J7N$&:9G;DXF[W+@YA$3'$3&464V%0H&,.
MX@`%W]@!J-6J>Q+#`VBTQ(X4,^D#'[CIE3`Q4%5OB`A&P"*7JS@.WYAA\8!L
M'7V-=-$^Y8VZ#E<3"J8B!UC"HH!5"B9,@!\(*.C[))$23+\1@]^X[Z&FNBHT
M3?.\S8G@7KAHI?ZC%.32KFM"ZFI="(!678.XUC),$%Y$41452D)QHF;M$=_,
MF(G`#=)K\1T5UU6P&_8]3L<A7)/(=.8SD"<B4S$R5CB8UQ'O'C!E(-FRL>[=
MI'%X>*E$5RI_&J*3DAN@&T)`T4#BJS.<RXN24:QC7)]"`[]4QBF5NU<,JZ",
M!JJL!-I,443(BX0`";BILH781Z[-H(<JA]3H@<J8^?HR*Y\D5),[)8[!V$E9
M&3!XBZ3=IQI0%G).&SXZ!7SHA"+E(+<W>!BJ"4=]9>(H$J.%$M)F/#;0RPIY
M*I;A\T%DF9=_;(N,12.^CF$BS,D=X\:`]]1&RC=4OA.H3L6)N;<0#0/+2@48
MD\@L3;,%&4CG$B7)M0!@Q=IM7SEC8HQTE'.90KJ0;).?EBKI9`'C=NH<AQ#Q
MJ>,P`81*.U>(H`Z$-[5E@LQXM?SK.`9Y1KTE99LR)H"#;S!2O)8@!(-TU(UD
MY<-'<@!G$4](0J1?B,W4`-]AUDAZC14@MX+*RS1C2<<N?198ISE%JF\(^[K5
M74$6QVKL[=SYTG$HD"2;15@N4YMNT#)'#?<AMLL1]`HP`T2XN7L4&,LS)DNA
M2#AFW-("V2LD6?M9@V=.5'+5G&OE5WP&:M%CF\1#CV$,(E$/:8`.E2?!7(Y9
MQP\;MW*63*B5N^<(,T$E+/$*@9^MV>FC3P[A="4:2)CB4H-5&Y7!3[%$@&Z:
M,FB3HYEQ*Z!%TADJCJJJ'73176N4,R<@X:N'#9<R</+2+9X`(.&RI.X2`4W:
M82[AUUK@C'BDSC+V+TV3&3?Y-ISN)D?6BP?MI=-TJX,Q(V!^BB,;ZD"KM4WJ
M7D34ZE*H7<-AT<)I0+,PS%C1TK/QL#D>JJ.ZM$OIZU1SF>:"^@X2*(L:1E9)
MHLJ4C*.CTVAO.J=,H)%*'<;82[J$.=49]5=_:OBEXU(]=Y2HQ4`.(;IW>",@
MD9/<.U8CF3#TARB`;%+UV$-B]0WA(TX(QX:JA\S8Z!J]=%R11G,;&']/(JQU
MH92KAD9)\A'?UA.,<NYHA49%VFF)P2%(AE`$=BCOJD`::I]_T]RL6RSB1KW/
MDLG4]=P1H\D05"UQSOO91S.2>2+M`\<Z67=I,F<.[.J(]O:1N?<.FHY'L*,?
M<K768\5@B<TSE"@?E("[%N2X5]-^W1.4RXJ+M_7E,F(!N8Q%$Q5`=P$`'?1N
M2`'4!*U,J8Y;2#*,;7^L(/90D<I&(H2/S%^_3E`2)%J,U&97+5RD](N4$CHG
M\8E-[0U&`JFM"DS/-.(9J"7M:62Z:^@(Q]#1+BS#9F2S!E+V,K-2NL7+=!T(
MMWLT1ZB+9,>TRW>':`B`[5^(1B*+9?VHXZ*5%S_:G1EDWFQD52WJKM&SLW80
M13*E\Q,NY.4BA>XHD[@`P;^W4)>I2A&B2$S%B4Z$>]0R322)OW!46DG&2[:2
MC4U#MR."`]=IKK-8;=LJ3M,X,W(83E('QF*45%:I))YCQO%R")W.4*WY0,V:
M*':SD2\("LPM'(Q(+"Q=+D*F_772(F938@B<-Q``$0H%60!QHL+[,V)%DVZI
M<O41LJ5^Q;[FNU?,U\QU4Q3+WHS3CTHD3-W;CL0H"'L`0UK:U6=&.G!6RN8Z
M-%JS+)]D>OIJQC65&7\TD!DF+>)3<_,U7RRJ0HI-V`(*^0QA[2@4W74CL);B
MH`%E#,V(G<179E[D:GL8^QJOFE=FS6J.+#R[V'!,LNW9.G#P6Q%XHRA0<E[R
ME0W#O$FJ014E4@BB1.\EXWB47)G63Z&FFU,J=<PW2OE.5`RX%2<'1))G5%(P
MF(7O+W$[@VWZ"`42!-5*FH5$,Q8V^9D8.LBU([A\V0>L'R=FC`361]4>+\;6
M;!W\I=K@_9"0K;SF<"8AMB@!3"&BW!&HM<_RCBTL@T7#)U/4-(JOXTCXMCCC
M-CNXIHTD739XZ.N+%NX9,GZ1U"+*$,4JZ?:(]X;QPS%`_)*DLIXXEW,9$IWR
MBS,B]7%*)3B;7!2;]Z)`(BX:,V;5^NY=KE*L42)$`ZHF`.SW@%0^"[%=!7L_
MJSE)<H=BK<XJ^5,3%$%$5$710.<2&V_C`8=MPZ::%1W#K,0[233.@KWQ\D(=
M@B<2D*X-MN"2V_<V65$>J2NX&/L`#MI4'P6G9(3G,3\J11`1+N4KI'O3[P_#
MW!L(*(J#[3%*8>OLW#3_`(5%58Y#M5%5%6D@T3$H."K'1273(;H4QRF`H&_#
MU,!=^[81V$=]6K\BIX+0K3"B9/$Q0/))*`)>V8!1JU3[A$O:1^804<JE]I02
M,*@;`.^_76A$.Y0\EK'4')*'36>F.JLHD"C=1905UD0*<Q0(4[4BI$P1'V&=
M%#MW[@*!OB&[HC33Z?2BK'5+62$RD55DFY:OFJZ_D41.JJL;S?"0BCR:13.L
M4PD^$Q3)F[2^PO0!`3$U+_3P48I8+E85#-'#(5"(""?IH]9,[1(2].QP<0`Y
M-A#J'8)_L`.NL4-05?!;0[I-\D!'?<HNU(4I638`(0S8OX2J+*F2(3TXF`-S
M;&$@_#L`;:"GL5=E:=P!Q*"RQ$]NT4V;,PKK"`?A+XT@'8OP[=X_"`>P`'KJ
M`-51UL'""RY$U2)>@8+D,)2=P%%(2#VJH=>TWP`/0![2@!@W[]1P/:E%FCU4
M4OZJU*46RQ!;F5,!O3)=P[E7$_05U$U=C?#N)NNXAOI($ABFBU,O#,W8$9/!
M>BY:O/5E.R>+L7A'A$U$/,+AJ=,R"?B5$O40+V#L`#TWHJ.84:BU8U6/23`R
M\O91,8WL3LDV/<8PB()HD!SY%!Z[![Q]O[,;8F@BHP''[4$J3(0,HK)V5,!#
M<I!M$P(I$`-Q%0X.^T3#[_<7V?:.FV/\OW*L.?VJB=48JF[RREG*B`;)]UFF
M@,L)A#\P`]5W%3*`?#[!-OO[-M[MB-8AE"/'[2O-/GOG&_<>+IAA"EW><AJ?
M9D+0ZOJ("6<EA81RE=;)NHIW.++-F[V)0DG#E)`2D3>N`224523`YC?4?V[]
M)]J]28N:,NR+F9:%L6CN,0Y$Z2VU(+`<6J0"5U3U!W/+P+]N./,QM2C(R8`\
M0!JH+3/,3E,9FJS89E9LY*I/J9%W"=1A63.MR*%V/'1T1<(R2L;-%(]8-,3+
M))<6R2JC9R_21$@I(*.5N_X_H'T<"+MW!F;-V-TVH2NSE(&UNE.W(0)\VV,B
M'9XQ)U.T>BN>H>\WB1;N"A#D1C\)+`Z?6GK=\GL[FR!'T-AD.QE5A?15>PIO
MX5DSL,W/M$#,)253C56Z35E(2LR155%NB8&Z#8$S"G^+O]%'T;Z7_ID^X3LP
M,;A-R)C=)A")+B#N2P#1)-7*Y#WSO!R1CQN$&(`+Q#GQ8ZD^%%UN1^<-8JL[
MC*E5R_<A,CW1-9:N7E+"53KUTK-UGXT74=(MJK<K.G$PGZ@8RPI`\)$)2+%$
MW>D(D.G\7@]J_;F]DV<K-S+&#C=OVB5LY5ZY:G:A*H,K=L[MA'PF9B30AP5[
M"_W\"5NW;N79WQ2>R,2"?!_X.%?C+F?$95QV]BZOE?+T;F(U@<O(U')]:BJ,
MK/0L`#B2F:ECY!BG+TRVV1"(>-E'+<SU.4`A1.F@0A3"?/=?V\EV?N(R<S&Q
MKG91:`/R]V5P1E*D;EW<1<A`EVDQCPW.0K;[W<NX9A9N3&8).\H@./Y8LX)\
M*%-2VY99\DX7($63*<JPL<'"R-OCK&E$QWR:)B:<JM+V!";.]9+,8^%EJXV=
M(G<'*X6:/DD0`_:)P/[RYZ&]*V<G%ORQ8_+W91MFV;L]\Y7`!#:!)S*,B"P`
M>+OI3UD>^]XN"Y`3)F!N$@*`"M6+`$?:HN7_`"9:,KQ\/'YVFTYF4AX6#R18
MK(G`HL)^$@+&VBV[:"KTY7%D8=6Y61!Y!OT6CI<Z*2"R3HX%,S\"W<.V=EP^
MR7IW/3,#;L7)SL0M[S*$YP),KDQ,;A"'YD20'<&(I)QZ[*RK^5(#,D)2`W$D
M#<`12-.;C7^"<S"3R'E(_BJ%N/8E'T[]1-K+0@0#UF$+&3@5O'JK)M,HRB#A
MPXA46SA8A#,P9G7<$(L*21CJ[^%WZUDV<CNXPQ9C;AZ;$;FX'<8[[E8,WF>O
MF=A1S1>5AF$K&-&>[=\Y'3V1T7U=AK\K!N"^EJNJB-$1HBC;S%D92(XJ\A96
M%"(-*QV(KR]9%G[HICF#,LV@7BH%F+XC=<<*U",,4H@O(EGX<S5/=0':`AY"
MYF^TMJMVVWA]%$CZ:'+7`U^X_P""<.K<A.-DQR+2ITG\\PKCSE-2<ZW2,-$/
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M*253;KF2`@""ADP-J)`U7%(%;C`:,FA0/#+#-"])8K&!_G=02HRPE&25,!F=
M<233!DP4$PF(&VW>)P((D`@BEJD=%X__`%$>9'$O$G-^D\<.?&#:QESC5D3B
MPCD2)N,WQW1SK&X2NL1E:RURS3^0U(^K6JRU+']P@EXQ).420%M&OXC=3L!P
M99+"YHB1B\35UZ[\<\F<><H8DI\KQ?R%CC(V'8B#B:_4I3%]NB;E6HZ(B8]!
MG&0I)"+D9(6J\<Q1(D9NX.#E+M[5"@8!#56""#75.T%<KQ9I6RA`PP6)=HW8
M+SX1;$)I9BT,L=JS5E00]<HT;'<*"FF*@D(*AA``[AW*+<Z(C1$:(FYOJ'FE
M\6F]%;7?I\C)K^2L*^)BPVI%W2];="^)7S5(/+XC$W)_M%5F/=TV'L?89[,3
MN@WXD-W;2&O!Y2_4XQVXU0U^FYZ_DQO!JN.E^K;75[CV&72[C<V=Z$GQ2UNW
M^BS1OS:'=B5VD4_4RQB]&+C:ZXNZ+YSOJ-,)1WRQS?W0J2D$KPUK3<LM\NBU
M5SS!LLUPR;49@Q#2S!LBD)#"@4#IG'=3L,)>GZ)_;F=F/I7`\QZX[Y(LY^'Y
M>==NA/!]>"Z#Z@.WN5X\?E'_`/B`7F*6%4"M-&2[,7\O/7RL.,>1R1V#M1_9
MZU(,(^9D?*_9GA(@A(B>31.J*H._5D0(FJFF4RA_I]V8N91N.8X]K$N1O2+C
M\NX)&,6!W$[HOHVUW!-%UJT";;`D$D&+?S`U]U64S:O'/9SDS*8KC$)";H.8
MFR.1;A4VK]")BJ^Y>)2%Y<WNFPMEDT2-$)ROQ9E9:/0^72;E)\LW4;JD;I$)
M\\R+L?\`2<>[S,;?=,.1L6[IB2;@>-OIW#`5$26A([H@Q!>I*]Q"UU,WY81$
MK%WSF/(MN</S%3H34<`MIPJI4KFF5;YNM3<C!Q>'E\R#*1D0ZA62]]B:Y*.6
M%/K!KC*V^.:5<:_#B5DPCS';)QH)).U$N\=U,>NLZSV2R?3^%+=#'C9M1E(2
M_*G<`-R8B($S,RYE(.9$F(Y+D[;BRRLP9-SX")$@4W".HJ0!P`Y,I"3N0\7\
MR\26VXXGA+K2$\6.*?7)TUR?URVC9YU[&.36BA-JBZLZ3J3C422YD#29&BS&
M?26.*)NQ,2CUG'[?W;T)WFQB=TE;NG*W3CL$H[`"!"[OV4E1]C[K;#<Q*\[,
MEC=TP[ERQ"=N=K:'E(5(#F+/IP?BH/P<I=Z1AS.3N`A20E@X[Y;F<(5V>CK&
MP3;T/'%[BW-A@G+15:8EIF0E(1:,?(Q"#,RS^'<2A%"J-E&"0I?0,G'P.X]^
MP(9%PW<+N>)#)N1,#^;>M2VR!#1C&,_*;A(`F(D,1,OZ<"_:Q)7($=>W<,"0
M1Y1($ZGD01%M'=<[;XN)@1X^)!Y$V3"KVN7@[1,,1=R"V3\F(5^1B;%9Y,%)
MZ<2=R$T_9ORNV#E0S=+P(N3"NFNV/S]NR+^:>Z3F//U[496XL`+%@R$H6QY8
M[6!`$A4[B*$27CW6@+-1TV,@><Y!P_V&GA35/K]->O*1/+*++*-"LGL;2[Y"
MKID<-WBS1PQ*Q0=$5\:9#_SI>TP@0FQC!L&VXZ\']T;XO^D)2@YC*_:D"0P(
M.YOI5>5Z<B1W2$3_`"3^ME]$@]Q%5SMC$52%0P^(5`Z;F-T15$=NT/Y!NGV"
M&OS#^&/L7U-6;IF4$4CBW7$=S)J$$`4'[3HF$`.(^\Y!W^_5J/8HHU\M[]E'
M%6%I_)6,'M$CYRH/:V=\E>ZC/W")EHRPVNOU'TC(*[>:)(PKQHXGRN_,HH\2
M5*B*(I`)_*6$L*:J@!ZI@I'F)E2DVNV8\FL=_K&7I?*S%O'A[E*(I:L#B%]%
M77'N,K1-2;HKK)$W882Y)2EV=),F@)/6J10:E445,*BFLDN=I5VC[%HL0\O<
MN7:^87-;(VCUG&V5F^*(%D[@JW-VV+?WK(''R"RU)ULV28/(%@4QMDMC;)51
MLRJ-FJS%L]KI$7B4VJY=(I#1+@694CZTYU@Y!Y,1DLT61A,8+J^/L-9<GL.+
M4S($?:XK(=WGHK%\3<X^9C+E'V=.+CIRS2]@;C`5P8)Q\VATSN#2"*BQ/3@3
MPT4TI51V9<M^3BF*\$6V:JCTLQG"TU9BG'QW$W(DC,1M??\`'K)&:K`\H6/H
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M9B,4WS(IBJFTY=0@.G:89SRO.\3LR9$B7].CLL886RJ:S,[MBJ]P,`5SBZLF
MNJ53NN)7M_9S5,M\I7';,5#L;%,1!`>)O&CAXBJ5)/+D^;BA9_`IE+9S,S1C
M6OW]A8*"WR38JE@SC;EEE;L74"1C<:03_.MCO;&1C[Z28RE+V>O0T#$UQJ+9
M5DNY47,5PL<I2BF@5N\$V@U\5RURYWW27#EXIBI'&D$KA*O7;)F%96Y47(MB
MCLK8RPY89C&&4FDC)(6*B1CR:'([%E)1\E#/'C-*MSC,RR1UC&4U=QTXIM9G
M7JM5DK$P@6*5RG8VTV5HD9&2D:G"/JW7G[_RJ"+EA`K3ES=Q;1%N)`%)U).C
M"H`CW[#VEU]ZR5NDU3@.Z9&K8VVP'<//*N`B/4"D%(");^WIOO[PWT^MU==4
MO53;)$!%PY2<K'V,X*4X*`41V,1ML`F'M*`@)@(4@"8=AWVU"[^".HC7RPT*
MVR,XPL.;<)OI>LNKLQJ%=RM3*HU1IMN09K,XU8CB:?EG';2MS`M!<.&[<$WI
M4/'W[FZ0L@I6J:B93A+50RV,_P#V.[EE%C=I%A9+,QILQ<XMQ$NF\ZJQ@I,(
M2"G;,E9U#MTU#R3U--NL@S$J9=Q*8)I6A2I+5";9K:Z/$Y?Q1@N=1X!5S-60
MZ9*77">,5ZOD!I<[4E7UI!5Q)4R(FH.-029PTA'2SM1554SE0R``"?8JHH$,
MGH&6N;.RY#(7)#CU!'OB=YRC]/.$RKB6)F[WF>+D$),\5%49]/'JM<FK([?0
M$S;'/GN[:;0,C%F;+)+&;G(0[<IO(:/$AT`(T=+<:\A^-N>[3-5NA91X)6_,
MZ\/`NJ/6FM?LT98GE98O8>)M8H(9,J<?+3,>6MD19D^5MWAV/J"G,3\)ACN:
M4"A$A4NR="O9%L6-X9S*T*9X'8X[H!!2SJ-75SJKQFQK1#N8F+M2,H="YR""
MT2W?*D<O&R1T`2'KL9,YK2/M37FMG0N87!W-.4COZ;RVX[W;),+#N9"+82-+
MCHF3<1:#8[==S1<B7!*&D+;3H^4E"G,_AS/TBMG)!,8I%@,:.YY(1+B"`N(I
M]DQ/DR*R[2XN=X*WO/6/K31(F],*3C^7F(2IP%DC)&0B8JV0<!6Y*1"4M[*)
ME",WJ:?I6K=4PJB=3\I:$15-.;+G\<<BL*W*(-DFB7?Z<=AC8.'R&TL-WB$[
MW'I1J=*AYJ/OL3L]B(AY&MXIC7Y5.4`Q@\3-,P^(_<(*9H5"_BFZ-SGX8P%<
MIL[+YS^GO%7>VHP&6:9(P-6O;R-MF-SM9N+CKK(N3T*QSC%2:LE<(7N;IQZI
M46:IP6[3?$*H!T`*>VF9.X\Y>DS5*KY#^GM9;WEW$"F2,=EQR5W9G5T;,KG!
M0ZMF;3#U@Y%Y!Q\P=^@9!%<\DV?+D`Z(%0$VJRC$<V7,6WGEC7C5))8ND<Y<
M$,2VJ<1_7!\?P\+FEE)1<=+NG[*&GYR*@ZD:20=V((`[=4CF/;+IBF!R$,02
MF"`L@!/`J55'R/Q]R<VBLGQ^9N/)([(D=#C<X]2AP<"ZNI4D8]*X-/U%D$T#
M=9FNR\D@<I%)!FIXDQ(`D.)`UH,H:*,.$,I\<<L5_+$?C.[<%<MY'Q_::V>$
M?T'&=DD86MF5>&35L<K%Q]34<6B+GE:M(>@F(0%H<D@B*0.53)$`)KJJ7XN%
MT;3(-4KV7L=X`?2'`:L9JSO"O9VLXS4A\C0=RR96:@XF),YH>-7@(=%^5@[K
M*2@H+*MQ0*V5,1`Q"()C0G!ZL%R,IR$XZXZ:Y9JUXRK]/W&60<05M*\6>,J[
M!['.*[BE_-VRD6Z2OB;F"D3&:N)QC\L]-&I*.U4D'1DS)=Z"X-.2,>#E:_#&
M=N,N>K0GB_'UX^G[+6Y>M62S5NAU:L6^/M4[<%89S#,YN'BLE5BM#:X1HZF&
MQ)%)LD]*1N!#*I`10.V4*$$5+K;XE^HKCNV.8K$>%N37!!.4:1\TSK=8BE\J
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M:\"E0'X)-0LEXKNL?G:"K^1N`4E(XTNKK'ENBZ,HBU6KE[I-B8R5LJ.08ZX1
MQHI3]+P0O4TU4V#U-RN4IA6W34[=C;*E`K5P"Z9%/E[P5<1^*Y>YY7^G8RJ>
M1:I='-`4QY5,@6HULKD'(3$+\RK,(G4))#PQ-R8M2NS+(D<(E15%(>U?XL4B
M:(TO$IZ:YSK0R%3Z;%L.1W`_(T1EMG8H*I1![!<7X7EG2(I)7)+N3@56<6E#
MO:LFDHLYA7$:W7,F'B(F=0"D/NAJ&"&/%BK\K<@N'.+XRJXRY*9NXM8?O;1K
M<Q#'S3#CR[UONB;6HTGI6O,9:#6D(1NBX5:)O#)I)-W#O<2B<`W"&AKH@W:A
MRM_B6V8+R,WR#E#';SB3D_",XK+5>GNJKC*Q'M#*VQZTZI!-LB1:-6/+,VC-
MP1XDZ2,R*+Q,AU$S'%4Y5*PD**'1CJFOHV9L8Y@O+/`U$M?T];]E"K*.6$91
M4J[DN,<D;U2T+,;2M5X25K49`SQ*Y:7$FW?-XI9<T;**@V<J@MY>[(D06+(Q
MU+LG7CGE1F$;W4+2]X*)PL?^JPBH%@1-H^9W1FX1@)([B-M*+BOHMVAH%UYG
M7HWYB+I%*8AB%4$=TYA#X.MG3&\,GDFEF!UP9>32MHKTFE)4A59[?I*-2<HQ
M,>_J#=PFDP;VI5C&K(&"/*38ZQ#'3`$TCG#W*'3BI09FS>UQ-)XNK,1C;(&4
M[ME^S6:MTRJ8\<T"+?E=U.F2U]L+^8DLEW?'T"PC$H&&5V_KJBJC@2%*B81$
M=:)(U=1GJF[5Y#YGW*"W!;D0X`H]O<&0.)*#@A?L`2<C=C``A^'8H::\"JPY
MA55Y#9B.7RDX/<G(\`*5-PJM>.)@LE#B/P*%!?D6@W`50Z"!1#<0$=^NH]69
MU&;C]Z1M\[Y@54]0ZX)<BGB9`,8%OUOQ+*4Y-_P%65Y'^)(QR^\IE-AVUK<U
M`"%H4XK-_;_F),Q@2X/\F2)F(!DB.[IQ-!-1$=RE*,FIR0(<Y-O;XS`7</9J
M/2H48&KA+6.>\Q.4EFI>"O)8!$!5;)Q-]XEI,U'!0`3D4.?D@!53*I@(#[=Q
M`.@Z&3</K0LU2$@'D)EXYRIK<'.2!A+N44`MO$UH"8"&X`L[1Y(I;;!^P!_D
MZ59V*H8<0ERV?\Q.4DE%>#?)-$"D*W!LUOG$-\*IDP^$P&/R.]44AD^ANT"!
M\/XO;J`D49`'.JPI9^S0@K\'!;DLW0`WQ`E;N*95%2G+VJ@(H\F?"F!R"(;]
MHF_9JO\`7[E&\0LHY]S"W442)P8Y+E`=C@(WGBSWJ$.`&(8Y_P#M(B)A$!#W
MCM[M"2SL?L3;XI2AR#S"JFJW'@GR0.H&RZ0C;>*CM0IDBB*G:*_)4O0R0B([
M`/4H:S+FR-XA6DY`9E4``4X-<GC%V_WRXDMB"'\GX>21%A#K_*U27=A]R,.8
M2IUR%S+XT52\%.1C%,2BB<PWGB,H999``+Y.P>2:8=YTA*.YN[<?MU!0:%5H
MGBDJ?(/,([J(\%>3"JH%V*HK=N)9._<>I2'-R/V(3[0(78=5^848-J%S-QY<
M6W'<*-LR9P]Y%U.GLYFIQ$Q8'-CXR3$?`!;[;!4N,DWT/6^0$U8Y%BWFK"V\
MWIFCE8J0F.1(PEVU-Q]R-R-5-=PFL"JJ*P@B1%11-38_YAQ3.)#"*@#L@F8>
MH[;G^\!UH4#K)K1>)/U:(Y!S:<&+MR%.9M7<AJ@<3H(-_`8],3%N58XF^%8=
MMP$`ZF#V]=_NW[,W#&SW!G<RLZ5KYZKH?J\B.18=MNR;_6/XJ"N,ZTT>9+)4
MGT266>NL/RV,,F%4:I+)I)R;Z$6JD$C(K-6$HI-(Q#J.9HK@X2B6+EL@<PI(
MD57/WCON7<Q^TSSK<C"V,^%['`U>,91N$Q<Q$92WDAC.420'+`=>P6E=-AGC
MTS&56U-/J8>_BR4A>;\GQBR#="&DK7,4:QUK!N-[_,6!B63D&V6;,I'+QT\X
MD)A&R1-AA:U"/6C24<KN$$&4@FDD\338MRDQ_3<$^J\7%`C8Q\FW/+OV8Q.V
M,L>VX,0`8RC*9$I0`!,HN8^8KRK>^[B2OR>4K<NG&1(TFY]M`*'D6X!3OQ8A
MCCAYC:3S!DN'L<K0ZM>(''RE5HZD/!.,<0RH.X\'["N?JDTW?&3R2E1.*39!
MRZ?F7.].?<AS'^?]YGW#USWF'9>VSMC+N697.I<W'K2`$FE+8UIAIN(C!A%@
MX"]I@"WVW'.;F>=KHBT2!M?4AR-P/+[4U/*^CC>,;P^=:-&/8O\`4^+%\N5*
MF3L]7;%(TJQ5]-O.5^[?VA1-S.$--@#PZR9C&;`H"A&"R)A)XE/;>C>X'MW<
MY^G>YD2$,N.-<N0C("<)/&5DVS`$Q+:D4^,'BN'N5D-#N%H2A"5O?M)!9I:N
M"SU'W)H[PXG+@]X\5I6.D:[0.1U;I.9K%$1,TP;_`-H]FN$-ZM2IKQT=,L7<
M108^SQSE-9*1<((K+/%72+915!(Z?N\.-GM^/W3-<7NX]LN7<>V91)-FW";;
MXD@B5W;($&+D"(B2`2%XUZ/YMK'+QM7A&<M`);N!X@/I]?),A?$1F[1G-RS:
MLPL<M>&UYDT$F802$MCF/91XUY^Q50C"JBT2>69%RJRDQ*\9I`U*0$5"G0UV
M3M,^AA]N!<XT<<VP?B,<B1)F"'H2(D"4/+([G>A7K,B0E=NB/\[UTV\&%&U%
M-=/%/M@6+D(YEP\3CXIN^2#G^V=33@\=&28LF3BKXT*60;O5RK*Q"Z:JJ)3J
MHCW?&*93"`E,/HO4%VU<O][E=E*)/IYHAR'(G=H11^)8^U>?@'?#'/'YX?=%
M?5_K\IC1?3T:J(T1&B*./+\T>3BWGX\J2*4C2XIN8O"SJ]#:PO@"&==XR[G*
M4-8L;HQI?:N:=8.XH$P'U*1TNX-9G\)6[?QA>9GTQ[G],1\SP[7,7FX4J<V$
MJ=8C3"F-(7BTYS>H#8DF-D5-:N/5#I=;=$4K1P%V$,V;-/2F$AR#VG$9"0-.
M*U<MD'<`-ON^YRO<'6UQ(T1&B(T1&B(T1&B*+?-I[-,.)F?7%;;Y4>3XXYFF
MT,TP@]:QV674D^!)DS;41\^6:,VTXNNX*0AU'#0@$$V[EK_SA,M1^(*,WTP&
M!X:C9I@0G<X3K>&RI'M2CENFWF@0<)(*8[ISFP5:@U+)-SR)<80U9L2SIG8$
ME9N18J3R+APR4%LN01*SUX*6F8[/8JS;*2X825]C8-5A._-'%8K$7:()JY25
MC3M7UDC%$%Y^19-D/,"K=AXERH',N10OB-ON(<'1<4BQ"=>AW&.O5<;SL:]C
M'Y/4/(]VXAW0O(XS^.<':NA:+&*1;P*')WD*J4BI"'`#E`P"&LD,507"YII6
ML2AFVSVQJ$"KG![BBD5JSD"7%>R)XE8VW(4E20=5XSTY&,"[M\G801=E;)B\
M7252,HIZ8I4XM5;P7@!SAQK].OC]S^_M%REF*-^GN>2XBSMX=9?X^9)#CO?[
M)DY#,U<B6$A)UZEHJQF:9Y:M.727RZ;K]B3=-C*=S<X%W+%R1,C&E:J+?''Z
M_P#F6PYY;8+XZ8KS[]7C$+551F_S;0^.Q./V8:OVNTVZ![`)9$F'+TP(S`5#
M2+^.QD43?B3.`]X%HVPSEHE?73#OEY2(BY-S%R$&YD8YB^<0DOZ$96'7=MDG
M"L7)C%O9.-&0CU%!16].Y<(>0@^-10FQAJX%L=$1HB;F^H>:7Q:;T5M=^GR,
MFOY*PKXF##_W2+NEZVZE\2OFJ0>7Q"3<G^TE68]W38>Q]AGLQ.Z#?B0W=M(:
M\'E+]3C';C5#7Z;GK^3&\&JXZ7ZMM=3N/89=+N-S9WH2?%+6[?Z+-&_-H=V)
M7:13]3+&+T8N-KKB[HOG)^H.U8*\ULS'(\5&84X65EKZ0T4!VB$<KE^M]ZQY
MA&02.DHNIT,B=`PF(7<IP`1#7Z']`3G#T5A%O(.^R+O5_EY49O>[KH/?_P#W
M#()^$8@^R0.B@4SKBC.O0$(C%M928R3DVNU2O1DDFD@4[6L/8FRW"6B5Y)Y$
MM&3MH96-*N+>0:*HLP45$%$2&*3O>1F1GDWKT9&-K#P[ER<A5Y3$H6XR9S('
MSL)1D#)A0L_7[,)2`H\;D@!]A)\*-Q'%2MJ3-%'*CWD(^:#.Q]2L,@WQ%4K-
M'/HR6G8R'M\K#VK*5Q8'8+`0TL0TH>&*JJ^=KG<(`9J9H@DX-TO+E(]GCZ7L
M2V2O1$LF[`B48SG`3A8A4?"=G4($0&EYMQ,5[:&VQD_.R:8B/RXG\0<C>3R9
MV%2"1P3;LED.%%K93LA#O&&#W$S+2],L4O`*VNGW*F9#F%).P8]LJ3:,]?6K
MU"'!NP<L'!5TY"(2!XT,F"BA#>T)/K[#./OA+OHC"%R,9"W<M3LAH7(;BT[=
MPO(2BQC,[9!P"LD7>V9`R6!QZMN#@B6L9$:$?;J-4Y>8.:6$LP,X#&6`H*$2
MGI^O4Y-]`XBQW,R%PM,76:\Z6I5`BS.HM)N:6KBB+1HV:J*D(S75.#@.Q`=>
MN[+Z&[YV:Y+NWJ.5P8]J[/;+(O0$+9G+\RZ1N)VRJ3(.94(!=<W<>XC+M1Q\
M2,(SD`"(@^:C`,SAOL=:QK@^/@\8SV(;G!M*I>[W;K%G:Z6MF_7G?[,\K3$:
MDWJ-<8R\/!G-+P+(I56TZX9H.B>>27,T9G\#=8)+U%E7N[6^^]NN=?"QK4<2
MW;,=AO6(E[DS$GRR-)0!()VC=(;B%QFQ$6_D,IOF9>>4N$),T105!J)<G=J)
MM9PCIM(X>8VZ.3:2B5DR!@2YR;N(0080EPF&,%&TZRT<$W3L[MA=/4)S;)Q'
MQF[QPBZ(5=)9)04O;8@L]+/G@RW6)6K.9:B"3*4(F1NPNZ,;9>$HRDPB8$@@
MA_#N6CNM1O\`Q1$X2X@&@B1X-4-Q=//]/&`7KW*V#2="=DY3J5^9NT'"9Q73
M=-T&**R9U%0,L)TUTC]@[B)>]38?S5>[U_[C94,OTD9VJVI7K1')JD?8>'AR
M"\ST^_\`5(O20A('[E]!CI!(JZQR`9$YE!$QTA[-QWWW.384U-OO*(Z_-\',
M?8OIA^Q)Q\I@[#D;N2"/X3$\9Q$>FX@(*)&-M[]BZTQ%5'6HF(.%GXYW"6"(
M0E85[Z?UL1,1[::B77I';=^T]2P>)/VBP-7S5)9/N+\"J93EV,4!`X(X.K5U
MC>TVE/&KGUE9ID@I,6IK>I,[^`C3+R-PB6D=%Q5L?&505,YLD>QB&Z*#Y0HN
M4DFR1"G`J90#C!+U5T7'1&!\,L+G#7V(P[C2-OD)$1]9@;E#U6`862&@8Z+"
M`C(J-F&\:B]9,8R`#T#8B1P].P_JZ8E1^#5D2#35-?8E<_AW$TS?S9,E<44F
M5R$C&*0*%W?UFN/[86&/'NH8[#]0.FOS$Z`P[Q=IU4[@:+JH@()*'(-C%P]%
MEV2/'_'S"&+Q&3QOA7'M`=L5FKQBXJ-3K%<58R:47*P#-\T4BF:)FKQK7YR0
M9)J)=IDVCU9(!!-4Y38!JW!UH^.JW3''%"C03"/H=2CB(-;@Q2(VBXUFBBRR
M%+)SU^9H$;LRIH-+M.($>RR10*20=$!5<#G`#:Y-`P4U*6*X_P`?,JZ\IJ%+
MH#:KSB)%9ZNHUV)4AI<5(R,AD2RL4#9%F]\4#",69043.`-FJ*0?`F0H2))K
MQ5<@IO6?&CCV66M$JCA3%*C^^-K`TO;@,858REQ86=X$M:FMF=*PYU9E"Q2*
M?J7H.3+`X<[*G`5``VH37@CEM5U<!C3'M0J*E!JN.:O4J(NVEVCBG1D)$MZ8
MY:S_`)PG4'<"S:J,%TILKI0'@JI%,Z`Y@5$VX[S<57)U6T5QY3G<;,).J=3U
MVMDBH"L3:;*`B5TINN5,SA>O0DNU=H';R,17U9!7T+90BJ305E/$4HG-NW<2
MH-66H>8MQI)QD-7I"@TF7AZ[!RU7KT')5N*39P=:L#1K'SE;AXU1E\O8PDVR
M9((O&B**3=RFBF50A@(7;8?:IXIQY!,I#`D8IP]*0$P%RV(J'E_$L8'+/8P;
MJ&$`$PB.P!K(D=S<%>#JD>4QSF6[N\C8GFV0?)J[G`P%1+XW:8B&ZI@$0WZ@
M&K(LHK#BN4XF.+W<PB8X^%J<3"8=QV\0']_O'0%QXJFI\%YOV&P5\;[D6&')
M_#[YFYF+9%S;2]4@@W=GY+(1HI`OY:.@JRFZ:`W\39T0RCY47BG<+I8PI@7!
MD12BT-'X+?57(Q:U/5B"POG#B1"+7""I3"51"MG23G+.S;KQLG(59M5(^'-8
M'LF]?MO1)O'BHE0,0Q$BE4[CPDFBATT*\E><%LLESY6XZSM8,BXL>Y.XS\7\
MBYSQ6YI58EXN;:S.,N1^`)22I"K6X-5G;^>S-@Y2T,V$<X25*Y1?B!`4(/>:
M.>"W$`!FU4">1(Q]L;<O<QQLY6&=PY+\.4\HKP>2\7,(:9B8.6Y4Q%2PM5X:
MOL*Y$NF=IK>$("J3+]N4GA(Z4=HF,5N<X%CJAZ#@"O2*2+E.#^H5QTM&0>0&
M",\4FJ5W)3#`63:1QI3K,33<^3M/5KMZQUF"KXB:V&VO+!9,.@_=T-^=^V@U
MT&,B@JT]:@U6&@EW6:&)#?:I4Y(M;'(N"K7&TQCQ6RPIE?"5NL52P_1,+76J
M7[..-)RCSZ#.M4E_96-6EX^VW.*9O6\4)E8M5HY1:F(M\1Q4$NH(L7JO-&A<
MD\842Y8+6JW*SCES9P_4,?W<]O99XXJLH?D]Q0IU*XZV^<N4G8\@4ZF8Y=HO
MIU6O-Z1\EG6:]BF#2*((F56:NU3`66B'>A!6#CS=>07&*X\6.3CAYQ*K-LSW
M;KG"\E5*E9+E.VYU6.:]SB,CXF<9+Q)#8PK;>*BN+-LK\;6"C%3\J>&82*Z:
MA@;"LJ)"`01X)C.):DA`QF->,5@?8I+C7G8E&Y)R;(M*=,&NU-B,66^SL>2M
M1F7JJ)W](L67Z'5JG$E9*"<99"P.3$2!8BZA(WU*FM>2>CA^QM,A:,+*8UY`
M<<\/V$?I3<5(FU*\B^-$;D6%_4<%FO+R#VD(,(ZRXV<,IB#BVY$7+U_\U>NV
M3ML4/&((K`4DWB:\TZD*_P`,\$N0?%EW#<B,'*KL.+W,-M>,]SV'YF9IUUS-
ME7E1C++5CA$8#%U4D'N.'Z!K-(GB(U$$4V5?34;)J['[M5V+!&)!<'5<E:,^
MU-OSBS+:*US;XH\:8FV<1.*,E6+";BXM;:)DM@G8\YS;=:(:Y#IKUW!2=1A)
MJ-7D_3E`[HCMN1;PG;]K8:J:QT.J]'9_DY".>(DOR!QIE[AORFR[`84RA*RN
MV.(VJ'Y$7>*2>F901*BM`Q]O:O;0\8HLSHD?1Q3/U!("*A%T3(QAP6=M=K$!
M>3WT\LV)\8.35>PQAC-6#\Y06:*+3Q:<BX&C9::5[CK4*Q7[U?V'T_(NCI5.
MP.*RY7R197LA7T7C\TTWA&2\;*JEDF\>F::%:D'#D%_I52EY[2E^R!RBXWYF
MJ^3<!W7+O'7`&8L]4AY2*;9W$I*W#$6:.,%@F,/H('>NYHM@R+1E)R&;INO2
MB=@[?)'!+<QRB>*D="#Q4(.0<ECO*+7FSR#CI^#93W*_@'D#+%7JLE1JVG*U
M*)EN1U3I''*D/HH849:+M33!=;KLN[C#B1^205>([>-14#%H.&'(_P"U3GM;
M?.%<Y-\>[WF'+N-^3C`*CEQUPQR?@7C(TJ6.4<Z?HF7IF1L&9B94R)GYXUYR
M/B9U(QE%=_.F,2P,61,]8G>MHY4UKQ66#,S<ZJ,/'/(R%6'BYBO&N8^.G(B%
MH]KJ:-DXJ<CN([YOR*X$5FL5BR-+/;K/DR.IU/EZT7CC%,W<2Y7M191U)H&2
M:M7SMP^:*.:%H\2Q_M7LW$9LQGD;$L_=&&6^&62K7+2MEBTGT-3&U<6OD;$L
M[1`6&GSQ[I`JSSZ6MEU8)-S&1+%(JE3W;NT@4(<0<K!!X.%XX<=\WCB^L\7*
M3@ODCAW,U28WO'Y5.(.4^-*SOD?P369PTG!263'^1*_24;#%DXM5^5>L4)2V
MLYHDY&&.S92#T[]HLI'(HMFI.X'^!6G89:Y(I35#^J`Z?\6WKNX\@9[-%H=,
M7]]MF?('B5EZ`K?'YM7K1BAM1`9MJQBG&=#K=V68)S8/HYPP<."D,X<JMST.
M*HPK$.RYW'0U^BV')\4SLE`1=_4+SARGX_97E*CCB#=5S'MMIO+N\.SY?7?3
ML"^L-%K<SQ&R=<'L6],NBX%Q5HM$#;JHZ%O>A#MX?V?VIU.(E`R[$9FXJJ<=
M[)B7#\?_`&*?4AB\8V&:XJ7O,L/5:2[YUUZ*J+%VXKDG1D',I*1"(.XJ3-(.
MFL=&(F;JI>G=%/J:JGB#X*CUC1N(W('C+><E<A^*]LB+#G'FEDS-V67V"[5`
M4>NY"RMBK&<''0SJC0[)TSK$>UBX<6-<9%%<Q7R+E1=RHLH[`S@LZNP/!=#F
M+D7C:V\R*KE6.YX\4\/U7(?#')["M9>KN%8>WU.\OG7(BL#*T:W1V0JM..6%
MA!M'OEVLD5D9X+9DH4PK%*JH<2Y=4`@,QU7J-QJY$JH8;8Y$J?(_C)GZ`K<C
M,,KK<L+8HD,=VK(3^&1M4A5H>P1L=#-:_5GGI*\I'`^5:MVK=$AUQ4V(8ZE!
M/!8(X,0O`CB=R2O.$^1.`<GPF3./N>Y#D>29E,GIR>/LTN8?Z7LKG6^K9`S/
MB$]3K];=LZ,OES,$JQ8,E79O6?J%BX%06\0[1[8Y7(0X(7TI)63`LG62_P!J
M>8N+C>X,W4PG/V7'..L>OX.P11G#!E'&F&5[@9MPUD8I-`R3Q5JJ5(AE>TY0
M`I-5V7&QX.R[^N0R+'-$`_B'=%DZ(>&K_P"EU(K`$I^I'3F4J-<09S</E:O4
MQ2GLH1X=%5^0R+PK1)%X9J842HI^+0E+BA9DHSH*H<F>!?:9YN&1N1G:/IVY
M#`8.,%_W$G>0A1Z?;OTZZT"Y#J#X2GKS)892`B*FY;6(*2PM%VB:]9[V\/!>
M*G1+J-FW:LD4)5HZ@(]>;G(YC$H.WZ*S1LM*%.9,YP(&AD06X(`%'*:R1;(%
MK.M&&>8RR+R>-45<:S<34L=$"[71?,4_7!;017<3(LK9.14,$3%.T8T1:+*J
MB\3;H&7(*:1:O%&==+7;X^E<T66M/<J17R('.7XYJWKHX^FHZLHT698PJ;J9
M,JU9W6@VJE&1=$D1G$)2"EWA^Y!1%(&Z*MC(FG!&#>*Y$V5[4MA'#=L:YC<6
MB8MV75Z?+S4;_P!G]LXD(]:/O9D:[#IV5K"8_9/F;B`9.A%<$WIBK&`#'*HF
M36"6XJ@!V92RHZ=J4KM6_7+)BXNGRN."T)5A<K&%"<!,GKDVJI3H("3RA\?8
MHJB"G=X]T^W?D/PL5*.H?0F4[D[JLJ\4R?(F0DJ_@F8O\\1M5^[!]@R-E25J
MV4*XV<I0A6-:)3ZPVW3;RQ'+B(,V%XX,<J@B.8DZ'15@/:MJXR<LI5J%'-\U
M1L;<IR<OK:G.)%>BPT1>*E4<HNJ[%98R-,2D:<DE4S51F@F5O$@T4GG\D0S3
M8QR+-892!=`/J3W1%I;GS3E.D'R*Q=I,J52+%&5<\Y42OZ*N]D,@,)U1LS:L
MFLJHBW91$>[<_-C//"8Y3")$52D'3_6IXIK7N6IV+XY,,O0^386Y.L>76X15
MK<R]FQ^TCLB0T7>;/48BMRMBCH]&'J<V$6YCI-LNP;-Q<>C*F)!1<F,&8R)]
MBI`=E*2E-9V-@:TWL%@7N,XTC(Y.:M;=*)BV=E?B@F9_,,8Z%%.,9Q[\YS&;
MIHE`H("7J8=S#N7PK-$P-BODK!3_`"DAX&Y,[?8Z+CR-N5/J#B2K4B]JLH:`
MO2KN.0A:^T;3,BR;/(>/552D!=.!54`@J`58A-02/O5X@KN<)6`9J)R$R;7E
MMD6OUJYLH^HY!<+0<F\L4<M2*;.2R)Y:M,H>$EAA[%8'K8%4$`\94P;G$5$#
M#J.=S*RHF[RU?+%!9$BHR/N#^(.VC<5O:C3$$H9!OE:8M^7EJ=>X=RD_CCS$
MP2MU%-LH1*.714CS/O6K"8A2=NCJLM1:/GR4R?%#)J:22*"?ZEP:&X_&H</^
MT3B7M,()@!-Q]O4QM0U#JQU4RGR11D70J&,N;UJX_F;=@&\YNI4B@5,!_:`C
M]^M-Y5E>,7U5V7S"UX73,8%$F]>O+@Z0(*'4*`.Z<)B)>,Y=U#))F`3`&Y4E
M3D_"<^_VK]HKG2M9Q)8;K7W3^G+CJ`NB>KX[KUDZEI#ZV4%:TJ%5M\\D:!>R
M[O%>%FB$K\BCBR%GF,AY#GJY-UR@23(7D7+O(^49RJ+0X+MI%N$6R<K^1-`A
M_%WK.C#/P(-<C;LYO<"1N.V$;-F,HSN`L8Q,3$U!B=\HAMQ#^DQK/1DS$SA:
MJ.)D6,1PY^-`>"=>/P3"OL9WO!=K4A[#;\W`D[M5[:FD/E]>R34+'\[I59CE
MT8HJZ5*:)-5&\HY00;E*,DIZ=9ZBV;Z]+=]29=ONUGU)BB5KM^!Y;=HL3*S<
MCLNS(>LY4E`$GX0XB9%>18A$6I888WK@W;FI&X#2/LU<\S1V"78;Y5U+CA>F
M],Y'5Z)J\X^L#.SI57*%75?IT&^MUI2/5N$/<H6--#2->6:MVQHR71].T<QC
MDBAB@J0=:[WZ2S?4F)+N7IB<[UN-K8;F/.(ZL"(DPE:E(3$P7$X2=I!@ZY<#
M,/;KTK.;$2\SM*).T@:Q/%^#<%P-OO$?S:G'=*P'7FYL:A!+TA=E6JH_IN/\
M1T>1:(.;+:++*RT21<AR.6J#B,C6Q1?R\OW()J)I"H)_-P\`_M_C_.]^F?ZH
M9"\#.<;MZ_=B6C;C&,J%B1.<SMA#S5+!8O&]W2_TL:.VS'R@"D8Q+%SJQ!X'
M5=IE2JQ+X\/D/'E?-$.L.5QE2T:89BX>OLKX2H%32B5/&@2+*S7R=&1Z#\R:
M1O1G,BLD=NL\=HD3#U_:^X7X1N=M[G/JV>X3-TW-!CY-ZYN#U?HD['-0X((C
M$DIDB-R77M1`O6O*!QG"(8R=FW"M/J<IEKQ$-9>QYP@6J:AS,K#`9<B952/!
MK8+AC^W-8J+>S,V1L]G'J::$LK'*>)VZ;^)\1PU!L"R*@D[#VV_+%Q>WYMP_
MEFU<Q91!>-N[;,I``G:/A$_AB7!C)V(?UV1`=2]MK'<)@\2),Y]E11Z>U=QB
M6+8MG7"M!T[\2[+Z@S-6.\49ZHJCQ2FX[\C-1<'B!(U)=(ZAN]0BH`<H@0I3
M#U\3NMV<SWTQ#Q_T]5SP-RX7%"]>#_8O*[>)1MXYYYP^Z*^K_7Y7&B^H(U41
MHB-$4?N5L*:Q\:\Y0)(=:PGE\96U@G`MX2V65Q-*N(EPFG%(0%$GJM<Y=9^H
M()%;Q<DP?*&,`(KI'V.&9_"5R6B1<!&J@7].W"7(2A5O$$K+5+BI3,+L*C,-
M&-<9\>LZ8[Y3P2#E-^2/C[#9<MYHR-+M7))8P"]3DO6+K,A`I50^`0Q``:`?
MQ^Y<EXER"9/2E&^PE>NNN5>.C1$:(C1$:(C1$:(H\\M(UK+<9<[,GC7(3]$<
M86YR##$_JAR,^<1\2X?LV5029L915U+NW;4B9$#-72+@IC)K(+)'.F8J-5"'
MZ/E=/#\;IR7E*UG^M7"V7%O.W<N<6%3CV$[8C52OM7-DQH-)J](BINNRI4`&
M0E7\0QL4C-D=GE"F7`IA+4]5ZQB`#L(@`B`[AN'L'80W#[!V$0_?HL+`W:-6
MGG]*V;MO4KG=.?3HIH^H=*@4JCE?QE+Y5U"D*!CFW,(`&X]-$7S.?4]XU<]N
M57U1,<8RX-<FK'Q*BC<'(USR:RW"2,DV!&C.LZWUOCN"81T+Z::E;>_ED9T\
M:#9[%F002>&,\2*84U2Y8&(@\@]4X7&K_NS?`3%<X7(G).0R?SJS`Z<!(3-P
MY#VB1=U=_*]X*&>C0HQ^*4L0Q]]TY^0G@$!V$1T0WI&@H%[]43'M"Q=68ZE8
MTI-2QY3HA/Q154I%<AZI7(U/8I>QC"03-C&M2B!`W[$R[[==%Q$DU*Z_1$:(
MC1$W%]1*K+XM,9I;G(HY'36*>L*>-@R-^B+NGZNZAXS^6H@504Q+N7_:2C,=
M^FP]C[#,QQ.Z`3Q([NVD->#RE^IQCMQJAK]'>OY(O4XCI?JVW&YW'L)-ON-S
M;WH$'%+6X'Y+-&_-H7Q*[2*?J98Q>C%Q]=<7=%\Z?U"&#R0YEYD9H1K=@1WP
MSJY"6EPRE2K&5_M?K1%63.3;(O(U,6R0E,F"K9<Q72A.XIDC&(/Z$]!786O1
M>'<,C*0[Y+R`C_R\ZM0^&HIXU70O4$1+/R'=OE`__>'WJ+#)S47;B\4^1GWE
M'CFM6;UK%MFE'\$WKC]D20;H9&E'C2XKQT<M(7%MD-V\>.XZ476-$QSEB502
MMVZ6NQ7[?<+<+'<(6OF+IO2ED6HB6^)9[,7MN=MOI1`C*(`G*,F>1*]/;Z,P
M;$9&$1`"!+-R)KS!)?D&X+<42\L,:MGV%\T*S]>)7'\>-=LX,&;LM.0>1(MC
MM)%O'(H'G\:V):"4D6)XM=Z@V6%91B"S=?8F,_!N]UD.^]B%N\+P(N622#,@
MO0_AO0$A"6\1)H)$2"W9ETWQ<XF)!\DA4Q_MB0`07(%6U4D$,]V9C1Y7&6%0
MA\C(/GAF-UR;)P[Y[C^DN44V,.PJC=P[BB5>WSL@TGV[MP=,LCZ($2(I-E7'
MYB'5)^G\2?<!W+O1GC3A$&U8$@+UW4F9VRWVX`@@$[27W$MK[&&;.UCG&L`7
M!(^:X1Y(\@'H2=6X:+18US#R!Q9/$G$,58_L<4HW)796BX_@*G!S4NWB6YV#
MIXG(8WKT,^_5D?)/!1F6QBOE`=%,1PQ1+Z<$>3N/9_3?=K70CFY$+@>4;MV5
MR5L&1<`B[(@0D!Y"&<5$C5^/'S^YX]T3G"U.VP&V,0),.1C5Q^(<]0N<G<Y8
M7K;@MR:717*KIZ"[JNU:.AU8=V*D<F[5;.,BQ\LS8*P2)I%J!'L.HBY=JNDE
M"``-RE6U[#%[!WS,B,$XWRD`V^Z9"6I%+1BX((^&X"`Q!=Z+BNY&/;N=>,S>
MD22(,S4IO?1N573%U]FA'L;9D?+5H?&5R94GLA$U\KRI0MRO<DQ=!&U&S1ZD
MBJSN41"G>3<FI!*QT80$(R,D'#!4J:[4VO=Y=PW[UCM'8[(%K&O",YM.5JW%
MMUVV2/)*7DCU!*592A&6A7BQ@(VY7<LD&<2=H(!)T!;5JDAAH"RDUP;`\ORE
MHMKD%58N?E<:W9M?X1X5R=\%JCEDV"TZU;N&D<Y(YLR#1JN_%5!!('"2JR#4
M/5J+AZ#UR)XWI;(P8@2QH9=LV9@!MDGEM-2/(\@`"6!`,O*`O8=C,#W2$P?/
M*W+?[0['W\?:O>9T4PK*;`._>._]W?7Y\MD`+Z.4F[#_`,D=<FZ*BJ!5`$.A
MNFH3%5;21*.R*(AW>-JW#8>NXJ%!<W0>GXE1UPQ^,'@RUP*31K5'U`G.V2'Q
M)*K=4B#MXDE#![OY6VN29=F4"1J-D>[<&Y-^T`[MNO3K_`(Z6RT=4.J7J-$"
MQR0^G)Y%7*AC;EW$Q4$R$)OOOT`R@ZR#YO:G]B1MVJ1E0#TZ)3*"4@;I$]IC
M`7I\/MZZLR\0`>*#5TKD`W>+"F7M*4YB%`H`4"E3'L*78-@#8I=6!`=^:A_@
ME+4.UJ\5'VE;E1*(_P`M<Y2"'[?&4P:XS\96N`"UA`4W_C>S[1_\>N4F+<%F
MJ4OVY`*S*"8E4!L!U#I"9%3O7,*OQ'3$IC#XQ+[=]9@W%%8Q;*F7()S$523*
MHJ*;M(JA-DBF4[>\G8(;B3;J!M)$<-57HM?XE@$1%%=,1$1'TCCR$$1ZB`(J
MB4`#<?Y`ZT\?!`EJ@E(Q3*HHF(KKF$0>L!(;L1*!2@*H>,@E$Z@^P!]FN,E7
MQ0S8F74+V)M_&*A$P.B]53[CF'8"))@`=ZHB/LWV`/:(::Q\4TU4)IY&V,)#
M.:MFF6QXCY+>5JE.2?&A^Z:X\CH-S/SJ\L[L:T.C'Y#"*@"@W8MO4%;RBS9`
MQ?*JJ853#@5>'BFOC+Q-1%%K^4G6<>.Z%/7MZU+B;<CQ^D&TD@\B4)MVK'0X
M+/TE696;*.4].]\9&?:4HD.85@2"434L-4@8Y%KBL7/L''(?C*X<OV[:5KJ5
M-PTDP<,XY"13D9,)0I*S.'F&AVDL5!JW].D=<SPJ*BIE5P6&*D-S3=5?E_AS
M(F2<I8T2Y6X!G;[C*M':90"K<>I6NI0+Z^5AR>J65]<[3#332=AB2,NR(]%@
M5<I%VZ"+@H&.<AA0`ZLFGC/J6XAJU85E\>\KL72;-7*MLP"!<2<.<N6%ZI:\
M;5>3D)%NR8U>LNY6RFKC!@=Z5V5,L4I'$.JBJ4``QPYJF+J36*></%',B2=F
M?<JP&^T9*JLLEP+W"TABMVU<NUU3-)0:[EO%!\C1M4MI45B).D7QFAQ26!LH
M4Y#`6::(QT729:O*.!<;WR7SEE*OI(/+'186F9'+Q!LMK9C)2S^'9PM/@8.I
MU.16RK9K\((QS)-EY5$UESB@GVIE*C6^I9!!TUY)IL)<NJQEBLVS(%.Y$X)C
M!QC(0%3R>RM_$^[8SRG7WV0&K]M15+'3[BE"V!K6;6P9J'+(I)FCEF+)Z!5M
MT51;QT,:U?ZUPE7YT\;97C=<,^,.7F`)BH4.;FI5Y.UCCA8&+^+B\7,G25E+
M8:&VI;RW6EPS6>0SY`&3%@F[B$4G+91-%=,Y55H@[F8NNFO_`"YP;7\'1N=;
M]RHX_CAW+TAC[$]7OM.XZ33J)>Y1RT+6QUQ*QMD:W:959I/P4+*G>%5*FFP%
MR8SGQ#XU$GLT4`:C%TW\I]3S'5&/D:N0'*&I1#?&UBFHS+=YI?!;/Z^*Z%*1
M+B#:LW4W>Z]4%Z<>+`DNR;2,B[D&S5NFND<'!2"!37[TVO4J8]7Y:<5K;-9&
MD(SEA$3=UQK,,*!D4D51X$E/3OB](KLH[1CI*4QL[G+#6`1G6SY0R$PY22\G
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MH<B,(RV0,&3&'Y*\U:!XXR<+`U<+"\=V")?RY)J`<?JI@ZCX0/4J,G:JD8<H
M)J>F443%77@JS-2A36M?J1X_0KB+W'G+W&TN@VRE<,/NHK$W#_,]I<RF7*%'
M2-KN,35:;2X!Y,3]2_3D%(OU)U+N:&.W,)5%@'\NNPHJ(\PG96^HAP:MM.S9
MD>*Y=O\`'LQ1XE=6ZP^1\%.ZG+526M\?(FH$@_Q_/X6ALCVM%S(H">%13</U
MY-XT]/W.%`4)IN`T4VRT`2;#_)"J\@H>+H6+;PW+F^KI)Y3D`NW`_)%-GIK&
M=J>R5?I%CB:=9*C7WB-$;R""R:4^R5<D<.X\K591`PJ!J:UXH0Q?@NPL&8"4
MZI9TM=AY$\;ZU2L0P!ULL2!.-TPW-#O(ZSOHIH:18+-'XV>43L+,B41'L6\@
MYD9/TXMT3>H(00^%RJ0_"J:3%7-'#6:EF4'0^1V)ZAE:M-W)+'4,F<4;OB)Q
M/05NDC0T;+U;&UUJ<=9YR'E&C9RR,\:OU4P>B+9=/\\J1<_>C$<'"VU>Y68>
MR=C+--_H7)'`EOB>-MWD7615X3CG+)0%5_2#&5B)9^6O.*V:6L\6Y>V%D,=)
MQ[M5"1;1YA;*J]BZ8U&JW$K6H_4>QA4\&5#DV?G%@D>,CV+I=A"4@./>04Y-
M[&S=B5@'M?0H$*R"RUQY\T.FV:`='U*#HPE72Z`<T^Y&<LQW*R^_48X;45]D
M^IP?)+)+"VUUO`+V>72XCVO)&-*"^L+*"R0Q)>9;%F#`9>M&F*F(Y14D3K-4
M7*IU2^H2[R-:*L=:)S*SFVOY9:5Z'P3F''&0+KC:BT^V9`NM+XJ6"^U"WP^7
MDY-_C:RQTM5X-LRB"RL)391/TK(YC*E4.=8$P\)#7V:J::IE+CS>I-4OF9\+
MKY:A9*Y88FF;+(4'C7Z<N>\J5VG2T3`,K$Z=3<U2J198)P^BH&<9&_+7/X&K
ME8H+(**)B@5V\?XI\FV:JS(QE;EX3D=QK0(XK</%VB+G,,NV<3*D?S!7ZK%M
M1S03*:ASNH]_#-006?F6341`JJ!%!*)`HH1[4M&PL;!%*H5#,N!YNZ8Z4N<]
M(Q37!X+Q3>HR<-76"*S2L$CF3I3TLDX<F46*_2(X7?>,QC@4I4FJ.VJ[/'><
M[4[O-&@T>2^(+'6G%FB8`E(@\<3<?/S39U\L8NH)$C)VFVI\HP?.`106'RM2
MMP4\A2"B?>N0H8^%5UG+%Q(T;+O#_)?Z!R;=ZACW(^9_UH?&-#N659ZN-K?@
M&[52O/Y6LTF,FIM*+>V%\BU]45$R)%%2`<Q=]-$!W!N*V1.8^.G3)VR-AGE^
MHD<NZJ!.#W(QTFJ@H06[A%P*U!50.DH0P=Q#E$IOOU'JJ15(/^U[CGO9@;!G
M,IP$<(#'BMPKY"HHQQ@1%L4T>1''X&9[-Q\8>(A=D_A_#TUR2D"&4`KP^M+'
M7+O'(.%W26#N7C522;H%?*-N#G(8B[Y(B?85)VY5QYWO44Q$X%`Y3%`!'8`U
M(D<5"#]"KV/+7%()F:GP)R^6()55$DE>#W(99-)R4H'(X11_L\,BBN7Q!\9"
M`;;W@'LS(N::*L6=Q]:N+S+H8'`1PWS.VW$?_A+>1W][]!:Y)2!BPU90`@U9
M9G/,/'!V8%)A#F,!7*CL'Y0X2<B2IO3KE*54[PO]GP)NU%VX@103]QCD``-N
M&VL0(&J$<`WUI.WY@8S\[$SC!?,!<C$Z/IB*\(.0JQ6R2784B;8I\>'!N0A"
M@!0(``4`#8.FK.46HIM/T*3..6F+P?.%_P"P?E[YSJ+$.X'@[R#!RHF<0(<B
MJPX\!<Y3D(`"!AZ@``(=-:$P(MQ1CX?6LR?+/$XQKID&`>77@,NV=&;$X-<A
M`;"HF`H@J=`F.P0$X$,``8P;AV@`:P"Q=4@GE]:$^8.."E*4,)<R2%(':0I.
M%7(TI2$`H%`I"EH0%*4"AL`>P`U92?31`/8ZRK<NL7)NBOT<#\OT':R"1E7A
M.#W(5-RJ?M(54QW)<=E75`YD2B(B80$2A[=M9?DJ`=2RRQ',3';(2-&N$>8[
M9MXG"2;=GPEY$H(I^8JAS>-NWQ\5,H&6,)Q`"AN81$>HB.MRE$BBRQ^A29?F
M)CQ55%8^%.9"BS8RIVRJG"?D2=9J==,45CME3T`5&YED1$AQ(("8@]H[ATTC
M(`50@_0I@.46>&N:L(V/%V/\(<N7ENMUKPZA$I3G$S.U6ADDX?-N.+'*O96Q
MV"FL82%CHV$AG+E=PZ721322,(FWV`:9`A@K$,:LO4%V'>^<G+\1#.UCE,'4
MIBBL80,`^\!`=:,@RPO(7ZD+*+/DW"$Q,>-W'5RJY*ECUT3NS+6:9;MZTO!0
MSI)$I@5A7<FBW4<(IF3<K`W,@0C@CA5'7US]M)WQV[/M8]+ERY8B9T&R,MPG
M)SQ$26+,"07BP*Z7ZG$#E6#<T$9D#F0S#Z]?!>>B\,MD.H5DT#.SQ\K5R4LM
MON]&=2-:D;C.6R+$[WY]5BK!%Y&/,,X&P2:T6U0C'"Z3:)E&39,A5&R0?1(W
MQV?N5V&5")[)=A"W:O`2%J$),#&X:VQNE".\F0<SA.1)<KK<!U[439D3D>:4
M@2-QD*^6KE@:!BS%D[=6S9CRX,HJ2M]T;T"\PL8S6G92:0;MZ7<S0R9V$A9H
MIS',]XN3D&T<5Y(-19%!\;R':F.J8$B^LS.P]SP[D[>+C?-]NG([!$DW+6ZH
MMESYHAVC(F@;<``ZYK618O@;R+64*$FD9M^+P/$AJ\-4Y]]SOES(;>O(U7']
M.2QU26,:M6)',M3BR#D.%;%%`<@3\9DV$<M:A57,5(I/E6P)1J*0*"`NUG`(
M"GZ3!['V;M1N3[AEW3GWI$7!C3D19D?_``Q*S(=28(VOYG9V$25[#([AE790
MC;A`6X#RF8!,P-9>;X0=>`]JRP&=\A56E/L;YGB8ZJ4<R[=1CD^!K2J$+1Y]
ML[9JL:C>HJIUYO!1S6;<V1)J:46C6`,E&P&[W#8R8H2_V#MV9EQ[GV.Y<O9H
M?=9G-YWH,0;EJ5R1E(@1W;-TMSL`"[YAFW^A/%RQL@:[P*"0KMD(LPKJ?M"9
M&]9:K#2,=XRQ7*S5RN=FDXJO2%O@&1UF2C<[AY(/ZC1D&#60G'<U821"K5_(
M,V[;=J"R+03D6%4.Q8'9\F5S^J]XA#%[=9C*0MS-78`7+CL-L21*,)$^8Q)J
M%ZZ5V`?'QB;F3)G(T`.L8<7YFE-%Q2Y8?&->J--)(FOEW@[#-1-FK]9DZE^G
MX;'"C-C#W"I3"6/5+0^DRJV'(,D9,[A5NW:2T4^?(^$4VRFO*A&_WG*R,T0.
M/VZY:$K<KD9[IWWW0N1ZNS:\;4',0283A$N\@LW!9Q+<+43ONB1$@""-K,11
M^)+<B#X+M,<PZ</.\2V<<F2W0A/J)]T?+':2"TA'1IJSCQ1K).58MR6*;O"$
M2(4"J@X2(U$H^1PMWN!X<Z[+(L]ZN7R;.0?3@,Q0"4M]R@!J1[&)/`"B\G$@
M(QQHP<P&=3V`17U1:_+\=%],1JHC1$:(HR<T7+AGQ,Y%NF@TPKE#$%Y40/D6
M1^441-4L$[[%;=+?J"J?*H!(?B<N?F;#P)`)_.EV]X9G\)7):_Q!K[E"/Z7G
M%+`+#".!^4S*A8V1SI8*7,J2=[P]DR_7#&;XDP]EH9VI4"/\L9'JDC%/(A),
M@J)NGI2K`82*%,'PY@`SL'6KQENVO+:PH2_\2O7?7(N%&B(T1&B(T1&B(T11
MUY<-,5O^,V;F&;GLA'8J?X]GF-T=Q2\LWDR1;QOZ8B<>:#9R4HJ]</54DTD4
MVSH%SG!(Z*R9S)F*Q=Z:J-/TV:)@;'&.<@5;$MYA+UD%M:*LXY&NZA)UR2H<
M3F-;&]23F8*B*T6CXXH#BLPR+<&B;F/B&[I=9NJ$B8S]-8I"U-SKHO2#181H
MB2E9,B/59(C1J61<-6[)=^5ND5ZLR:*NEVC15T!`74:M5WJQTTQ,)"'6.(``
MG-N1*M$1HB-$1HB-$3<7U+R2^+3>FM[CQ9'35[ZN?L8-/_=(NZ?J;L'C/Y*@
M'D\9B[E_VDHS'?IL/8^PRVXG=!NPXOVXC\\>:7ZG&+8U:9%'>OY(O4XKI?JV
MWO[CV$[.XSV]Z!?%+6X_HLT;LVA?$KM(I^IEC%Z,7'UUQ=T7SK<^V2TAS9S.
MWBG$@]EU>%U99EKT7$S,K)+(KY8@U#NV*C-)1DT.N@0Z1B"'D,4IC]0*`:_0
MGH*Y"UZ*PYWQ&...^2)G*41'_+RH7+^+Z+H??HR/<KQB[G&#<?Q1X*&]7^0L
M8&2I5[A;K&M&<LS?N6T2TFXZ<K]G9E!NX;-T'IF+>0%_6&CMJ_9O3%2%L!E/
M@.F50.WY8R9WX=Q[9.S*8B0*^2Y;EH"SEXS,90D`[TT)"Z]"5N$)6+\9:^^)
MXGZJ$>/-;!U()#1X&J6>IPLG'UY_",Z%F"RV%Q5:G(">I%5EV1VULL3BL,RR
M:/ADFS5HT:EF%0.4K!\H)U4O%^6-ON%S-Q+\H7K@E*]C0AU)AYM%C"`G0^64
MB3LUW0#`ZE*%RQ&W.U%HL(W)2(]U2:\0/;0I=)0%04BCKVS*.2,FIPL?'F;1
M[%=YC2FQ<*X"2;03Z.K,4M*K1Q7<<=H@BT;E:$!6-1.GY`%0JF<?*SNN#@XF
M)BQD95(CD7)2H9`W)"+UW$DN6D12C<UP1V>:5RX>1)C$,*%J\/8D;"JXS+(E
M,CD&\6)\SCSR+.Z0-F?1+^E5J*[%*E%!$%>ST7+J5:+;M'+HYETU542()@H5
M$5%EN6]F=UC8D/E\>W`R`Z4X"Y&Y.1_,+M$C>7$0Q`>1J6`X8?+FX'E,FI<%
MI#DWM_%IR'-+VYX>$N5;>NGY<^2;19D^J-7L:C6OY5<GA8I=ICV![$I1Q;,H
MQBB[!NX>2#<SP(PQC%`B"9TW:/C@W,K#NV+4?Z7:(VW)V]T[%9/=EH(V2'($
M9-NI4UB>:,+<<@;Y"_MT!&V7';H2XYL>'!)(N4CF5A<7FQ-I]7)ITXTT15VW
MZC7BJT^814#!0RTS(.K%8[!:IX6U)!S'^M<OVKLB_G\ITS%1+S2Q<F6##MV'
M.U_27\UUXB=P&4Y2`&V,81\YC(@`T9A4K$[UOK=6X#UPP$3H*,"Y))---/:I
M&?3U@Y9+DY&3:%7G_P!.R5#NOH9Z1AY9O&.E1>1A5G:4F\;`S-(-U6IVW8"@
M[E45_C;Z]!^XV59GZ9EC2NV_FHW[3Q$@[;20"`=&(*\_T[;N#N8N",ND;9`/
M"C5=>^ZP[K*C_P"D/_YPZ_.PT7TP:+%JHC1$MDO^>*!_)$A`_81$I0_N!IS5
MX!59="O#?R6:@?YYTR?WC:A0)$([B(A_X;=-`&")<N;9LR)_Z)8W[SKJ`/\`
MYNA&BCN2L3$-WC7[ETA_@.&J.2O`^Q85=Q44,/M.<QOX3#J`N$2@NWRY8>NY
MGB!/NV*FJ;^^(:O%/[$D`=O[W\/3WZA#A!JELB/];4+_`,F":?[B(IE#;[@V
MU4X!7,^B3L_\EH?;_AJI)_WCZSQ*!(2_B#]_]X=4Z(MRN4C=)F9<-Q!#<K8H
MB4YS'44/W+B&QDR"&WWF#V;>W0"B.DS8A'CM,RB":HE*J8B0(DV_+3.<B:90
M#H'<`>S^_HYW([!>;UGRU(0MRO<4GRGBZQZ&;N)V%+L.%1M#A@+>;+$,V83S
M9259KUF+=(J("W*DW>>(#*F+TW.^]77A1;F+RA6(:,0@,Q<A)U=_;$*Q=Z<\
MI^,#4YP>&M$;)K)5\6[6#MRT^0QB`KV*1[11KX42CL8XIZ>W55N2VU-N5'MN
M56">,,UR%V@JK4_5VC&+C$#>:L%ZCHMY(MYA5I87=<@A`Y'4TU249HHHJ[LR
M`4`'RF&4=@I5G-"O"#.5<Y/\=<_<F>7F.F5P1L>1N4=NXP19;-QL\#J5JG(3
MB=A>5IF1V3,"KI)8MPKFR@1;%:20*Z%FT(_.JHLLNZ2T7)0M%<Q5\'S^%,Y8
M.PFPS-DC#-&Q]S[S-+L<BP6`H1_/-Z(EP50HM8RY'3%PQY<::I'9!L;8\2HB
MYC)%))T\\Y%$W9O)J)JY.K?Q4@>,5TD\!Y:Y82G(;DW;\GY./(8>J]<Y2$XO
M2V1&N8,#"G+1E&@*Q"U"GM(C%\EB6T6Q^VMT`SC5Q%RNUGE%%FCDP-Z*:J2#
M@"*DO]2"[23ZG(P=NRADRST1[F/&F0H\^(\>33;-F"&CK>]4/..+I2NIR%ZD
MU\,F,P5>0[&.:2#B)?/#(@^,W=-51KIHI&/)E"*T<C\WFQ#R#Q=3,\Y<SC4<
M^5W$6",&\T\@\4'.#;G6[Y?K9:J3FVFWR?0QW5;3E;#&`L66E2R#8#5^/=MI
MA8T8DZ4<+'`D\%H#B?J7`Y6K>3\3QG)?`%4FZC<*'R&XT5]Q4:+QXP'E)RR=
M9DP5&XTQ>GC6PMKU"3%CJUBR5A5*"D&JK0K9"2_2K@#AZA055B:L>12K/."^
M3LE2\R8<D:U?ZMQ]X$9%JEKP$>=X]O4ZK<8W/?*C&=AJSBHF</WKBQ.L#83F
MI>'=D*+@8UHBH0P[+J&3>*@(%>)_L4A,<XLO.0ZIR[CLK\SLEX6XP<I.57)B
M!G:+7N+=.B;'DO&<U!4B.M]GBLCV.H3=PQ_6LBLY`K)(6S9<J:#821RIG&RP
M/!1P&I4`<4FP+R"QWQVS!S5I<IG"U5J(?\B<?R6.)R$X19DRI'/Z>UXQ81Q<
M,O#7V'HM@CX6.:/*T[AS&>*"Y.K%'64,8BA_(?DM$.`3K[4W>+,\#B_(&<SN
M^<_-7CQ3+ES"Y=9%QWC>A<'KA></2];D\XR,I3YQK?#\>+=*2M<R.5R9==&/
M>*BEZLZ0*-#E3(8H0_`.RG3SBOSJX<3INI6W+4CD3#>1,\X@QMR3M6+^/G99
M<4<<;TE<7-^G:Q6E*U8I"WR\?(UZ/%I+M8M9]6FRB<NW;J.6I$=#R61K3DHR
M?3/Y!R>-LF7S%5KR/.1&`L93[:=PSE:\<<<B-;CSGB\@VZ_GM7(+)EYNT"I:
M(;(+YR_@X*5*J@BYEU8<DHT*C'.DD&Y@M2%/I1<;FND\S,$\I.8O*C"-5R7=
M;D&>7&$4B-.,BS^*LF/LP\5\'-Z5?(!PW6&,?XYPAR#H-:01?)D<BPC&LDZ7
M6%0[HFE5!M(`.C)K,<8/LF.G6'TJ9EW+M+P%COZG]TJ[?*E0P)7%[O#PS?Z<
MA*0IF\OZSHEMK#.C9`L22\0_/(13Z..HHHL"P/"B;3[EHE_^)OXI%,(2T*7F
M52>0^0<F\RK=94>,<Q"9GK.)I:'O&2^+=1O#^7AK5A4:C5ZY&XPSGQ#L5HF;
M(^K\>BWE)]VV;2+9Z<'9VR3VIJQ%/[?[U+_#')/)%0R+?K]0.5^=L\<2*AAJ
MP.#YNSGPP.3,>,,B(2C2R5;`<!9Y7&N,LCYQ92U)AY&:G8V-A'[N->QS8J2K
MIU($1*%%D@$:-+VJ5W(6WU')/&#+D%<[!>.6D#(DQ_D^;IN`JLK@G)D1C*+N
MM1E;1.5>Q+PIY:<N^,GKY"S03!H>,FGC^!(U;*H.![="Z!W7G?.\MKK0[7<K
MCQAY)9VY6XWC>/%J@:#.\F.*"4)DZM\DK19JS4,2XHALS.\'XNNMUK21;([M
MUN,YCG*E>:50BKF244=$23H5:C$`%<8KQNYF\4<?V>BP-ACL^X@Y0?3SR)@8
MT]@+C!DF;8N;=AC%.3+O@>6N+6>E9=]^K\FPUTL$,M-%*W7&0;1Q'"9UU$`+
M/!'!+\7YIE+9AS.]RP!R.XLQ#RX/\(\?N.V3N7T%'AA$K,9;,F1L(/J7'X-K
MJ9XTTG^LJWR!M%_G1A6J2ZB#5&&72*15=(H7AX+0(!<ZJ8N-JQ?+;ESFPTB^
M>,S@2FY(ON!6$8BSXI5JY2.5W#?BOB.GRMAHUJO-4GY>'E*])M5X1JJU07,W
MD&(.0[5Q$-%DZ"C_`.U8\5Y@H?"7D+R]@:#E/+]=P=6,&<1J;B#]-\0,Q9]3
ME:WANIY!J,;`NK/7Z1)1\.6C%FF2#UP]4:KRJDD18IRJ=Y3#0H09`$ZNN:Q/
MF"K5SD)S<>Y+YL\ZJ$YRIR<B[O0V7&CB++SE3N\$_P`"8>B75J,X>\5,S/!D
MB2,4XA%&"+QLHB6OJG4:$54-JN0KRH-%Z_QF>L,SUII5YC.0LDC020];DYVD
MWC"B[BT2KV9^;KQ[VWV%I4&BE7F)96<0)Z;PH.T#LR)_E*^8!+#$#Q6VA%\E
MV:ORMUQIF]2]5"X/[*1G\HXN_/!BG2$GY'<!,D=3$8[]'#JS8-T06(<KE%IN
MIY3BJ?4JA\5N:A-6%;.E=QS8,VLUIMK'1$_,4I[QUC:W\W_V-'6=0R=L2*ZC
MJI+OBV(6YS]QEO(W5;`<'*`J*T!T?BU%/1TF5FY(<B":*ID$#F[4D]^X4BD4
M`W38Q3=O4/88!TJL@_4H^Y[NF:ZNWJJN$:66XNY!6P(V2'"!=S)C`DS8C!%;
M.TI6+8P;8SE9=98[M5%,Y6_8DN"WC:NQ#!U?:F=HF0N5,BI8BVJG^$S+#3V?
MK22N.['`HSN5R,)U=*ONW<BU8(LF[:4:LVQ&RJC-9R17N("A3`L$!<H0`M5#
MY/YIMWCW]8XN8.TZK7CR:4%7:L^4'(:L=<Y_YM"0-Q%Z%:9S\A16S1:,,JJR
M14?N2)';B(*@F"I`?Q6%ID/G$WD5$DZ#69)Y%7EZSF$TZA+L(52E,'K-FC)5
MIZ_D6I;0K+M'"SI))J^.NJF@!0.W5,")J78(PVE;S%F2.5$[>6D5DB@GKU51
M@;`JM))T&;BTINQ-S3YV+5-VY<OA@8]L"#)$GKC,5'9S&\)GB1DW2@.ZA;@M
M0ZO_`#D95*M-OT!6).[RE:K$I(-&=7<FJ[*7L+&;6M/S"TEGD&]?DL>.V\<V
M3BE6CE22!RH<JBX$,="!/*2M_8<B<JXZE5QZTQ\0UY4QU;)&2B(BC.K7'2&3
MHR4G&,;6))ZC<8E"HPB42T9OT)$HO$IM58Q&J0?EME*70`+4JW3FI(RC\B-?
MA(J!6B8U6*L3S';QY+KS*:F-#S2#NHR4U4I".05:6&P"@LX*F14T,4A4B'$#
M.8Z!F6J5S#SI0!^=CQVBG)&$;:95VQ4],H[EX=XVG9&B-H-ZWN0QI+G"%<Q"
M,S'N#$3<N6+U)$[<SIL*5JA`H/%=)?LB\IXS(LG#4^E'>T-/(?RE:?/C>:?'
M@Z,G%1R\7,0LC'RDL>^+6-^J\(\.C%D+"BV2(J(><#E(PXZK2262.=D1$55\
M;$=4M:CZ`L<Y/1,<P492,3N[M#*O5R,76LC-HK8H\Y(Q^X:N!.5TV]0W(Y!9
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MR(B1`)+3``!U<GAX+HOJZ$YW;6QR(B3M[0]>%%`A=_7IPM/FR*VB.O\`6CUT
M\,9=A-O(>V,JQ(UZ>J<=*0QWS)RVLCUC4`9QRL?V.'2:NPG(I^>'?A8R;(O8
M_P"5+M-Y]P<;K9G&0G(';(&(E+=*,J`Z4HNM]2UY9#<+\&8C0LS`@$%VX\>*
M5NWR=@MD+(*M8O`F14(:M+O)%XZ+>+I+2T&@NC`3M9KE@L<I<EV=KK[5L+FR
MH+J>A.J(!(.CJ%01\:$3A8D[0N'N7;S.>V('2M1$Z3C<N1B(/"186MHW?R1U
M/-,B[?Z@B+-P0!XRD2-"(DNTA7=IQ=)W]8QXB[BU&N3LFHV-ZFJ>L97M=JD)
M%PTE8I0(^-.>`2?),56S,K1LP555?O#B\0153*943H+<V-E=S-F4?E,3Y0?'
MCV[<8@Q.KS(W.:D>4>4D&C2''<-HS$8SF^HE(DU\!R]_LY)1"UNB,$CR-!R#
MDZANQ?K1M<LD'/RD]&61^T;R9XQQ)5Y9VT4226,9M)`T2=KHK-V:*)"K)^15
M3&;E=PDT>YXN)D6XPW3A.`C*$7BYC<B"P'P@D`O(DM0#<!;_`/"G<MU8$%P?
M`QI7CK_:KJW,-:XC8TZ75H3(LT[<5N,ELBTU\X9-(2HJRKY)V]L5,HMFAAJ4
M_:9!!$IZZ]$A5$R',=M))=RB6<C&.>;4L_(N8V*'E&Q=!.^ZP(C"Y.,NK"(/
MQQ%"U8&AMF1M1E&W`3F368.D:AV#;7Y'QH5S"'Z0@**%8K:UDGE94*_^H[$J
MTE3HRRT8T;I0R$#&,%'45'51U8F#YZD=,J;ETNJ;R%**9$2^Q$>X7<_Y[-Z=
MOIF>R$2&C$_$9D@$S$#&(&D8BFI)\.1LQMFS9$B3J6J3R'@"Y_V)V\<P,I!A
MPECK#'2])>L_J"D,1C.1-C8R,F8M<QLFE"^,[1)%)JT.HIVJN=B*""A?Q>SU
M6?D8^1+OUS%,+UL^G0"82B8AIW:N^NE!447M\"-V(QM\3&7SIUUTBOJ>#W_M
MU^7HZ+Z4JZJ(T1&B*.',"?BZIQ:S_9IN=3K$1`8HNDO(V16;<5I&!:,(5TY5
MF%K`TJ&0'<*C&E3\QW*4'+*(E()BM5S`"9LR^%;M_&%XK_2TY<\(\MY2Q31\
M;?4KS'F;/KVI6YRYXOFR1:+_`(7($="RCN:/$2LQQIPPA+MZ]%IC(-UC%C3E
M<%$/"<0V-(@M_"G\%JY*))85YU_B5]&^MKB1HB-$1HB-$1HB-$47.;4JW@^(
M_(J4=VTE%:-<37#U5K5HK/):$0V6BUF[A1Q1I%)>.L+5RBJ9!5)R7TY$U145
M$$R&$"L?B"AA]'ZQDFL-98C26]E-!7,K-XT:C&Q%3788^`]`IZS>)1R32G4C
M`Y--*L?"\\X.5EX@BA(XX$*W(0"U/5>N6BPC1$:(C1$:(C1$:(C1$W%]3\DO
MBT?36]?Q9'34[ZNIV,&O_ND7=/U-V#L/Y*@'D[#%^'_:1V8[]-A['V&6W$[H
M-V'%^W$?GAY2_4XQ;&Y9%'>OY(O+I?JV&_N/83L[C/;WH%\4M;C^BS1NS:%\
M2NTBGZF6,7HQ<?77%W1?.A]0<$%.9^:$U(9H9<.%E=52F'"TD4RZ266ZZ=2,
M2\1TXE)TD)163\@'<*"&Q1[?A-^AO0(?T7A><[?Z[)XL&_R\@_\`-X4+<UT'
MU`2>X7XCAB@__%%0F@7=$J]6_4MX@DI-5R];Q4-%.Y1A!.[$=%JWF)>Q.W8R
M<;+,8*"@D%MEF2:KA5^)$"&)N<X=QS(9^3F'&P+AB-KRD(DQMAV$`&(,YR,=
M2P@#)EUVS&U&UUKSSJPJQ)/$\6_BRZ-TA%8\@XJU6JTVZD90M98%RC6XMFWC
M(&AP$I55%)IZI$.)FP6)O&VE9L#4P.XN*!VT;*';M'I"`NEX=J]D=SR9XF%9
ML7^UV"1*9),[TA(;6.V,=UO4-*32(<Q=CS2A;QK<9W)2CD3J(Z`!O`D^;V"G
M-=":?GI2MJ/9'"T?/U]PHDP4NN`9>.EX!15UZM="O/J_8W\JXAU6#%W%M_2O
MCM'J#MTL*B``CV*<`QL2UF=.UGSM9&HMYD)1F`&CN$XB((+3(,=P,0*ARW-.
M,Y61,VST_P":V014<15J,.%5GCIFU3LXT\G'2R/;(Z.^BHB$JI&+6L.8WYB<
M(V+MLB]=2DNTGJPL_2;3C1$"J)%\A5C).D%/+QW+&';Q9/W6T,4,9&Y6X"U9
M6XQ$8F,P";9KS#QE3$29W(GHGJ"@`!#@<"[U&A;VEEH5+;7[)8HZI9(EHC'D
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MAU$Z';RDCG*!RF8F(I$^*,*@&R8M%NY585``XD.@!1'<VYO2_N,X](]2W*,P
M<BW7B0Q`/U4]Z\STV2>Z`R!`VS`'LII]J^@I?^>5Z_\`&'_OC]VVOSD-%]/&
MBQ?O_OZJJ/W_`-_1$MDBB#U;?I\8#^X2!M_<'0<4%8JK,-TWP`(?\T,/O]RR
M(_X-0H*%(=OO]X_WQUHH15+W"8>G9&W'?TQ]_LW*NM]V_LUE`-5;'!N^;;;?
MSI/[H[?X=5&HDJ@;&V^[_".H$(9*@*(QIQZ?"]((_P#"2/\`^+5H_P!.2O'W
M)$'M#]H?W]7^Q99+9$`]<YZ^TX&]_L$I=M3@KP"O:%$R#L"]1%$G:``(B(^I
M2#8`#J(]=1M4Y*\$B,C`8=E'0=0*;8R;<?=N``(*+`(!T]A??N.BHK3@LCE)
M1RJW+OWG,U1,)A'K^$PG.H81'8"^\1T48+*U!)$ZB*&RA_3N?(X'H(F!`_PH
M=-R)A_*_$;[@Z:(U'7G.>U6F0M6;9"#Y#93K\?0W%FEIFK2''B)FFK<S:QR3
M-*N8\>*+F=V]1<D7XF+9N<'3M!VBN8W<(`C`^O!;;3F5H87-+3YA27CGE;DV
M48(/6,5*5K_LR%9.K8X:/U#NV+95I6G*$861,BH1%9L"YFK=R(`H)>TVA*@%
M3S6*OWV14A;6M6.3.32L:X5NHYCD\!H,GK)::F5XY240M5\E&IGB5B?R:3P$
M`D3.>ABI)$.!$"&XH?!+5,K2MCFY9U2.3>4@CI*+MEHBJ\&!@<>A)`UYW**L
MTYF_D;-T&+="N*=C)`J!%CO4]S%\ACE&I0@!;"L9\J$?6G260N0N8;L9U(1R
M\6M6<33]!5KTZUB)![,U"+EX.%=(6$)`RP+)H&64*F9J0$3"(#I1&).B=RL&
MLDM:Z)D.BW//-EQ2[KS)=.NNZA7Y.$L2CYU,1[V1L4K<9NN7%D_*=V4SPH,4
ME"(-TNTY@$P"`4?A1W3'1MWO+Z)R?,PO)G+2#:@O!3D(V;XTP<G._,9"4?Q2
M"=52,N+RVA&R#H2(IM3]K=JV)Y`$BBBBU/+@M$`:ZI2RS=''LK1ZXY690G6D
ME&N84M:5XW.6CLTB$5)IDD&TDPK9EVRC!^@=TY49%(58K5$HJCWIJGH9`'%0
M&26!R._&M.["SY)90D(F'N4"E.,D\"MX:7%-=!XT:L%[;:Y%.;LZ:T?#O!17
M2D)*541%LF0%5S$(KG10_%0+*3*MA?M[?*5'E+DYS'(5VS6VOPZF`DE6[)B#
MY[+JLE9>\^F>2R3=@Y0:HMD56P$3\0@8I=MPT3E1=!7,\XX8UERWOG(/.-O%
MO,S`P<U7,8V;'[ERD1BV,^K1RP$$LSM[J&")<.4C"HH<B:Q@)N0-PNM4(KH'
M3NU<UT5N+>WUB[9MGL8W&KQ#>I0LA2ZR[JS,)NM5IBSM<G+3E@A;LL\C'#/U
M[E)=B@9)VL[#L4*8"BIPT63]J9*L9!N9<=S]P:\ILOC#TR5K$$JC9^,=?=6X
MBDM\C25!BR.<3S9HDGD-,.TNYLR.DY6%,J::6V?N1JLU5HVN:6$P_E%)'E3D
MZ:;VF)DRPL(?CQ-PKR$>MF7:G,.):OPT?.(HP3%HHHL#)=D!E@.J10BAP`VA
M1::C,$0.4UE6<7='?(C)=AKD):6-?GFRV`HNL/RL5T'5@^1/)-\LTF)Y%LQK
M8BL,8I)+JBJ<Q2*^4.TC)#'91N#:'D'%>Y6Y0FBUF!A)\#../[-'_P!UH\U7
M8F6]4^N*C:8G9ET,]N01<$%(Z2IC`(%*4Q&"<^,S_B8*G#?KC/F=[3,I%FHX
M;36\=W#'Z=@9M9;L,=>#A*VJQEEJX@Y*BL[1%191$HJ"!O:$]BRQ!3@-6F0_
M4Y!=,;[F^5J-Z@WYJF[/0*6:*QE%65)Y9VECK+N1L+6R.)*OM)<S1L+UB`D\
M*2:[9042CIX\%0*IC8_)=P7QRED4W)_*[JIQMQC:W(,9#C'!IV\HN6A9'RM6
M3CUKM)DR8*J&6EC%<)-"I&W'N()=5RRH%69BL;3,$6O#S:#KE7DZQC-LBNX)
MLEQXL-<<U6,2E82?E!=KP<?%2RT>X9B9FFBJ\;L42N#D,!RI'2+`JU6(61KE
M)5U56%RF>263YR`*>U0CEP3`;&GO(6PJU:33^=MT$U(VPO7-9):2+*?*$GJA
MO``CNDBLJ2^Q30Z)&ED^WGC9)1CRMR:Y2@%8%"6DD./$5%%9UF=695QJ9L%@
M%E-R<PQEWQ%U79EU3@FW6**9SD*!IQ1J:47:,.1>(XJ.K+RW9ESO89EJQ:KO
MI.&HMZID1;48R32*YL):?%5H6Q6Z9GJ"+T[3OW*4!'\6XS1"#J&==<O#92@*
MQD5J[R+G:9:/&RDY!9"/CFA.EJ9#U=NO/*A5$PLQ966/98N."/*9XT!519;H
MF@=4Y@TS^Q0&M=4U<1DNWA0H:]2'*3(I:>XLLE4I)T[XV56/G5%63::?MGLK
M%OE5)):MKD;)F!TFW>.'()]@"!U'`D%RAU9EK6&8DD&K&NNN5.5WL[,V2L2-
M:ECX`L,'\HC)<MB:,%W32+91KR<BIV9>HF!S(G79[LB)N$#$44V#Q6MH/!./
M:(K*T57[>]O62<S#&1%-,D[DVV&Z%&L$G[":@$6]GAV%0M[B5E'!2MCJHMRI
M%/X#G4`2G*!!CK(9TWTCD>[1M,JMJD^5N2(BN7U"X.#OC\=J\@^A5(%9HJR1
M<UAKZBPQ[WSN"I;'!Z603`3[@42G/=%H@<JIW*SF#$TU<Z9"CD[-TS<7SZNQ
M*S)Q6KG6:L\LS>*CP2"P5K]/EBZXQM`%%X*9SD9'$Z@@H7;8#G@HS*;"YB*)
MM$G`;%](GV+$*'D2^(X;CMU52V#J4>O3IIPJLMQ6-L@=LY'W]S9T9,Y1W(<`
M;*`!TS``;@&W[0'VZ:EN"<%CW(\#M6,!''3M6'X2K=NVQ5AW[2J#ML!_?_&^
MW1W/BGW*UVF=)JT34*)#D.[`0,`@/XT_=H`R:E8F`?UQ#;KNNC_]<(&K(4"N
MD5@5_G5>H?SA_M_E#]VBB5%)_4%.H=7*&WM]R;@?[PZFKK(^+Z>"1B3H/7[O
M9]O34=UH:I8_*/J#`/3M31#^!!+_``AJZ%E!HA@`B9UMM_S)?^[VA_?'0BB%
M(1#81Z^__``:O!:(XI:X*(-&74.I%A]_3\\X!O\`MT`<J1#DJQB&[UKM_K"7
M_GAH0FBPK?SR@[^TYO\`SC?^/3@J0L?[_P"_HHJA[0V'8=PV']_[-$9>+_U4
M&R877!ZR:(K+'B[R0Z;?N4D%C@K2P(V30`%4SL7Z"AP`3$^!1$_\H`'[?^T@
MB<?/E)G!M5/"DZ^T:_4NB>K3^?8`&HE_#[U!0K.N+2M6QA6JBWF\C6D\&VF%
MVY@F#5%M9E8I)U$L*U7YHK^7F8:LR,FYD#O?1HQJD>J!3I"@HX)WLW,H6;W=
M,R]*':;&XPC(-U90W,3*081G(1$0-TI."Q<`]>MVK=R0QX`=67$&@=BS/J`[
M\`JC/5FH2+&HT:_L+$\58P#B>-FI\R2HM@MMA3>/I&7)*5ZPR\.RGJ1%.A9L
MWJL\,?W-Q*X?+)_EMD,;,SK4LWN.-*W8$Y;#BA[L+<?ACLG`2,+DFE("V)U>
M,1QLNGCW>C9+N!NWD")EI2I%-!5M5TLM8K<R4:2`\=INMV0T.:3@6\Y(0LMB
MN.:RK--9.R2=A,X:NFD0PB9-N5=<7*S$7RJBJAP01[5O#L6,.5F5O^IVY6#)
MI;1*-]P:VQ`@C<2"SQ$F#`.7&I"Y&X)2LF)9QQBW-^'UM45X+*RFK"1E.2$)
MQ^E(HB#]9>2GLLR</2L?T64DSO!3\QEI.->%:-)-\P(8SU\1X=@[.'C,NENK
MF[C8DKD+&1W,3)B-L<>$KMV[$,VD9`$@2+".T2B[@2IN$)PE+;;>KO-Q"+_5
M]I<\EH8$E8RR[68J7*94OD:ZK[BJ052;`M09",/)R+J6QM58F;FZ;8EH-FL@
M5VW:IK.I1P+902LY$Z8F2\S+EE]EC&X,>![3,$2E<_QHR8;;UPQC..XBA+1B
M'`>''$(V<LRMQN'Y@?"!2)!).T`D'V4YLZY-*3JULK,B9M3V$!D*O#&!:ZVS
M?HN0>G>"UB)*?AHZ0D%+%&N8&UL7Z3Z.6:@DQ;E3.D)2=Z1/(A#)P\T"5\W.
MWW92Z=P#0:B$R!ME&<#$QF""9`@^/!+IF%(-=B`XY^(>M#KP"<[$BS!!#@SW
M-3R#MQ]0(`;F7=R#4\<NI4\;&-+J$0!5!5RY0(=-1!P!4B@<G:'>)3Z\+NM;
MO?Q&8$?]/!V`+^>[Y:\G=XKV';S,V<:0_P#.U>O\NGTX+ZM@U^6`S47TQ5U4
M1HB-$4>^6307_&?.K$(EQ.B\QA;F@0[.L.[H[DA<1#A'TC2IL+51GMA=+=^R
M;1&9BU%C[%*Z1$04+F?PE<EK_$'^S[5!KZ=--Y`0E'PXYD\UXKB,)MZG+IQ_
M&D>+K_$^8*TF8LDC',YNQ2W)K,4G%NXZ2'UKA)9)^HX1,!16(!NXN8`L]6Y,
M%JZ1N,6!E2KDKUIUR+A1HB-$1HB-$1HB-$3?99JMFO.,,A4NF6MO1+7;*;8Z
MY7[FZA#65O5Y6:BG4<SG5($DK!'E@C57`*@@#QL)Q+MY"^W1!0IBN&/'G)/&
M+$#;%.1,Z'SP2&=H#59UQCZ/HCVO018F.:JUUTNVL-FE;>!95LNZ3DI5VXE3
MD<>-==?QE/HM2(D7`92VT64:(C1$:(C1$:(C1$:(FXOI.Z7Q:/BMZG9D=,_=
M5C=K!+_W2+N7RW<.TW=4/B[3!T_VD9F._378^PEL3NE<,/VT_P"/\9_4XU,;
M_J./_P!$7ETOU;'=W'L)V]QDW>@?TO\`AC]%FA\VE<.K'3]2<:J<?77%W1?.
MQ]05]*LN8^9E6%A1.1+AS554JHH\>+J*/`RW7#"[^4*-'4&BW?MDQ0,Z6(NN
MC_.$05\?:/Z$]!6[5ST7APG`@GO<_P`Q@P'R\Z;@1*FK!@="0ZZ'WX[>YW91
M!)^5#\CYHT47X2385N0LEWKD&F2R93AE'N/@G9=W'L8BR5QPSLN4J3$0%>,E
M9[1--4,?1CIH@X?J%=0SU)KOWO%TB^^R+5W-C:[=FW3\GB7&O;`YE"8,;%TR
MEY(Q/5()'PSB9&D05ZBS<$#+(LQ>=T>1RS$%Y`#B0W'4'Q738FQ_'N8LV7\I
MU\MLO%M?I3M:@K$]7<)^!1DY5E+I>(]-%HO-$D[&\=-6D>\4,LH""SE\0P*$
M3'B[QW"]:N?T;M%TVNW8\=MR4`!7A;M&K>4"4I1YQ$#0E;LVHB'6R`+F3,[@
M]0PXG3W#ZT_-ZP]7G&/#9QEKQC_CY;8MX$4I.RZ5=JM.R<V<LFDTFG;A6;1A
M9R?BG$6U:LSD0D04:F,1=`W:5='K>#WC)CW#^AV,>_W+`NC<(#?<NV#6),*G
M:).9$$QK4$:'V4\&W/#^=G.-B\"P-`)C5B.)&@H4UN):)0L\W2+HLCS-HUQB
M732)6=0M4MK:1OLPH6,4(G18=K8(:J*OH^`7:)$6[`DD7)S>1)F*BI_![3O6
M;W3L.++N%KL=^Q<$B-]RTUJ+ZW)[93$3)Z?"W&5`_CXV)+*O"U=S+?2!#B)K
M*GP@2`]C"AX)P[5CZB2[P*#>\<4^HP#`RC&O/:3&'K+G'C5VW<M&[=LC',VQ
MIBJPPB111DZ277<FW73.#DZAS>!V[.[A:'S_`&_+OWLLL9BY+?&Z0Q+$D[9'
M\)BP%`1M"S?M6ISZ%^W&,.$A0Q&@`;4#B"ZC#7Y*TTJ-O&*,EP))6M,4#U:"
MB$[+)QKJ1O\`D-T6;KC'&[OQITR?6L$Y3TY)LT7;&7(HX>E<'0^:&`.T9%G#
MS;N/WGM-R<<Z1,YG8)"-JR-MPWA_B#;&9C*0+$".U^FO"MSN6;<\:Y%[,08@
M<1*50(G0\]./BI(\%TDX3E50Z*S;&.G4,<WEC9)%5!J#B?MKI4LC846BK%&/
M:HQM<?KIM6ZR*9$'RC=XJ9J03(KFZ_ZYWY/I6_W*[([[^3:-N-6C:#B!D"27
MG$.QK%XA]0O8]CB(]UMQUNQMR$M*FKLU*4!X%E[VK_SRO_K#=?WCK\]C1?1^
M"PZJ*NB+8275QW]=E$6ZF_VB9`F_[.H:#BM#X52/ZG<$_P"49N2;?:()BH'_
M`)FBG]J1'#8P[?=_>U%9:K8K;"R:B'\7U"0C^PQ3@'_EZJ/JDK(_8Z;G]@%6
M3$1^X#E$?V:<%%:Z+V.%B?R%%"A^PIS`'][1"E">XQSDNP_`NW5Z?8(*IB(_
M=N8-*.G$)$3\0;_?_>U%1JMB\3%1R`D*)S+)H'*`%W,(F03Z?>/=OJ%W4X)4
MV$B!7**)@,N+183K$,/802=J@I([?C'X1[C]?NZ==73VI4CP=:]%(ZQ]MP(4
MH=RBIQ$$TB@/4QQ_:/0/:(]-9#E'9*Y!79!HFW$W@.B(&,(=JBPI+*$_,V$?
M@`P;E+[M^NX]=;0/[U6,3$5"JK#L0X+(D*81*=<QT3E$B?3?M#?J;V%_;IXI
MPHDRCE=4R8=QB%3^%!(@F`B)?9LF&XFW'WC^(?MUC4II5;-=51NV:"<YSN"@
MN4""<3$2$5.[N5#?XEB`<-BCT#W_`&:UI7BIJ::).P,Y<.RB*BIS"583J&,8
M>P#)F+WG-[@[A#[_`+-0%E3HDZKDQ2F1044%,?QJB8_>MMM[`W^!$1#?M]_O
M^S1T8NY2A8"^".7<"8XII=Z")NJGF(JN!5@,.XHE(0^W<78P@.P=!$=:IQ0Z
MD#FJ-S+.S.@.("<S02E[A`B21`61$0`1'8B92@.X^T?OU-4H$"N*8D0;JG'J
M!#N>XP&.`B`&*EU`4D/N]I@]O3IHZM34K.Z/X'+A14QE%3+*F10$QA(0O?\`
M"JML/01[0$I/:.P;]--*J!V#:(<'.<C19RLIV%0`P;''R+*'54.8J/L`A0#M
M`3>PH`&P=`#1N/!.8"JHHHLV;'7.*;8AES]I1'\/<"::"("(=QQ*0VXB/3?<
M?O)H6&JO5'RI,CK%[4TS'5;)AN*IE5NY`A$3F`RA3&3$W>H`[[*"'OVT3C35
M;-)`IW2JB@I`9HB5`AMP`K3IMWAU$!5$.XP`._:&V_4=/O6'HN<DGYUUBE1.
MH1N@`D0#N,!A#^,J8V_<)U/?OHML0/:M;YE?^54_SS?;O]OVAJJ(\JFX#Y#[
MAT`>\VX!]P[]-$1Y5>FZAQV]FYS#]WO'4U1+F+\Z#DBBH"L78R9_('</B5V!
M0"&'J43``;["&^W75VT<*ZCQ73+)D!=FZ2.4PJ!XA5$0,*Z1R[`DO_%\OB'X
M1'\1B;#UU!HH-"$A(94BKT$C&W!(X+MS&$WC4;F$X;;B)O3JE[@*(#W%$=A]
MVX:.FNJQ(J*E1='044.B*0&%,YA/XS)J%.HBN7?82J)F-\0;`8/?OJZ5"<0^
MJM;")E%%6RAR[MW!#I@H856Y@2,<HE'?<41.7H;V@/0?O>*I+ZK"107)TU`,
M8KLAR&[0,)2+B4P&[D@`=DE^GX>A3>T-AU&<NA#>Q476`SI8C@3G[%'":2X;
MBX;%44**A$CB/=X%#)E$Z>X%,)2^\`T*H%'&JL="JU29&35+W%*X$BB8[D4(
M*PCT`0ZE.`]2C[/8.J-0I&I*SMS`J+A9$PD5!HOY4`,81^(@AWHB(B82?:7J
M)=_LU-5#1:\K@0'94#*$.7L%0.BZ90$3!XU?Q"F!S";QC\&XB.P".^J#P6@#
M[UFD"JH+MS)G/VE;M_"L3N+W"1,O4H_B(<HC[/:&C467=TJ9KG7(\/W&3=BU
M$@J]W85P)E4RE\@_Q5QV[0$-@-[^NAK0*EPW):PJR[914Q=RJ*&`KDAR=5^P
M/&!')1#=4"%Z!W=2A[-M0:UY*BJ7/D^X$3HAL5-HW!1$!$3)`8GD[MAZG2^/
M\7N]^H7X++G16QRIBF<%4[C(%;KF,7WD,8@)]R(CT(<W?L(^\.@ZUP]RU(4'
M-)7"(I`4Q!\B2G5)4O\`&Z]2F#VD5*'XB_X-0`*BOM2]04E6S!%P.QO3G,1P
M;<WC[E3@0B@>T4MB!U]I?=HLM4D),S0.E)))F+VB0Y3_`&E$"`*G<4P")3$,
M!=P$.FVJ=`M'X:+6"/<81^T1'^'<=!JLC5+S_#'$]H"=W^SHFC_XU=0(15(T
MP$YREZCW#M^\>@?W=&1+7P[NW'L^%04_NV3`$_[Q=9/VJ1T5&P`5)XH`]NR`
M$W#I_.+)!M^\`'5&B'5(3[=/WZ!U4M=[`W8D#V@V`X_;NHJJ?^#M$-;%)55@
MSJV.#^O-]P'X3]X^[HF4QQ'^`NH%DZ)(<=S"/VC_`(1TX+4M`K-%E5#VA^T/
M?M[_`+=%1JO(?ZD\FRC<DX59S;552KV.HY)@Y]RU9%=.X5*73J\:C:6IC?F.
M%81V=%0S0!2379D<B<5S@DW-]B_;&S=N8.==QI`9=JY8G`$L)F.X[#P&X.!*
MI$MK-4CI/J>5L9%D7/A,)CV.17Q9>?$C(VBNT>+Q'28-PA.MIES0<K,T;*XE
MK/-2][(D\B!=LXEK'4B`JEVKM);"V<O&WA/%JN4CF14E#)A]#M6\',[E+OO<
M;A^7VB[C$QVQ$;5):G?*=N<R2`7W`$.+;KK1-VUCC$M`QEOVS(U)EQ<:!@S<
MCXJ15&QU6<>HQ,)"5>NVF\/V3)I=[7+()V9BK*N@</9Z!JD1)1QXIG&M'K@6
M;A4S,RLNF40[@;")-=>[CW+,[E*63EW[MK"$B;5N+P.W2,[AB1(R(&X#<T:?
MB"\RW9ACM:L6XSN4W3-:\1$'APTJD^8<64'!4]7#QG)O'7'YI:T(:QOZ%/3#
M2(>XK>/D5I%4:'#13&<GDZ2W!)-HB@9C'N%F_815=PD<ZB6.R=R[GWVQ.-_M
M-_N4[!E$7H1)%X"@%V4C&)G^(EY5>@(`7D96!:QKL3;R!9A-B8$MM)J6V@D#
MEH?:MMB##U3OU1E\L(Y5QWGZPU0&;6!IL0Z@[K5JBM*KIM@N%C8&C2.E+I%D
MA&BS)=>)8IG<*G67.X5[2H<7>N[9O;\VWV@863VS&NG=<NR$K=RZP/Y<)`GR
M'<08B9HP\HUUCX6ZS+-E=C>R8AHP!<1>F\AA[B1[4WV2,9P60H*:L4-5(N"R
ME#J,955O"N@9Q-WB(]5TG9/3PKIJ>';7:*C5UGXK%*V0E"D624#U)R''VW:^
M[97;KD+5R_<N]CN/!YAY6Y2^#S?$;1($2"YC0CRA>!D6HWX2E..S*#$F(%6U
M#<)<7H#7BFP>3JV6*U2T<E,7/ZRB%762[7.Q<P^>66-Q:1./8O'%GJ-Y;OUT
MY.UW''4:TC%V@M!7DW9G7:BG(*J%]E;QAV3+R#VJ;X-QK-J!B!`Y#DC9<MD#
M;;A>E*0+@1CMJ8`)*Y+*M1C?C^8/-N<_!0&AXD@>\N=5VN-YV8EY_B?))OV-
M5:2OU$#+*UY*1=1HFBCUS'BB4`BF"@%L9SG5(L)71/*F`'(95PHF597QNX6+
M6/9[Q9F)7KD/3@&YG\V^YYA_*.%"W$``L.7$,9FQ*(VCYZ@]FWZ.OJ>U^85]
M+1HB-$1HB8_DO2+/DOC[F7'U*BZA-6VYXZM-:KD5?V4=)4E_,2\4X9,&]I82
M\/8HMW!G75#U!'$>^2,GOW(+!^6;,@3$@:K=L@3!E0+RR^GUPIRO@*_X[F\K
M\"N`&.;76ZU8XZP\G,!VIHQR@_D'\6]9)A'8\@N-^.*[&MI]%R5F]*VE6Z*;
M?N."9S#XQS`'\0K]/%<ER0(\LG')OXL%[>ZY%P(T1&B(T1&B(T1&B(T1&B(T
M1&B(T1&B(T1&B(T1&B)N+Z7NE\6CXK>IV9'3-O5C=K!+_P!TB[E\MW#M-W5#
MXNTP=/\`:1F?778^PEL3NE<,/VT_X_QG]3C4QO\`J./_`-$7ETOU;%^X]A.W
MN1;O0/Z7_#'Z+-KG?]'P.GZDXR<?77%W1?.?]1)ZPC>:F3A22.I,.^%,*Y.O
M\P0;H-V+3+<;V-_E)DBKR;PSE$JI5RK;))`9/Q&$Q1U^B?V[MRN^B\4$M:'?
M9!FJ2<>7'@&HQ'BZZ%ZB!'<;A'_EA_SA>?;&PF<UZ#$[E[`2T)DBH6C'DE'M
MG2DW+2#&;AXRT1<$X8$0F1!)9[&.SE(\9($,@F*RRNQ4P[[>PXPRYPMM.S<Q
M+EJ\"1MMQ,92A*3O'A*(\I)!+-JNMV=L7!_Q87!(<W<.!KX?4I<4-9D?-TIQ
M],W;Q>/LAS$A9JXK4HQW/26*W\W-2-QND$98J$S)'Q];&;.0<I"*[Z+9M'2+
MXB1E`<*AT/-MWAZ>AZEME^YX\1:N;R!&^(B-NW("@%V!,0:1D3&4'9@O;6VN
M9TL&9(M7)/%@28.\B'KY2`?`."F\QM7F/+^YQM^N$&H?%\BXLD778^WQKV?K
M]!Q-CB>7;DB*56VS=*,<OIAJNWE7[LIG$E+R!54@\2"9$E/<=ROR]$X)[;@W
M(_U>&R4S;D(3O7[\7>Y)W`B7A"):$(L:DDCCM0N]QS`)DC&B"Q()V1CP',MJ
MU24\N9,&<4KO4OUGQT5Q_D=U682D1%H)6ZDY@)"/B;)7W#.M1$=/UI8[J.M<
M8T?M_(W1`TI"JM$CK`8Q%-O0]E]1>J^WYWR7J<Y./;O79SAU+@D#*,WD90G2
M4)$$!VA,&A9>;FXN%.T+W;IBX(@;@`06E4$<-W,:A-Y&Y>=IXBOU[FF]DMF5
M<.7V=XW2JMNA"21;J\4B_48\R+DE089.)%W",F\AW^M3.A-.634ZK7=5PLG[
M2_V.$N^6.V8QM6NS]PLQS8]*6TVX[FNV;57\Q9F/Y8E)I,`#X_S)^7.9=B^5
M;GTZU'^Z9<*`%W^(@>*;JP&8PQ\+2<U*M'KIVZR7E^<>$^8O8#)N7;.A5WT6
ML[)*.I:*374G4649&`X9,048MB`W<)E43-KV6"99)[A9PX[+8E9QHBFZQCVS
M<$VV@$^5YS()8R)()!7B7?*+,I_'$RN<?.9<1]G#1/;].R5>.>5D>W?MG8.D
M*E>"R1729_6-Y`C=@#L/&L0"[@Z7,0Q``/$)5.[J9(ROK?W'LVK?I*4[1!C*
M]98AF(\S:>&GN\6Y_3I([M!]>G/[OO7T0N"@"R@>X#CK\U@47U358=@U6",%
MKGLM&1KJ)9/G/IW$X\=,8L@H.E".'3*+?S;LBCA%%1NQ31BHQ=85'!TDA\?8
M!A4,0IHP1DEN]\I-%K\=9;I:H*LP;I-PV:2LM(HH-'RL?#S%F718'**AG[@M
M;@WCX$T04.9LU4.4!`HZGM4%20MO`2T3)I0DO&R+)]%S9&JD0^;NDC-Y-&0;
M&7;^B,)@%=15MN?Q@'D*4IMRAVCM2P"$46584TE_3J*I$6.5=1-)15,BJB3<
MQ"KJII&,4YTT#*%`Y@`0()@W$-PU:%5G2I15!.+6,X700(U<%5.===)!---0
M!3.8ZBIRE*`*`0H[B&QA`/:.IQJI1_<D?F0147*HN@D=JDFLZ(HLD0[5%7R&
M26=%.<#-T501/VF/VE-V#L/0=".2H`6::>,6BJCMV\9M&YVB\D*SET@W2]&U
M:`^D'8'54*46S%N(J+'#X4B?$80#KI10`,M#CR[U7)E-A;Q1Y8)^GW&!2G:Q
M.)L9..0FHA?\]C*-&LRRCI$&+]%(5&ZAT2`NB8JJ?<F<AC3[D-&]JWR;=14Y
M4TR]YS"``4/:/[-6B&@6X<F!%NW\8D$YT#(*K%'?^8.(&23-[@V,`&,'4P>S
MI[8IQJDT:F)W8#T*EVF(JH;H1,BQ/#ON/03#W[`'O'5:@5D:+$Y5#L%ND42(
M$-^$?Q**%'85%1#H)M]]O<4/9J`50<^*5D13%@V7<@;L255*DF'0R_>!3@'=
M_$3`Y#;CMO\`9UT\."CD2HDJ*RAWJ*Y]MRG3*4"A\)$P,``FF0/84"C^_P#;
MJEM`JWEHEBR)F)S%*F91P)C=IRD,<B`"(["G\.PK]O\`&Z@4/9UZA`/K4'F]
MB$6JSAH7<AR%2<G,90Y#[%343+W&]@G./<0.@;B(CHRI+25I5A1<-D2$410!
M9,P@<HD.M\8%%50=NNP&'8/87?\`?IIIHH11SJ@&WIQ,=5(ZI@.8$D03,8HB
M41`%%MO83;J4OM-TWZ:,CO0+*=!R]0;J"101(9P550Y#`4A0,53N,/;\!0`P
M[!]VP!IX(^U"1#"1TW106!,6RNYS)'!194O:8#FZ?"4.T>TH>SW[CIX*<76%
M!(&0I^0O<\$Y>U(P;@W`Q@V.<NP[KFW^$H_A]H]>FFI5)?V+*Y9B"SE9=);Q
MBNJ"9`*?O<&\@[%*(@(@3K\1^NWL]ND7)=`2S!#QHLNX(HHFHF@FW;`;L3,`
M%_+`WA;DV$.\>O3W>T=:#$$<%06##59';<5#H^5%1!DBV1*!/B`154`5/`D8
M0V,L??XC#[.N_NUBFO%0?_$EA6QE'*B@I&-Z8@ILD"]Q@3\0`DD<?;VI@J&X
M#[Q`1]VG%UGP6&23,Q;I-$05.=P455S@4YNX1,7R")MA'N4,`!U]A2[>_5`=
M!YC[%SQD%AVV15'_`.)G]^VWN]^@#+8'-81(("("40$.@@("`A^W[-:8*L%?
MX%=M_"KMMOOV'VV]N_L]FVC!&"KZ=;V>%7_WV?\`\6C!&"H*"A0W,DH4`]XD
M,`=?9U$-M&",%T$1V.2*QZ_<!5""*6V^X=NQAV]X"0VQB_O#WZP5QFE1JE1V
MRB*S=SXU3+EV(Z^$P>I0(/8HJ4`#J(HB7N+[P'[0'34^*O!E@2:&1=B9!%04
M%/.@JD8B@]IC$/\`EG```3(G,4!*;_"&@0EQ75)6J'B?)+HE."8F$IB*`(G1
M,8AMT5@V+W%,'L'V&#[PUHCRLJ2=K'583-16*1=LB<``R?D1*!S>,PCL)TAV
M[C)";V#ON4>@^X=**@\"E#IN=T[<%\)RN`4,"9Q(8I%R@/PD.(AL54"B&QO8
M;V#UZZA`("S4`<E:J11)JV0<-UC(@14RQ?&)3I&%=4`.0PE#L.4`Z[]!#H.D
M=5?%8VR!T2O%DA,H4[<"H+)=P"<3+)`.VVQBG+[P]P_;JRX<T)!U0+=1V`G(
M@<KD`$RB8)F*1<`#^<3#8`*KT'N*'XO:'O#6:*NQ\%F7%5)RLD=!51N82$.G
MVGZ^(A4P43-VB!%"[=!^_8>FKK[%*-XK&HB+=HNH'<*;E1%-(3$$IQ`HJ*&*
MH0>I#D,`;^X?=TT9DU(6,G];(4B@&!8NR:3D2F[#;;`5%P?;;IO\)QZE]@]-
M-4T--%1V<R+Y42B)#)&\8?<"90(`"`[]Q3`4.@]!`=.*H9JI00B:K9VN@02G
M$B::B10$2E$5/*<Z([]PIB1+J7;<O[-/$*$LSK7(+>(1(<OD1/T52$=@,'78
MQ1Z]JA=^A@Z_NU`$U*622`D.D)-S(E232*81#<IBIE,9-0"[@54#&'<-4C@4
M%?:KV!RB0Y5C`5-%NL*2QM^YN90/$``(!N9,PJ?A]P]0]^Y0T]JU2R!VZO8H
M``/X@$!W*8H]2G*8.AB&#J`^\-5@11:#:A*'7PMV:8AU$JJX_P#Q502A_P"0
MD'\.@'U)J5C8I@=VWW_#Y"F,/^*3XC?W`T+:(=*+`J/D54./M.<QA]OM.83>
M_P#;H.:H"5@'9'*;AU6<I$_:"1#G$/W"8-*.ZFLDB(4!,`;;]0_OZ$4HA')+
MGP@#DR?_`")4T??[4TRE-M_P@'49_8LQ!9#/8OF7]R3=;<WV"<H(E`!]NXBK
MHW#BA!T2`0*([A[^OOU0%H!4V#58*L%4H!N'[0_OZ,$8+Q9^J])ECK1A<0*8
MQ5H2[D5#R"`BHFXIX($*!!,H0NRXFW[#%'M,4>XQDTS_`'#]HK(O8^>#PG9/
ML83^G]@<CH'JX$W+.W5I?>'4$:FSBKK<9>%G"+'<7'!RU2R+6B(23$8"PUNP
MUA:O6E^,,]A4CV>.9Q$5*,RB>3D5'1``I4Q4(D7O/<Y7>W]MC?QI#IV.XBY9
MF6.^%R$Q.W%W.R4I3A(^6(!:HB2O08S7@1+_`!)VS&0Y,?++V@`<SQ3ALL^.
M8[!=ZS;:FII#)F'9"(IT$\KU>37J=YO.1;$>,J.0VYR1P1#NTP,0#]11D?TZ
MTIZ)JLX4="JY!/U5STR)>H;'I_&D(=GSHRO3C.7GM6[,-T[6NZ,)28"0<1!D
M(LP?SK=TG'EDS?K66B"!24I:2)T)B`::E@2]4XV"<!X9C)E;(7)B5@*\DPNK
M:M1^1<H0ZUELLUD28<RTJZLMVM5G29LXTTTXD2+^L<I(1R*B"31`OC3,&O7]
M_P#47><D'M?I,792E:,C:L2VPC:A&($+4($DF(&D29D$F55R8.'8G.67W*6V
MR;@`,@3N/`R=F]I39Y<Q_5L'KM,Y<:&R2-094V2RM3+'1:Q)5AU+Q+9DV:S=
M6M]<4*[:3%'N97Z31VS?`D4S5$7;59-0H"K[3LG<\GU%$]B]4RW9D[PQYPNS
M$MIEYHW+<M8W+>UP8DESMD&-.*_CG%R!EX$G@8B49`$4!8N/Y:MXZK<Y5M$)
M*_V?8\I!'$?2>0]7A<C3TG,1KPCJ/QWDNM%?GQ+098&+59\_G7K&2:N'<<9$
M[A=1-FNJX036[?%[7A7K4,KNW=#&67VJ[*Q;C&0$3>M3VC(NQ<@"(,#MDX8&
M40*+>2PVV;`VB]",RX+F)J81/M>O&@)3)WN8;MK3FYPP$J\M+6R+BCP31-TZ
M"FXNIL-!`U+77L@O.NC5!5X[BF;91G(JMC(LT.]!,0*KKLG:L<W</M]JZ?R(
M6)2$W`WW[LI$B6W:.H`)DB47J2"=%Z_,N@W;A#."`W\H\-::<>').%BZ2:_*
M^&,P_04,=+ZA4(QCBE?)-4RO'=4QUVO)!FX05<R"*;4JJ*:1#$4(JL14Q^W8
M%/%[M#;D]\LP80_TX7H]!<NA@105:M:.&Y>7A2>&//\`ZT/_`-V*^L$/_'K\
MHA^*^FHU41HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1
MHB;B^@49?%O<6WF[<CIB4:L.S`AOT1=P[KOT'>H;"("'_MD+/78^PDC$[HQP
M_P#VT_X_Q_YG&_RW_4?_`&>LNE^K1$]Q["X[B2.]!OE?\,'Y+-KF_P#1\_\`
MJ?EDX^NN+NB^=?ZE;J4;<LLA#ZM,D/\`]C6,$C%N[BE9!23'+D:0'8Q)^Z;,
MU(W,*?E(11D`B/F#IMK]#_MK&Q<]*XL&/S/]<-6+-\O*C_"_A\7)=#]1O\_<
M(^(8T0/89C^*\M8QZX?U8B7^U)&1>Y,I$%1';07X3$!9W,NV=3#V%E8QN_G&
M+<S%NR9&345;(JKN4U0506#\WZIE1A8RS<`B(1Q+L[PIMG`1(@)1)$37=+0D
M")#$:=7M/)P/BW!FU?B7X^Q3(KDTVC\XR.<V<TI!8RH"SK'E;?UN;C85?,9:
MU)2E6FV%:C(V9.^-C.GL5'399LU]*S<-&#9`A%U16(E\\NX\[GIVWZ:$=_=\
MIK\]T#(8PF!=AO+`=6XPD"7D#*1<,']K"1MYPS7`LQ;:TF,V&TL.3%N1``\!
MFXLWY]QNMKG%4[99,\+1T+;$S,TYGIRL2S+$5UFW3JCVC'%E)8&4*C!O".`2
M16.HD:,G%#IJD3`!\G)ZL[=#U3B#O6+:C')O&WLB(QG&5ZT&NPO1VF6X$%@1
MYH!ZO3>#DRPLO9,DV!N#B1B1&7&-6\?:I(Y.EL!<;L76>B\?'!X2+OL#4;WD
M=A:\DNK#!?)V<.+BQ915B*U9G3PMBL[-FDYE)+P'1E3@B+<#=Y2&ZMVFQZB]
M6]VLYOJ$=2>/<G:M&-D0D9[O)9<Q$3"!)$8OY`[M5>QSKN'B6#CX`/YP!+S<
M,!J&)\QXZ_4H6Q-;F+1B;),`O?+'$7#D)?9S.D6VN,ZE7B2L`SC2Q..J5?6-
M@DG+`5K1'.'JD8@\-_LTYHY14[9(%CH][R<ZQA]YQLP8]N>!VW'CB3Z4>IMF
M3ONW+1B`?(0!*0I(=0`$L_J3`G'.,YC?NSZC$BK`@"1XDN2/%JZKG[A*A+R.
M#3OXST<VT8Y"QE)U5^B:13Q_EZ@L:[%U].R,DS3T5(.HETLP%HI)KI>")522
M!4[9N1)7G[?9&/#N)MW#.Q.=G(%P$#JXUZ4S/86C(`M(2$0?,"6W%QP7GN1L
MD@QG$2@0Q&V08!WUX:\&&@3S_3*F1D.4\2=V[DY)4]*O*BGJO*HH9R"<>"R3
ME8#*D\Z2ZIS=O<5,Q0#8I3%'?P_W2QXV?24^D(QCU[.FC>9F')O?[5S^G2/Z
MQ"C`PF>;EOHZ^DU<HBX5#K^,W4/N]O\`=U^6A\+A?5^"L\?[?X-'/)/>HP<I
MN.KSD;4JY6&UCCZ^C!R%V>O6\LTL3F.GT+7B>^8X1BWBM5L57FV39L]N*3TZ
MJ#HJ@%;"!2F,(`,+G@J"`FAL'"FQ6KBGC'!$C<J`\L>,;Y;;8TL<ACUL->9Q
MUV@\NU8L=!Q,"E6_33-2A<I`+66(W:'?OHXJZZ"(N#@2$-10'SOS"9FT?3!(
M]LM6?TW(D)3:A7I*)7:T2$KLQ6X"LJMZOQUB96[TMK5Y6/&-R-(36"G3GU*2
MC$5"SQCJ./(DX!\(/):W#WI^>1'"8<[YED[U*6JNMJE:XFBM9<[FO2;K*539
M4^&OT6^JF,+>VEFT=7J;DH+P)K`B=#R'%NL':N9PD=F8K,2PJF7H'TRGC==-
M3+^7HK-AE[(:\S$=;:,LX@I2UV?%67H_,;LD-*3TLQ!ID//&42W%JW5(HG$H
M139D0#G(FX)0*JF7)<Y6?I=/FEE<OKSE=AD2"?NL>N+`VLL+89)W>(JM7/`]
MKG:/<HYW-FA9FFE:X8581"3WYD*+:2(4R:((NO7F;2H5W!2<Y!<.WF9\C1MW
M:V"CQ<"I6\859P2;ICR9NE#:8HMMOM*D;B*7;RC.(KL)F".MX0=N;+-Q(ZAF
M@)[."G*DB:JS$J3F$:`AB/%N)L6,O0N&N-\=T7'Y5XF-)#QSX:I6HRONI!A$
MI"H2/0DUV2C@$0,82>40$QAW,-9M5"Q!3H..UF*C9+XU1$Y%UP`0[0`0#P);
M]>W^4;;XO8'3VP:(*U0@GZEJH03%3!NL543&#<"D5*!%3?:.QB%^'VB(ZFM%
M#0I.HMOV$;@9-)(P&)OOW'.4?YY3;VG-M[/8`=`UJH/,*@-KJEJ[=(BIW*FQ
MD3B55!$?:N*I04$NX;=J:8F^(?W!UU*DK(6!,5'0.B&$PF,0BJ9`#H7P#^!,
MNP;%!,X[!H]-%2-.2KT9%[2#NZ-OWJ!L(-@'H)""`CNML/4?XO[=/8FNNB\[
M\VU=]+Y%ECML-<EV@MQ<JKS.+K@X<U6X!,.32P3:2#MA+,FLJH<H)>G*9IX%
MU")&V22,J2`L506'!,K@*WXPR_;['7,=#E?)3S'+=21L]2FLU0Q2(J_+86Q2
M#5\[CH./E[$DW&\L4TE6;E=F4P^F;K@F9VB`\^"I<5.I6KE<N8EQ_=H*F6B:
MY>8MR+DB0D[-"8LB+S7FQGT8T,1)E%D+,/8R3C47KN552BD7)6LI,+%`B!G`
M^`A0977DR?.ZSM6PMB::S!F:KY0F*;&1[V9+9L[YI)6,E),HR%7>.ZRSJS$\
M:N[EDRPC]\UCT!>/G11540[R"1,MHH&-`F@A(]K8X6*E:=4.8<_`K'!Y"V:&
MO4?:(.6<,%U&C=LLYCJQ,1\R9Q*"=L<BP.&!7##9XJ5%FW65A*<:LZ9.,YF<
M,74E7\-M[?E*3O%LR6VQXPM,'>[*H]9WUK)!"*8P87F4IL1AEW;SSC!5`L46
M34E!>]R)NUR!6X2B$2UX)QY'D=A6`D+Z2SY7YJT]+%V1L<T')"F1K*6HTK'-
MDRHUAW.-:7DNP+1TJG3(6V,)"/,G(R21DP3F&PO'*0N`,6JUT#)WL[6"C065
M\<X,?XVRU6<K7*M6O(53K6),HRELEK!3*@9E$6E_.,"L+$C'5V"=3;8#N'C=
ML@HX=)-T5E5U_"`&JS$T?@N(@CUR9S-5<&_*>3C#)=AILIE5ICF]Y`+$OAH5
M5G8BI3=F?3JM.!DS@"/7;)NL+9^)/6R*9^TK[P'$"U%78/1::\\@<$TR]9A;
MV24Y5X9E,7W'#^-[Y%X[L2\G#TB;RZ]C([%S%Z\F68>(N4Y%2.(P<J&=('.]
M`B"B>RH:B@!:C*1$9/UJ`F:/$7V*SM,S6;;?+4G%%,Y&9->U*T2-NKM5L^39
MJN4B,C4%`6(>D0[ARHX>OP;JHQ(I`)5TS@K'4/AH%#6O9OP?F;'=YSW05.2\
MCA>"G,B%N]UJV1G;ZHXL'&KB2_M)BY5X6MR$]'1^.@A54W:!!=+E9K$!$JR3
MER*-7(`S"CKF;MS0XBXABG=?R9/99&Y9!H->R/`P[FP724O<?CV\GEE(#(M>
M@Z+C=2O-Z_9"MG!&RSP`;K'9G*BF4O<H:NJSZ,ND?\N.,L#AZIYW2SES2;X*
MNEBAL<8\R1`V!*P4:<O+IT\;_IV$<59M/3LE+R$HF]172*R64068+HHHD%`J
M.FY&<M1UT\7ROXLYD1>4#&9<@6C(<-`!=K&%$R%D"(R\RJU:,DI,9!DJG>*A
M6Y!]6)&0V1>OX^(=,DW*_;LD?PIG/PXJ,1KHHPT'G?PKR7)UJ+HF3.2LV]R#
M.0%;JZ`+7I>%GUIQTW3KCV%F%<.JUN/B928ERM@<E=($,W2227'Y:!C%;G58
MCDG(RQS\X-8MRC=Z-<\E9OQ1:\*J/\=WA_C6S6VSP4#=XY-HE,&MUTE*P2J,
M9N-;R@G>&6?ECDP*118A>](VFY`":A3DJ2K<]=FLE.F')R\XXJ=-7MDNKF?)
M"<=37\"TB`D4[_47M13FG=U(:+KSI^12+6,0Z+\#(HK)N4"E,5D@>#KSUD/J
M.\$;_?'T!2[=R.;6F0D*[%1U#HTAE,4D)*=?(5V`<QJ4WC)V]A&EQ>N_4LW3
MI=LBH+9TN!2JH%34CU3;(:LRFCB.ST.S4O)&9JK7LSY*Q[C%Q>Z=:7ECR&_A
MDH^P8KDWU4O#9E'-JG7I^9L%'E:D^0?"9-95%<AP<`JLD3L/59/\IU3(S'*3
MCGB/&V(LA3^4N<=5Q]F:`C9O$RE<E$)93*YKK7TK7"KXS@(E!>UWUVRK";5V
M+>)CU4V*"R9WB2:RBHFKA5B7%'"<;_M-<:)/C5D'D(QD;;D#%^.E7D%E7+S;
M,<^&7\7/7;HB9PR9C]Q$0%EI-JK,?)-2F8/X=-R"'@,9-9,YES*)_N\5H[Q+
MU;'SNK.;K"<N:>>^76O8RI!K%;55&EVOUX"2+"U*$20HCH5IZ79P*KAJJLBV
M7**ZZK4X/UCI:&FJL31EPF7.9W#/$]UBL39&N>7:C;\;R3&,R!;J%>Y^WMJY
M=9E!):)H&5[[$UPN,J%=$74@S1",4E(]TW]6FFH7M,.C\4`)TT*?&TY9QSA1
M.B/<XW+EE4H2\9#JV.H1MR-O;*BX^R+=[P+E:KTL\E#M)-,L^_4ETP1;$*P0
M1)&'.LX2].J8PGFH0_PL[)+GZ^8PQEF/$^+;Q4,T8NO65WLM4\2U>G964=1N
M8YZ&B@N$[&T]S+LI9E,6B`B2E(HD"S,X+"FF.Y2^0%'0:$ZKE#Y1POCF>OYL
MF+YKKXX.P\/(C*<#ES(<C`-*_B!](3S-:USKQO2&,U+1A;(R>LVY&:[@QQCE
M4VNS8RY#--49Z#BFOP_S@XC9<N3#'.*LF<NV^1[M*V6W,\35*7DX-U98&MH"
M\=QM*)?8BHR%F9QK-TX7$(T%Y([9/RJ&,@"(E.YHJ8D5++TZQ+0I@B]8L<G1
MLN6=H,JRDF-QS5DT6M[K+&.(W04;2=+8I-4!39OV2SHK947/J3.#'*H*2A"%
M:+#T;BI6D/ZO<C@W:H`CXEC?:/4$E3"`?!N/PC_%$?L]FCH$(;17J^5F@W)\
M2:HJJJFVZ&)V_DDWVWW`WQ?<(#J`.@8K*DW(Z534)VIB!RF=(@&Q2D#J=9/J
M(>(0`=P_BC]VBFB3E=F\ZYCD\B2QS"JD._:8HF$0VV`.TQ/XH^[1B*\"M,&'
M-*%DB-V9U$CBH1RJ4A#>PQ4T0$YB*`'X3]XA]P[;Z<64!<U6!`2JD]*OOL8=
MD%NW<S<QA_#]HH&'VE_BCU#W[B>+,$):H1(D,#LR0E$`1332(.VP"1,@$`P!
MU#M.("(#[]4:45CHAH7QIN5NOY:)BE^WO7$J90#_`((F'4J?:A2(2?%OU]N_
ML_\`#V:KGW*I8Y+VH-4=AW`@K&_REC#V]/\`U92ZG"FB@U)6)F@!W*(&W[0.
M!S[A_$3_`##_`/DEU7YH318E=U55%!WW4.8X[!_*$1_PZ.510)20@D8K>W=P
ML1(.@_A1#RJ?M^(2:FJA^)(_'^W^#5<\E?>CQ_M_@T<\D]ZJ5/XB^WVA[OOT
M<BK(O#7ZO,F5G9\+D.LY:`2`O(J+HIN"$\?J:6(*&6(=(/,F4YP*!5$Q,(]1
M$I1#7WO]EK?4MYY#$[[-#[)KY]ZOG*.18C'^2=?>/OT7G_CVUQE8O"5QL*Z\
M<]IN"7=RMTP1N9LK995W8(!KCR/`R"3"$=7<&DE%M6#X'1Y!*25!8B:;I$3K
M=][SAW,S!_IV*`87^Y"W:%"(1C&4KT@[R%L&-R4H[1`QH28D`>CQ*W=SL-CG
MFY9A[0&KJ]=5U_\`9G:0P7>L1/IR7K^3+S*QN4JUCJ"L355OCVSX\LII^*K0
M,(J;,W89.L,4XD!26676<%,+!L=PFL5RFAX$>[XL_4./WNQ;$^T8\)8\[LXD
M=:-Z.V5S<16U"0CH&;>69GV(&-F>/<#7[A$Q'<3M,26!K\1!)YBG%U,;`&1L
M1\AJFEB7.7KK'BZZWQO;H.N)6R8J3J_2L:J_4GZUD:LSED8J3)XRTLP];%MT
MU%B2:"1BB*8D4/U#U%VWO7IKN)[WV(=+N%BQLE/IQG&T)`",K$HQ(#P/EF?P
MD^(7M>V9%K(A\EGO*U*X"")$;CJ1)S4>SBF?Y/Y2;2U7K6$</6*RR5>1ILMA
M;$TD2YREXR'(6A\S3:/(E2P15B<UM*!A(4G?(.S*HHQ\(8I!`#%%,_MO2/:;
MF/EW/4'?+<!DB]')O"5L6[0@-)")B#U)2)VQ`.Z?UKQL[+C.<,;$<VH1V1<O
M*IT=_A#`>`\$WET:*5YWBJ[52S2=MK/&>NQ&/+!`%L;,7E7J]$K9H5YF2C0L
MC,1[^+AFCT7CN0;H*^-1RV076;F;**JI>PPKPR+.;VS.@+.5W:Y.[;N;"!*=
MZ>X8UR3$&9`C&)(H"0"X`/CW9DFW?MO+H1$9`2\P$6>41R=_?70IB\AK-8>Q
M9R3B7")5HR_PHC98MNH5L]QA.Q$>I3XVK.UVZ#:-J<:Y28*H-(QTJB+%Z@D/
M@;D*DIV3LD.KB]N%T-$XT@($Z7[9(G*0#O<(W@RF`1*)-27'K\H?F7""/B&F
MFW@![*.WAP3^X6=R:]0XF*1SKK_]$+A4I8CM2):`YC35;'@N$V8S!BO')S*+
MIBF+$#.E"]WE$?S#&]'Z@A9AG]X%[4^G"8MN+'JW/Y:#_M>7EP7G]O.['QR:
M$YPYZM'Z<E]8(?X1_OZ_*;NOJ*KHB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-
M$1HB-$1HB-$1HB-$1HB-$3<WW_V7Q;TN'_RQD_\`X%O^8!_[I%WZW?\`^0_[
M?_CGZ/78^P_Y3NG^3_\`;3_C_'_F<;_+?]1_]GK+I?JW_P!Q[#_[E_[T/\K_
M`(?^2S?\]_T?/_J?EDXVNN+NB^;_`.IND4W+O(YF"3MU.&X3Q2:1#I,5(INU
M4S+&E3*X5%XSEFXKN=Q4*W-N9(IC%`YR@DI^B_VUG*'H_&E<VC&'?JZ[G^6E
MH&(/OX\M1T3U"'S[FO\`EA]DOX*$E0APMLU*0%7:QS>^8C!!K0XN5C7@.W$Y
M,/X>DW.YDM<"TDG+.?E)&;AUD4U$6S>*3!JHW\)D'BI^X=POSPHPR<S=/M6<
M/S9`AA&`-RW:V2,7C$1N`ER9^;=N>(77K$3<D;5HM<AIK5Z$N/%J<M&5*=-L
M)VN1.-+,:+@,F4V=7K=5=VM5Q"(2K-VB_?O*LZ=2[%FA!7&$M*,@=JE)),G#
M])Z9`RAG21DU.?-LSLY4NYXO4N=HR8B<^DTI1D&`N,"2;<H&`)@9"&W<`(EQ
M(Q$K0LRVQR8$B.YZQX!^!%6'C[E(ZRVC%<AC1/#^8<*,\V9(=@YD,95)LY54
ME*/&$0!.8L5GFJL)+S5',_,+LUV<01V)'#(".%BI)@`K=/Q,+NUCNI[QV+-E
M@=K$FOW94C=D7VQMQF]NYMB")3VAI.`YT]IUK-O$%K-M=6Z6Z8!<Q?4R,6DQ
M.@=FJ4W.*3\2,6VIO>;+Q&N#:OLXR(8M+G.S%UR)(4VU*1CES#SD;!WIHG47
M%:=D(W4BFKANH[:I@EL8PE4)KV_>(>M>YX1P,;O5F5^4I2E:MQM63<AN:4-U
MKS[Q42((!KX+BQ,G!L2,LC&VVX_BW&1$C^)B&(-*%V"W.0'D8%L3O^77U74K
M3V:.Y5"'GF-A=7]8$GTPL[QR$9Y%YF,LS%L79^0C1HP1>!Z@Z)BF3UQ=LMW8
MX/\`3NRPO1S1%O-`P%G2)%[=\)B22QW&1'E!U7C96XWS?RI#I._EDYEQ\C?A
M/U!,Q#L+#D9I=\HWQM&1>/U)\]W:/U(V9F6\7=L?IP\9&EJ#3Y(>#D%XI.1C
MXL[E5R)'CHB"3XZJ3)5`WN,K(QNUW<;M/;R;O<A#I$"48[K=TDRWG=NB"1*8
MB(^4.8`&0*X;,;U^)R+I,;/Q5<N1P'L##7VJ3OTZWJLSRRI%L1C6L8SLV+[J
M>2!$&Y6@6B,3C(RP2C!N$@OZ"/L4L@L\*R3\YV;AVJAWHMVQ"*]>_<>/0])7
ML*4S.Y9RK3.7.R6XPB2PW&$2([BVX`$N9%O:=AVGNL+@`&Z$_L`!(Y.?JX+Z
M/52AWG-M\7D/U_:8V^OS/$EVX+Z:5CUR*(T1*V6PJ&0_BN$SI;>[O$`,D/\`
M[](&LRY\4*3F#;;IL/O#4B27=$J'\UJF80#=`XI&^WL4$RB8C]@`;N`-21;3
M5.*3IG%)8B@!N)#@8`]NX`/4/V"'0=;X)X+,[(":IR@("41`Y!#V"10.\@A]
MVPZQ%]QY)P56X`HBX1'J(@59,/:(G2W[B@`==S)F$>G7X=61(-$\5EZ-2BD7
M8%S!V*'`=_`F/0R11#V*&#\0[[@'3[=9)YZE-?8JJI&<G15*'59+94QA'L34
M0`I%3G$/PE[``W[^FJ#2FBG@KTU$^_TQ!V04*=(QC>U510-B+'#W=JH!VA_%
M#[]]3=55N*3IMR%`5%RB5),XD$H#L950O_%$'KL`?QA]P??MIN.O!%D7,*Z*
M:P@`&2,9`2D#8`3'XT0``'V``&`/V:/Q&J`5994!(Q43,;?SF$/(`#_S=(WM
M^X5CD-_P0'[=#(M7537V)-Z<XKF2^$!3,;N.8?@(F0>JIAZ!V[=0]X^[1Y#V
M*KR]R%CQ1W<+BH&"N0\DP7MUK?C.1.4U$HQ\JO).I1!XP8(5=Y*-8J6E$>Q%
M%([A)HW]250WIG*GK)JM#Q9-3B/@QB7C[_:'?<>\2+FO<^24ZJK?WK3(L$XR
M/$N#3UBE75C;1K?&5<KU*CW;N2%OXR>-DJP:,TP2***>ZJID3QT6MN'"'$&7
M\QXTRQ8^.?,1')=`<,HC%=\MV38&'CJ$C".)I$7+N332L,S"Q$Z9^*SI4[=Z
MH5)-$R!4@2V"53<P8,R>#EQQAQ_G?&2.%<I<0W]\ITX\B9Z6E<6Y3*:9?R56
MEX]TC$SLXYIS-ZT"U^H.DZ!-$`=HN#E%9$AE%$J792)+N]5Q6(^.D31JS5\=
M4[CUGFMUVNU]G`1,3.939&C$HFJ,Y9"%=.9$V.'30SN5116='.@*+EX[4['X
M&5<`FI:H2_UKY_5YZ+H'&B&R'A^R->07!EA>ZM78/A5F`:O7^15:D7N9$Y(V
M-J==:E/0URE,\8XOCL?D;*WTV7=KR21$U71C$*]'#GW+EU+'XOI]B]!8::P_
MC^Y_65O_`"-Q+;KYAU:Y\<:!8\$YUR<[EKMD&RY"XHXOAJ[CN)I3&)MHV[+.
M1)>90BH(4'Y%BGE/&!4DT?*GL'FL5(B(FJ9C@-BJ\88RU<,%<P\)YZ<<P<DT
MBH6G'5G-F4K^1M'$.IL&T+`XPI\^K4B24[9^,DC+J,KFDQ,62FIZ1:V3QJF.
M1TR@9BZI((<-M3LYWQ%GZ5^H)B=G@*.?8UOKG@=EIP]:Y1J$9GV>D:TCG;#<
M$H>L51R?%S.O/8XTLW.E*'47%3TYO.!A[U1FI4!&TOS4)\C8PRGC6,^IDEF:
M7S%D.>Q3F'Z95RR1?X>*8XFJU3HM+M5'OMDN%]HE>N-Q*1A4J?'/31,RS<.D
MT6S8SL6[?L[=%006;BZ]4.5S_'&0.1WTR\>XZCZMF&VAE?,&4)AYAK/;'*F3
M)C%T5QIR76WV0[19HBMM#15:^?W&'1^:*$7"064(V127,H)=4`.LQT).C+PX
MCZ58N+_`#(/*6%Q9F1;C[G_#O*K'_)N/CK`63K<#E%_=LEU+$W)F.00BYR*B
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MI.SJ^FU:O752FWRZ/5<G],I#DFQX_<4[E(<K^+%BQ5`8AQ49+CC;X"O1E[M%
M+=PZ)6^-:W+M<O\`S!>Y'34,BD[7BC*MWBR0^D5[$&R=&B29R*IY^+>7L&XJ
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M2%RID6(+6LY9LA)ZKVW+$MD^HNYQU(NVJA`\#8KI!%4#D\H)[*/:J3%ZZL%V
M7`>-@Z/G7@M9LU(9%J4!?_I5<<:YQ:L6<,UMJ?B^R7%H=A=N1.-Z):QC9V,;
M)W.GS-452K8$:O)&&CGA1$P--BE)%P6YU7$_4"@V69LF?4WLG'/#PS=-QQP&
MI]#S[9,!V_\`6N.[%GN"O;S)L,^FIV&@ACKM;<;823<-9B.%(\HS1<LDE``B
M).P:E6.@?FI)YHM.),LW;Z<D/A]FZR)+7_FEA3*U0KRF<("ZQ-PH5:I5RN&3
M+`E%P-9)(LZC#PC@O8Y7[HI@<C=%N@@=0I=76B@T+\E$O)DHTIV/>7N0..>1
MCU_`*>1<\V?E9]/3E<M5X*KL+6TLTLKES$"EO@[Y4,MUIOEN9.Z?0D3,5>QB
M[9R#4S0RK59-`L<LM#@^O-/CE"C7CFE?IBE4'AYE?-F+<%\)SUN?QUD_D;5J
MYD+"7(;F+BFK2]0CSKWN',"UYP1A>O).D(QB59Q&O+$FZ$P*K@W!JLAHZEB_
MV!1S2IA^;Q>`F.<L43-%<SQ4HKFQB[),I#Y"3F;E0>9_&V$QQ$/[[2S-XA?Y
M),57($8C8TTW'K6IF4@!5E$FZYEE[JK\+LS4^I,UFNYW:VUGZGM*S!A.X1_(
M;%'TLZGC/D8@$NX19UJ]UC+N29ICFNF(OJW&M&N*LQ4J9:V-HT*=11HU<'8`
MJ"C<$V\)*T.#:.O2SEG:<8YGKO###6()3-\OR3G>3O$N<P)#/.0U,NSS'\/C
MZ>8.,MVYG&U&S6RPT"OU_#<1-%E99PU*1)%X@"IS>?TRAUB+AR?A8KV\7J98
MS)./6A.-[B";M;7"3Y+SC;(JKZ#CA2=NF:S"U$6KL<J]:-VB@.U6ATBIJ$\1
MBK%,/;JO18UXJ91V_88H$V4*MU1.&^RFX@78P;CVJ%'H8OM#5)E[D?BES@$7
M*GIQ$`.@4J+=0=]E13*!?$H(^SO.`B41]X[#H_UK(<!UA;]S8'"P!V*IE\!.
MX.I5E##W;@/M[4RC_#HY:JNJQG234*=PB0"[;>=,!'9,P_QR?^A,(]/;VCT^
MS3=)J&B>U9SJ>("-#AWH$3*"R8"(;J'W4.<!V^%5,3;`/NVV]FAE7Q0<^*$4
M/"L"^X'22(9PFJ&X`?M^%(!`1Z'!80`0]PA]FJ9<]$*PE,"Y016'<X"/A6,.
MW8)A[C)G'KNFH<=_\41^S?4$N2,JJIBB@1$Q1(=0YE5"CN!@*3=-,#!]@F[A
M^S0RD`G%)4DO*L1(.G>H4G[`$=A'_@AUUMZ(LCHX**J'`-BB;M)]Q"AVD_\`
M)*&LQ));@BO;[$1<+#[3%!L3]JW500'[DR;?\+5DZ<4E-^(?W:HJ$*5N0["(
M(A_Q2?<<-NH*+#WF#V=1*&P;ZR#4!/%(M<B(T15#VA^W4.B#5>(_U5"$')>"
MW[Z)4G:]`5C)4_8(HKH&(R3.'-2GAX9.0(Z36CRRB0&2<*>,!3:JJJI+I+)%
M*I]O_:.4ODNX6[<^GD7+EB$),^V4NH!)B&)'X1H9,""#3HOJN,#D6IS#[8R+
M.SUC3_8O-)S%V*0QVEENDK,7RLLZB;EE69CJW,0$BRGL>.H-A&F>Q#"%D:VX
MK%=>2S!P)%'!VJ;<[9XL`.6:SA3Z5:R<7'[Q+L?<1*$80E;QP9QF#&\"9'<9
M"0G("0--S[H@[9"(ZY<,]G7A\)+G_=((Y!F>IJS,X3KU^587RP-KE0VD.2?%
MG$2-XH@2Z3"T,K"[17;R!V0RB[;UU/>6%FJX0E4'2S=D1V4CD$#%$!]=G6)8
M.*>V]TW]!Y1M7!$&W*V&82$=+@B0##:"2/*X6X>:YU,5C<(!():IUKR\>#U7
M59BF>,V7IZ#F%^-4IE2WUQXTB,JY?QK/V*H.KE;S"\:D9T*>Q\Q0AYI)9^DD
M9I-230[EZS*D8`*'D4'U_8\7U5V;'G8AW2.#AW@38Q[T87#;MACNNPNO*%-;
M<9-$N.`"\[)R,,[92LF=P4N3B2`3RCM#'P)#D>];#$MCP90J9*T+'F`&>(LR
M7!L9U$3TK)2*J&4:"=<3/JY'7#(I#6"+L3]DYCS,63)1HVEEP`A>Q8HI*<'>
ML3U!W++CW#NO<#G]FM%I1A$?D71I.5NR1&4'$MTCN,!4T+K6/E8IL2MV+/2S
MC%Q*1<&/(&50?`>]DSMGL\7C!A:V[Q:$D,IS3!M$13)B[1<NJG"6@KXDU)VI
M4B;AA'S3FK(.6<?%.5'+KN>'<K(D33W4['BXEWNMZR("8[-:ENE*083E;`,1
M;XF(FQE..T#;M!?3U0,+1E<-;YBP`.@.NYJ.U&][+EIJ#=XPK=3L>2XF/5N$
M@UCL?O*NZB9I.>L6-XZ.KMC".EYZS,H!>MOXU_:(,K10ISNV*J;9JH4J#9XW
M'ELY']6S;V)V>384#*^+@E$1A>)E!XP@9B8D(7'!:,ANEJ8%64)8UL&]M,I>
M7;5VXGP+-XT\$[V+8WY3!<5(B;]41Q#_`%+(QG'OVC>*/ZE=&L45NP<2AUW)
M7,?ZM$IP7,FFF"BXB1)$$?&H?U7<[_6O]XO62&EZ9J"33\R;@,*UT!X&I>B\
M[!#6+`A0#.`IQI%?66'^$?[^ORJOIJKHB-$1HB-$1HB-$1HB-$1HB-$1HB-$
M1HB-$1HB-$1HB-$1HB-$1HB-$3<WW_V7Q;_\%_\`\L9/_P"!;_F'_P`!%W_^
M#?\`^1#[?_CEZ/78^P_Y3NG^3_\`;3_C_'_F<;_+?]1_]GK+I?JW_P!Q[#_[
ME_[T/\K_`(?^2S?\]_T?/_J?EDXVNN+NB^=7ZE(2/_:WR(`QS<T4;A?'@20%
MI$B]!_\`VN1J9TVTH<Z4JV*BW7`0;;B@NJ<HB&X=?T/^VI@/2F,Q)N_US1RS
M?+RJ1\)]NH9=$]0C_P!1G+A\J!_\?)>>-<95NT5L*G.RS2"FDW23NN6Y\H9^
MR10DSQ\?,0-G=H-)5Z6#5:`99)5!DY49O2;`7PG.)?H>;<R<'+.?CQE<QS$"
MY:#59S&<`2!O<L1N`E#B[+K-II0Z,R(3>DF+>(+58M]?@MY97=;NS8Y;XK?G
M>6Z^V@J]98^N0<;+1^2(T8WY-+RZUM@0)V-8^P,G2JCN3*Z\Q)`%2N$R^(YO
M#P89O;S*?;OEQV.]*5V!G(B5@ONVBW/4RBP:!#&+,:A>3>G9OP!NF7S-M@U&
MDU/B#'ZQ6E:)#!S=PJ,<]KC::QC1H3UJXOH/&-`BKV_>RQA3CTYF?O$XVC'-
MR3<DKL*^574D'Z[H/4F*@W6,F!.6[BX&=+YF=K*R;[?%D796H[==L+421`C?
M.(&V('EJ0L&_L&P;1`:M$%M-2=='XA=(WRMEE9TE(.;C%0-@9MT6\2DZJ%7O
ML'(IQKCYB\E)^1.YEWC5K;9"-1)\N;-7+)NDJ\.DS(W,W0#Q!V#M%J)MPL3N
MV"7D1=G:F'I&,-`3`$^8D$D0>3N5F&;>N2ZAD`U/A<>]QQ]C>#47#15?II7K
M:<R&5C78,RBSB5L.$*^]DJY,0E90DY%5.R4=LWA(VBREWG3J*)IBFQ;.TS>9
M9N99,6YO/N9G<HVI6>T[[M]@!#,D(RA*9$08W:]6-J(8UD02PDQ="+4YB5^E
MH5W0&NOX2S/2M!Q9=HLXC9MQ#7R[.$25"N1+*O4;&3Q.-"5=_I1&)BU"S<=7
MH]E$05.DK"RDG#PZ#E-R].Z5*FDJ)U')?6PC>LVI]JP0/ZC=N&=_(`(`,S(G
M:9&4I7-AB`6VQ`C4'RJSNQN3%V[\$0T8$U8"F@`8G7B3]:D7].==1YS`:O'J
M[EXJZI%W>N5$WK8Z9E'1HA5,@M2^`&Z:!C"84"!XDQ6+V@&P:]/^Y0C#T<;=
MH`1CD6@.9`W>\OS*\_TV7[I$SJ3"7\>"^CM4H]YP#K^8;_SAU^9(ZN=%]06+
MM-]G]T-<CA$=IOL_NAHX17%`Q3%,'02B!@'[!#J`]!^W69&E$2EX0!4!4@?`
MN7S%]G03B/>7_@J`(:1HBJT+W"=`?^/()`Z]`5`0.D/[1,4`_?J$DFFB>*2=
MIM^H;#OU#V;>X>@ZT2&1*U2^1LD</Q(CX#^X13V$R)A^W;<Q=_N#4CXIQ61#
M=F!%C!NJ;JF3?\"?L,L)?Y1R]"![??\`9J'GQ3[EA7;F*X,1,!/W*`*?7J8J
M@@9/V]>I1ZCK7@H]$L'86ZK-(1,8NS@YP-\*AR!^<F4/:*92;;#[Q*(ZR*41
M^/!(D$!.8QC")$4]C**;=2AO\(%Z]3G'H`?OT-652I\<5CIKA_-JD^`OM!,Q
M!V6(([!N83B!A'W[ZR11`KF)3(@('$H*.2@"!#@!@`Y1$R2YP$.@=X;%#[]]
M:.H4/@D12*JJ=H`8RIC#N`CN/</XA,/W>\?=K#%:HE[DVR*/B.`D$02<*@'5
M1=`"@3?V@*12#\/V[".M'10+RWLF.H)2_P!XE[-B@]7@Y"WSBM@O-QSRQK5)
M%-*8G4X2=?.%8J73B4%RK"X!%),BK=PJF@IYSK"8(=%IZ(G:BRG'B]J'C/.Q
M\2\]+3JU=<(YQK-.H[V,65>,6]E83(G@"G1E".TVJ#X155>`Y42*B!^JX4*K
M^*<''F/XR01?V%KBV)3*4QZ](53/O(1:]D:RL>PB7#IU'Q3*.OU?CWZ(%%!5
MP9=!Z587A3I%2.!C%EZIF'E&:VIR_G5N*CQJPL:J:TDRIN>()E"-4T&ORJ07
M@8J',FU,!6Q`(=-FH@99R^(<!37:]R`:*O75=76Z"G$T^<O+/`=6M1WB#>(=
M0]BS+$3<LPA7:+0A;/$OW581K4#'LV'8W;22STADRI`8"B43&4U1O%#[4R7_
M`&/>-[#+!LB)<"Y.%R[#R"$<;**>3,6QM[93JB\0J-V=6*-52NK9R]8+B4DA
MW$=K1B2A$T2$.!395$BVM$_61\-8Y;5F&AC\7^/64Y&<F&CI[=*_D.N2F5$[
MC18Q)I%W5]>;/2H.R2=XC&\$#4)9)PO)MFS4R(]I"@70K(/B4U2V&*A)S==D
M9_C1\OLL)Z\\1/V7.]>?#6:Y)FC49B?2E'$9*.ZXSE>\[>061237]`B816,4
M@H@X>*M>=%WDECVE3-HCWD%QBB;S8L=UU.L0E^P!F2EA:I2+EWL,^47DK"+2
MO6IVR;S#0'BZRQD$$G[=$WB5./<@X>*/XT2F@XQQ+'W2UOU,6U*K6E9)C7KU
M%\@.2,'8&^4U&*,K`1)[7"1K:[%NBM=CU3IH%FDTC-43-2MR``'*4X!1Z?W)
MI)_!F%\<VV=G:?P;PSA>4EC)0;]SB/(F*\.0=R9P<PLNVG@0B(.NDFTQ%[ZL
MHK-RK&20*@JGLZ(5:CFJ#S)704/&.*H&D6&0B<"8DD:95H]:`:XROF8:A8ZW
M,15A5>B:*+45H*1K;@5U)!P[60DWI>]TZ5'O74+WETX90N_BFKL?$#BOD\K&
MR6WZ?+3(ZM>8)5\DV3(^#[9$H$7A)!2/K5?DE1.F6)J:?<C'LTP:HL5CE,FD
M;8QPE%7(XJ5<WB"GT+&$5#?]G/!-_KD&[;'B6LGD>(EK91VBIG(Q\Q$3MNIT
M0TKOZ'.]!"/49/4E(E59,&A]@WUIPHY)3"/<(562?UV0G>*[[YS6G#E"BSLI
MFRN3+^,>V6!DX*>3@G[Y@[4C9&4B`"/%(I#FDD3*$#M3,'?'`5KS66P<)N-D
M`I6J\7Z<^!+.RAT5KY"6K%)L3MK?-2K11PH>(;6:9HU3EK`C!G6;^8K4Y$F2
M!2JF6Z$(L\J/(\5K*?P[XC9#RHK?PXB8E>94C)MQ?Y*^Y=ROBR_N[3*"^8O5
ME)J2K\->IV<?$-MWB^2(EZ4C@IEN[M[H&XLCR9GHG@RS6FZDHX6D^,E/9-JX
M9[&LK!0\VUZA5>SIR;9FZ[5WSAA!"JMZM$&B1G:"2[55454AW0.=.N%`N8QE
MCW%K2V35QC\28YCYQFR3DEDKAGRJN'EX69K+G:P:C5C!S;V:(:1<&*U:NG!(
M]%($P1!!)QZ?63X*DEET+C$U7@E%(U;A_?:&E=9A_9YRJT7-='Q]2[`I*S8K
MS<.VJC*6KJ,TU>_-E)&89@V,!BJK>H65$WYF0LOXI<ZQ#B*HXPBJ5/<6\!90
MH`F@6[/%F9<DT;(3W%C!"KG1@(1:M9#KBU4KT;$,8XB2<?%/%2%4$XM0.4V^
MJ/8CGFF<H&)L55N(2JU`XRU^CUZM.D92*B:3R%I$74ZTFY7*HL\4;UE((N&0
M933M)JF5=$R+HQ16[C$*@4P/[UHECJNWA>*V&<..;?'TS@MC51:PNF+QYEK"
M\_C2!O\`9[2LZ9//TE%7J1JE#F':DE(,15>LTC)&*X!58`,82`2!0DFKKA#\
M5.(.3LDJY!N''7$T1DJLOX5Q&9&S!R`QW+V)L,#ZB(@(RE6N"C[I8&I*VC'(
MKMTG`(`W("'C-N3Q@5<@:T3PWFK1LPYF5*UP]QLFFG:WL]^LL,Y.I%7:7>8:
M1J,`:;D[#$0\>O8`59M")KIRB`K`1DFW4(/9X]:#`*`\RN3@N/.,#NI>TU_C
MS4(.Q+R5@LD<C)9CB4++D>UMH[].2JD*FPJ\[(2EL5KE?192@@]364:$3%PJ
MJ<Y3)J/31'YE;B\X(H]Q4NUEOW`ZRP2EKQVRJ^1I.OW[&M4K*]%2<+J.ZW(J
MF5C4Y"O(-!\\HVD!59MNY8Q=P`5%!J4<B@*NQEQ!PEQM:S=[PIPQX\-)>V-(
M)%[3XVSU4MP;Q\C)>N28$(XH+&$:/V'S7M=I(R9VRA4@*F=4A"&'5`*,Z.3J
M2NJH].9/LMU^Q-^/#BIBC>H]X\E(#,$;+5JNSP/4E)$H5",`XP[>/9(HN19`
M``4[A-J8J8D.8D'BIPU7IHP-XP4.J'Y*8E/OMW"1<WPHG3#W'#J(_:4-M4UK
MP6?O2-9!1)02F^(!V$JA1W*H4>H'*8?:!@Z_<.JX95;%P0RJ2:`CNZ3*"J@=
M.Y;N(`[";;<RR:12_P"5N/O#60H/L21B4Q%_)T[$2F54W'X3$)_Q8@'X@5,(
M%_?JDNAT5'*0G$72>YDE3")M^IDUC?$=,X[^SWE'^,'[!U00`K]Z4IB"38$5
M0'M=&$^X#_-)IB)4U"E]X"<!$?M*&L<&4XI/Z=0%@1';N$Q0`0'<!*8-P4*/
M3<G;UW^S6=M57"4*B#LQBD`OD2*!4!W`!713+L!#>_R@`;E^W?;W!K1#H*+`
MD`IIK+[=0***?_K%0V,(?>1+?^$-2(8IK1)"E$!]GNUJ50P1*7(&(1!#WD**
MJG4.BBW:;M$/M3(`!JQ8!$-D_(H0#?@+\:@^W9-,HG-T]_=MM^T=9.KG1."Q
M+&%0YSC[3F$WW!N.^P?8`!TT#[G.B<%A[3?9_=#7(X1':;[/[H:.$50*.X;A
M_>U":4U1>'/U:1!2Z8.12[6JH0]](=TA)"Q74%1>CB07(@('(D0I!2(9,!$Y
ME^T1V*&ONO[.?Y;N(U#V=0_"?^WW+HGJ^MRS1R!+[P5`6-?M6TK#Y3J$DTB;
M'5TRO\@TTQ630]OBXP8I&RKUDKB/DXV06LD`1^$O'.CHI**.UC((N$E#(I]^
MR+/Y%WL_<(2NX5TM9NU/3G+<8"3$3&V9&R8>@`)!#GKL+@CMOVW%P:Q_FIYB
MS$&FH(]CKB9J!H<N#:9I42]MI_EK:5?5W*$:6IXYK$[%?,*[<:T\6CE?T]<Y
M"7005<MHMJ9%N_,79=`2)E55\ZSD=TLP^7[K,6H[S$2QSU+UR,FE;GYANM@:
M&9<QU$GHN+IV)7(SL`RB',HS`B`?8"`:LV@\%UK7).3(I*-7;7"KSTC#-T&\
M77JUCV%H-,>P3=DE`FA6,^B6FSD*H\8PK)V!FK2-6<$.\3*L94R2AO%GV3M>
M5OMSL7;=NZ7,YWIW;HF^X2E%Y1(<RC64@/*69PN265>MR)<$?RB(`;P:O)(Y
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M4+%/-'8NF-?2<>BF["FWGCM61W=FE[&[<EDG:9'"*2!`*W<K"=10.3&D<Z_"
M6/;E8[/8_P`.VVTSVN(R,0_DC'X(D@DN9`4"XKH,8G>=U\U)U`Y@'B?YOL3U
M8<3D%*;Q!49QGS0B?U$8L'*C]A'2YFD>%4H+A=XQ>*"(PSTOB%0RR8%542Z=
M1#<?4=\-N6=WHSEM_P#UPL`6<]2="!J.#'C5>RPCMQ\<?]=%OJBOJ^#_``C_
M`'QU^55]05=$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB
M-$1HB;F^&`LMBX!/<"]^1DR@%6#=@<?T3=C=EWZAM3]B[F_^.0,]=C[""<3N
ME,,MVX_X_P`8_4XW^6_ZC_[/672_5L@.X]A!/<@_>@/TO^&?T6;3._Z/B?\`
MJ1C)QM=<7=%\Y/U*6S$W,>_O"G<$E6G"V'6`GR](R(-T<Q,%49%O*F?)/$GK
M1P78$&Z(^0NXF4*8"AK]%?MN;A]&XUMH]*7?=7.OR\G#,S-Q)]RZ'ZB89]S_
M`/IP?JD%!BJR33Y5)9!NDO974<:;(R0B(.9DG,];)]R5F[G"IR"C9^:-*QA5
M57+V0<-U$FJ9BH)]RIR[=YSK,NJ.T]NMVXWS!S.41LMPTC0$/N/EA$%R:F@7
M6K0!'5N2\G#A*4N0-135R*Z)=9E6[ZNLYS(.1'$-*9!<5VR5G'LQ59"P4AE7
MVL2QF'3FP3-F2:%=NHUF=E&,G3%5V5%&-/YWS<R:@J>-@B5O)G8[9B"Y9QA*
MW<O1N`7#,R(&R,"=2)2E&1!>0:,G7D3@=G4OS,;LRXA4<*DR/@P#`^U<\:*F
M'#,'3G$V1JM#2Z+IRSDJFS1RK0Y"$5:OGR3"#L:",0G)@\KKR-*+GU4BB=26
M(HJFDD58`\NWE6(W.G;S<6_D#6-W\B[$@@$S@7VM+=1HEHT<LN.=AVF83A:/
M$`RB>-"-?IH%<E"VXRJBDQ0+\_L#QK#)1D%3:I)SRDZPEG*R4$S<RTB\,>'F
MH^:D&Z3MNHV=*(&?$[D`70<(AN6;@$;L;(QXXX,MURY<C$0E$>9@!YHD.Q!#
ML:L05@6)FX($3W$THY;P;[E?$-H5G8XEK<U)#!3UPH\B$'I"1]PRV#*^1;P]
M/FY^/70AWM#2;NR*(NFR2#%9^*1G"95!*1J?AOSR+N'<GV^,.Y60!(@[K6.]
ML_F1@:BZ30@O(1?:2-5S=$"8A=G*U$G74CDX&@YZ>Q=J0SV0EH[%MDE9QI=&
M+-FO4;BDK9HZORQ+*6)M==KDG#3$7#.JG(+*W$2-WK@K5,IC>-9)0@E7+X,2
M+&//N^'"V>WSD1=L^24X;'A.491D8R'D!E$/*C@\%F[",[O3N2(O`>656D&<
M>/&G!/Y].246?<L(!@[=`<(*D9"0CVC]5ZNBR<N%(D\R#-LX4*2+=O#K%461
M(`]A@/\`8.WI?W+LV8>DYWK40#<R+1)%)$5VN?Q#Q7L/3QE_5X0D7(MRU]G#
MDOHX4_G%/\L__G#K\SC1?4%9JJ(T1&B)63\UL<GM.ANJ0/>*9A`%0#[0+T-M
M]FXZ>U.*2@/:("'M`0$!^P0$!W#^#41*')>XQ7!?PN`[Q`/854H]JI?WF#</
MN$-4H.2S,BE^,RH@")P!'X@Z'5,("F`?:!!`!,/N#I[]%"DJPG%4_D#90#"!
M]_<("(;;>P`*`;``>X-1U1HM@83$:[]/4)I@F?8/S$FR@CV[_8<3CL(^T"F#
M[=6GO4XI"W!3S)BF`=P&WZ_@[0ZG[Q'H!.S??[M%2LSP0()44M@;[`L3;_C!
M.&XJ&$=A$2_A`!_"`:*#[5F:$`Z)P5)WD*85$2B/:*JQ"")T2^\2F(&YOLV#
M[=$.J0'4,H?R"/Q[@8#![A`=R]H;]`+L``'V!HJE[K=(OD`O:J[`?,(=/&/P
M^5$NVP@8PCN;[AVT*@5C(HK"H@(_`<I3B(;;IJ)F_+,7?8.Y3<2`'O$0U$*^
M>KZA'&=7-')3`\!C;%?$KDK9J$GR/S'.\1LJ99?UHV3ZW8'U*JSR_2<PHUF'
ML'>,8S**+&.!>.DX1DXGW)3$;'$'1(:KDB6C4GVKSUR=7\8U#%&=\=PO#"U\
M/LE4/G'P`ME]Q!=>25:R%@_%SO*^=,,S,#(XC@Z<*%<'%V3&<"^>2+5BD?Y5
M*>K<&:M0$0U%H.[NX8I;]3U1CB/EM=&6'R4.GXZRQ0L56OZAEEP(Z%Y#<?Z-
M.9"BL=U[DC&.&;V`/C[+E_J"S^KRH)(2'EKR9+0LU*:)]0J2%8N?<O6VIX2Q
M]3,='J-1P-AC%5)JV-)KY#%JYZ":I,6>-J2J+-&.;0EDE5K`BX:L$F_K0;(F
M?%.Z\I"$#N<4++GB2O"R;B.3KCZ'<++/N"N'6V*I+A9BEH;D)6N83Q.Q?V>P
M;"E-8JROL%(8Y;QIINPD8HGD(0)10BCDG:LL!FY0"<%NG4UXZ,O8#A?`,87F
M;]45LSQ;AV%EF]OXJ2+/'&8,AM+I)INC<?!(@:LV)8DU'HM;!(-%D0,/B!FL
MAZ90H`U`I;Q6)?"->*\2)#"\UR$A^/%<K]:@,676V_5$^J59\?9!J&2:TY0J
M^2J8US;;Z4NA7WECCZW^C("W0#5H]9@H@VE8=J)2*&.^`!BY'8GDP3G9+RJG
MFIURGDE,04"'S!6?I%<U<4<GL6CD%6?E\09>QME1G^H9MA*V)WY9-.;672L$
M$X8K.@EJU)HG`RBJBJ8%`&;DZ?OD9Q'PAQ_X-8<Y)8GX45[CIFN-D^&$?1<W
M4G+4+59ZU2UPO^(:3,UB8@*LLT=R\-FNI6R32DV)SKJ]JYW2@D5;E.!02)DS
MN*K@;\C6ZC)_5(O5K^E1Q.YJXMI',>_6&XY8<Y/Q[7,BU"%CL,81>V.+C8)S
M1YS,,Y0:Y"F>S"KB%4=N70*R*Q&IET#>4>:?RU(+)KF'&*28V#Z5.+WW''C9
MS2DU.-O*V22_7W(.(B\*7&F/U,13F/K7%Y`E6F0Y"/2QA3[4SCH9!:'(^>,N
MQ4YSN"JBF5?6I%5)_EOQL:2''7',=>OII<8./L5;?J`\)\?+U/C7FFFV+&N1
MJ_)Y:K,(]6M)*Y3:6P6>V:.EEXDSYU'*/VC=4@G)VF.8*I$L:$Z%2`FN/&)>
M)W-_@P;C_P`;<-<79W-]]S/B?,N')2_1]AI.3L4UOC]+7]OD&YU"&(O6XMSC
M&Z042E&3)FB4KZ^8.W%4[9^8NFBCF42[EDS_`-3^?I-DN^`^/%_XQ1<E7,UY
M%<95Y!5[`\K9\L2,KQ[P.+-L^:,\>XL2ECQ$;>[M*PK0[U5HQ()$'0*#NH)T
M15AS"B%)1L?RR^GQQ?Q%9(MQ`9=I7U!<'<0L@2<[99ZE\A_U%2(>XIXYR-^D
M[D[3)0Y::J/Z9F2F>J))BJ19J;=N0_DBK[9.-&=.F-MG;-R2P5@G,O'E&)Y,
M\8\!\[Z!R/@HO-!:_#7J7/A[$URKG("A)R;IO^E*-E"&0"50=HJ%:K*JN8H3
M[1JB29.#C0LK['QHP!3OH2XFY"5C`_%2JYEHW$'%>7(#/&/@A*+R.K&3(FI0
M\U7K1-V!HQBY:UREGMQVT1+1"CMS\T^:&;F26*8"@X*.>HU6=>K\G@*@96K4
M+#9=X@89LC&2;U.8DJ_;<WP=KK)WR3-G./4Y2+F;4JV`8N:0!-$IVJP+((J.
M#'1$4T-51ZZKS(X[?3VQ%FCBGS*HE)X68,MUK99X^H7B[&&5Z!/4NMW>O2ZF
M4[W7<<(1,W)$:3,Q6J1(M69H<CY1!NG&M"F3W$2):H#@K6X@Z\`FMC;4RS3,
MXWY]M*!"5)O]/S'_``B&:C;]DU6Y1]LM6:)LKOF:F,%)N9%V#R)Q%>8<'K91
M!0T:6,,0HB[331)@J,WEYNM7F?'*V6IS#V:R<8<'9_<<M_JOY5F*Q1K%E."H
M6-\G8JQ7A+-^&,*5I=%^C*MJA6T:WB@MC8/G4*8SUR\(4HE%;\RJBE'TBGIY
M"\=(VC_3UY^3,_\`3MX?\,OG.'ZS#H'Q?R,K^5I;(<<O=&[&3BF["J5:`&)<
M0$:+=Q&J.55B^HD3+HF36`XEIY*`G>`Y*XNVP=DPK9^(_`S-.&W\ME*B\U.-
M=\PQ>W.8TF1N1/%NS35ZJU.1.9N]4AG65,/MSMJQ89)@H)X\`928F(,GWJS[
MTU>0T8J3<EPSXF5[GUCJJ5GA7PBG*O)<`LX7^3Q%/$HDPR<6:3Y"8::+OI^T
M2D:ZK[C)%6B9MZDV=D6!,D>#X&RR91+O5-QVZEW3-<@N/^3L$9UB<=<:Z)CW
M$%6^HG,/,5QSE#-#&1'C3R"@*9.R=_Y`8V9-;&JF$ID3`=4D&"L2[<(1R-P8
ML'"8@/JR.15!<.>'VJ8MM^EKCQU?N'[G$5,K<?CWC55T$G.',89KEBFMT6VD
MS.Y2&RG.K7N)/,34W&/Y!L=S'H%(_DW)E)1T_8I^E`W%9W%B^JD'R)X:,.0F
M+I'$<_C>S<929%<)22V7Y+E7*2KB%;+OV+VU5<(J.LK(DL\G*VT>1;4CE"5B
M6*DB5RLR=$(8FC*1DQ?5=-6L!,L=XZQ?AUWC3#.9$,9T=*)6RO!YH>5:5O<E
M,F.I=7EI">NI[8XDI5<QGP)K2+UNV]1Z=FHW341\%0DZ\TR7T^.#J'&7)TW(
MS1T+,^NEZC[J$C=\XO;":CS:3Q=W*UFB1"&2;<-G0?O$VB3-R^:$F'2S50DB
M[<I(H#J`*R+A>][DGA12*F!BIJF\P]VPB4XE^%$P@(]4TS;AO[=]]:7'JJLP
M*O\`E*AN1+=5,XB!0(.X"*1A'H":QNGW".^B%)5#*`L<Y]RJ=YC#MN`D/W"/
M3WAVF]FBO!+5@W;>0A0(=8"*.2`'4I0$P)*`7V@FL;J/N`=ONT4XI*TW%4$A
MZI*[%6*/L\8=1.&_0#)A\0#[MM%2AV`^7N#^:$H>`0_"*(=";#]H!^+W@;?1
M!HE+<1%`0,(`H;N0:'-T$3*!^:3N]Y0(.P"/0#&VU%%KP`Q#A[0.`]/:!BG`
M1#W=0,4P:JJV+P.\@`7M[D.KHA2[;+*`4#J^T0[1,7M';H!@^_44"1MB`93N
M/_-I`*JO4.I2?$!.OM$Y@`-OOU52L1SF.<QS?B,(B/[1'?1$H#\EL)OX[D1*
M7[D4S`)A_P"&H7;]PZ!.*2:(C1$:(C1%X??5BD7$)=\*/FKH[3UU9R'%/%6T
MDZC17CW+FCIN&,BLS`3HM%E%TA$3@8JI`,78`+N'W/\`:''MW\;/C<B);9V9
M!P[$"XQ'CK[%T7U=,QNVB.(E_!0+8.5JW^G:FP>6"2R5D%&-AV1F\C--(.AE
MN?R2'AW4L5BTD5)B8>0=E*JA'HB/H43`"R*RP`D3Z#D".7"[F7(VH=GQB9%P
M-UXVS(D1<Q$8[HL92U.A`JNLQM2$1")E+)DS<H[FY.]*L#3BN4GFT0><:14;
M8F^8;NA"QU?7K]L9DH$BC;+4X>3A8ZASTFFVL#YG6(0!($,Z;I.)!9'QE9I"
MF5=7R,:[>&/*[>LGM_;NH91G;_.B80:+W8Q>(,RSW(DQB"^XZ+5V-HW>EO-V
MZ`S$&/FUIJ[>WW),>'MZCADC%8[RE!V!5T5&)@;[5W,8S:+2#%20+*S%N;?(
M6[5J%;E6("95BP`ZTBF*AO$@JJ//;S,,6C<NY>+>Q!64[5P$T+"/3+E]V[\4
MJ1I4@+CGC78G2X)M2E?KT^G)8R5^S.VB+>#Q3EFU2SA!PX]$UJ;VM5ROR;UV
M_2.TF)]ZC-+GB7EG>M0.L=&.,4DL3RKIN"."%MS,P[=W=?R\3'@X%9[[DQ0@
MQC%O-M>CRK$L"&*S;LW""(1N$C5@PX!Y$^-'71TAE'SZLC&TG(:%2N:LQ7[;
M$4>FQ*]DIB\:FX29/$7EWKC.5E+'.564(V<I2RZ+AB<&9U55F8`=(W@]PO3Q
MX1N]PQ#D=NVFW*]=(A<$C4'I380A*-#$$2J``=5Y-F,9$BW,QO`T`!(^L<?%
MF\4@D)B/O%8D;Y#_`#V#>,EHMQ<J;,RDNX;)-I/Y:9*7A)QRFB=U!*3ZZ[8@
M`+AS%J$)WK*%4*;7E6+5S`R8=LR]EVU,2%F[$`$BIVR#D;]C2=Q&<30.%X]W
M;<MF]:W1A'6)&AEQ?D].)!3M8U58V"O<19B:D73B2=?4>A7ZSLT6:5D).7/4
M\=E:IRDH\>H/&Z3LI3&!<A%1.9(=P[.NO2]T@<?*[S9L1CT1Z;(9]H`ZMS2+
M%SX/]J]G@R?'QQ*L_G(N?=%?6&'^$?[O77Y5I5E]-5=5$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(FYOINV7Q:'DN"??D9,NU6+W
M,%?_`'2+N;QW<>X.VG_#W&'K_M(K/IKL?80^)W2F&6[:?\?XQ^IQJXW_`%'#
M_P"B;RZ7ZMDW<>PU[D'[T!^E_P`,_HLVF=RP^)U_4C&3C:ZXNZ+YSOJ9)RB?
M++(K]"N)/FB'#"+`DR,6NJH+C^U^.\L"$RO(L(J/.[0-Y$P.(CWAWF[@(!#?
MHG]M.D?2F+&5QKA[Y\.[_IY>;:`26_N71/41(SY\OEQ_SA0.K:,/'K6JS3<$
M%Z-*1S69QM6)!.'+CXT$^DF%DLS,BEM86%NSDH*!J`1\NP;1C1=B1V[[Q3!R
MT54[IF2NY0LX-F?0A"<H9%QYB[NVF$"T#$F,I3>$C,Q.T,^V0'7;0MV[4KLX
MQN$R\H#$4+D5!J!1F66#BGMNBY#-N51D[9(7*:\D#3EY?P)6AC'Q[I9U+V1Q
M$M4G1J9#R4T5G'1D:A&QKER@L5,Y&R*:)^2]=&#.'8NSF-G&L6P)W=K[)$MM
MB)%NI(1W2G/=*((+;BXS&(N'YJ^!*Y(T&@;G3AH```[:T4DXG`TR..+#F"G6
M;'F&#U]V#VQ5N?D6=?QIE(\LW92)9Q52U+N*/7;_`!2E9:1[A!)1)-_L5<#H
MN"E!7J.1WZQ_4H=HS[61W"W<I&<8[[]@Q)!B\`+DK4MQE%PT=`\5[BUC7+V/
M+(LF%LVX_"2PGXAZ.-"-3JKL>XSNN:K,-5CN5^&5FK:#;V"0G<=V^H6R^-FZ
M#!ZY&JUV#K22-D>60KMDFK+N6_C;N7(F5,X5.=$!SW'N7;>QV8Y1[-FQNFX0
M!>MSC:<D>>1D\-M6@)!P`S"JQBX>1DWMD\BV8"+EIC<:?#%@"_-N/$II)K&=
M&6GRT!6G1>)B+.SI1,]69%ZNYJY'KA^V3BKP\FSN4[^F,NZ;N)I=\+%Z1UYU
MT%$RF*CKWV'W/N(QSW&SD2S&CYK<XC;<VU,K6UNE0&-L1W19@0=5X,X8\[O1
MN0$`]"Y>!T:7\WB35-S79)T\A9[%^6:ZLNI0(UY6(BRHK52=L=0>S[M%Y`UV
M%^;02]JD*^1_&.G,.BUE$BK,W;ULR`_<@W/Y^9BVK=ZUWCLMPQ&1(7)VSNC;
MN"(_,G-I;(S$3MD\*$1,N)7%;80EC7P?*"!(,X)T8ZD/HQ9G;52K^G<,Y'\L
M*;"3((NI=OC6Y2EF?O%UEY<LA848J;0@9=VJ_>.AL,&A(D3D$@4=(-GH+LQ6
M249^)3K7[C2Q\CTE>R<<-CG*M1@!2+1W1,HA@-DF>!H2&DQ$G'L^P0Z7=81)
M!F(2?GH/MY\=5]'RH;**?^L.'_E&U^:/!?37JRQ:J(T1&B+,@<4U"G`-^T>H
M#[#%'<#%'[C%';44*JX2!)00*(BF<`42,.WQ)G#N+[.FY=]A^\-54)2U)YBG
M;;B&_P":F;;?QF*'YAA`/XID]]_OVU!59<ZK"N<IQ`A`$J20=J91]O\`C''_
M`!E!ZCJ/]2.4K$A#)D>J?$8OY1B"`[*N";=AQ'^2)-A-]HAM[]7@A/!(TEA!
M8QU1$X*"8JW3<5"*?B_>`]0^\-4>*O!9ER`T*=$H[JG`/*<`'^:-L)4PW_E!
M\1OW![M'1W*$4P=)BD)P*+?=4IS!T!$1[EP$>H_`/Q`'[=7@AHL2BVRI!1#M
M(CV^$H_Q>T=^X=M@[SCU-_!J:HR4'(FCN]#;M5V.T3VW[5!W\O>'L[43;]OV
M]/OT^_BG@L+?^L`=L<1$R@BHB81Z^I#V`(C_`,L'PC]^VCL%2A4Y4MD$1'8A
M@,=0.@G6#;J&P[]B?L+]H]=/O0<UY)<F>)5)Y0W1]8LG\:L>V][$6Z5BL?Y3
MH/)VRX&R56&"SA[$6*32L-#M"4HQ/*M6B:,PR1`JC]=!0CEJ(D(8D/BM`L&!
M7#XJX2<68*A6K&CK&_'['?ZCR#CN[79GDKD1=LX9'O\`D+$UIKM]IEIMV2EL
MC,I]\O`VJ#09"P<AVJ-&0M3%.Q5\&E$).JU,?@'&\2\RN[<<>N+TPIG:[S5Z
MSL\D^0BT\K?9*RM$:]-'=IRF2T62T,SJRK6)BH@Q&,6R9+F;I$;D3`KEJJ[\
MTZ.(<+U'%>$38KQAC[CBNT6@"XV@L7368Y:]656DN"D;.6+&]V#*T\\BD(=E
M*BP;@FX._00:MTR&,DV;$U-#X*&3ZNF^D>%>#V>!4>/,UPXQ!$X-BZE!8?\`
M2N.7LNT(A1XAY$R#-ZTDUIA"3264F6PF$YWJ,L]V[5U/SC[A5!(N[U]BQ\EN
M%_'S-DU5+>I$X/F+E%52(Q8\LV%^2&3N.]L?8WKBSV9K-;NLW5LOQ`9*BV,R
M"ZK9.455?MESJ'2<I^910I(R/BSKFJMQ0P37`PE!1''/B[2XS`[^44Q,:'Y#
MRIH:M(VBOO8&6DI(/[7D)2QN7QK=)N#%<IO_`%"BZ\CWC(&*FH#)N-:ERNZR
M/PJPEE#(N3,C/>*_'3,3Z_X(:\:+%=J1G"6Q>>[X[<H-S_*)%DWN<JV/,5]F
M_.D6:<)$GB)&;^!=1,I-E'KJ@D>9U6@PG]/_`(G8>R/#VW^RG#](N>'%V[C'
M9\^\M\J\GHB$<G9R$,E-4NA7K)Q("CS3.`\7IW:T8=XF@]3*V41,FH`@SH9$
MT_@NR:X=IU7M>9+36L+<77TUEB_2N2KK-AGR39QUKL/RN%K861"#=9#`E;:.
M*Q3T51C$6Z;=!5D0H@`KK.&QAIP=0\!5@H]L/IX<6GM5KL9#X]QICYYB`+ZT
MP;6ZAR^RY7+-'0^495O-V6A5^PTCD,W+7*;ZF%;+MX55X,4S$QB,TR%,834@
M.MF12^5^FW@]/'%@HENXLIS]8&?IU\E7]C^HYF%=XPM]4(Y>14K5K%8+S)SM
M,)7W:2)5.UV@510`.43E1(?49-Q?7[$[^-N(W'3CFE8+KAVJ<;;YD2X5E.AS
M[S*N>,BY1OS#'DP[1<SM2B,C9ARY=PKT2@_42,Y1BA8)/W)2+B)C))%`RA).
MNBY]A@K'L1D>;RZC@OCJSO\`8J37L=C;VW(MXHY0I57>6MT6O,$W.86:5?8*
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M`KE<8RRDR>I\9:@ZATEIN#3ELL+VII+V5RX37=HHP[7+,G%I*V"<5,NH[=)@
MFL9)NHY`5B%*A5#[US5)XWP=(8S`L.(6&O+:;Y:LYVE^UY-O(Z.?7:]VU>S3
MJJ<<O+S)64<Z=RB\B$<FH:#0*()H%Z@4)HH9'FE6.N,W'?%G''+>*\8X\XE1
M55SP\R%;LDX8F\IR]L>RT]E",",OL<CDN4R"_"(3-!(&(V/&%8,VI42^`C<^
MZ@0@`LH22>-%'6Q\,<%6/'.*<:/L#85@J/AQY`N<7N*)R_NM,LU/F:K#!6XA
M8MNKF;82P&*SKDZZ4<N`?*.SJK^84%3")CV@6C(OXKIX?Z?N"4*?:<91-#J&
M9Z1FNG-X;-E)L?-#-ML6AHB+L,/;(]M#2EVS9<TX.QK2R:)%)&&13!0ZOA77
M,V4$5'WJ;JOQ]B<2\\3,%Y*MF'IG-7%SC]0)?'-V;95QSD&9Y*R\BXHMSAXU
MPQ*W80]?LE4DWL,=H1J@M&LW9HKRG:+*)*>F*)"`D:%=7F#%M&L^::IF%[C[
MBC?KE4,=RM'K%^@<KN:$A&UNSV-M8I^$&IM\C1+!V^))5AL\0?B*BO>F#8JB
M)%E5$GBH]&JN/2X_XGN5VQO9[_C'C52I'%-ED+S6)C^W:PR,3!WDM-FJ&\54
M@*[EMDO:V;:FS:T.B219$*DBJIW(I$32!4:JN4\L[0IG(BZLU:.,N#[8^GVC
MQH:;KV>DZ0P"O1**QF2B#"$E9(C5:;<(%;BJR4^-(?ZT)"@8IKP4=M%T="B*
M=64[#.P4!Q3Q]8Y,K^/7H5@R(MD%0SB,D'QHM(LT%N+`1HRD@ZVW3C4EFGF$
MB@'`H`.=5*\'3*SM=;SSV2E;!A'BZY<3RCB4LGRK-T>B"CYS&."M#-HAMDN)
M@C@^?);F*)FI1()A*)SF$"W15_:G\Q!&MH2Q521@(#CLXG+'96S6YP\/?UKC
M<H.!:J2+@+#!RL[?[`DY>&%JF9))DD9UZ5)$AB@5$I$*ATXJ>Y5@.HH"^XIK
MB(J[;")3?Q%"`.WQ)_9[!#IHZPZN6(#=,K?NW4./E5,4>G9_Q)0^T!*/?^\-
M#HA61)(CKM$YMCHAW+#_`!E&Z8!\8?RE";=OW@(#[AT183+F%<RVVX"/:*8B
M/:*6W:"([?Q`)TU'1UE.F1!$5$S"8KH.U(=MA(B&_E*<=OQ]X]OW@`C[]71"
M5B;[+@#8X]3F_)-_(4'[=AW\:FVQOL'8=7@KHJ.A`IBI%W`K?\LN_01-N(J'
M'[!,I[/NU$"4)]JA1>B`F4;E_-`2;E4/L!4%1^\-_C_9O[]5/!(2*BFKY/Q_
M$/>!NGD*/XRFZ^PX:*ZI6Y*5NB4B8FV<"581,`@();#XD1W#VE$1$WV]-/N4
M"2(I"L<I-]NXVPF'V%+[3''[BAUU*II[%<Y4!14>P-DR`!$@^Q,H;%_SO:/W
MCJJA)]$1HB-$50#?H&B+Q%^JOWKY(P5#D&(8FGJQD>#:34PH9G'PTQ**4UE$
MRTG*$7(O',T7#H$S+II"#,ACN5'"!4!!3[A^TTMF%W&^1*4+<[$Y1C4RC'>9
M`!JE@[?B^$`O3HWJP;LFQ;&IC-O:X7FH>QO:'28=.IP4^;)=@)(5BX72<"O0
M^0H"P71)LHI`1G?%3=\;2SZ"BW3)%1"81="W=2#I#9)5NNK]+&'9[IW&Y<SK
MD/Z1!IVK<)3-J<(?CDQC;\LB)%X$.(1E4$+K9N]"SLL;NI(-(EG!Y"C^`+\^
M:[.(Q?7:LI$U"3K4!D"UR42R0L*EI,:1H=5>OF#E[+4V.A8U=JS.W`CY!C)R
M2KU1\=1%4B!6X@'?P9/=<S*W9<+]S$PHS.P0`%VY$%HW#(@D:&48"(#,[NLQ
MB;4^D0#,@>8U`/\`*PIX$O[&3[W+#MHPZG2GC+/V)\>U6_,DG\57,T6V"CYC
M$:9$78I51Z:]-5;-<J,T:L&\?ZENFL5WX0.JB03HFUU?"[SB=[NW[5_MN5EY
ME@D2N8ULF.07'G:VT(3+[F)H:`ZA>RNX5^WLE;O6X1N5:4O-#G%I:QX.!7EH
MD\7@N<NN,9/*5JR1CK+]<CY`D*TQO6;4TLM2D)%=ZV.7(>6Y:@K(LGHP2M8:
M/DX]^N<\FJ<OG\*0$(HN][QNW=SCVK`Q<K`OR&^5^Y;,;C<;6.+KL9;C$RA\
M(K'BGREWY4Y=^=N[5HP!'_>EMX!G#ZJ-]AI*,Q&3%SHJ*].N](=1LXM`0\HZ
MCV$TVCWSMC.6VI,45"R-8M44WE$W3E",<.FSQB159--$Z1>_N.+W"Y:O0P\\
MC([9D`QWRB"82(>-NY(^6<"8[`9`$28$D%>K>)!N6_)<B*-QK]_%AP<T2"9>
MJY8@J]8&,1^B\EV"4<S$I.Q"U29UR:K<JRB?GEMN\A2XFGNH>)5L]0<.GJJO
MJVXNY)\W('>Z:-SRS:EV7*NV)S.1VBW;$8QF;AG"X"=ENW&<KFXB,P`!M.V$
M2:1D5RW3'+M[Z"^]2&`(:I.G$/QU\4].*7[N<@N*T@QK#19BI]1^/58)C#.E
M_D,.>L4`R<VH9DZ11@US(G(4HK))F3!7P*HIJ%,*GJ>[0%C)[O"[<D+O^FJG
M</-+J7'C4.1[#5G!(T\K"+V+!&GSP;ZH+ZO`_P`(_P!SIK\K,R^GJNB(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1-S?#`66Q<`JW
M!+OR,F4"U8G<P6']$W8WBNX]Q>RG[%[C#U_VD5F&W7<.Q]A!.)W2F&6[<?\`
M'^,?J<:N-SR.'_T3>72_5L@.X]A!EW&+]Z`_2A[<OT6;3.J&P^)-?U(Q@U73
MC:ZXNZ+YQ?J8MDUN7>1U&\JF1ZGPMB"&C#-)-PLFD.8(XY'J+@C8\4W(Y,'A
M\9C^=8X!V!N4-_T7^VD]GI'%>'E_KI\S@?\`X\J,[TUY+HGJ`Q'<I[C3Y8?\
MVB\R(1:1C()I:2.?1J8WR35+9&2KI-`"MC6)W&0]D@&4A(Q$NQ/ZX\;'+K-4
M6X>HCRK=ZJ;8/S/IV9"U=RIXD6;+P[D)Q&HV"4H7"`0:/(`DTD10R75XRN".
M\:0D)`G0GER-`''%E*I"#KA,I+<?91..;(N9=\XP3;7SQR2R5-M/6V8D)#&U
MV>_.GC*0<Q:*LE\A%\5BNB=`GQKMW"2"713DYA[-_JC&,M^V,<RR`#&<HPC&
M-ZV&#/Y.HVX%^!!)]H;=J>1\IM#-Y#Q9R3$\.;<1["`D..*?#\OK$,G8FZ<M
MA4K^X0T,RMDDUC*GARAT:3$%[!&L$YUG,NKA:!;MY*:F$11<G;"9BAOVD`WD
M=TS+_HG#%K#ET_4!$)S-N.Z>1=O#_#)(,1"VYC"W702:JN+9.?>VQFV/$%@:
M[8C4^\:LGXS-Q9XQ&@T+KQY'%-PF*[3\>,YU;&]G5AYZH5BQP[@(.\PLI.SH
MM8BX)HHH.&DBFB,JDL@!GI^Y42J=;[#ZP]56\K^G^J)9=O"NW;AB+]O=&=R,
MO-:D!$&5O42A\-6B`-//[C@X?1,\"=N1MQCN`)I2DA77Z%1Q3OM5DJ-:,E9#
M7_7]RQ5=;1AF2:3#=U&/LG9-BVPOZG;))A`2JBQ#/XD7A[%X7"23HD2OV.FZ
M[Q$Z?:I=MS;/<K?:.UCY7%S;,,F)@7Z%@EKEO=(-0L+='B9QH1$A>M>$K9R<
M@0G,$@@DEY?A.O*IYMS*Y6V1+YY*8A--KM9FPV21R'R$N#*/3C'4!8[5$,H!
M"EUBEQC,)<1C:JG`(0C-NQD&IFBX.02!58FRWF=OR+$;>=\H)PP[(LX=N1=X
MP,I=6Y<D6\TS(SE*43N&URQIQWP/RC/_`!CNF6XFFT1;@P8#VI[OICG?FY90
MKIP]!XJ>FY!<KF=BIYWKY\#)=ZJ<KA(%DS)N3J&!,=MNSN#V#MZ[]U!:CZ1E
M;M`"V+]H!M&&YOL9>3Z</_J,3^(QE]R^FA;\9_\`UA__`#C:_+/%?3N*PZJJ
M-$1HBKHB7)_GMQ3'XE4>Y5(?:84Q$152Z^T0V[P_?IK10JXXBV3*0@[*J`51
M42^T@`('22ZA[0V`PA]NWV:AI13B@R(KG(JGL4BHF%01Z%24#XE>[?V!V_$&
MJSH:JX'!!4\74K0Q/``"'X2`/PK"'\L#_&(^WKMH_!%:5$6XJ*JE#=(_8D7I
M\:VW<4W7VIE#XMP]O0/?J5"<%:(^I2'<W<LB&_7J)T=^H>\PF3,;?_)_9I4^
MU*JXQQ:=J9.TJNY3KCMT$0#<J!@Z[E`!^(/M'[M4JJX6Y#J`H7HV4(*W=MOX
MRE'\Q/?V=Y#?"&_MW#3QX**A50<[MC=I2CMZ4NX=J2A`V*F`^P`6`1`1_E==
M37VI56E#TJ?D'X5U0,5(/PF33W[3J_<8P@)0]_M'[-7157F2]49-=,"@*IME
MM@^%)4H=RAS#[B&*'=_#]FHRB8F8XS<>+/-R4O-XDITE*S!^]Y)NVKL5G3P9
M,)@SU0I7A44G#R6+Y5E"%*=41V.)B[@)E7DR[A]BW'3NF(T64I5?>5-%C&P[
M2ONF0';(Q\$9J,<F*QC^N.#(S%(J9A5$XB3<PFZ[FIXJ.5PH\7,`*J)NTL7P
M*)U0$KERB\GD5O@7.^52<KHS!%738SU8[H$U!.072IUMO,<QQ-55R%T-AP;A
MVZHQK6PX\KTLE784\'74'*3HI(^&\)45&:)6SM$#.`;DW(X-W."&W$J@".^B
M.4AI_'G!F.)AE-T[%]5KLRWC3Q(/X]HX\Z46X;MFHM#D<.ET5MVS9,3&.4Z@
MB0.O=N.@I[4=]4LLV!\.VB9<V6U8[K<Q/.$6L<:050<ME7+6.#9L"Q&3IH@J
MFW()0((E$=P+N(]A=JS("=!HLM6P7B"B2(S=3H4)$+)L%&3(Y32+Q%%JZ13;
M#'M6D@^>,F;9ND@)2D13(5(#'[`+YE>^-5'/O7*N>)_&YQXWKO#M/=E3:OD4
M#.TI)<QU)@ATI'RF6D3BY<"7O#S*=ZJ9=@3,4`#:L-$<^].3'8JQS#5)?'L7
M2X%K3I5K+QI8`&7D9C'39W;R2;]ZYE7()/'4@IN`*!V"80)V@4H```+H#5^*
MXA;BUQX38J'2Q77DCM4C,D%$'$R@NDD!4&3E%%RA)IKI-G#1!!!5,I@(LW01
M2.!DDDREC5]JKDE*'^$\2RT)`UR3H%??P=9=+OH2,<I.E6[-VZ4.LX64W=>6
M0,HLH)]G1ER@;80`!`-J57+KGJ]QFP!4Y>(GZYB>IQ$U`NCOHF4;HOCO6KM1
M1XJHN99R^7%V<YY!;?S^0!!00VVV`(CE=1;\-XKOSUC(W&AUZ=?QC->/8NUV
MZS5=NR<J^==J4\<NS[T5%1$=C]VP&,`;`8P"1RM57\`88JDFPF*[CN#BI"+6
M.YCCHJRJS9DX4.Y5660CG<BXC2*+KNSJJ#X=U%@(H;<Z21B$<K72O&G`4Y(*
MRLSBBIR<BO-*V%=T\1?K'7EUC"<[E8@OO$JD!S")$#%%NF(B)$R[Z(Y794K%
M>.,<PZU?I%*@*["N'9GRT<T9^=N=V=FTCSK;/SO#E$[-@D0Q2B!3=FXAW"81
MJ:ZKA2\7^/B8(^+%%:0%LH19H=NK--E62R7J1178JH2J:K%PW%\X%-1$2'3%
MRN)1`5E>^(Y72?V'XC&JGI!J#!GJBLDC+JPRGKSHK2*!$DDEUG)WHOU2%20*
M04C*BB)`V$@AOHCE<JCQ6XYMGI9)OAZG(R!)8DXF\30?E<)2B:K)9)RBH#_=
M$J*D>@)$B[(D\8`4@!N`F".4\%CQ7C7(48R"[4N"GBP3]T_C17:BV5:.'#8$
M%U6RS`S19,RA%`W#<0W*4VW<4HA"SK-7HN&9<8\$1;E`8S&4`Q=-'B<JB5%:
M8*V%V5=ML[78C*"R=."M62)!.J0XF0`R0[I'.0VF&J;BE=KXZ8+R%*2<Y;,9
M5F<?RB[09AX\3?`HNC&$(#$W8V>H)-T03;`50B12$6,4!4`P]=&0$BBW%*PS
MBNAGE7-%H-:JQIURDI/ECF(^%T+9>1=M5S(.5'""`I'DW'\V4GXP+^$"`6,'
M4))7+R?&S`5A=RD@]Q1573Z2D7,L]$47Q"/'3UZB_<NU&S=\DV*Z-(MT%S"0
MA0!5!$X`!D$A(9U7.CK>1^$L1QD-8:BPI,2G"6A))O.MU',JZ5DU4#J+$.K(
MO))>32$[APH)CIK$.8QA,81$=]5D).O%<8XXG<;!*N=UA>E*.)!)DW7`[5Z'
M:RBR+MV:*90?@#4NRZN_B`@J=QC'[C#OJ-1'*<V>Q;CJU0"-6L-.@I:HM21J
MS>*=LR"DE\F*1.+2!=(R3L56G:">XJ")R"('$P&'<P2KNF^)QBP"L*ZZ>+X)
M%\8`.JHV>3[=5ZD07)RE=G0F$SO3M%WJBR(JB?Q+'%4G:K\>@JCEUV[[%.-%
M['7K6\H\`XL]7:LFT))&;'34A4&"WJ&",>W1539(*LC;=JH)BJ`?#W=H;"H%
M'3AE0(1053#W-B$!8IO^5*(B":?V]QCAVF^S8=&X\$5O>9V42GV\Y`.=,=OQ
M%$1.HB'N^$-Q+^\/LTUHGW*HG,U(0A!V5.)5E1VZE*``*20[[A\0#W&#]@::
M(&5?3D5.10FQ6ZG<=0?^0[/YTAOV?Q?M[@T9$`N18ZB1]B)*B4$=_8W,7X4O
M^")>A_;O[=75%8!!;$.H<.U4PG22#I\(!N553?[``>T/OZ^[4T]J*@AZA,IR
MAWK)B4BA0ZB<@B!4U/O$!^$?NV'59Z\45YE0;J$33$HE1$?)O^%90P`"Q>GM
M)M\`?LWU*A$`@F4XJ[;M@+YBF-[R[B`)"(=>_P`GP_NWU?%%:14'`G26,'YH
M]Q#C[$UMMB;?80_0HA[/9]FHZ(V].@;N`"JK[D`H]#$1*(@H.WN\AR]O^2`_
M;JZ(D`^T=0+0T5-5$:(C1%4-]^G]S14+PE^K^@NYM^%2BX,F@:O9`;*)$,EY
M0;G5I8F7(8A#KI`F=0VP;;GV$`U][_9:0%O.)#M*R:Z.TV"Z#ZO!-ZRVK2^\
M+S[HM>4L%L=,)"1>P;W*V%@F/61YD(N1BKYBR:KJ]4R/(IKLT9)1!HC7$'YW
M2D@BD>/<N2`AZ<`\GT#NV5'$P1>M@7;.'W`P8UA*S?A+JVN(IO,0!$M.,:[M
M/0XHC<+3(CNM4?A*)\IKIIKR==@&4:FPQ_>\Z2L17('(6.!/&7&`A2KGKD_>
MK59?D5`MT/`+2[UL:GBHN]?.V3-TZ;G>1BP%4;MW;9%+UTNTYMSN>+Z>MW;M
MWM67Y[4YL9QLPAON6S)@1<I&,92`D(R!J02>6,K<Q+)VQ%^%#$&AD2PD!HVK
MC1QR(4A\"<9<4VRR1>0^3DA4';U*[M(:(R5F:<9/)W*ESFFLC+/?GB<78!8@
MFW6[`CX^2(M&QC5L1KT4'=3KWJ7U3WG$LS[3Z4C?MPZ)E*SCQ:-BW`B(VG;N
M<ZRG%I2)W/R]AVW"MW[OS?<91C:E-@9GXY'AKP;C1-+EW%M/XY-/[6>/#R!0
MQZ6KRN0(VZ4"7+)P.2X<O@:V+&5SAK!8E;)/T>72*BW1\I@6BGJ1GJ*8`)>_
MVG8N\9GJM^S>IHW)]S-P6=EV.V5DD/"];(B!"[$ZT\\3M/%>-EX\<"\,C$,9
M8YC0@FK%I1+G3[O>M1=G]6;.86L8Z7B4K/G2OH6%2Y2RJRTCC?#N0*TM*LV+
M(YIF,AFN1I"'?/T62QU57*;9`J23=-RY(X3YL.&9<M7<SO&\=N[;<V"U!A&_
MDV9"+FA/2$XQ)&CER6!"X)0LV;@M6Q'=>&[<:[(2&@X;F?Q:FI3+9&8H(3V<
M)&*3<-8]A;H3#4<S.F1Y*5*AT=I&+A$R#V.CFCIB$@_A(U'=P=\5V^(Z/Y2N
M1.17LG9YF>/VZ.564K,\DDL!<NW210$D':)38!FBP8Q8CP\D-=N=,4WF`;\,
M8FFG-O>GQPXF<:EQ(4?32#%0/J+P*QDREE5!<&_26/2$ATU8I$[9N9X<.X#.
MA\2Q2]!V'IZ3OIW9_>ML''^G#RI^;<+L:TY"H7LL,"-C'$=/G1]T77UIA_A'
M^^.OR@5]-5=$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB
M-$1HB;B^J=DOBT/46]#RY'33[:NGWL'/_ND7<_I[L/>3QU`>SO$WQ?[2(S#;
MKN'8^PQW8G=#MPY-VTG\\M*/ZG&#XU*Y%6:GY)O572_5L]G<>PC?W&.[O0#8
MH>W+]%FG;FU#8E-Q-?U,<8-5PX^NN+NB^=_ZBDS7W7+7+<(>M">W1?#F`>1]
MN)9'R)V\*]RQ"(N8,M2.F$;)JK.%C.`=]_>CXP*(=HB.OT#^WEO)AZ4P\CJ_
MH3WN0-K8[R^7DTM^H;3:S%=#]1",\V]$#SC&C5_]\<-%YP),EVU8B9JQ/G+9
M:O7ZIQ-`D46\4.ULL\W%S,D$H@^$(B:1:PM<$"D65;F*9P!414$PD#Z3D7X_
M,SM8L0>IC7)7P7?IPC(19O-`F4GH"[59EUF$-L=TGW;@`U:EGI[`IG8Y;R,+
MRA>9-6<OJSCG%@M,6W2U1+%*;CI^1,G)4?\`LTIJJT>Z8O&]6A)0B,DLD:1D
MVB4:H^W,4Z*A>@9LH'TE'M(`O=WS)&_:MOM-N)(N=:Y4$;Y1>((C&6\1&A"]
MS;C*UW`9<R86;31)H0=8L-10&NI`!*Y_BU<;%QRM[+"ECM3\38]=VNE2<I7`
MB8ZP0U$O4ZXD*);ZZI,0/?8*VX@4A>,7!%7[%5Z[%LN"*J9B*>3ZLP,;U1B?
MU[$M1%S(C:N`3,C&=VU$"];D(R)C,2>)BT3MCN#@NKA9$\#,Z=ZEH1D'#.!+
MB'9P=1KJGUO,7ACBUB:ST3`]CN*T1DQ2M6V[M[T_A6=4;24/".7UCR))&FD'
M`'/>FT`HZDD3'%BV3[3MVY@.0H>APKO>?6'>+.;ZAC9W8VZU;Z8END\VMVH[
M0`3`EA^/A(NZ\S,GAX&'+$P)3E*Z`2"S!M9<Z\M.2C5!5"Z6W`F7PC+1*2-[
MY+Y:E<Z5NH+UY=JI>\3TRN*,JM!N6AHB/G8B:G8YX[7@V[1-)Y+-V"(>F[7*
M:A.TY'<<'"]2875L`=M[7B1Q;DQ,$6<BY+=.3[B)1B=HF23&!D:^4@^'*%V[
M@SMB39%V?4$6^*,7XLX)))B!JS,N%LC".M)./[)8':"LS7K9$U2".M%GF&>1
ML8Q]9BHZOVP6Y"RR*]>GXQ&,%!)FU(=N9([I3O447+YN`;N%<[I<&V41>M2N
M3#[)6+\IRE.`/E:43NW.6(.T,P7A9$>K"PW\D@!H7@P$2=:Z#BS>)3Z?3I5E
M0Y91CB26!4TM3[O(NE6K5NT:I+O0CEA*T;IE4$@>J$Y3I=.PG9VCL105/7_N
M5*U_I(VX5VWK0#ZD#<'\:-7^T-Y7IP'^JQ)__CE]=%]'"WXS_P#K#_\`G&U^
M9>*^F\5AU54:(C1$:(EK7X!]0/X4?B#_`!U>OC)UZ"`FZC_B@.HU763JJN0[
MA!<O4BPF-[_@4]JB8B/M[?:'VEVT(=/!9TC$22!!01#U90\@^]$G7P&$/\KJ
M8!_BCII[428J!Q6!#H!Q$2CN/0H;#N81';X.WKO[PT`8HE*QBN""5,1'T@=J
M91$1%1N'XC_Y13!W"'\D?NTU2BP-MT`,['_BC`5(-Q^-80W[1#IN4A.H_M#5
MHRNJM<$W$BI![DEMSD$1$1`PB'D3-[Q.0W3[PV'3355*2B!$P8";M,?XSG$=
MBE7W#QI"/N)V]#?XP_=JLIXI(@@(JCY-R$1[CK#MU*!!_#[@`QC=`^_49'6=
MT;U10<E#M-N4BQ.H]@[;)&`>H`0Q`V^XV_VZ)I3@KT3$;)"FKON[#902[_E(
M>PA]N@B8YQWV_DA]^E>"&J3`V-Z@4U!``((G4.&^P)%V,)P'[#%'I^T-&JJZ
MS.C>J)Z@O04^TAR"._:GMLDI^\.AO\;10461("(H@W5'M,[`#J"`CLB7H+<P
MAO[QZF_Q1U.*A-5C;D,@H=13X?2B`B`>T5@'9,H"'N$W41]G:`ZO%T_BJJI"
MLJFHD&Y7)MP#I\*N_P":01]@=@]?\D=&<NBJX`BY`\9A'TGY.XCN)T>XWC4_
M;W[[_M#0-Q5"N5(`MO2`.ZK8/,;[S'+NN3;?KX@$OL^P=-"@-708@"T3;[B*
MR``Z,7KL)5-N\H!_*(42C^S?2KGDG%*-@*JU-U`&(]BWQ=P@!">H$=]]@W4$
MQ?W:<"IP\5E63VCW8`;<3*'6+OOL*2RQ#$']Y4].(*OXESH>P/V:I#%EI&HH
MC1$:(C1$:(C1$:(C1%OX]/OCUR@/Q'443*`;[B(E2/\`PAX]9D/M4XH$2>L%
MX(B*'A*B7J.YU#&%L8=^G0$RF-K6D63PXK`@D"(*(G'8SDQVI![AV#L_XS8-
MMP%42@&_NWT4U]BL;B")#%6W)ZL3-Q]H"1,!$#J;;A[%=@Z^[?4XOQ3V*QL0
MS(ZCA0OQ)G%%,H>P5#`(*;^P1*1/[/>(:LF5)<*WTH`X'<P^`I?,90>HB@(`
M(#]G>;?M_P`K5]B.X578BY*5T!1$1,":A?;V&`/RMO>(*$_\H!U*(%E`@`3Y
M>`AY#!Y!-O\`_90!T2#KV]O;\/\`E:4-%'YK`WW1[W([E%$W:F`].];^2/\`
MBD#J;]P:@",J+D[U`43`1*X'<H;[B"@B'>G[]Q*<W\&A1DI$"F)Z(GQ&3[CD
M,`]#+@'YA``1_`(="_XP??JZT1)VP=@BX$>B(AV>T.]8=_&0!Z;``AN;[`#4
M`9&5'``<0<%#HKN)PZCVK!^,H?</M#[AT(=$H+VI$](H.PK@4RA@'^9/M^20
M>NWP"/Q?M^[5=$C*W,*QB'^`"=PJFV'\LA?Q&_RO<'VCH*%5V"4+F!TF*Q0[
M3([)F)N(B"/L1/N.XB)?PF'[=A]^IK514;CZ0I70A\9_@1*(_B+N`+*"'MVV
MW*7_`!NONT<(2L"Z6RH`F/<F<`%$=AW$IA'X1`-_C*;X1^_5=4%+/@%/T`#N
M8`[@.`]!=@`[D#KMV]@]F_\`*ZZK)X\$C01[CB)Q[4TP[E3=1$I0';;;V]QC
M=`#[=0(3]:S.3>K+ZHH;&*()*EW$=@Z^(X>T>I`V$?9N'VCI1O%-$@'IJ*JF
MJB-$1HBN*.PAHB\/OJQ(N'MTPPV9G434^47ORJ$$IPZ'HYQ`Y'`@F5,&XF'8
MH"(J=@AT!0ION?[/786[.=O#RW6F]K3_`(_31=$]7?XEJK>6?WA0>Q\JTKV2
MS6&5E6\39BX>E,L7]9Z6&:Q[&*CYVNC`RL.VD!2<QTFTKC-HX;HH%D&*SERF
MFJ40.=(G=>]1N9W:?D\>(EBGN$+%C5S*49;Q)OBCO,@26(`IP*]!AQ/6W"DN
MGN+^VC<BS'C4KH8C$=XEN+N2\=^KGJ9=[K-4_.F'\=.815:4C4L76EVN+Z0.
MXC`EEK=9(=R_6B8XQ&[>1*Q(LV*N#E$B?#?[YV^SZLQ,\"&1V[%M7,7)O"31
ME*_!FBQ;IPD`)S#F&XB3;2O*MVI?(3L%Q<G^9&V>42?!W()8<0':H4FL/7#%
M7*&D3.)\T35DDL3W.XQ61DV%*<L&T;D,B#N0/^C["R8P\-.1APFH%5=[XP82
M2#]$4%@,&PZZEWG#[GZ3[E#O79(6X=SLV#;/4<FR9``3@290E$QDT23($%PO
M-P+UC-LG!SS*-F<Q(;6\S<.;^(9-GR:R"Y:5V`P9BVV6J=;P^.5L%XQG+,E"
M2=QM%CL,:VCXB)A(.,AGCI`R;-BJT670*F@WBE?5.W1``?+[3TKVX',N=^[Q
M;MQE\R,N[&)E&$+<2=TY2D1J9;HASNGY8Q?3Q\_*-R4</$W3M1ATP9`.22"P
M;DS>Q:#*=;DZ<^X^S,/8I*VX\XUU?'F(;#*1T81-IBZVUJN)E_7B3Y.(5))T
M"5L$J907<FB*:JK)1DW64/XO'Y/;,N&?C]SQ+UJ-CN?=+EW(MB1?KVIS?I,_
MENB,0!&+%I"1`JLY8Z<[5ZW,RM6(PMR(TA)M2&<QW'7P(3#W*NF;6S-J<.HV
M0L];N;&B6-%,(Z1A(BCS$9$)UUG#F8.)!-91D]JOIR/73I1XJ58IQ+VJ"KKL
M_:\D2P^W_,?Y:Y9E=MZB4KT"1,EV(!$B=@B`&.C,O7Y,)1,PWFC/;+D!1C]8
M9WK[4\&%)*&2C.(</;:\[FEY+G\P0K4B2R?(EZ]/)53'2J4TZBF\<^2L2!FX
MJH^`QDR!Y"J"<H[Z]/WZ&1<R.\WL.["W"/IX]2)ANWQ-RYY07&P\7KR9>PP"
M(V;`D*G,`U9J0\"OJM#7Y:%0OI2-5$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$:(C1$:(FXOJOCE\6E]3;V_ER.FEV5<G>P=?\`ND7=3TUV
M'R$\=0'Q]YC;&_VD1F&W7<.Q]ACNQ.Z';AR;MQ/YY\T?U.,'QJ5R*LU/R3>J
MNE^K;FSN/81O[C#=WH!L4/;E^BS3MS:AL2FXFOZF.,&JX<?77%W1?.[]0@UA
M'E]F5)FL@O'FX>5@S*)2=L3/%)G^UNM;/G4<FDO8`C$B%(51RW1<)($`Z@D,
M<@$']!^@!CCT=B3G$]0=ZFYJ!M^7G02)$'\"03H]5T/OS_U&^!J<6/\`SA19
MCX)P(OFD`XA7]RP@BC/M6@2IZK*362;J[:P,C,QSAZBI3[E#X\D)&M-8UF=5
M9(TXDFN8YTGA$B^]OY#2Z^0+EK`[B3"4FWB%BV#*,3_XD)7A&Z9&C0IK%UZ6
MW9)GLMM*Y8B[<92E0D<#L)C]"NXP=,Q]RI32B@C6XB^P:CABPB"O(^/87V.M
MJBMBEWM=9@V9P[B]IVMX],^(W-VRC=1)PW1`WD(3QO4%B6!G'/>[/MMX`F8!
MG*T8#;`2+F72Z8CM<>4B0D='YK'ZFV+$@/F(`@Q+`3!J?#<^J=W-2.`Y7$=;
MJ?(G%3ZV7URW5:8F@*R,I!W)*OL1.TDNVV1)6CJ-K"5O7;"G'NT'P/G;@QT&
MH['<)>A[#_J+$[O=S/2V5&W@6ZY$Y-*T9RK\$GC*YL>L=NT"LJ,?99%W#CB1
MMYT#++8BV-);>6[^5^8+\%'3"=<X&5?(L%/7+$^27$01C#5UE:LE6^QY.K<-
M/1,*8`AW-0"%JC68J9$!:EC$U4Y(B*!2>9GV*B5OVCOV7^XF5V^YBX65B1F\
MIF%BW"S<E$EWC/=,BYJ9$&)=VDXKX>%?[*+T3D6KD;;:R.Z(+\0`/*^GAJ%+
M&\(.T;//6[*J<=2H%/M:3LH]>QI5Y(L6BK(*P]1\9`/.2ZK)L460-BO&YVRB
M:QQ*D8HAU'MO2&+#"[/NR<F9W1@(EHF7EE*X]1'<6D)$%Q1<UZ%XW3=RC&,(
MEC)ZD"H$0->`#<U"Z&/-Y3E[]8)!C7*3!M)M;-,<Z>3R<;%P&0:TWB#.S2<>
MP:-[5D-_91DZX2P)+"1"4=C'%)X!.J8G=K\<;LMK$P;5R=[+N6_EYQ$=TI69
MDL8N3"U&VUTVN,1O)>B\#\W*G.\(@0C(S!D?A(^TF7E!YEN:DUP;1\_+2CVN
M*:$/6KKCR\V)HU;H.FWZ<FUE"MK)7)-!P@W701B9-,31ZJY4W3MF\2_J_P#5
MG"X]<];3$/2-_"O$_-X^3:@YUG"NR0J03*/Q,X!C*M0%Y_9(B7=HWK;;)6Y%
MN3Z^YQ3P7T"*C\9^O_&'_;^(VOSWQ7T;BL6JJC1$:(KBE[N@;B.X``![1$?8
M`?>.HB5.#>/M;!U!+J<=_P`2Q@#R"(AOOV#\(?LU2HSK,S$AA4(M\3?8%%!'
MV$,00\9M_=N(]H_:`Z@436Y/S/B;#YHE7+62Z3CK]2.9%O7_`-7V!A"#.+Q*
M+=>43ATW:I%'X1K=VB=84@,"1%2";;N+O#JC$Z+:/LNXJC*V2S2>2J)'0JSZ
MT0B,X_M$0UC%7E&;34A=(PC]PZ(V-)5-C6Y%601[O(S08.#*@4$3[:X*L4HF
M+_3*HO-%L-OK5?5JU55OED+,S+%@,!1D%WK1Q<9LCE9,8^K(N(YRFH^5[6Q1
M04`3AV&V@1EAM64\85IE;)*<R'2H6'Q[78NUWE](6.+:LJ96YPKU6(L%G<*.
M?%"Q$V2-749KKB1-RDB8R8F*&^JZ`%::EYWPE<6E=?5?+N-;&QN-K?4>H+15
MQ@GPV*^Q$(]LS^HPJ"3T7#^S1E;CEY%S'D*+I-@D*YDP2`##%9`K0R7(S`$7
M;(BDR>;\5,+A9'/I8*NO;W7F\M,.U+-,TLC=DW5?$%9PXN==D(E,G0RLFR7;
M$`RR9B!50"VB=:7ME7C)NN4V3LL#&W.WM9I_7*N^EF+2PVII5D&+FQ.8"(77
M(_F4JTUE6JC\S=,X-BN$S*=H&#<2L@?4FX6Y`X)AJM&7^5S-C!G09R`"SQ=N
M5NU?-6YNL&L$'5`FHF6(^.RDXT]ILT=&E61.<OS!\W0_G52%%XJD'3BMJ.8L
M2R%')EEGE''[K%SI=HW0R*E;H+]$^H>SS>ILV*EC]:$2U>FL[I*,%!14JI'Y
MRMS%!40+H@?3BK;QG;"V-HIRMD3+6/J2$?8/TF^/9+7#Q:C>PD@V-K-6G*;A
MT#E.6:U>5;2JJ`D[D(YPFX4[$3%.,)Y*,2:!;&+RIC!PYEB-<C45[^GW5+CK
M"BUM<$\&+=9-3C5,<L9`C=\IZ5?(1)EF,(!]OF8.4A;>3N#>.E2MY+6NLQEH
MKM1D[+!,;;=&L_(4^L/I5BVL-H8U=)BO9G,!#JK$?2R%;0E&QGID"'*U*NF*
MG:!R[TZI77DFQ-RBXW.X"USC;/>)7,3CQ]&1MYDV]X@'#6!?S3US%0C=^HW>
MJF.K*2+)9HS%,%`>.$%$D1.HF<I6J;2LC'D[QR4EJM6$L[8J<S^0X^O2E%AV
M-V@W[^SQMO=O(NL2T&W9NUSO6%B?L7#5HJ3<JZR*I"CW)'``+!&/)8H[D[QQ
M.QN<\CG;$[B$QNY9L+Z_;WB!<-JVZE9!Q#1+.3,D[./?-3+15FR%,#E=NT3H
MHB=4AB!`C'WKMH+*N,+`[Q^>!R51YHN5FLS*XQ/%VB&>FR+&5]H61L;NF$;N
MU#61*#8*@=]Z4%?2E-^;VZKU4(*YJE\D./N0WYU:%F[%EQ\<Y$02B==O%>E5
M@FK(K(HUZ$!!J^.H9[/KQ3I%D0H"#I1LH5(3&(8`>Q5CQ"V)\ZX7;Y,>8;6R
MQ0RY474:,RX\&R1PW$'LI$IV6-:N(,JIGC=P]@%2O"$.4IS-5"J`'88!&L/>
MJ!Q2B7SW@^O664QY8LP8XA+Y$5-W8)BHRUP@V$[%PD-#.+1(R+^/<O$UFJ<?
M5D3R2Y3@"J4:F9T8H(`*FLDU1B[\%9/Y1QI5&,])VC(-+KD95:_7[99Y&=LL
M1%,:[5K8]?1E6L<VZ>ND$(R$L<C&.6[%RL8B+I9!0B9C&((!HFJK%:29SMA2
MNW]MBF?RUCR$R8\<PC)K1):V1$?:%WUF*)JTQ+%.G*:X/K$`?U!`=E7@B`(E
M.(@`Q&.O!<K'<KN,<O$62?BL_P"))*"J"3):SS#&[0KJ-A4Y.3^21GJW:+@Z
M(J2<S_5&Q$Q.HX<?EIE,80#1&*[Q?+F*FN.T<NN,DT9+%;EBTDFV1C6>(_1C
MMD_>$C6*K2?*Z&/=J/9-0K5%),YEE79@0*05O@T3PXKCGO*#C?&LZ;(/L[XI
M;,LAH/G-$<&NL(8EM0BY9"`E5(,$G1SO?E4\Y38N@``,V>G!!4"*[DT1BMG;
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M"!-'Y*,>`JG,99?Q*E&R+D^4*`FWKV36>(9]<UN@B$A,MS+J&B(7&4H<ST"L
M;[)R-GCD6\2IVOEE'S<I$Q%9/N2J0RE?L6F9YIPU+5^ART3EW&LC#9'0LLEC
M^69W:NKQ=XCZG'/)>V2%5?DD!;3K*IQ,8X<R:K<QTV*"1SK"0"CL!H_%*N5K
M:YR&P)D$(5Y2LUXPLS2:M3''L,XBKM7W'S.[NX61L4?56"97H*N[#+5N'=2;
M-JF`JO&+=1=`%$BB?1ZHQ&H6\M>7,6UNIK9'L>1J7"4)&0<0JUND;!&MJ^C-
MLIQY6'T$60%?P+S3:S1[ED=JGWN/5HJ)=G>0P`)JZ@!T7$J\I^-3^R4ZH,L^
M8F?6B],(E[2*^TO$`[E;@RG/3?)Y*N-6KQ89AG+`]1\:J`G)NH0!$!$`T)=7
M:6T6QBN27'FP5BY6""SGBB6@<<%:.;[-L;W7'$36&<@Y<,XUS*OTY`4$6#]^
M@HBS<`)D'K@ITD#J*%$NCT90Q+Z)9#<@<$O:VYN;3,N,G-41@7-C5GD[G`C%
MLX-E/'JSJ<>N%'I"LVD?:R#&*>7L.G)AZ4Q07_+T"NTZ5=;?(V3<?8@JDA?<
MI7.OT*G1*C9-_9+*_)'QZ3AZMXV39,Q@,N[?/%?YI!(BBRFPB!=BF$(]71B2
MKHW+^*+A9&M2J>3*'9+0YJK"[-JS!6F$DYMQ4I=%D\C[4A',7BR[B%E6<FU<
MI."`9,[=T@J`^-5,QJ5""M&OR(P%"QUQ?2N;,5QS6BV!K5KD[>7JMHH4ZT/E
M'K5I#SZJD@4(N5>+QSI$B)]C^1HX#;=LL"8%5C[UV\=9JW*6):JQED@9"T-(
M2)M+N`83$>\F6=9G73YG!61U'-G"KM""FG<6Y39NS$!!T=LJ"1C=AMH-5&.J
M;)+E'QJFD[HM$Y_P^\:XSBYN<R&HGD"LIITJ(KD@>)LL]9C'D2$BXB%ETQ;/
M7:H@@U<;(J&*?8HTG@KMER6ZE\_X,IMOC\?6_,&-ZU=IQ.O*P]2G;?"QTT]&
MU/%V%1<I,73M,X)6.1;*-X\P[`^6**:/>8-M!H@!;1=%*WVDPQ[=\ZN-9C#T
M)M%R%Y^8S;!F:HLIXBRT(]L@+KD&(;31$%!:*+=A7'88$Q,)1`)Q48K*VR7C
MN8*DUB+]395V:\S>+UDXZQ1+Q9;)=4:2K^PT$I6[I05+C6X^$>JOXX`]6V(T
M5.H0I2&$*=&5(*2KY-QO#H/Y*8O].BXN)L4G3II[(6&+:LV%HB(=Q8)FJO5U
MG)$V]ACH!FJ]6:&$%TFR1E3%`A1'0(`5K*!F;%&96LC*XFR/3<D140JQ;/GU
M+G64ZQCQD&QWD:DNX9**)$,\:$%0@[B"A0$P"(:FM$8Z%7AG##;.[N<4O,J8
M];91:LW$@6B+VN&3M;9%"(&?=@K$F>`Z1>)UP@R/IC%]0#$HNNSP`*FKHC'7
M@D.-,RXFS.S?RN(LDTW)4=%*L$Y"1I4\RGV;-240.[C`6=,5%40]>V3,HB("
M(*$#N*(AUU==%6;5.Z^-^6'9V?&INZ%/V"Z*7J7?V=H%W$-N@F$=/O4&J2-5
M"IG^/JFH`IJ!_B&]^WO$AMC!]X:E=$+K$LF9)0Z9NHE-MO\`R@]I3!]QB]0U
M51HL6B(T1&B(WVZ_9H-55XW_`%+8QQ8,I838JKGCX)G6,C2-EE@:)./25V+2
MJLI(I1A5"'0>V!V5#TS-LJ)#G6=@J0%BH*(C]A_;/(&+V_N$XQ,\J4[,;8_W
MY;P'Y1'Q$Z,&+."ND>J(QEDV>H6M1$G]E#_L\5YUVL9(*PQR%#QM*DXW*<S$
MRUTC3R)7D#%0M"EHJ-KF/9BA6EF27CX]L_?5L\DLP!-=Y*!&.1,F191!/Z/A
M=`9\NRY$[T+V)"71)`C*4[P)N78W(';(@=01!<1B9Q#D.NN`SZ0S+('F(D>(
M&PL($:AZ$MX<U+NJ2A;X>OY$H;9&;7%Y&V&Q5WYD,S<*9:I,YF<LSE6RC).3
M50+8$5BQCP&P)N"F*4Q_*.Q>F9N/;[>+G:NY2Z,6,83$2+=RV*AI5`)BQF'=
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M7/PB[&!D2-P.TRE*,2"[&IW@Y&+&W*&+:D.YB+C<Q>/':6`%.8?DZUN0Y..Q
MW2)EE9H^!<VFSQSBMQ6.WCAN^64@KL59M9IVY0C)`55J\6N'7,Q:K$9*23HZ
M(@`-R*"'D]LLS[IF6X8DK@QK$A.5YMK3M5A&U(LTMS`D.(Q!XLO"O2EB0,[@
MCU;@($!RU)EX<A1RF.81RK>K5^YWYW$L'US8ML,38'EOU),K5MO$Q4]7;[&U
M6KL$X.`=4]:2J:3A=8B9GD"5H@()JNO*7WMZ[&]E7NW=J$IV<4G)B0-L1<),
M963.9W3$P+T@!\-PR-=J\:8E\O&[DL.IM@7K*@!$@.#>7^RJ[O%["UPDSQ4B
MG9V[1VP^HA\OF@"2B$HV:C4*_CEJ4T$9\JDZED4CE2,`QQ%?C%1,BJJ)#*G\
M;N-[#R;7>,B,9&$_3@,0Q>,M]S5G;_M>#@$LO+PQ*/R]N0TS@']T:_WKZH=?
ME\:+Z8C51&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&
MB)N;XL",MBXHN[<U]1D9-$$ZNGY&#T?T3=E?274?(3Q5$02\@FV-_M)-F&W7
M<.Q]A@9XG=#LQ);>W$O?+2C^IQANQJ%\BK-3\DWJ\#TOU;=%ON/88FYW&WO[
MT(MBA[<_T6:=F;4-B4W$U_4QQ@U7#C:ZXNZ+YTOJ`&9EYLYH.F>2/,I<)ZT*
M)P&.",8-#9>@=C"L<1E$G7E`ZGB(7Q+AV@8>@E']#^@A,^B<+<PL_P!=ES<G
MY>7#1F]XX+H'J`F/<;\N'RL:?]N-?<H;U"NKST*JX86II4KVNY3=M[8,C)U3
MY["2R4.QGH>PS<3-0HLY!$S5M+-I!TH)3N8])(X]H$4+VSN>3#%OB%VR<CMH
M#2M[1/9(/MG",HEXU-N40'`F2.2])9<G="0C=X2=G_W37720)I1BK[<-(N\?
M\WM<TM6LU,9"MI9#@8BO(QTQ9'LW!R"X2B;QA,OXY[9#3CIP59VVBXUXKYO,
MX:/Q3,X3X\3^J]MG\OBVA=[!/>;4I2)%J((\LHRC&6W:`T3*88,#%V4O"Q?@
M+TR1F!MPC'XO%P6)?7ZV*[)O7LJP;:5DC16.,3OI!RU&=G+=*OLN9@FGL<B9
MHHC.3[&4G%4XU0U=8.@09EC8L&[U5)%$P)`57PIY/9LJY&.[*S(1!:-J(Q\>
M(-?+$QBYCNE%Y;I;@YD'<>1.WDQ#RZ4&8$GS3+5YEAX!@RW9CY[5DFC:Q/L6
M'=^%RBWIMO@6E@KESC8-X0I)%U+M'TO&0<19W#$4H-BLHBSB$'"OI?3M$D15
M\>-OTW;QYSQH9C4)N6Y;)6R:L`0#(P?SFIF0!+=,EM2.9.8$S;$M`)#<"/MH
M>`H`-&";)2@PC*Q5*.RZT4Q=6(AJMVH1%M=WO'TY3ZK'.G]Q/0FCZ?F)2K(3
M;\JJ;:.]<N<Z!DA:D:M@%PA[6/<<F6->N=A/SN7-AYK0LWX7)R:!NM&`F8AB
M9B+.#N,CY3Q2M1-R,KY-NP!5ANBVAV5)#G0?<*KI&**UO0AG+F<3A\'0$3'_
M`*?H+%1>N?KQJU0@'TD5"H0]UE3&:V2Z#,O92;D'DR[,L"9U7"CANBDCXDXR
MP#*T+1EZBNW#U+T@)]$DSB#U#"/PV]@A"$8`5\H!).[DNI,O-L"`VB(+/0%B
M'XEW)_V/O]/54Z?*YFQ</D44&5+NJK1E%QZ;)@T?/%XQ9<K-DFFDW;LG9%G1
ME3@`"+@I0$QN[N-ZS]QB)>DNI$'S7[8)D7,FW`$DU<,&\."\CTVP[L(C3IR7
MT*J?SBG^6;_SAU^<!HOIRLU41HB-$2IKL3R.!`!\!=R![Q6/N5/;W_!U,/[-
M&0\DF$=QW]X]1_;[]1$J5_)031_CJ@5=7[BCOX2#_P`'XA#[PU44<LKX"<YC
MRSA&ZKW:U5&&Q3`Y;CY%.B76TT*U33B^GQL>)0),U=9J9Y`L`I3@SYFY5!-8
MQFX@0XICVSBJ[.H=Y>X79NR37K_C)E8L1QM#_7G+G+F.;.YD+F:VRENY/5#*
MT%'4^Z5E.K*0M=K=+ELPR2KJ68R4HYD&K)J5-B@HHOVQE01JI$,\?\CW&<VF
M;)^E\>5H>T8EC,(Y#IR63L@RZ49!1V1;#;G$U`.)#"#-K;596"LZZ*D8^1BV
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M+..4=`L9(4B&4!`#*,D)]-O+F*F>*B8NOF-7=<Q]0L2OF^.+&I:H*`99TJ6>
M>-^7<IS-9L<3`3SVO8]R\UP.9\HS&-568VB0</B)F3?N"(ON5W`FNJE"]XF3
M^1<)9NQQE$,8OY7D5R(IV;LC52,;S,ABN,KD)<\++6#'S-U)Q<9-6(++1,2'
M*^D%V##UT[*KK"@@D("!1V+IK\8\1.1&",FV#*U=OF-LT69.=R;4JLQRY)W*
MM._[&;93>.E9H;VT7&$K%T>O,MTQ'C\TCYQRG'G;VN+5*N==H[`Q3"%200W!
M<!`_3)N=#9U>4I.5:Q&6MCD'BZI>I8L%)(1N0\*X21P_-RU->P`>L0A9NKY(
MQLYE\?JF,]0A63M:-<&,W?NQ*8NFY^'-/-<.'.:K;EBO9H/R.>35VQ`\Q:EA
M]Q:JG0FC67@H2>GY3+:&3'%5Q[#+P;K)\/>Y.`.E5BQ[9:.C8I5Z5PLDH4#5
M4<`,`FKB>#^;XF)?0QSXB^0UXN-T:9CEEEG/S*+:2M$G["^5MN'<H!$CESB`
M",7,)DAJQ"O[C7(PX+MO&+54PGC*N/I]*KJ\9\1N1V,\JP>0I:Y5NX@[J6,*
M]9UXG.N5\9^B=4;(V9;4_1GZ=3<8)4S/JS>O9/9-1D9].&<6!W'N'#Y%`S]4
MQ:Q1P5SD/P;S?'5R5B#JX>&O0S7')*ACICE3/;:$+)4&Y2$X%RQ!D08S^USA
MT+-BX3^35V!D[?7XIT!DP2%KOY(R&0=;"'X,<B'LE0\CV+/D"&2L)/*J^P[%
MLXJ-E:ZN;^UBU9,R;#9#N;S'<5=961OM2LB=2DYZ'1B'UA;QY9*21.Z=*H@9
M0R`HU$VF+/I\\CL=M,=S+.TXQFY[$*6!XZ$@[7E[,-QA[FGAZ^3MH!=C.63'
M#I[@V(/"2ZZ#:N03"5C%G*I#KG*#1N8:S%EHR#^!4KL>8'SU7N0EYS1.&JI8
M#)=UJ5UGX*K<D<V,86L*1.$*!BR?C4\1!C..Q[DI9.7IPNFLE)+QBZS=5#RI
M)*-4P&'5UEPN+SCPTS3E+(N7WM-L6.Z74LK1MY<RTDC;,B*HV52W<=93"[./
MNN$)*&L6.D+]'2KAB8V0X"2AIXU?9)1ZK)P!3BL(XH"`/9]/H%R-F^G?.6"T
M+0I,P69+$-NJO'^(RBC;;//9BR%-.,"M\Y/F%;AAS(PO-61H<U<<G0\BHS<$
M,FF:&4%-$BJX*!2*K6[ZUK*UP%RZS<,;-<LU$N5I@+AQ;D%JTYLEX:8HS)6N
M-[.%KI7N9:BT;MDE<AS4=7F%A9OVJ;A!G;(]IYB.(U-1LK&4)'!6T'ACG6K8
M)A\/3YZ+;EJ8KC9]`2$WRAY,O6K]]CV<=ND'^/E&-0K\IQ;M*+-T5Q&2M;4F
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M$E,FTX<RC8<68/215JILJ8,RO7<KQT'=<DW_`"73[@XKS2ZUP8"RY6L520O[
MEVXKEU5>,99>$=*Q<TS:&].X11W&J4'L34S7'?D2Y>Y/M+-+C(YL_(G$$[AW
M)4&[9W.,IN-6#ZYY8L<3.U-5I5I&0R^J[BLN.RVIM*-ZP:SS+!!Z"S,BIT4S
M*N/&B:>#^F-?*[-MD662ZD]H;C-U#S^^C)EK-K3\WDO%&3:FK0;G,ORMO2&F
MU,$HRD9)=I3`I/M(=8BGA04.7%5-_P!;+@X3Z4M_0HE:Q_-Y6HJ-;Q[1[E3J
M"C&P<\\"HJY>PM:8'.JZ$<\(Q;R\)=L[2L?*':`HT%:N)N6AS$64`-:`5W!Z
M)_LB\)K_`,C\APV5,\NL;TUU'N<>1I:YA^>MDL[A(['-*Y&)5+*%;NT_4JF^
M:94KV4LTL96O$-'D;P+*%$HN7:CDY`$,64W`4"[!GQ9R\WXB8ZQ-:YG%^1\O
MTS+=HRS8K(UFLG87C9N3M.3,EW16PXUO>.SN;YA2\$+>RJ(/$&DLS3$'<<HW
M78NS*E'@CC<_!+H+B3D.9IF,*_D3),<X?U[CORUPO;K#6T#HS:DCR+FZ&_AI
M>NND82LLYZ0HL%5U6[Z7=LXUY.R122"J":[A<I!%4)'#P3=2_$K/-XF,17>Q
M.\"5JV\9JEC>M8PKU/<70]#R>>AY!HMR>.\F.'E2CY*AUU5I06Z=;B(]I8AK
M4JZ4?>H?>(B)S%G1QH'JD5_X6YHR7EF%Y`3UHQ)3,J4&/-8,>T2G(VV0PVKD
M..RH2YP2&7V+V)BU<O-GE4369N;(O',Y2-F9`96,8HO&#)8*U'5!`#<%(/E;
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MF_(43NX%ZZ01`3]A1JR"U/IXJ+E`X+YWP99,;RV-,FTW,+&MW2DY;M,)F)=7
M':\QF&.PUF/"^0K/%S6+\8S:?AOT7DF,DW3B18O)1=[!B+APH+@5$P"T9`BJ
MZK(O$#.-[)D&D.9;$4/2+KEO(?(8\\E-7.3M4=D&_<>+!B93'0U]6E1\._J$
M1=[">1+8O7I.W,,B5#Y2FY,*P1E`1KQ4@.,V.<U8BJE9I=UB8V;CV[B&C9ZP
MGY(98S4YBH>$H#]F:3B"95HM7=PY92V1,>V)$L3G0*@^5='4`S8"*W121'#5
M-/:.*^5YP;/CMI+8L0Q7.\FYKE0VOSA2RCEYM8).<<7A''RE<3KYZV**5L5+
M%&LA9KS?HS>.",%;\T3*N/L4H>..%1X]8<H>/%K=;[G)PM.IT2_DK9=;/=6K
M:4@*G#UR3_2:EK<+O(&M*N8TQVK%,$DR`;N["F';044)<I[VP]XF;F$-EP`"
M;^PJQ=_$;_A"/:/W#JII5)A`0'80V$!V$!]H"'N$/NT1*C_G($4_CH[(J#]J
M8B/A-^[J4?V!IP4T2315&B(T1'MZ#HB\6OJHJ.0N.%6[5P=L#R&OC!ZHHD+I
MLX:NE:8'RU>/-WE<LE4/,9SN'8<IB%V'8VOMG[2"!LYYN#<(RM2;Q`F7!YC@
MNA^K9$7K('&,G^L?7[%!N/:2M<^46BG2K(U7539M<F8K,N#F+?Q[@]?BK^Y:
MTN:G!JUIK=JJ82BKQL+8IH\Z"`>9(K5LX2[O?%K.A/!SK4_F]<?($?,"!*5J
M)N1AOA*$]L07:0<L3(@^FM&,&G"439'QPU!T!H2Q!^SZFY=O6J<XL<5,8<<V
M7(!92M1\JZIM>L3[&8M6:?K(C(3.=L![3*SB,,M)H.G*+8DR#QX4Y2-9!4Y3
MI(>7/+[E'%E8]0QM8T(73$79P%XR)#V3"`@([@&!)MB(_%`"IX9QMFZ^/NF)
M0?:/(W\P)=_MT-"Z<%G&YJJ:43&5L<-1+V&ATTHO%N,V3J*3E$HIF@R4"-O"
M4HB,?9WS6,*\1?)2:\H5-XJFFL#@A2+>KG+L.=;G++&=*W.=;]^0I(EW-L1^
M"+L8[1%P"8[2XY6RHEH&R+K?#&@\:\RW-SSX+$]@\L33:0:3;?#F5PA9D'3J
M#<,G.-[;$RL4LH]63QU<X&8KHL7*TI7&+)%:(?F0\SEPL"*J1`,LC<[)C2A.
MQ\]AQG#:)TO6Y1+!KUN49.-LI2:<78`."6%'S%PDD6;DXG0%I!M6(VU?E3PX
MKBX*'QU6)B8G,BO9!U=T+7`P47CRWLV5[DQO,BXF32CB8>DGZS"6-BP8*K@D
MY=>>*645**;*3[.Y/V65>[OGX\,;M<(_TTVS*5^T]L&T-H$8Q:4XR-"0`)4+
MSAHN*T+%JY*[E']1$L($/7B=:MH^G!BL\S#6)]!2%GRC94+=D&;.V<MHZ5D7
M=I1HP.E8BQVL7HO)*0AFUEF)WPL"L4&3?Y:A%(F["&*0B4P[^+')&-VJT<?M
MEORDB.R5V0>,1H)&,8>>4B3NE,AVUQD;I6M]\[\B1?5]HY\G>A'!EVN+W#-X
M7@^^DI"2>R"WU!2'2?HH-5"`Z_2V/"-C23IX;U"1G:`K)J>(3G\A"`)=E.[7
MC]S$X7/4$+$8](>GQ3D-]Q]K>-:^*\W#G*=O%,C7YP?_`"57U9:_+`T7TU&J
MB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$3<WU?PR
M^+2^MMK3U&1DT/'6$O*Q??\`ND7=7T5U-Y4O#4A\7E$^Q_\`:23,.WKN'8^P
MPWXG=#LQ)[>VDO>+2C^IQANQJ%[]=K4_)E>+T8]+]6W>GW'L,>KW&WO[T(MB
MA[=S]%FG9FU&W$IN)K^ICC!JN'&UUQ=T7SM_4#4E6G,K,;X(J+<QC?AI6ET'
M+^MUJQ^5Z7+U9;F070E47#ST"9G*?<F*:B0'4!0"@8F^OT'Z!A:N^C,.UNF+
MDN^2#"<XT^7F7!!`!\7!:BZ)WZ3=RNRIY<4</]X:J$]?K\/-L)2P6>RUFHL3
MOV191\A7ZP+-"=DU@CVL#"5^-:QZLLJY!\9R5BS!(B"2/J!%(J'D#N>;EY&-
M*.)B6[MV\Q,(F<C(PCYI3E,D@`,!ND7).T.2RZY9M#)!N$@1XD#2M`(\>-`*
M,^BZ6&C[*:OM+DQ_3S>HEDXAG4&2EJ)2LN2_ZJI:)I%"8?XZF75Y9^.$;IJ'
M:/SMDYARH45V;H@`HCX%^_B1RY8LA>/<)1)N$PZMB'3N4(%R/3+R<;X[C;B"
MTHFAYA'(C;ZT=O0=@'$92H79CN#>X%ZNL*\UB!['R<$RNDM590[1I$.J]EA@
M2DRK-@P+-@V4=N"DG8%A)NF\.JX=(B<IEFID?*0QE4@/NWC=[Q[T+T\>-ZTY
MENL$W8F1$:-29B#(`%FC-V(`*XYSL7`8VI2C*@`F-I;F^CTKX>*M9R^'"OG;
MY'(CEC%)1<K77J5L>+N;.Y;,E'35A)5>N)!,RDFRL+5IW1:R:I")OC&#HJJ1
M9;5ZUWN=CI'&$KQF)CI@;'+$B<CMB#`GS@ZCP!`W^F!+38$_BUIQ`%>'NXK9
MPX,;M(Q\7BMY)'+-/VB<9.Y4D'U;QW;)V$9/)6HEC:NN]D:+?(JP;I][Z?;*
M.8MPJ=,I$A!9PEX]R$^V6Y7>[`;HQ.Z..!<O6X3(C<,K@`N691KY+1VR%:T!
MYXM,QCCOU)T&_P`L20[/'X2_.2T,;!1]BD7+:2L,*RR,@U^8GJQX^I/J[9%%
MFC*>(ZI,ZQEK'7)XB\3<FASM6ZJB\HH)G!A46,8I/+NYDL6U&=JW.7:"0!<,
MI[X5,&N1(C./F@:R'ETI%GX>D+DS`RB+M*!B#1W!J..GU*3/T]9-T')R&A6+
M>O+1T?C^Y>GE&M7K;>;<LP=1*CA52?8Q;>47%-V^13!`ZBA?`/3M(F&W6_W%
ML?\`ZS+(N=07)9-MP9R,!Y6#1,B`X!JPKXE>?Z=F1W6-N&TP$)58.S<VK7QT
M7T'*B'D4'W>0^W^<.OSM'EQ7TQ6=Q?M_N#K3%%4![A`"[B(^P``1$?[FC%%<
M4ASF[2$,8W=V]H%$1[OY.VV^^H0U2B5KIG2201[3`82'<*!VCW"(;`80#;N$
MK=/M[_<03=?;J^Q18D$N]1+O`02-N<3"`@`II_$H(#_DA_#K)Y*K&JH*JIC"
M`]QQW`O7H7;X0#?W%(``'W!K1=GX(LR1_`@HON)5%#@BD(=!``[5%3AT^S8O
M3[1U-=-5#R0H`+IBX2+U`0*NF4.A3G'8IRA[DU!_@-^[5]NJJO4<`BH#?\22
M)?"J0.H*"(]RY@$/X_D_"/N[?LU&/!1OK54TRHF%R`^1!,GF3/L'QCOLF02^
MXY5-NX/NTXLGAQ6(BA%@\"IA[]S"@H.X[',/Q)G$?^+4,.^_N-]V^JRJR*`H
MV123V,FJ8_F4]H&(8NX)%WW]H!N;]^LN$U5Q")O#`L'P]HB9X7?8`*4`$ZQ`
MZ=%.H"`>PP_8.G@5-*+&5<3J*G$@G24#=4A0$0(EN`%,'\DR70`']WL'3<%6
M5ZH`W;]A3`?U0]Q3A[VZ8]`_Q3&4-L8/<)=7134JY$"/#)I&$06)L!3C_P`:
MB7J8@[`(^0A=^T?>'3W!J`H:::+`+K^LJ'#80_FU4-P'9,Q"B5)0`ZD'PB40
M]@AN`_9J$A5G"S+E(BW3\0B9-T<50,(=033#M(D?W=Y3F'?;H/0=4HLC;9<>
MXY3&6:$%3H&XK$3#M3*/^.0XE]OM+^S0%_:H:>Q)45MQ.FIN=-<0`X`&Y@/O
ML54G_I"B/[!#IHX5*S.3G0==I>@(E!,@B'PJ)@':8VWL$JAA-O\`>.CL5`'"
MO<%,1!L=$AR)&$Z^X_Q%3[;)]WVID(';OU$NCL@0L;=JDX3()!47,HIV[!VK
M$*!2G+L/0IS`80]FP[AI1.+*]94Q$VCHJ>Q%!6,J7VE,=0PIJ%$`]A%2D';?
MIO[/9IP3P2XBIDEW)0*;H1)VC[Q%(GB`Y=_?NF38?O+J%W1G"U$B0$7BP?Q5
M#>4@A[!*K\0;;>[<=:%=%0D7<7[?[@ZK%$%$#G%,OQ*`!1%,OQ'`#E[B=Q`W
M,'<7J&X=0ZZ,41W`'O\`L]P^_J']S1BBJ`]W0-QV`QAV`>A2E$QC#]A2E`1$
M?8`!OHQ14[B[$,`@)5"%43,'Q$43.'<10A@W*<ARCN`AN`AHQ1'<7[?[@Z,4
M1W%^W^X.C%%D12,X6223`3&,H4!V`?A+O\1S?84I=/A#G15;]\=104D4R#NH
M[,DD(=`!!L!`/U]@%,H'40]P:S$\>:@852<#`L\=?`/ITDW!!*`[")0W/VA[
M-U%52[[?9O\`9H.2G!TG0/YC.U%2F,F*/><I=MMTC`=)$G_`((?:!0$=-0G@
MJ-1,Z<+>3<"K)*>4P!T('P^,"AN`;E.4H%#WB&COHC+$58QW*(I$,/88A$D@
M]H$*/\W[?:(;]P^\1$1T=57O.Q`3-$]Q(4W>H8?^,,.YB>\?RR$-TZ[>_0D:
M*`<5><WC10=F*(JG)XT]P'8#I;@5P/V[I[=H>\0W]FC\4:K+$T*9QY6_7\PO
MD[]A'L,D(F$P[=1[BF$/O$0T'V*FBPJKAW$*GN0B)MDPVV'N`VXJ&^TYC!U^
MP.@:K%`/K2Q7L1$KKM'RN2@H@00'\HQOQJ"&P`(@??L#]^I7@I58&N[@BK8!
M`3&_.3[QV*!TP'R"81]@"D([C]NVJ0Q3QX+&JN0NR*(B":9@$#]0%53_`)4=
MNH!O^$/<'W[Z,3[%4I4!(1!ZH'Y2A`."8#U4<;]BJ8[;"!04`1,/V#]HZ:^*
MG@K$CJ+**)J@.[H"]HF`0V5`O>W$`$/PB7H'W#I4:I0+&8Q6I!3WV<*%V5Z#
M^2F/44ON4/\`QO>`=/MT8HK^WU9$5"_B+^0L;?X0!,HG(J8?;MX@V'[>W0TU
M5T5H.DRJID3`PMR=Q1*(;"L4Y3%5.</;W&+[`_B@'VZ,?<C?6J@@5%10RX"*
M21Q(4`Z>H/MN4A!';X1*.YA]P?M#4?ZDX>*R',HJBL58IBJ)F,LF!B"4.TNR
M:Z90$-P\0=H[>[;0%S11EK@.`"`@.P@("`AOT$.H#K3%5*G(E.)%R?A7(!A]
MNP+%W*J4-_\`&#?]^H::HJ-3E!44C&V(N443CUV#OV$AAV`0^%0`T:G@A6`P
M"03%,&PE$2F`?<(#L(?N'4XMQ16]Q?M_N#K3%$=Q?M_N#HQ14$0'H`]>FW\.
MII4IK1>,'U29%VQN^'"`RA5$)2MWYFHZF*U7986\:16I).EXZ8F&#UW#O4%)
M`NW@%(XG.F<INX.GVC]J;(NX^=(;_)*S\,Y0KYB`0"-PI5W#.ZZ/ZNG.W>LB
M.UY0GJ'I1_8O/4U6K<.T@5%K&W7LU@30;U.GQL'6I!Y)D?JQ]:AIJ>(#J*C8
M2N2+VS-CKDD3@C+(E,8P`G^:7Z-'.R,B_=C&W(8MH_FW#.0C';$RG"#N93`B
M?A%#05HNL1LCIQE,QZI^&/$U#$\`*\?%=.Y2DJT1F[R(F>7+*PU>NC^/P9/#
M8VL4ZD$7C&G+S=-A9HN,)M&0AE47,A85UG,@T(J80>N`%5)'U\)6,XFSVO=#
M;=G:!RHF!F`=US;=E'K0:3B-H",),VT4)YIQE"0%YAO`D]L[F+,'`\I<5,M?
M%UI7T_AA9&+GHW([F?A8%H_?LF<2NZC+]+/7!GBK5LQ@9!-K(R!7Q4/4%7*Y
M.5.',`'\B:R2*GEVL;OMN$L:>)&%VX0"9`2M"-*[P\8L2Q!#F6FA*XY?*=0$
MS)@`7;XB?$&O.JS)3^&Z_'G1<Y&-.)MYA])5^(JP&M5LG!=MISP,Y0A"MX^-
M<R"42LD+-X\4\DJ)05,LHHFHIF_C=YS+L;D,80!@!.5P[+<6VU!U(#@[XBD=
M&`(6H?*["#+\3#;4D<-*/X$^U;!&(LTFR=R-4)$E@H-6J5UW!Y2L+20R*VJ$
MI.NY!C(Q=<R3.-XRI2KF30(BZKT"Z1;+J&*8B+XY0.CP_,8%B<+&?U.O.4Y1
MG8B8V3=$1'89VXDW8\KMV)(J-T1KL6I3B3;,*`!I%Y;7)H):>,8E<:K!U-W4
M4[/7+4TFF`&BQDFTM!0J5FKSU:+1F(:*L#.23?2@KNV\J*!I'N,C)*MS)[[M
M_"3V4<K,^=.'E6C;R6F`TB8W(OME.!!$:&/PT,07X@G@N6;<+8NVY#IDAQ6A
M%=I]O/0MX)Y\8R-@F"\+Y`8&M'3_`/H@2R<C\@IU8AFK$JE8QDZ<.D$8U@P3
MCU$5$D_&Z;ID470\B?4I"[>H[E8L8Q[Y9G.Z_P#IT&+SD23ONAB3*3ZZ$ZU7
MLL*1NVL4R$1,9M&``TCR7U,:_+\=%]*1JHC1$:(C1$:(C1$:(C1$:(C1$:(C
M1$:(C1$:(C1$:(C1$:(C1$:(C1$W-]7\,OBTOK;:T]1D9-#QUA+RL7^])NZO
MHKH;RI^&I#XO*)]C_P"T4F8=O7<.Q]AAOQ.Z'9B3V]M)>\6E']3C#=C4+WZ[
M6I^3*\7HQZ7ZMN]/N/88]7N-O?WH1;%#V[GZ+-.S-J-N)3>37]3#&#5<.-KK
MB[HOG*^H*YB&7-C,[Y47IWS?A=5BNVR+-(C<T8IEN!(H\-*"JN_%5NFJH`M6
MS)T9P0>P"*J&*D;]#^@1>GZ)P[<6$)=\DQ<ON^7E3;0-XF0;71="[\`.Y7GX
MXP]WFB%%=C7JBT_7(V6;5DJ#`1D);Z+2:C\_3D;5&VYS&00V)ZG6I2L,VBD/
M`5N?B5W4A+/!:2CCM,8I62R8=CNYF;/Y<84!#N=ZY.U>NW-FVV;8)V`S$S64
MK4XB,!NB*5D%Z2%FS$S-\R^6B(RB`#5R.7@[DEP=-%MJ_3E<XHN;Q=Y8])Q-
M6Y)G`UNIU6&<H@D<8895Y3<<1[@L7%MG[.(EV2DF_<&74*J#;U8OG@"4,9&>
M?3NWMG;H"_WF\#*Y<G+CN87+Q\Q(D8R$(#:"-VW9$UY8P^<'S-^6W%$A$`!]
M.$=.#;B79^:>R7Q3;QIR5KQU7YK*V-8QP1&>H^0BP=GNM17;-XI[!J8WGI*J
MEM;VJC7*\J55FH>2",7-XP;&1,*J/7K?=\6&=+$[E=CA]UD_3NV=T+5US+=&
M[`3V"8D?B&S<`Y.ZB\R>)>N8PNXPE=QA2<2091`T,3M=B-=6Y+5UC'6>[G<(
M2'K6!*M3;21E'R3&VV^MG"M5VNN&:+R%E04OE<$B1'AXHH0\:B5V@P:)D;-H
MQ,J"P)\F5W3T]V_&-S)[E>OXDC(&U"?GG*NZ)Z4^)/GD6,CYC,D@K./BY^1?
M`A8$2WQ&+`#4%I#P\?`+56C`58M<JT0I5\R&&3891DA7YC):@O@NQF+=9&FI
M1Q8I"%0H-@.Y33"/9MFAXUHB5)MND=`JYO)PO46;A63+,QL7^E7!YX61M-H%
MC<<'<;L6K.4I"9K*H++-_&M79[;=R8S0?*95$@-&TVD\!4:!-'6K'"7QK*'M
M+M]2<ET:KO91+*"32V1!7#ZIKP_R%+(3V#E(I-M8J^PC'<*\D)")=K+A\H<N
MW2AV;@^O:96+?[7*V<#9?[+E78QZ&Z$B!<!W&UN!)@21,",PQZ@``D`N#?#(
MWF8-O(A`^>M69A)C\7!V)T=23X&I)1G)O'[5R5JE=)?%]KL5P2ATV[=A"FF-
MG<$U702:1"!I!Q`'26632036:I.VOG:)^8%Q]!Z\E\QZ:R+EMQ@V\JW"WN=Y
M[7$B"\J"0(#DB3%I49>7V$"/=+<?_$E:D=-`>?N;ZU]`ZOXC_P#K#_\`G&U^
M>8?%[E]*6'7*B\\OJ8TC.F9N/45QQP10WMQ>\B<E53'N694UTD<95VG<?XPS
MF\9>-8LFPT/9)NBFR+7JP%/8/6,9(O"/)\#IH_`8Y<R<A@M18%SP7A[E?A-]
M0[D+3,?0%\PC"3.4N,G`C/''IW)9)A7MYKN5;?0<[UB(Q]8^/>1BW&AHUS.>
M0L!M@F*G<)6-6;A--U4G[)N0ZIDN,NMB41["5-&@83G8ODTC<<Q<-^6^=L@2
MV6.+]SXQ<DY>W+UA_@CC93,'8P@;%5LK7)G=V*U.O-'N<%:G-TI(1RY,ARTR
M``5ZDZ$[9'7Q62:,"&9=9]/>@<]\;<PKKGSD%A^8K^-/J!1M_NN0V"&2I&\2
MF";[0K4]G>.T3D2AOJ[$1&'2)<>Y0M*>-X:2GD'D[$MUG"J*BNQAU=)&)##4
M*,*F.OJ+14'R/Q-4\<<@IVC6;)?,.]SE*R1CW%LKBTZ-HYV4B\<<YOC_`#BS
M5>VVRP6C'DA:)*<8RKMTV8QJ**@-V0I,//:L0J\2W.GW+K^1?(;ZIF':QR/O
MTS(YHJ+2LR-NC[(_FL8X-'%=+D;%S;P_0.+33AE,K1AY3)SF_P#'*S2P68EI
M5D44951$SE1@[[4`@)"`0/T\.*PS%3^J7.6&9SY45N2L;=L4X"Y;1>`9:UT7
M$+3).6:^GRHX^3F#,;\A*(-94J#2QW"FQ-A751C(Z$EG4$P;K'79KG5(J+ZI
MY&:C$IP+;=OJX6;,V?H>D1G(C'N.+'=J]7Z-)35%PY9_[-(YGS;QG3)VQXTF
M5<>1,!*0,IQ&FIJP(E=?J5%-LB51P\4E6SI!-N(0;&JS_P!R59/BOJ[12N7U
M,?Y9Y'OV<(7G<&,(]/'7'61)8$\(1>))'A2=5RYQB#Y\XSY8GUD3E50.C\X9
M(F;(EC@3*J8Y=^*@V$U9_HZ=C'G(#F_0.8.8+;R`Q]R'3XBLXB]5]A6W%(H5
MBBHZ\GS-A.B84EL5RM8K-/?O(*YU6Y3$F=H,K87!&2"@/G(2;?TA;N*>7:P;
M<NZYFT7E^YYH1.0^-S+(4%&R^`>/6&93)5/B:S865?C9WGQ1GF:4F,7<V\O6
MOU!!<?EY65,Y<1ZYD&20J$[SE*F.64CM$:_2B:?&%K^IK%9*PO`9@_[5+JF1
MM@L]9AK#CC&''>62R2XK_,3*-7=S?,&2LL3$M:;3)#B*PJ<O&R%>"!.^.\?N
M6Q5I0&[$U))5.T\OH.'O4X^3KK*>1,9<<\F8CJ^>*A,Q&:XNZ35!80C".R##
ML5L59@KL)'Y+J`*SZ+BKM\@3$&:0;E6630;J^H5,4B(J)/%9'(\E$&?L/U'*
MO8,:5Z`6Y"7%>+Q_2U+K/66K8YDJ]8I^XX7R)/7>0!I5<60-8AG=&S*ZAXA%
MLO.A*-C,T")1JD<9R]<&>BHVZT2^XO/J,X_BH]"(G,^9%-&3])FFQT*1CLEA
MO4E/87QS-V:EKW&N8[G(:EP$/E7YX@R"4K1Z^!EE6DE+QR#=BL:,WM1XGDN8
MJ-'YS8ER=%PF.V5\C*5?,\9)R18)%_48:WJW:QW'F;D)O;%<M2L+5FZ+6JDX
MNLZXO`.I.7ABHM72RK)RZ=-6D<E2%7CQ^E%U!9WZAD`[XW,5W'(*V2DI'X"M
M69G4S6:`O43+7C+H0^?J*\BZ=BADQK[+&&+4?.0LC/Q[Q%-RFO&)R;L'2B(5
M4\M31,Y3ZGS^K^&\-1F-JOFV:M&%,95YU5VF>JU3X"0J7(9EQ*Y2TRT0%?28
M-H9M:<31LW*4IM&+R9Y)FXL#HA2O5P.\\$T6GBZG'C^9YE*\2<US*R]VFLPQ
M]R5'$:]AHK"$RL;&!0Q^-J?QU<N4#4$+/=HM%6TJ5SYU`Q8.GJ3-NHV<MBI.
M73Q6"SMP3-L'?/Z6DYF3@[)GQ*B4B1KTEAZ/NE%QM$7+*]??\@ZO#S#7.,4\
MIS2;;O6F*UYTZ;1(D$^^2$92#DA)$!'5*UY6==_RJQ%FJ]<N:D>G2^=X2@OT
MN*2AK-1C0JU)I/\`9SE3/KK)TN@I-PDM%P=R1KEN@>X[M)<7;%XH=-)4S0HM
MJU%F+"/!ZK@,.VCZDRV;\*1N54K:QHI&./XZTHO*#&+5JT4I*HV]+)=ER%+0
MT$PK]6R<XN[%DLCXI9BNF`L_01#EJZ>B6!:.T@MJK\L->9E(S=RAD..<;F5Y
M-76_.K-6XN>J5)><>I7';3A;28-O:JQ8YYB#E3,C7.]78,(R*7DT&[A=%8B[
M(8]5R\*]B!BS\/[4AG+=SQ3=68E-7Y2O:`U:7Y7C).3F+\>)Y9N^448/$2E+
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M4"V<F<N#1Y"MD3%`Y2:-]2KAQR`3;.:]SWQ93CM\3O,P24!=[1F:VVV*L=>K
M<A+8KKDGSF5D8Y;&3"$I$E=$K7:./MQD9-1FHWGGRC9(SAFU([;HMQ5"4)K]
M**1%PKF>K[Q!P,.8:M;LG3,5EJF6GDAC:(KJ$%><I8.A;7<2)0$E16[I@2>E
M$(Y>LS4]``5JM8&\6[;'CR+.31>A<A2CT323PY\J+`[7BQA+/F`<6OD<IV##
ME!@:?77J%GSNO9*&G5C9@H%M;SBO';CA;V@R[@D*3]/MT$@?/G!F+U=B@>5X
M:*T.K.N2FKOS:@;W6:<>_<@)7*ESHV<<H5C'D31,6OZ-&V.#Y205!Q/`Y`>)
MTE"0J^#!Q"J51VZ<O2+N4G3EXL]*^!DD-<J^7P;^Y=I!.>?UKM-9K+ZP9ZJ$
M?/7:LLL_6-6C8PBHK'3X<GV-.28<:IJ2J4@WG,4O,8-D_5RRZ4T+8@QJQ7*<
MFN_2+'-5/*WBFUCEN>E_MC1_>X+DS%4*O93P=?!A"PE?&;BY=+(.9:I=:D<\
M7CJH,;/1F%8E:NZEF46A+P7HB@[;23TQ'JP9),@KY1IJMNUFOJ0QM!9P==C\
MR5O)[.@(P(UMCC3&">%J;CQO@>HITJ=Q\]5KYFS_`#BWS$)D'T*JZ=-T$?F:
M2\>E'-XY88-%&B_@II+0W(<,(Y2I4S^JLB6NO\J*E&X[E[K`TV0L]NPDTS;A
MV;6L<HWCH2)K<NE!55S/%1?`Q0<I-HTJH`+I$JQK59H[\&27BR?E7#IS*^>[
M-?[(E-<<J!?UU;Y"4B*1IN=7LUEMED.F5X*=7X06T5%UB,K;A1B[!\*)C@L5
M<3N%@&:%N"I;@H`5W+/U$KEA;$EQQW-9^G*-<Z/A:V9#OMMQC66N6B9(L.%L
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ME<;./]!?HERT]2H]:XX8S:8FY`U^A5>P7G/.2T,B8GL&-L6KMHUA*6:A8[F+
M#1[2"Z;A\=RA#OTTGCDZL@DB!*M)%2XYVP/)-]A9KC*GS&;KHTF.-F<Z;:;)
M@VHTV9N^0>0KBD5.O8R:75E)0Z[2K8PO(N+,Y?.&!8UJV?\`I2*.V9"H>07"
MD6=_%-_;G_+J]3-0Q/(TK,#6"IV:)"8OEM)4(2*J;FMUGG;QTLN")"FV_9,M
MH;U3C6VGWSDR`*(^)HX3E`4>)^+4)JGE][?P3J\?LH<E+]QKY!Y4FE'UZN-3
MB[KB_#<=0B40YLH6W`T)/4F?S%0I!PQ>51\XSQEAHZ=Q3=VFYBVK-BU(#80,
MLFIK<60LX'T^@4<X?*OU$:]1\F!(U'/=O47K_(*!P:X2QG&35G4O#ZB<:9W"
M4S9QGJ;CV;95QC:761&R,C/0D.AW-Q;/&X&"/*ID%J\4\KC1(ZUBKF#3,DY!
MR%3Y7D(6=J-KL;*)C[0TJDK6,F0]G^H9>+4XA5W$O77+J6QZPXX7$DDT/%*L
MEVB+A4`7!5BBW0$E5XD-3Z!=_0S\][I<L:UR<LW(2IUV=L6-3<B;1*T?%<&[
MIEZ3C,U2&3ZM@R1<U!^R?X&7?1%8;)RX(2HD1<LO2OS.G4CXJ"=%/*U&371,
M_P`^(RG.(*@0?(FDWFB\7ZC$1=%F,3TX<.W;-,E3:N_N3^I23&B*P=*C<20*
M4BE#1ZTJ)[)>''I_2D8,D49*$U5.UW+)!;&7.V_4>-JM\#D)-U^0M%(>8Y"G
M8UAHR2M",%RAJ<I96W(]>RUR$N%?AH+$T4FZA7Z[.J.Y%GZPRK=60303<-Q0
M;1R4R.5%NY:!R4Q?#85B,JH8T;2N#B6:5KD7!RV/YNN6G,$A!9O7D3*T.5/&
MRM)Q?XGJBTI8(TZ`J-UXA@]4(\.2<%F+`5U4(<(UKE_C",JS*?=<X(^L2..N
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MS@@'';J`*%,)%=Q^T3EW_?K(^(*>"1:Y41HBJ'00'[]0Z(-5X[?4H9QDUDS"
M]:DU4$U9JLY'0KBL@LG\K-;RM:R>OQKQNY\C5$9-\4J!'"H)-_4K-D3BN94J
M`_7_`-L9WL?!SLNV";5N=GJ`4EL>6X@BM!4@.=HD:,ZZ5ZG@+N58@[2VS;VT
M8>\KSM3G("F5FGWN460NV49U&6!G).XZ?E*;C"2KKB%B8,AF4PJSIKF4Q\WB
M7JB+(M<<MTI0\4F<B?R]8I?HUS&RNZY=_MMA['9+9B9`&(N7HS$I$N'F(W'#
MGJ`F(F1\876S.W:M0OP&_,8L[D19@'>CBM&(=N13DT_"T;&N8.YY1M=\6R+8
MF$+/0T13Y:9KEQK*C]FLO7IBSW!\5W*-IP*R=MZ%`K-4R)P3.[5,4@-M>OS.
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MX6$_@G<.[=KM7K>#8O\`]0[F:@792N6+4&+RG$3VW)`$-&1E$D.0`RS8Q<DV
MSE7K9Q\44\H$93)T`<.`^I#)J+1C8,;MWF6\+6>7"$CW<,VME8L#)60EH*,F
MI!:'/^H5ETIF*M6.92>DT&YBO6@%06]-ZQ%4H%<![_&[H.ZMV/OUJWND";=V
M!VPD8@2:$1M-NX(Q<",J^;:1HO$-D6)')Q)%W&X$5B]'.HE$FCG1ZNN:=M:Y
M::_7;!C-1O17MXMZE<FL<3H6=I5'4(W;Q-W6EH(+'*6ZNC!4DT19%S"4L<XC
MX]XW$10,Q7,'/:GD8&5=P^[_`*BWC6!<A>AM,Q*ML0EM$)"5Q[0/QB4HRUWA
M)1L7HCH/&4Y-*-1'1R1J"`=U:,-%W%"&J.ISA\6,-($@HOZB*;2K+C'(N0E2
M(5W'B;$JQE'R#Z";)E%0_:**PG43*8IG"*A71_&RXYD;7>_F-IOR].`S&YMO
MGN'D1(T'$:U8AES8&P?+QA6`SF!\&BOJH#7Y<&C+Z:JZJ(T1&B+S2^HKRKLW
M&AEC(M/R1^A)6Q1F5+;,M?[%:EEH7]&Q?#UR5ML^#B\\B>.D'#A46\XBH+!F
M^F)V:]5VL(]7TRYBEN(=;*IY&S5@CAO5[9E_(ZN5<K7'*TJ6$OU5Q'/W;Y[6
M<TYVL$GB@S+#7ZRHMHCVT/BVRQ:"D&A*NGT.1J9LB,FJ@0KDHP,J:+J<,\A5
M'E/Y+VR<SG`YLC<91:.28V>I6+8NN0%=ITECM:R(1$&2/RI:S6P$7]>D#G8R
M[^(GF+GO;N@3;*,G!B$5`9:'CWR&L>1<R5:+G\VQE@);L56!ZZPJA@(<862A
MVRK2E;?/E;V64S/D*[5&R$B+6F0J+EFI7IED9!Q'OCB!#NR$!ERQ^5DU8<I1
M+5MG&.I,'!<E7&,U\6RO'DC&X9&K`9"M&$P<P=FFL[N@N-&#(;'TRE@K$2I(
M13YLDM)1K9EZI+17;3W+=\F>2U@K=WR9C&LYG880=U#'D%/L[38L%,+C'R5J
MF(^T6)G6:GD"S9QH>/%+LYA:N=9*!G&+('C<%!;.7(@OZ0H!Q3BYGY+A2H[`
M8Q=Y95%MEVN2UN>Y"G\'V2ZTN!JL-#U!PYM%WC6F4J'.XLKQI*ZQR:KQY\R;
M1XN@!^=JBDJZ`@&JYJ%Y%3M;XA(9(=9!D<KW.,R`WQ,%Y@\)L)A[9;2]S0WQ
M6Q488MI>6T(6V$!P^23]1!V<R3XA1<MDCK#Z`2-YF6WP/F><N[7D)X^0N/\`
M*:\#`UB\4^RM<;M*%CO'T5:J=,),V\H[:9,O$R]C6%FI[Y>6CYP\58899-RF
MLGZ19B<I"-%"?Z=&3LR9DNV-;7"<I;+F^*8XWM@<W:M?[)5Y2`K>7GB\<RQG
M(<>Z['83Q98(VBVN9B[`[822"AJ^I"LSLCIKR:(JH1:D`!HQX*?O/F,^;<2L
MMMO[86.!P;I4N6/DR6M5SHT-&IP.1:C.*UR=N>.Y6%O=6@,AIQXUU^_B'*<@
MU9RJBB`'.4$S58CJH'_36O53F;IS%-!9IKMXCX3'N#)1WC_'_(GD]R@QCC5N
MY3SH4T^SS)R`50O*MXOAHE7YM%0D.Q:QD?$1BA#NW3DXI1:F]$QWTE\<YVMV
M:+'R*O%QNUBQ\\JW;3HEUFCF]&8HBZI=FRTA3W^/,/<C#6,N2I1_'L@-(V*Q
M3JCUF19(6;!EY12+5J9#-Q]RZ2"9QU\^JNYIB^0[)*5\URR9;9>I..1%HIPM
MI+&T7"O84*'4,?\`-:SN[2SC+<0J$M"R>/(&.4:I/?,F'HW*"D4_`L_U5IV:
ME>06)J;3+)+5EW7FF%9_)MDC\Z<W<8UJ"IM]R[9J)3ZGDYIQS61H=;K&9;>F
MI#-;'XW=B:K-U?*5!D@BMJI#3_8I/\W$AK-`X64"XVS("$:[R)#UO(>`,*3?
M)2UW[/T-7L.6H]@KM2R'BE5#.,JWQH\9$LYWLXZ9LIQ.+*2:<%47*!BD>)3_
M`'`.)ND-@V7;7"4RHY9+9<RH\QW7<R0V38Z\X]Q4XM+DV/Z`_ELR.'>3+@A`
M0($$DI*JJG,98S9!11HV0.8I+53;T64:(FXOKGP2^+2?,+8Q]5D=-MXJRAYF
M,G_[I%W7^7W,WF2]/4Q\'F$^Q_\`:*+0O;\7<7L?8;?4Q.Z'IXES;VXE[Q:4
M/U.,-^/0O?KM:GY,KQ>C'I?JV]T>X]ACUNX6NIWH1;&CNA=_19LNGF'<-N)Y
M=YDTOU$,<;:N''UUQ=T7SL_4"1>%YE9G>+PI#PJ?#>IIJ6#Y8N?L='R[7BA"
MJ3:BY63,5]RJ$0[#'4$>X`$=MOT-^WQMR]&X<!/\[^MS\KT;Y:?FV\6YZ!=#
M[_*/]1O;M!BC[9Q4%HZQO'E9K+F+2:/1QG>V9I^(>*B6NRN.\DH$KMGBY]JT
M6BSR$/ZA0[;L=2#5NW-,++(=[DP&#NV1A6[>3?MS:/S>*>G)GE&_9&Z$XDN1
M(@.2(DG8`6C1=?MW#;MC:/+";_\`8E0CV<->*D[01-*V-UQUBUU7%LA5'B6(
M'L@QCJ_!7?&DO<7SAL@W@X[YBSB;CCZ'=K%5405<A)?*ED?3G71.N?I_<)3A
MB1]370?D+T1\Q$$SG9OQ@`29%C*%T@,"PAO!!`("]I$&]/Y*RYN1D]LF@E$F
MKC@1J35V;5:1_?<F\@K$CA;$&2+94L9*S`T^"E\0KMH2W7^3@)E>OVF]7*VJ
MIL$8N"5D&I649#,UBE39JIOGQN]4B8^39P.T^F\4=[[YC6K_`'2,.K.&0#*W
M:%P;K5JW`.938O*Y(?$\(L`2DLF_D9`[?B2ET]S>2F\C4R(_#R#^)719&XR9
MOX<C!Y%I>>,Z,4'4:U9.2RUS89.IJ\Y\@?G";MU0=.W2<S#R4DW046:$3$IV
M[E8C0X&3(.O'[9ZI[#ZS,NV=R[?V[J[B1MMFS<V;AY;<X@;9QB_F)X/(:KR,
MK$SNT;<B%R>P@.7<.1Q#LS^"6ADB*LU$E<]64T1!15?/8:#E2MTU]Y%(3+];
M:,5VM1I+R0C/5+-;TN]0<H.'1'#F,:E<^I;&]$LL'CGM>3A]S'8L,SN9%W;=
MQ[ER+;L:;@W+@!9[8!!%!([=I\P!X)SA>M_/W1MM1+3`U$PS`/PEJ#5J\DQ,
M^>5G9^C624:$8KW>TV/-&66Z+%K"S4)CV@Q;68QQ09I\B_FU;-$L:K)O#/AE
MX\$G[^6,1TN"94P3[#B"S:LY.'9F)V\:U#%QR291E>O2(O78Q+"!,@!$0D-L
M8>4.2_@WYB9MW"&,Y2G(<HQK$'7AJXXU3Y<`9]*R<LV<RY1\LA,5O($LN.R8
M**K/BQ[EZ=8Z)_&":*CU/;83%`HH@`["3?UO[@8<L+T><>-+5N[9B!PIN%!P
M=J^+\5Y7I^YU.["\:SE&?]O\5]"BZAO,J7?H!S#[`]HCO_AU^;A0/Q7U`BBQ
M]YOM_N!J[BLIL<@Y3C\>SN*H%]%/I)?*]SL5,C'#-=HBC#NJYBC(F6G4A(E<
M"!UV:L3CERU`J7QD6<$.;\LA]-Q5`=0=;?4[J[*A*Y;F,'WAABUZ:!JT'9VU
MPI4I-2^2K7QHJ_*.$I9*HFJU4C8MW2[&,6>=<NR-6\J@)U4B,3@[+DEU3&K!
M;.S_`%#'E/LEOIEAX\V9*U8B0F93.C.-R739"(H4!#RV&6_S.KS)XYF?([N4
M@,YQ$FV9E;1*I2MWC9<R"Z:`.0+*[0>*??/O+*/P+E>B8OG,?S;^$LT,R?NL
MEK2Z$%3XZ9G9F8AH6HM9!Y$NH5S<)!Y$D%./D9&%</DG2)(HLHZ!9JD-=5D!
MZIHG?U!X8).BQE8PW:;3)V^C8XR>X0/<:K!M:Y3[QA*Z9[D7<DY<INSNWU6J
M5&<-A;()&-(2#A`J8IH"HLG=Q94QI1-T3ZFD!*.FL3;.-F16S<:?2[I<D4E4
M+TPJ!\CT"<R]C)A*R$947%'<"[J,.Q7E'*TJU^2R$DD1NG($;.'*>06+J[>1
M2FU?49MQ,<Y#:U+CS+1^<(/%5ZR_'U*QY&I;RN1F/ZQ@JFYFC[A*65!-BQEI
M5/\`M+B&#BN(^,QW9'`A(`T3*\-225!$/K1$=]3Z,5)/M(S!.2+@M%NE*5#3
M$>FXKE:ON38'(V-\06B!&8LM?8U2GQ1[]D+>*=?.)19=G&.3.$&B@MTUX=:*
MF+<5)3/?*Y?!KIBSE,5R]FDH3"-HY!Y98PUQKT>ACC%F/'U<A;NYAW\RU;)Y
M%M$9)3BGI(YN5@F]19*'.Y;J*M45YKJL@./%TVE.Y.9\'CS8\QR]1I$[993F
MBA@RE4].5&%AZ_B^3Y>Q7&=!PI8$&R[Z4LQ(<KJ0%5PW3$9%4IO$5N0$!TA`
M=O!,S0_J)W=U5\=ER-B64C;K8F,1<V2-(=5:>;92H\DCR%;MD8&)?S<4./[!
M)2^$2D;(NGC\1)(-A,<ACN4VT"UMY)^I/FP[GN(V3>0=:I497KSCR>9T-[2[
MA,R+J-J-NGIZC0326R4W5A*3=:S%51ID%I,3<?)Q<+*$CFRIR`5NJW>J5W'B
MH(M*NA7/Y`Y77SB;,A0LJ6"J\G,DV>=;)T*N8IILSC^[1,.VH5SO%F6RE4:V
M&6#1$2NA1W/Z6>M6V\F90R3L$4V:\B,%$V[A31-;?/J,7%9H:T8\P=*0V+&:
MF5&4W>;Y/1"=W0=T'AM8.5"I83%)!0.E(0>T<Q=-Y:2;E=.$G;<HHE%)V-W$
M:*B(XZ_0)3C_`)UY8/?[/2;Q1V-FL=QRS?<>X%QW7'L#7HE-&KY@N>,(M:VY
M.?.'[ADHYAL<2TO)&/$KB!P(BS35.HBAJ.U4,0`XT6;*_P!2UY0&]XC*QADC
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MF!`J5AAOJ+3#!W=);,6)7]2B'4=4E<6UV%G(6PV!:XV_"$%EVC8=GIUHNG$R
MM_RZB^=HP1FJ0,VSMH9FH=41364"138VFB?[D)S3A,$Y8IF('V,KY>)N9J%=
MO]I<TZ-F)@E$I]@O3'&35\D6(KDRWG9`+&=TNNW=+P[8K"/44*Z,X40;*UPR
MS$.'";&L_4+<W"7J-/:<?+*VMN4SUA3",,^R13R1]TBI>:R[%2,U8Y]LT=-\
M?_*H_"<N_*V,E)JOF[AFFGVNCK((0%@KMHZ;^@_4]=AABL96R1B"6=L8FM0D
M3D.TU2PUAB1IFV:P`^Y#M<>5RE.7[YZ_K:]/1:L33H2)FJ4N]+V)*L4G+Q*:
M)LY+MK=]2Z/QD-FCLRX!M]`=0U(:V)@P);(^QO+G;IF)J,U%4_'SQA7VU<NQ
MC?K)HWD#1;]W*Q#MN[5=19(Y-%^X`E3:>"X2W?43MDA4IH,<8,GH:]4R5H:>
M3R9$>G@X:B0=NY!P>%64Q7HJU0M+M>2F=B1-)/&QP8PJK-)`OE2.Z,FS4UN+
M+6T:G13(Y?6C)F../^9<CXFML#4;9B>@Y`R0V4M-&3OT1/MJ+3[!8$ZR\BSV
M*KJ1Z<N\8(`=\DN=5%,I@*F83[EID660SU457O+;,>'\A6.AY2B(K*-6B:MQ
MT!;+M2B8/'CNOW?D.KEUO7VSG&KN?GSV6);R50BFRW@?M!:I*'7$S@3J)HS<
M=%6!#^U.IQNYE-<YWV*QA(T::ILM(8P@[[!66TO&4,?(;8:WCJ6L4W5:J#(T
M>_KC9UD!,@K0TS.FC56RJ,FG'*':E<!(H8LFXC^5.0X/'DWRRR7D3%M;P-%6
M[DA`OL$'I;IOE%.%P,YR['-HRF7H]O,M;\[R1\2+2<C`+Q3:-3CEW2:1D3,0
M=.&XHPT&JXNR_4;M2U.O3^B\7K"&4Z9B?/.19!MD"PGIU2@JUAS'V-;^64+-
M6:EU:Y72)F7>5HIH=@PC&@@]9/0!<4B-W:S<5=O,K32?.W+<?F&+BI>)B:UB
MRJ23F/R<HUAHBQV9>P.\\XFQ`2N0Q!EF:HUBLM+H[<?-40+(R!SE-Z,GA*@L
MW'CH@B/>GAN'U(BXUQ#%9*LN!9)F%HHCW,\%5FN6*78;9+X2;4-E?E;6C`4]
MA8K0RL*$4]*U<-'48A`,W@[+3I6YR.#8/+@L[7E1<L/U-GE?L#VOW/!MHG)E
M'(&7TT@QG\]LQHC!="S:VP[7+D[;QU7F$5KS+2*ZZKJ+<.(QB1NP6,1\555J
MV5NA5V<M$^W(OF`\X\9'GJTVQ]9,D%84;'%M<,H%JJW8P:%RM.:6+^QV">AX
MZW6AO7XUIBD$77A@7#9FNY;K.'"#0SMRSI(%0H(N'T2K-?,5KB2GXQME2Q@^
MRXCD_$^2,W?[!OU+BHN&QKBJCU?(MG=)6%16;A+2\D:_:$DXTL<HJTD'/:`N
M4FIQ=$$L@B[IBLD_4+DJU7OF>,,(`];66WSE+P?,VBWPT9#6]SC'.^.L*Y;;
MS=4B&RDUCTD0-O=*UXZQG:;X8_N<)M`5;(N0Y!41>G@I1YIY15?#63(''-GK
M$VYF+I#U23H2R4K",6=T,M<'%;R<U9OI99FUCC84JR"5HGW#HY&X0BWD*8ID
MS[:=@P4`IXJ$$M]3N4M2#8:M0CTM*'>K.;`1\"=V"6J]FP](9%QU+4N2>(T6
M,>'.^C%$)(R8/8I4A!.PD7J1R+ZR"=51!CX*3_'WE=:LX9Y6J;2@-ZAB":P@
M_P`GT*=D9N+F;7=$6^9WV+T96091JY%*<T58QAW(Q3A-=8H.41,Y!<CEL@>O
M@I*-/%_X.N1)ST9SG]CD;0L+62WW#.%+Q)<J;69"\U2J,FJ.7(?D%.QK6R6%
MV@^38-8-AQVDQ=N6[9R*QGS<K=,XE5V.PHKM3#F^J)7I-X,I(84M60$W"<?E
MK'M>KE7=R5KH6(V7'_C5D"Q2;]6&A+NTDLFLK%R)7CV)$30[!=FFHFI(MP$A
MG)U=C)VY7ZCC:!6R=%(8!O:UAI%I;0+6!<RCQO8)*FN)^\5]?*DI`QE,F[+'
MXW\U)!<DQ`L+7%%3E&A'3QH=.1(R$G0J;7#\$^UOY.EC8;"3O'U`-E.9SI1+
M%D^N0[#(M"K,"TQ[3JG5[9:YA7(<F]?TN4=)MKI&M8Y-NX%C(JN#+G>-F**S
MLF?%4@)H*SSXISM[B:"8X:FJG0LN6<:7@25C)^F*,[!"0.>:=QXL\S,5.%`A
M:`A`VJ]QSUFS*H\+(11S`51NZ3,U"O1019WU"U37ZBJ;Z1<?IG!MAD(-I*0]
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MQ3^TCE!=6=!Y@7C-E"A*.OQSR(>N,J4QO-8=`,8VPQAZ_-&C[(C]>)K;M].S
M^1%TT7"J#$Z:2B*`MCK$+YP9D(%&XID8KZE3.5!4R.`;EM5G]D2RLN>WQL6A
M1HRL9=I&(W<G",+76*O:KFL^=W]E)MF:\7!KF9(.2*>-<K<CF[J-P3;XIXL#
M<J[=GK,KZ&"@MZ;B63X_Q&7L;2CZ9BIFU7%L^RQ9*"A/2[6+7WJ)'</!).!B
M5TUU4!<D[G)EB.6Z$!JZ$,/%U-([..E458R9CV,M%2!!:/XV39MG\>\;K;%.
MD[9.TEFKE'?8PD.0Q1$`Z=-5WU4:CK*J94IS$.8=R&,40'KL8/A,/7WB)=4$
M@*)054RK$^X@)VZP&#H'\VN':8-OL*<@?O'331"&*1]YOM_N!IN*([S?;_<#
M3<40!S;AU_N!H[T5&J\6/JIN$6]PPV==-$JIX.[';'6!$=BIO*,BJZ(4/(J<
M2+N4DRCV]%?&'43%`?MW[20E/'SHQTWVG'-XW*?V^#\%T'U=(QNV91^+;+[P
MH,-@F+G;)B49NV;<E]H4'DN@R4O$,+(A`YRH$NPJ_CA(B0?0<&S0L3MQ+-9$
M6R4@H=*9]2J<'92G3[MD=#M>#;M2%<?+E8O;9&!GC7HF8W2B#(]/R2BY#=-@
M-I+^BC+JRE=<@W(;H'_?B0/M+@ZZ\U(.)R?5I:ES/(=SZF'JN.ADG^1ZY/R3
M9>P0^0']C2A*SCX)1^R.`PUU=R#<S9\L0@1Y4')#K.U62P:Z[D=JSK.=;],?
M'EY!B+%R,2(RLB)E.\PINMQ!!B'WEJ1$@O86IVIQEF!A:B'G$N2)DTC[):OP
MKR6NQ_B;/7-FX">\97RC#Q=5.A\VI.,;*.-,4,]WLR1&GUQ%9=A/2`PK9%HV
M&2<$5DI$YEG?PDV#7E=Q[QZ>]"XG3[;AX=W(O#RW+]OJWY,`#<GK$"1W$0#1
MB&BRY,2WG]XNC=*<;`H1$[8QY-6O#5SQ=<O+/\S\)[!(4VU9(ON3\;,D2R]M
MK&6YEE:XUS1TXD[Z1F,=VQL,D-7N%6$R3UF10Q(N5.N5FX[%#)'-S0AV/UW8
M&?A8UC$[J1LMRQXF)%XGRPNPH)PN5!+;H`&8HX6+L\KMM_Y:^;AL4)!\P8T)
MC4M(>!;@RZ_)TPZQVT;4^OR83MWRPTDT\72<21LYAVN.+G6$GC?+]NBW;=JF
MZCF\;)*BUCE2MT0!BJY.9XBD)#>#VK'_`*E^LR(FWV["(-\$D2ZUN1!QX'A*
M4@'G%SYA'RDKCNCY4;`=U^X/(=/)(?&>8K0:!B5'.=<-J?(Y77CDA9T=B$#@
MO&C=DDU81YXQO_[LEPECP`.IZ*B[))KJG5DU6+Y)P4TTY;&0]+V%)VK#MS[A
M9PNJTNX2,\N^363GRVH[CME*(#"+Q(_+C)]SKPK\HVYW3!]1$>`;S<V)]O$\
M$X>)5%'BO"Y:,ATG_BY^,BOW!8UX]0@4_P!(8V\TD1VU630CE5`,1+R*D,02
MK%(&P#N;P^[`0/>^M<(E_IZE0#+\R[0\_P"Y>1VYS#';AG#[H_8OJPU^6`W!
M?3T:J(T1&B+PG^MG97$-&\=(V48/)RDRRF959*`9YHI&&G"MS:0M*8T&R1DO
M<[92T1GZ:YF7KYL[3=.DVB)'")F@K/&[MF7);XJ6=]GHUI].V&OF/,IV>]DQ
MM1:QD&+M$+<;'R?E,@V3&#U"=?T.QY$Q8_)9\AL9FT0:L)*S$:]:F*!5%5S@
M@1=$Y0?$Q_L2_BDE:+MC+/DI<;IF2+N%S1-'656>P'8\/!69X:8Y9N;[C2`E
MV<I`WZ1ETGB2AY.%2*S?*1K4CF.0D@?"Y)*A":/@M=+IDS)K2;N<OEEA^C:3
M<Z34XYYQURQCW'UJI56LT30H=:9RG?Y.?=3T\@-,&>2A["J-D9O[!(&;/G4>
M!VZ!)!@N6B[!>'G+N:Q`\MV;OT%1^1#6T0MOA>-F5IWU%JNLFGD*3K]DRDHY
M4C*+1F<,H%,1DV3(::_KSET#QND^.VE=%:,_@NBYKV6ZU3.Y:Q7YW*\E5<P8
MF=KY"B:=QPRCG)2HP6/))I"L$ZFSJ,E"Q#]:SR.2C2;WY2<ESC5X!!9J[,F=
M!D)2.G!.AS,L-XQ?CWCW;J#<\F2UN8OV6,V!B8LN.0)>QCDJ%A:E)9)LE?@&
ML3#,\@5"**YD8]K9VRE><R#I9%U'F5!!5F2+$E)Y$'D5]/FRVEA:<NMGM?":
MRPT8SN%,KT>WMG-:R(K?$\1$PX@^_M:KM"<.8WY`FDSE5%$(57SM9`60)'`G
MXN"6<1)^PVC'^><@9)D,IR%AL$-&/;C4;3@*4Q#72/$JM.2+R9H#&["K1<DK
M6"-DDHM:3;"U;.&D+'I2[-%^#Q=V4EP`4)?I%9!JK+,6;:A3XQL%`R32<2VV
MK66:L_"=W>"7BOQ]R;6G'DRQXJ/VJCQ*(J!HMZW9K,E&\$8KLH')ZLHJEJ8I
MX^]>O7*N-SQ,8#R!'<:)-O$9E<H0`5IXH^@XI\:*2M4&M>&-:F;3!6BK0=VE
M:$G)M8%_*QKZ,93*S5=VB=NFH&BQ%GKHF)X_8,RYB+(W)=_>;78LAXYGZ%B6
M%QO?,L3-)MV<IAW`1.1)J^1$]:*10*LX-C*NR]U11@(V3)*/6TF>9<HF(T>M
MT=%20=-5Y^_1M<P%<R7R0KL4I3H*NV2O8?<TZ(8L82`E;!8H!;*)K\=@UD</
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M)Y=YDTOU$,<;:N''UUQ=T7SC_403:)<R,X/OF)%'*/"JM@M#*-I8`*A_:W7!
M*\^:)HFC&B+D`,D9(#"JH(;]I@#M-^BOVZWS](85H0\I[[+S4U^6G1M7X\ET
M#U`P[AD$Z?*1_P">*\U4'1WM6]>@V9MGM/NM7=1L*=FZ=PUM5LEABET8NTQ[
M18)#R1B%<6>(NCO4"MTB*(G.@=4#K_3KL.CE].<B87K%P&3@2M].$O-;)IYM
M^T^4N6-0&'6(L+>T58C_`+3\'4PZF_1+S(:R!T*_/1^,HR.C[[*W,RDDQH\Y
M)-I>L-Y0R\0JWBW&49]W+HNR`B+%F28.Z,#0YFASI?/;UHQ]!&R]R.1EW93M
M1A0WHQE&9I*HM1$3%O,=HCYFD']W:G`=QC?)'2@0"XH"01PXN01PW.XHEO`R
M4AZ`SA,8W^KUB$L[%/,V-EWKIG).(=.SFFUT7;W(<Y&6Z-F(L7J30%7C8JK<
MAHY--=)(@G*8\_<*SD=RN7.\]LO7;F+(8MT!XOM`=K,#$B3;M3N:3@NS+D[9
M>M6\K9?C4BY!S0/IYF(+<*<*J0*F*4>+N'+U7,@97AL^S.228E1J+V-2M=IM
M%=6CHULUCJ62&EKLXBG.,:FK'@G7N]LHX63$3.A.HF4"=8EW/_5O>\?([7B'
MM]C'ZIN!X1A.I)N;HP!%ZX_G#L_PL'?S<BW'MV#<%^Y"Z9B&W4D4T8GX1H"U
M74#4HV4>X2Y-2[2ET<27/DA8\E5EDR^8.7475,<UYS&66[XZ=MY*9;B[3D9L
MJ\L4Y7+4S=D_,4$"M`,C]+G?LV/4/:X7LB]ML=LA9N2DU;EZ>Z%N\&B6:/E-
M"";;ONKZ>DL"48`;I7-]-1&+OM\`]=:`\EEN[IG9O^SY(LY-1S6#XZLL[$S$
M4OYYB=DJ@SA7D[74905)L(0+0K'*IRA)'U)C/U5P14].L@Q4\7M=JYB2[I:N
M1`R?G(0,9?#;%PR$)@>7<8`O`Q8;6_$#,<62USHW(.;6PL6;<1J/!R*N]?`A
M/K]-B2-(\LXQRE'13-T]IMZD!3CD5"-447(,G!4VR0J*))H%*Y,4I0[!(8#@
M)2F-\7A?N=8Z/H^0E*1A&_9B\BYHXKX_2J\GTY+J=X!C_))VT#NOHV<?SR@A
M[!..PZ_,(T7U0,5AW'[1U48)F<Y1_'Z8JT+%<CT\6N*<_N$(A7&F6'L"RAWE
M\6(\:P+.`//.6A7%H>MG3I!%NV,+ARV572$AT3JD,+*^Q1WKE"^G30$LHY29
MS'&=6.L]E_L\N$_.63&#RJ4]-7&-0Q$AA>,,HLG#0$"YQ_CQ%N6)4[U5&0.B
M@86?<F3(92I->2ZRJ(<&8EJVHD=&\?*K&662D\;UV)DY''K=')+6P_H7(,FE
M7%#3;]Y<(>R/Y>#=B=<PN'CI-J(D,7TAE!;W*E]4K9Y'X1<@YW$^9`G\&W&W
M6&J.+GB&:M+ZLM[TO2X"2FY$95A#S#I"85C*Y*0TB\1!P@H6.<M73A($E4ES
MEM$`(#)/BF$^GW%J,XG$"?%-"3N$3-S5<CZ1+X[<O;-!MHNS4VQRD,2/D%UY
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M(B[!Z6/*X$J@-0.F90"2;B[Y=P2QN%@XJ77`-U:U!TVG<Q6JPV*H8ZC<"DK#
M>\M;-8LPS]B?Y":+1T4PR6_"2=/U6*<BG)B9X"(`45@AY*!W?BMQ'SG`*Q@Q
MAQG.*,JW@<?_`#M@D$]C%^A"XK:-9Q^K(&06?J-D:"A&7F2<*F.'I$FLNNL;
M9)P8Q[055\P#U6WJ%CX6UJF1="HUKXWQV-LM2EG@8BM,+;0WM6R9)'%"JVR)
M,W=23QM<G?81"*>H+>I,4@(LC%`H)(ZFB!W<NF4PLZ^FSF3#E?A:;1L"5ZFY
M-D[!DJI4&V%QY!62\LJ02QU-?*D?!MK))V(8Q2MP,@V;+N%T71(%!PV60;H$
M<MBJ'VH=PEQ9==E:S<(ZKQ\<YKLU/Q?DK!4;:$YJ-/C6HU_),;8;A.,/[$W;
MBEQ-6,JRL$R>JJKPCPK,X@6$;.$3@*")B!20RTQ]Z<"[0/">:G&&/K(EQT=3
MN48U">AJ;*R=+:6BY1E@LSO(3*=@XT[YM.R)9NW(.9QL^:?FKO$UG29^XBIB
M@S599B2R;QO$_3*9P/ZY=?\`8SCZ_-C*8T86CYKBIO7W9CTA"@66HL%?F"<.
M8[C&DHVBI-!N4JJ\$X0*X$[;PCJ4U5\S\5VV)S</XN4REF7%L;B2JOL5V6U8
M@RODM!I$UPM6EL>E@&=MAYRQ2*K=NP8MTHN-*\>&.F$D5F@9=1;PI&!P0EZ+
MC,;5;Z?E!>QCNF6WCW*VW,^2IV_5VQ2]QQY*73(]TF<U66_LUZH\(Z;N9A6N
M98D%V\>BR2\S>19((J"J]1*;5H5'/'1:'^S/@-R"O>1L7UVOXVL%LK=BQYG/
M,C_&:=7?,Y.5@\DW!U#5VZ2\0>1)ZX^0J?)/Y6)(#-P=T(/!4!TH*NA#EE3N
M!?@N8Q?D?@KD.6Q=893CNRQ0PD..LWD3#-TS%C*@TRG2W'ZIQ<7$RSJ&EHFU
M6"-A(NLPF7&P>"<3CG;9C/+@CMY79-2C>*%R/>G6N,7PSMLS@><6RCAN`9.[
M]2\HX_JT-;<6,([,EOQ>T3H>(7I%WB3J>LS7&$RH@WA$8=VU,24009K^8$@;
M#2W!*U"IF+,W!.?BX?+F;I7##Z>Q;4(/*D6SMKJG6/(=.JTY)U61B7YX&(E9
MAVHW^>.X9X4A#.V'JO1NRCW`W7$X:J@$@&YK;V5_]/F6:DHEEG>*2Z+5]$8O
M0@W5GQV4[&?@)\UHC*(F5"53=Q<Q"6N?,\2;IF2<LWTAN/89QL=13S:AUU%4
MPQPMNK]T-!QUQYM$GC:OJ8-E$Z?$TV91I$<PKS^JO\53+2'%PQ@'+"IRSJ+]
M$L1-TSCG:S/8B"JB8@*/P1R"_!.A+<=>/]AM5FM,_A3&LQ:+/67-7L\C*52+
M>NIZN.(1M7U6;Y)T@HV='5K#1*,55,F+@[!%-N*@H$*F$8*`EM:+EYGB;QG,
MRHR2>",6.H^B.UY:HE6J$6L,#,OI]E;'$LBJHB9=U(.[5%MY0RSDRZGS1LDZ
MW]0F10*&`JK&1T)7:GH]-4J,E0%:O!K4>9CY^)F*BO'HK5^4B[4K(+6:.D(U
M4IV[IE/*RSHSM,X"587"G<'Q#K5%I:Z6Q?C:?7>.9RA5*7<R)Z@H_7D8-B[5
M>GQ\J_7HAW*BR1C+&IZTJY/&B._I#.%!3V[AW,%5I:C@S#%`LSNZ4;%E%J-L
M>Q*,"YL%>KS&,D30Z#.'CBQZ2C9,B;5%9A78]%<42IG=)L&Q5C*`@EV&")"'
M'C`@7R=RB.&,9J9$M#2896.X+T^&<3,VWL482$L?S%1=LHW<.;)"I@RDG`I^
MHD&8>!PHJD(DT8(_!4K7'C`U.B7<#5L.XZ@X=_#VRO2#!G6(X4I&`O;.!CKI
M"21UTEEY&*L\95HMJ\;KG425:1K5#8$6Z1"&"+H:EQ\PC$+1:4/B7'\8UA5H
MMRQ%M6HX!9K0L]"VF'525.DHJ*[&SUN/D$SF,)BNV*2V_>F40P0N.1(%5SC_
M`(;\0U8H8L_'##:L,\DYE\:,/1X4&<@M-L&\'),'+8J`)N*X]C&B3=2-4`\;
MZ=NBF"`%33`D`)*`R6XD^,/'"3LC:9E<&XPD)Q.WN+N@[<U&+563LKHL`5]8
M'`&1$KJ1DC5&*75(H!DE7,<V<J$,X1(H&J("=O@MO>,'X=R>[%7)>,Z;>I%Z
M6%9K/;#"-G\FR8P3V<>PJ",H8I9!L>-6M4H*0)*$["23H@[E<*E,9Q754DM3
M1;:1QGCB1813":HE1D8Z%JT]2*]#.Z_&GC8>D6B(8P-BJ[!@#<K9A69R"C6K
M-PQ2*1!=LW33,7QD*&E%7)7$RO%_CG*2U\EI3".,'"V0XT8&]NUZA%'6MD4*
MT.\/&/@,AVB#EU`1ZZYDP34778-EEC'4;HG(;ZE!)@!Q3AV>B4JX/JA-V"E5
MBP3%1;V9G49"8@X^7?UMK:8I6N6I"'=OT%U6*-DKJYF4B!!*5VT,9-4#$$0T
M#.@XIL:_Q5XR5B,?Q->P/BJ.0<M4@>>EJ$88')64<M"M6RBRZ2KA=NQ@':K%
M'O,)461O3I`5`I"!"S^"$DKIZ1A+#V.+59\B4O&=*IEQNQEQM%GKD"QBI^T"
MXF7%B=-WS]LF146*]B>KR"J9.U$S]=9?L%=90Y@".31:.O\`&W`=$LKBP4+"
MF-JI.NIIM9"RM>J45'2!9HK>TILW[9PW0*HU49-[[-IMR)=B3<DN\!,I`<*]
MVHLJ"65DEQ?XVR<''0K_``;BJ095Q['2D6R5IL,9E&.F-?KU.;IM4RMBD5:)
M5>HQ$<JW/WM%VD6T142.1LD!8Q=1R[K4J<4N-DL>S+R."\8*DMLVA9;2[-56
M2;B0GT)*3F$Y5)RW!)U&R*DM-OG1Q9';>=R^<JJ`8ZZQCT@+1)T"[#(6$<-Y
M#@*[1;GBF@V:D4PS(].JDK6(Q>"K236*-#M6\-'%1(WCV(02QF*C5("M%6)A
M;*)G0$2"IH5(Z/Q6B/Q;XXNFE_6D<%8N77R4=D\N@&J48DM9E&%@0LK5T]%%
M$AFG@MB24L4S86YCRJ17@B+@/+J4?P0FM%L*_@?"U;9,H>LXBQW!Q;%U6WD?
M%0]2AV+!H]I[V9DJFNT9-VI&Z*M;D;&_79=I0!NJ]6,785#;E*C5:4.*/&&$
M6:FC,!8G:K(TI2@(@E38@S5I2',$XJRU7;-C(G;`Q&LNW$5W=OE)%+'8D,#4
M?%HRCDZZ+?EX^8,F;A.WN4Q!CR1NEA;M/GEI?UIBO)22L2M`.(]V_6,GVJ/T
M#52-*+H"E=*)QS4AU#$;I%(94E@*IF,,\+,)X0NULR%"-WENN%FDH&00L%L@
M\?LGT`I6'F0WL,ZBBTBETY!>P)JY4G2KS#XCN6<HOC)J.!+W`<RVY.J=$W&O
MCRW?P]D;X0Q:G,1]2-0&;T*9"G!O4$()U4R5\K51L=B=B6GR2L27O2,H$4LH
MS`_ICF2$%`:D)55N/^"JS2+!BJ!Q)0(G&MW<N%KG2&M=8A7[4Y?L8V)=/K"R
M5(K\XD5(Z(9H@Y7%1<I&:`%.'A3[1%?!"2SI%$\=,"UEG*0T%AS',5'2I';6
M8:M*O&E)+INYN+L3X94YTCK22S^Q03-^X57,HJX>MDUU#&5+WZK!D=ZKH*7A
M/#^/)BV72@8RI%,N-S<&-;[)6Z^PBIFQ(NI9].K-I)XV3(HJR-89%P_].7M0
M!ZZ77[/*LJ<X,ZA+D<DX91$IBB(B'4/?[/O_`':<*:JT*5/@_K)E0_`L5)8!
M#V#Y$RF-_P"7OHU/%05'BKF@]PK(@._F05``Z=13`%B_W4]19+I&<>O[Q]^J
M%H#FK-Q^T=55@J@([AU'VA_?U1JC+Q#^K<J9&TX5*9!%T9Q!7XC5)=53M2,"
ME-*9<"$62(!2^0W?WB4A4P,(B/=VF^[?LU'=:SR'#2LN1[)_2G%E\^]7D"Y8
M<D.)?>%!7%#HA<HQ%J(JV)&SV)K%:[.RD`!O$U.%A7\;&.FC"4$L>R;5"<-$
MF=.F"0C(E9K'30.W753=K]V]0V]W9[F$`3=AG6[<&/FNRD#(&0J>I$2VB7PN
M`2#$&(])@MUQ<EM`V2)'"(!;_;Q'M7+_`">5L/$?,[N.@:O,_/[WC_)4'(SI
M9-.V9'I&.;P\8V=U-.$Y)@5+'K%.7**PHJG5,NQ?',\$S412\Z61:Q_6F!"=
MR<(V<>[8GM,=EB[>M`PC$,3U28M4-YH#;YJK!/R5T%GD1,&NZ48$@U_E#A_%
M^2](*-7XGD5CR5Q92[]&X!O2&9("[CDAHVF8::@6)V0R#*2Q,O"7-A#3EA/'
MMDVY%G2*R#J.4,H<PF*FH7YAGW+GI?O$>[=PQY=P[;/%G#I3E&49RT,;^Z!,
M0]3&+$2``:H/N<+I=QQ_E[9C9R(W0=S$4#U@QJ?;]:9;E6]K5#P=#8D+'4._
M6W'W'NQ5R;FXMM//Z!-+/_2,V:C*Q3]T>3#*<D)1N*HI(J(+/)=(40**8E2-
M[KT=#)S^_3[UOOXN#>[C&8B\1.,8Q+@QC`1-N(+.S1C4\2N+N%VS;LVL*DKL
M+;2,7,7=P027?^-&X)E[>F-%M?%16W1E7C6-,QYC3$%KL20OF2TS?:O3A]91
MLINOF*#8.]U+H(MW*:[4#Q!%3*HKD:F\7N\6<>X8/>H8LKLKU_(O9%N#BEJ5
MVEZP&?2))!!\Q#$;@_@WY_J+$Y;=D8Q@2Q#RB*QERU9^7L*:>^$<QEHS9(R8
M#(S`Y%<4)U$R::3=D3>/AUT+G/J%;!'2UTGTZLLBLZ8*MF[5PFN<$VY%4VA_
M?]J$;^+@0M$QMC$%W</B+;@;43J+4#,$1EN)I4L9#U]\F-ZZ2^XS,?X[O>VG
MO\$]>$3H.6_"M?UK>)13^H(AXD01F04EU0JN.T@CDE6A7*")C*'%0P.U"IB8
MAB;FW[S>F[]"5N]WV(B9D^G0^GE\]RM?X>U>?VTO:Q__`.N'W17UB:_*:^HH
MT1&B(T101YR\F(CC3!46<G(;CK(QDRO:CO7_`"'RC:\70\*S@6,6[=/H:1K.
M!,Y).P*D[$STSLL4DW2(0P*+=QBIEJ(>E4T,E+<@<A\$XZQW_&:%1S"&9I&;
MA:KB%M(6JD5NLUGD?..,27)S#PU-L4]E3&B6/8V&FWZ36N!(3S907!6,>JIN
MT*T$O!:GAO3+?"X9Y$1MMQUE*OWFPT!*2L,%#W"7B7-RLMH8Y.G7<WCJ,MM/
MQY*8RO\`:5IP@"7T*3%@D,4V[D7C"0:-"2U"X#@W3LD16>D+#DNBW&(DGE=L
ME>KUQ:M;CCFM2--IV/\`"L!!5.R8MN>(<3)JI5-,GHF3YHAYG$LTD'"2'R\Y
M/2E9,U%R@T;)BG*II)SN-LF+8XK&<YR0J$D"UPJEOHT_>.4.,I:7GY2^*8?B
MZ%EFM9'CZ\FX9-"V603A<>I/(5PY))+L$%8CAO%EUW-ZEY,L'(%9.`QI=KCC
MN5A<;RM]8N$;R6&M#3'S7(D]%/*7?Z7B&^IXZ94:2="K+Q:\JT?3SMV@#-BH
M)SA(5(D-XKL.9U9R?)8%P$GBRLY1G;*WQ%<*XLO(-Y+(;OT%JQ?7ZU*U:W%H
M^/,J>/+EYBG3F/BK>#=I#1#@9$[A\"#T&SLI%G73A4)UAP:LE:K=#R+&3L-F
M!VM%5!*9F;^6LO:_GYH\2D$8Q:CS%RMF$ZZX8?,%JZI7',J^KJ*C-)!05$G`
MD?S52;A#!7"J53/\ED*CWFMW::JR-OMJB1[F]A[M-SETS_97=MJ6,)FH8MMU
M3M=D)+$5&+:-V_9#&@X[R-Y-B^0;DDSTT43?I98IM5CS1,YRL4AE.CS$=B[&
M4VG5)&P9HE*+D+%&7:[=9/'"DJE<N8'(NL,;_!O&SA_+0SI`LM!&.R#O`CH5
M%2U,T;Z?<OH"T7$N?MA"J5:RIG9_,2*5^9(>/^:!!^N*:.<E,S^=F42+#^I`
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M,E:H_P!7D=-L5&MH>9E*B-(NZ_RVXF\R7IZJ(("N)]C_`.T$&A>WXMP['V"T
M;F)W4BWBW-G;3)[Q:4/U.,-^/0O?KM:GY4KI>C'I7JZ^+/<>P1-_/L]3O0BV
M-%X7?T6=+I9A<;<7R[S+S?J(8X:KAQ]=<7=5\WOU+W32,Y>Y244C/4'>\+H0
MZS]8KQ1<2HY?ADVT+#MC.&T0Z4=.DDU3%,8'9E0*FD.YP*;]&_MI&Y/TCB&,
MP-O?"T7#5QY/*5#(,''+B>:Z%Z@C_P"I7I"LCC1`'_:%64`8:J-T(AG,1T4[
MMD9B2>:WBX-6,:TL<;(WN09IM(J$/'I-7=E;1-"G8(&SEXDHV"3(N]2*5N1-
M-1;O.5G2G?GCY4XV9YMHVK1)V$68GSRW%H;KD9.`QV-`N26'7H6QL$X/(6Y`
MR]OX1['UYIPZU,2MLP^W0BY>P*.H"PS;C*M4!5^>6F['<GKVT)7:U*O@&8EF
M<JI+N8PJCH!1BEHXJ0"`&3,IX&3BX^%WV4\J$&N6XC'F?@A"$1;-J'X`0(B;
M1K,3>K,.64KM['B;9/2C,[@.)+G<>)U:M`WBGNG:'C&WXXM.6ELW2W'O*Z2$
M76)2SQ$,TLDCEN0AF:LE',0I:@MW3JQTQ%F5@O8HB106315%!T8Y!2*;KF/W
M#N_;^ZV>S?(P[EVO?*<;4CM&.)%I2Z@=K<R=PM7(MQB`O8"WA7<7YF]=Z5V+
M1!-3,C_=H7'&0+<UJJ90VF6KXT@,W\_7EHC%J`A#-*_%41UCJ)L@I1,BVE:>
M[O5O4?)56^*ID<%DY!HS%ZLHX<&0<%4`P#SYW<;O9L`Y78O3L,>?S)GU)7>L
M8$D$7.G`#=;XQC([:!PRU;CB9=\6\C+W$0#>4@%OP[I4!\6*1JD=/,@PL?C@
M\AC:J5%BI"0AV!',-%8]JD*X?IR,/-^K#RL6E8!JX5D3/?"9XZ04,J4ZAMC<
MD(VX]KNW>\;,O*R)[I.1*=VY(!I0VZ[W`AM<1#,S!>#<N7)Y(CC/","W$;1J
MQ)X-J^I3#HK!E*Y2;BGP$TT:5/(\AF6E/T(A<D9%QS[Y6>_1?JIMA(UNGQML
M6K"$HFFV3#Y(=1TJ7S"9!N?L,P.S8$(YDXF]?Q8XUV,I/(F)/1D1$BY.5O?L
MW'XVB*5(X82N9ID(`F`F9"C#@_,`4!'VJ2_TXT*ZQY@UD8-59:+G<;W*9B2J
MK)"_C57+"(7FZ>NJFHY!61J4H9=BN=MW(KI-".3"D1P@F;KW[E7<F[Z,N0R6
M%ZUE6HEG:0!D(W`"`PF&D`:@DQJQ(]GV#IR[KNB?(8$#G35_9IXKZ.EQ'S*!
M]AS?WQU^8@:+Z6"L6XZKE5RFAREB"(RM,XEE)F169H8JO-BNR#)!DW<*3"UB
MQ%DK$:K5)\N?O@G;!ADI9\W>)$5537:D*!0`XF*U5<KS1D_IRY!P+5:7+X)F
MV>4LF4NOQ6-:TXFF+=FW9XNC\-Y1Q;&?JV(S!EFQPMKF#HY#,*QXN3KD;$^1
M56/A5T%7D8\C,M;G=]'3C8R^FM(5,N%I!OF<*[:J`ICB6M4I6J>[1EW'Z(J&
M`8J;I]8LL=;ZVS?T^POL$@59G9H6?B11D?4MXUI(M470F4,G!6F8?2RAVLA'
MJR.9'$PR1K54@)%%Q3+$V<&7QG6KS3L8RL&P;9:)1X]W%5VVMADU'\'*N73]
M@LNP6BR2"R*94R+KJ+9]+K']KFS2+_(<LA3YRDT.HV.NM(B;;2Q)?&>!Y'`<
M#8:2X97]GCZKHJUN33>G2>5>9?-WB2I&SU%!VLGIM4W-3E_$IXH;B'-.L4\J
M,<7;*T7.SO*JL-*E,VJK8HBJ7$4]G'81@<%Q3F.I2MJLK:==$AJ^B_<%=OBI
M++J&;$*DT(DFFX()5]B:ZX<([-.Y?QI9YZ?96EQ*YQE<K\AKM`0L)CFFSV/Z
MUC_%5;JN`X_%JD[;IYW$V^[8'H<T^=>O72*I`/O,=--TW9Z:)N8-X*1F0N,"
M>1\ZU?.+N[^B958^%I-]3%JFUE32\[A.X95LU5?MK(M--QBD7P9@D4W20L'*
MA56C5=%5,2*$4%'HW-1EQ#]-2LXER;CZ]LLG/[%'TN9H]O=0DQ`6!)R\N>.J
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M.S41>B/P')-DK]*VKLW\$O\`VM2#R+_15*@IIL_KL^Z<N)_&=*N%"IMGK#=E
MDV-HT,W]#:2.7*,A!33XJ[13T;UF#Q?;)H?%-_@I96?B?3,E0?&W']JL=C2H
M7'IJV61JM2D9W'JEZLT-CD^,ZE//K+1;#`S]<0J\+*RZY(YFL+=VN_3!4W8V
M*570#AU'(<A>><I].C*+&R5K"$/8',KQK5GZ')7&_P`\M45;VQIN-<3Y,PW3
M*=79!W)N+Y$6BG8[GX.#;*^@DFDH+!646D&"CI]'.<U=EK<#[4^M,^F/7Z_6
MI<DGDQ.9F)K'F6,8.Y1G2ID?'#9!P?5\%QDP<E\R?DJ=4E*W`P*BYBIR*4>J
M#P63=NQ:)$3&D44,JLGW8<59=IA;-&#XK+KV()EG(3R^5RY,Z@FE,T967>5"
M7F8-XFA9VZM@824S6W)?5L7,%)M6$AVM7"+YNB_U0"R&GF3,5+Z;L/4F%V0D
MLK/9V1O<A'RJTVG4W(*QZC7E.GRG=(1LE8[M;[6[27L)`BP5?RKM^"2:;M9=
M9T01&,71W3X<=.)S_!DT[EELDL;DP;X0Q]Q\HL.TQW'TR1A\>8JL^0IVMO+1
M-M+#,FN]V<)W\Z+UV1",:K&:^=)HBJX<=]]FJA/U*,\?])[$4#CJ*H%`M">/
M%CX,Q[BG*4[7:'',5<MSV%[S1\G8OR?-)0L]`3=?L<;=*@X":2CI1`]@BI95
MNNX3<M(YZU@"ID7?Q7#3W`;+U&M-:K^+'==G*AD:ZX/NN=[]*-8P\85[B7EE
M/<DG@5Z(OUYMN4JY(*M[&[;IN2R%O=SKU5)1XM%K)*/G`AE1(&AU7>*_2]%B
MPDH.NYZ>P,8?$45CAVWC,>K-UK%/0&.J-08*XWN&)D-.C6IO#'HC1^DHVAXZ
MTF)V1R\\K&H(H%H9TC+FNIRO].AUE.D1-(;YX?5:/D/^T*_N"#"CNT&%FFL_
M9T<9OD9E%I7\B545I*MRRAXQ!K8%;%#.V:GG49%?)I+E?<IN8GDZF/AG#[G#
MM8;U!E:&4G7AGLK6-1NK548B56MV3<O6O*KU\[EV\RX1]$P2N2L<1$S455SH
M@Z47*)Q2`.1T4=RZ?0?(9-FKN*<BB!DA,80`%SMS!^0;[%!2,':/L,`[:'7P
M6>)Y+9))-C^I0'<$#D\H$Z@=OY0[C!VB&XI[["'\DY1`=O>)6:^]<F[:+-%U
M$%/:4=RF]QR#U*<H^\#!_`/35,F"Y'<.$E'<!VT=U'*IN.CE'*-QT<HY61(A
MUCE33`3',(%*4`W$QAZ``?>(Z$D55JS\%U_I"-&A&_>/D5."2ZA/>H?^<33'
MH4R@[@0/<4.X1]^H2^BP2Y=)!%#U9E#%^%!(YV;??HFD@7X%S@'4/(H("4/X
MPFW'I[;455JWM25#=N9==<PG?`@NL41,(^F$Q!`AU!V$17,8_0O\7W]>FE/<
MJ:T&BM8I>%P11P(F<*=RQ$A,.Y=@,IYUQ'J&X%W*7VF]_3VC5"7%-$G*45-W
M+DYO&8P[F`?S%U-NI$]]]_O$>A0^_8-0*FE`L[X%W+U1(OL3$2E+OL1(@=3&
M$P@`%*'M,8?WZ%R:*`45%U/&R0004W_,<$46`.T3_P`UW%3'8#E1,(_\+^YJ
M@M[$`K559(^(155$OYC=QXT!W[EB^$XB8VVPII=.@^T?=TU`"-5"D!SJO%2;
M`)C"/:!=@`I"E#V!M\*:9`_8`:U6K:K;`!;%XL5$J!$MA44:H@HX*(CN4I3$
M\:6X%$A1[/B'VF_9[<D\%@>.BP,$^Y-Z=0#@@*"I3&+MW&,0Q5>U(#=#'`"=
M?<`:I!6I'1M4D5==X@0I?&W)_-H@(B!1'8!.81_&H;;J/^#2I'BJ&*V;D"(>
MG56+WK&:H>-`Q>A13#M!58!#80V+T*/M'V]-0EJ\5AWTT6!FH=PY6*(F.HN@
MN3<=NI_$)R;![`#=,-O<&G\5HTBL9EB-2&(D;N6,`E67+U`"FZ"D@._X1_C'
M]_L#I[3\.*CO4Z+,9(SANS,`@0I$UBJ+'_`0A%A,`CM[3;*;`4-Q$?9H7>B'
M55;.2@Z;H)`)$"JD[M_Q*B?X#**#O_)-T+["A]_75-/8AC1^*U!@$IS$_DF,
M7]X"(:.WL0%+1'O8=G\9%T4=_<!5DC!M^\R0:@)9T)JDA.XA@-N'3KIN<-Q5
M>E4H?@)7:IO<H<%0Z>Y0I5/_`,[5?DL@T5S0?(5TG[-VQE`W^U(Z:G]X!U`[
M(D1C>S;W?^\U0XJM$$)<Z$1:,#_:B<@_>*:RA?X>W;0?$D!58X\VSUKO[!6(
M0?V''L'^X;1U"Y"P+%$AS![-C&#;[-AVZZ/P5.BQ;CHY4<JXHB)BAO[3!_?T
M<BJ.5XC?5F91,KD7C_#2[Y.$8N8"^.)>PJI$<$@H!J\IJDO-G00=HOU4VK8#
M>)(`*FZ<D*W%5)15$3?=OV>O7;&)W&]8COO"5G;!VW3:>V.C,3J=0*L0"W0_
M5@B<BQ&5(M*OOC]R\S)ULO6XW]7N*C82QV6XBFPZ"1$550B\5U,T&ZEZ.>[4
MQBV347L3ZHMFSA5P=<J*1';$2F$472WT['F,V?R(O6_F,*Y>D>&[)N"8C<Z<
MR[0%PRBPU,9<XCK=P2M6R=OY5QJ<#$$/70.S'WNI)R-BDS7>!OXV-[.TN:AP
MFJ_)*L&P52"J<K'.`D(`D(7MC&32*;`XBI*)*8!)Z8Q3D,'4_6;>!C_TZ?;H
M6Q9[A;FTQN_-E<C(-<W&I)+3A<-*T*YY3F,B-V9>R1Y3$>7:1\+:#D8A;^WX
MWIF*9_%LA@SEZXP`HY1=3SO$,W3WN2:GBV*ECS4HM#W*3C0C;,T@R.%'""4%
M+(OG$<*RJ13)))[Z\/"[IG=ZQLN'J#LH[E$-#Y@7!9G>,=H>`.Z!G0/<MF(F
MP)<E>=..'B7(9&/D]&Y.NUC+IZU)%?\`LD./%4H&.L:#19'*N0>1DSR)R/2K
M4K+,*G9ZT%4_0]D>+NXR/R;(5MP$I:+]&0;AKWM%7CI&,B5W0JBBFN)!,[KW
M7N\LR/9^V]MAVKMN1:V&Y"8GUH@"4K,9^6$)2!:6T;YLP)`4A;PHV)YW6-_(
MA)C$@AC_`#G4D<>0XILW,H\C:)E:8NKR5"I6A"4K:M7DE53-K;;+6H\9LG,.
M)0553F:^5ZM..)-D959@1F4O>)CD(I[KH6[W<,.QA"']0L2A/J0UMVK8>49T
M;9.EL6Y,)&3M1QZZT9",[CDX\H'RG24B=0_$:N-&\4T18DL]#R62+HA/UV)R
M`RK=&O5DD8[Y:W0NE<20>,\BKKSZ!+)8B(Q<`B$@S1>!WN7C]Z4P&(1LK[;Y
MGY3(AVGMQMW<C&G<NVHON_*G0V?)Y(5F3$D4$81X[A@@70<BX)`28$\I<R^K
MM5BGFPJLSBX?B&HO'MCRT7]1IA!K-A<K>2)E#U7'1'<HDBS+VR9#HM!(F9V)
M0,U<%<@0@"D.O5=YG*YE=Z(G^5/TUNT^(;[GEKI4O30C:^J\SM\3;MX_#]=7
MQI&B^M</\(_W]?DX!G]J^H*NJB-$1HB\3_K-VO(-'IF)[13LX26)85C$YI0N
M,&TN>.H5M>XEY7:LDY;GI&0^3_&MEE"2CX+YBU9QI!LA4E905BLT'I6+DI<E
MMG4SLVR#>,X=4TK6KU;)<8_AL)P@LLG56&<(.H^7>U:/1GPQJE8Z`QG+DU%=
M-PQK["6B5E)'L2:*E.1-,XK(^)1HX)SKB9Q[RER06J5!S-+5JNPX5AWG!.]T
MDY:74+BZBJ*:5L-_RFK5*$)9KSA(.9(D:JE*KD;LTFS#S.BLN`3?\*91I:^5
M$2FC3J=4VM%QS=7L)"4RYJU:OL6MYB,4O'LVQP.ZS?F!E6WZSXBL89",18D)
M'-FDNX<"289L6Y66BY6W60]BY;UNHJ8ZQM54ISDG$R4NXI.14<=GMDEC//41
M*UU>VE99M<U?+C^10K83[MTYIZ;]M9(\:LF@,@LH_:D&GN7<_4*O*\#E&6:!
M0\=LS!2ZU!#D]I;34?*#6)MT;D$':BEZALY8GD61(A>),1A5Y!B^9RS15](B
MY*V8.VVB1T3G<LY`F/N/G'B':XLQ99DX'&[M6&0N-L823RK3-,QU`&@X.J9&
M89!Q'*5>)ETRJMY'(+!PX0AD6R"RD:X!XD5,I'4K#CYVA&?3[F9M*H4^_-[I
ME"PS$E'9#L+++$;.IWK/8A(6-_%2N1E'=@N#+Y@+IC4E[>K-&EFZ,<,D+\>A
M/Q+F^$$LG9*ERTN4FQCJX(4.MTYP2`S@-D85Z$IS/,#^-C*ZO.91R6ZQ[!H,
MK2>60>FEVL6W=RKADV1`D.J]=DE0A1N^A[+SXRV9J_&2LA9\>QM`Q&F@O9LK
M2;^:I#\DQD]PR@(+$[OC'@1@-:G'DA*K'MK->18R;EF#1JLX2:#Z8M7%]"^B
MXEKY9PLSBY)VWCEI==K'O'"$2W.V3<2BR#=11..0.\509D6>G*"115.1,#&#
MN,!=QT1>8OT\\YCG6Z9GL<]QCI>!+ZA3L1$L$M58N]5^4>,UWV27#7#UXCLD
M8LQ+,S5TPG)*/"O9B':RM7=FG`(Q?F.DLD0MR#<74;L)ENZ/U6;VU?X]Y1Q\
M>XM^;;`.5;!8+FXI]JI;JJQL!7*'<JR\BDL916$J=8H%P^I+F-?*S+MQ*Q0*
MMR`G)*F*GX."ZSZB_"[+F?<ZQF0Z_BC^V>F&PI#T&MQ-?MW&^A3M#R'%VR^3
M,K/W.3SM@K*4A/T.QQ=GBDTB0[PR\8M%NC!&.3/`4*2,@`R]6,#4VTXZP;AC
M'UYE(:;NU$Q1CJFW":KD>VB*]+VFL5"'A+!*0,4RCH=G&0S^68K*M6Z31JDB
M@<I"HIE*!"E@U+IU]%$:(C1$V]^=>FE\6$^9VB/]9DA-KX:XW\[*6WH]X<?+
M+>?SH^EJX^G\XJ;*?[00:E[?B[B]D[!:ZF)W672Q;FSMID]XM*W^IQAOQZ'=
M?KM:GY4KI>C'I7JZ_P!'N/8(]?/L]3O0CMQH[H7?T.=+I99W#;B^7J&32_46
M\>.WS.'(UUM=U7SJ?4H7=M^7&1#FL#9%G_V+XXZ%<%^_!1PZ#+3`HR[F&]&M
M&.6J!3`GZHR@&0#N`2CN7?\`0O[<1M3](XP-L[_ZY\;4;Y>7EW.X)Y,NA^H8
MB/<;ET-N&,.?\XHO/VA(V=PE*VW':A'.4U95!W/0H1Q9/]2QDC)UB3C7]4A)
M)O)*R$Q7[+`,7BK1LS4%=BF=9(GC!=(W?^YC#>WA=V`_I&SR3W&)M2VRC(3F
M&:$HR(!)'G82_"NN6I3&Z5C_`!V#AGW%P7`Y@BH]]5L7M;&2&,S-BV3KF-^U
M>(_5+"*MJ+8V-+18:ZI)*-8V`1493+.N22S]VS^6+(/X\R+($E0`@E/KQ[&;
M.Q$]C[O&[E%ST9RA2_;B6W&9!CN@`#O>,GDXY*SMM'YS',(`CS#=6)/(<CP#
M'0A+HVU(SJK";E\>9`OTRR:O&$-<<DNZ5CJCP[+SMA>U''^.9^OM(&%*>RU)
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M-_?'7YA&B^GC18=5$:(MC(FV6*3W>G:A[^FS9/H'\&@6N"I'[`=P(CMVLW)@
M_;XQ+_>-J*!(C_B']W][0*G5+U0*#!H`"/4[H_[^XA0]WV@.CU4XGFR3-`W=
M-@^U=$/X5"ZJ#C[%:Y'N<KF_E+*C_"<=#H$)2E,?Z@Y'_P!*V)_""QOX?AT\
M$%2/!(B?B#]_][4*H2Z0-LX``Z]J+8O7?ILV2Z>[49RL\%E8+"0'`CU`6JH&
M3'?L4#<I>TX`/L`!'K[0U1R5.@6%1LD8@KH&,9,/YQ,1#R(;]`[]@^),1]AO
MX=AU7XA4:^*5J*$*W9(J%[T3(&/L&P*$.+A8/(D;;\7V@/PF]^H_U*<7XJC9
MN"3I)4#=Z)@6%-8OL$2H*#VF#VIJ%'V@/7WATTTIP5>C<4E!5)QLFX/VG`.T
MCD=_8'0".-OQD`O0#>TOWA[*#S6="X2I856;=GL(IJ%4<CON`_"84MA`0^$R
M9P_:`AJ$G@K0U5[($7#M!<G8DJ0_QH_A(?H(B=#?IN._4G3[M]75'('@D*;G
MQ=R1R@=(P_F)&W`0-[.],1W\:I?M]GV[Z@?W(=?%*71=FS19`PJ-R^<OF[1`
M2&%43%*I_)/L/[!]VJ0P\4'VK*T6*[.J4^Q7)FZZ95?858!2./Y^^P%4+M^/
MWA[?MU!XZJ:>Q(P64:F.BL3N(([*HGW`!^PY1#<2G`/PF#V_>&E06X*DO4)3
M(^1-;UB`[IF*BIW%-\:(F2)V`J`=2[@'M_"/]S5`<JQ8ABLHE!\T14("::Z:
MJJ8I%Z`L90"J[I!^$#B(#\'0!'?;[-11V/@A-3U399NN8J:B!B*D6.&QA$H@
M@9-8>@[%`P?$/4-NO3V74)H7"J3O4169N1`AVY0714$`$0!/8@D,8O4R/8;N
M`0W$`#IN&H.10L"X2@AUS@!CG!-\R[2EWV['+50=NTY_PG+W#L!AZ&[OMZZO
MCQ4+>XI2JU]>W*F7<%2)F.U$V_>GL(@JR<=.X>PQ1`AOL]OWQN:E`?!<BH4Y
M#F*<.TY1$IB^\IB]!`0]H"&@9J:+2LU5%4.H@'O'V:>/!4-Q73QS`S5,KA00
M3<K%'Q&,`]C5`0,)G!@'_C1*`]H?OT=Q31'>BJ)A(`.A,8PH=J4<U-\9N];N
M[5EB=>Y4X`)]NHB(@(]-M1W4UHL`>1F15?O[WKI3P#L`*>+L\:B@%$0^)8#B
M4.@;%'I[0U7HW%76G`*P!%DU66$Q3.5%")=IOC!(>X%S&.81$#*@)`';J`#[
M?LT^]/B+<%:U**957KGJ;TRJI$3";O6\NR/><0ZD((J^T=A-[NG71F*$OY1S
M29(%7RP;F*4H&(F)A^!%$IC?`F4H=`W]@%#J.LU*.`LKYUW++I)%["&6/W]>
MY18P'';N,`!N7</A*'0/VZI/)!S614Q&C-MY4P.X`[A0B9A`4R=WC)W+`'43
M%%/H3[?;]FJ!6NJ?$?!6L@.X<G4.;N`$5SK*#OVD*9%0NYNT!V#[@#?[M163
M`4YI"HN1/^K-]RI"("HH;^=<"'\O;H1$-NA`'8??N.MT9QJKQ<ZI<HDB"319
MP8>WT^Q42B`**B"JVWM`133ZAN;;K[M8HP=8XEN:L:*G<.EDQ]@LW2:21`V`
MA104$I$B^\1']HB/MZZIT!&JI`:B3F*FR`!W!1V!@#8>TZ38>O[056`?^"4?
MM'V4'GR34^"5*D.Y39CN)CB@J9510P[$`'2W<=10V^P!O[??[`ZZPSI2KJYF
MJDF\3;(?&4_<"JYBB!U0,F8!*0!_FT0]P>TWO^S6G\J'1(DFX*E%0YO&W*.Q
MU=M]Q]OC3#IWJB'N]WM'8-9`XA4CAQ2APL46:)4P\:1'"P%)N(B/Y:7QJC[#
M*#N/7V=>FJ=**/7Q2%(X`LF8/;WD^W;8#`/]X-`_%4FC*YT4A72_4>BZNW_O
MPWW:2<K(TJLR(@+5WUZ!X#]/;N!CAO\`P&T'P^*AU"0]X_=_X?OU-H6DL?[=
MS<P?QFC4?WBD0!#^'5`#H!2J(_85S@/L,V=!_P#RZ@_X-51(1VW';[?\`:<`
MM22Y8?\`9S,1_BJNR_?MNB;;^$PZ1^)(T*3-Q[5T3>SM53'?]AP'119GW_.%
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M-JEF;5NQLS44(7)TK98]VB^(2?95]P,E38^>J,\X$!F'C-NHR(!O.59`Z6_E
M2R,/OULPGB@YUN4[9Z^ZQ&!#>0R\LY0G$$].,CNHS%9V7,8O"Y^46D-I!<<Q
MJ'!I5ET+:VTFMD<R]LPA.QS)63:2-QDLJ6BKW;(LE."DD1[;IZ"D&-:M<P"]
ML9OC*-D#1*"RSQH*RBB:WE#Q)X/<,K\C`[A`W1`BU'&MSMV8P!_PX2W2A$[#
M'S2$R`),`0RY)W,<3><`8G7<7D_$D4+N[L0#Q6%>V0C(K.UPN)[[4'\;$F"/
MOF&[70YB7JE7<FCW\E&6^LI5MW$V.(E*K6%TG"$TW:'=(2;8'#DYE3)IOZ?D
M7-V%DYN/?A*?FM9-N[&,[@<`VY[Q*$A.8:5LD`QDT:.9OC#\VW"4&_%`B@/"
M09B&X'WE(8VIN[M*DR%E>Y1\Q18)6`AW3E[.FH4CY95VZ)$X_C:?*JN9&I>C
M9NG#E=@PCRCYFO\`6%CKF$-<^5W"';[9[7V6Q.'<[H)&V/4C&(`W7S<%+E0P
M,Y:%@&6;=J-TF[=+V0T==IYL.3^%&?BD=H&<NE7+=,@PD=4V[L[!QBNA1$4G
M7@;$E65,=(/RQ;)&*F4Z3!U2OQ,=&*F3.$BHT,":HAZA17>",;!S/E>USG>D
M*9%^4C-R-[Q!+QWRE*4IL0(@AP[`<.3*4X=6\!`OY8@`:MJW!@&/%/?B62EG
MM8XFO#6!DP>R'U$XD\DBG*.8E&?3-6*&=['HQK1J+:2%RHH"A$!!#M,F<Q^[
MM$2^G[Q;M6L[O-L0,H#TWY:`[?/.I+T]OBO8X+RM6"22?G1]T?J7U<!_A'^^
M.ORMQ7TY5T1&B(T1>&WUG)5Q'J<:F:]AY&U^KRZF86EL/Q]CIR1E'[)%ICQW
M"18%K*R,XQM4K;$(]HV<IB4"5UQ/$*=-8Z1@+DAQT=3IY%0=FLW$.NLX>NW2
MUSH1V)'[I*Q0LN\S/'H-7,"M,V-BSJZS52,S+#M/*N54ZJ4>A(@H#@1;]Y#%
MD?$F3X>T!U!X8Y`5R-8LKBV5ID?4*K%YGF'-YRJ_BXBE6*,AZ%F:+K\Y9@98
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MD@KL-7RL[+8>-#:;3LE)2:0U*D85MC*Q&D8>`@L6K3M>0<'-*K`H(QD4NW*"
M[;RI$B:E+6=2MCG@;(Q<1!P5SM"UY/8@6J;RP7F\O.S,+6<<WAS,UN=DW[KD
MC&QZ9I-9XE)&CVMG1`QU2LTS$*3\7T^C+-P3JC>C5#+K0ZJ\K6X6ITNNPI<S
MVI.<S!%UJKQMT\-)R&WCYBW1E3Q/7DGQBUU@B@DJAZF5$[4P"F)R2+J*_P!,
MOFGCS+^>;]BS#7&7BEABARL:_GIG).)<JR<=9<M62F(,8-H%.PW;^/F(<DV6
MBUN-4\19^20BXQ%(Q0CB.DU3'"+4XD!R25[Q:JXEJ9YP1G!33M2*=3J;6)D7
M!X1DW2=O9DB#-90T4T:+F(BZ=2!2^%-,Y@*<YP`1`!T1>!O!*_<>,E<GL3W;
M&?TQ*C@.QS./K!$/<]8W@INKH4>RPU'2M]NQ?-1K?#^-X:7KU'89/85>?DGB
MZ(_VA+JQK1@[3BC2+<N20(#$NNWG^4W).]<\W^$X?,\)*8CALR,Z?`8SXZPD
M3C#,)TZDD:P7%#*UAY2T&9JV4*O$MJY,#*+XTGHIVJSBWS1J4[UNH31&&UVJ
MR]T=%QHT1&B(T1&B)M[\Z]-+XL)\SM$=ZS)";7PUQMYV4MO2+PX^66X_F1]+
M5Q]/Z@5-E/Z^W:E[?B[B]D[!:ZF)W672Q;FSMID]XM*W^IQAOQZ'=?KL:GY4
M[I>C'I7J[(Z'<>P1Z^?9ZG>Q#;C1W0O?H<Z72RSN&W%\O4,O-^HMX\=OF<.1
MKK:[JOG(^I.[8)<RK\F*;L[]/A;$+JB22\;9=DGF./,2+-&`W(Z5,\5W[ET'
M20IEZ"&XE$/T7^VL+LO1N.Q`@>^D:5!^6EYG=@W(A=%]0;?ZA-__`"P_Y@_V
M*#%/C_U"ZD)9HG#UV$A18O929DWMO9QE<;24BR9QR:JA)-U+N!8O5TT6PE*N
M\<'(`)B)`4V[SG7)6+7R\]]Z]=)$8QC;,KA#F19A'0$RT`XU9=4L@W)[B=D8
MAR9$,'T9@2!]I*7V"O2EM;3&3X_&S7]/RTY"G@[;(/6*=FL#=X4)4TS6JWDQ
M69C))@FB<9-X[;$6,P=RID@>HD\0*^+C9>/ARCVN]E2&3"U(3M1!V0:@A<G:
M`,2?@B)%I"+[35O*G:G.)R(P`MF7Q$UEXL22>=!1<45]#VU:4<15[A[D\D/6
M]KBP2:U;L"R+52>26L3^.O:4<($\,"[>BEY'A@2;"9=(OQ%/[&`NX-N`O8\[
M$!M^$"4`X'E$K3_S`?AJ:.5X=UR20=T]P<Z%N9>BQ'E6<ZV=3!GJ$7&12(13
MQU97J44#%P4LRN#XC6;DWDP]:SY&:Y$1:D<BJLU4(#<'':4W,T[`Z>V4YS8Q
M$!N<4H6&T$./B(8$$EEIC/0L.+EEMX"$/DQZRK=9/"Y4,P;6B`;1]B>DKE.A
MI!>+<NHV+A;19F43:E371!4JC0T0YCR.1,5);RNC)(:\/*R(]GA/*R]^%OZ<
MB8#J7)`&LIP@3`"V:'?&3:@[0ZY[5N5UK5DBY)S0E@Y-6)\132M-5VKEL:PU
M]&";U]*$LM&;S+VQ8VEW%T93[&->RIK(O9VK>2D6P';R,9,-0=@@1!PB1(AR
MD41'R%]?;O6\;*.5<N2N8F1*(MY$8VS`R$1'83$."""SAG)J]%J]&<W`CLN0
M!>-7I4GD1HZD!].IR@ZY4014V9F?@H-Y%V[14D!))&6&*!))ZC)/EVK,D2)0
M23,Q31*IW%$V_<8->E_<JU.WZ3N;Y&0.3;:)9A\6C,2^OF=>=Z:,I=UC0@=.
M5:-I]-%]$J_\\K_ZP_\`YPZ_,PT7U$:+%JHO._ZD?+RV\&\58UY!,FL7(XOC
MLI.Z3FB,>0RLG*N8RZ8LR,AB4]=>HN45(AZXSW'5F-7-V+`X;29DMBB('"$L
MMP&XLO.+#_U/>9,W;87'.7H7'A,G85R#A_C'R=K=2IR$5%V+E/DZ]Y]?1$+7
MIR?G'!Z;0I'!V*X*2.X03?NFREC27*10H>/4!9:VAJ)]<#_5]N%AH/'^<ROQ
MK*V=Y#QSPGLV8;M0LH0#BL4EQSMN-\H6*UZ?1W\8YL]H1:3-)!S)L1>D7CV3
MOM!9RY1%-4_%3;JQX_<M=%_6UA[%AY]E^O\`$/,3R,6D\>2-<(XEI4(9[B[)
M=4R9;H7(4]*Q&,)RPQ[F$98P71F6$-!V1A&*23-PI*"P*\>-0-$V59U*G$7U
M*Z;F+DU6>.#+'+RNPEUI+:WXMRY(W9E(UO+9WF)*AFEVTQF,56G%-NC".K5J
M435]#95)M`(]5VXB$(]1!THHZABP)7'63G5FZAY:RHA)XDIUEQAAV3Y5/YY"
M$O1(.S&QYQ]D.+9VEN3>3%?>(O+=\MS%+`,&F5%J_5\`'?,P0[UK5!$-K5E(
MKC[S(C.0V6K30(O%EYK->9CD]Q3[_,,[$A#VUOB3+(X@MB+L9>EP$-&2#ZPC
MZJ-3BI.Q)&8$4!XHR=I^D,=U"&#J+F./J,6^NUZJ)YMI4=9).[907:61YCR7
M<O`Q-4[KGO)V&<3QA8*%QVX9R*38F/3++N;),0,A,F65&++(J(J-D#J[:TY?
MP3DR7U!9:MUW&UOM&`B1%:R)"UK(1IUOF>$LD/2<0W"$K,]7K9DA>J4F;D\=
MRKUK8S)'/.,XZG)+L5@&S;'0,I":(`D,1S[NDY-PM5J^#'&0I"4NT!CH+3,Y
M,K6.&A[??[+GB+I#)6%9U6U'1KL8PP8Y"4?IG.Y33=MCH-':HN4T3J-2J;9I
M]3]8DQ'V=M1YV5I5NJ,,G6\>%BRN[8.0\F,>"IL=0?S^FQEIEE:[$/.3\D$J
MY0AY)\N9$OI&JPD;(*N*UM^GUJ5K_E_*LN-E<Y`PV$KV_G9R[KT!WBYP2QMI
MR"E(RX6.FV&;>-H^@SF0YBI1RE8</B%CZBZG%H]5-56+;]CKTM%."RU6)3,H
M?5&HLX[?O(K%<^ZQ]`5U<9#)C2QG"C(W)'CZQY(&AAO#BHHXM+4%:_,(1"<Q
M^I/F)Y94@A#>C,#D3@JF)"<KC%S%LN?<]+X\4IWZ!BZW4,Q,KI79(E@=OU;Y
M0;5@!*$E8B1MM0QQ:VM?>T_-`^1K)5Z.=@\#<"F2(FJL>B2'EJF:L?.O)%_)
MAF"Q)CR.Q^]SO><*SM'MUBM\!<'BG'V[Y6?T"RS<O6"5=9G3LG*GCVY&T4Z&
M3:I(22A@=B\8.&Z6>*,!KJ$XV7N5F?JCR.6P]1<7T"XU6/O6*(&*1D[NM59Z
MQLK]QOY0Y?L*,K./*[/-*@E"SN&(\S99NUD55VY%D#([N?,WM=$8:^"S8!^H
M;6L\94HM0JN'<ALJ?<5H&(1R(_:S2D;"W:7P+7.0ZD%-'0IY:06(:56QI1H.
MV]E7DE98NX1A6"A'HRKNAC36J7*9TR5(VO,F29K,.,<58HP7R3'`\GBFTT1O
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M&K[5WU/Y_&N-Q9U-O@N1BXF/R)C+$^39]3)L"^"F9,R-F3,.!F493XIK7O\`
M[HE;A;[B-T=S)^KBA/$OD'"+=1=-PT2CNC$56VSGS]@,$Y5D,>2^.9"WQD*Q
M>,9^U5^RN!?Q=G6PED'-\36IB,3IS^JPII*M4/Q)A*6*/FC^O1=MXQRP*+D:
M35_!-I:B::__`%$<DQ-&RW#5S`+"'SECW$&5\N!#V'+$!(TVN4JDX,QEEYE9
M@L@UB,1M<^F&9H9HYK0(,VPKM7QPE"M2HN5LNFT&HT3E\L>4V;,&+8\C\=U&
MFVME;L+/LBN9";E%8Z54L33.7%C&K:O0\>X;'C$(B>B\W/DE5G*Y19N%4'(%
M,#4R+K1(4`$JZ56B1^I@1K?8_&SK`%X7M=?M(UG+2M7D9VYQ-`<.>0=FXY1K
MV"L4-CKY);XIS8:@\E'"DVM412B2$32]0_$&FLZT*;*/P74YYY19/Q?R7MU3
M_3=7F:'"XMPDC4*>29=Q]IOV6\RW'-+=PZ5&"QW?KZ[85>I84>J-8VNQ<L[7
M(*[EP@*!3K,+4:*`,%P-7^HBO?,9O<OT7C[.V"DQE8IAWK)QE*FP>0763;UA
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M)M71`+*F52<II:$N"$-4J.T?]3<'Q:J#G$<U5K4]</JVKB:2L35"?)8K:YPI
M%8N2N<Y:Z=5)#'[&4L&7BE7EFK"6@73)JX>1K^5:D0.H?DJ(UJ5W$9]0F36G
M'=?D>/JS!*@7&(I^89@F7ZW*L*7(63E18^)\?)51).JMCY`3)<*X$LJFX&$%
MO#G.53M?IBS/';35&.K_`$U3<'^IA/SC^+:UC#\<1@-HH\_/2,E=IAVUM>#;
MEBCE%D.+G\?S3O'U<B92RJ2''!4I7,>:;J[EHZ(+*6==QU$*FU.59/J,0T#-
MMV<;AZ9GHZ$HK?+5S=MKS!L2U7'C'C[!<C+3)MF`1$B[L=FB*K.),F<:3T_S
M-\)#"NU;J"J0_P!2FU@_'Z!<:G]3@[*ML[%,<;[M6B(S2/ZRGK'+VN#I],I#
MZHTVYL+BXG)K$,;/LVB[&X^E7D96%AZDR>,5/-8$V[I@X=Y=J\5=K^Q2;SSR
MJ;87NZE3#'CNX0E)HF.LE93L1+C$UMW7J9EC*LKBNJ.*;7'L7).<ASOS^'>.
M7S,KB-(W9(IE16</'3=J>J`#AK_<F(K_`"HS="</<>YRO+:MO\EY%R=?H>/K
M$$2/)38Z-!UES](U5Q*#&L9`8=JTH+=%W)@@M+'$YS`)NX0+`ZK#<W!=KQFY
MD3&8+_5<5WW%S6@W&<Q5"76/F3V=Z\@;O.ITC&EJN1J$W<T^.A)^M0[C(8HF
M(SG'\S%BS,$O',"+-E%JY"'F]%P;;GI:)S-V.HI3&[>/PSD5">J5/E#6Z(?7
M:?L[3EYC#BTVMT_"A'M5:+%0\K9I)T:(%204>H*-RF<-7B2S0A1F!;Z4=:)A
M]2F+@9K)5HLM.<FQ+'L&D!5G<2^BUIYAD)#_`+3,:QKSM\7N1F@S1/X%+%US
MQ%2,VEW[1F?RG=E[:_U*F*>SDUS#;\94:4:PX[7L4C+U0]YN]?C+4X//TJM,
M+%3JK..&3"$I=H+,?+9JW"D61E3URNJ*-!1-)I.%T41`@%2(=</=^><L\<8=
MK6,,=1YYJ_WZOQ,JE;K>DW9QM/)R_3XMVIPD$3%/'BU@?.3*/XT3D!LCU(H4
MYTQ*8]&01U)U7%X)Y\Y1MD-A&GVC!45(<@,OXVQ-?Z6Q:Y1BJ[0KC`9!QQF6
M]/[1-S1*E+K8U=-&N")KQPB+:=,)GC("N_&#U5HX!60H>26UKZB#C)YJI:ZI
MCEK3L5R4NYB&-GR+DJL5R/F9%#B&ORIEF-J.G7IT<:U&IP,BS2<6!->3%X\;
MJ]C869@7.?ZD$6]O]ZR!]1J59/,<0=LXP9+@9&V0-4R/8V<8\L]J=U7%.3\M
M2N(<7W4B4=BMJCZVT&KKJ?<1-B4JKJ/A_"D)EI17Y>F!HAC5W3AX%Y:6C*EO
MR!8+32&-(Q%$\6,.\F*&SC;#'7RYS%2R'.9M<K3,Z6(91@PTX[J>.V(?(`*Z
M(U>>4J3YR)S^*%9(I35U%+/_`-0W/J=7KZV(\7TZAW)[15<_O$[5?8:^1,MA
M><XR\@L\XZ:%>Q]1%I$6N7E,'NV\^Q*106S9$I8Z17(^*^:G*T(CBGMQCS;N
M+*.M%6N=23OMAQ*FZD\\WIY;J%C-I7ZPVO)<>(2-&@PB6D1D*4-/1LHN#`%(
M-11JV12(<[YXT:*%F0=EJJ!]1^3R2G1F]>XRW=O,9"/!3]>:6:UKT6)5QG.X
MDO&:"VD)V_X]JA7UCCJM0';5:.:-W$,I(NF@H3:K)1=XVKK6UN*E?QGY(I<E
M:?.3[JF+XWLE1FXNN6.@RLM*/;-7EI*I5VX1A+)&6&GT.P0<DO%V`GY:L<+)
MR5/U,>\?L5D'2@:J,P4G(_HX,/N*V=B/_1E0_OCHLI#[Q_;_`(`U>"IU2U;_
M`-CFWWKNA_N-PT&JHT/L29'JJD'_`*0G_G!HHST6=Z.[I<?M76_^N#J#4J#1
M)-5$#_A#^^&B+Q5^JB[;,[YA<7*"KPJ]9R"B0#?-CI1BYAIW9*MTXEXS66<(
ME`I`2.*B)N_90@@8!U]R_:*W.YC9XA(Q(E9/X?,&GY3N!#'Z^2Z)ZND(W[4F
M#@2;PJ%`6`0^1UY6=D6;1,EWB)NM5.I$<W%>=O;V4(E7$XR.9PTGL#%O.O4%
M53F,"97"94VZ2B@&*7Z/ESED9`Q;6Z4L:<;ERZ1;V6A%Y.9$:[00`QH7D5UJ
MR-D!-XQ)<@`ER>3`"E5S5@@7^-Q2EK%!EQ(21KCM=5]6EF5EEEU;/-R9HBL6
MY!%L^R17I:TE<D=*L%'";)N4X'<,TTA06'=C+L]VC*QA7)9TX7@PG^6!LB'G
M:W;;,Q"H$A$R.@D[A2[;NV)>8"!G$EAP<:%B6?E]BT0OHJ(:MK`WEH.QQ$2H
MY2<O*Q+I2;A^HZ"92+&H1)G,-:1!9&.<NC'6;M!%LW445.9+L$_L("[<D<:<
M96;TF+3&T!FJ9,;?&,:$U(`JO%-N6XR<"/$_[:I)(O&$:W3F)6S0T(*Y'<['
M+.),SR=E4O\`;S\JC.)A1E9Q.4;I13E`R;I)I_661TUE16[C*7;=R8G&LV;E
MTAHGRM".@K*6V+'<"#$GRR<!F6V`'GD.G3PUTH!X<5VL149>=)(7Z,H#7*C%
ME9(A\[L;UY\FN]AAI=L*!+.>M5=%E<W5?DC(BR?/)@KU]'$D=E%6J^Q5/6W^
MX6,3I]LNY,L.X;9B(B.ZU"0/^'U)[K8D-8B&T2:@(T\F-N_/=.,>I%ZDFI''
MRN"SZFJK>CM95N7(42[C[)5[-)CZ>QM5[&JY:OGS1A+J1TPQ?2Z[QG,LXR01
M`Z8'4()-CM53`!CAKMC6I'MMZ,K.9;C6#0`('EW1(#;20>7^\*A9O0-P]4'=
M:/%S3P+_`.SDG5QL[C`KO$-PYCW4>W>?4=AB1D:UEDT64,Z_2>//3=JTJG)V
M"6CTDS_$0S@BOYI1,?L,(:]3W6-V.7WJ,)B<H^FSND14CJ7'T:(/L#>#KS\$
MR./8,0`/GA]31T7UA!_A'^^.ORJ5]/5=$1HB-$7BQ]86$;R<7AI=[1/UTBI5
MN1%8B$)UWDYS28>[7*FU>%I,RG7L:<;>1;PN6XF:,#VHS;A&&")5:O42KK$?
M*I`7)!2BLV0,I_\`8OQK+M*A)(9%<R.+Z#;HAMEK(%`6K[AI<XRE6V2-F*]X
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M.-W%#K=]45:9`8TRMC>\ZW>`LQZ*XSJSJ9[G)Y<N$!*7^BQ3*K+*O`:3$:=Q
M$-T08*I>!,#:*TW571<>5'2C;E%'M6&?JLJK%5I_)3.9\D66<M<'>GE!DXN<
M@HR-L#@8*K/ZDSAHYT65K;UU6IIJ]9ND'1W";LVBAX:*(7T8;RXFF.?:+*32
M%LGZ*PP@M+W5I;;-?"VI6=B+XW^9S=FF.2'(2)-;W:T`HYD6S,(`2BY36,W6
M260,E`M3X%>XFJN-:.SK>FK5A<>F6>>"#EEO2-TTE7#KQ,'!_3()+.&B*BR_
M;VE*=5(HF$`$Y0Z@0:KP<^CU4J9=K]E',TCCC*%7OL+1\;P[`+'CZ[XUQE51
MFWN3?G<+2FEIF')K?<I*()'N)]^"7ID&YXYLD1-5%=1<N2Y2BT^(J"%O^J_F
MQ1LXFL-6V#O=MGI$:KCVH*7NU4Q@UJ[YA,2^3G?$XK1GC?*0$306:K6Y634;
MF!ND]46`@E*GX/I_:OH7T7$C1$:(C1$:(FWOSOTLOBM/YM98SUN2$VG@K[7U
M+.9WH]X<_*;6?SH^CK0^F]0*NRG]>;M2=OQ]Q>R=@L]7$[K+I8UW9VTR>[)I
M6_U.,.I8#'=>KLVT_*G=+T8]*]79'0[CV"'S&=8ZO>Q#;CQW0O?H<Z72RSN&
MS&\O4,O-^?;L1V^9PY&NMKNJ^<[ZF4LZCN6.1P>2!&];#A='*OFA)&!*<ZQ<
MO1:;A^]9OUTY)-BV:*EW,G^68`,.QCD+K]#_`+:6H7/2F,8Q?('?:%I:?+RH
MXHY^SV+HGJ`?^I3DP?Y5GKH9,H"PL-&/XBWPUYGBU7&M"G4IIFB19G^L)A[8
MI"!@XN:-$.8&^R3I5I3TY)\Q.6,8-A%=GVF33<J*CWC*R;PR;-[ML!<[SD6S
M%]I-JW&(E)GW6PYN"(D\I$@2<':`NLV81EN%XM9@=*.7H"Q!=HO[''-8$F"V
M6WZ]O9A%8KQ=4GT378B2AT9-Y),$/D:JD2P@%FQ$K!>;@:`2C06F94[1I'(E
M16`K0JB38.:,H]DB,"1EF]YR(FY<$FB)$RJ9@O&%L2W;80!,RX\S$I=!R3OE
MLABVRT:%_92I+:GAX:)YC4BP)UA[>BX[;9IQU'N2A;[C+4*IM,I4-T+.")`,
M)JY1D1**Y!JDG#5URX;S+M,[@%7)TW3@CA4JBG78YN/',^1^9/;^ZEQ;A&[<
M./>!,B91MRD!:G&4A&4`0"SQCM#+V(A.>.+UNT;MD4D\0XY.>(I0GWEUL8Z`
MO-WL\7#5#BC$2UW+#0S^/C+/7XYU6V]0BBL7[:>E?FE98$_19%(=!"'14<-T
M2,12244<&5'6+MW![7C2O97>KGR9G(2V3:Y*9<&,3&4COJ\B`:N:,I"U?O71
M&UCM?9Q0L`.)<?"WN:E4V-BQFYL#UA$5*_KV:TPJC0D!`2U;;8SJ4LWARRRL
M:^QK5JNBA7J&9RM^0P9RZ#=2;:+MS.E_4B)->XP>YQP[1NYF)&S@3CYYB9OW
M([MHD+L[CSN,*RE`D6R^V.U<$X"],QA-[@-*,)$`OM_E8TKJ?%:BJ3%;OP14
MO%/(ZDYOH\`DYAU$"MZ["V!:J_IQC4)%2$=4^6@JS/N6T?\`+'S5G,1C1V\;
MM%0;D%ZLBIRYEG*[49XUQ\CT[DW:@O.<-^XS$2)Q,H1)$XDVY$`RKY05+4[>
M2!^#+@.;"0&A(;7AK7ZU)3Z<#A)?E537YV*S&=L^-\A3ZC5ONI$%AEWC,(M_
M&@:0DEUH!^S2+Z50KARV,*::G<GYD"F]!^Y@$?2EVU$@VK659@"?B,F.X2H!
MN!-0P(<BK%>=Z=`'=8Q)\THRIRHZ^C%P<I55/_6&^_VB(Z_,D02%].T%5A\I
M/O\`X-:V21<M<Z71\C0"U4R%4*S>ZLX?P\HXK=P@8VR02\G7I5G/0$BM$R[9
MVQ4?0DY'MWC142"=NZ0(H02G*`@V%'2*0Q!B%27=VE7%N/#V*QVZM9/FYXU-
MKYIB9R348<M7K.0)61%AZM_=*[7VQ6+*25.=XV:`"29RD^'6-KRHJN6I7&OC
MC4$&D)4,"X=K$2@^JLBTBX+'-4BF#65HEDF[M09!NT9Q:2*+RDW:Q/Y:(.4`
M-&R+Q9PW\:JAC#3%M4<LN4=<0N([F#L-67XP8`/6[7;$KY9H+^R*BEBYV[()
M/6Z%KDFI(0J3B>0;R;I(CG8%").UTRB!%E2GH@2%22#J5W\+@'!%:MQ<LUO"
MV*:[E`D:C639!@L?56(N)*ZVAF4*QADI^/BF\DBP;P46@P(F50H%8MTFP?DI
ME3"!B:>Q#]C+.?$&(7<M;YMSB^@.I?(+2287^3<5&#5?75A-,(&*F6=I<*,C
M*3K:8C:K%MW9'`J%<HQS8JG<""?;9`Q%>*`E;2+Q9BZDWBWWRH8[I56NMX<'
M<6RW5^L1$38K**SOYF<\Q+LFB+U[ZJ0-ZI8#'V7<_G*=ZOQZ").BCE@"M&G@
M'`KR8C;0OA?%J]GJJ31W69]6B5P\M`N(RSNKDQ=1#TT>*S)Y'VJ4=R399,2J
MMWKI=9,Q3K*B?.UC5'*Y9#C!QD02:-T./F&$4&%D6N+)%+&M333:V=PFU17F
M$2DBP`CA5!D@F8G\R*:"9.SM3(!=&!9-Q3F)XNQE&*QTA%8[I,<Z3>QL\BZ8
MU>&:KI6"#<V)2,FDU4&9#IRT:M:I,Z#@!!5(\DY$I@%=3NRE2N80P;@15H\K
MSG#N+UX26ASUF2B"42O+,G4$HSJC`D.X:)1IB"P30H4"0B8@!4PA6';V^D0%
M-JCEE61PWB:3QZQQ-(8FH+G%T2=F:+H#ZLP:-0BEXQZI(,G<;!%:G:Q[]I(J
MG<$<)$3<`NH=3O[SG,.AM5XNM8ZX^<?I!?YRXPKAM>7"J'QTN\3QI67C@:&K
M!_IXE2,;Y89(8$M=*:-!OV=A8\?3!LA^7K+!'+\5TE!Q-B3&ZR;G'^,ZI1'R
M:;Q#YA4*G`5I9RA)'@CRB3]U'L6CUP>64K$:9TLH<ZC@S!N983BB02DJD,;@
M?#E1G)R:K>':)7YF>M3*\2\M%5BOQS^4M<6\DI*'M#MTR1(HXEXZ0F'3E!8.
MJ3EXNJ79194QS@%`\A5="XQ?CB;M`9`7QM57&26S*/9)W=Q%Q)[*$9&-K'&,
M6*4\X`LDFDR97*5013\@E31DW29.TBZI3:!#NH7T>BYB!PAAFG6R/O-?Q!1Z
MU=X2NLZA$V>(I\,PGHJKQL6A!1\!'R+%L+R/C6,"U28)%2$AB,$B-@$$"E3#
M)+EU=?8MK+82PY.Y+89F5QMCV5RW&-FPQN0).F5UY?HY-NT<L6RC2P+1J<R9
M6.9.UFZ"P*^=LW4.FF8J9C`+C10.S'1:VK8(PM5(V8B*KA_'U31E',W,'<TB
MIU^N2;2;FJY*5*6G8Y9K'HJ,Y<]6FWC(ATS;)M5U$2E!(YRB+$TT5-5P]7X=
M\7ZIBN`P_$X/QA+8XK@5M4L3.T:LOU9&;J];;5&*M%H34B40>VM6OMQ;+NSI
ME!=!95(`\*ITQ@H%7+UU3F6_`^!;TT;QUPPWB^P1HRKZT-VDW1:Y)1OZ@F(M
M&!G)%=FZCE4#/):*9)LWAQ*(.FJ2:2Q3ID*!190.$F_[/>"EFUK8O\)XK=%M
M[!)I9T5Z+6UD[/&-FU59@SDS^@_KR:3*C0?B-OWD&$9&*(&:H"2FJ'@76YA,
M0XF@6T4VK&,J%$L(4:>:/AXRIP;%..3H#V0E*,9@@U8I$[J?(R[MU&G(`*,G
M+E55/M44.<5."5XK6V?!.#+=<7-TN.(L:V.ZO&2+,;M.TF`E9YW'$B7L(V3>
MR+Q@J[6,2`DW$?Y=Q6!BLHV$11,9,1`(='(T5UUP#@R]L`:Y`PKBVZQAWS*0
M=LK'1ZY--EI*/KC>GQ\IL]CETUE`I[%&*#O`Q!8H$;'**92E`R#D-5TMBQAC
MF]GKLC:J%3+H[I!'85)U9*W$R[VN-7QXU9^UB3O&RRT4"JT$R5,"!BE.9FB;
MJ9%/MK-11V]ZTCC!F$+'-PUG?XAQK,6FK3\O;:Y+RM+KKN;A[).S);-.3;"1
M58"X+,2=D3+)F=%'S?,B`Y'\X"J!".*%QKHM[:\4XHR8"R]\QK2+TX-^G_5A
M:JS#S$BJE4G4T\K(>=^U576&LN;))&:E`P`D$@Y[0+YU@.HRE0M0YXJ<9'SA
MH]<<?\-'5:TLV/6B*F-:D5HWH:C1=BE3P9FAS-F<`BP>JMDVA"E2(W5.B0"I
M&,367IXH)$46SBL+88J01GZ>Q/CJM-ZTB#"!-'TR"8+LRD2M[<Y8T$6)'"0"
MED">!10#=ZH3;X#&_K;@5*&34-Q*1?V-8=31:O%,58\;E:LHB+BU5*;7SNV\
M97D(9I`MVP`P*9-M"-*Y'HL44^Q)H1@W[.T$4]J*Z*N79**1B?%V/'-NG\?X
MUHU#>WA\9[;).N5>$@WEJ?F7?NE'MB>1[)NI*BF[E':Q$3;I>J=KJ`3O55.9
M]R'5M2FLD.)W'R2H=GQQ5,7U#','8V,JT?2N/*9286;1+.!"EE48Y.1K<S!"
MPFF]=8M';!VQ=QSJ.;@V70.W#Q@'@J2=3JLN(^+N$L*4EOC^L4J#G$CR3B6D
MI*P0-5=/YJ:=9&E<LI.9).%@(2`31BLCS;B5C&#!BSC(ET)3-4$A*`ZE![52
MYKH%NF7&7CI!E[(;!>(81HG+P$X*D?CRK-E'-@J3Z4DJW*($1CB&,XK4A./3
M1H@)4V!7:Q$?&14Y#4:N=%`3IQ6SI6!L&8Y9>+'&%,7T@BJS])LWJ]%K<0HI
M\SC6T/,JJF91J1E@D85HA'J%'<AF21&^WA(4@3A31"Y-2N<8<4N,+.-AZVCQ
M[PN6+A[&K9XB&2QS5`BH>Q.6K%B[FBI%C.PSI6-BFK<Y`W1%JT01,`I()$(I
M[T<L[KM[CC#&F0;36KM=,?TBT66B/O7TFT6>MP\M+U)P5VT?)+0,D^:+.H]5
M-]'H.4BHC\#I!-8A053(<MHH*!N"V(TJCH5F&K3*BU@E>A)0).OQ;N!BTXF'
MD$AD#GDH6$!L=",<"M-.ME2%35$7"VX_F&`5(BFJ,Y7#T+CWA'&4TE8Z'BO&
MF.9E2&:59*7IM'KM=ECU]HA'LF\*R78,2NRQZ3*):(B4@D*9!F@F<3%12*64
M]RTY]I6LF^.G'6=D[W)O<$XRDGF2>]&^R#FA5_U]V2&9C;`)K(\59-UY,5+%
M#-),1./_`+)-TW?_`#DH*ZJGF2"7XKX7>1%.B&]!CZ75:C>:!>"4FBQ50K=>
MMDEBN;?W7&L9<F2,*X?*URD7IZ$^P:L5F!RRA`,H<Z*BZ*MDS*N3IJNJR!AK
M$V7'\/(9+Q+2\A24$B[9P+BW5V'LBT2UDEFKA\QCQEDW(IM'+IBW6,EL8@N$
M$UM@53(<L!YJZ+7.^.7'9M*6J4'!>-AFKI(L9BY/OT!4EG-CFX^QL;HVEK`\
M^7*N962:W:.1F$SF-NG*I@[`?4")QH#Z<UES[EGF<'X/M<&O`6K$^+IZ`2@Z
MU!(0M@H$$K'HP]-5E@I4.T048D19QU4-9)'Y<BD4B;0KYR5("E75*?+5JK_P
MK%-85PW:X%[5K)AS&-BJTDN=U(U]Y3:S(0#Q=6J-*(JLXAW$<1@H<]'8(0V_
M;_[%(D:_S!"D#E,8A0.Z1H\<^-\.:CJL,&8IC'E$D'=BIR_Z`@$7%5G)*2:R
MJ\I!KJL!%D]5DHUJ\!1,VY7:"2Y=EDR'#`B^B%]7U788XQ#B?&TY/3..\9T.
MBR=P=)O+;)5"J0M?>64[5W)2B8S3B+9MCR*2#Z6>+))J"9-)5VL8A2BJ<30M
MIQ2NTKEH;`.`Z]&R$)7\*XKA(:5D)J4D8J+H5:91[U_8:Y)T^<<.6B$:1%49
M.H3+R)5*)>P8UTLU`H(*'(.MA9U'*W4EA#"DFX@++*XCQK(V&M6A_9ZS-OJ5
M7W,I"62159R$I/QKQ:/.NWE'TBP:.55@'N,Z:HK?SJ29RP1<L-4<@^"UU2P5
M@^D&4&D8>QC53KRDC,G^04:N1??+2\*\K<D]_JL<F`*/*[(N(\Q0V3!BX40`
MH)*&((Q(U1R2MG5L,8;QBNU:8YQ;0*(E"NY9>+3J54AH,L<[G(^-B)Q9F:.:
M(&0/)QD.T:J]H@`M6B*(`"21"%HB6W<$<FAU3HLC`7U2@_A*T5+_`,)4R:11
M^WIWCK/L4T*1=P;B._M'[_L#3@M$%TM=F*5FQ)OU%-94?;_QBYBE_?LGJCXF
M"@XK$Q,51XU(&_5=,1W#W%,!C?P`&J8D!RHL;A<IE#F$1W,=0WL_E&W_`,.I
M&)-52L'E)]_\&M;)*(!4GW_P:;"CKQ6^JX@G(W;",.*;]W)N*CE)_6V$;V+K
M/95@E2'!6B+9!9&64<'.U*JL5`R9111*45$SJI=_W#]H9F&-GW#MZ75L"9EI
M&)-P$DU'%@_$Z$`MT/U?;WW[,3_+,MST7G:I8Z]7&-4RW='D#9<CS$-ZW']/
M92J3ZJ1!X,M8:T4TLG7H!XL[B(:(9?-#1Q[2W*_!-BDJ4Q'JQUOHQQ<W.OW^
MR=L,K':HS:_<E%KDMQD;AB\Q\4CLW"V=OF(^$-UV$;=@"]=:=_8\0[Q8,`X;
M@*LXX)/3Z%*1RL9;+-;YRES%IBHB7K]<H\7'.[!)Q;F-D6L2]GZ\_1:XT!@E
M#*I+,ZF9-8C[U*9G"2)>NN;-S;5ZU+#P<:W=Q[-R49SNR(B)`AQ"47NN9`B5
MT$-5B2N*S';/?=)C<DQ`%2QT)>FE=NOL3TK5.XX^FZE\UX\0E@=S"+)?%=OQ
MM1HJGM<D0+6-:,26:N0C*M2QZ]='D77D'OI.X3LU%P*LU`5!,'78Y>'W/$NP
ML=UNV+<3+KV[MTW)69.^PRE*.ZWND8[JN!22]E<MY-J0E+'$]T7A*(82'-@#
M6K_>%KXBF66;@)"X1>&:WC"@PCY)K)Y1)BVH72;0NB,O".8ZF8JB;+!-H]J]
MD'-==M_7N`>A&LW`J.5""HFD.\C+QK.1#"O9MW.[A*(VV!?E:MB&T@SR)PD^
MT"0EM#&9#`44LVKD(F_*T+>.P!)@"YU:+^(;0D<PF?DH68I#U'*U3FD,@0D3
M+P32>/<TG=DGV+J1D'9&<?:FTF[*TLD3\Z(T(SGHA\F]:.2I)',V.9/?L4+E
MCN$/Z)G6OEKLQ(P-IH0.P!Y0(&Z,A%Y&$XL8O(.%Z_;(7/F+!$V9P>#Z`Z`A
MZ../BL,R6M-JD[LF%ER.(&]2[:N3N/WLH$I-LC!^FIZM-((SFL8[GK"]AI-Q
M*QC%T5S)K+H%CS'[S.E4=9QKF:,\8'?O\WCVS<MWHQ:,@-T)=0[[L8[QLD0T
M:[_Y05;G3VF6,&M[C&49%SI1J.PD]?K3Z8J4390W%R/K#H`BX_ZDC2&='DW4
M"FE(LV-<HZ;Y)H=\H151VFLVV,#5)-V*Y13.7L42[_2=W)GD=VGD1:[+TT)-
M$2H3<FSMPKQI]1;S\&EC'BVF:![:17U>!_A'^^.ORR5]/5=1$:(C1%XG?6?Q
MHI>J-BF5CZS)7*:@(W,L8UJ[*FW3(2DY&6FO5EO+15<KT%Q'Y85RO9+D0C44
M*]:7J%>D(!=1;T3M9-T]2+%R0+?3^]3%Y.QYPX5)!&0%A0OD/5,</,0PL[?(
MVO7:%S4Q+"DQ.@\M5SD8QG,6^-O)F22R#U0ZDJY`Z1B'.KVZJR/B\$TG#)G1
M9?$7(F/ML/69)XBS=43*4L3DTVS$O;:M`5NP12K"U2KV[V23PZ:/6<S39:-?
M2ZY&2IUU47QT"E!N5EJ&^Y-'P!<NWN:3M<CQ3%S>6-,M=DH[^9Y10%]N-9HU
MF>55G38P<)Q5NGHYHRE\,155,%DB4&#5VW;HF=,473@[EW`K+2BY5JC',.:"
M\+,0,2[PQ+\A5VN,(69Y9UZK1I+O$W>OWO)=NJN.VEZ<MLFOH_D#.QSIW6WL
M:E,1DIX&[9T!?+$GJ?A\673\\Q/"9\1G*_'L@K8X]BU\Y!(\I(3`%?LL^^DE
M:AA.$G9<;I#R]3DG<!+W!%FJ\CY&&EP_*7:'%`KEN2.GC[$Z7.**CV^'^/A<
M81+6*F6<>I"P;B)S+"4IK6N/@5.$E<UQYY\;[4I">IHXUK:17DM"RB3Z.3;H
MO&[Q,QB`N4CK5951K,I].JPS\!689"QNY"6NE=85WD95LBE><A"92&7J-A89
MSD))E`6.QO\`+*3)Z5LZ\:BSLP1RK451%`Q/Q51PC4!/'O(@7R%6;Y9KD4A5
M+G<'W)HF65I![6V=\,1"[%);;I,8/2K=\>6$'4>=^\00<*NU&:_@1(U:$EJ.
M2AU]%F0NM]M^9+V&4X*:A(BKXNJ>1(:2:)VC(MOO[1O>/5/65WF,[9GLZ&!J
MC)BZ_1;L56:5@4?RJAFJ*C<QU8K-@%]"FJN-:*TN`:5FQNA4AD0;04NX%6QK
M';UY($8]PH*DZX3*=1"&)V[NCE`3%0`P@`B&B+PM^B\X1?WKE=)**<=&LHXA
M\`IO8CC[5SX^B$T74->;2R75I,;VUL\0R2M@Q[655*2QN5F:[>5*46S4H%R7
M-!JO1NI<`N.-)Y-R7+2OP,^WRU*.K?*+JJV)RM`EGKR$DG9)[T`I`]=/G3:;
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M<BT=Q(B2(_F-$S<O(08`ERNL6Y[@!)]L2`1SB>#_`'<G]RD+%5I=XVD<(L9-
M56[XED9L"U\C!%Q5,IURP6CQ0^0:_(FDGL@UD3PCJ(3GOF!2F!%N4Z*RAB*M
M4.KW<\0([]>A'^FYHB]QR+F/<A#S6I!@#$R$S;(XR-`")'RCCRNP&-;)ZUHG
MRMY9@GX@>8#/X<>"[!"_9=R!).,%X.R9)8RA)%\]J,#=,?%AY/(&4[)"2:T/
M:'<L]4>D>UC'$6NFM#0S)JZCW\@X."RJ@ME"$UX![?V;MMJ/?_4.+'+OQB+A
MM7MT;=B$P\!$`-.[($2F2)1CH`X)7F6LK)E=&#@R`C\+QUF>+EQY>7@N^R/B
M+E/Q+5C+J7E'FV2A9JL5^!5B<Q)?JBDS%Q6C'R9FMI9SDY8C)4@7IA]2@S;H
MR$4W?B!'AE4Q$_KNV=\])^L3+`O]IP;5^,Y2$[#V[D;<3K;(C$&Z!H22)F-8
M@:>5FV.Y=K$;\;ETP8`O4$G\)#D-[O>FH>OT+XDIF9X_#&C*`3L9LE-ZZ:.M
MBF/;M473!:3HT`[;RPE?(OG<Q'GK)_5HMSF>H)N%D2E752]O9C<[69=@L1.7
M>N2AT-SP%ZU=!:Y,$.#$"0NT-(D@&@/K+HCD$9>[9C#XMO`@U`\94V^WWIG+
M0560DJS9V3-U`L<U7JT9'FF1%TWDO"XBHC&*.SCK&S(V>5,TU>X]U*24R";F
M.^8@Z;H)]P@CW>^PYQC;O8=R?5O8%BW8B6VQEDWI2!E"3[]ELB$+9:6W;(GB
MN&YM)W1BPG(R:A(B&8'3Q*D9]-Z9D9[F)&R,B"+=T]H=O.3T_P"6UC(YE'0S
M""A&B2:*:;=M#0;9NP;$(()HM&R:10[2E`/2?N;BVL3T:;5DO`9%IWJ92)D9
M2)-292>1/&1)7LO3T[ESNXE+3;+AX-_!?1H\$/(H([``'$1$>@`'7VB/0-?F
M.WHOIA"0^5,P?D@HO]Z9/@W]_P":<2)#U^P1UMS[E$"98O4WIT"CTW64$P@'
M["^,N^W7\6H2Z!+E3BHR;F]4=04%%4!*V9;EV/VK$$%3$6*(")C;=0]FN*)<
MZ+1^])VPJ$5(J7Y@(I'*<!`R*`CVF`>@@)/<'OZZU/3@@K17O&YDW*Q#)/"E
M*H82=SL`,)#_`!E_FUMA#M,'75!I13[UG;E,HV=I>-YN"95R=KLAOB1-L;<%
M5P[A!%0P^\>FL:%4I&!3D]T@7[?YA4/WB'E$?W:$OJ@I[4I=JF.5NN*ZQ1.B
M5(?.Q,!?(A^5MW$21`1%/M'VCJ@LH*E8VC\$5R$\K-P)P,D=%$YRKB58@I#^
M60'';MW;[FV`-O;J$N75*1K'<MQ-YVYFG:82")A2=*"(#L(%224*.^_V=X[>
M[7()O0J!M4I*X0=,^T_><[54#`:15]&D!%P*!NQJJ0@GV5(`_P`W[^HZQ(;>
M*HU6,%3@(>(ZARE$IBE9)%11*)=A_P"<*_"(%'WE,&D0X=0\EE>%1*L*A`;;
MK%(X*!C*R:Y14V$P&`NP%,4X"`]1V$-2NYE1\*RM#JJ@LW/ZK99/=+N.U9)^
M9,>]/?N_-`1#<H>_<=4ADU]R0F.EW=HF;&$0W`59)0YOOW*!=O[X:"+AT)JM
MT/8LU1.9HR<H[>G7(58_>10A1%-0BGIU/&)T=@V_";MZA[]0^.B-6FJQI(HM
MS@N9NX](/<DL9LL83I(J@)#@JD@H50@@4=^A1*/VZGCP3PXH.<QC>+U9UB(_
M`50Y07.F7H)`$QO$N*8EV$"F-N`#TT3V)0H&[1,'*9#@W.)F[M,14;G34-N8
M@J=H*-%DU=C`4X%_$.QAT*#58$5%$E4UB'W53.!@(L.X'`!ZE%40%0!,`;")
MNX.ON]NHC<M%<X*0BI5VXG*4X&\*I1`%4@Z"HV4W[@,*8CL8AMRF#8=A`0T;
MDJ]*ZI4W52=I>B4`J#SN%5IML#9T;V+)HB(_U=4X=HF3$1+W!N4=A$`%F92H
M+\%C2<N&:GC41$03/N**P"`D,'M,3H!DSB'0=N@^\!U6`XJ?$LZ[8QR>M8@)
MD1/\2('V7:F'XNP2E^(R8>TIB^X/NU!$$NZKM0ZJJ2Q9`I&[LQ$%PW*@[[?M
M'?QN/8/8(^PWM*/MWWU2:MJ$8BH5@'=QQC(K)@JU.82+)B(F05(&PF$I@V$B
MO3<!`0$!#58<U-?I593-#CL^B'!CE+L;Q[]CE$>O<02EZ*;?<'4/<.@:-"HX
M)8K(BV)*`)VN[1^D(&4(4IB-SF`?YU-0H;H'W]H>P!]FVAI57371=`BS22.E
MZ@Y2R)Q`@.@2W\BF_4Z:(F$#*E(.PJB4`WZ]=8<$N%D_8JF`?(1)P4".7'E$
MC=/O4:N0+L4AGRA4MC*#M[N@;>[49ZJ^S1570;K&2(](4[O;R((A\8I%'?<A
M#[I`Z1*?8?'^(`^WVZH<*5X:+3NXXS<RCV6<'<$(($(FW`VZFW4I#&$`*V(!
M?=M[/9J@Q-!JJ_"*1)I+/A!5P8K-HF7X!-N5))+?H5%/H.WW_P`8?M'5E$G1
M5V6%5914!91Q5`;"/<8P`'F<[!VBJL;VE)]A=P*4/;JA@FE2LG:2*`#`=-R^
M,0VR6W>FU`Q0`3'_`.46V'X0#H'MZ]-.-:([AN"Q)-EW8&<+'\:)2[JN%>A0
M*3IVIA_'$/8!2A[=8(<^"T[4XJB[[N`$FB0HHE(5(![NY<Y`'J`GV^`#F'<2
MD]HCUWUJAHLMQ.JH)@8)F!5,?6N";(MMQ*9)J;HJNN80W0(IOV`&W>8!$`#W
M@V@*N9&FB2$+WF*8Y@[MM@4-T(F41VV3(`&\9.OL#XC>\1'6=:*Z52AV<AC%
M#N,4B)`210*8`-VE$QC*.%`$>U1101-V$ZEWV$VX;:V`74!("&>X"JLV0%5P
M!#)%.(@5)$Y@$JIUW:G0O@3'\/Q&`1#IJ-5#R*3G4%KL8'7Q%]JR1"I)D,.P
M=B!UP55$WV&V*8?<`=-.%$UU5ZB)%R$332<*E0*8SARZ6621%PK\:H"9RH45
M#E+VE`"D$1VU-4=""2*7Q)LVR22("NNNNL?R+"00$B9>Q$"I%45V#8!$1Z[C
MJ@\E#37BM,J=(3[B9H!QW'X)!5+VB(CL';]H^[6X:(0MB!E$V12$,ZW<G%41
M37:/""BENFF`E4_.ZJ";I[P#6#JJ%K4BE5733$&W>H<"`*Q%8]7<0`-_*'<!
MNT!W$0UR2%%!JZ6/53&6$P&<)(AL0@+D!Z@*2902)LLF)E!*)2AU,;;;68\4
MX55K5=NBBX<="F[!1(I&+>0?(M\(]S0@"8VR(&W^`_MU)"KJ\&X)$DNJH?9!
M,SH"CL8IRE9KE]NXF*L8O<.WVD)^W7*2P4U*V#MZ*:;1HJ+9HHFF*@INE#^0
M3KB"GP@)4DE-DP*'P&,&L1'F="&58\WE<)"9P80(85#@V9F/L1(HJFZF(N78
M0+]X:DZ45&C\4G.<ZJRBAOF"AE%#G-\"*(=QCB)NHE2,'4?V:U7;[E$L[#I,
ME#"F]W76*B7N=I%^!(OD.(=BPF'<YR@`_=K`#J\4D(0XB`%2="(]/^>"8W7;
MV`=8`WT,6"H2E\"A%A1[9``;D30_G$%=C$(7OZ"<Y-O((_OUJ(XK'CS0R/XC
MG7%PNF*""IP\[/N)W&)XB`)B)$*`B=0/:;4D>"T0D8F64$!(=JX#_P!$<Q#?
MW16+_=#6H2`#*2^U4!0H?SI%4@#VF$@*$_STA.!0#[3;:VYU499D=CF*8H@<
MG<&QBB`E'W^T.FI(^4H*%UXD_5K>2$9>,!/8M\K&R3>-N;^)E6ZZC=>-F8Y_
M1W<8ND9-,5"N6KQ%-9!4ARBFL!1#82@(?<_V:M6;^/W&WD`&Q(6A*/\`-$B8
MD/8U#X+H7JZ<H7[$HN[2/VC[EYW0\=(6Y_.Q;!A%*IR5&KN7Z!`ODUXFO%LE
M'EHF.MN.F,;"M6\::(MPGFVXMW,AWG?K-W8-0**(&^CY-^S@6K5RZ9QE;R)X
MMV8\TA;O1D;5W=)R)0_+-(L(@PW:D==L->E)X_ERMF0X!PP(]]>7/P3Z(2U<
MFRK<@&]DGGU`29S4Y(DFV</&W*H2,2^CH-CCE20;OE(=>RRSZ7C&+!9!8698
M]T@N<&QO.V;]=G#.M"/IJ[:A'NIE"$#`F5N[$@RE?VFNR,8RE(,^X$!Z$\_3
MA<D<R,B;`!)'X@S`0?F2S'E6F@<S&]:Y.<O+9$L4LWY'Q97Z5*B:S8OX]NV\
M15*>T<A*'BHB$M<9*Q,E(S#!DJ5M)S+X\HB+YVJ#<A6X%`_J^[9GI7T;CSE#
M`Q\W,O#R7\L&5R9#/*4&,1`ES"`VD`#<7=O9X<<WN]T0C<E"S$,8QH(\F8AS
MS)=UR%BLF?\`B\N^QAEO*MLS55V23Z;M,#E0C"-L]7H1R'$UUQC-/9:2FVMX
MJQ7`R3F+=RJJ$@R>%*B@1R(&'R\;$].^L+?]3[/B6<#/80A*P21<O:]*]#:!
MTY_#&0@\2*DQ7#>R,S`O?)YAE*QM=B'9SK$DD@\6"XVVQQL:,[$@K(JSTOE+
M]1T?&E+BFD<%>N1YJ.2>1-XL$DXD6:2=!8.W\:^5*45GQI!("E*BF15VEY^'
MDR[IT96HBSC81A=R+TB3.WL)$K,(@%[LP)1X#:3J6BO!%GY<$S>4I/$`:2W:
M2)/X10CQY!RF0L1Y>B3]YCX)]YF&.4ZUBNDRA#*OFCJVE2._M.08YS,L6TLU
MF#MU9A-LX:N7Q&K"71:"=-3M.IV'#%GNMC&N9+F62+F1>&GY3M;M$1\IC2!(
M.TF4#)B-/'NM;O&,2P@=HYN:DGEIJW%D]&%E(TM-X?(O$'J:1?J*UQO$MH\[
M`$3NVU/QZ5D9XW=@BL:,21*82%0`#)`4AA'M^$?4=\A<_J'>S:,3$^FR3N>@
MZDW9N/M7LL")GBXTH-_G:^#;5]:__A_AU^3@7?P7TQ&JB-$1HB-$42.;K)1Y
MQ^G3)R,)"%86:BR:]AE)H]7E:XV8VR*57G*+;AV8U#(C`FYH:3>F(P:O!*9R
M8J/>.BU'51:X=U]W'XFSM3G]DP3DFP)8;J21+`V61N<+.PUABLKR$2QRM8*-
M%,:Y>JY\X?R0/W+$KB8?OEIA9PHJFX8F,5EK[TV/!6)6A\R5]U(9)QWD1M:4
MLGR$"1[>8?*.4JP^A:5AJ$E(].V56/%Q%QYRMUD6\7/O%5&%>:QR2::;P70"
M5EHN7)7'L=RGLDXYR#AL\3%9Q@H67Q3*W*-G(>,5N7+#&\W7)3'>,`CG63<>
MSCZ::LI*QO$CM(V7R&E'.Q%:(2=F+$X+NN9]:G'O)Z,D8C(.,:(Z:5>N69K"
MSERKD$VO1*Q"Y`\Q+WC^Z1TFUR7<&3I=%&INHI!1:&2,Y47.B<C<X52)HMQS
M)KZ-HXY<:6]=MN+,<QTKC-S7X6S-;FXQ9%-R63'E63A*[$V.^HBS/@*:*U*6
MS04J4TM*QJ#%-%)1RBH4"1U*[=ZU,]X19(2";Q=ZZ'S59EIRXP+AS5&2#VO9
MY1/)7.%GV;"-@:QF5-)F#V.E6:*%=96+P+!V,R'$"?B2+A3&%K-(S1$V.S4+
M*IVV'ZM-N)R@+5[*=YGJE8;;R.G&<5:)FMQ*5$R9,+/W,H=0PE>/Y.T.YH[H
MZK)S'"8DDQ/T;9.IR\SR5EL>1E]_L]FXO!4I7;+D?#>+\;3TV\;L\E5RR,8F
MPXI*W@++3JS-5]2.9,C-FI6+ENZ>-R';2B:ZI6?#FO<S1<:Q+H(ND5FSE%)P
MW<)*(.&ZZ9%45T52"FJBLDH!DU4E4S"4Q3`(&`=AT1-/B7`.$,"QKB(PKB;'
MV+(YVBFV>-J+5(>ME>-D9>>GT&[P\8T;JNT&\U:))RD10QBIK/ES%`!4-N5)
M)U3NZ*(T1&B(T1&B(T1-O?G@-9?%:8S%CBO79(39@W@6HN6DX(T>\.?D]I/Y
MDO1UPP-O4BKLI_7FS8G;\?<7LG8+)NX?=9"SC7>GVTR>[)I6OU.-'J6`QW7O
M-LVT_+G=+T8])]79(Q^X]@@<G-Q^KWL0VV(;H7_T.=+HY1<;,;R]4S\WY]JQ
M%O,X<C76UW9?.U]2-O*'Y=7]862"\('#6*(=P#6*\WK`RY'F58+NE=YDS9RU
M$![4Q*U*/53N,(`/Z&_;8VO])XX<B^>^<Y:?+RJ!\+_:5T7U%_GKFG^6!^J7
MLYKS2:QB;^J.P(S0CX9O:JN>\M7$NG%&O3>6ML"-9KT58?$9:+6:&9/GI4E1
M3%=9,%0`RA![/IEZ^+68-Q,KTK%P6I`;NCMMRWS,=#N>,7JVC@+JUJ)E%QJ)
M#>/::?;_`&J8V/8T]@YMT)-9@XL85^";"N\-,S%-;TERK&SS)O:I!VU*`,'%
MAL<XVDRUIH+IDNC*)MR',!C`3Y_E7OE_0&0-PMRNWRT=HF;P$H$Q`EPA&,H=
M4L08$EE[JQ'?W2'&(=RY&UP0"XT<D$#2K*[Z?\ZQQLRKF,+/5UZS;GA<PT:3
M+8+=::_'2=U6M2M>([4EXMA\SK$E(N6RZ*ZK1=1./0;>4Q""<!4?N/CWNYRG
MW3"NF]A`8UR(A",S&UL$R&?;,`$'S"I+.RY.T7;6->%F<1&Z=\/-)O,WU@\'
M'M4@WE.R=Q;PK?H[D!E!EE>?R(WQK'TJ2C\@6J5GH&-@88B+W'45"*_,*_V4
M$OJ2,)U8!?S@',)T^\1[>M#*P/5??<:YZ>PSA8V/U#=!MP$92,O\4R#'\RCV
MZ1@0T2R\Z_"]@8LQG78W;ES:(^<FG&(!+!N$M2H)C47#CCQRELQL=/VT!/<O
M74U5V1+3/.G4!&0596BK/?&5?=$9I7=NNZM3,545@[HI5P)BID304,G]%CGP
MAZG[3CSR8RR+?9MER6V(W2G-X6I2#],M`L1\3,[R#^EG;G/M,[L(!C>&UI:,
M)"1;\6H%=%EN;1Q-/<+R49)LEI-#&D^N^?.U7#YO<:U#PD#-66":1#]FF^LB
MMHBDW0K"Y020C1'T:8^F:@J3Q^U3ACV^XV;]N4;9RH",`6E;G.<A:E*0^#86
M8.\@=Q\TB%P9`>-HVS0VB_.0`<T//^[0)[/IN%9%Y7Q:S"*%BQ5J&0'$<BXD
M0>J-VCDD<LV9N#H=K90Z2!NAQ$2*F2,/3L1%3P_W--S_`$C*-Z>ZZ+UD2;B1
MN<\]?O\`:O+].';W:('P&$B'X!O[U]":PE]2J4_>\7*H/:4P%$$P$1V-V;%0
M;E^P1`##]^OS0*1"^HNJ*";\;A<$"[]H$1'XA$?X@*&**BAAW]A`*.KIHIJK
M0(.XF2;D3Z=%G(B=00Z=>SN,J`?;W&)H`B5H+'<)N&PN'#DYR>5,K1-,B?D;
M[G[15Z[`*0G#^<WU&`KHA)2,VY`W.1),-@$/5/#G,(?<GN8#?N$=]"`5799E
MQ(H@@X(1J8X%%`_CCW"H=R0;)CY/A*83I=O^:.@H6JRBL;*>-9%3TZ78)ME0
M&,7^(@E$IP-L8!#X##MJ2`JZM2D[E4K==5$A2'.0XDV3,\:AM[2&45.0")@)
M!`>O4/L'5$08NJ>:N376525;F7=G4+_6$&T<Y1=F^$`!<5!5`'6PI``B/Y9/
MA^S5VAM*)XI*9<Q0!)4[9L!MQ*W6:"#I3W&'R=HI=V_M$I#_`.5IM":%*'`"
M4B#HC=5F#DH)BLBX&1=*+I!VJB"'<8Q2J!L?82GV$?9TT`#H58W=&*OV"H@X
M$Y3D.E()BJ]`B@;"9-HB'C0$F_<4PD+U]NC`U*`4\4E<B5%50CA-9$Q#!W*`
MH#E`!WVZ(-1*P(4=]_CZ[#[-5J44.J6MUWCQJ=--0'8(`*B1`$4=T]RBNF!6
M@(-C"3M`P!W;^W691$941UC(X%N8IC)+-#[%$IQ8M#`!NABCY?(Y`1((?RMQ
MU2`>2+:N!\X`[;KIG*K_`#J:C<A3(+^U1,Q$_"8A#C\1!VV$!V]PZ!M`LA40
M62(?QOD$R(N`!(SA,`$"'';Q*%5*4BJ2J9PWZ[=P;AOUUDQ"TY*RG%[&K&[%
M3*=@_@.8#&,F8`$ID%S?SI#E'<`4W`P=-PTV@Z:JDT2\H(3J:7@,1M))D.5%
M0H@F5R0HB8&Y@.&Q3I#N`)F^';<.FH0Q\PHII7@DB+IXR6415W0<)?`NB).Y
M)9(Y1`HB0^Y54%2[AL.^P[AUU0(R#QT*$O[%F%ND/89B<")J[%*W6.&[5QUW
M:IJ'W$R"A0$41,/382;_`(0UD`.TD<@+$FY%DHH=TD*B(@!'B!R[&%,-MEB!
M\(@NV`W<`@(")=R[]0VIB'\NB5/M2MS'&<)^1@KWIB)3I;;"=-8@;E.F8`W.
M)?>4=C["(;"`[Z#:-155ZU5[>5(\1(G(EV4+^6*GQ"<AR"*:A#B`"H4Y#%VW
MV,`@'4O7?24'%5&;19C-WK?9TQ.5T@/0P)=IS`4!#8JR29C&W#W"`[A[=P'4
M`B*%'?757=[=Z`@HV<LW.W15-`ZZ0G]P*%`H',!@]^W<'VCH8@>;5'(]B7MF
M<D0H`J=HX:]H`(N?+X^S?H`G%(AR"`^P!ZAJ>4A0GZUD391[9R14C@Y%S_A;
MD5,1!01W$2)G.F"RQ`VZ;AL(]-]'D:#3FH2_L2AQ,%(KXCMA1[NJ:*8"J[,H
M(ALJ=(@^`NX![Q,;[-3:34JLL1WSM+N4,H11J4!(+5'=9<"J!OLY44,*K<=Q
M#?J(`/0`T(9&!]JP%=.3>,R*Q8]$P&_V:=-,55MPV'QE.(>7R[].X4]Q]@:,
M!355GUU5R<@NH':U*1@5N8>]-TF4$1$XC[5S``H'V_B@&_V#H8M51AQJLXRA
M43E1%(IEA$I1*Z%4J*Y!#82-W!A5\A1-^$5-P^S59U&57B+5ZHGZP7#$PAN1
MJ"A!'H/8)@1V,F(]/:01$0_BZ.>%4%%A.T=E2!*.]$DB'XU43*G7`=A'=P90
MG<GM[=Q``#W:@-7.JM#JM8FV0;")URN'S@#B.R:"GI]_;N*B@`*HB/W=OW#K
M1D-."K*PY)*0/L)?3-BB(]ROY*)`#V"8YP**I@#H`![/<`;Z/$BH3X?:J>K9
MQ13'3V<+ID$PKB&Y2=NXB(;?"7;W%#<1]YO=H`YIHJ03KHDK1D[="=X^4[3.
M!!=PH?;O$-A`A2@82`1-(OP@8PE+[=O;MH6T:J::+`Z=HG$R++M!%$W813\1
MW"Y>BBVYP#<A##VDZ`'01`.NM1@QKHLU=SJKTV1C'[7:IFJ!2>5R8G8+@J9M
MP213+_Q;AR(#V[]2D`3;>S0D,K3AJL;E^<Q$VK4GB;IF!%DQ2]AC&$1#N';<
MYQV$QSFW'VCH8@:\4\>*5-VI8TJ<C)F!PY[3*-VYA`H);`/YQ@Z^E03#V?QS
M#[1UDL[`,GQ4"UZCIY('+L8R"1S;((I$V5$#&Z"`&`WB[Q'W@90?:(AK31:M
M0$%$.!1;E]"BB1P[(8%'K@P@<I5=OA0.X5%0=T0'XBAN(F'V;`&FUZ\$KJL*
M1!4.`N7"#=(!W4.1$HB5,-NX"=XF,J<0'8``NXB.M,U`FOM21=V#A8WB(JL'
M0I"%8-=DTRAVD*8_Y(E$"EZ[B`B/74V@FJ`D45J:KQHW4="`,`,`HHB8RAS;
M&`2KJ"4QW;(HD((%]X;F^[5.K:H12BUI54U!$2^=R(#U.F<K-+<`]FQ!^6J?
MB_C``CJB+>"CNM@NLHV!)J8[1JH4.\Y42%;R!U5"E^$I@$C9WXBAV[%`Q=]^
MFH8@U5!XJC9/U;@`53</RHE,NJ5V<(UPF@GL8YD]O"!]]M@$I`#<?;I+13[U
MB.Z%551,BC4PF$3BQ.W%PX`-_P`(*E('D$@``;F(</\`&]HZ``1<*DI4DLJ@
MV4$%GK59<103;O5$&Z"B0;&6\1@,"W;N!2AXS&VW'ITVU&!DQJ%0DH.2C_/$
M(0P[;&,L[>)G'?IVJ)I]G<(^X=C;_;K3<."G%;1W\!B-Q;I"#=,`.(1C@=US
M")U1[SCN82&,)?8`_#K(`%1K[551EX_4%562;`1N0S@X*QK@@;)!WE`Q@[NW
MO4[0_?I(>7WJ!)RCY3&.4K=0YS&,;T[I1)01$>H@GL&V_NW$/W:M!0:(EH*G
M;,AW7=M3NE>T?,4BZ'A;CN(BJ(*``&6'^67\.H8@E5)3`<^QE4D7(=!!5#8B
MGW=HF,._L]RFJP&BFJ""([BW<&'LV`R+@!,8G7H4PF[7"?W"(F#[AT#Z**H"
M050\A3-7!S!VJ$,4OD'V[%5`O8L/7\)PW'[/?J'3P3P7C!]61,Q['A(JC=-X
M<]=OB*0@(HF(H=[3OS`VW)ZHX>PNPE,FF)A$#$3(?[E^S9VV\X@LTK)^R:Z'
MZP`Z]D?[D_O"@_B]H5')]4F3H))PQ\>3SZD5I.2]$_J]<_4,7!22<FFP2,JY
M;V.3:/5U9YGZAPP-_6TP,LCVI=T]07'[)?Q@_P`P,N,;LFW"Y/8919S3;$Q`
MME@?A+`NO08<=ER,_P`,HT'(`L?M?S:\=5RAJ5,V/AYR4FHRIN[.;^T[$-DD
MID+'-PZF2JM6;NZ_5#=K6D0*5&-CWEK9'//&317(DJ!2_&FJ5+SSGV<;UGVK
M'G=C:VX=^V!MC(6+ERU^6\]22('\MV<>(?FQX3G@7[A#@7(%W;=$$@T'`&0\
MWNYKTCHZ%FSWCF;Q5@R])81R%7\QP]M97F3MUF93M&JS3RHK3,?7@;0T->/$
MV%=@VBY/QF].H9QN?;N#YCFFUV#O4.[]]QSG]MNXDHRMBW';<FVAEYC:)/GE
M.%>'%>XP7R\7Y/$ETKT;NXG>1(1<UT#L&#%,IRQEF]0PG$8.N$6WNE[HW'ZS
MQ=O:U_(]PL[*1L+B+:/$WDE:)=JZDW3=;N7?I)H*)-&[Q(6?>)>TI_<>C<>[
ME]_/?<2<L;`N]R@8;[4($0+AA`-$`4B34LTO%>/W2Y;L0M8DR)9%NWYB)&1!
M)=R?$.6T'L30W6J25$O?#]I8:\[B9J(P7BFJ6>9/9K&]):)Z(I:S.:QR_130
M<.L;2(L)UK&@U;)>-\L[!<3]IS')[O"S+7<>V=\.+<C*U<S[URW`1B.G$W'%
M\$MU8O&4R2?+M;@`O%RXFUD8^Z)!Z402Y+EO@;@6+4]O%,U=(I-"1R\Z5%&9
MK\AD)[&H0WE:I2C/(#V*KS\MZ<(`55E4F]J9LGQ1BD%3[(D(B!3)H=Q.Q=LO
M;K.%"(,,F&-NW/0V1*4>D.-S83$]0\7)+E>MR8C?<D2\3<Y<:5/)ZT_L3W8C
M0DE*QQ,&+BFZGB^H5"'DSK),95-E&FJ>/!6DT5Y0GG;KJ*DZ*,^UQN8W>`@4
M1UZ3O1M#+[OU92<^G"U2'/5N4.VA'A)QHO/P1^DQ?_ZW_P#M7U;!_P"/^X.V
MORNS+Z>JZ(C1$:(C1%%KF+:YRGX5<R5>NRE#D7EUQ[!#+(NE851^SG;A$QDA
M7RW)*O6S^SX)MFX.B:=&,>FCRB)DTC+&3T6HARH2\'K9++8KY4Y&E,A01[])
MU"O7N2R)'XFJ0RJK=QCVRR]/R?-M\>P<6G=O51)$U4:X]!Q/,S,%?5^)23(V
M1*RU`X+C>%MOF[WRJ83]SOD3=)!ICR^P%2DY"-I-_LQ$6;/%+J[5-KE:)HE/
MO""$59G)Y1=W()MXAZG)(Q4<F\0BDI%P5E\*XVQ9`M=XY6UB'LV6(BX4^G\D
M8MV,98:I3;6G598G(>1I&-5X>F6*BM+C0WS16GO:FD$`_?KF=%0N,@[9-BM4
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M94NFPLW9ZM*%R$O1K7.6FGU^`5EP?P9O0IQDV3]0,EXUQ(O469YD&2!)?8O5
M#181HB-$1HB-$1HB-$1HB-$1HB;:_O?22^*T_G%BBO7Y)39>G@F?JFDYO1[R
MZ^3V=3SH^AKIO2^I%;93^NMFQ.WX^XO9.P6>MA]UET<>[T^VF3W9;96OU.-'
MJ60QW7O-LVT_+G<D_E8])]7Y/R_<>P0^9S,?J][$-MB&^%_]#G2Z.4=PV8_E
MZIFTOSK5F.WS.')UUM=V7SF?4B+$H<S;Z_5]>K))<+(I,[$L,@Z9N&G]L+`R
M!T9`79I(\@=R(I%:-6BQE]P#<#B0H_HC]NM\_16/;EL%D]\E4D@@_+FAHS>)
M(;V.5T3U"6[C<;:_RXU-?B'T"B$XKI&U<JKF:CI)O"4V69Y7R$W*UDD$GQW\
M<]1Q52&ULK"Z+B"D9`(@[B15<$49(1$X13XW*)DR=G^<ZF;?LV9QE>R8'&L%
MP\6(Z]W;*D@':#'<9VV^$NO0QC&U:B94V'=,^WX(D^/\>:?+'CMG:<56:VMU
ME9><M%J<3F8I)Y&QYK8%SF)5>_U%6<G&T+%!(T&,;OTDH)`H(-4G\:L*K4CT
MAAUZ#N5J>%W>WA70(V[-D0QH[B+8MQ'3F(@DM=D0]PU.V8:1B0O+B99&,3;K
MNF93/%SY@26^#^7Q&B[S(&#JY>*)/YWJ>9F>!+\JI6V-VF[1!Q]DI=]LT?#/
M7<1-NJ@Y(W>,\CK13%5@L^C63M1\S*'JFQA`Z^O7=K[_`)7;<^WZ>SL$]Q[<
M-\K<(2,+EJ,I5CO%#:>HC,Q`/PEF"\XXMC)L'.ZD;=R)`EN\PD0->>[V/];I
MOL<86R#G+(,-4LC<T<=R38U58MF];Q;CT]:N$ZB:O2S%^G7[7<Z_4$8&]H-7
M+DS\&_KEHYPZ.=!F/A4*C[/N7?NU>G>WSR^T=BRH7NH3OR+NZW'S.-T+<I[[
M;@;1+:)``&5:YQL6&;>%J[E6Y%G`B*Z:!Q$;N>I!X)U8R$A"V.!IN+X5"%K%
M;JBE.J\&Z8(2%>K]-EX]=.S-;*E+QS]*7A9EBNZ<3JC\K[U*ACJN`,<PB7TL
MY7YX]W-[M<,\B]=%V<Q)KD[@K#9M(:42PMBG`!EQ`QE>$,6+1A!@"[,=3+F"
M'W4/-1&3EHFTV]O%XX)-/V6)K_/9/Q[$G82+\DECJRJA)WZC5RIMD6$=$11)
M"O>>MKSJSH$VSMX5SZ9)J7;NG0R,3`-[NVP3S\>W9NR<1,;UORV;LYDF1D1-
MKP@!6,=KF17A$V[AC;QA^3;G*4=2\3\0K]8?@:J3'!]@SA>8D'&-D3(1<A0[
M=-5>8=M2MBR]8E$BNH<"`FDB4D@B@P5;NFAMW+9TP6[RBF4BI^M>MKAO^C97
MKI'S,+]NW.(X3B3N+\8U$A+0B0:I(7F]AAM[S';_`(,H2(\00&/V&G!JKWA5
M$J*BR*)`[SJJ&`IA$0_&/>JN8=SB`"/MW$QAZ!KX`'8>Q?2E9L1#\T_<LL8>
MPI]MU3B(?S:)`'M3)[]@V``#<1Z;ZI1!B!V"HZ,4Q2]?%N/@3W'H`E#85S[]
M-S!L(_A*'O>)19$S+=Z:O<9LFF8#D2*($5,0![OS5`W!`H@'4I?B`/:(>S4U
MTJBR+H$!3R,4P1:N`\K=RJF)U%B&'H">X^0_C.`E$QQV$0W`!`=]!]JITKJL
M22I3BHR_/>*.-BE`5S)I%<%$03-VHBFF8O42&';M#NV$P#JL@//5:A=+XNQP
M)05`_:#-FEN8!_Y-9=90QSG+U$2E$NP>T!#1*.KUB+BW*)1(T%N4"&:MCG%T
M=,XF%(QQ;(E23^(=A`![Q[@V'IHXTU5\%KA7?M5D@%F*91,4=D_3O'QS&#IW
M(JBHH03;]=SF./W=-4L0SK*QJS#5HN*0%?1WF$W:B9NH=ZIVFV,!P>&<M2`E
MM[?.(@78?AWVT$2WL1U8G.,$$U`.FHDDX*;99L?T2JBR91[#J/E3G;NS`8WQ
M%1,?H(_$`:UM**U)21>"+=1HFR1/OV%F4?"LL8VPIF100[R*]Q1_&L81-T[=
M]]0L!X^"+;HLT4TTRNW+Q%ZF!4TE71DUV:R0!V@@3N3[6_BV#M`#B`E';V@`
M#'=:!`6<Q/2'*LNT34`G7U;9$I5D0WW[S@D0ISI@'XOAZ!]NLZT=3BMD=JH*
M`/HI0CML(!ZAF8Y?RS&VW!-0@"D4BH]4Q[2AU[3>S?4?@4<E)4?2N!*)#*M3
MG*`@4`*F<.N^Y$C]Z"AB&$>[LZ>T!UHN$9*-E2I=[A(%$C'40.LW*91$3EZ&
M(H@/<LGN40-M\7PF#4)Y*,L[1RDHF+)=3O21`#M')?S#I(JB8`(80'=5(BA1
M`0_$&P"'41#2O!--%8=%1HX#H'C=`91-0@[I'52`HF.F</8*B7M#H("7W".E
M#JJ*K8G?).!;>N#<R2A43*[B'<BX$$S"<2E,<ARJ]INXH"`[#N4=Q'62""\5
M`!H%>[C5T43NF!CK>$OG3,F`'.D9+XRB;Q]Q5"`)>NWM#<!*&@)EKHJXT*R)
MR#1VF4K](0*)"]IT@W,4I@WV*4P[D#80W*!A)_BZ,VE0A"PL&JX)>2.?)J>'
MR)"7O\*W8@J=(.]%3X5/@(`CMW!UU'#M((?%94#&5<.2/D6CD!4(<5DG39!4
M@*HD`>I%`*H`'3$=A#?[PU3M9Q17V)<5JW3,95N*)@3[1%4CMP94N^X@(I(I
MF4`0VZ["(??KC<E3P*6^<A_B7*<@G$O]8$/$0"@`AN)'JIA6,8=NH$`VGBHW
M)4*JL4`52.+A,?:=N!00`I1#HX6=`;Q;#MN`)D#[!U==%?:DPJ-U3`D*G@44
M$WD39=ZA51Z[%4=""BQ0'V#V^0NWV:`\$8ZJT3N&I>QUXF[0.](J*?<NNH41
M`3`FX3/WD-T#VG*'^+JL&HE#4:JU$G<4%8H/1&`>TRSLP%5$##M^6Y,`(]0]
MH`!3_MU--:I_Q*Q4[4BO8]14=.A_&J1,Z29C#ML<[<3$%QN(?B#L`WWZ"OPT
M2JS^-T8!,\.FY:D`#%1`AO4)%'H'B2(":S;I_*^`/?OH>2.."M07[P!".^#?
MN,*+H!,H;H(&%-<0!%,!#[`3'[QTJ!1"!^)7_DMMB+F.F8P";TA@%RS,80`0
M,*HE.9,!#_D^\0_E!J4&JM34+(FLZ6[0`@$1(`!WHF!PR*!=_B.?R$<MQ`!$
M1$3[_=JD#4*4XZK+YDQ`1((/%!*/\R8IRD,!@$/RQ,W>+`!=_:80_;J*-[DF
M5)ZH3++^,Q4P`ICN%GC4J?N`A06*<H"'\DHB.WNT6M-$B=E;I$2*T1:'.==`
MAEE7)3D$/*!S`F@HL.Q1*00$3==O<&E-$#G5UB?`\6;*O';I`$TRJ'*(K%$@
MG*41V322`P',(A[@'6XOPJII15;K1\<DD1HDHY<%2(4ZZI03#N``W%,H=YR;
MC[1Z&'[0T.Z1K0)4ZZ),T:/9`IWB@>-LLLJ<5S!VHE#?QD(F0!^(03('W;^T
M>NJX_#JI0:J\KAJS<K&;?GJ(D*V(<VPE`QP*LL<3!MV_B*7M)[0*("80';58
MR%55KU?/(.2)B!US&#U"X!_&*F<`2*;8.TJ7?UZ_"`$V]F@#)P?@E2ZY8],2
M-U2F>KCXA=``"FS*8HBJ9`1Z'6(F`CWCL4.FWVZ`/4\$HM84?RA!FB*A$RB/
M>H(IH_$;8#"<0%143J&#<P!L(C^+5!YH0VJJJ5%'X%ESNE3!WK]I1`AS!N(E
M1;D#RE9);CMY!$#?B-U]E%=%`ZJV;.'I!67,$?')@4Y@#M\OC,`]G>!1*D1=
M8/P)[G``ZF]^TH/$H7X:I"8&[E7=BS3,D3=))TY(10@$#?X4!43`A@*;?N.0
M@E,;?I[]5RU2@6([1+=0WG=J/$]BHECQ2;E26'?XEE2I&-^3[1+\.X[;[:`U
MX(RTRWS*.#QII-WO=N*R+),JLB8QA#L,JV4`&2QAZB.P^3V;;@.M>66M"BN&
M::&0!N=LLHL&ZCI%_P!ST6H$$`(D"#8QUH\X"(B?R?"4=@WZ:;2@*L"<;+*$
M:%]6[,)1,DT.GNJ(%#O$[55@)TE2D*`["=<.H;"8!'3:==`CI8HY=K+>G09*
M>G(4J)47Y6K)V`![#`(F4554..YMC*"(C[#CL&HPYU1+F:;@1,JH?N!(`#T3
M\ZX*'7,`@FBDHL1=/W=P@83`)0'8=M0LJ05C32`#F[!],L(ANW>(D.W$1$!#
M95`Y3M^[V`8!`GW".B+;^0&B!6[A-9DX<[+"9)904P;E`11`4U!,3L.8>\1V
M.`!MOVZRSE^"E50C=4YDTE$RO.\P`':F7SDW'V]I=RJ@`==R"4VWN'5)HZJ5
M.S@*A18K"X:IIE30254$W>0H#W'27-\1!44$Q@`^X;C[M(T%4I[TD(4IP,HW
M'P'W$IB]NQ>\/Q$71W#8X>\0V-[]Q#VE$?"OT,4R:R.P"(#LJGOOL9)38.]$
M_NZ=IMMA#<!#5"*I#=PBW<%(<3`(ATV37(`@`F`H_A4((@)B^[V@.VI)4%EX
M_?4TCU)7).`("+;G?2DQ#WAJB*HI@E'=IZNZ7D7KM5%1)I'LHUDLZ747-VF1
M:G*3O6["#]B_:^[;QL#N63=D(BWTCS)I,`1&I)D1$-7S<G72/5,)7<FS;A\1
M$OO#OR857GW:%FM<DIN<]3;(B*RG7(?%E/",9.ZU9&&'(DC1.\3R:3E&2J-A
MF;D:J`1@4I&[M&.D'IUG"+ML8A?HN+"]EV;>''I2R<.Z<BZ9'?"63)^E`LTX
MQM[SNUCNA!@8R==9E<C8W2#BW=`A$<=@8$APSRX>T\5,D#0T7+T-TR80OZ!>
MP"S.KLX:OM&5,E,670KB3DJZ2$6C2)D9OCR*Y)WRMQ=*O"G]6LHKW'#I(MY%
MVSD6S*?]3Z@-V4Y_F1O6R!&5#PITV+"+;6"\\SZ=ZW,@#'`:.WX3&7T\S\=7
M*X"_8!?X5L.-Y#"'*NAXVAIJ+B9N#QAFBLKW92OU61+,R+)@^N,&QL]H;T**
M*_79L#R#9@Z;M3E1*X7*@HJ3V';O4ECO]G)Q_47:<C+R+9(E?QK@M[I18&4;
M<C&'5DSS,#(2+D@.`?+R,&Q@W87;.1"UO8B,J['K4L:%VJ!_%*<18#B9BLNL
MQ9ASO#9^=4ZUPL@WI=7I[.E5^#N*BDLSJTKD2%=-(JP68E>=L5WT:T=136-]
M6?RJ"Y,4Z),]\]27[>2.P]B[=<[9;O690-R<^I.5M@91M$$PAN#1G*,S+;0-
M0K%C%L2LR[AD7(W8QD/+$-YGH9.`2!J`P#^"3VMO%R^+<BR5P6>A6I9\X>_.
M5HML[L(Y4L[8T%4YZAOW\6`PM[;*@FH[7`S1(T2T5%[Y&Y"IZ80R+'<L6UA[
M1GP`B8B1Z9L1\UR%T`UM$?`&)ZDAM`)=>++9T+MRZYL:Q)H3<<L1RD.-68<D
MPD.9WDE>UY`3)(NO[7VT)#RR9FSZ83C\X5]-_+1RSZT2[5C!,HN^QD4JFDC'
MLV_IIR=.BND1NV!0O8[YAVJ-GM8VB6`9S!<1WXLS$$;(DDRMF3DR)>%L$%RO
M&\V1"Y>(I>`&FES74MJQ%.:Z?'7RQW"\2O6)NHL6'U&($A&(0Q':XR:=7H:+
M=H\,JNU<Q+=V8ASE7235(N4A3E`Z!BJ!Q]P$H7^\]$B<9^G"278`&Y<TU!(Y
M48^-%Y.&YL8XE0C.`_\`ABOJ]#_"/]_7Y97TQ5T1&B(T1&B)FL^8OF,Q8RF:
M#"VP:BO+.XA9XX5:2;R+G8F/DVSZ5J%A2@9ZJ60M<M3)`[)Z:-E(]Z5!4>Q7
M;N3.5!8NF@X_<8I["-`R528V\1M6979LJ2IPN-8BP-JSBB36B)".=6>J)Y(M
M^19I]8)-Z[1>N"KNB1GE9(@FS(8SE5R5)=<?QMX=3.!\BN[P6UU)HVD(&1B;
M3&4:'R0V7RG,.UHU1A;\A.\DY8R6D26A/0K';ECDFZQE7RH*.3H@5$2&3AEJ
M2\*[.&?4\V&R'73SZ>03VT,AFA<B&RZ-.4LGS<^)/,?*QL5)U(]9`*R*A:R`
M?)"@<&X2.S\";J,MGR3X;S6>LA(W0]NJCMJTA(N-JL;>8?)#Q;%$U'JOE'%P
MQXICO+&-V*\Q*JNTEU@DV[A<J[)(".@0_(*028,NTY"<9)[-]&QS39&[1MF8
M4UF=O;(#)$79%ZOE61-%1D<A9K6EC.XXWEVL]&+LW#ENFDX5BA/(+@HR.8K9
M5L0%BLK3C5;FO&-7`1,JJ)R1W1C(S:$584J\TJAK<2?'$Z++]<#D#^SL]:*:
MN&4_4P3@Q:AC$?$4[0*1ZNEO%?C>_P".D?;XPLQ66]>LCF'=Q./:'&W)A2*K
M(L0E@FI]@>_WK(-C<3UP!\V*_P"QVU8%)&MQ2:E6,Y7<$D74L=%E:J;G82LQ
M;N<L<S%5^$CR$4?S$W(-(J+9$563;I'=R#]9!HV(HNJ0A1.<H"<P`'40#1%Q
MU$R]BS*#^VQF.,B4V]2%#DHZ(N+2J6*+G5:[(3$.SGXI"3+'.7`-PDHA\FL@
M?JFJ`'*4PF34*0JQ"<;11&B(T1&B(T1&B(T1-O?WOI)?%:?SFPQ7K\D)LO3P
M3/U32=WH]X=?)K.IYT?0UXWI?5"MLI_76K8G;\?<7LG8+/6P^ZRZ./=Z?;3)
M[LMLK7ZG&CU+(8[KOFV;:?ESN2?RL>D^K\KY?N/8(?,YF/UN]B&VQ#?"_P#H
M<Z71R3N&S'\O5,_-^=:LQV^9PY&NMKNR^>CZ@LHU6Y@Y8C']2@GI8SAU7I%C
M:'\7-NI<IS97ADS5I@L+T]748KN')'!P6:&=)+@10BI>TH:^^^@;$CZ1Q)QO
MW`)=ZD#:!B(']/+SFFYPS#S,U"%T+U!,_P!0OBC1Q0='/QC3_9[%#6L25\9(
M7C(U714E)NRR31'(%4>*G=L9&,=2M8>0ME$\98*Y*24=%7"$08NB+.'*B3.4
M>=PG1<*;=N[AC=LN2L=MRQT[-N)%B[%A*,A&>Z!)C,"4H2,PS.81`8Q"]%C3
MN@SR;0)E+XHGS`AP1(@,6!`!?1^16Q;,;=#-XW-6"IA6LP%B>1;:1@W\_!2S
M6L.)B%?6'].SB?KI"9M=8D6RI#)LIZ/1DMV9NTLB807#QS?P<B<NQ>I("[D6
MGVS$9QE=8B.Z%`(7(\96Y;:A]@#+E$;UD1S<(F-J7Q!QY>+'F#P!#EF\5B<Y
M"3R@Y83+BOW+.,E7T3#7XR@4=G4<-5:%E':$C,IMCNI)W9[6_=S52D&YI"5.
MV([5!$@-?`=!$^X=L_I.^Q&]9P+=TGJ2NW3=R9D!H.(C9;B(SB=L78`DR<$B
M7+XR!&4H2N2A\(C$"$7J0VI+ZG_8M4B\QU/HJ+1N#<DM:M'/17L5JH;AFI/U
MF5BR,QFDS>LD9,'K^KQS9?YLN8`8/%B%<MDF1'1$C\TH=TQ_\?N&(<DBEN[$
M[)PE2+[0&$W\@^*.DC/:ZQ;-B<P;=FYMJ'CJ#SK]O#V+HQR!F7.KV,HE=R&S
MEF\Q+,8R^KHUMCBFY*SDM".I:=7RG%-)!U"2*]>BU3KK(1CX8URX27=JHM1,
M=0GBQ[=V+T[&7<\[&E"<+9E9'5-^TPD`!9D0"!(CRF8WQ!$8F5%Y$[^7F2%B
M,QMD0":1G0?C;EX4-20L4.^?).7>+*`DO%0_R`4,H936D49%T#6::8]G+2[1
M2K5P5I+*,ADCM(2/CF19A4S=H_25<K.7ZXDQ<%J^+??.YG?D&9Z&*'C$;3.,
M`1.&^4R0;DI$P%8$`"(="72?%QZ6V\\S4U8R^$L!P`#\>93]?3^7%3D?4ZVE
M$J-HRF4'(R<"$H+!Q+M860DXMPY;@JQ;HM6WD>/T3G;H%("A4S*G%0Q0./KO
MW#A_^MW<PF/4OY-HSVN([A$@,"3P&I]E-%Y/8);NZ1`?IQA)N?L7O&F!A5<J
MG`0476,<2C[2$W'Q)_\``(/7_&$=?GA_+%N2^F@<U:D'D447'J`&.BC]@$(/
M:J</L%50-O\`)*&A-&0!T;"HN/7X&PE[=O8+@Q0/W#UZ^%,0V^P3?:&CL$:J
MHMLH<$A$/&0@*K[F`I>W<03(<1$"@01*)C;^T``/8.J*!#0I1Y%I)(D<B(H[
MBLLFY-N58R14RBY0:D,'05Q$O88VP;B(E`1'?4^$NIP=:P1,F0C6/*!#*F!+
MU0B)@3\91$ZA-Q[W"B)"#V]0(4VP;^[6FJY0TIQ2Q8I00*>.#O=F,5L\<*[G
M!-0_Q"Y$WXEQ$@"8Q"`!?('Q"`FU/:C%)D%!9F(#$"JN5!405=N/C3`#E'U0
MB'0%3%3`1$I=B]P``F`=-==$XJCA)-#L!DHH**Y3'-*J@!EQ3[@!0B)>W8SD
MR@]@=H`41Z@!MM6O%"76K<.&OIC,%6HK-%E2E;LOYU9X]*`@1P[.!3K"@GOL
M*1!`Q_:(@`!JU%1JH0Z3FJZS(PN"H(JNQ*!A9+&*LS*F8-RD0W-Z4X]OX?84
M-]@/[3&"YNHC,'6P:.P>)@S6(`%3$C0[)Z4ZB;950P@B@=90/4HHJ&'M3$X'
M(0=@*/;^$4`<43=PF:<4S&2GV%X3)%5G<G1]>?6M[0&4LE,S3"M1DDSAI*0?
M+Q_K&C1-C+2"+82KJ^05#]G9W$4[8>:K)V6A`7$S9N86T@AU!BL/<D[0$#&3
M4:[FV\I.TQ#%3-L/;OL(B)=0\^"E7;@L#57TJZA![F3A,XIE,`@*2R*H`8B!
MQ,7Q+$#<2]BI0'8H=/?HU.:N@2@">0[I(R)5"=X*BFF`F$OE(!S&*B81/L"I
M3#\(F,&_[-`Z%4;JN&BZP-C`N@LD@=5LX.)R*=IE$^B@]QMR@4/Q=0'V&#3@
MFOM5PI-'3LIFJAF3OP+>9!82IF'91`2`)S[IKDW$=A/M]QM*MX*<:JY5=VP4
M0([3\1#.`V,8HG9K?DK%W.!]P3$W7KN)?L-HU**\$I<F:'0/NF=`XBGVBF;R
MI"854^T0*<0.4-^H;&-]VLUX:(R4=AT?(LWD$2B4IS#VJ*MS@&PB._>4I>@?
M>.E"&X(EC(RAVJ";M!FL)440!<IF?G`?&4!\@>5,5@W^\IM_?J2UH@(U56J*
MI$SJHM&*I"KN5`<)N3D[0%RKVB8"NP,D/3WA^_62'+O5*:554E4E'+L[E.,(
M.Z!`62*990@D2\AA%,OE(J(^781$0$?MT?@Y5:@9TH#S`4%&RZ[@H"&_RY%-
MN!!'V$5V_.3`?\@0^_4]I*'Q5XG(<1.Z;H-5!`/ZRJ<JS@1+[3*-A^%03#]A
M"FTH[J5X+&`J;E505<R(E#8?`<4DD>OX%$"@94I?N[2E'[=*C75-:,A10@I'
M*Z,E'";<?ZGV]YQ$?PK()]Q@#[Q.3]F@?AJK]JM2*HB4WRQ'UB9]@46,/G)O
M[0!1I\)$1#_T@&$/<.M'Q4\#16+>D6,4SYP9)<-@,FU,+A(H>P0VW,FW'I["
M&.'^*&E>&B!^"S$/()E`K)LDJS(!MEO+Z@`*.W<)G0F3.U'[@\6WO#4)C^(U
M2G%)BIQ_F\@.3E<!\78550R!5/L]<4GDV'[0*/\`E:.P\%:I0H9ZX*8JS5,6
MH["95NH""?:'0#*.P,8BNVV_YG<._P!^@8548<-51)1LB!DT70.1$=BM7(BD
MV$=MA#O.42*F*/OW2W^W3;QX(?%7?UA8"^1!=D5$`$%VZA$FB8#M\?8<Q4Q$
M=NHE/W#]FHPYIIXJH'0,4>T[626`WXEB@TVV,/0O<*:B^X!UW-M]PZ$-[4'U
M!7"+I41,H#QL0H!W'6\2K)(A=MA`%/$0I0]P%W';370I0<DC759@5$2*LG"I
M7B`B=9N9LD4!.*0CVE1#R$-Y/:<0#[O?HQ%:.K56OTW#INX5\3!4"HJ%%7U&
MR:?P"``!?4$(0`_D@7]VM1D0E/%*P,1N!020CUU!`!!<QFG@+W=0,F11910X
M]?:;M#_%TJ5*.M$@591LW]2_1$I2`7853J``D$Q1`B2)5"%^(/NULZTU2BM1
M]&05_P"?=']2I\)`*@GN)4Q*(F,)SF#LVZ;%'[]&/&BJQ`Z7<N7#=B@)ORT"
MBD@`^$`**X_GJ$[U%3`(^S<P_LT`:+E*,ZM4:-T'"!Y-R!S@DN*;5(H*J"J!
MD``$6Y1,F4W:(_$83&#1S]J-R5KIPLX\"`%!BS\_D%$B@&<*BBDHJ4[E<?A$
M0,`=`W[?=MH/M4UUU5BB``B4I">-)RJD05#]W>L01[SF(03>9<#$()>\1`G7
MH8?9JI58WKCN(5`!.X6[@(BB40!-N=;8#*B7X445"DW'N-N<=NG30#ZE7655
M$$&Z9G2ADS+`"3*.;&$JJP"`AWF'X5O`DF43"<>P@B78`'VZA?@H-?!)7*JI
M?$T3'THG*`)-6A2F62;EZ&/W``$((B(``[=3CN)QV'5H:JEDE5<IQJ1@#^KE
M(<4S(-3&%=9T<!_*6>=HJF<?%N()@97N]_01U6)JLK5_I]63`JRZ)6*_?NW0
M0$Y%%!$=@!T)?(8QU/8)C^500'X@#J35W@%D`2EL9&-([C@9$;./(4LJR^$$
MA(!A\:S-7XA2<;B'D[3BFJ`?"(#[:7-70B@/!;!!$%C@T4`[AN(',DL?N]4Q
M`GQ+(K]H`<R2">QP,&XB0/88`WUDE@_%4!TJ<*)&+Z%8WJ&C8@BVD2%`BBZ2
MHCNY<]@B)3`<G;W=2;%*)@*.H.?%5_K56Q"#Y$Y3=9LT`@@[*':90BP&\"1Q
M+L9%100$ACAN0Q2B8=M]M/8H"VFJQBHIWJ(/OZPB'8HDX-\1R-S")4RJ@7X@
M!L)>P%">PNV^W4=#6H5)'O2UH96**;8!<).D3BP4`>Y=J@)P3<B4I0W<(_$!
M4Q#XP`QMNX`#0^9N'-0E8$Q*10HD,!D7'>8HE$!*"Y0[C=NW0OE*`]P>T#%^
MT1U#H@\5<H`IJD6#\)S%17#V!L;X4%/\I-00+O\`R3?<&@-&5:J%P$H`N7\:
M.XB'\M$1#S$'[?A^(/\`&*&@Y(0KU4Q5)L00`Y1!5(_N!0H=Q!_R3>P?M*(Z
MC\T(HO(/ZF$HM'6G$2S!NBJ_FJ=DN%4,F5%&20B94E)92::<@LFH5)-V1R4@
M(&`Z+@6Q_*D<"EV^R_M78MWK68;OP0NV)>#QWD.'\-14/0A=$]5W#"_:(TE&
M8]QVNH--7#FLPU(Q]9&+RP8;L)/EL#8`E%(B4HCVT3%#9RK9H\2G%:NTE<>6
M<&SQ--_$GCW3=.2\HE:R*AT^\781R,O([KA2Z/?;/FE`/*%X0$Y.8[-YC=@#
M'=&>X'9Q@']#">RW"S=&_#+,2^Z+L[%V!B6-1Q/`J]M-91P.JVB9*\5:,QK.
M,*U)LW%PB6-\@"!<S.'#"5K]+K,])LDIYC+J'9*(M9A&+D/3*HN'BA0.D71M
M=E]2CK6<>]+NULSC(6I&U)K8J)W)Q!VD!Q*43.+@B.A3J7\&6R<@;1`(!&X,
M:N`#J.-0-76F7L-6<)OKK;\796N$18SMYF]90R9$1<8V<VE19`TE(?IRKR\0
MV2KB=J0?-W$=&NTESJ`FV*Z3(LF17EMXV5TXX&!FXMB];)%JQ9D9M'^4W)B3
MR,=I$I!M9;2Q(S*=IY9%VW<G"53*8`+^P<`:`#ZPE["ULJ.Z2N;"BY.P:Z]*
M>#CK,I6*]DK'\I4I1LQ>3T;?:^O)0Q)-%:#J+QPJYCG#-Z'<DY2)YEB&5Q>P
M99]OY&[DXF?`RW;.I*Q>C<!82LS:0!$I`",A*)8@EA1"<<=LF$+EJ;$:"4""
M-)@MP#T8^"5E2R%FMTZN60+@T4QA725EU'?H^7K\77"LIY:22AH:FQ%O=PC.
M*?S28%77?.&CN4=E:',1H^$X'+QW+O:^P#Y+MEJ7]:NN)&Y&4I@Q9[EPPW/$
M%PP(@'`,HLM1A>SFNY-S]+#A&@_X8@T!/O)KJM#+S,WDBCMY]]!N:ACZ!FT)
M;'=*B7;QU\WE9%O3795A>6V=L;M5.HTJ#8>=\HU;*JNY.0`H%6<K]ODXF-B]
MK[C/&MW/F>YW+9C?NSVM"`,P0!",=IN7)3$8O)HQ@=(A8RY2G:$I@PQX2!B`
M^I``U)H``Y;4TU3N8[L1I9QQ,DY6G0$NZN?U"05DG;EO/'D:].EK>-W#VRQR
M\+),DEI'M.5$[F2]8B=NJ.P"*>X^N[CBQQCW>U;O7+=JSZ=&T`Q:<3.XT)[@
M:/4"&T_6O/P9;X6#(`RGFOQU:/C_`&KZC=?F1?2$:(C1$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(HO\`,9\ZC\"3IV=TD<?J.KIAZ+6L\1#UF=E$6,MF&B1TC%1\
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MG6K,-OG<.1KK:[LOG9Y_`0.:69!>RZBD<?AG7"JU:-F%(J8=)_VK0`+2C<)6
M$EZR)C;E0*L;9P``9,I!$0,'Z"]!RG_HO#C9@.M_7)-,AXC]/)@6(EXMIQ71
M._`?U*[XXH?_`+T=%#&E-+@\=F4QL-ECU!5!>NIH66(0G&<2<NP]\B2#AD&[
MD72J/D<?D("0IP$J8G!0O<,^6!"R1W3HSJ!,B$MDIN^A,GH),&)76K'5ZKXQ
MD-6J'`;P]OL2%K\E=RLW(`R?/EFCZ"1OEC(G+VO$[KU5?*K56;2M8XF:R=$/
MFZ"SE!,[Q-%NW3[W;.0(03)<MXWX6K=O=:A9,2;,(F-N_20$QNNQD/A(!&UR
M6VR@=;!I`RE$D`M+C$N*:-Q#ARPY)];.7)DU59&2>6.)N,4J0OHI&GOXVQUP
MEE3.Y1GW1254CZ,`L@^(8B`IHD_K!#=Y%##L'6\"?:[.5&T+<[%UJB<90D8L
MX#W&/E#$N30AB`O,OPRYVW!!8T(((=VX4HL7I<H.+<T,><AIR89Q$NE#R58.
M=TTC+$UD%C3RLE)(+OT&BS*<4,YE15<)G.15(^X;^H/O?V<8<XQM3MQ,@91F
M&,H'X&!9W#"#`Z$>"2CERNASY@&!!<.-?MU^M<E?CS<D\)&VE\WNLHUCYY&2
M98\%]*9!91#5*8<9,B75IJDNX@:Z]E?"=15G/Q4T^<B4%D#-O&=P'E=JC;Q[
M)N8P./:E*.TWFC:G([>C(6[D=\P`=;4[<1H=U`M9$3*LVE='\M9``^8.'`_[
M0)U+KEH8MDDZ:@[JJ\I_9>@*7ECR6:MNE8U11Q("F2R$20E%%I\$7;7T;ET"
MRK=J*2"BRRI#&#V.2<.SF[<KIGNLFJ(28@?R:,'!W"+.:L'"\6<+C2-I_EA*
MH?C37[&*DI]/A.,/RAC4W+6PEMB-)MB;^45F(96`7<&],LD=M'HUUG*$$T;N
M0ROJU$C*'_DB0`ZS^X9N_P"ER8&W\GUK>V(C(2!8N[S(U_W0P7M/3XB>YQ)$
MA/IR<\/"C?:]5[T*G[57!@VW!4P]=_M'7Y\`<#V+Z8Z1MU!!N@`>](@CN'7<
MQ0$=_O[A'6S$%*JA'`)D.<3;F.Y6V*!1$YS=X@!"%_C#V@'W`'MV#4V@_4BP
M`<!576<B0"D,CLCU,F79(#$`_P`/]85[CCL'4`-[`$>NKM#449`J&.N95<_A
M130*()B/:8P"L81.N8/O('P!]H;B/LTVAF5J%L'!P?J$>&`&R*3=4SE$NZ0G
M'O0)ZD0`"B@W.`@`D+\6X]=@';6"-M`IQJDA7(%<('4[462::P"AL8HN$S>)
M/Q*E(`&(F<HB`$+\8[A^S6F\M/B5\%>[(05DUREV9BEVMF(;"H4ZJIORW90*
M4@=A&X#M^`"]1$1Z!(D&A^)&HD/KRHINCK&`QW"_I_*382LTT2'`1CR&^$7J
M:1%#"<>@`/Q=/AU91DX$=%EDI8QPH)I2"Y"`=RELT[0$Q&K,QA,1J!C;F]4`
M"`KB/QF.([]-1^!3CXK;'E(]FQ<JR[MLSC&#9R]<R3I=%LVBVC5([AV\>.G!
MTD4(YLBF918RABD3(43;@`#K,A7<-5:Z+SDR;DRW\@[0\QGAUD^?1Z+5('+=
M&0EJO!2,+*MTS)6[/URB/16*D8LD6#HJT-1X=PWO5W0,5RM\KA5!65U$C0K0
MTHI'8/PU2\-5QS$PY&TO9%TXQO9;2,;$P[B4;UXCAO'5V#A8-!"$I5,J+=TX
M0B*Y'%291R2@J@95RNY=.*0QIH5DZI^%R&3,@L(^M9JD52*KV]RJ9TQ36)N.
MQ3BHF`&Z?"L4!WZ^W05+%`4I2=D564!YWO$#MD`]0GVG=%*"C@`\I>A9`FP[
M#W;+;![3;;:DHL!M357)MU`6<*QRA7[4J;<?&D<XF)_/"/8!@!9(Y`$-R&#M
M`?>&IH&.J&G@K$EB+.EUBB`G(FBFL"A1*83=ZQQ*N`=I^\"[;&WW]G40Z:59
M'*R"5@\=%3%0S19%N8Q`<=?S%5`V,V=H`('#L1'?<I1`/:&VH-T==%?%9#"]
M:K($\H+MB%67,L@<BJ9"]O@+ZE`#"4H&\QMS]O;M[0+IJ/%3RE"Y54C(@5@!
MBJ*D.=`R2J!!30`%3&;F3`A4>[8H"&PD'</P^W37BJP5%G+15N<I6BY%3B5O
MV^<X'245$"F!0ATCB`@01-M[-@Z"(:O'4(R5**-4TU#@R=""93&(4%_L#X"=
M&W7<VP?OU![0FJ4LRK-DDO#'.0.FF4#*"JY`N^VYQ$2%1+L8VX]1]FH0'<LG
MAP69HL!TQ5<),62CI0[KU!?3G$I51_+`S9117X2IE#\(`;??IJ;0H_*JRG,L
M4@+?,U%DRFW`8\I@*GL(@'D`!0*EOMT[B[#H`GN54ET7)NL>=0=AW=`41^+<
M-C*HI%1;GV`.O4!'WCJ$!`_-7'(YW$22"`$2$#"FP#\W;\0]S9L!0Z>_N,(!
M]NJ$]JQ%?M%E"%%F=RIUW5#X%3&_E"V1`$U.W[QW'WCJ&#*UX%9E$7?>7L>)
MI%`.\J"6[=PF'V`Q1^,3@'NZ_MU8NHDQGS(IRD69J+K`(@=<Q2MSB;;8!%N0
M.PP@/M`W4WOTV$U!HK[$J]*_4.FH1X=`H@(IIJ%,S4*`=0`C0A=C[A_)Z&T.
MFBE%A5>-$#@1RT,JL7?O54(#0QC=.HM@`R9]O;\7M]^H([JA6O`T5W8Y4[%T
MI`&Y!$"I@Y_J8;#U$J:0`**I=O<7<!W]FJS<%%:JNV;F)ZAAY5>HG<"GZ1,P
M[;=R:10,DKL/7<0`!^S3;]:550%PN7U*,@9)$.A?5E].AU'H1(2@=JIL'N*`
M#]VK1F:J<5>H*:(%,HQ3?"`]QG")/"V$.N^P-C'*H'7VF`N_V:SM!JJY5B:I
MW1A.DZ=M`3Z#Y"E!JD7??M\B1DDR$^[LW'[]5O>BM7%-5JLFFX8/W)TS"F)@
M1;@D<OQ)F`ZA4EE3`<H#TV#]N@B7\SLHL1EEWB*:BT?Y$3I!V@W,J5,@'*&X
M%(D=1(-M^NP>WVZNT"B"FB8OD!DZ1PM@;)V4X>L-+!/T&JKR<5"S4A(1\/)R
MI'S&,9MI5XP9N9!NP,H]*HJ*!#*]@;%#<0T(;0JLY4+\T\^YCC/%9"KF5Z)C
MEYE7'N2J;#"RK=^F(NC6['$_CJ=S5:K#`+6.*"P1UXK6/Z=+LV\(OZ@C^>6B
M4RN2I21?%ESQ5`?319K_`,O<Z51YG:6@J?@RX4+':/&B3HK^MIYCGK'=XGE1
M?(^J8_D5X6"92;N0^1P3CUCQC$(N7,HX,FBT[>[8SWT1HG[5MK!RLY'Q0RQ8
MS'V*'`T7CE?N1=^:6R,SCA9P]K5"O$O7RU6IUZ_UIG8*Y-/8:(<N"OYMD>/4
M6.D)"BV$R@5V1HCZU+*^9EH6,,3)YSLQ;>[J8UN!L2L=6:C*VNY^AMB46M$I
M+P<4D8L>1N>02!\Y740C8Q,JB[M=!LDJL76XMH@<^U1WG^>>/(1.--^AK4_L
M0XML>:%81G9<9KPBM)A8*US#9G2K^M<"47-%[DT:YXS1E)=6(L2NY)\P7:)%
M\QH"1[$8G5;6N\[<'6Z<DHYVZM-<CXBO8UMCBPR,"^D8P\7D.O!,RCF4<5U.
M9<5J,Q@[D&,79GS\C=E'RK])N"PF*IV-W)-I]Z3RO/\`X]1DQ78R*0R9+1L@
MT":D+0TQ3=21U=AU:A-7="7>03^%0LBK1>G,4YDBY6*Q313M)V`"F544SE9V
MDKNKMR:@JAD*0K[^IV5>EUU#%*EPRXR>PKR(A'>;WDY%X^,:NG>?J^98.W\$
M"#ATT;./3F>HB1%0@*G3H.VBO@MCCWD[A'*+QO&X]N82T],+23=E$JPL_'2I
M4H%6QLYA\\)(QR)TFD;(521046[Q2]81)N!_*LB0^@7HH01JN$=\PL1TJ]S-
M(R4G9J-8*Y/O*M)K3D0NXA(=^<H3%2)%NHKYA\Z9W+'_`'V@S]L4Z$9&`!)`
M[=VHFW/F4P2PT5$:>"[(.:O'8JMF9PUHL4Y*4XE@7N01%!N;P*C$UG]-_.YV
M75&&1:L(5!"X1YTUSG!9V5<2-4E52*$+!K5&?5=52\U8PR[97=4H5D2E+?&U
M"(O[!HYB)-BWF\>V1%DK#VZ.>/&J+)]5ICUZ:8"=1)TBJ(^1!,0W'>Z(YU5:
ME=$Z!7Q/2"BWW1.T,BL5PIWBX3)UV8NN\0%5BF*:B13#U$2_$(#UU1`@O+4I
MH?!;%(IC.43(@FD?M5]4D<VR!T3)>3S)G$-BB<R(``_QC"!3!OL.H>(63JLB
MRZ0+)"P*)6Q$5DS,U>B@&`Z1C*"'X2+F$1'LW\8@/P[>T0!)JC-[51F0/,1V
M7<S-,JQ56^YDSG.4Z!_3M1$H@DN&^YB#L4`$1Z#MO9`"G%5OK6-PL*CE)RV$
M@`)UBF:@`IIE#PB)DTRB!1;*)B4.@AL(^T`$>[0`$50!EA64[O&LV$"*@Y0!
M5,P"4IC=X$/YTP#<JH$,/QA[OY0:HB-"HLJKCR(+E'X%"$W%,?QD$-C$'<-P
M.41#X3!T$?OW#3:`7X*I6*@F$0';8P"`].G7_P!YJ;!JE5C;*B*3?<=P\1"F
M$?>`%`N^_MW$-0PH>:$D"J\A/J=A$!;<,D>M9IZNK#7D(<(J5AX]LPEUS5E-
MJI)-'L!,2DDV,OV#LW5;EV$Q=P-L8/L/[6"^+.=TS;$`;1ENC(O'SDL1*(!U
MJ7]BZ'ZNV=6T)N:2`9A6C._^U0+CT[TSK,@_5DG;:E"@=.S"\L=:;13Y]\O6
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M'U./<[1+`G"%N<K9G'9"`_,W/3R@._$$"D7/BM2A>-^($N%9$T;D?`Z*R`;9
M.9MK'(+SC2-42GII>_SKU\VB*Z^8$4?K/#*O9<4XIX*K@QG0G.JY;BQ$!/YB
M[+#<X]HN3MVX6Y2@81%N,8F4Q*E&`W!OA`I+?HU0N6`R;=R1).M2_E(\7H3_
M``YIFK,HQ4D32]I0DIE0]N@F:MIQ\=_7:*?)SR2D5%9V8E9V6F:39_FL.DH1
ML_BTXF)="40!D[.`*I>\P>I&W&SBRA:ET)$V[XC.Z+(C%HQC&(N6]LM8W#.8
MIYXBB\2[*+R,HF41^*(8;]Q=R7!IIM;V%*[0VR'Z!B\LCYT\(Y8M%H)VUF89
MQ&NJ^9,55DZX1O&2*;>!5CU&AF+9-0/2I;E.7M,5$F\2YVLWIV\.(B!([GC*
MDRP&^HKN$GD:$FE:I=C=V@W'E*4:5!&T5IX<@G)Q::(\O"K]*.IFLLUN?I%%
M8^TV!%U(3K`:MC8R42D>OUR&92:B8#Y_3NB)&()/((F#M*3U7<>L)=]&6(7K
MO^GA6$6C$[[GF:4Y$<G!XLO8X,H&WBRMB0?,JY?^7D`%]3^OS"OI2-$1HB-$
M1HB-$1HB-$1HB-$1HB-$7-71XVCJ=;)!X<J;-A6IUXZ4.E*+$(V:Q;I=<YD8
M3_;2I2I$$1*S_K1@Z)?F=NB+Y[/HZXFR)9,M6WDI8;26S5U[5$6D`W:9+S[%
MTB!J]Y;_`#>I-\<X1M>><R0BAEXZ/WE)JY.7%G[A3*W],0RZ!)]RY9FC+VAY
MAR"S'C5EAN@]6BE+%`(4KYV2O15G9UY*]2T=3G%CG8R=EH.%1JT`WFS/)5ZZ
M=)(1T<BLZ-W`CV&JXXZJ.OT\9:7;0U^H3FVY$NM5JZ-;5QS8K=1:3`5::I4=
M.Y`Q:QG\<W&LVZX6*[52Q.<4JO6/ZA<GD6<0NP,BJHR<-BI%J7->D.BPC1$:
M(C1$:(C1$:(FVO[[T<OBM/YY/0_S#)*;'TT*Q]8UL&]&O+OY'8U/,E\O@3>D
M]6*^RG]<:-T^W\SN+V3L%CK8?=9="Q>Z?;3)[DMLK7ZG&CU;(8[[OFZ>VGY=
MRY)_*QZ3ZNROENX]@A\UEXW6[V(;;,-\<C]#G3Z&2=PZ=CR=7?YOSK5F&WSN
M')UUM=V7SH<_U8@W-O,<>Y)X'3_AE46QWSA\J9L/J<PUUO'M&\(1J*[V1]<8
MITE$5%.TX@4R)^[K^A_0?6CZ'PKL"\(]]F6`K3'D23)Z!N!]KKH?J!OZC>''
MY8>[S14386E6V2C\@T@D@>J5JF2T=)9!R!*K+_)9$`>UME3(L'*MCJ-;4K2L
MD_<V(S9-U(@L2#55W[O&B'9\GN&)"[C=Q,?F,N_&4;%F/Q"DC<)&V<MS1%I]
ML=O4`#5*]'C6;H%RT2(6H,9R.FH$>(#%]S<6?@%MV@9&R"C&XNPP24C\7T`T
M:J2;NTHFWA$VQXI[7D;-<&3]1E5*S&NT63<K:,C6AO*914NTFY`JX>&8=K[8
M9]U]0B,^\9.XB%J+R%0=EN47G*0<[IR-*?`'"Y)=7(B,3%<68"I)\O\`Q2>@
M>K`5;F:K#9L85G'CB)7L48ZJ2-@[64%E?!UNML+3'*$/X6TC!VVGN()S)4NQ
MK#.3$@"$6NY1<%<*NFK0J13F2Y<;N^5GFY''(O2LUEC9=NU*Y'=6,K=P2`N1
M:,(O(`AA&4B:+DN6;-HQZGP3-)P,MM*$$&H/&E#R9<^E`X=(LQCH@,UVQO,R
MJ<:OC.'=356-<IM$IU7OS%DM$R[60?*,`>M9I\D555XX4<E;QR#<I$D_(.7W
MV$92R3V^T8U%^0C/IPX")W`L&!A%P`!%YF3D^.3A1D(6S=E(EMH_F^UO;]B[
MQ7$N9L4N8JV8[9T-J\I*S&9LE7QC,NYV?BY"HQ9VSF1M-IL";&T9`CG#2-(V
M=R3$BC)%P104D4&_IUB^NM]Y['WB,\+NTLF4,B.V%S(B(P(G)P80@\;1!/EA
M([B&<F3@\T\;)Q9"[CR@90/FC!W``YFLO$BBUD(WD;?+KY1QT]DG5_BJDK)Y
M!QK,NGTTM:8B!CZ9"S8MI$]GA;E8JE;ZQ$HRA".VTRLV4BYA([M=1%!4V[[8
M%H=D[M`?(3NM9R8`1C;,S.401LE&%R,Y&/E,`1*WY0"0K#;D?J+)/7V^:)UE
MM828NYC(5XZ'DGV^GY'ECN1]#F7#E\V;W7'61E8F(F5#*3@1<?*-"*BHHNRB
MW2XK/(A-3L5;).@*DH/A*D4RH^K_`'#OB_Z;OX]MI2Q\FSND-',3I4MJ10D<
M'>B\GT];$.XPDU)1DW-F_N7NX)NY150.I3'[@'[0$1'W_<.OS[%MH]B^F<0D
M22G8D5,"]ZQ#JHE3W`!_*,8`.8VP]J8$[1$WW^\1VUI58DNU!5P*@^1<YRG)
MV`.YBKE[A203$?A("A#;_LW,.B*O\TX%9QU,JF'C*&YBIG((E\:0=1.L8J@?
M%[1Z[;!IP1E:<>U9)RYV`!*9)-(`[NPXB"B/3<?(X,)3`&W0!'8/M&\&"+(*
MRC9PU>J&$@D4.DDB``H!3*E[B%,380664%+MV_"&^P?;J,"&1DK73*JJ@[0(
M47"A7)`CB_$+8W8503HF'<3I`1,1.I[4P'M#IL)N/3X]%*NQ25NX4:.GFZA3
M&.U1]:HI\29&X>8_A3*;<J8CV[D_C%'XQW';?1`D`0K1)4V7JUVX-`$6K%DD
MX<MBB)U6PKF\J2"V^_D.J)"JJ']H!L4?XV\$CQU4)JM^5X1HBLHY50(R2247
M>B[6(BT2;H)&5<.7"ZATTVJ;9$ACF5$Q03*43"(%`=0CB-5?O7GWG>O9ZY4U
MF.6PLA$L<&(W2.%W"REP/0;OG6DMXY\J]N=<LB]&O+&MU%*?](6!3=QAS3#4
MJTJ;Q@6+`V7/'55=[1\HK\?(4E:R3QJ=8"Q:BZ7?JY`I=RCLWXU0EI1\F$A/
MY5GX>)A\D5B4EG:_J9&T3L4NP$PBK(2R9NX0TP;Q4(JGII]VPQ<'%I:8=M=(
ML1Z7/':WR*HTE&R,?$SEH>/9=YZN5@Q4AEYY[(+N'B^RIG'F.<ZX]QA$:`=%
MFO%.*U4=-SM!`137*91,HJ)B*#Y)`BZ!DW*)R]IU$@+L([")1ZEZ;AJR,2&!
MU5+$):4[9RY<JI)C'N"%0*L@`"9NHJ;RG$3$$1.B<Q1#M4*)BC[P$/9D/'Q2
MJM;-%U3+/(XY5%#+F`P)*;'$R($1['".X+)J;D$0.`#\/\H-:<4>BK\"KT72
MCH#J+I"5<RO<)UTMG*9``$TBJ'^!19!1),#!N(E-[0$!]D,0.-5&&H0W4CW8
M*%<(+HJJJ>1,$%04(**8`1-5#R`FH'0.[;N`Q>[K]HS\P>Q/,*JQ`J'D444>
MF*DH8$F[A=$Y3>-,PE*5QXCG[!.H)A`X!VF#;<`'VZ>6A#HLB:9T%5%FTD04
M4A%N"!5'29M@ZN%6H&(!0W4`"BGT`1)TV'VQZ?#5'\$I^)TX!9&83`S8O:5P
M"[HVZJ@;BD8!3`QR(IC\11V$HGZ;#OK#GB$\%:=R=94C964,04]EW*?D>*E[
M2F#P"0>POD355+W`/00[-AV'6X\V0>Q#DS4Y2I'>.UCK#L<02,``@'58P&5<
M;[]@]H=/:;5:7`!*K.06@"`(M7*QOXH'6'8>FP?EHI[]/\K6>%2$J]=$N(,@
MD/D1:I1_38%5"`D;8?:'F>'$W7W[>W48>U6BRJN6ZR?;).B'4*78OH1,<WPA
ML'D2V(S-[`Z@)1^\=1I:A%:FB@&QV"8OCE^(.]0Z:R8[=V_I4O&H.WVE.<-"
M>$BFO@DTQ8$8*&EIVVR<+6*U#1[J9G;#.R;&L1<+$1Z!EW\K+3#U9JV91C-L
M03K+N3`D0H"8Q@]NIY6<548/10M'D1D#+Y$7/%VB0!,?2+UA&QG);D@ZF\?X
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M,`IJQ4IQ9_J2=+D=DO&3,);DM08>;QR1JW>.>2/&Q&UVVG0$<[(HNTF,P8'G
MB2&9\012C8OD4D&2UNAFB0"L\=LT0$X!(QH*JZZ?3^"FA7;%`V.`B+'0I^#N
M%7LL8UF(&R0DRPG(.?B'Z0+,Y6"=,EUXF38.TQ`R2R*C@A@_";5U\TJ*'Q6T
M4\KD`/*-?`0OP@X.=1D;<H?A(F8%"*;!_%(GIH?+62::+&B>,;B8S1RJ*X#\
M)G95$D/NZ-C&,<0'^5V@/V:I$CJ*)KJLJJDFX#XQ:/T^IBE*#58H"/4>PA>U
M9/J/N`-0&(/%U*>PK5G!,G5RP51W_C)'51W'?V@"Q50V#[M<I/(U2O-)$3,B
M*JHD5=HE,(K(_"FJ`$./YI-RJ(=2*B(]/<8-&+.0%:KFKQ4*A?JM8*'>&;:U
M4N[Q3F$L-7E$WOH)IDL0OJ(YT5NNDJ5)PBF4PG(HF9,4]P,`[#J$/^'11R#H
MN,H^`L-8MDF<_1Z95JY+MB65N,V@$L_F0+=`K);,N^GIQ>1FI9Q.)TR);.G+
MQ9=<[:/;(`8K=(J89')OL1R=5JW?&[!3NFR=&/CRI(4*5AL?UJ6K;9*88H2-
M:Q4Z!WC6.!5BY;OV$?CUV!5XCP+)*M!3`2&*`%#5<"C+1+>U<K+</.+T@G#)
M/L3UZ?-6&[UBQ^>2-TL*"</(R[>P2<!)I3UG=IVB%>2[8CKY9)`[8%6+W>(H
M&$#0`&K44W%23659-B@=GZYP\$2KHF!5-N=4Z>P]YC)@<4TA`!+N`@!0'8`]
MVM@2XZ*>;BN5FJI4IZKNZS*5.MR=<?)O]J^>$:+1H?.$7:<F2/9"CVM'<LB_
M<%770*FX5]0H(G^(VJ6XJIM'?%[`K@A)5]B&CM/#)+V`H>A.P3</']FEKK(F
M?H-G2`32$M:+"\D5V2Q%V3AZN"AT3F32$F:.P#IN/!+''';C\#UA,.\5U1=X
MTC%*P@1-BX3*:!=4MOCL(ER!77:]2_13!"+3(8@^%D44R'`3J&'.V1T1Y<%;
M<,%87NMB=VJW8PJL_/JU1C6#%DD9!S&?IJ(CK#$QC:2AA?\`R216B(JPR#9J
M[6;*/&R;M4J"I`$3!1"HXA!1:"D<6L-5.Y,;S"5U:M.ZS%IP-<81S]TB#,SB
MYER19Y`RW=\[D'%PN!6[B4"2?.D'/I"$!(@&<`MJ0;X4))HG(MV(L57=^K(V
M6@P$J_6F8JP+R*Y7:4FZF(6&&N1KMY(,G31PY32KXBQ4;"/HW+0?$LDH3IJ"
M(9SJ@6JI7&_!U#4>NJMBJE5Q*5(W2?JC$C)$>HL5X5S'MDFDPM(I"A%+UN.%
MFFF4B++T*`(^,$B``F(%&=-R=DB$8Q-(_)XQC&&F'_S2;<LF;1J]GY,44VXR
M4X[:I)JRC_P(D("BPG.!"%+N(`&I&-7*+6+,E47S=T<Q46;SR-5#+[^(7!D^
MB`%_XSUP$*7;^*H`&W#<V^G$A3@H5;Z@%6\<@03IMBK!Z0_<7SI+E15(HFY/
ML(*'^`2@`B)=@[?<`CIM>:):W;&7<BJJ<C4[9N<3',&Y'8'6*5--$HCW*D.*
M9MQZBD/M^PV92845>J'#@7COR-R%;"S;@B+4!^`/,?O[%S`&ZRAB(@8%O:._
MV?"`185XJZ)*/YS@%$ORUD$S`L0^^XG4$"D26[1VW\9#"4P;]-A#<.FM</!3
MBA39PJCX_P`MPF8RBG<&XE!(NQ$U@`0[TS'5`0'?V=2^_1%1QVN"%2,`I./(
M0FP=3IE$P'.<OL!1`R9!_P`4??L/L!%G,N)2*>0A2KE2,8H!T(K[0*9+?KMW
M"`"4>I1'KN'48C)0F4"%2(.WY9"$W'W=I0*/MZ[=-4HO)#ZE<,:QVG$:#-P!
M).,HN6+*5F@7MDW\3'$J#AZBU7-WIH$,@R3%,?&*O>53Q`J;N3U]=_:O)CBV
MLTW'V3NV(/P!EO`)\`_LYLNC^J+9N7K3!Y"$RW$L1]J@LVBC>AQSE3(*LU#5
MJ.9@[Q3C=`XMK%:/TG+U!RV49JV22>2$<O?+7%`YE91O63'1:1$NL!4Q(W(7
MO=RX1D9/9>V1$\N9:_D%C"WU!,$':`#T[9:$#=8F=L5JNO1@(VH9&66QXUC$
M:R9@#J]3Q8NQ\%N8JJ9BS`Z:7R['I:5*5:0",*TRTK/34+9$Z>FM"1;6`*G(
MR^25$V[J-3>/)=NJ9RV[C&]4LOXTB\5W*['V&)[?VX9![B)2WRQQ&$XF8W2,
MW`LZ$B-LT-`P%586\O,!OWC"-F@CO)((&FVNX^)"XIU2<95=T_I5WC<E8Z<5
ME-DWM=%/:+!D2A33HAB,E;3&%CXJMN;?0WLC\Q?>91:/47(Y6<M7:J@=P>78
MS^[Y-B.=VXXF0+A.R[TX6KT`:F,WE/9<'EC02`81E$!<5V./CW#&Y&Y#;J!Y
M@2=#'PJ>.FA6U@L=4V[2ZT!6(JW9'?5]`LPO*YAO5KB\;X\KS0Z+=9A9X^&K
M+>;DIIZTFY>/3B&?H$'JAU6S=99)(_BQE=VS\"S\QERL8T+DMHAC6X'(O3-7
MB93VQB#&$C.0G*-)%B5S6+-J]$QL"4RSF4S(0B.5`_L`:JW:B&6\$NECRP$L
M>*[8I"P)W..I$]:J[YK'FD)5M&Q2=<*X5@[-%>%N*T;)QZZ2J1EO*T?(E34)
MQ3CV;U$!&P96>]V29CK#?<!\H)F9,)0-6E"0;R^:)<%ORL21-P;L.8`)B6!'
M*FA'*0^L+DY6IOJC1R(U*2E<A8BMMN8P<`[CFRK20JEMC0K!(8CAA`S]LB(J
M6L=1D3QDFBJPCB+.*TZ)WH@1)37EXV9#*[D9Y]L8G>,>T93<AKMN6_<0\8$Q
MC<&Z!W2(%V.KE<<K,[5D"S+J8LY-0,8R8,#JQ(+'1V/).-1VS.OSG#NJR#I*
M8=P_U%?EYW#66;-A9SAZOC9QZY9D1%<\BD]:)$`OB%-%0BB:Q%%$MS*>#E7+
M^78[UEVQMMW/38(<.\1<NAGY@OJY&A`.GEX-LVX8UH_%#,`/_P`+KZH]?E]?
M2T:(C1$:(C1$T.<LG26(<>OKM%4Y]=G364@(P8ULI*MF$:VFIAG&.[+97T!7
M;C/QU4KC=R9W(.&,1)N$6Z9C`W,4#&*5`<IIL(<C<@9.QU>K?;N/]OI%AIM>
M2L,?58QQ.325[(\AY:7C86G25QI.,9-W8GR$:B;TR\:B1%*48^14JZCANU(0
MQU6LPGRIL^8+VUK@X.M<%2WL,J9'*)%;(>M)W*'J].G;74G<=;J%0YQLA$2E
MI6BVTB*`I/GD8Y)XT54U$4BI#>U#/EA/*<A;%AESQVSF:GQMH@Z7%9BC,<7Y
MS4EIR2AT))_*SB\E3X>#84!DZ7](G.1\I+(G6*)UDF[?M7,3;1W"V66.50XI
MO5FH[O$V1[`X8T^*GJ;)5NGY#M3*Z3$@VLB[QH8]$Q_<D:_5Z\YAV3.0DU5%
MW;=[*H%^7BB)%U2@#K>9!Y`VNB.<.+I8&R19X*_UN?M6158%`LA:<.Q4(QJ*
MITI&I1K21/<IM-_;/&O&1CL9([>/>*L$)!1$&YR`.NAHN<E;=B-SE=WCB]LD
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M4*6!JHJ\"ZE"4"S99IE6J>5*O"QU3QC-R2=RB:I`4=>X6^SYDL,RE0H['2T[
MC9X5O#NHT2NH>;DTD:\K"L#^,6)5%RU*M2O2;181HB-$1HB-$1HB-$3;WY]Z
M.7Q8G\\G8;YADA-B#:&8B\;6'>CWAW\CL2H*I?+H(WI/5BN('_K;1NGV_F;A
MV3L%CK8?=9="Q>Z?;3+=<EME:_4XT>K9#'?=\W3VT_+N7)/Y6/2O5V5\MW'L
M$/F\O&ZW>Q#;9AOCD?H<Z?0R"XZ=CR=7?YOS;-J#>=PY&NMKNJ^=?ZA0OW/,
M3,T6O*HE@GG"^![H8DPU*JJN;+%=2=/'4,H<KA1,[7\KN+L51+O`=^T=OT+^
MWVV'H_#NP@^0.^2JQ;_+S(#Z4-?:RZ'W_P#]PR!_T@_YPH4#88Y2`ISV4%S)
M1#RP1N)\@O!\DW,M:Y*MI%;&MDCV;D&]7:2]1?R;X47;]X4KU".8QX`!"%.3
MMTL*]'+OFWY;UNW+*QQI$SBW7MD_&UP`/&(\NZ4]:+T5L;X1$A1Q&=7)C^$M
MHX.CFK`*0^/&\=`4*?QW%L8]G:,>6MQ$9%JL9(,YZU2MD<R_Z#H=W4D())>,
ML%2LU?;QQ(YNU\@1AES`5L)5!=+=9[C=N9?<(=SOR?%R;0E8N,8PC&,3<N6F
ME6-R$C(R,OB#.7&T>9&T18-JR09PD1,<3(E@::Q9@&T>FKKK;]GN?J%>G^/V
M&L8T.X6=9S%1^1)G+CDZ.,6]Y%@Y8+4NML&*3)]>[+6F2JB\D]%P5A%NS`U#
MO=%V)X7:_3>/W+(M>HN_9-^QB`3-OY<?GRM@N+DR:6X3=H!B9#S4BO*N9T<>
MT>VVXQE=)`F)!P#RB*.1Q+T/,KEJKEWE1QYO$-9[KA[C)/LWM-@8X"XV8J8T
MR`9%G7I!4*G595ZL\AW4N4(]9F51VW.A*+HMP5.!3IB'FY78_1WJ;$GC]NS>
MZV\B-X_XQZUH/(`7)A@1"3@T+Q#T)HMV\[*[?<WSM6FD!4`1+`:.!\0]A?FG
M'CI^N/Y"!R+CIR,12IBN2%UA+38F*\*T@F](:N%KDQO<2HQ4-#2=2(D=K(11
MTW:JQS%*5NLD=(X^JNPOVK=[MO=AU,NU=%HVX'=N,Z6I6I!G$RQC*@',%UPR
MB;EZ%_&DT&)C,AA2LP?`<15_85#UW%UI.R0SJB1*,-#9LO5@@ZZ)731TUAL,
M49RBA<[K!/*P>4M%&4NHRJCJ*)((+MX1C%E4[S%<JD)W6W=R_D[EGN5P2O\`
M;K%N4@!4Y5U^E;EO:%SI;8B9B7G*9'X0O!E&U;(NP;IW9';5F@-2.3ESX`<5
M)K@A),YGF+&3;146R`4:TQD2P.N11O$U:,:MVU7AF94Q`"M8J//LD4"E#S.'
M*VP&74$_7O7-F>/Z+E8D'G\Q;G.3,3<D9&Y(_P#$?J``X!>;V6X+G>HW8T!A
M)ARB(L`O=957P+.FQ2]ROF440(([`9,YS"(B/7M3;G$0$?<';[Q#7Y]CI'V+
MZ7Q2;N!HH*A^Y0[L2D$=OB5<E*/8F0!'8A3IAL4/87MW'6]=."J#B#<WK5Q`
M3E**2O:`F*1%0P;)HA[1%-381';<^XCTZ;-:!&X(5[@#U2H?F(CY$DP$1\9-
MNPZ1=M^]98@B`B'M,(`'3VO#@B#""J0NC_")2E5;`([@B/0Q#"`;]RRNW:.W
ML`>T/O>Q%:)_*AZHY3%5$I3-DO:9$_<`D2VZ`+DYP[3_`&?A]@#NXJJIG"J)
M$7J.P/1.19+L$WY*9=Q4*`]!\:"1S=_\LW3W@&C/0Z*:T2AP+5<YP*!4EBMC
M&/W?S,B_*H!B%$P#^2H)G`&,'1/?;\(%VU@;H_\`"I4+#%^=F0RZ9E2*N%C*
ME5$1`QP2_JQ#I[;?E'%(3%]H;&UH[9>Y75,I-%0Y"6.0J9U!;87I$ZI&7]PW
M+_5,QWB$=)G=8\*JW7,;^S>FR*(I6DH)]LS)D",_YJWD"N.,@C10/HG!R1D:
M/QN2$9A&2-LNEL7>,<?8^J2\6%EN3R+;%=21HP\D\C8F&KU>9&(M*2KU9O'Q
M:!B>0_E4015!B6*T*J,V02U^-^6V+F??26R7L)S-Z)Q7Q@K+.J=8)`5/,R@H
MG'#!!"_\FK6)"@BZ=SB05S;O5^51R`**Z&+?"5#X)[.-F.9G'V":/1)2%CZN
MI$DM2T?C^-?M'C7'=8L-QL5@JN.FCMDFC&/2T.JR[.(,9GW-0,S$B!CHE3.8
M),4]J=!HX=)D29.C"H!7KLJA5@$QD'J2/:1=,AP_).X!4##VB4._?^4.M&(U
M%"LL$L*Y;*I.'`HG0?D5/V`D;R-EPZ((D%-4P*%0<"F`@/>;QB(_8(#=I!IH
MJ`0KSM>]!$8]VB"XAZ7M5,+=43E`1<%7!8H)@*9>XQ3@8=A$!#H;88X?SBJ4
MXK.H,FJDFDV\Q5!!1N0-BN0113V*Z153`52F2VV+L'\8P&*/OU6CJ4HA=R=<
M@M%&"*2YMB"!4!16:%*78RZ1T@2#8I!V3-ML81`!]X:RPYJ4YK&J\1`A6IV*
M)%S)^)`2JJD2.D4.TRP)&,J`@B0?C(/3NV]PZU`-H7"H!X*SU#%BF1,&RBB0
MB1)KW.AW36-N!4EC"B/<F)OB[_:4`$!]PZOF)2J!5;-">5)JHJ8.KE/U)MW:
MAM@$Z12IE[')E!Z!OL;H4?8`A:\2K59TA(=#S@S(*AA%P+H!<J`F/MVZ&*`H
MIIE[#%$`[@`=]AU@L:.I[TH:*OE?(J,8@@N($*9,[8`!%'83)"47(#\*W4^_
MMWZ#U*.PQ`T-$IS2[_:`B`+/FR!?;VE<D`0Z?Q4V@'$!_<&LDQ;10,]-5@4]
M(4?SG:C@?L11$W_EKF2_O#J@$Z!EJK*P'#8O1!B*H[]#.%CG$1^Y)$$B^S[1
M'0CF5&YE:VT6Z,I%5L-TN,S%TJEU&$D['9[-,.$(>%@8"%9JOY:7E'RO89)B
MQ9('44-N81*78`$1`!FV(KJK33BH*L("=Y22D#E3D!`R##%"0HV_!/&6XL'+
M.%C:_%.VBL=R/Y4LY`K:'LV0$@>MY6OX\D71&M:8=JRZ2TVFLXBL[231P%=*
M#7FNC><A*O?(5\OQWG8C(>0;4QN&-XS*<J1ZK_9QEFR5"+NN'(Z4J<]#N'\!
MA?*OIQ>P$NHFZA/4BQ$AGJ+T%2PF0H2Z,>.BYR7XUW+,T=6)[D59+C5\<8RR
M):IJ(99@LF,7>1%L<63'E2*_A[7=JBA+U&"?Q>88-1Y%S$>NVG6\`'A(];'6
MV&>71`0--4WLE+\%B9)R)8('Z@F(JAD[(Q\RQSP\1R,Q:Y7JZ.;'.,BV`U.J
MLYDMW!UVTPR&-P!G(-F*"ZCQ[ZAR18S=-,UJ.(^M5I<J+KDN*67XNE<>Z[Q^
MY`F+B3#TN_BZ^[I;P6,X]H-URRE-.9160K4S!4>PR6(<4H(Q42W40D8F4(N_
M!2*$RC4I8P]ZA(_%JM[AODU8LN92RG5<C8OL6(K!2Y/)%Q6R&S9-ZHRQ-BZ*
M&`J.-D<JR]N?_)+QDFXBI.K%,DTD("%;1BZ0+`X:'5,!JT49M$DE(64X\3TE
ME_CA747]2L:CZ^9AXQ4A=E+5'*E<>G0E9[._$&/,[(>'S)6HF3:O+##M&S6#
MO)UA3*4LLJSDG&MLQ74<DJ:24Y:7=87(]/K.0,?6:.N]*NL)'6:K6&)>`]CI
MN#EVY'3&0;(N2)N"^5,VQTU$B+(J%,FH4BA#%#0(/@LEN-%N%5P*/:Z8$(;V
M;D!5J?\`;L`^,=A_Q-;'@4;Q52F8'#X5':!^G10A%B!_PDS)FV_X.HTO!6J4
ME!QV[(2+<0]Q!761$=A]Q5B%3_NZC@'0H629X,@1,B@H(.EBG#TX$(T6%902
MF#P"9(NX@L3<!W'8`ZC[-6DN8"E.!339I+D5;$=Y6QC'.B9"5BF@P:L2DQ1G
M&Z"4U&&L:%7&?.6!2MB59+(!%"]V;?-@0%4>S?:$-0%`SZT4-),O(I\\VJ++
MD\WATTJ\EA4M[DJ4J`V$,G2REZ>\G2"/SD*,>A'C1@TI0%I((LCH0'YR9KVG
M+AC5:IX+DWDUSPECT9Y3XB]QS[&V.8*.R36[N%'C(G,V3*S2,SC<V$=*@L^4
M;Q>09%]6BPUB;"@S0G$&9SIBT2?IF$3-4("K8*ORSB*\UDHNQ9Z?S#][QR/+
M025C4F!CXA_C.7>YS/%P-3>QLJS-$Y/39-G/H'8G3`XE0,9L90!SYQJ4IQ\4
MC>0W.)A+W&492V6&]-GBW2/J*,,1G:KU&L6D-BM2JJR%#M5A@$X9JJ"=E.B]
MBI3]3G=E%LJ8KAPW7`Q)=Z*^7B@I^=!8)1Q8H;.K:OMZJZ^21U3GX)O?5;@D
MRL:5,<RLTC")VUO2W[L$5YE-1DYE6SM:*1DP=()22AZ2#XJ>3P6DL;?ZBJ"`
MHR)+<$/-V&?MBKBMOZC*6S'<*IE3#L.XQDX)3QAW]JC#4$E@E8*4B`0>"BM)
MM5/$<D:!XY&FB/%.WCDW(LF5JV:5+GM2#:6JD(R(W<&+;%1L3-\,)?K;U[.=
M>R5P+D]SF`@J-1`YY,I>P5%/E_E`:!.1\"E&HN#E9CZB"DQ+2;*%.P92EML>
M9H"M%FZD]C%:)^CLDP4-Q9NC]2$C'U3DY!RPK,A'O&R\H5E9)%55P_58)K-M
M(QF"_BC13F\96'*E*XUXV7/[8V:'H;PKDW^TM:I&H1FCBMU);&A,=LX=9P^"
MY)6<S[YD+,`9>'U@.S&4%EH)2W50D<$P\/%\_:_'T!I>9?+,H1XTQW-6]U2W
MTG;%T%G.*KX:W-))Q$RD+<8:RH9/-&H/X=@8]<;IMV3IJJJ1T[1;S;*5:H=I
MJ$[CESS0=7E9"(ALP/W+FUJJVN7>SU31QRPIZ7(.CK4UKCJ#EHQ:,40<X`]8
MC*JB];2C=[\R^:(K'%DH5I5&B!X(Q74^3TQ'4@M_LW(2.5@\T12-BD7UIC:@
M\M5!<8DGWMD<SU7*M8EXR,897BXQ`2,Y:2C5E':WRA5*+5%%(\Y4#HXX)G#0
MG/VRXKJH1TQE9AD&)H][G+^-LDYJKKN;NQJV.C5B/J17\C*1$]-)S`6%2.8$
M%I4Y!V0B+PR"*B:I*'C0:JO$%=5'I\G`>J*W13E*\AG.<[0XLK3'[%:(LI,/
M'5S(%'7JQG4VYJ34'"CNG"Y;Q!&ZR*!1*Y,)2N##3(EQ5'X!G4\L*/,G/L=5
MLN9U3_VFQ\)76MA5&+C(YN$DA6H<\J9)>%>.(::.$NNX*^=,R-FAGWF202\*
M22JEB)1#%F669.>B;RD,Y``2<]QCG*<1`I4Q*42(JC[?"9$`,4VW01[OM`=U
M]R*Y$15)ZLH"1<YA$Q#CV[$*``1JN'N$A`W`?XIAW#H/6\6X(J)"#C=XF`IK
M#^6GW[@())[B**P%Z]BAC";IOL!@$/OFE."(`P.U?.412.U$Z*0]!,FN;;S@
MH&X`=,``"_8;J(>X=71&53G!T8J!R]AT#$66[3=4S]0;F2/[RG-N8!$.H%V'
MWZGBBO.L80!N?HNI\!1+L`'2]JC@GMV`B8]0_BF$`]X"-"HH5Y*?4X<J1=[X
M]SK-\Y9R,!'7)[$+-U42F:/TE*PF0I4SG**A%6BJB*I1*8%FKE=`=R*G*;[!
M^UEN-[#[CCW(B5JX;494>A$_XL1HT@#P71/54IPR;$X%I",C]H7GU*L8NP2]
MAA6M;/*Q55J41F['T5&RK&,>S=)469(Y*Q]^L;:+),3L',XNK%DB4U3M0A`C
M/)^>JKKZ%:O7L+&LY,[HCDWLB6)>,HTC=8]&\(0X-&._>1NZG4:@"Z]>M6K^
MZ`K;C$7(@'6--T:^TZ.S-Q4R&KVL3CJJ6!D_KS[%K>N.K&RL4$BNTIE=QA0Q
M7KJHG9&9N1AG-;/&E;*LA)WO'1R"DH\55(<W1B,W%A=L&,[?>1>$)0D7E<OW
M?,&/$3?=NTC'7:`R]EMC>G&<B)89@^X4$(1IIP(T(XG1UQ,]GG.V>;5CV,PI
MB#"4#4*6A&-ZU+Y\AE+=DF*KK;YPRBI>1I+11I&5MC*1L:+\D'XEW")#-A74
M!P)=O:8_IKT_Z:QLF_W_`#,Z>9=)W0Q);+,I':3"-PO*9!DQG2)(DSQ6YY]W
M,N1A8MVS"V!M,P)$`<2#H*:,>%2L6-N0MNI4$KA3D?B_%%1K4M8XI!6V85\Q
M(ZKSIUGZM=F,G5%Y\S6+6Y24=*,EIQH=,(KX#N2>G$IBX[KZ8P<K(_KOI;*S
M,C(A:E+9DU,P&W1L3H\XQKL(.]B!+=0XAFQMP/;\N$;=@R'FB-K'_>%?*7UH
MW)DHOBS&HX_R#$W:&0\1I`]08T*0>)L9FX9-ATDK)0XVCO72)&T9+,7KEHZ/
M,&*BB1HL*13/`6,W4Q@=;+SL:Y@3,KD8=6=X#RV[$GC>E<`^($"41#7<':+.
M.*<(VK5V%UQ;W;=IJ3(5B!34$N3RYJ.#1LE0Y2XUEJ5%%MAEE#P,?-MW"#9_
M(9LLC9\S=S*$I7"2%-L;*H5B1?M(PJ;A%VBI%L9,H=ZG:GVF4I=SM8^9,D3S
MS*4HLX&+;((B=S7(F<XQ)H01.4-!7P9[<;?;C65IAKK.6IY%JCW`KO,.`X9&
MX:MH:51;,G/U`T1?(NI=BR&1;.:OC]\Y:IHN%BK/U#O3BJ!&VYSK&,([@J(&
MX.\F$I=[E>MDD>G0S`T_,N`&@I2E>7@O*[>'ACDAWS1QT817U9AK\K@N'7TU
M&JB-$1HB-$1HB-$1HB-$1HB-$1HBYZVOVL55+/)OGC:.91U>FG[R0>RCJ#9L
M6K.-<N'#QW-,4UGT0V:I)B=1TB0RK<A14(`F*`:(OG?^DU1\GY"Y-7/D!E*V
M2EIDXC'[1U6:W*9QY:2<93,89:]>OC*\T^B<J\)QM\RK"Y085.1(G<G5Q*U$
MT>NFVB&IN\@%RS(9A_!>_66,7U[,=&DZ#9UY%I%R+^O2R;V*^5G?,)>J6**M
M<`_2:SL7.5^2*QG85NJ=I(L7L>[(04G+=9$YTS%Q@L734\<^*>)^,YKD;&J\
M\Z=7!PQ"PK3;^(6$BS*2L=D\:;*`AH"-;K.9N[2+PQCH&533=)M43)1[5BT;
M$))U4G=%$:(C1$:(C1$:(C1$V]^?^BE\5I?/IJ%^99(38>EB(_UK:Q[T>\//
MD,^KYDOEL*;T?K!<;*?UIF@GV_F=Q>R=@Q^OA]UET+%[I]M,]UR>TV?U.-'J
MV@QWW/-T]E/)<G)_*QZ3ZNR_E>X]@M_-Y6+U^]BWMLV]\<G]#G3Z&07'3L>3
MK=3S?FV;4&\[AR-=;7=E\X_U##1).9V;@4!^WDQX3U=19P5\V(Q4C0S!7B$.
M6-*W%ZZ=MW1=A/Y1(4I@+X5.X0-^B?V\$_\`1V$1MV?UV7`N_P`O+B[,W@[\
M0OGWJ(?^HWQ1CB#_`)H_8O.:*E/15E\[BWDB\9M;'7AR&<&S):PQL(E;ZVG`
M3%/1=&2BVCD'IW+1=P#U!R!G!?SD43B9?Z1D63/+$+L8BZ+4S8#G89=.>^-Q
MG)HTHAFIH30=:MR`B3:C7RB5:AB-I'!SK]BF/0Y(T-S<H;HSF=CW2M=`I%:?
M&1LX64,O$V3U\3:'TXJ4'F/8RS-TVX2C]%F\5BFC4Q&AA\"J/0,F'7_;W(_P
MY6XY'XR8F(W0:5H1_P#$,"28Q>.XS<Z@^]LR']8MER#M.G$[2X+AB'YL69EB
M^G4UK4W%U&QR\U9'F1V#7+LJ!I:(K<E-CD%.UK23=A5(*6LS!]8'D;+N%567
MF=$1<.7BJ*S8@F$33]S)9./D7,:U;MCM4OEH@QG.,3:V@/<E&+6WBP+`E@"Y
M9;[/&S/)C.Y)[XW<GW,X:)8D\:\>"D[*S'(3)F$<A*<U*^K2IJ!0QHOC&.7K
M54A(^=C9.';%=3*5B<VY\1MDNW@1P,_#F9.$850OC2`PF#Q]6-OT]VSON*/0
M]XW[4Q=%TF<Y&,@3Y#$0C^5`,+=QWF/,6:OL[YR\C!N_U6!A=B(F#@`.VH+U
MD>(9>>0V5$G'SEG"(V#(KRF)\Q#_`*8*M7HD$9`1KAG4[!V]=%Y)R$+56LE%
M196*C45&ZCE!F=9%$XIBA]0CB/ZH[/>N6L:.:>S><"1HTVA.#L)7-ID^ZK&3
M$\?13,?Z=<CNETS=#&E:%]S5&@TH2SK87QS*HN,/Q44JT(L;&4VO9UCMVZ=;
MA*@K"5AE;GS9!FO/+5Z1AX3R%C5HDZXOF@MW)G'J%U&!_`[1&U./<;E\3E`9
MD>GJ)RGOF;8+[=T2?CWLQ!`&T"0\7*:,8DACTZ@Z`'XA31N#5:NI3S?3=/%J
M<K(XS5>9<L4JE??E?S%)MZQ)J4D41([DY"D3\QD2I"H80[MUC"4J8JJ"MP?N
M=&^/24A=V=3K679V)\VE?;]7%@WF>GA_ZM$AA#9*GW?>OH'<D,0[AP<Q?4$4
M,<Q@W`HD`QMVQ=Q$03,`[![Q/L;VZ_-$?A`X,OJ:Q$`'!!64$2]Y1$@".QFA
M2COU$?PN"&#<_P!@AM[`ZZ-**JB!C.-SK%`#I]"I"&Q1*8!`'0E-[G!=^T/X
MI=P]N^B*UN8QU"E,.Z:?Q,=Q_GB!T[S>X3HAT)OMN7XO:/0FB$AW<`)O^;"<
MPM?Y/J-Q\AA'?8""("*6_3??;^+H=/%%0H@"XN#B!6R@F\&XCVIJ[#Y5S>P`
M*Y`!`GV;"/M/IX**TIA2,H<Y`$7>_IDC!MV"<?\`FXAOL'DW\IOVF]Q=%4G/
MND0J>_>:.^$YQ]JAW@&;MU>NX[[*]X_88-"']ZBW40]5;,&**A4UTD4R"0I]
MP%(Y#?B;JD^-$>XN_3<N_M`=9,0]%-H7-T3&U*QU".*]C]DO"0;F<F[$6`>3
M4U*-V,C8GZLK+I0AIR1D$HB(7DG"BR;!J9NS045.*2).\V\T1JIK;5@5]-Y3
MDLFM<N95HSF9I\%292OT[]!,`/"P+^7DDVL1;)JC3UWK#"6?S`N'[>,D&A';
MI!%83`=(NSRRIQYK5%V>-\.XGQ;ZUS4*FG&V&62!*<O4I)2]RR'92B(G-^J+
M_<I";NLZ05!$P)+2!FZ8C^6F4.FH8D:54+ITO0BJ&[9=!<!ZE*!_$N.WN%%;
ML'??^2)M':A%4!;5<Z*CE!W)HG`Y`545;=JY?(!7J_@40.0%2#XSE[1$-AZ=
MH:UY2!JI0E*Q507].)FA2'CB]KGTQU""L8I?&8GC4\Q>\.T52[;=1+]NC&.G
M%*C17"5@)CR)'2R:`E*0041[P%H&PF>`*)C")@,&_P"'<R0!MUVT>>C52JO]
M+X"'E"NFQ1%,!52[U"*@U+OXBE*9,H&<E`>[8!^(3=ON#9N&C(Z5>*0(47Y7
MI/*"8&`2/TS!Z7\96O1;KW".X"'_`!@]/L&/#DE.(52%D7*7K%5Q(8Q>]-0Z
MK<3LR)B;8H]QA[5"F$15#WCN7V!IN`H`CQ54`E'0'4<`F50I3("@H=L!2)J%
M#N,8#"7_`)T38W7J4NP".X&T,@*`%**QN:3.J0JCL"II%\C`YG+<@J)A\!E3
M&`P#Y$@'M)OU$AN_VCT&4>54IR6,Y78KCW2*8,C+[+_ULQTSO!$=C@"7>!FX
M*;>0>H"KM]AMSP9FJE&\%E7;H`(*F>E5<I@/PII+'\J>X&,B)U2HAN8.I>O0
MW[]`3^$40$\J+(3Y8`%."CQ8#%`P!VHH%$!#W[BN.X>S[=#O.@"#<ZR^I2W`
MK:/3,/N,L95P;[/PE%(@B'^3J;6^(U5(IJLW^U3%#X09IC[``B3(NP^\1$$S
M&#]HCIY1S*RX=05S,='-><X_#3T"3.)^/S*D9GS?%`C)/XS(67+++F/QEPI8
M!BXV67&JQ$K&&O%E)Z=PDF1"`,X(9HJX*8230"@^@6Q0.-5W=WS%-X:RGC7'
MK?!ESR?(YQ"8?N,B0]FQ_%&4N-=8OI69@)U"91HL5(GJU!CTE&"R[YN]DHQM
MXVR#E=LYVA,M#HHQ(J=%%Z_VZJ<4\C6+!O"?&]5G^4F68%WD6PM[G97T!Q\X
MH807L-BEW64\S3;,[=6@8B5NTU-R$%4HTY)>U3+EV1N=O'MCN&,(C&@J5H5K
M+1,-&<9:=G*62M&3W\I]1[)S27_VA=,^*F<\<:V1VFR29R.).,,#-0F#<;TY
MG*+O2HKRC>U64_RD4WAEE%E5&\$=U=4<\**2D7Q'N#>FJQ,OC'AB\.6$BX<*
M1#\=,0L:LX>C)2CF0L:3M_C=9K'BA'G8,SQZC)VW7;D=F2,BL9N<'2+>*A/M
M4:G_`!>A\1V68GL=TZ[_`$_<HR4S99*N9,X4L7<EQ[LD:S+`#4JOE3B\_>2>
M)\T6FWS,[\N"(CH".F53-U?22"*YVXJ0Q;4,J"?:G::V]'EQ'6;A?S(JU8J?
M)="F2UUQM=,5R\C)8>Y%TNM.R0CK-W&]W*33,I[117RP-)NG6-9U)T61>%5[
MW,>N5XI?+,,:%-/,-%Z8*EB$*96&"K&)Q<LV0J\14HXTUZ6.JUE:-&J=5J)3
M0LQ#MK4VBW;5)J:,:.")2R"`I%`R9]]:VD5=88J*6+7#+#/(1]C-@883$G)E
M:]9%QY`NSQITL6\E:J`3^?L5$1@9":CH5AE:O.OU_&1R:Y_323:PFV+Z@B98
MY%)"A5+D.=0IV$3DB_"@X(N3V=J;A-<HAU$/R%!W_A+[]:W1X!2BQG663'M<
M1R&_\H4%6IQ#[0%(Z1>O^2.GE/%`QXJTRC!0H@=%R@/M[B+$5*&W4?A53*.W
M_"T`D#JX6B[)$1%HJ?S@Z.4!`2H%6;#N1(>T/((I**_F+"7?V="[!]NM.6T6
M0_%,9R9+F5'`^63\>GQE<L$JPFJ*3!2*)+&DAD(_YJ-:2M1"5A2VI5?UHQ99
M+_9YI;TH./R?+J2(8T\RHVOY@O.FP..?Q)FDGQD?F.,*+*KAB(F4EN/:K]Q-
MI\@YHF3EN;(1::4@THA,`&CS54B($F?`+DK@1G/`&N+1F"HV\0/IR4;:-"_6
M_GUH&"M]@O\``1R:5"I:5F<6#%M8/.MI/*U>R#;<C6^P5FLVV8KDBSH-_7I[
MCT,6[,"=,5<$;BHY\RAY'714]-2>4@?J5G>3F)IV^Y=F)*JP.4K*ZY&TB/Q;
M2JCD%!MQ,QG$XM@J:L[^9.XZS/N5L=873J%6C2'1;.%E5U"M56Y0I)-&4\FK
M!-;8H3ZGD>]R+&0%PY,3;]/BU1?['IF0-3)"-#/4QAY=YD4;%.L4&%;9SL%E
M!VJU22?,CD)X4"M>]/830/4-P5&SCS6(K;ZIL38\9-)"1S9;E8"\9?@+$SBS
M8S=X_>09[Y/-ZA:ULM.6J4Q=(:*QPLP>QP6&LQ#R4%0S5LLREFJGEU'<"PU5
M\K45CN:^L4C7:^1E54[/<:[)X.RG.O(MW3:I6+'3\:X.J3O*^"$SVP)EX_O^
M:,P2KUG*D;E:))N(QR=@\9(BD)J]T<$\JT%K+]5AH[R!/M'^<@JMWR*VEZ*P
MKI*99;#5L9I<J;LS>QDI&-6,-,4*?9\>B0(-8Z*7F$IR,>*.3/&TBR4;J3;/
MQ4:/%E.?)=4Y'V&,X@O*7><]UP\=$V5MGR'A7]4@EY59IA&UV"C.,C1M@@9B
M4":F,SQ<-&+@V<D,=!<[=0"E.=8FP*@Q/T93RUYJ$U6+]7/'^.)1/(#?--\N
M\UCBV0\$G6BXOMZL-D_(?%^HJ8PM[V:DTZG)-(^F<BD)I&RLUV9X^I.DT3HJ
MR46[(LG@&;<U7@31=Z\KGU&IN0Y/02EMY+1@,KCCB6Q%;X=WB>FM3,U\\?I^
MYTZEQ"L;<V%DJS7`\HK+%F6SUFDH1DU%Y'-ILKDJK\PZ:)2FBEUFHO)UCR#H
M,+1'>?IG%,=0*%'T%[C=7%"M'F,J-KI9FF3)/F`\N;)*=<4ESC]*!<-CPR2+
MA<YY,6`%E!;%+2""_%0,U=5Y[S#CZO</"T2<QU&9[G)*O_V:RV6Z?FK^PMM(
M7++HX^RU'9RJU!7K12MF/&LEHD*N^KJPG35^9,0(U4%J9T48#<:BUY5LZ76/
MK(1U&LDP_P`CVV2N#:@TC$,5`V9SCMO(V^XW7%]&I]HS>FT2I_Z0H;3%E\DI
MJX.Y8SUX=VZC_E80ZC-4IQ-<-3JH1!ZKH*<I]5BR7K%$/=&EMHN-K$C@["F;
MY6ON<:FL5`L53KN;F&3>1./)OT;QE9Z9DEZT@'3YJ9F4[-Z[B%FK8C?YB@79
MZB>4"FJ?J%<\V9?A1FJIR5BO3/G:XJ!I^$L#&AU6,K%$EK19)"GTB,QC%/'T
MC69DT94Z.-AF6+]VY4%[,J&.J5-=NBA?-MK\2>5_]U-Y:K/]4&T\;9ZCU;'\
MK4^6EEY`W[MR`C*T%GB:C85J5ALDE7'%;LLTWFF[B&R&-'9M8M@\BG$JA"6L
MI%U$G1#*HSS[6X_3Z>]7ROX+T^QQ<Y^_4N`LMEQ[:<865]#PBMQI-I;L47L-
M+O*]#RTS'QKB-E)5K)QL7*R*[!%V50!7%FML7M!,Y]1<BJPG"7,8HD.VV%10
MH`<";"'I@`-G!0W`HG1#\`?Q_P`/L]E]J*BG:BFFLW**A@*4B21#``NB"&Y4
MP'I^9[3`8?9UWZ;Z(J@4/&#DJA`6[3+&7'X2'_Y1)3?J5``+VAOU)V@/M#J\
M."J$]G1?./<FH8=D0$!\K7M'82G+_+4'\9?8)=@^_31!JO&SZKZZ"<_A%8[A
M5DNE`7SR&;>-4%5"NJ4<P=JZ@)=H`1(O=V@;M.)-S`8Z2GV[]G(R(SA$/YK7
MNI<K]_O^L?/_`%A_BV:4:7WA0RQ(^,&2*FQ(LY_2#RCSX4B1:@4TF\CVM@A7
MTRG:#J%CGLY9(:SJNT6<:H)XUPN=-`QF;907:_<_4<0.S7[LMHS!DP%UW82V
MD1Z8#B,90VF4OC%2-TAM'H<3;*_"#'9M+$:MJ0?8>&GN7!.;"\B^'/(V-8RE
MUA&KK,&&DK0TKD)%+52!AEKLJG8'=,?C((/'UF7<144*[1N[]#Z5-F11R<?#
MX?8_+VKOK?M5R[&U<NG!OF!F2)SETORQ=#$"+&8$C'=\3#5^7&E+^FWH$R>5
MV+Z,U7;W@.--%Z?8Y6R+1\=3]EX?0:=XS++9EBHX:A)155=Q<O55C*NW;')$
MRA:HAQ1*H]0\[X7B;4SE)\!4#J*%."A/E.='MF=WF&)ZRF<?LEO#D=\97`8S
MYV08RZTQ([1$EC%R&9C[WMXNV\0W.V/<R.J`Q$7,?]ZH:/%OM3%<O46TIA.(
MO&892UQ>8YOCS:5,B%+4JM7;U&608E@P*>1J;:WO%BLU$S'9I'0<,0^7+G<J
M@<RADS>]]%2G;]0RP.RQMS[/'N<.F3<G.V8!S2>T.=),0?.&&CKQ>ZPC.%F>
M5NCESM'?0#S`CA7V`ZD>-$RELL3VS7;AJ>R2MJ7GR8`Q2I/_`#NNQ!HR%,K2
M7;NPS=%6+*183UE59-D5'(NU$Y%*703,4CHQ42I>^Q\:WC=H[\<06HXO]1O"
M!A*1E(BXT8714QMN2!M&TP)<BK^#DW.IE8^XR.VS%]-M!5N)DS%S5Z<DS5Z?
MN5Y/*RLJHJTK#*_2:<.HP4*_D'61&D564Y&+AY8S,[BQT*OL1<';J22B:OA7
M2,1%JN<[13W_`&BV(6,*6.`<B>+$R?06'GMD0_ENRDPEL<4-2/,O6Y#B4R:1
MZAI_O<0.<0-';7FGEPP>+[.%/K!E'#@_U"61&JC<\>BFO)DIV.3D/()KIK*/
M6[=L*ANU#Q"F80.`FZG5]5WOJ&[WX0VM_IVKOIU+FC&E>;\O9[+MY:&/2GSO
MWB"^L?7Y0&B^G(U41HB-$1HB-$1HB-$1HB-$1HB-$6LFP:FAI<KY^6*9&C'X
M/)0YF)21K46JH.'YS2:#F-*5FENH(N$U$``OYA3$W`2*#'#RQ?3MI@#B?B%E
M/BS/W"P1K>>LS##MSPN\O.05*W'MF3NY6"#Q@I'H//3$<^13T;!M%L!=&*V0
M;(G*GHM2W&LG9/)R\DY^*P':EJTM4VTH\G\:PIGEWL%GJ]:8Q4_DZG0L^_?3
M%)M=*N"2S&"?N56R49($?.G1$T4D79E`:+E(ZIH.(40C7LE<@(E/%">*9!9M
MB:7ML;*Y3DLE6^5N2L'88:1D'DC(Y+OBU@IWRF#8E@K$K'UEW(-@48.(\JT4
M<2E3H%/7191HB-$1HB-$1HB-$3;WY_Z*7Q6E\^FH7YEDA-AZ6(C_`%K>Q[T>
M\//D,\KYDOEL*;T?K!<;'_K3-!/M_,[B]D[!C]?$[K+H6;W3[:9[KD]IL_J<
M:/5M!CON>;I[*>2Y.3^5CTKU=E_*]Q[!;^;RL7K][%O;9M[XY/Z'.GT+Y<=.
MSY.MU/-^;9M0;SN'(UUM=U7SE?4;^:(\L\X+'<(,X`W#FI@=UZF`:.22!,N5
MH#IG.Y_V\+-1L<H`=,Q&P'W*8>\P!K]%?MOTCZ5P8@;LC^MRHTB&^7G_`-EW
MKS]RZ!Z@#]SO[?B^4'_.%YMQ-95%G4(Z7=H(,WMM@<BWLR2C9&3@:%"Q8/Z)
M'C$O6#EN27MC=>5]&D1ZR<MG!VYW0(HKI&/]$OYHO7+\[,?S8V)V;7\L[TSM
MNR$@7VV_)N.T@C<(DD%NN6K?2`W$L:R:K1`?W/7Z%/\`15IE#5Q[F.,0CU;I
MF*<FW-TO8OYL%JBG$3R<S!XVJ4*Z?O5X.,@*\I"+.A4,HE+I@F&WITD0'KUW
M`MC*'9[YF.WX-N(M61$?F[X;9W[D@`)&=SJ"+5@7XDMYTK@%GK6X@7+U92<T
M(+B('!AM/CIP3H)XIS2S3G\^<?X"!O:C-12XNZ#)6-I2GV*;--N%I2>GJQ:7
M1&D7*4Z[(*N9#Y.61:OHN1,"Z`]B@$UZ;^L=DN"WZ;]3SN8L2=@NB)N]>$*0
MA<A4QN6VC'J;9"40QJO+M8U^[^MPQ$F'F+4,2=2"6<&M'<+KK(XYP\H9)G4K
M'QT9X[@H6EP,X,SDG(B,\S@)A",=>FOB=0*_L<O:ZR#LBBC5JS9>HDBMT4W+
MD>XP&\/#M^@O2.[.Q^Y2R\F=^0$+5DQ,HO\`X?4(B+<N!)DT7)$5Y&1#NG<3
M&W=M&,8Q!+F@8?$SU>K`!TU#@BU1D66(85NAE*$D&DM#6A*RK.6+G*LC>'K8
MDO=)7Y>=,6$Q/O6[08H!,`PY6S,Z`"LT2/KV\8_U&W/O-^9PLH2C.V8C=&Q&
MU$F%H/K&-3<_GW2!I(KU<YBW.-BT(SQ@X8OYS(U/OIM/X:<4QEC,W2EH"N5Z
M0-.1&"\C6:!BT7CGN>/,-WY.)3F(U>=<M[&ZFW^/'?S2-77C6J'S!J\;@T$S
MA<$0[#B"<K%S+S81MY'<<:W<.T4&59,A"0CY1$71LE$2/E(.X,'6;MRW</3<
M3$)F/NEP?PJ'%.2DG]..&=0'+Z'BE9-M))EQS;):+=M%D3-)^LR\5!R5<GF@
MF7/ZQJ\A99FL"A1**/J`25*FH`IAZ#]S,NWF>C)W8P,)_,VXR<-*%R,I"<32
MAW"0;BSAQ5>7Z?MQM]WB)$F8A*NKAJ'WZKZ#E!V>+IF$3-DG!@0.._Q+@<WY
M*@CON5#^((^TP"`]2AO^:(Z1YLOJ*PJ@<5MDP$R(=IWJ8=1.;H*?C#;J8"AN
MH7?XB[=-_;NC>*JN7`7!B%04`3`3O.IU$IVYAZH'$`Z@X,7;?\10`1#4%-4:
MBM5$')"MP$Z9]^X^W11J!.@B7W`<XB!2C[#%$1]FKH'10XS8PY32.673G$4T
M,/1J?B6KVI.(?.4#U^\W2-M^0'MGI*-=3J<C(661MU6BH>+`YIV""$%^D[0,
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MR2.)[;8JQ)WF*Q5`/(IHT?7'%E//,Q[87[=5&1G4@<1I%XU6-\N29*L'2]W<
M>9,$\G'&/ZGD7(=#7>T^-ID5F"N056RBHU1FK7)2UBD['!OHAM&1#]A'1\8L
MA+PI98&;Q)TZ%NZ!9(V:J42BO7GG-;Z#FNVV6"DJ18X_C=8F>)Z!7*BZ9I.\
MSN'MA=HS:#&WFDY=Q:(@&C2/9-S(*,5T"E=)>7U0EU&)]J$#[5>[RMRXJ\%#
ML*3B6RY%;&K,Y(3MKOE;NQ+%%7`UM,SBX9O$3+.A66?@@HPNY<3)0P'1>13:
M,(=PI.(*L:\QI51EL6><>8K2&5EIK`2S^7+&OR)T^MXZN#I,CXV,)"7I4PG:
MWES9C()V_*'IXR5B0C4%ZJT*<7SHFY7!V^7$*T]RX>#RS]0FOP5D45PRWR!/
M$D+B[C7DS%J56+2DJI$.)**:#%L+`JFYB[PT6)%PQVOD]2^1,X.?QKE[=,PT
MJRC0*=*QVWD)/4+$<C987)=.5FD<I.,J$P%3DU<D(S\:"S/"HDJUTB9:6K];
MM[9$SN6;J-C"S>&9H/%48\[@VAW,X=U6&@3!5*=^H;6[@ZL5Z9R=IAW_`,E9
MR%7AZ0SDZ9CQ!X\G&5LM%;K=<LB,UDDM59Q;5RQC&[ML9^LMLB<?,)3/.*G5
M&"?K$V4.7EQR>PK][Q1"8_QNVLJJDC9I"HV,LB%08PUO=L3-"KW$T*22N"\9
M$G*JD[E"5U6148N4W"Z8*%/<T90^"G,BFS.X,!W2I&P;KL@.U$.[8?S#J`"N
MQ2I&-W)E'V%-O[@VT\VX*55/"T4<@;U?]25-N3=LL'E=%#<JIB``[(J%+\(?
MQCE`=MA#>/-N#I55639J'!8KP1;I[)N#E;*#ZE/O'<I=Q*!DFQ]S&-_&ZE#W
MCIY]&"561RDT6`4D':P&2$QC+%;@`E4('P(D$5P^)0!$IA_B$'WCMH\QP2JS
M$",,@0"@[.D8G:*8`@D!2B&PI[_F]HEZ@/3VAH\@:I5"#EJ4@IG:G561$4S*
M+.3?&'XDE!*DFGU.F(;]?;OH07<%D8JY%<Q5CI-V#<`5W72[6YW`D-N`+%**
MQE0`.X0/[/XPZC'4FB>];$1F#E$#',V)]@J(LP]P>P!1^W[-9\HKJH\?:L!&
MJ)UB`\DD""<Y2G.457`E((AW'.H!`3`I"B(B(FVV#5<_A%$!Y!>>O&:U5J/P
M\^Y*7-%^NEE.Y98Y>V$Z3!O(/UHJU6%3'V`X.,0:S2<Z:2:82@H>+CV8L7#-
M^<3)E616*4#P&1'M6B[L-%RF-,G57#&%,L\IY>Z2=AP=@O&N5[>C&/L6WS'M
MLM<N617R%8)Z\+WF6DX&\Y<8O6:M83G:XW39N7L@]3\Y@,FV;@&&XU"$/3BN
MPXH<9G<=Q[G)+D.V&=Y"\L'[7.?*B?1=.&TC_:%:(]HYK^.(>03."[2DX$J`
M,:E!1X]S,C..5,HDIZQT"J(`'BJ2'IH%-N`@86JPL=6ZW%,(*!B$`;1L1%MD
MF;%HG[3BF@B4A!7<*;G65$!465,8YS&.81'0IHHMMHY1:^6C&4Y%24+)I&7C
MI9B\CGR*:[AJJ9J^:K,G'IW;15!XR<^G<'!-=%1-9$P]R9RF`!`[HH4\F.);
M.R\;XFK\>6,=0LW<<7[?,W$FT,T$6SBLYKH\>X6C8R1<-$FYG=8R_%>JJUH:
M[%0?P\NL4Q`\:/CP8@CQ5!JYT*:W(&2[7R+P/QJYA\<JH!KKE:J4YTE8)&ET
M:^6'!-<GV:LO>I)K(9DO]7QAC5S1'C65A)%^9DX?R<KZ)LLJDU24,06(!&J;
M0"R=CER[4:86ELLL8PS*RX:)C3F!6V3.=+/)QS_#$XQ>95B(]Y$P)*VY9VK$
M4Q*Q;EXG)*&EOF2QDFY6Z?>-._52(*G9VQKGM782)5&JY"KM%E4C@19LL4%6
MZJ:J/E*8BJ)BF`=@`0'6ANXJ5XBJ6I$DBE#TSP%"!L($1>$,'3H'Y)U"B/L_
MDZCQ>H4)#U25VJ_$Q$';0BGE^-0ZK(H&%!,0$P>5--,VRIA`HCO[!'5`#/$D
M)KH5C6>-RD$?0)`H.Q$P3563W5.(%(`%,94NP&-[-O8&@B3J4KS7(7Z*4EZ!
M;XJ"D[5`6!Q69D8:7K$FT83[><19+NXU2->N62R*#EU)))D-Y"F3,FH8IOA$
M1!Y]`K4'@O-]LPYO8_GX6V,U\C9%JD/#T%%>J3EBAI6PS]D?<>7TE,Q4Q"J-
M(ROC2W&?7R3*4FTG:<I!"D3TS=6/!0Z6?S%721D'U$*^I&MI'YI:1I2%(Q];
M5F+JC/6N0`G\VH2LMG>F6!:$JJ2DY2<6N$(JPQ:S!BV<L/F*K5$7C=L*[\Q6
MBV6-*_S)LUYHT18;/E2&HD599J<R+:;TN6GN+.V3BZ9Z:%:0$`A-RD6NE(DD
M3)(,Y23J4@H=0S!9)L0B):.KQ1Q[UPB49STG,;UPE?F\JM\E!"Y#E[X6V/):
MF-W4PSHB7Z/BZY(OF+Z'D9(]M47]"U9@C77BY4DGBR+<2J%GYG$:(X]RD=F2
M;Y>DMM<E<%U]W)5"+Q&G6I5O935>O/;7E3(U3L7RV\KU)=E)$1;X7M437COT
M2RK)H@A*2Z(HOBH("G?S":T4'CJF>2DN4`7*H(L(CE#'X>3M4F$C)VUZK,7Z
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MDX\KMRU;]SU!N8V`9$^]:<<%L\XL>;;2\9HG<;2%X7HCV8O$3C..K;UA)2K:
M/1Q'CQ>JJIU)VU20C8)S>1L*B,VQ<KS82S9)DHV!J]!=O7F@8ZZK8/)GE<Q>
MU,T)&YUF4"J4%&MMV[@:S$+@MD"W)9C=Y@<7.O3UC4<LJBK$'A4)CTD>XBR+
M@P<I2?:.H7=&#KC8EAS6F(N_1D]*YY9V)SQ\>2D++,EZI4FL!F*(QUC]>M0\
M`=)O8:Q;'%FOB<P"ZC16+>(F4=-Y=HJB#!P4\_L5HZW%LC^;E*N=[?5%Y>+O
M2%I"ZTG&S6;L\7+O5%Y7#V/XC']FN[1_%-H^&I<3DV3G)=W8V8/);U<6#)=B
MHT>`=+0W[F"49:.J%YS1]PJ4W>QMA*7C.0Q75L@I0<G$S[C(#.N/<IL;UD:M
MU5G#PL5=F&0XAA5UIEP)(V3ACO7#B,8F,U%L?3SW!U*<%Z=-7@+M8R01(N4T
MPU;.BH.T56RZ";UNFY:@\:*@"S0[0J@)J)'`%"J")1#NWUK51*BB+97P)#W'
M==RY._;HN7;U"RH@/X#EV,`=-Q`0#1W%452#Z,?`414,N8ZS<!V[U5=P,X`?
M8!"%,;NWZ`4H[![`#36JB$MF@G*H?<%=U"G*!NIM^K9,H;CVD$VZ90]PC[P'
M4U50D4Z:P&5'M!;N%`GN;".YUDM^A>]4"]V_V@(!T#J-11%;L(J@<1_J:IP'
MM'_C'.X`14>X.C<X^P/XRFP^P>M'VI17+J&*KND/:`]H/%`_XE,0V(N'385@
MWV^XG4?PANX>*+QK^JS%2<S>>/5=@!*I.3$1=(V`C_(W*#B2<R=&:-%C)K+M
M]BD=.$BF<F."+;O`ZAR`.X?;OV?O6L?%[EDY%+$#:,S7X0+A(&M3RU.@70/5
MHE+(L`.WFTU-11>;\?,*51]8)^%LC-A&2="JN%,?VAF#F305@[&[@G^1,F-"
MLFU:L;9M%-S2AFY#+.^Y]*MU2E!DL1<WTR_9CW"W;L7;1E<%^>7>@6'F@)"Q
M8+[HESL<T\L"/B!"Z["4+1DYVP;8"/PN:D>ZOO4C@2CX.2;8::55O"XO6B96
MMM(!M/N929LT=:B-)U"UR5B6549.KDKV1\HRE$P`R(MFJ!`%!L@F'5IG*O6?
MZ[<NFYWH7(W#+8(V[9MO$VA'46P-T)QXO(GS2)7D=:,;WRVP0QA$C:]2#^+W
MZT\&H$Y5/@>8/&2>I<SCW%:7(>K75^H*]]I5N:4>X9-9,220Q+E2@O%Z^\0M
MK&')N^,)9**?KMR/`$@J=Q_69U_T;ZMQ[MKN67+MF=8B`+-RW*Y;LFFYKH$G
MMD_`/+*(.TNR]ECV.XX%V-['B+N/,T(IN%>%"^IT*Y=[B_D5FZ+=9?Y!TZ+Q
M%65'SF&E"L[DC>[GDF'1.H5ABE@\;'FUZ4SDGJ2[>7?/Y!-RLQ2(S023`VX^
M5:[MZ;[!/^C>F+\LW-($HF5LVK5F?'(-(]0Q#&W$182\TBN*_AYN5(YN4PMT
M:I)DWX16GB2U.";VQR3C),+=7%B08L4J<:>OU(R'&OI!A(8VM1/2QE<91[)H
MY12E*F]GDH>//$->TSE8J;A,WG2((^SQ\7^F9./\H9&5\0LWK$XB0OVRYN$E
MJ7!$SGO.@IH2O7F\+\I1NA]FZ49`L82_#3C$Z-SKJ$QTRE)Y$L-PFX]>/;&S
M(2J72!0%=!@FVRPV0%O,TEFR(V<K">48J32T>J_EBH>C.R;[%=K%1-V#'G:[
M39L6+HE*6'*[:DP=\<EXW"2S")Z8EM@^[<?A!(X;@&1<D=!)I@:-+B#[6+>`
MK5/YQ[))K1_#MQ$%2<LQY_LQEE%$8HYXU@G5<6G71(E))C*1[HSL4P%%J<KI
M(HF[P\13;>D]1RM"]WOKC;,^G?*VZIZEYB6H0W$N#[5YO:X2-O&E,U.::<-(
MM]*^U?6-K\HC1?3T:J(T1&B(T1&B(T1&B(T1&B(T1&B+E;TDW7I%R0=PI;(U
M6JMA2<UT\@WB23[=2(>$6A32KQ9LTC"RJ8B@+A51--$%.\QBE`1`@U7A!](F
MEV3(]M?W7*A[*X;<2JVRQ;QL@RY!QE;*90J;DB`;,I:L*O*;BK'=YO=OJ%0I
M43&FL4^]F6;M%VJDU-ZU!^?47),MIQ7KCS"%`>.>1T091$C//6T#&T%K,3-L
MKQ1RG)VB$88K7B9NAU^T7.-M#/(;F-6B58QDH["330[3HANNG5B.JBW]-YK'
MP+?,%(?M,2!D"DR<%`6Z6H4OEN2MTHXBYR_P,Z:]IY1Q]1XP5$LJP5I,5_6#
M+P<O+*2;L4D'9W!W!:GSX+T\T6$:(O/ODSFSD%2LKJ5#`3S%,@XC<.N<B7F#
MSC.UVF5FOUIE+3K4;M0Y=&P1=LM5I:F8G3?QDBDRJ::)&IG<_"*+;NBT`#JN
MIREF_)U;Q?QUG<0%B,E9)RDK6$86F7!.N5.+RND]I2EDFPDKU&69:O8K70C6
MZDD5]&HVLO<D+=I&R(*$.0C!SR3P<<K[?LB8_=3&4F$#!9"C[;8Z];*C6B(K
MQ%)E8=TF@I4F\\WLEE1N`Q21B=TP!H\7YC]YHZ./W,T2A`!IHG[T41HB;>_2
M`,9?%B0V"8@_F>2$X\&L5'^N;V41H]X>_I^<5\J?RR'-Z+U@N-C_`-99HI]O
MYFX=D[!C]?$[K/Y>S?Z7;3/=.>TV?U.-'JV@QWW/-T]E/)<G)_*QZ5ZNS/E.
MX]@M_.9.+U^]"WMM6^I')_0YT_E[Y<=*R=G6ZE?S;-J#>=PY&NMKNJ^<#ZB[
M*'<\Q<XBL,BN_P#^Q16C.V";1DC'+1J>7*]VJJR:CPS]<ZBIQ14:D:*MUD3"
M14#%,8NOT5^W1OCTA@L`+1[Y+S.7!^7GPTIJ"[OHN@=_W#N=^0!88@JW^_&B
M@K698\'%6^QS,"E=L<7>QHLY6D/F[0\K!RZ<K"66#*I)R*$U*(M)I@25BT';
M0H$!5V0O:FHU03UW?.QA?OV,3'N?+=WQ[9V70[7(RC*,BT6#QELD8RX`G21*
M]#:N"U;E*X'QYEB*/J#5]'T!6$K:2QM,HMJ,V#)6*\@_*[%$5J7K:[8L\@E7
MEGD:S?M(WY,:IW.)A9MF!9*)[VP`H9,Z"[4O:7<;UGN]GJ=QD,7O.(]N<XW!
MY7D`X),M]N4HR)C.HX$2+K5R4[$1L'4M2J'!K'F>1#LXI[EVK^ZP$G$$J]ER
M97,:U0SUV_FL156V2UEM%OE@9P[E*R93LS:JN:FUDH1@[EV*,6Q;R*48FQ7(
M<OD(HZUZN&!EV[\LO"Q+V9FD-'(O6XV[5L/(;;$#/>TB(2WDQWF0(H1%<^ZS
M*UTA(1LD>:$3)R?YI$!BP-.6C+.@XH5)G8J4J')66I-L*V@5VEX7.H*$;%6`
M"Q)&,@QKD0\7-7)(9!5RBS,X]9'(MU6ZT811J*9!'<^XV96,OM-N[A;I`VX@
M;B8AWB9R'G%`9"+3)!%PB3I"-NS./2R)1O&.M6]A:K>#N.(7.SF0K,(LG%$I
ME0@9&>D&31K?L=3$E?*Z@ZLR,RC^G\=+RB4*ZQPFJ9^=RJB_9OIF+\J+5J)2
MD\VO+PNW8IC(=SOWIV+43(V;\1:FT-IW7@'ZI#,#`B$ZF6K+AD)0N?IX!Y?"
M028C@0'H')9CY@:!EEK</%4,S&ATJ):3&8;36$R/;HXB85K"4U*V1U>D8R,C
MG5AAT%3M:S6Y8R[V16<B8CY\NLB;Q-$C*<>5>N]WC_5LZ>ST[9NG9:!D97>F
M9!R($@&<X@1B(_#$`_%1`0M2%N`?(G&I;RQXAGT;B3Q]RD/].%LP+RGJD8JH
M_?NZY1,E-3602OVC.69G?-%&)BLUUQ6;Q[;YB7P(G$024<*"1NAW")?3?N8;
MA]+7LAH0%V_8.P,3`[2_F`8DM4C4`.2O8>G6EW8`Z;2Q'&A^QU]`BITTRN$C
MI%*9,PE%N)MP4[E!(04S#U.550P?%[0$>O77YM`H/8OJ`JL!!]"39=03I@(J
M&<CU$##N8X+=.OQ="F]@AL`[#U&MN--454TSH@98I=_*85G"(#ML)O>EOT*<
MA-@$OL.(;^WVC6B*B(`N7U21@!14?@,.^PHE'9)!4H["'3J(?B*8V_[1U8Z(
MA$2.1,<P&37[MR;#^8DF01(0R1MME$E!$3#[2F`VPA[M""--$96H"5?O!Q\!
MU5#"D<@B4IB(#V)G0,(]Q%`V$PEZB'=[RZII4(K"J;MS>H^$YQ5717+L7N,`
M#X1*.PE37!,@?"/0P>S<!$`A!>B($#`+(@]A726Q2![$G296ZHF+[1Z#MOL.
MXIFZ]0]M`UY(DK10&[H$P+VMG)UD`,8`*=-R@<3HH+=>AO3J=I?;N4"_8.D@
MX\46[UQL41HQ1&C%$AD'/I6QS%'\Y3=%`H;;BLH`@40$>@`0NYA'W`&^M1B7
M1(D`]*@N5$QMTD`2;!N8@;$;$\S]0I-A(53OV`/;V[`&PB.VR'UT1EM%7CE0
M$D_.*B:;@3.EU0(H94ZY#)+%`ZA3#W#W!WCN`$``*'4/AP(@>U1E>JZ35,W5
M.U9`T()DC?E^'SIG*)B]_B.F4&Q%$R[=/C_R>@PQ/.J,KEG#98Z*ZC%(C9(^
MQB^9=(5DU=@!1;O4-V($4*40+TWVW'IL&FV6@-5&\51RJU<E(J#11)N@<JO:
M#D>YR0!V5[NY(1(W\1A$`$/C';?8`ZT1(U+JL>:JL+9XF<B2"Y$1`=E/4@(K
MG+U3!,0;E$J(*`&YOX_L#IN(T`Q2JRE<LUTRD09G*D)2E44]1^$NVQT$0!'M
M$^VY1-["?M#;4,9`NZ55S1=HF@5((]+9$3(_$LN._C,)0,/:8FYCEV$1]XCJ
M&,N:,>:$W12*+$(S:%V."Q>XAU0V6#X@V44$-@53,/\`PM-I1N:N]>X37*)!
M11\J1B;)MVY-S)&[RCT3[A$"J&#?[--H-3JC!6N7SM0$C*.%C`14@#^88"@5
M7\DWP]P%`/C`1Z>[38.&J``+$.XCN/M]_P!O[]]&)57&9(?.8O&V2)1D)@>Q
MF.[U(LA)T.#QA5)=VU$@[AL<%T2[??J$%D43L0Q#X_$7'];IM#HF5IAOQ$XO
MQ$7C:^SM:C*I9F+S'[959C9%CUB6E8^,<I^=PBG)>=B_<MP(W%B(NG(P`LKQ
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M6E[&Q%<B)*O02$%%NY@S1DW;Q#XD:Q233(+4#J*K4Q8>"B=O`;]W+8$P/*OS
M&,^E,(8@D7QCCN<SQ]CJM.G1CB/43F75,(_?J@%E#JG8T8HJH+K$664354()
M`31`2*&+[`\I_P`)@Z]RH?P:TSABH0LYI%V=9(IEO)XRG5[52)J_$(`D01!4
MAQ'8#FU-D63:%:Y>"J4J9V[0PK*D(8P-B$-V!N=4.Y+L$`,D00_?H(D>Q`/:
MLBSQN5)0QHYL;8IN@&<``B(;%+V^82["80#;3;+FHQYI.BLU9ID349@=N0I0
M*KZE0ID!``[O((@83)";<0,/4N^P].NFV1.M56/-6(*M4"&6!B<R*YS+G2*X
M,)D`.(B0R6R6YDP1[0,0`W`0W#VB&FV1HZC'FJ)KM@57=H,O(BH8">'U1S;D
M3#8RS<2IEW,=43"8O0#AU#XO:,3Q-48\T$<-O4*.V[!%1+L!,R(K.#`8Y^U1
M5=(`4)LN!0*4Q1_%ML.Q@WTVRT)58\U;ZHOJ3.6S5KX2I=IT@2,KVG5.)E5D
M2K'/^;VIE`Y!#<?:``;VT`@5-4;Q5"OEB'7[5"@R4*D0OA(DF5#N$RXB4R12
MB5$3J!L(#\!@#V![&T'VHP2!91=4A?.9590'!Q/W'$3/6XNC%/[1$H+)=W<`
M?;U#8##M1&(+A-$1:H"@9J)NX[(WB`P@!?(@(F%NJ!0]A3$#;;W"7;W:3!)=
M5;36&*(T8HC1BBTTDL)U`:EV`B*1G+A40W!$YORF@%VWW6$YQ,4-A'NV^P=<
MD`6?BB5)B";G?M_-!!$K5KOMX$RG7+Y%#;?"8VWQ&Z[!\(;CON:B*PH&!L9$
MH^9V)3`8X_"!3(*&\1C[;^-(HIAV%#XA_>(ZC5<Z(KU3=J`&2#S.C%3=AO[1
M$H`;\P>OB2$@B4`#W#L`".KQKHBO5[4T_/N*K@>TZ1BA\:HE#N\*10W[$C)F
M$/L#?<1]^H');@BJ<HG3]0<Q0.0H+(!W;I(=-P^+IW&5+\)C#[0'8.GMC$4&
MB*T0]>D40[DT#@0Z93;@=0X?$0RI=NXJ9#[?![3>_8.@UF/BBN\GJB&2)L7N
M`2+GVW*@8/A.4@>PZY#>SW`.PC]@F8N4*JD<J:8)F#O4*<R1B!\1UU``!,H(
MCT$%2&`QC#T`!_=J$'W(%XY?533;M[%A0RK=^NY>4S*<0V7;.7`IL';Q.EM/
M7)-T'#0^[9K($1.<%6RRJ"RI`5$IC$U]L_:"!G:S@X`C=L2((#2$=Y,2[\GX
MU`70/5QV7+1/\DQ]9"@62,B)QM3\19#0:*SSJ+;L<9Y895^'=-4"V9W!JT[Y
MBS:0;R8=PR;N25B9-,QTW[-%ZJF0H+,$R'[_`-3*QKN1W_M):P)/D8TC(5CN
MZFV1E&((`$X4:1#NTZ==L=.Y;CCWR=VD)!F#L0_$\CQ'N6DJMEML>F%1M-,8
M7!A6V<-!Q\Y-S9J&%-A749(R,2P?Y*4!\!Z0_CWA6P%<QRLC'E%+T*IB`"9?
M+S,?!O1^=P+\[,[TI2E",>J;DQ("4A9'_B@U<3$95W@&JP2)$6L@`[!\1>-!
MPW?R^!JVB[@\[2LD6&+/;^0#*8E=HUA6XV@N9&#J..(I:,1F4\>X_&\1$<2(
M9,6DLNS2>O'L.1%%B<YE7'I_('J^AW#M.-(X7;"+)W2N3O@2NWCNV]6Z+9)+
MD"6P1FYD`T79>3.,;\HF]>+-Y=C[8AAY8[@-K`-J*O4ZI+#VRGUQD_@JIFBH
M3U:FB%&7Q5D.<L=-K%QE22[!JA=*]8(NH$94.UU\7$P[9J/&8M6QFRR*SARF
M11,MO8F?DD7LW`NV<J!\E_'C"Y.W#:3T[D3-[D)`0C(`N000`[J6^G;A*V+H
ME9XPF3$$C0Q+`1E5P_VZ+E'(7'*$VUQXC`DQA5G3F)FIF/>QCM^HX.V>/H]G
M;+1/,3OW=PD%Y&72*R;M&[:)9BJ)T4UE2BMKV._MW:L<]VN7/F\_S0M^8"LH
M@[+<"PMQ8'<9$R+5(C1>-&W<RB+(VPA$AR'+MQD1J?91R%BG7419Z)(Q.*HY
M6CXWJ4LA*O95_%PC*S79Z\:5N%K)2_)FD%)-YN6C&,G+*HM5$VC+YJ404(1D
MV,9B6LG%[G&]WN0R.[WK1B(@SVVHO*5PO(RB8Q.R`XR,"*[I+4YVC;E#'#8\
M9.9%G)-!P=]9-H.*>?$?R%\\X?S`MIB(+)?4;-*,8XK1&0(>3=UR@'].Y<.G
M[-1@U[%CKK':MSB=<W>H!Q4.H/JN\0R+1[U:B8S,?38$B[4$[C%F+FC5.GL`
M7L<&L,8'7YP?4T5]8.ORF"Z^F(U41HB-$1HB:'.5#N.2,>/ZM1KPZH,ZO)P,
MA\U;+S[$DI'1,NTD92K/I:H3M8N4'&V=DW.S7>Q$BRD&Z:HF34$.Y,Y44*:;
M"''O)V*\=7JD3G(*XVY_:*ZE'5FQR;BS6:4Q[/KQ$NWD;)"RN2[C?[#)F3DI
M1OZ1H[>G;)H13<ZA5'3A\X7*D@G1:W"F`,VT:]M+WD+D%-VQN2'6K+[',>ZO
M+^@NHB-J]/KU9F4DL@W>YS#6Y#(UY]*R;\%A4?.)8Z:@J&3,X7(2&8*C/C_R
M$9\A;%F)'E2Y0HT]:(-PIALF-W;ZO#08>(0CC4[U,WDF5B8B9<NB'=FGHB*C
M7ZC@WYX+H?U<".&9JK9Y8PWR$M=ZLTUC;/T;1JE;:A%UM[`SU5N-A<UTT:VL
M;5X--/5\GX^:P+JR*V%)XO,)%)/-7,6W32=&;""*)0$<0MYD'"F4[.YP[)5/
MD';Z;-XHK<^U?O@CTI"(RA;9!C46$;,Y/I[5]$0%G@`1AI+U<<4K58BDJ*T>
M[CW*"2P$!'$+H*+CG+%;Q&YJ$ME_UF1GDU/S*%\"`>6!A7&\Y:G4^WK41%72
MPS\U+0E?BG0QC123DW3H$"E-WE`B:1"$ATGK-(R?0JUEV0N^7)G-;JP-'4W7
M(:0@:1CUG53,:K\N<UVOR+9NJR:Q<Z[8INC*RQW2;-VLLIW`@;Q$)0KRU^C)
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M5&O1R6/'.1JOD!XS77F$V,DT:U-W!.2.W`$,[CC&<'+;'AR6OYUT]7(>7("(
M'CM)\PD*ECMI:FN-4[58L?QF!9Y6:LB,3G!"=340@+-:ILK!9HP81OJ+HS"(
M45BD3%76W)'VLNOY:MSV[CMQ[KDU$6OD%%VV0I`VC$=)+.53(N?4&M3+)BI7
M+%)PA96@.HF233FG3B6E:<D1-$4'TY'=YBK$&IX)^>#\9\CP)$P"5.EL:1T'
M8K''0^+;$H]=V?&,05X5RRI%FF']2J+BPS465R)U9`/FZ+LJQ3HS$PB))%R4
MEJI>:+*-$3;WZ0]#+XL2_4$O!_,\D)Q_I8N.]>A9MZ/>'OZ?FUO*E\KB#>B]
M:+G8^SEDBGV_F;AV3L&/U\3NL_E[-_I=M,]TY[#9_4XT>K;#'?<\W3V4\ER<
MG\K'I7J[,^5[CV"W\YDXO7[V+>RU;ZD<G]#G3^7OEQTK)V=;J5_,LVX-YW#D
M:ZVNZKYTOJ0H2*7+W)3E"'`(ASPY@"2=A-$@L=NY)ER-[6R,V"R`M"H-4P<`
MS$Y`763(8/8(Z_0W[=&W+T?C`S/6'>Y;8;@'_3R+[>+Z/P!70O448_/W7)KC
M#C_OBH"@C0W4E'3:\+4O73*$RNV8GK2U+1EX^TL2NV;I@65JKR9E&$C\P6;(
MN#M%!<@FJ`+E.4Q.G?>Y1LW<;YG.:S*`!W"YM-LZ$1F(Q/$Q<$.*,Q75[5R0
MN'I>8RH(D!C[1_!5L$\E6B6JD0&1K;'4X+%77`TOO>P]0CWD>X<QS)LTMDU_
M:$E'-FA5'+!/T((IO6C-%T+I,RI!/Q8N';RHV,_(Q;1RA:FUYQ*Z00"9&V.G
MN)I+S;MI)&TU;R-\Q;E:$I&&X./PCV%RS5\"M6\2F*01\V95AABXR:SINS9U
MF%)%M@=)N)4ZE<9V<$9"3F(QM)R;AH#<7;Y)%)=1($1)N0_/8-CN!%RY=N95
M(N;DGHP:1@#$"3`%]L7(!=ZCCD9"X1&,0QK0C_XGK]/8M<R`(?U$)`JBG%3*
M:R[R#%PO-Q\[,JI.V,RP>Q$D_L#=\K%,W785N<ISI^J4**)5%E5#>7=A"Y'K
MWJ7H``3^$QCJ""!$C<14^`J6`7&)SCY8`L_TYK;L7LYCV41GX<SG#LZ_C[](
MGEJ3$I)3<Z^3C'$9(/G6.%XM\8B]<;F*S;`W<P0,"G!L0J@B`%\*[:Q^Y6Y6
M+X&=BPG:`C>FT(!W`C>W`G?\4@1<W:N%Y`NW,<]6WNC<)HU3MJY;0'F:+J3.
M#05&:RM8?R[AI9E9R/MM^4KLB\L[Y<LVHU&I2L_,V1[8`CV\+'M%2,#JM4)$
MH^<Q%>T#%\2W;MY/<96<L1%RT8FW9$P+<1M!WB`B(N9$@R8F.CAU93E"SO@3
M*$W>9'V/R#"E'4B_IRH-4N5E;%KNY6=T&]*/VID08E2*!8X&;M!49-^$RO*!
MWK+#XFX)]@%^(4]]>@_<HWCZ6N&Z!$?,6F+N3\3N&&UM`*_:O-]-C_U:`!?\
MHTT;7Z_X+WN>I@LY$@]/$HJN!R]#IG[C)I&(;8=A$1$?L'MZZ_.42T0?!?51
M5)E5!_+;K]NRR@;J;`"2A$]CF*H&PE3,<P%*(#T'?H/NUH<PKX*BQ3I)BFF`
MF34$J0I=/(F50=CBB8=MRE)W#V"/3;H/NT%375#1"X`*2BS8P$4[13#H(`)Q
MV3*FJ3H('*(AL/0Q?V=-!0L=$UT0H)`2$ABBDLBD84@W^,.PFP'04V`JA1';
M</X0TX^":H4$$6QDG``)"(B4JH`/8(D3'L,<-Q%!7<-P'?;?V"'LTU+A!HJN
M6ZJ,>/F2549G0,F184S["!"!N41(4`4`@?QB#W%]X>_5UEXIH**QP&Q$1,)E
MVX+IF*L01,LB!@,F!A$H"*FPJ;`8/B#W@/4=!]JB1.4`4\I#F(/G(DLBY`>U
M-4[<0(`+F)T15`!+VJ!T`1'V?AU1]`BPDL<2W>Q4+*2L<PG)@SI&%CI!ZR8R
M5A5CVQWD@2(8JK$6E'<<T2,JZ3;%4%%,!4,`)B!M9D&]BL2N@UE:1T`!$1``
M#J(CT``#J(B/N``T1:$%1DG28@F4[<HG,U(8!`5TDC%*9P<1_FVZSDH=?:8B
M>P;[CORMM'BL\4H`>YFY6$_:FOYC.'(_"*H'$4DDD`Z@0G9L&X?L#<1WU/Q-
MQ"E."6+HG],551$Z3(BK<A">(=E1!PD!`.!0VV$1W!/J(CU-]@0>&JI6-R(^
M,JJWPD*LW\2'XQ$_G3`HJ`7?R*#[B!N!?;U'4'(<D*N=AW(**.!!-,@`<J1N
MH=Q3%,11;;<3G`P!VD#<`$/>/L#5@BRJ@*R:HK@"2'8INF?8!,&P[G<#["D#
M??MZ??\`9H*::H/%42$[A-/H9-$2$W$?A56#L+^$.@II&^W\0_<'46A\45S8
M`*B0A0`I2&5(4I0```I%E"E``#IL`!J'5:&BJ3^<<?\`KPZ?8/@1W_;O[="I
M'15Z><>O7P$#;[@5/L(?W=."<4'_`)QOL.WYAQ'K[2@BIO\`W=M!HA5%OYHW
M3?XT0_?YT]OWAH%3]JS#[1_;J(-$G=1S68:.X=_MZ"7:.HE]OU`64FW48NP$
M!Z;"W7-HBA[PCF)!?C[@R$EE'/S6I8F##EB9'<S"Y(Z[\:[;*87MZ*C$L6:!
MB5UGT.4QUE'I'KXH)E(@9)N90N8NWN5.JWG.7#MESUQ%SUC&BE*;(\C2@M6*
MP.(%`V6<8S<1E#%Z/>.WC]9>Z:P0$W\4JHCJR#AAJ@+)T<!YLJ_)+"6*\^4T
MYOT]EJDPES;M%0['D))2+<"62K2B`[*,YNH69!Y%/T#@"C=XS53,`&*(:`N'
M1,W;.<N`Z1=[3CZR/K8QL5-LJE8L`!615CV3DBD(`2OK2OP*:O"VF3.#/!*!
M$F[%V=0""B`'FX!&*UT;SOPI(PA[">+R1'QJ)GK9TF[JS%:>:R3&-F)A:.-3
MHV>?W-R4L7"*JF>H1ZL8@(E(NY2.!RD;@C)WT>0N/U<NL<)J)65C<Y)N^<LE
MI&'29UYTBSJ\#;DS-9E20$CDTE&3Y"-2)IF457;KE$I2%(HI7#LBZK,67J=Q
M_P`39)SED%X5C2L1TJP9`L:P_$JNQK<>J_3BV20;G<RLX]328LD"@)W#QRDD
M0!,<`$2`'*B8;@+BRWX@XAX9K.1V@Q^4[)&6/,&6V!QW4CLJYXN=BS/?H=8?
MXRU?L-Z6CC#_`/NFD0PKJJ=57FA9U8/`^=SQ9TUIY+`]QIU?8I.(Q1XO>L]N
MV>(,;LPCUHE::25E;+)>)LNU?((J&!5-9%8WA.C):(%*FO5YK4:]7:BQ$IF-
M2K\'561B]"F9UN*:0K4Q=NG:*#$HAK6E%%M]$6)/\2__`*\=_P#WTEL(Z'^"
M@T50W]0??80].EL'O#\Q8##[?O+J\%*N@VWE;[_RU-NOO\1O:'V;;Z#14NJ+
M?@#[U4`V]NX"NGTT&JIT5RPB"2XAU'Q+#]N_Y9A_?H-4X+&0AD"D\1>]$"DW
M1#\20``;^'[2?XG^;]FJ:ZZK(^Q8FP!X"+-^TX'[SG2]A5#F.<3F)OMXEM_:
M`CL(^W8>NAU8I77@A``,*ZJ`AWF<*^9(VY`.<NQ`!0!ZHKE*4`[MNH!UW#J`
M\CHBM1W.JY51^!0JX%51.'8!P!!#M[OQ>-3V]IPW`WOW#J%/!^2!51_&Y,B`
MCNL'G;'`"B)C(([F`!W`%#![_P`!_M]^H>#HD_84S18A`,9%-5<Q-@$%FBY%
M3+$$I=N[L`1#H.XE#W"4=:X^*B2K*J-EP>I)$.*R(KJ)I%_YRD`$,Y40$N^Y
MA0*4_C]QDQ$-P$1$`&VG1.+K>)J$53(JD<%$U"@<AR_A,40W`0UQD,6*V*J_
M1$D=O"-"E`?B66[@13[1-^$!,94Y2_$"*0!N(^\=@#J(:U$$^Q0E:QL@<.P!
M^-PLOZMP=4`[4?$4!*=P)3=AG0&$OP%'M3W$`$/;K9/U+/WK8(`8RKD43#VB
M")%'B@%W4$I#',*0;`40`%`V'\!0]@#K)17->I5"M^A!<.!,N;<W<(K'`3$[
MMQ6./O,/P_M]FH=:\E>"JV$I4BI-B@<Q3*$.<^_C`2J'('D.&XJ'`H="A_Y(
M:'5RG!4;]J)"@(F6<`!T_8'E.5)0Q`V#\*20;!U'8/M$1T-3X)HA`@@41<&+
M^0JH4I=_RDB@?O3'<=O(H!#``&$`V]P!H>03@ZJD)U!53`!22*H)B].U91-;
M\P-@]J).\3!O^,=O=H:)JJD.":JC=`A1'M*J`>Q%(P_`IY#!U[OA*/:'Q#OU
MV]NFH<IQ97$)XE^\1$YUTQ*=4VW<8Z0B8A0[>A2=AQV`/Y.FH5T*\@_JEM6K
MBWX/(^0V2-4LA':=C,)`\G()+U$J,>Y;FEXP$F8I]RGF#R^(Y`-XS[``?9OV
MD-P6<_I@$[[+O+:P\Y)'E+GPH_,+Y[ZO(Z]G<=L1&9T?B%`6MJNIZGSD=-+O
MY"I5B%E9)K8%JLH^>T"7,W0=L)*M2K:?CY6+?24\S02%NT72"7$-SMU#%#M^
MC9\;6/EPO6"(YMZ<8F`N$1NQJ")QVF)`!-3$[-`0NN69R-O:`^/$$NVCZ$'4
M$E@W%<P_E9"\C'0\G-2V7B0]0F4(Z'O[ES#?*H2N6247:3<1&J-QG[&[JBYR
M>C?N)M95$B@*&9CY1.'DQQK7;HSO6+<<&=R_'>;)$MQG`/$R?;;$ZF41;&C;
M@I.Y=O$&1,QM8;N`8O7\3</N2&454<`-;GTTH:&5.JI-U1-A^AXJ-*162>DE
M%(&*&N-(QPC*O3)`=4&X`5TH03*D6.4WE8\+.WYBQY[@^&9EU)'2FXF3A@[!
M]!H0"N$B4HFU,SVD<*#ZF'U45H#+34>O#/(\MG:QZ#QBK#R$6:RHUJ*(A)QR
M)&3UV#N1K+4\(],87B3EJHB+M4XN%#&.LHG''QY]:W,V;DO-NC+892<&H#";
M2`\I!T`8!@!N3D^QY`,&U`84?BMJ2==PC.5HRUUL>.ZRM=(=M-46DIO[#7H%
MQ!QRZ3:$(^A$H"6B&E;05<J(12LE,)+*M4T%%BCV`;PCCVKYAW&WCV<O,&/+
M9=N$0G(&7Q;3OB7T-SIP-26U7*+D[<?EXR-NUNJ(@L#S?6G+C[EN<CJ/H]9"
MF%8E@JS&KIJUVJ1M?2CJ\\;+MXUDSE"&:3:R4ZI,1;%`QY519PXE2@7O<B``
M(<?:(6KD)9UJ?7RY/OG*;S!U,/A\HB26@`!#@-5F^9;Q:N#9;%0`&%!KXOSX
MIU\4MSMX?B2Y@F"L^VC?J)1J"$JI%/%7;&(7JV-O439V)'DBUJCE(6X-S'76
M6*9N)TBB)AW#U7=Y_J.\_,$0G/TX^T&AEU+@VNPWCC0"M5[3"D)V<:<"6^='
MO<1U^]?5H'^$?[^ORPS+Z:JZ(C1$:(C1$:(C1$:(C1$:(C1$:(M'9R+J5JPI
MMD%G+D\'+$;MFP"+APN9@X*D@@`;B*RJ@@4O^,(:(O-[Z=7$K)?'Y_EG)^2Y
M.&+(9QK&&$X^I-'EBE;!56U&8WAZJWM<C-15<;I2ZBE]\"C%%BJ9DLU5W>N"
M*))MRW,@T'!2GY>N9-I@&XJQ,U8Z^Z&3HJ*DM6@EB*-H]Q?ZPA*A8G]?L51L
M,)0'$8HLG9)*/E&#Z.@3NW*"Q5$B[EF.JA_],NQRMM2RO9)'(%SR,VFX^@R<
M/.3TD>S12$0_DLB/HZ#<V-[DK*,I$WZKM718N2K2KU`T-%LXM9R5U)/Y!\Y+
M4UZK:+"\&+\N).8$O8%'C9.R,L_P4$PN3B>62Y3Q42M;H9FC5J!@W^V%E$63
M#ZT8X%DA+GK!C+U=5:1,Q?*E%VM%R#X?=[D\?U!X:HSF7:\C=:7FO)S-KB-^
M,-7.+CEK'Y&JJ[N9F$Y.PYW<H5WYC(\?I<B;=$D=(2DG6WKQF[*_K$P)4SMZ
MI%VHR<'EH,0CQKXV!9G[A*`+*8\2>R'')*%5SJ+X::8D.;B0A&QD'+*SCA_V
M@J2JQB4X-:%T$>S(7O3(0:GZ?6GZX(FAC\?X\]=+.C"&M]R-'+WD\*?+CM(9
MA05G6<#0KU\;^V%1UY`FPD!2F"K%*6011>`LD4I+53)T64:(FXOL@#&7Q:E^
MHI:"^9Y'3CP:1D:+]"SB-(N[W].S*P*)_*XDP,O6BY$#[.62*6WYNX=C[!C]
M?$[K/Y>U?Z7;3/=.>PV?U.-'K6PQWW/-T]E/)<G)_*QZ5ZNS/E>X]AM_.9&)
MU^]"WLM6^I'*_19T_E[Q<=*T=G6ZE?S+-N#>=PX^NN+NJ^<OZEJ;(O,&_+KR
MK1%^?A7&MV+!XV>($1*KF*-(620E^\\25<[PY$`072,HIW`!.@F$/T3^VTIC
MTAC`0)M?UVL@1_Y>5&^+2KA=$]0Q_P#4+D^`QAR_F'TY*"M!;66696O&&/BI
MLK-'R2B=[M:(OF<82*93=6AHJ!9NH2KW.4CF<E;)4CA^Z%"+45;,5P,8&[=0
M3=Z[G=Q+-VSW3N0,L6<7LV@Q,I;92E.0E.$21`;8Q\S2D"!N(;K=FW*0E&-#
M0F6@`<`"@)`?4\O!*TK19W#ECAS`ZSB:K5?+&FFW"U5A(>&N,S7J\K!EN=O\
M#9K)UVM,PBC+(/K'*.)9(S]5,AF*ICMR^-'`QHP/?O4?Y67>D]L;Y$V82D_3
MM`[A*Y)_-&W$0.T/NC4\MR[>DV+BDRL@C=0",N9T<@5(>O)JA4BZ34:(I%LI
M*1NN*)"PLI%6#>U'(+.TX9LK&/,R9R;N'!&`EI^M2L?-VF844CY=9TX8G*W/
MZ[\M)R$N=QSNX&=RS#'SK=J8$X7+)M9,"7,1/S"$P8Q@-T`(R#^2IBM3MVX,
M9F=J9!8@B4#P8-5WYZ<UE58X)AHYVC%9%R,QKLB:%8S\10#!'3\S(%2WDTFB
M*U51*UF7D&Z?MY8JBS>,1<+E0;F<(-42DS;N^I+EP2R\7&Z@W2$[QW0@.#^<
MG8"(F#`R9R=ID7R(XL9"4+DVI0`.?937F=!P<!(P@<KX0<.+33JPM3R0<TQ7
MN:S&S1^4;[&SC:)E(R>;Y9D(<C>(AR34&AX'QF48DR8JI+LWJKHW>(\HN]I]
M16QB]RO1R)7(2%I[<K%DQ>.TV!)S(QD?*93,B")0$5-M_&N]3'&V5NDJO(.]
M)<*U>E-"MY"E5%NKF7'R2<M5!KA666,<!'A!MTUJ\PIT;9V9QIM"D,?+-)U!
M,DK'RK0U>=H%<JB9!)=HJ13Q+DS`Q[!W,=/.%Q\;(<R?<9F#F=P7*'R2A+J`
ML`Y$@1MI2/6L$2!CYH,QHQ.@:HJ#0_4GY^FXNS5Y3P$Q'NVQXB>I>3%HI!5!
MHA-*HM'<8@<[E%FX?MU7*)$TS**).5TR)N!`P$.;8/5_N9"8]*3LW(F.3;OV
M-Y<F+D2-':AKP&G)>?Z=$1W($T.V;>SZ%?0&IU=OA^Q1,@?N[SC^SJIK\W?A
MC[%]0'!8!`!6`!`!`$%.@]0'O.F`@)1Z"`@7WZO#WJG5:9W%N3S,))H3,L@T
MC4I1%6N(*QY(674?MTRHNY'SQZ\FHYAP0,+0B3I!`HK'%0B@]G907]JA"S2\
MC%Q<9(34M),H.-AFBLI,2THZ;QS"*BXXGJGLA*NWJB+-M&L6R1E%5E3E23(4
M3=P`&^@IKHE/>HEMLU9>Y`5UT_XU5:LUG'4O'1CJH<F,TQMA6K5S:R2+)V-G
MQ/@Z,4@;M;Z]\N=&/'RL[*UN/>N2?D$=MOS3R+GX49M4UF/,JY[SG+Y4Q-0,
MJQ#ZGX9RA*T7*7,%ICB&K99T(>K0#NTXLPA6W#^8HDED&F6Y[)1E@M*XNX:N
MILB(%0?2AUO29!<MR.JU0!TY/%:GT&T3>2N3>/FMF-"Y=:0E4H5DLN2+W=SY
M#Q731<KQV3@C;//S$;!M;S:Y1^M#+-")`XK;:.6*F@5<R.M`!W*R2=%,8-ET
M?@$6CA4@#VG`!245+T$P]?&<2J%]H"!^G76M#S"*-^?.4>-L"M)!&8]=8\AQ
MM5F+TKCJK%(\D8^H0;51Q.77(DLKVP.*L<Q;--15S/3RK)`Q$5"LRO7!`;&A
MD(TUH@!/L3'<2:9DC*C2&YG<G()"O9BR#$31\.XS(+Q2O\7,'69TW6K]=K1)
M5DQDD,E9.@XYC+W:2D$$9!911O&>%HW8&0%!S67Q?P0ZL-%/U"0.FIZ22)X'
M`)D4!;M$B*J1MA(L8!$?$0X=>X!,F/\`*#5,>,=$!:B1O'!GICHD[TX]'M%P
MJ!3@9V;^*V2`NRAP5$.B9?C4]_:781T`(_\`$4<E,'G?DQBOC\R9P]KES3^6
MKLS!7%O'NFNHR5SGF>16='BHR$Q[1S/FSQZV<R*7I3R"PMH2,,!UG[MNW35.
M7,IQ%7T1OJ30V+/]QSW-PF,.,4Y&5I.<CI=Y,YKDHD;"TKS:J3T)%6A/&<7Z
M1_7IQLP,N^C$;>_!6`<SB16\*27.A('89<G30\4;FN/L-#>\?6\ER6RE9Z+!
MKX3A;::`D,E\E,V3]=L$!M\H:6K+=JL,(V;.<I2M+,X;-63.'E8QE)OC"T;*
MG%)5.:#<:!74MQ4B,9<HZ!DFF7;)LI'3.)<>T%]7&LO=,V/JKCR)0-,4RLW-
MX,FE*6`5Z.E7CVQG'NR3I8YX=\"A"HB!!U0:$Z11N'%/+2K[4LEU6)NU.D74
MU7)LSA2'E7$)/5U%]'M%CD5E8YE9XV'?+03PB7>UDO$+1\W.19NJHB<IQHJ'
M&BE>*;&U\I^/]0IKR]VG)D4QKS=LBZ3%"(L\Q(N63_L3C96*K$'!R5GGXJ85
M4\<<^:LE6<BN'B:**J=-3=$>Q&)*[#'6<\992*<E)EYY=Z@P"15AK+C_`"+C
M^=;,@%NF15S#Y`J=7?(B8[I(H%$G?N<.G0=H&)6C2B=A,OC3(4PA\!`[S#[-
MPZG'?[-Q$?V:O%30*B(")>\>@K&,KL/00*;H0!^_QE#]^AU04"HG\9U%/<)B
MI$'[2I;@8P?<90YOV[:'D@5=^Y8=O8B3M';_`)1;8PA^TJ9`_P`[3@@U5#_$
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M"I=RAU']:O%/?P-FK5IC'[<1*M'6&.,]C9)J[`0*J45#E#J54NX"76M:A10L
M3J7/Q03/T)3"+29<P\BW37LL?3Y`L>]=L5QC6DI(U>BMY&:CH=510JIFX-B/
MY`&;@4$&8/6AHTO!THIF3TM4Z92#7W+<I1JK$TN`93ETO5L>P<-5:LXCV;%S
M,3#BT3A(YC$1S>08%436.9OT12$"E$I"EU[47GE$K3?U(L@46Z*5Z<K?T\L0
MW"%R-2BVZ(?UZ>YRY@J3X).@70U3F6[27A^*&+9MJ29APDD$'-ZGV[5X"!8I
MDD9WBLB_X?O5T]J]0G3I)!-=Z]<HH(IE.NY=NUTT$4R[]QU5W"YR)IE$1ZF,
M(!N.MK*A+<CN\Q<@,3XB\;X(/'DS#<O,W,7?S9%.`)"^N@>*.+Y>(D9*3:P=
MIG[E&K6R49-A20,I2Q<"F`/4S'R:EOIX*\%-[6E$:(L7X5A]P+%`Q?L\B0=I
MP_:*8@/["CJZA30H/\*B1Q_"/<B8?<7R;"F.W_K";?\`"T&A0ZA"OPE!3K^2
M<JH@'M$@`)5.GOV3.(_NT"&H5RI!.F8I1`3"7N((#_&*('((#_E%#0:H[A5*
M8JI`.'X5"]0]X=P;&`0]H"`[@/WAH0R`\%1(3"F7NZ'3_*.&X;]Y.F_[#!L(
M?<.AU0:+"1/M%0$A!-4AQ';;=-1(XB=,5"E$-]MQ+W!\0;>_V:I//13BK";"
MNJ0>Y!P.RJ8]!\A!``4*4=@(X2*H7<0]I>[?X=#IX**W<"N>Q8/`LJ4!06*(
M=AU"%$ITBF-^(13*!O&8.H`.V_MU>'@J@P^-R`+?D'6*!4G).A#*IB.R1^X=
MBBJ3KV&]O:.PB/L<**?>K=_$Y^/9N=?M%-<.J"RQ"@443@(@/<H0H"`"(&#8
M>T1][4>"NBPBE_.-`#PJ"<7#9+O["G,!A4\C);X>U5%0=C%V#<A@W`-Q'5?B
MG@D:"RS)45`3449K*F!RW[1!9DY,(]Y@3]J953!W`7HFH`[D$!$"C2!(-^)1
MRE[F2*7L29)^L<+?S79W"B78-S"H)0$QA*`]2E#H/0PEUD1XRT5)/!(D$?,J
M<ZIO4*;;.UDQ`OD,0X&!MZ@HBDT:(&`>XA1$QA#81'J&M$L&%!]/M42Y,2&[
MUC@"H`7M303#L;-T$Q[BBH8WPB<PB)A`=Q#IL4!UGP19"]I2][D145.)G!VR
M8;D2W^+8Y=]C"F0`#=00#IT#4]BJO3[@0(=RH5$A]S"D4QMQ%4W?VJ*!L<XA
MW[=I0`/V^W0L]$JJ-O(H@GV$].D;O.03%#R"0ZASE!-+\*0"4P=3==OXNAH?
M%."&QB`54&Y?-W.%]SB;X=P4$OYBX_$<P"'L#N']FJ?'DB"@0BBIUC^13RE[
M`[1V`_A2W!!$.XPF`-NO4WWZA<LVB#Q5P`JHN<3=R*9D4A$A1_./\2P?&<H[
M)!M[B[F^\-*`(U5D[2D40*0H%*!%R[%V``#\L_0/VAJ/170JJG3Q&_DKI[^[
M<#]R8AO^P^@4D6JO'3ZK;5%[8L,&(M'-S1--R7-/RO3E46=1S!:E*J@BS4V\
MI4A[4DS`HB4JKH04,4!`VOMG[/3%H9N\2,IW+$(MSEO9SRXGV+Y[ZND/FL>(
M+$PG]X4%V1D[1"U2^SIG$%@:D`,JPKRL8[F)&[.H&0IP2R*C']/MJ7)3M\L7
MC;)#*6)9A'H++E$AFK`Q%>]9$Y8V7?[5BPZWJ2^&-QP(68SWL-QEOB+=LNT+
M8E(L7W2IZ&+3E&[<.S%APKYB&<Z,Y/,TX4"YA%QD;-C7U,]"0EAQA'%K$%'M
M+?)Q>/*Y'LZVG)?+*Y2+E&Q\%`-Y0;`@=XX4;Q+B#CQ*HJZ8`!S"/FFUVOTZ
M=F)=G:[K/=*4K<97I2,FW3NVI&4S$1.V+S%R5!&=%3/(O$7+C&V&%2(@-0")
M#>\`,]66]:P&*68+U6X7'*->85N;;,;GC[+$PC,#&6!JW,V?,WS^N51R@O6V
MEI<RZIW<8IYRJ'37*W`S<BQ/%GE=[N;<OM^/AWIW($V[]@&#Q)<$1E,$2V;`
MTQSB2Q(*4;&XV[DI!I,8FLG%-0-'?Q9N*1.:A0K4FQJ$).97R8X8PKF385`E
MTK^/*/$U&/5CT9E]DF>DZBM#PC6,K5FE$CHLDWKA,2(M4S)BBBBG1G=TP!+,
MS+6'AQ,Q$W#;E?NRG)V%F`F\C*<8D$D`U,@7).;4,4S:&^Y0T<1`&KR)8!@[
MLL+*S7'$R\95\@PK,N()W].F"$K$57YRC2;.#</%H*;JDK=U+'%2L]!M69FJ
MS5V_;3#-%RKV/693".N6_@87>X2S^U3E_7;;^:<I0NU`>$XV]AC&1+A@;98/
M&12S<O8\MLQ^EF7HQ!\02]1]>H<+!:XF1Q91`K%A>FN-`FGW9C*ZH-YM%&/<
MM&5,.BL1C<*O5G+:+M%0EV9W4>,M)%8.VKKL**[58I^7`N6>[]P&5C0&/W&$
M'R+)V@2!W@_X<Y^:%R,FEL@9`Q!I($+UHV+1MR(N6"3MD00W'VL0=-`U.*>3
M&K%-O`\2(Y]-1B#R)^H]&-B$:-7ZQ7C]M5:`@>')\O!!NQ!5ND"@%>ID`A"E
M-U.<`-Z?NEP3R.\7+-N1MS]-G4@,.K<\U:GE3[EYF!&,<:Q".HS@/#2/%?5X
M'^$?[XZ_*Y7TY5U$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$3$\EH"/L^%K?"R
M;JWMFSI2MG*2CA"+S\B\;6N#<QT($997T=`V&'G9!))G)13M8B,K'+KM!W%8
M`$J-5&?B?79*BM>0DH3'N2JH\8-:ZWBJXXI>,\84JQEB*O*3J$C1,98UL-P&
MOW1[(S:K"6<RA/6R"36-43(HW!(H%959<%QKNEVL>7L/2UQ2Y4-[E9L8VHUS
MJ%YM\1/XIJD4\C*W9X>>1E*IA6C4/(3`THI\K1D/7QUIA954S)S$$17=BW*F
MG)<"\S/F"C99LE?J-ALL7B^+Y!?IHU]1KR,CQFKK&4R-&Q,[2[F_EL*3F45<
M@'>OUHEPNPN*4&C8G!`*Y8-4SLD2K`CQ9*OJ!VB!J&7:Z[M>8,LX"CY?%#MM
M`V;CW'+3EYR9-QTO.*KT?*C*.M7S"NXFA$WJ"Z<VI$039@O(.=[I7C&$KJ*1
MKH`5)7)M!G[WBOC)6*UDJJ<>,A#^ECUJZ1\[ZJU5EVSH9UY>`Q)63VRPTO)L
MF^CT%&ZK"=?6>""-*H[60E103,-4XGB$]7&VJ2U)H#^L6+)3++UIB;E96MHR
M(C.2,O+62<2<(D<.+8P?2LNTJ%J;H%31=PD<="(C?&1-BU:-O&U1*'52`T41
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MG9347"P;WUS.`N]G8T#(S+UDF$4VFV<:0]1OR-0KJ/KSC,2$PX?38%\;0",%
M%$?&NZ5(KW^_A7<>]<R8[996-9-ZR6#[2?S;)N2\M``+>LCN8TB".O1N1E`6
MY%A(B,B]#R+.[#_8G2@JZK$8A6J\5%E46K=ODFV;4#2C8+?5;K!2#^FUYA8X
M([F0=,80$(45H%P)E4GSN0<`#@SKO1)ZF]G0O][&3D2(-VS'Y23$VIVI1%R1
MC)@-X,C&Z*&,8QH`Q/*;%V%@1@`80D>HU)1D[`$/HWPMQ)3U265F52HM^P90
M\'U',]^74AW^16MXEB05/J]J^7+LHMG!3H"UGIC+*=?D57DJ@WDHI&.;D'RK
MJ"91`>NV.T7LW-Q_4'<\ZY@8#R%J5H;KMV`+[I1TC9W!H&49&5&#,5[&%VQC
MX\\&-J-RY.LA)FB6X%P=W.K!9JGD/.F!+RRM63>(?'U5`,<L56\_B>=,2VPC
M=W$/556E5@+'9+S#S^4!`5TUE%&C8TJN@*:,CVKF,MC)[;V#U)A'$[1WON/4
M&3(;+\!TID$`;Y1C`QM:-4[`:PI3FCDWNW70<C'M,8!F#,"-07(W>ZO-<6U!
ML[NM.NV%FK>?J4E#N+=4GKYVSA(Q6H1ZL@6?=V8\NJ5O#J,$$':%F*X<()L@
M%P=PH5-,YM>RE=-OM]_M_J&73R87!;N1CYI";`P%O:"[G:;1`.XLP<KUQL;,
MF/R3D,X=@T>)E7AQ3#A'1U(M99S'9W`1V0<E2&.\=3S&1F(^-+1ZVI$(WZR0
M]E*J,"_K[>9L?HH,T@FW,_1:./4BHV<B4??[[W=,,6.Z1:[BX@OWH,">K<W=
M*$H?%OVP$KHB3M,AM:07C2M"W/K6CY93.TC@`/,1I2K>Q2@^G/+0TOS#@745
M%JIQC+'-MA()!TX65=*QT*SC&?SV5=#^4^L%@<>60>O#AYU73UR4@D;F*B3K
MO[D8^59]%2^9E'KRR;<ID!@\C(B,1J(0'DC'D`36J]GZ=N1GW2+1:/3DPY_"
MQ^JI\5]""G1X^*(]3*%4#[PW,F(_PD_O:_-?X8G@R^G3+E83?"LD(^PY%4O^
M$':J7^$"FU1H5$*[@!#@&_C5(8?N(8#)*#_P2J;_`+M!6B!>=4=FO%7-?D)G
MKBB_I[^^X<P7%P!+LK(5.T)T>VY<@;RL$C7[3:#.8ZN2M2A9&"]&WK:J3Y.R
M+M'[MRF,:V;^JR)/+;^%:8Q`/%/CR;M^530M5PK@UE9FN4,\J3=:8Y5B&:+:
M&X[T*&;1P9"S+,S3Q@\@RV>JQ$NDVJ,,9,5YBR.6Q0)Z1L\52LN0U4#:\$T/
M*5)KQ^XFUW#6$<<Y7?PMDLU$P($5A2DS-_O53H=PE7+C(M_7@XD[9X\E9V`9
MR*+J8<N6B![!.D>/WB1!77*F\8T%$C4N4T4FSYRV;D(UEW>"6-5PMAO'].'`
M>!(3*\=0,2O,C6-JFH\L^9,N5!X_F[:VP9`QHPC"F1E5>0`/'P+D,Y],WD`G
MF)<:<E?*WBEF":']3G+->M3[E?DNJ\>F=^=M"2],P4K4K!;Z!!13J3:N*UAR
MSMTK/'5`]O8"@M*VR8E+%8!54$(QA!F2(X-1OD?,6*$Q&E5N,Y<>;?*/JCQZ
MXP8ZI]-Q*[G*CG/E+:[U,3\6MG\E/MWKJ;@MWD]:`R!<;9:;O8H8\G<)B4++
M&1KJ`1XB4TSW)I1.C4YH#Q.O!.3FE'Z@%UIUX98CM?&S`UM=03O]/.F*-]S3
M/2-A<G,8Q?U%9*?4:1C;=(W:627K-K!)0PJ&:&`I=]F-PCA[5`8`\4RM`QCS
MGPM3\LQN-,4\7II68!.\0+VZ\B<ZW>UY(R3^D(UC+.<H7JR4H9N=M$Y/18((
M.&AX.#BXXK9!HU;D`XIAN@[,9>]2A;5/#1I#G@I`5N)D*MAN*MDBV&0LV0+Z
MH:'KE(4>M(LYJM1\"XVNF3+)<UHY91VG\PDKG#F6.4IE#&(;5)D0Q'O^G]J,
M.991RK>!,F8<Q-E/(N4<0V#./+_/]P4Q]EW*])O!G^5;7C><6F&4%"XQEH&'
MAW'&O"$<CZ.*3B(A9-.`8/G$S).%GR:ZHX$*.:R_@M;G--$Z3O.\#QG;M\6W
M6P8W@>4T[0*)8K7>[#2;DRQ"^8S-SGHV"QICAO1XQ2_7MCC:')*MJU6H5L98
M6K)%:4=1[F0[E1(C0UE]BC$^Q=E6<#R^7E'4SD56SL,:6=1Y(65KE0&;O*^;
M4'T8F%;1EJLX1-#<:L2U5^HF[84J);)RLJX9MSSJA!]6@^")D7DY3<P\5P-8
M^F#0H!QAN1+FW,F1)'"<A=YBL,<SPN+;_BEU.W]L)9FYKX7/0Z[1TLCH2XFD
M4+3V*SYGCAT=PX<>J5'63;`^(J[C]:Z&VY'L\43+_'O&%GR-DGDFYBDL25/)
M&1EHF468Y!OT##R,C=5L3UB&K5.K^%L14B>:S;NP/V\9'2CQO\J8?,79ENY*
M1T"@Y\$Z^%*0E-'JS].KSE=PW@HKFKXGA;9%OH.\Y:O=1*M67F9+%`/W#<D?
M5HY9FY1I#!ZU2,15PI)H(,VI(DI:!P#[52G8Q)EDV26T._E:AE"#L,S#H2L\
MA8Z!D6`JM0E46+51U6$Y>^05=4:N&QE`)XTVY2.G9%5AW,.^@-&&JR4^'_.=
M@#^8`0$QAW`5Q`>A"!MOX=^IA_C^P.FXZM![455#&.844Q$!]BRH>Q$HA^$@
M^]<P>P`_#[1]P"'-15,8$BD22*`G$.U(FX]I2%#;R*=-P2(`=1]IAZ!UTJ:G
M155^!!/J(FZ[B/\`'66..X[%Z[G.8>@>P`^X--2HJIE,`&.?;R*"!C[?A(`!
ML5(H^\J8#[?>(B/OU#]BKJ_11&B)F,[8A_MCI3:+B;$>BY&IMBB\B8;R6W9!
M(NL<Y2K:;LD!8%([O1&9K<FR?NHBP18G(27K\D]9F$HK%.2$/[5063=X6SH>
MU(VZ.N$"I0<D8Y<-F_(#$*[YY-2&)YYS&R+I"_5"0>2(N+CQWR&SAVYZ@ZA(
MPWF,NMYBI/49)JS@/`ZJD?4FQR^KF[$=]R-R5?O0F:/C^&EW]=B:_?IUNPL%
M*)2W%=J.%G^+56*=4C)^6S5/)V"P9`?OS%C8QDBFD=JS3<II"X+\$H0R9:@\
M5<:WNQL[5C"1REP:Y#Y&I[G+MTE>%][+!8@N#%U94*S'6N]X<NL#:\'SM@NT
MR+M5L88%\Y>M6*ZY9EVEXUE(`^E#X*DD!M1XK`<<S(5MA8#_`%CC)465EYFO
MQEE=<.>.06)\_KV0H'%,V@VG!B$(99S&WZT1S!1T$-Z;^NI.@`69O."O/[$]
MU?:N)DL3\:'%R8*9*OV8/J$<EFF(I+D!Q\J_+2XMC8BM,A!+V4S*/Q?A&J5R
MF89B\@I!3WKUHFK5'4GZ1(%FSL`!11&,.-2JY;D$_P!0(_DCG:SXIY"I2*6/
M)&(C9FO35>N$"\:T:3QE8'"MKQWEO%\/#V:_(+R]IH[]NSM5>)96@C(H,"/)
M!)&)7C)*AR74+"B?S-V<(^KQ5;0@J\KD>SY%>+1>"L.QSYBE*Y]LWREI()R#
MUV)I6-BN/%9AYOU]JG9%LV"(!B580.<S-N^I*@"[?`N(7>)*G+#:;$C>LMY&
MLCS(V;LCI,U&"-VR/+LV3!P,*P7.JXAJ'38.-9P-9C3',,?!1S<AQ,X,NJI0
M&]JA+^Q/=JJ(T16*$[R[`/:8H@=,^V_8<OL';IN4=]A#W@(Z`LJK2B5<AB'#
MM-MV+);_`!$$0WZ#TW*/M(8/;^W5T+J(3.;N%)7;R`&Y3>P%R!M\8`/3O#^.
M7W#U]@Z'F$5I1].()F_F1'9$_M\8B/\`,J#[B@(_`;V;=!Z[;M:\4U53%%$3
M'`!%(YA,H0H;F3.(=52%#J8AOXX!UW^(-^NKK1$"41_/0[3]P%[R@8`*J0OX
M1`X_""I0'H/O#H/NVG@41\*H@9(_8LGN`@<H@(`;J*2R?XP*;IU]P]0$?>TI
MP5X+$KXERE37#P*E,)DQ/M\*@!MW)*_"0X#]FX"(?8.J'%14(L:OE!,4G:)W
M"!NOD2**AR"'X3@!2B)A+_C``@'3<VE'<(L(*]R9DP,D_;#L`IE5(1P7H':`
M$7,0Q#EW`>TP[[^P0]FK]DD\4G%R3M.@3^N)^P[57N2<D`!`0,0=CD`2CU*(
M"!!]VP!K3<=$JDAG3E4#MTVGE`@]R*4@N1JZ(<H?`H@*17"@@'LW`NPAOML'
M358<3]2SX)`NVEW)Q]2Z1*()"F"10%DZ,AOW>%=-<%32*`@(CL("7[/;MJO$
M:#^/^Q2J3ILI)D"AF92G;=Q1<-?.HV;K`4.X/4'<&)));]H``&`$PW`.[M`"
MZNZ)-=?I[E6/!;A&217(0CPBJ!0'M38%2!%@?8.G]<)_5G:0"/0"F$!-[0]V
ML[2#Y:GGQ^I4%;4R@*;%<+)HH%[3$9MC`*JO:(&**IDS")4P_DAV]WOZ=-8T
MTKXJJ_XER"1,A6C/H954X%[U0`V_80H[$`#?QCF$W3H&XCT::UDCH,<IA%)J
M4R[@Y>T[DYA[44S;@<QE3`.PB`_"5,NPB.^VVGB=$5ZPD1(7SJ`81V30:I@)
M2J&`-DR%2*)E5]@#KO\`"!0$=@#4#G1%>D54B)$P[6Z29-C*'*7O``W$YBI`
M/8D`[B/Q".WV:&I\456R0$**FQA47,90QS_$J)3#LF4QAZ]$P`!`-@`?=J2/
M#@HKR?$HL?W`)$2C]H)@83]?N44$/W:<%2@?B73`/^+24.;]JIBD*&_VB!#:
M<%$+;""1?:)EB#M]R8&5$?V`!-6.JH7C5]5>5+"WKCY,+1B,O\H@[TZ&&>I*
MK1T\P!Y3RR,4_13%-%9I(,UEFJ@G,"B+=94Z!DE>U4OVW]H<>67C=QL0D8&4
MK+2!&Z!\[2#\BQ;0L`7%%T#U?/;E6"P/EG0\:A>9\LDRN",C%O%K7-Q>*:S3
MKI7)E1[)6JPJX>D35YG=3*K-#L:ZRL=6+92.Q0.8ZJK-J[.=`7KA0QOI]F5W
MMY&1;C:C?R[MRS<%(1^8&XVJ%Y&,S!G%`91`.P!=;(G=>,?\.$8EQ4B)(T_X
M7?W<U)J2@_F-T@5E65<)CMC5%24R<CK&WE\?R.+*?'+,I&3&7:F$ZU::(,7"
MTD<5"J%D#.$G"23A-5(O5K6?L[==C9ZO]4-X=6$XM>Z]R5(L1\1)`C1MK$$Q
M8KS;EDSO1E+:;&T[2/AVQ'T?Q<:KK97*ETSE+8>B\`\8L.6:MUYF$#5\DY]=
MK1T_(U5BE)M(]Y=:1!RE46/4)*,*HZBFSM2=?+MR$<=B/F434\&UVC!]/6<R
M_P"HNZYEC*N'=.SB@2@)3()C"Y(2'4!83,>G$&CD`$>>,J.7*UCXEBW(P8"4
MM2&TE44'`%RD5:S(M`4!WA[/?'_'V'"VJ[M`;W/'T\2S1$A=6CAXM5&^4S2$
ME99>`ITK-OG#6.>MYI=D@\3\*C5$#G6-O)[+&]GCOGISN.3GBS8)-N]'9.-M
MAOZ):(E<$0#*.P2VU$B:+C^9QXXQP+EJ%O=)W`_$]-[DG;6A!;PU39244>#I
M.76MZ8)Q])1._0<24M+,V\VID^J&D)6KP=3B'1D74Y>'3MJ9J#+98%HA\LHN
M"3<!7)[>.4+^?@2P9;^Y$QD!$':+%P`7)W)?AMQB2=W_`/)$,Y++UUNS.$;D
M+K1Q]U7-=\:@1YGDS^-*IG!6_LV1GJ%-QC]PTQS'UB:N->5D9B.C;-E^:*@U
M_3<O`33A9.<@8EC,+IR"C%93U#^*62[RM':@./=FU_5I6^Y8\HQO9<[D;<]L
M9&&/`GSB40-LYF(V[A2,P?BB&P=EO=9G6$6<&GFY$>_@VG(IZ\,JM_TEQ&[F
M1I-5W]1^'4?N57$LFX3D%ZKC]XK,&3:>-JMZ5<QQ!%4`9-O.8J)$RE\8>G[Y
M"4,_O,0=D(^FJ"F@N3#?WBI:I.J\W!?H6!+49P]](_>OK7#_``C_`']?D_B?
MIP7T]5U41HB-$33Y-SMAG"SBK-LNY/I&,QNSU[&U5Q>;#'5B.F9"/(T.[9-I
M687:1A'1"OD>TBBQ#*"H`$`P]-%0"=%H&7)?"LIB\F8X:Y#.T!S<9W'L7*0%
M?LTY(V"[UW($QBV2J]8K45#.[-99<;W`NV#=-BS<`[%$5D14;B"HD8NW%8\=
M<FL+Y1IUJO58M3QI7Z-%N9NYC<:K;<?R]7AFA)HSB7F:_>(.OSC2+2-6Y%,7
M'IQ1!Q'ND.[S-ETTR$$%EFJ/)3#-XOJ>+H"U/?[0%:TPMR=7FZ?=JJ_4@Y&"
M@;*@LFI:*Y#LU7Z$)9V*[ID547S('`%<(I'*<I2,0'X(1Y+X.5RU*X.5R'"1
M^3(IW&1OZ?ECKQ2<M,RL42<;UVMS$@BWA;):$(A4KEQ%LG"\@W0,"BB)2;F`
MC%GX+?3^;\7UB:M=>FK01K,4B$C9ZR,DHJ<?*-&\RQG)2(C&1H^,=)SEJE(J
MM/G:$*P%U,*M4/*5L*9TS'(Q*UECY$X6J3_$L?8K]$Q@YS267Q;(JHR*L!:$
MDVL&[05"R-V2T!#)29;+'I,3R#EJ1^Z>H-FXJN%4TC$8E=1!Y6Q[8*K(W5G:
M8]E6(:;FZW.2EA!Q5"04_7)Q>M341.M[.A$.X=\QG&QFXD<II"H(D,3N(HF8
MQ&*TC#+V.LA0F34L87*(R1+X^0=Q-FAL;62$E+'%S[NL(V*)A454WHM(Z<F(
MN0058'7.1`YE2F[]BG[2,1JO&WZ=L!><^YYA\V7.Y<E8EQQUK#YJ>C9AR;?<
MGUN3DL[UV0C):GOD\DX/XZSU6RYAAQ2B)3ZC"+GX!P,FDDTD!4*X(B6Y4#!J
MKU*YH5MC:>.MS8RU'8Y%@XR:QS;[#59-!%_&.:Y0\EU"[3\G)P2SEB%LCJ[$
MU]:17A2.6JTRDU,S26247(<I8C0I@N&4,RM"&8,A-:=D9IC#(U(HL%1K/D+)
M%2M%GGZ/`&R*BPJS*:IUFF'3R-KD).H+MIF<DC61$TJ:*?+>2&`P%9'AQ4;>
M"H'=YPK\3:H>XN&M0A<A/<%*S/(+CK.-*?BQ%TK0L<";#F,[W+3:C:W8GAVK
MA.>AD%(*:6,9V^;F>)-Y)0M2T6ZLN,*C,\MI*P.<NX`A,N!FN*?0TK9KA!1V
M0XB'834:K'4A+`[>OR%.M%@?UI#Y?%S3Z80GUTW*3\$T7!$T0<4?RM5EWO.&
MV2>/\OQ,W%\@8?B*:T8R954^2;15)>^QV>I-.<LSF"P/48=>O/J]7LB1AW+A
MVQ<Q[A]:WX2WC80LB1!44BD:C1UTW*R!+,<:^/-,=XQO5\K,H\H#*Q<:JB]G
MV.4;\QC:D5VTJ\/?I&K1TI4)6F/FR;YY(RSZBD4*T,F\F(OO.DJ4&J?K@[&A
M"8"B8)"G2^-HR%L5ECX7&%C4=N[1C2)3?^1K2K1+OJA4%[#.Q1E3&7D`^<).
MO*!TIF93[))R26JE[HLHT1-Q?9+T$OBU']1R<#\UR.G&^DCHSYBC:=Z1=WWZ
M<EEO(G\IC#>A]<+K8^R[%)+;\W<.Q]AQNOB=TG\M:O\`2[:9[ISV&Q^IQH]:
MV&/4GYNGLIY;DI/Y6/2_5N;\IW'L-OYV_B?,=Z%O9;M=2.5^BS9_+7BXZ5H[
M.OU:_F6+=MOS'#CZZXNZ+YTOJ3&7/S`R$F::\3,G"N,.>'2<RH&*H&88XQI1
M=F5HK#*&,D44DU#J%4*4IP[3;@`_H?\`;9AZ0QR(>?\`KOQ,/_+RH[[O$AN2
MZ'ZB_P`_<;XCC#[)_P!Z\R&S1F>J+M6C@CA*:M=4^>R;N.D'\1C5G!6R*+"S
MK^&!F=ZY?R;B<=MD%NI$6@KE*`K&.HG]/OSF<V-VX*6[-S9%P)7I2MRWQC)V
M`B(@D'4MPH>J6HSC$5^(AS_*'U]I4SJFS.XYJ5=LL^_3(W2%;I2C)Y$2]J2R
M#*)LIJ57K2K>,?(@M(Q<[7&T2TL<88K(7,<5<0%,RQ3?/KLY1_;^\0#<G8OG
M;+<(&S$RC'<"?PRC,R-N7F:?,!O>6-I[O&.D9C1GW2`)KXN-H.G%*/IZL:Y:
MXVHW.W6)6QW\C;--N:%>UJ\SZ\->2647DDQ>4^/?LF-T;LY"0*JL*(^5\*_I
M>PQ`[39_<FYE8=RYV_#M]'M@^5A2=L"=O:`")D/;T:M*;ER]HA;EE"],@SVS
MD'<M+_AXZO3V*1+R]9*SCA/(<GRDQK'8IEZ6EB17&\:RHMMJK>30D8U!6,R"
M_N%>D4"-V]L5<B?].@FJ]KWB\8]NZ@FZO\EVWT_WW&AZ2RSF6;T;W5)G"3$$
MO:V$?@;_`!3Y;FH7GY%V]FX%R7=("&P0V@1(U&OOY:A0!5D'9<'\KV[7(BKB
M/C>6<E3JY*.JQ/-%K0WL%<4DK12XZ9D714*<DSDZPR.[<."^=\@@H"9RIN%R
MJ?3XV[4O4G:;D\8"Y/M`NW(;XG:83VV[DA'_`!"1([0*`D$_""/1SM#Y*Y.)
M`C&X!0&HD"2*_#4#773BLN0F@QCC!7@AW'I4,9V*&=UY!N\1FZE%ST-#M;E9
MHYY*)N%H-.L,Y!R=09#X942+OBI^E7**?B]GF;LNY&[,=4YD)0N$@B[*$I&W
M"0&IF0`-OPTB^X%^.]&,)6HPH3;(;@`0"6Y,>>M3HGN^FNV:-N5S,C680DTV
M]2O#<DB@@Y30?-$THM)FZ1.LB0QD5T!1,0?S"@4X;[`JEMX7[H797?2<C.)C
M(WK1(.H/F<&IJ[_0%>7Z=&WNT8FGDG]R^@QX)BKG7*7<4U%`4*`;F.B8VYP*
M'7<Y#`!@#W["'OU^9XU`'@OIY^)U8<`53^$P=>TZ9PZ@!BCW$,&WM`1_A#30
MU35":OD`Q3%`BA0V52'KV[[AN&_4R1_XH^_]N^JS5X(ZTL)!P-3:NF$#"0]?
MCGTM*3SM.$C&,2U>3<X[4?3,Q*(L&[=-S,RSQ057+Q4#+.5![E3F-U$SZ(_%
M;D?(3N,B/<14P**(=W:10X`(`J0W4I5-A'V]!^T!ZZ:T*.L*AD%``5>Y$Y=P
M*8Y13,4!_$`'$#)G(;;J&XA[_OU0_!3BN/N5\J..H0]@O-PJU8KQ7+=D,E9Y
M=M&,E'KD%#M62*JYS*KNUB('.5,GE/XTSG[>TAA!1G-%6.@2F#LD!:&7S:K2
ML?/1PN3,PEZS,H3\6+P@I@9J60C"NVYU@,L38AC=>XNWM#6@/%19FKE";:)/
M63UG,Q[DAU$54CIJD7(FHNF<P*-/*D<I#MU`'O\`'_-FW]@ZH+>'T\5=KI8D
MW3;B9(A%VADS$[D2IE=E(=0"%3*9NEYFK<Q^X.WR&[AWZ>W0DG6OV?WJ,U%J
MK#8J_4XQ:PVF8AH.*;KQS1:9?/DVRI'$O)-82(:^93=%-Q*3+Y)HW2((BLX5
M(F0!,8"ZFGL^Q57-;#`/9>2KK.>B5IV()Y)>%*[93,]'D]0JU_V@V9JKN6`@
MZ1.GLIN8IRB`["&COI7V(RT5OR3C['987]<W>I4<EE=*LX-6SV6/C3S:[5-L
MHY38DF%BMU"MDGJ(JF$_8B54@FV[B[PD#541)%%WB173<_\`5DG:!Q.HB+A5
M-9,_>).Y5`A6:Z:HF$A-S$`"%V#<>FJ_,K*UXR$8A+(0J\HU^?.(UY,MXQ9R
MY3E%(E@[9L'\HU8!NM\O9/I)NBJJ4!*11P0IC;G+O"7H/X*M]2V@F*/XA34Z
M;@)O7K=-_:)>@".I]."!9"G,7N!,5"%5`A52M&?A\I4MQ2!0Y^[O*GW#V@(_
M#N.VVB*_XP,*GC`IQ#8R[M83J;=-^NZAMM@#IW`&B>*M[R*#N=11Z8-A`A"[
MHE'^*/M!$=OM.8=O=I7V(LAS'$-USE;IC_$*?XS;^XRP[`4?N(&_WZGL14*8
MYB@1ND"2>VP'4()0#KU\:([&.(_:;M#?[=/;4H@IR)B8B1175$0%0=P$1'V;
MK+;=A`#;H7W>P"Z,37@@60A!W[U1*HIL(`(`($3*/M*D4>H;^\P_$;[@Z:/P
M&B.RR[_<&LHZ-_N#1'1O]P:(Z-_N#1'3&Y@P5"Y4>5NY1%CGL5YIH"+Y+&F;
MJ.FP&W55M(J).)2KS49)I+061,86%P@F:5J\PFM'.S$*NB+5\F@\1$/[51+Z
MDPA<V9"P259KR(HQ\=-&H.!)G3#M=M&0>*=H,*=C<$DKC48A.6R?QDD)JQ3X
M2$XH_9O(Q4Z($"PNB]0CD:I0Z?3^U.M74L19:!?)%#CH:\A(4:3QT7(?'7)3
M&<9/**L*;-C#&1I=GBVS=PV>7*6>Q:2K9VK`>!RX3<H.%2$449T<BBY-/B=Q
MQ)!PM#98IN<14(3(CB\P=3CXJW,JW#S4]5W."I9L@3TQ_3TN4A8\LJ\9F6%`
MBA6\U^67Q'!M";CJNC=P^%L*UB"L<U3:;C6(JE-QG6(>^9^LE8J2<#!XQ@;6
M&.@<35OEG\P$O3)-Z=)T=,&[]168.Y(JY.10`4%4<GVILCYSN>;SD:<;:,ME
M=JLX36;YHR;"V3&O$JHJ(/(&593,,23;,<E<DI^L3T*9Q%*UADVBURK"DO,,
M0_-T=]/[DTU_O_N3ZX@P/&8SE;!?[/:9G+F=+RR:Q]_S7<&K%G.2<2S<&>L:
M12:[&[P>+L40KU0RK&N16R(K#ZI\N_?F4>*`&]J&7#@GXW^X-51T;_<&B.C?
M[@T1T;_<&B.L:A.X0,4>Q4H"!5"AUV]O88/8=,1]H#^[8=:!X(L8F!02HK)]
MIS"'C,7O$ACA^$R*I0`Q%?N'8W[=&.H3P5QO.CW$6(*Q0W`WP;*E`0V$JJ(@
M!3^WVE]H?Q=*'P*BL3$>OIE"G('XD%!-\`>W8AMA41$/L,!@#[M--0JK3&(!
MA,/D:',.YC=O<D<=]]S]O<@;]H]IOOU>'-$")E-A,1)SL'P*-U>Q4`^X=P[?
MW'V'3[$5HG.'PB+@"C[2+M_.0=_M43_PF'518NX@#\()$'KU*1\W#I]A2B)>
MGNU&^E%0"58<A51[@4,!MM@5(9^*FW7IU()3E`?<;<-4%OH%"X6$R1S``+(*
M."EW$JR#=<%"#[1^!PY$2B/^((@/V:KCA11&PB0V_C71*/0JCI%JJ0P?XK0"
M`)P]OQ"0P>SKII[?IS16D,4P=B1P7Z[B@FW%%T00Z;D>*D$3B4?XP[?Y6GM^
MGN15,78Y3'33*<@?`:46$KLFXAOZ=P41(<-M^@'V^T=/I1.*Q*@17X5#K./)
MT%/QE:$/M]JI0]$Y';[3`80]^J*:43P6(J!F@;)@C'$ZB`&`H&W]PD\IBM1-
M^Q4^X^P-5P?$K0CQ2D%0-VF4(Y<=0`%%5%$4?V@H9N1#8?\`T9AWUEN`99\$
MI(JH(=H*,FI#"(]J2X'.(C_&,<Q2F.;I[?A'[]0@>)569'TR1A.0WG7'<!.F
M453;#[0+V`;M`?>(B(C[QU"Y\`FBS]IUQ#RD`B>X#X1$#&4$H@("L(")0)OU
M[0$=_>/NU---40945!$B`@)NH&6#JFE]NP^PZP;]"AOL/XOO`<T\5<)B-TRA
MM\(?"0@=3G./7M+N.YCG'J(_O'4J2Z.A(#`!C'`OD4-W'VW$I=@`"IE$>HE(
M4/;[QZ^_0^&B*P@^10RWM3*0R:/N[NX?S%0^TINT"E^X!'V#K6E$!JO&GZL1
M4?U!A(ZK@Y!+!WH$BE(X6`%1=T<P"*;<JZFZ:A$_84O\[M[3$'7V_P#9L^7/
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MB27:7)P'&OVKTZH<K8L08\L%[XYTEIF?,[S-T+6'E1?URX336ZQID`3]`%FG
M'P1N*W?R]?URC]PB*"`H^E1-VF,`_*,Z&)WOOD>W^IKYPNRPQ9R$Q*`-HN[[
M8C\\.T0(^8N_!>\[>#BXIO8,8W,F5T`^4R>+:?[I'%V3)<KPA[3A"%R-=9=.
MC93MO&^UR%Y70Q[>Z6@Q$C2.1"'98_2D5F0`F[=$9*KJHHMC]XO$@_,W/[WT
M;*_A]_EVSM\#D=GM]TA&V.K;F[@G<;C5\L=VT5_"=%P=VA;O6[=ZXPRY6?-Y
M3'C0`?9]J8NS+OI^Z<0%+'.*RZTKA?&-XM-;+5[&W=U.<L5+4>RU]E.QWZ[(
M,B`P327*+;L9,T&Y4Q*4/.)NPXVS%[9WR6/#:(9MZS;GOCYX"XPL1X6HG=*%
M:DFG!O7Y`'S&.":].,C0^61%2?YBP=Q[.:9R]H*'L&96LH/RU,V19"S(V0@E
M60<V]**A&SK&TN_1150M<O7(^<="VD68^)=4KI3\UL;9/WW9S&W8P+EH;I?*
MB!AQ%K<2+XJ\!*40#&569VEKZ_(<7;@9MTC+P>GE]H\/'@4^6(14:5#A^2.F
MB1;=7ZA\&FJ0SB89I/VH5&@BM$*H,F*Q'HN#E*FFFY%`"JE*(B;<1+Z3O4A+
M-[T9Q,I?Z=-:%OS;C&II[G7L\)S9L/K\]'[HKZQ0_P`(_P!\=?E0KZ<JZ(C1
M$:(D<A'1\LQ=Q<JQ9R<:_;JM'\=(-D7K%ZU7(*:[9VT<D4;N6ZR9A*<ARF*8
M!V$-M$38,,!X2B<9$PM$8FQ[#XC27?NFV-8BI0D726#J2L#NV/'496X]FWBH
MQRI9WRL@51NDD=-X<5B"538VBKEWXK?5;%F-*/%2$'3J!3:Q#RS%C%RT7!5N
M(C&,I&QL86%CV$DV:-$DG[-G$E].FFJ!R%2,8H!L8VY1RM30\'X=Q>1N3'F,
MJ131:O9:1:JP%<C(]RW>SC6-82RZ#M%N#E(SZ-A634X%.!?2LT$0`$D4R%*D
MDZK&C@?![>V/;XAAO%:5YDIYM:9"Y)X^J1;4]LS,"`TL+JPA$!++S;7QE\;H
MRPKD$-P,`Z(YT2>\<?<%9-L"-JR-A[&E]L3>,+#I2]QI5>LCPL8FJLL@T,I,
M1[P%"-%'*PH"8!,@"ZH)B4%5`,0$C1=;/8[H-I0;M;+2JK8&C6OS-4;LYJ`B
MY-DE5[$G&)3U=(S>M5FP0<RE"LRN6O9X%BM4@,40(78HL$%C''-8IK?'=?HM
M3B:&U!0$:>S@(Q.N`*STTFNH>(],+)9=Q)G,Y44.0QU'!A4,(G$3:*N27XK5
M6&BU^(H-_BJ75Z[7W,Y4I]F*,'74FB3UV>&D6[$';&O(-7TD"2KHP%32'S"!
MS%3$#&T3BO$?Z/F-GN,[W;`R;QYBL>9(?8JHM$J-^KW$?,V+9"4J](?VN6LJ
M>0<KVOC)Q\I0NI16Q1*#.-(@J[?*12CI5110P%(7)<+^Q>Q'*&EV+(N"K[1:
MU6VEO=VEK$0TK6G,FO#KS%2=V&))=FD+((V2GHHV<]0]:,4#J48,5)$$2.EB
MMC*[EQBAJHX\3^/UVQ7&9Q:S&(,7TB$RA%H2==K[:0GWE@=J)3.3JU"4S,\H
MKD+)L/8YB(Q<UJI7\Q%&*1PY?/4`%T1J@IHJ2Z9?B'QES]C[+-=MV4:7&.8&
M+'LCI*X3#63NF-BQ.+W53:0%!FXC+>2'4EC:/>V1[%5Z.DS'5&*6>/7Q6<@1
M#UY61!%$JMG'+/4CFBP/V%4L2M"ELZ1UU+C]O;HQ#C#8(`;M$V9Y>;K%*9M8
MY'+D504%)=TV95-2'5LJ*8G:NT#*NE(@(;Q9.UREPQG:ZY6):\&T;#T\X>8A
M>46XS7(B%K=MIJE>=R\NZ-5\61#9F]N$1?Y+UISR:LJ):<^:@R*Z;/5F^R%4
M!#,>:=+(D#R$@\087KW'1%Q$Y%@F]4BG*627=%6H,;#QE9(TE6V:T(!%:7F&
M28H`DFG1#MG1I;Q&372C@7$2!GKHG7P*CF)"@)DSRY;.\G?/)P9Y>&"")3CD
M%Z;T(X^2B4491O10:=OR].<[Y\I.X'RBBFQQ*%GIHGGT41HB;F^R0,)?%J(V
M62K_`,UR,G&@S81@R*-K$:1=WWZ:E%O(3Y3&F!CZX76QMEV*26WYNX=C[#C'
M(Q.Z3&-;R.EVXSW3GL-C]3C1ZT`QZD_-TME/+=E)_*QZ7ZMS1B=Q[#;.=?P_
MF.]"WLMVNH,K]%FS^6NEQTK9V=?JU\]B%MOS'#C:ZXNZ+YU/J/N&/_;-NS5=
MCXW9^&$6JG)_,7(&59%S%&^1FC%IH'9G7!P`"594Y%""(=@;`.OT3^W`NQ]&
M8]R,GA_73Y=HU^6E7<[Z<`/:NA>HV^?F#I\N/^<*$$=7U%:W5$(IZ#)&VVUK
M9[C/,>^13KN+<<`Z=N)F7C&;Z*G21$S+14DDR,W,Y))24/Z0$ECB42]POYXE
ME7^J\CCV3;M1--]^^P$8D@Q>`E'<[;8R,G"Z];MD6X1DP$RY\(A]??\`<I/8
M^`S,\MR!@R)1%XR%*29*C,14DRD:OC^EP-H,K$T>%*^K<>^6M\]76;0)X9#<
M6R+TY?2@X55=&ZCGQNRMQ]-Y+'MV)$=6)#3O7)P\UP@3(V0D3TMNIB#N8"*]
ME;G&W'YN#B_</E/"`!I%R/B(;=X'1RZQ6##>8J),_P!N/'FD$R1#&F$+:3'5
M.G(NI73&ER>O7UJLS&+]4S1;WBAR;AZK+,A(U<RD0Z[D.P6J8&"XO>^Q=QQX
M]A]47ABY&SI]:Y$W+=ZW$"-LR:MN[$`0)I&0K217-<P\C><[`CN(+TUA+4@#
M\4>-/8=%M;O<^;/+![`4J6XU9(JT9&P\<^-8<SVMG4J=&3DK7Y4AGTPBA$PD
MO,UE:0$QR!'F6?RK6/$"H%.8X$F)@>A?24;F=_5,7(O2N2`ACP-RY*WN#"-3
M&%QJ/+RQ,JDA>1D6^[=U,;%RW,6X@.22VGQ%P*'EX+;EH,74ZT;!3IP>^564
M83;N\.HEA&UR5RED^V)-"N[Q'M48-TA!RU?D(ED:`:)H2#9-%D4BZ*XJ+";P
MSW*_G91[_;`QLV$H"T"3.-BQ;=K<CN#QF#+JEP3N+&(`7%,6[`^1&ZY:8F0C
M\4R:.!_NL-OLT4:["U/7Y>L5P[IO+QF%;G9L?Y%7CW@']=A6\M6+&`M=VDW:
M\358A_2JY$O6$^5%*56CEFC58WB%9+L[7BR%ZQ>S!`VIY]B%ZRX80R;))G"U
M$;IRC=D8RM'RB>Z8#L7\&]TX&W:-1:)@2_X9:$^RH/(A/]P'B&U<Y<M84QB*
MNXFLWF,=$14W)W-D(\B+M(X]@'3?-U4')#$^!9!=)0!.0Y1UZ7U_E7,ST;\S
M^"=VT:Z@G?Y?;$@@O5P:`KR.Q1-OO>V7QQA-_'2H\*KW445,DLJ5P(!^:?M<
M`&R9OB'8%/<D?[_PC[MO9K\]`4#<E],EJK?&9,>Y'M$IA[C(&'8HB/7N2-L(
M)"81W$.I1^[VZK\T\%88Z*@E\G<W5+OV"<024+N&QNQ3^;.4VW4`$P#[PU:\
M*A17AZ@H?\6N4?8/\R<0'[>ADC?M#MU**_<L6Q0_XERB(^WPB42C]_8FH=,1
M_P"#J_:HCN/UV%YT'V&;)AO]X"!2[A]XZ4\%4U>3<=S-U<T2P5JVJ4FZ8VLD
MK9:I//ZY&VJ&*K/4VQT.<8S%;6EH)1^@ZK]H<"BHD];+MG*:9@,=,5458P5"
MAQ</IY5RTM)Q)GEV:@I.VOYB4NLTPHM86?6N7DEIY:/GGR$$I6V,;8*JK.F-
M%+LRMTF942I$2!N8R`S9[?N3=]2VK;Z=V,#'9O+'/O[8_2GQG7\I:J_#.',R
M`6#$$LG%O^]VY568)1.*W$24AC"'R^R2)-ME5"K-HT=RKO*Y=I]-J!4DI9_,
MYHN-F2D:T6`:-'%1AF3=G(L:;<ZA6+B[7"9,G*V^G_K'U4<_!))RFM'MC&.9
M8#+ZNT<4WI[<@\2(#(F8T<KV"SIK>"UT*Z$K*%7CY!\I*T)U1%V$&[LL@[66
M5HQU:&F_0B_2I^BGG[F1(X,<P):K`G=5O%0$LR;V^\`*9>[5E.X!<[#2IS)D
M](3:,]5:Y$MK75TYR,L#&S1S2RM9`\D^0M"UA,#XYC('<-$$FZG?V^74,07K
M_!!)@MG<>#\-;L:XKQPIDYTP2QLQRG&'E3UR=6"18Y8DF4I*H0L<7(L>,`G6
M%V)"0[5\XG(A%$I4W+%RD0J8&+,-%=Y"XR<^G<VFW31=/.=ACDVE@:3Q#QE6
MC6TJ^>1MC9V)M9I6:;SC9Z_R;,$15CYR?W23F(]1(AV29VR)PFWQ*;O!/AA3
MB36<'9%>7JLRQ56AZ"M0(Z$0K<9&2+1@]4QRY=_,+2WDU',O%LGF.B'BX\6R
M*<<61=%%181*?0``\/J4)>A4LP*M_P`D]ZC[/5(AL&_M``5]G76G'@HJ&(?V
MBDL/^6],7V^W<"'$!_NZ4^@16=I"#U*R3'<>JB@JG_\`*`@[_OT^M%D\G=L`
M.%3^[M:H&`.O^/VJ#M_P@TT17$()3=R;<"&V_G7"G<?_`,D55.O[0T+**\4C
M'W\JIC@/_%D#Q)_O[1%0_M]YMONU';1592E*4`*4`*4/84H`!0_8```!J**N
MB(T1&B(T1&B(T17IJ*)&`Z1SIG+[#IF,0P;]!V,40$-PT11VN_$KC'D6:6L]
MMP5CES;'!Q4<7."@_P!#WAPJ([^9Q=Z$O6+:X6WZ]QWIC;^_48*N0N7_`.Q5
M@8"^(ILYE9[;?+2\M.5Y8SLVV\?H@S5XO'MT[?9MJ;0FX^'U+I*;Q$XOT&:0
ML]:P3CO]6-3E5;7*SPZF0KLV6*.Y5VMTR(YM=I:K@/7O2>$-O[]5@$<Z/12-
M.HHJ;O4.=0X@`=QS"8VP!L`;F$1V`/9JJ*S1$:(C1$:(C1$:(F6Y&5*YWS!V
M2*=CQ=5O=)^'CVD$HA+A`K'.A8X1_)-DI@[R/39'>PK-R@`G<()J>3QG4(0Y
MC!#I354:J.&`('D]CNP'IUR&6GL?5&B6:WH19%(N2F7]FLN1;DWHN+F-NGW:
M-<>FAL?BVDGJ;.<7:0[M-!CZH6IT@,!EQ5+$*2YL@7DXAYN/V25.T.BB=FPD
M0X;?8!LM=Y=_N/K0/M4HK/[1KN0=O["LJI![!!Q.X3.3;[CCE@!$/O[]->":
M\5C'(=T4$1_L#OZP]-Q+9<))*#^W;+2I@ZZM?$*L.85X7^\[_P#PO^42A]I+
MAA7M]P]"CEH`]_V:C_6E%E&^WD?_`/0N6/M#_P!VO"6X_=M_:W[-'/)44]BT
MSW+\S'MG+Y_B.[LV#/R>M>/\CX`CV+/PN7#-;U;M?,J;=KX7K-9$_><O:LBH
M0=CD,`-RA'UI$;-3L(U*;/BJ?"$6`IT)E;*7'U2'6(==NV(9&3',PQRQ#N7:
M28"500%14A?Q'*`W=3C]B,DCG.B34CUR[QU)1Y8MT>/DG8Y(XZ(?*GR9R)JL
M9%R?-J9&3U-0Y2F16[3E,8`$NX[:.?%E`$,\YN)=XA&L,<66>>.G+EJT8,<D
M\<SR"[Q@0BK]HS;,LSBY=NV*)RG633+Y4B&`3``"&C@>'VJLKE<V.FZ;Q8^+
M9UNU8/#1[Y:7R/QY,@R?D<),SL'3M3,P%:/B/'":(HJJBH550I!*!C%`3_0*
M,E[G+D\S:G=O\47:/9E(LHJN>\\?2Q:::!7RBYU7#G,8^-)%.+=&4'O("96J
MPCMX5.UN\$;Q6O)FP"QR$X3&DX6&=&\;2=1REQT-$O%!,D4$F[USFD\<LJ)U
MR`!2*F$14*'\8N[<5H46SCLO34HH^2B,07*46BW0L95.,NV!UEHQ^7N[F,I\
MLS&X(P>AV#NDL4B@;#TZ#I4\#]A4*W),A7LP;EP-E+[NRS8)<=/<(&-E8-O[
M^H_@E$&R+>@WWP)EG_@36#3#]G3?*Y@_\6@]@450R#=3[]_'_+"@?8M8\)%3
MW^\H9;33-^\!T<A%UM8LEEGE7B,MCFS4)%HBB=LZLDG0Y-*1,H<Q3H,D*7<+
M*JBHW*4#&%P"*8@8.T3#N`-?:C<EUI3(IG$>\5U]NT>T`55V]HE*1,.Q(NX=
M0V*'VZM=."*[QG7_`)P/&F.WY`#W**;C[%3E^$";>TI?;[Q]VIIIJE4'5WW(
MW`IC!N`FV_)2V#V&$-@,8H?Q`Z_;MJ@5JFE5Y#?5"226MF"T#'3,Y&$N+9N4
MQ#J*/G+R0I2#=$R:!%#JK+O%T4442E-Y%%"`!1,(:^S?M-.5O'[A*):.ZT2>
M0$;A)JW`%]*+H/JZM^Q1Y-(-Q-0]%!TJCRF3]B6CW,*A&P-*CL,8X=SSY4:?
M*90LDLUE[3;D+##GDX\K.@RD;-GD%9"/3*G)-6K$7('.EV=YD;?<<2T+D)RO
M7<B65>C$#J1Q[<3&%O;+:7N@VP!&58&4VH5Z6)&/.6_;MC$0B3IND7,J<(U^
MQ2BB*!6*I`KX!(TE&^.+(TDX>^H3ZD*K9[#,/I%"<BLI*C\C!BVEZ\M%QIH5
MNDW\/IFH`X5=BHNJ;J.1W#.R,F/J0RA+NL)QE9$-W3A&(,967W/ME$R%PN^X
MO':P"]C&,82^2MB0QY!I.:R-#NT=Q3:W#FM#3$N87$NXQRU8P]=,U0%F*U9O
MLD8.DHM5O:8I=Q.2,>^+C99C+R=<M$M&BD[?1:I&;+UC-4S50Z`@)?+S3Z,]
M8XD[=_.L=OS+7PVLF-82:(D.L"!.V""(&LF(W!W3&QN[=NO[K(G*S*@,&\].
M(`.TC[6]ZTW]FG(OE)-/LCY[QW+84I;U9$MP=W^Q1MAN-MJI6+N)_1U'K98Y
MJ>)<VI1$[!W.2$>F$='H&%F*C@-@YI]V]->D[4>U^FLBWW#N(!,.G$PA"Y0]
M6Y-SN$?BC",JFA:*S<PL[.OG+S]UK%B0Y)+EN$1X\UO,FPSC)D-(V)1)K&7/
M%X2EIQM)INHV)J%#AJ_$M4(?'EJ!U!KD_LZF58QNDD<0;.D7CDX*"[25.U'Q
M.U7_`.EW8XUM[F!F;;=^+$SN3G(F5Z'F'YT22>(,`&$2'6;\OFA*=VDHO*$A
MI&,?PG_=8!N4GU4;Y9-K:Y7)$NW;&_1UTCX[,6-C+K.4(UC(PB3B+O\`1H;Y
MVJK/S$Q"1K*1<N"%CX\IXV%3?BD<BJ9B]MQ92[?9Q;1.W,QYRQLC0DQ)W6;L
MMOEC$DQB"92\TS!P0O`O0MW^I.W\):40_%O,*U?5_8Z[/'RT<UK_``Z(#<TH
M1;ZB-?0CSI29F)4WI:G03)/3H@R=(R:#1L!Q`BRB8E3,42F$VP%\;N0O2RN]
M$D1/^G)$^5W'5N4U#/S`/]O/@#=8L'0?/#[H47U=Z_*P+OX%?4$:J(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1-S?9+Y?+XM1_4K
M^O\`S7(R<;Z-E%?,DK5O2+N^_34DOWD^3L#>A]=ZKXMEF*:6WYNX=C[#C?,8
MG=)_+6\CI=M,]TI[#8_4XT>M`-^9/S=+93RW93?R+I?JW-^3[CV&W\[>P_F.
M]"WLA:Z@ROT6;/Y:Y)QT;9V=?JU\]B%MOS'#C:ZXNZ+YW_J,-SN^8E_:/)0%
M*\IPR8.)&`1F6*;M59KE5B91RK7G*#H).+=,1%NNHJGVB4PI%,43"8OZ#_;S
M;'T=CRA#]1_7*3VEA^GE^,$,06(;VEPNB]__`/<;CG_\>+?][A7AJH<-[M`'
M3O,K;H%G)XWNYH:K5Q]$)LRVFCJU).%FJY7H]RXDZX^8.G]1&=[/4/71%)$6
MJH'6'U`*]JO=NR(RQ[?;KNSO./ON2W/T[O4W1G/X9B33-NHC%H[@6HWHQ<MS
MA*5R.['.T4X$&C5#N`7T<\TN@K8^P<[<1#2&ALJXAN;Z'4CAA7*[:1D5D(%=
MK'O(1,BCZ=H&0#P+9DW592'J4'J"B*91>)HIK%Q=Q;?J*(NFY/#[[CQD);@-
ML2[D2=HW+1D9$2BQB=Q\KD+42,5X-U<:X07<Z^`#F);@:%AJG2N647BU9)2Q
MN26!\8&<-E9VJS%UJY\K9$=/&\8K!24A5()TX<T>MQ5=EWA$6#YTFJX,`N7+
M4RI$D"^CP^S2EE'+^7_J7=""(W(6YC'L")(DTY`"[,R`)E$$#X06+KR+N1+Y
M88PN&SBDU!(,YOQ8?"&T!^IURM8NCZCV^`F<>\HX2.OHLXY&+=69ZRBJR^K+
MEK&Q\9!R/J%Y5HI6G7KDE8?U:)NQN*7G18+)=FO/R<"'<L6[;[AVB9[<#)S`
M&5R,@293B!M.X?C8ZOM,P76+5WY>]&YBY0%PQ_%4,^CGZJZ<@RW=BSO(0[N!
M''^('=?N]S*U&$F).S1M\K$9\^CW80"&,;%5G3R"MCA`BY5FTP\4*>.9"AZA
MJBX`ZH>/@^GK>59E_4<ZW=[78B#*,82M3D(ECUHW&G"H8PB/.06D062_D0M7
M=V+;/7G(,9$$!Q^$@M(\B=*4=-75&M3H'IXA@PA;[EZ\5HT+$0+55I/U2NJV
MLM;4KJ3F77LB<3,6!K7999^_=-XYTR1D9*,1!=8&*ZNO:95[-[N8Y,C+&]/8
M]S=*9!C<GLW.1';NC$RB(1B9"1$9EGD`N*S;M8[V[D1<R9T85B':CNQ(U<4!
M:M"I-?3^>,Y?DKCO=TSD+-4\6V^MR4\P,BDRFJ^P<&&M@^%"/9`])#,)0J"'
MB(V;D*HB4WJ#I(G)Z#U_:-CTSDR@_P`ID9=NY$$%X2-9L'.TR()+N=='(7L>
MPS%SN5LCXH6Y!^8J!7C2GN')>WZJC@JBH'**Q?*<.],0`PAW&`>Y(YMA_<8=
M_LU\$`##A1?22![TG`R8#LFN=L(B(^,PBF41]O\`,K;$#_@[:UPT!499NYR)
M=A%)8!VWV$R8&_=LL4?;J,-=$6+LV$1%L8H^_P`2P%W']QD?9]^@IQ2B`%01
M$/$[#J&PBZ`=PZ[[;.3"&K1GI]7]R,$""@!\1%0+ON(JO%-@W]_0QNFC#Z!&
M"Q]Q2C[6A1]OL,X.([]!Z]IA_@'1J)17^14W0#O#A]A"E;)_9MU!-00_>.GE
M\$8*I2*;]Q2(HC_+-W.%O;[S&[`#8/O'0F/M1EE\8F_G5550_DF/VD$/L[$P
M*`_OWUE^0"+('PAVE^$H?Q2_"'\`;!K**O<;^4;^$=$8)"^EH^,!,9&1:L2K
M"8$A=N2(`J).WO`G>8.X2@8-_LWU1%ZJ$QCJM8-HJP[[ST(._MW>M1W_`(3#
MJ[2L[X<PK/U+5/\`V\A`_8];%]O3W'#1BF^',*GZCJ?;V_/87M]FWKV^VW_O
MS58IOM\PJ_J6J?\`M["#^UZV'[O><?LU-I3?#F%D"TU<OX9^%+_DO6Q?[Q@T
MVE7?#F%=^K*W_O%$_P#N00_I--JF^',(_5E;_P!XHG_W((?TFFU-\.81^K*W
M_O%$_P#N00_I--J;X<PC]65O_>*)_P#<@A_2:;4WPYA'ZLK?^\43_P"Y!#^D
MTVIOAS"/U96_]XHG_P!R"'])IM3?#F%3]6UK_>.(_P#<@A_2:;%=T.85?U96
MO]XHGI[?]H(?_IZ;"CQ\%3]65K_>*)_]R"'7]GQ]?9IL*;H^"/U;6O\`>.(_
M]R*'])IL*;H#4A5_5E:_WBB/_<BA]@C_`,I]@:;4W0\%3]65K_>*)]NW_L@A
M[?L_'[>NFPINCX*OZLK7^\41_P"Y%#^D^[3:FZ'@J?JVM?[QQ/LW_P#9!#V?
M;_.>S384W0'$*OZLK7L_443N.VW^T$.N_LV^/WZ;4W0YA'ZLK7^\43T_^."'
M[?\`E--B;H<PJ?JRM>S]11._LV^8(>W?;;\?VZ;"AE`:D(_5E:_WCB/_`'(H
M?TFFQ-T#H0J_JRM_[Q1/_N00_I--B;H^"/U96_\`>*)^S_V00]OMV_'[=-A3
M='P1^K*W_O%$_P#N00_I--J;H#4A'ZLK?^\43_[D$/Z33:IOAS"/U96_]XHG
M_P!R"'])IM3?#F$?JRM_[Q1/_N00_I--J;X<PC]65O\`WBB?_<BA_2:;4WPY
MA6C:JP;\5@AC?Y3YL;^^<=-I3?#F%C_4M4_]O(3]SUJ`_;[C?;IM*;X<P@++
M5B`(IS\*F?J8A_6M3]BGM*IV'.)#]IMAV,`@.VP]-5BF^',*(<#Q9PQ73*M6
M>3[$^KS]4S^=KMAE*M8&\U-G;3ZRTPI(R,.I),CO[5;)2<=MTC@V<R+]3<A4
MO@'.P^*UU(<PE#GB]@X)!C-0UW=0LU&A-$9KF=5R>@DT9^L05.D4AI-@8OZ:
M3:`A.U(Z+)%0CM<7)Q4422[9T_:G5AS"T,9PJPH@9NPI>0+(V$8X8V5CI!U7
M;\WL<%^I%+))PDRUL\>^6&ORXG*V?,VBC5LLCYC=A5';PZ[IT=43C(L"$X50
MXBU.GRE5?MK?/O&]4G"3C9@M"5A%1VJUO,)D:.;A*^A7DH-)K:*^@*@Q1V'J
M&(G:F`J9S;YVA5USQN$-&*^EI5G>[K'R;]>T&CU&S&I?+8%M;V;B-FDHZ%&$
M]"1XJP>KBDY)XA;O#E<H$2.42G;0JZ3PW`W%<#)QTG&W#)R989XPFX>+5FH9
M6&8VQ&8GI*9M*D<:!!N_>6YI;)=I*-5@,P7)+OE2()KNUCFK!'6PGN$N-K&V
MC8>6G[:K581D",)7(EQ%U<8R16QW5,:2DRC.0$<TF%5Y*$I$:N+<RA6B;LBP
MB0Z+@Z(:$8'5PH_UIW\+X<C,(04Q7H&9F9./EIM].E!\QC$/1+R#U_(.FR*,
M64K0K4'$@<$DT4&R2*12E*3VB.@(CDRAJG@$Y3#U,U$W_I$C(*?MW'<?VCMK
M34=&"R`4XA\)#&`>FZ+U7^^(EU&`_P!B40;R`'\T[-U#H#K;IMU'<S@O3?\`
M?JL/#ZO[D8($NX[^G4-[A\JP&_?U45`=34:A&"R;N"AL4J2)0_QCF``#V_"4
MJ)?9]^H`.-46,3E'HJZ,L(AU2(.Q1_:DB(F,'^4(AJB@T9&"R`HJ.Q4DQ3*'
M0!5^`H!_BI%$3#O]_9J,'<ET7EG]1R285N[X.LCH#JS#&GY20JSTY$1CX:QO
M6E=CV<T)0:KN&\A%!)@8JI15(F59,5$5A*EX_J_[8V+F9C9V)&EF5RP9C^:V
M#(RAP!!;2CL6(J_2/5$A9RK-W5A-O;1C[BO/A)"L6:*I&+[6A`UG(D-'+EJE
MI1;MR5:XHV<:V[I#BSO(2;:B@SL8/W#!60)$.BL5G\0Y5*)6CD`^A3GG865D
M=Y[:97>U3E^;:+]2WLW"X("43\(B)".\$M<`^**ZV86+\(6+HV9`!VD?"1*L
M=VNM02W+D5VU`RK)%-!XTNV+IVVR]:B(%K4)FD/X,M@+&%1<.JLWL4P^>HT"
M6@U8#TS=C-'=((1Y@(55=4I?&'!W'M-L"7=>TYENSCW9RE<A=B=FX?XFV`'5
MC,2>1MB),JL`ZY+&5/>+%^R978!A*,JB/_$?*1P$N`XK86K)$CD.RP#BT\@(
M.M/VC.,/C*B8ZN$3=6F.(11O'OH^M1<TW?04-.W;Y7*)MBR"JR15U4RJN'I"
MD*F/AXG:8=LPY'"[7=OP)EUKUZ$K9O%R)2$")2C;<$[6<.PB7=<V3>NY%V(N
MWA`CX8QEN$.0!H">9^LT6;'>2G=88RE1JN4J[F#'\X\:HRF+"WJO4NR+V=1W
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MZRBAA,0`\+,C<M7.[X^;$W;]KTWM$MIE7J3:1EP`%'H!H`O-QQ#IV6!`^?#>
MUH_9_L*^IP/_`!_W]?F%?2D:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(
MC1$:(C1$:(C1$:(C1$W-]DOE\OBU']2/Z_\`-<C)QOHV45\R2M6](N[[]-R*
M_>3Y.P-Z'UPNOBV68II;?F[AV/L.-\QB=TG\M;R.EVTSW2GL-C]3C1ZT`WYD
MO-TME/+=E-_(NE^K<WY/N/8;?SMW#^8[T+>R%KJ#*_19T_EKDG'1MG9U^K7S
MV(6V_,<.-KKB[HO%WF5Q5S5F;E7:K30:%(/H&;XQ,,?H7"0ML!`4I6P-,B-[
M(6#DV9Q<V1>2:MVQETEB(^EZ@01W,)B_8_1_J_LW9/2EG$SLB$<FWW8WNF(2
ME<V&R8;@:19RS._%=2[QVS/S<^1QX`VS8`!.F[<#J_(<DP%5X,<NZ@TD(PV+
MJ#:(]T#%!^R>Y!B4XZ?/%O4I9G(+@T&.DT/3/F"9D54U6SSO,`#\)E-O=9_K
MKTEW"0NV\K*M78R)B1:.Z#C;(.YB1*)+@@B@\%ZJ/8>[VI&4K-N0(J-PVGB*
M4J"'!U2IIP?YE,*X6HH1S9CC<[R(7@JJSL57M-LHZ<77OEX),7\K8:G&F;39
M%#LGP%4,@CV%6!H\,(&)QW?6GHNYD#,@)GNL7W3E&487=TG)D(B1>#;HAJNV
MZ*Y+?9>]1L[)@=)Z1<$QIP=M=#4^Q+V_`7,4'%.D*=QWI<0_20(9L\G[W7+[
M-N2OW$VNK%GF;9(R*`!&GL+PJKH6Z*ZJ#@R?D5]W$?7O:\B_N[CGWYV^4+<K
M40PB'$(;6^&+!R'#L%N78\\#\NQ`'F9"1^LK.RX)YM:J.FK+C[3VD`\2F)&6
MA9JY5*Q#+S,TH[7>MFDB_D7<S"MFK5^=M'&;.FXM%#JJ=WD.+@\/KKLLANN=
MPO\`S((C"4;<H;8Q9B8Q`C(E@9B0+TU`99M=B[A"3PL6Q!]#(%^8\&X+"RX,
M\EZG-IS.)<91F-IMRJY>"1W=8&U4M"7>Q[EBQGB)OK>9]5G%'1\/H&B$?,MW
M1TRJ'%)P0CG2YZZ]/9]GY;OM^YE6&`W1@;=S:"Y@6B!<%PZR,H&-=067)_1.
MYVYB6+&%N7M!`-:U--KTH:U2*,X0<NH?Y@(8YK$W;9AN9C8\DR62HY25DD7+
M=I'>*,0=KN4HF.6A(&/0=%`CAX3M%%)R9N4-^6]ZS](9`A$7\BW@6R-E@6R1
MJ9$S(;<1.4B'+<6<KQ_Z'WD2,1"))INW#<VE/XT=/)Q!X8<B,19R9Y'N];K$
M365*G8XI=C'6R/E9%@ZDEV!4(\K-B@1LJT=J,DW)E2+")3)`)@$3"4OJO5WK
M;T_WKL'],P;EZ63UXR>4-H(&ZKF1((=@&XKSNS]DS\',%^[&`M["/B<_=]J]
M0E:Q.B<XA'J"`J*F`0.CU`QA$!_G/>&ODO5@*DT8+O1E$C58QJ\Z(;#'*"'V
M"=`0_@\F@OVQ^(++CFL8U&7'VQ(_N%`HC^\J@#J_,0_F"41^DIGW1BP?L7*'
M]Y?3YB'\P5<(_2,R/MC%3?Y2Q1_OKZ?,0_F"E.:/TE,?^U(_O].(_P`(J".G
MS$/Y@E%E"L3I0V+'*E#[`.@`?P`IJ=>W_,$<<T?IB>_]KE?\]'^ETZUK^8(X
MYH_3$]_[7*_YZ/\`2Z=:U_,$<<T?IB>_]KE?\]'^ETZUK^8(XYH_3$]_[7*_
MYZ/]+IUK7\P1QS1^F)[_`-KE?\]'^ETZUK^8(XYIK<GXWNLZA#%B8%=Z+95Z
M9<".&28I@LFW!,1\SE/?N$@^S?3J0D-5Q78[V8BB:'^Q3*'^Z;K_`*;%?]?U
MG?!<?2/,(_L4RA_NFZ_Z;%?]?TWP3I'F$?V*90_W3=?]-BO^OZ;X)TCS"/[%
M,H?[INO^FQ7_`%_3?!.D>81_8IE#_=-U_P!-BO\`K^F^"=(\PC^Q3*'^Z;K_
M`*;%?]?TWP3I'F$?V*90_P!TW7_38K_K^F^"=(\PC^Q3*'^Z;K_IL5_U_3?!
M.D>81_8IE#_=-U_TV*_Z_IO@G2/,(_L4RA_NFZ_Z;%?]?TWP3I'F$?V*90_W
M3=?]-BO^OZ;X)TCS"W3;%&246Z:1Z4]4430=(%5*^AB>,%P[B*%+ZT?(J0_\
M<>TP!TW$`#5ZD%J,#'DC^R;(P]_=2'9^YJFB0IGL)V(G(B=$03V==PHF%43C
MN/=W``??IU(!:V^(5KO$^2G"JRJ5(<-S*^E$FSZ'-X3-EU%C&`WJP,/F*<"^
M_8``/P@`:"Y#BAB_)876),GNB."_HM8AEGIW)5/5P_D(@;N$K/<KLH>-,P@(
M;;>SV:&Y!243(:C59H[$V1V9D!7HBSLB8."*E,]A@%4KA5JH`@8SL_8HB5`P
M%-U$!-TZ;@(W(*0@8ZL@^)\F"B"9*:\*86(LSF%Y"E+_`#B)B*%(5X8"G(FF
M8!,7M,;NZAN`B+J06MOL2T^+LA*+'6-0%P,)RB0@/H82@3R@)P.877>.R1?A
M#J`".WL``UD3B"H(5<LM>7$V3R"0HT]VLD202>&\KR$`ZQ$R@4R2G8Y`H>40
MW'VAU]@CU'74@I*V_$):RQ;D1L#<%J"LZ*FEX5"&>PP`)-TA$R)A=&,5104^
MXPFW'N]G01WR9Q)<*"VVK+5N\/9,<>F$M-=`=%$J2HF>PY4U1(.Q`*FF]V('
M:&PF``$PCOL`[[ZZD.:=,N[A;)?%>156[M$M#<=RY!!%8SR#!1`_D,8H`)'`
M=R9$3BF!>G0I1]H:=2/-:E`D,&=8F&*<D-$4D5**NN*;@[@51?1'>;N*0@)[
M&>&`.WM[@'<!WZ;@`CJ=2*0CM#%E1#%&24B@4U'<F,*3Q,ZP/(7RF%8P^F4#
M=V':HW*8VX[_`!"(?9UO4@KM]BR?V59'%N1$U'=%[8_T9Q3>PPF5."*105%4
M[P%$MU4^X0*`@.X[@(F$=.I!&IP6OD,/9,>.U7"=/=I%4'<$Q>Q.R8>Y,FTA
MMV$]@>S]FG4@RS*!)H0D/]BF4/\`=-U_TV*_Z_J;X+/2/,(_L4RA_NFZ_P"F
MQ7_7]-\$Z1YA']BF4/\`=-U_TV*_Z_IO@G2/,(_L4RA_NFZ_Z;%?]?TWP3I'
MF$?V*90_W3=?]-BO^OZ;X)TCS"/[%,H?[INO^FQ7_7]-\$Z1YA']BF4/]TW7
M_38K_K^F^"=(\PC^Q3*'^Z;K_IL5_P!?TWP3I'F$?V*90_W3=?\`38K_`*_I
MO@G2/,+M\>XIR!#65)])5MRU:E8ODC+&=1QP!15,I4R]J3Q0_P`0A]FMPN0#
M^Y:MP,9.2&3]#6)W?_V.5_ST?Z74ZML4)#KG#<U3],3W_M<K_GH_TNG6M?S!
M''-'Z8GO_:Y7_/1_I=.M:_F"..:/TQ/?^URO^>C_`$NG6M?S!''-'Z8GO_:Y
M7_/1_I=.M:_F"..:!K$\(;#'*B'V"=$0_@%33KV_Y@E.:Q#4I@?;$C^W^K`/
M\('Z:OS$/Y@E$?I*8#V1:I?O*L0O]Y<`T^8A_,$HC])37OC5Q_:N4?[@KB&G
MS$/Y@CA4_2,N'_\`23#^T4#?^<H.VGS$/Y@CA90J\X4-BQJA0^P#(`'\`*:&
M_;.L@E.:J%7GO_:Y7_/1_I=!>M/J$)"@#SBXEYMSO-XME<=5^O/$:=#6AO+A
M-V=I#N%SRB\`Y1C6S%PT<MG8/!BOC4.JF3=,A3;``&#Z-Z#]6=F].V<NWW.=
MV)OFWMV1?X=P))<,S^)U74^_]IR^XWK5S%$2("3N6U(/*JBJ?A!RR<Q,-"R6
M(JDLK"JE<U>PL\HQC"8J$CZMG.QYF3QB4Q5(MK88=DJY!5NX.F)#':&(IUUV
ML>M?2<<B61:RLC9,-<@;1VW(F)C)P=),2`00^AHO3_T7N\;8ATX&0-#N'EX^
M\)6_X*\J[;\LC\OUI#(A8N*CHMNK`W&`J#.62C%';J`F['84K6>74F:D`H,R
M,4XQ9)\@B'J'RR9$D2\$?7/I3!,KO89SQIW)2D\X&X8;J3A"!CMVW*RW[@8F
M@@#5<DNR]VN$=>(F1%J2`!`%"3JXT9J\TJDN!N:7C9&(+QUHS*J2C9^WEX2!
MME4BI5@"R[TS=TWM"\J[L1W:3E^H=$GK5VZ3)51`R9DA!N.;7KSM-M[Y[CD2
MSHD&,IPE(<*&)&QB!7R@DL14.LR[%G.UNS$0(-!(!CX'59EN">;)MFY:V7CU
M1G[1\[?M8]LE;JK%RU6BW;:9;-#-++$R3>2?`TC9MRB/K%'ZA'3E1QVJG,*F
MLR]=]JQY"Y@]QR(W0`3Y)R$RX)>$@8CS1B?*(@Q&V@HH.P]PD\;V/:,.#$`C
MWC7WO6M5K6W"7F7'LGL#18AK3:BYD(%W(0L];H)6=/"QKQ]XZ#%W-E:;$^EX
M-!-P#M>17;1SATL4I%VSLWYA.0^L_1MZX,SNFZ]F@$"4(&,#(@/=E;:,82<,
M(1W`"HE'1!V/NXC*%@1C`\"02SF@DY=GJ3M6O7X,<JE*NRJL+AFEUVN,3-3M
M(O\`M(@W+QPX2C6<&E+3;AZ9T,A--8N'1(<I3ILTQ-NU1('<4/(M>N?2UK*E
MEWLS(N9,W<FU*@)W;("@C`R))HYXDKBEV#NMR$8"$86H<-P\*RU)E3^Q=%#\
M(N1M0A>,$+.4<;&K1>9\?E:P*TNU5IW&0M3;P5*BPMD^$R,6[>MQ5B%^]FS!
M1T042J@`B;L'BO\`KKT]FY'=KUF_LCD=E^7@+D)"4KF^<MD=NX`L1YB0%Y=C
MLG<,>S8LF(EMR]Y8@M&E>&K+W]#_``C_`']?"%WA5T1&B(T1&B(T1&B(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B)N;Y)C'R^+D0LSRO_`#;(R<8+
M-K$C)IVP!I-V?_IEZON'R9F;T'K_`%?791@1'_CM=C[#C?,8G=)_+0R.EVXS
MW2N;#8_4XT>M$?\`B2\W2Z?*Z9_@72_5N<</N'8;0SKF'\QWH6MD;75&7^BS
M;GRTY?\`@P/3Z_5KYK$;?_B)QM=<7=%3;^_OUU&/O3[E7;1G14V#V^_1JU=D
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MILC=!=.,<J+))^7Q=QA`-3S5,/.(^"<F-Y4VVF\8\V<ELN*\?;Y7\75ZT66`
M)Q9RC,9,@[5^E8E51U5UK+8:S7F;"TOK&5./333*NFD98HJB4P"758#1UDP>
M0B'KS"7<>LS<ELF0.6FUQJO&V1M%:AV"M`M.',Q.[IBUU?7\?,EF\/Y&73CW
MMSJUHQM.Q[,DJ_28*MY!C))K-6Z:R2S8L$8C314Q`8U^I8./V;>3URSWDC#^
M9<>X#CH?&-%K<Q9[?A?(^0;@2#OMQ=$>5C'<HTN^-:,D>4=4M!::=>F55.Q:
M.8\52@#Y(=6ON4E&&W<'<\U.G5`9_:L(U41HB-$1HB-$1HB-$1HB-$1HB-$1
MHB-$1HB-$1HB-$1HB-$1HB-$1HB;F^R7R^7Q:C^I75?^:Y&3C?1MHGYF2U[T
MB[OOTT\7W#Y*U-Z'UWJ_<HQ(C_QVNQ]AQOF,3ND_EH9'2[<9[C<V&Q^IQH]:
M(_\`$EYNET^5TS_`NE^K<[Y/N/8;?SUS#^8[T+6R-KJC*_19L_EIR_\`!B=G
M7ZO\UB-O_P`1.-KKB[HC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C
M1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C
M1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C
M1$:(C1$:(C1%%7G-2+9DOAIREQ[0X-W9[K=L"Y1J]4KK`[8CZ<L$W4)6/BHM
MH=ZNU:$</7BY$R"JJF0!-\1@#KJ'16.M4U7-.TY^JF%\75'"=*S'+.+S:Z[3
MLO6S!$34)S+>+L6-ZM*R=IF:"PN5CKL$VN=@D(QI`,I(ZJ_R49-213156:I%
M&+<!%R9,N<8SLKC?B;CF.P/PUR-$XJ@+D-%RMQSR!7X@^:'&#IA&R1]]M]6A
M6.1IME>+G*6*7;3#L7TL]D9UHI)*'(M(K)@9[%/Q:U3%8*X>Y.NO%O(6*8)]
M9^(N+I;ETIF#C]B:Z4NN7U[2L"5YQ3[%%8MN>/9"Q+QL15+EE>%E+&,`:0,=
MBP?),ERE(99J1JJ95?63)9B?!7(O'?%+F+7\OX[KO+FRVKE5E+(<-B&XTVGT
M:)RSCYSE."G9:181I9^:KCZ2N,&P=3,`QDUV[8DB1JR7,FB)E05JCU!=J)MI
M/BK>.1.'_JE$H6$Y_C_3>66/L=UG#.([Y%PN,Y:S9"QOCV796B_3M2@WKQMC
MY+)$PO$5_P!0Y.D\7:P)'JJ94S)&-0M"3;7+D*0W#B@23WDYE#.E3XT6GB3B
M.5XZX>Q))8[MU5JM!E;QE^GV^_V&7LY*G3)65C7\=1*Q8FL&A/JB`R_E.1L9
M9HU24&#58D2S$O52"X)TB^U;!S^T9<K+^HYAS1EG+^:LEP,JLU<2<5*7B_S7
MZ1A'BK-T^:[U;%L9`1")$UE")-V"9`'8H:HTKJI(N?`*9FJLI#Z]+^0I_P`^
M]!["_P`[_+_%_-_W?NT59+M%$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$
M:(C1$:(C1$:(C1$W%]_5WS?%OZ8]3Z#^T=/]:^G]'V?I']$7?O\`5>K_`#/3
M?J/Y;_,?G=_;_$[]=C[#_2/E.Z?U3;U_Z:?EGW?YCYG&^';1^CUOB\K/^+:N
ME^K?]1?U'L/]"W_*?UH?.[=C?*?)9K[]]=OS/RW^'Y]VW\.Y./KKB[HC1$:(
MC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(
MC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(
MC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(
MC1$:(C1%SLQ^K/4)?(/T[Z7PAYOG'S+U'J.\^_B]%^7X?'V^WXN[?W:)1<7_
<`/=&_P#D$_\`9_\`^2/\7])_Y&LU^U:_L7__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
